<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Tradit Complement Med</journal-id><journal-id journal-id-type="iso-abbrev">J Tradit Complement Med</journal-id><journal-id journal-id-type="pmc-domain-id">2191</journal-id><journal-id journal-id-type="pmc-domain">jtcm</journal-id><journal-title-group><journal-title>Journal of Traditional and Complementary Medicine</journal-title></journal-title-group><issn pub-type="epub">2225-4110</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12902306</article-id><article-id pub-id-type="pmcid-ver">PMC12902306.1</article-id><article-id pub-id-type="pmcaid">12902306</article-id><article-id pub-id-type="pmcaiid">12902306</article-id><article-id pub-id-type="pmid">41696735</article-id><article-id pub-id-type="doi">10.1016/j.jtcme.2025.01.002</article-id><article-id pub-id-type="pii">S2225-4110(25)00003-3</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>ZishenWan reduces obesity in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice by inhibiting p21 expression in adipose tissues</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Wu</surname><given-names initials="Y">You</given-names></name><email>202253013@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Qin</surname><given-names initials="H">Huizhao</given-names></name><email>20200941378@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Qi</surname><given-names initials="Z">Zhiwei</given-names></name><email>20220931097@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yuan</given-names></name><email>20210931538@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yongxin</given-names></name><email>20220931098@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Li</surname><given-names initials="X">Xiaochen</given-names></name><email>xiaochen961119@163.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Qin</surname><given-names initials="L">Lingling</given-names></name><email>700513@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Jiang</surname><given-names initials="M">Miao</given-names></name><email>doctorjiang@139.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Wu</surname><given-names initials="L">Lili</given-names></name><email>700443@bucm.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">⁎⁎</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Liu</surname><given-names initials="T">Tonghua</given-names></name><email>thliu@vip.163.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib><aff id="aff1"><label>a</label>Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, 102488, China</aff><aff id="aff2"><label>b</label>Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, 102488, China</aff><aff id="aff3"><label>c</label>School of Life Science, Beijing University of Chinese Medicine, Beijing, 102488, China</aff><aff id="aff4"><label>d</label>Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China</aff></contrib-group><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author. Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, 102488, China. <email>thliu@vip.163.com</email></corresp><corresp id="cor2"><label>⁎⁎</label>Corresponding author. Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, 102488, China. <email>700443@bucm.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">co-first authors.</p></fn></author-notes><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>23</day><month>1</month><year>2025</year></pub-date><volume>16</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">507635</issue-id><fpage>59</fpage><lpage>70</lpage><history><date date-type="received"><day>22</day><month>4</month><year>2024</year></date><date date-type="rev-recd"><day>5</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>14</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-16 15:25:13.347"><day>16</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Center for Food and Biomolecules, National Taiwan University</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>Obesity is a major risk factor for metabolic disorders, including type 2 diabetes, metabolic syndrome, and cardiovascular diseases. Recent studies suggest that adipocyte cell cycle regulation is linked to metabolic dysfunction, making cell cycle regulatory factors potential therapeutic targets. ZishenWan (ZSW), a traditional Chinese medicinal formula composed of three herbs, has shown therapeutic potential against diabetes and obesity. This study aimed to investigate the mechanisms underlying the weight-regulatory effects of ZSW.</p></sec><sec><title>Methods</title><p>ZSW was orally administered to <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice for 5 weeks, with metformin used as a positive control. Body weight and fasting blood glucose levels were monitored weekly, and an oral glucose tolerance test was conducted at the end of the intervention. Insulin levels and serum lipid profiles were also assessed. Histological analysis was performed on adipose tissue, and epididymal adipose tissue (EAT) samples were collected for transcriptomic analysis. The findings from transcriptomic analysis were further validated using qPCR, immunohistochemistry, and western blotting.</p></sec><sec><title>Results</title><p>ZSW significantly reduced body weight, inhibited adipocyte hypertrophy, and improved insulin sensitivity and insulin secretion in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice without affecting liver or kidney function. Transcriptomic analysis revealed that ZSW altered the expression of genes involved in lipid metabolism and inhibited p21 expression. Additionally, ZSW activated the PI3K/AKT/FoxO1 signaling pathway, resulting in reduced p21 expression, increased apoptosis, and enhanced UCP1 expression in EAT.</p></sec><sec><title>Conclusions</title><p>ZSW may improve obesity-related metabolic disorders by activating the PI3K/AKT pathway and downregulating p21 expression in EAT. These effects promote adipocyte apoptosis, enhance thermogenesis, inhibit adipocyte hypertrophy, and improve insulin sensitivity.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>ZishenWan</kwd><kwd>Obesity</kwd><kwd>Adipose tissue</kwd><kwd>p21</kwd><kwd>Apoptosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Obesity, often accompanied by type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease, cardiovascular diseases, and dyslipidemia, is among the most prevalent non-communicable diseases and poses a significant global health challenge.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> The World Health Organization classifies overweight as body mass index (BMI) ≥ 25 kg/m<sup>2</sup>,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> and approximately 2 billion individuals worldwide are estimated to be overweight or obese.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Weight gain typically results from an energy imbalance caused by excessive nutrient intake and reduced energy expenditure. Adipocyte hypertrophy, commonly seen in obese humans and mice, is linked to metabolic diseases.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Under over-nutritional conditions, adipocytes expand to store excess energy in lipid, thus exerting a nutrient-buffering function. However, this capacity is limited, and once exceeded, ectopic lipid accumulation and impaired adipocyte function can occur.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></p><p id="p0015">Excessive adipocyte enlargement is closely associated with insulin resistance, inflammatory cell infiltration, and oxidative stress, all of which are pathological changes commonly observed in metabolic diseases.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> These observations link metabolic disorders to adipocyte growth, which is closely tied to the cell cycle and adipocyte differentiation.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> The cell cycle of adipocytes is governed by several cell cycle regulatory genes, including those coding for cyclin, cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CKIs).<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Indeed, the expression of these proteins changes during adipogenesis and adipocyte differentiation, and regulation of cell cycle progression can, in turn, influence metabolic status through mechanisms like adipocyte senescence and inflammatory cell infiltration.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Therefore, cell cycle regulatory factors could serve as potential therapeutic targets for metabolic disorders.</p><p id="p0020">Traditional Chinese medicine (TCM) plays an important role in complementary therapies for various chronic conditions. ZishenWan (ZSW), a traditional Chinese formula composed of <italic toggle="yes">Rhizoma Anemarrhenae</italic> (知母, zhī mǔ), <italic toggle="yes">Cortex Phellodendri</italic> (黄柏, huáng bò), and <italic toggle="yes">Cinnamomum cassia</italic> (肉桂, ròu guì), is frequently used for managing diabetes. ZSW, also known as TongguanWan, was described by Li Dongyuan during the Yuan Dynasty. According to TCM theory, this formular nourishes yin, clears heat, and could relieve symptoms such as polydipsia, polyphagia, and polyuria in diabetes. In modern clinical practice, this herb combination is also used in decoctions for managing T2DM.</p><p id="p0025">Our previous studies examined the effects of ZSW in a genetic mouse model of diabetes (<italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice).<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> ZSW was found to reduce body weight, improve insulin sensitivity, and ameliorate metabolic disorders in mice.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> ZSW enhanced glycolysis and glycogen synthesis in the liver while reducing gluconeogenesis.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> These findings provided experimental support for the clinical use of ZSW. However, the mechanism underlying its weight-reducing effect remains unclear.</p><p id="p0030">This study aimed to investigate the regulatory effects of ZSW on adipocyte apoptosis in <italic toggle="yes">db/db</italic> mice, focusing on potential underlying molecular mechanisms. Understanding how ZSW affects adipocyte apoptosis could reveal new therapeutic strategies for managing obesity and its associated metabolic complications. Based on transcriptomic analysis of epididymal adipose tissue (EAT), we explored the influence of ZSW on adipocyte apoptosis and sought to identify key molecular pathways involved.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1</label><title>Chemicals and reagents</title><p id="p0035">Extracts of the three herbs ZSW, <italic toggle="yes">Rhizoma Anemarrhenae</italic>, <italic toggle="yes">Cortex Phellodendri</italic>, and <italic toggle="yes">C. cassia</italic>, were purchased from Zhongjing Wanxi Pharmaceuticals (Nanyang, Henan, China). The purchased herbal extracts were aqueous extracts in powdered solid form. The three extracts were mixed at a ratio of <italic toggle="yes">Rhizoma Anemarrhenae</italic>: <italic toggle="yes">Cortex Phellodendri</italic>: <italic toggle="yes">Cinnamomum cassia=</italic>10:10:1, based on the weight of the raw materials. The metformin hydrochloride tablets were manufactured by Sino-American Shanghai Squibb Pharmaceuticals (Shanghai, China). All reagents were dissolved in double-distilled water before gavage.</p></sec><sec id="sec2.2"><label>2.2</label><title>High-performance liquid chromatography</title><p id="p0040">To assess the quality of the extracted ZSW, six key constituents of ZSW, namely, mangiferin (1), timosaponin B-II (2), berberine (3), phellodendrine (4), cinnamaldehyde (5), and cinnamic acid (6), were quantitatively measured using high-performance liquid chromatography (HPLC) (Alliance HPLC, Waters Corporation, MA, USA). Chemicals 1, 3, 4, 5, and 6 were quantified using HPLC-UV with an absorbance at 280 nm (2998 PDA, Waters Corporation, US), whereas chemical 2 was quantified using an HPLC-evaporative light scattering detector (ELSD) (Allchrom Model 6100 ELSD, Alltech Technology Ltd., BC, Canada). The measurements were repeated four times.</p></sec><sec id="sec2.3"><label>2.3</label><title>Animal experiments</title><p id="p0045">Twenty-one male C57BL/KsJ-<italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice (6 weeks old, 33 ± 3 g) and seven sex- and age-matched C57BL/KsJ-<italic toggle="yes">wt/wt</italic> mice were purchased from Beijing GemPharmatech. The mice were housed at the Animal Experiment Center of Beijing University of Chinese Medicine. All animal experiments were approved by the Animal Care and Ethics Committee of Beijing University of Chinese Medicine (approval no. BUCM-2023090409-3111). During treatment, the mice were housed at 24 ± 2 °C under a 12-h light–dark cycle and had <italic toggle="yes">ad libitum</italic> access to food and water.</p><p id="p0050">After 1 week of adaptive feeding, the <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice were randomly divided into three groups: ZSW group, metformin group, and model group. The <italic toggle="yes">wt/wt</italic> mice were used as normal controls. All the drugs were administered <italic toggle="yes">via</italic> oral gavage. Mice in the ZSW group received 3.3 g/kg ZSW, those in the metformin group received 200 mg/kg metformin hydrochloride, and those in the model and control groups received daily distilled water. The doses of ZSW and metformin were selected based on previous studies.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p><p id="p0055">The treatment lasted for five weeks, during which body weight and overnight fasting blood glucose levels were measured weekly. Blood glucose levels were measured in drops obtained from the tail vein using a portable glucometer (Glucocard 01-mini, Arkray, Kyoto, Japan).</p></sec><sec id="sec2.4"><label>2.4</label><title>Oral glucose tolerance test and serum insulin measurement</title><p id="p0060">The oral glucose tolerance test (OGTT) was performed at the end of the treatment. Before the test, the mice were fasted for 12 h and administered 2 g/kg glucose by gavage. Blood was drawn from the tail vein before and at 30, 60, and 120 min after glucose intake. Furthermore, approximately 100 μL of blood was collected from the orbital vein before and 30 min after glucose intake and centrifuged at 3000 rpm for 10 min to obtain serum. Serum insulin levels were measured using a commercially available ELISA kit (Cat.80-INSMSU-E01, ALPCO Diagnostics, NH, USA) according to the manufacturer's instructions.</p><p id="p0065">The area under the blood glucose-time curve (AUC) was calculated as follows:<disp-formula id="ufd1"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" altimg="si1.svg"><mml:mrow><mml:mtext>AUC</mml:mtext><mml:mo linebreak="badbreak">=</mml:mo><mml:mn>0.25</mml:mn><mml:mo linebreak="goodbreak">×</mml:mo><mml:mi mathvariant="normal">G</mml:mi><mml:mn>0</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>0.5</mml:mn><mml:mo linebreak="goodbreak">×</mml:mo><mml:mi mathvariant="normal">G</mml:mi><mml:mn>30</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>0.75</mml:mn><mml:mo linebreak="goodbreak">×</mml:mo><mml:mi mathvariant="normal">G</mml:mi><mml:mn>60</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:mn>0.5</mml:mn><mml:mo linebreak="goodbreak">×</mml:mo><mml:mi mathvariant="normal">G</mml:mi><mml:mn>120</mml:mn><mml:mtext>.</mml:mtext></mml:mrow></mml:math></disp-formula>where G0, G30, G60, and G120 represent blood glucose levels before and 30, 60, and 120 min after glucose intake, respectively.</p><p id="p0070">Homeostatic model assessment of insulin resistance (HOMA-IR) scores were calculated as follows:<disp-formula id="ufd2">HOMA-IR = fasting blood glucose × fasting insulin/22.5</disp-formula></p></sec><sec id="sec2.5"><label>2.5</label><title>Biochemical measurements and histological observation</title><p id="p0075">After five weeks of treatment, the mice were anesthetized by isoflurane inhalation. The body length from the tip of the nose to the tip of the tail was measured, and the BMI of each mouse was calculated. Blood samples were collected, and serum was acquired as described above. Serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine (CREA) levels were measured using a chemistry analyzer (Cat. BS-420, Shenzhen Mindray Bio-Medical Electronics, Shenzhen, China).</p><p id="p0080">The liver and adipose tissues (including epididymal, mesenteric, perirenal, subcutaneous, and brown fat) were removed, fixed in 4 % paraformaldehyde solution, and subsequently embedded in paraffin. Weights of the liver, brown adipose tissue, and left-sided EAT were determined. Hematoxylin and eosin (H&amp;E) staining was performed for histological analysis.</p><p id="p0085">For transmission electron microscopic (TEM) observation of β cells, pancreatic tissue was removed and fixed in 2.5 % glutaraldehyde (Cat. P1126, Solarbio Life Sciences, Beijing, China) and preserved at 4 °C. Tissue samples were post-fixed in 1 % osmium tetroxide for 2 h and washed three times in 0.1 M PBS. After dehydration, samples were embedded in 812 epoxy resin (Cat. 90529-77-4, SPI Supplies, PA, USA), polymerized for 48 h at 60 °C, sliced, and stained with 2 % uranium acetate and 2.6 % lead citrate. Finally, the samples were observed under a 120 kV Hitachi HT7800 TEM (Cat. HT7800, Hitachi High-Tech, Tokyo, Japan).</p></sec><sec id="sec2.6"><label>2.6</label><title>Transcriptome and bioinformatics analysis</title><p id="p0090">The EAT of the mice was removed and snap-frozen in liquid nitrogen. Four samples were obtained from the normal, model, and ZSW groups for transcriptome analysis. Total RNA was extracted using the mirVana miRNA Isolation Kit (Cat. AM1560, Life Technologies, CA, USA). Libraries were constructed using TruSeq Stranded mRNA Sample Prep Kit (Cat. RS-122-2101, Illumina, San Diego, CA, USA) according to the manufacturer's instructions. mRNA sequencing was performed using the Illumina HiSeq X Ten platform.</p><p id="p0095">Raw data from mRNA sequencing were processed using Trimmomatic,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> and clean reads were mapped to the mouse reference genome (NCBI database: GRCm39) using HISAT2.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Gene expression levels were quantified based on fragments per kb per million reads (FPKM)<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> and differentially expressed genes (DEGs) (<italic toggle="yes">p</italic> &lt; 0.05, fold change &gt;1.5) were identified using DESeq2. Functional enrichment analysis of DEGs was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases.</p></sec><sec id="sec2.7"><label>2.7</label><title>Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay</title><p id="p0100">Apoptosis in EAT was examined using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay conducted with a commercially available labeling (Cat. G1502, Servicebio Technology, Wuhan, China). Briefly, the paraffin-embedded adipose tissue was sliced, deparaffinized, rehydrated, and subjected to antigen retrieval using protease K. After treatment with 0.1 % Triton (Cat. G1204, Servicebio Technology), the slices were reacted with the TdT enzyme and dUTP at 37 °C for 1 h, followed by DAPI nuclear counterstaining. Tetramethylrhodamine-5-dUTP red fluorescence was used as a readout for DNA fragmentation.</p></sec><sec id="sec2.8"><label>2.8</label><title>Immunofluorescence and immunohistochemistry</title><p id="p0105">Immunofluorescence staining was conducted based on tyramide signal amplification (TSA). F4/80 and p21 protein expression levels were determined using immunohistochemistry. Briefly, the samples were dewaxed and antigen retrieval was performed in a microwave oven. The samples were blocked with 3 % bovine serum albumin for 30 min and subsequently incubated with a primary antibody targeting p21 (Cat. 188224, Abcam) at 4 °C overnight. HRP-conjugated secondary antibodies (Cat. GB23303, Servicebio Technology) and iF488-Tyramide (Cat. G1231, Servicebio Technology) were added sequentially. Antigen retrieval was performed again, followed by incubation with a primary antibody against F4/80 (Cat. A23788, ABclonal Technology, Wuhan, China), followed by incubation with an HRP-conjugated secondary antibody and CY3-Tyramide (Cat. G1223, Servicebio Technology). Nuclei were counterstained with DAPI. Slides were observed and imaged using a fluorescence microscope.</p><p id="p0110">Uncoupling protein 1 (UCP1) was detected <italic toggle="yes">via</italic> immunohistochemistry using a commercially available kit (Cat. PV-6000, ZSGB-Bio, Beijing, China). Paraffin-embedded EAT and brown adipose tissue were sectioned and incubated with primary antibodies against UCP1 (Cat. ab234430, Abcam) at 4 °C overnight, and then with the HRP-conjugated secondary antibody provided in the kit. The tissue samples were then stained with DAB for 30 s, followed by nuclear counterstaining with hematoxylin for 10 s. Images were quantified as the mean fluorescence intensity, and the immunohistochemical staining intensity was measured as the mean optical density using ImageJ software.</p></sec><sec id="sec2.9"><label>2.9</label><title>Reverse transcription quantitative polymerase chain reaction</title><p id="p0115">For quantitative polymerase chain reaction (qPCR) analysis, total RNA was extracted from EAT using the mirVana RNA Isolation Kit (Cat. AM1561, Life Technologies). The extracted RNA was reverse-transcribed into cDNA using TransScript All-in-One First-Strand cDNA Synthesis SuperMix for qPCR (Cat. AT341-02, TransGen Biotech, Beijing, China). qPCR was performed using PerfectStart Green qPCR SuperMix (Cat. AQ601, TransGen Biotech) using a LightCycler 480 system (Cat. LC480II, Roche, Swiss). The primers used for qPCR (<italic toggle="yes">Gapdh</italic>, <italic toggle="yes">Pik3ca</italic>, <italic toggle="yes">Pik3cb</italic>, <italic toggle="yes">Pik3cd</italic>, <italic toggle="yes">Pik3cg</italic>, <italic toggle="yes">Akt1</italic>, <italic toggle="yes">Akt2</italic>, <italic toggle="yes">Vegfa</italic>, <italic toggle="yes">Pdgfd</italic>, <italic toggle="yes">Irs1</italic>, <italic toggle="yes">Irs2</italic>, and <italic toggle="yes">Cdkn1a</italic>) are listed in <xref rid="appsec2" ref-type="sec">Supplementary Table 1</xref>. The relative expression levels of target mRNAs were calculated using the 2<sup>−ΔΔCT</sup> method with <italic toggle="yes">Gapdh</italic> serving as an internal control.</p></sec><sec id="sec2.10"><label>2.10</label><title>Western blot</title><p id="p0120">Western blot analysis was performed to examine the protein expression of p21, phosphorylated phosphoinositide 3-kinase (p-PI3K), phosphorylated protein kinase B (p-AKT), caspase-3, forkhead box protein O1 (FoxO1), and p-FoxO1 in the EAT. Total protein was extracted from samples using a commercial kit (Cat. KGP250, KeyGen Biotech, Nanjing, China). Protein was separated by 10 % SDS–PAGE, transferred to polyvinylidene fluoride membranes, blocked, and incubated with diluted primary antibodies (<xref rid="appsec2" ref-type="sec">Supplementary Table 2</xref>) at 4 °C overnight. The following day, the membranes were incubated with HRP-conjugated secondary antibody (Cat. SA00001-2, Proteintech Group, Wuhan, China) for 1 h at room temperature, and subsequently detected using an ECL Super Kit (Cat. RM02867, ABclonal Technology) using a gel imaging system (Cat. ChemiDoc XRS+, Bio-Rad Laboratories, CA, USA). Relative protein expression was calculated using Image Lab software (Version 5.2.1, Bio-Rad Laboratories) with β-actin serving as an internal control.</p></sec><sec id="sec2.11"><label>2.11</label><title>Statistical analysis</title><p id="p0125">Data were analyzed with IBM SPSS Statistics software (v.23.0) and are presented as means ± S.E. Data plotting was performed in GraphPad Prism (v.9.5.1). Differences among groups were analyzed using one-way analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) or Dunnett's test.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Quantitative analysis of the main chemicals in ZSW</title><p id="p0130">To assess the quality of ZSW, six chemicals were quantified: mangiferin and timosaponin B-II from <italic toggle="yes">Rhizoma Anemarrhenae</italic>, berberine and phellodendrine from <italic toggle="yes">Cortex Phellodendri</italic>, and cinnamaldehyde and cinnamic acid from <italic toggle="yes">C. cassia</italic>.<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref> The chemicals were quantified by HPLC. As the 280 nm UV absorbance for timosaponin B-II was low, the timosaponin B-II content was assessed using an ELSD (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). All six chemicals were detected in the ZSW extracts, and consistent results were obtained across different batches (<xref rid="tbl1" ref-type="table">Table 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Chromatographic fingerprint for the identification of six compounds in ZishenWan.</bold> (<bold>a</bold>) Chromatographs from the HPLC-UV analysis and (<bold>b</bold>) the HPLC-ELSD analysis. Mix: a mixture of five standard references. B-II: timosaponin B-II standard reference. The peaks represent (1) mangiferin, (2) timosaponin B-II, (3) berberine, (4) phellodendrine, (5) cinnamaldehyde, and (6) cinnamic acid.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Percent content (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) of six main compounds in ZishenWan.</p></caption><alt-text id="alttext0055">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Compound</th><th colspan="4" rowspan="1">Batch<hr/></th><th rowspan="2" colspan="1">Average content</th></tr><tr><th colspan="1" rowspan="1">1</th><th colspan="1" rowspan="1">2</th><th colspan="1" rowspan="1">3</th><th colspan="1" rowspan="1">4</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Mangiferin</td><td align="char" colspan="1" rowspan="1">0.44</td><td align="char" colspan="1" rowspan="1">0.41</td><td align="char" colspan="1" rowspan="1">0.43</td><td align="char" colspan="1" rowspan="1">0.42</td><td align="char" colspan="1" rowspan="1">0.425</td></tr><tr><td align="left" colspan="1" rowspan="1">Timosaponin B-II</td><td align="char" colspan="1" rowspan="1">2.40</td><td align="char" colspan="1" rowspan="1">2.38</td><td align="char" colspan="1" rowspan="1">2.39</td><td align="char" colspan="1" rowspan="1">2.46</td><td align="char" colspan="1" rowspan="1">2.408</td></tr><tr><td align="left" colspan="1" rowspan="1">Berberine</td><td align="char" colspan="1" rowspan="1">4.03</td><td align="char" colspan="1" rowspan="1">4.02</td><td align="char" colspan="1" rowspan="1">4.11</td><td align="char" colspan="1" rowspan="1">4.09</td><td align="char" colspan="1" rowspan="1">4.063</td></tr><tr><td align="left" colspan="1" rowspan="1">Phellodendrine</td><td align="char" colspan="1" rowspan="1">1.18</td><td align="char" colspan="1" rowspan="1">1.19</td><td align="char" colspan="1" rowspan="1">1.20</td><td align="char" colspan="1" rowspan="1">1.19</td><td align="char" colspan="1" rowspan="1">1.190</td></tr><tr><td align="left" colspan="1" rowspan="1">Cinnamaldehyde</td><td align="char" colspan="1" rowspan="1">0.0702</td><td align="char" colspan="1" rowspan="1">0.0707</td><td align="char" colspan="1" rowspan="1">0.0708</td><td align="char" colspan="1" rowspan="1">0.0680</td><td align="char" colspan="1" rowspan="1">0.070</td></tr><tr><td align="left" colspan="1" rowspan="1">Cinnamic acid</td><td align="char" colspan="1" rowspan="1">0.0254</td><td align="char" colspan="1" rowspan="1">0.0255</td><td align="char" colspan="1" rowspan="1">0.0254</td><td align="char" colspan="1" rowspan="1">0.0247</td><td align="char" colspan="1" rowspan="1">0.025</td></tr></tbody></table></table-wrap></p></sec><sec id="sec3.2"><label>3.2</label><title>ZSW decreased body weight and suppressed adipocyte enlargement in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice</title><p id="p0135">Compared with normal controls, <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice showed significantly elevated body weights at the beginning of the experiment (6-week-old). ZSW treatment effectively reduced weight gain in <italic toggle="yes">db/db</italic> mice (<xref rid="fig2" ref-type="fig">Fig. 2</xref>a). At the end of the intervention, the body mass index (BMI) of the ZSW group was significantly lower compared to the model group (<xref rid="fig2" ref-type="fig">Fig. 2</xref>b). Additionally, we weighed the EAT, liver, and brown fat and performed hematoxylin and eosin (H&amp;E) staining of adipose tissue. ZSW significantly reduced epididymal adipocyte hypertrophy and liver weight, without affecting brown fat mass (<xref rid="fig2" ref-type="fig">Fig. 2</xref>c–f). In comparison, metformin treatment reduced liver weight but did not significantly impact body weight, BMI, or adipose tissue weight (<xref rid="fig2" ref-type="fig">Fig. 2</xref>a–e). H&amp;E staining showed that ZSW prevented the pathological enlargement of adipocytes seen in the model group, whereas metformin had no effect (<xref rid="fig2" ref-type="fig">Fig. 2</xref>f). ZSW treatment also increased serum HDL levels and decreased LDL levels, with a non-significant reduction in total cholesterol (TC) content (<xref rid="fig2" ref-type="fig">Fig. 2</xref>g–j). Importantly, ZSW did not impair liver or kidney function in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice (<xref rid="appsec2" ref-type="sec">Supplementary Fig. 1</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>ZishenWan decreased body weight and suppressed adipocyte enlargement in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice. (a)</bold> The body weight of mice during the intervention (<italic toggle="yes">n</italic> = 7). <bold>(b)</bold> The body mass index (BMI) of mice at week 5 (<italic toggle="yes">n</italic> = 7). <bold>(c</bold>–<bold>e)</bold> The weight of epididymal adipose tissue (EAT), liver, and brown adipose tissue of mice (<italic toggle="yes">n</italic> = 7). <bold>(f)</bold> Histological observation of hematoxylin and eosin (H&amp;E)-stained adipose tissue at × 200 magnification. <bold>(g</bold>–<bold>j)</bold> The serum lipid profile of mice (<italic toggle="yes">n=</italic>7). ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, compared with the model group. Nor: normal control group; Mod: model group; Met: metformin group; ZSW: ZishenWan group.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec3.3"><label>3.3</label><title>ZSW improved insulin sensitivity and insulin secretion in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice</title><p id="p0140">Compared to <italic toggle="yes">wt/wt</italic> mice, <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice showed elevated fasting blood glucose levels throughout the intervention period. Both ZSW and metformin decreased hyperglycemia and improved glucose tolerance in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice (<xref rid="fig3" ref-type="fig">Fig. 3</xref>a–c). Notably, both treatments also ameliorated hyperinsulinemia in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice, which reflects insulin resistance in insulin-targeted organs (<xref rid="fig3" ref-type="fig">Fig. 3</xref>d), and significantly decreased HOMA-IR scores (<xref rid="fig3" ref-type="fig">Fig. 3</xref>e). H&amp;E staining of the pancreatic islets of mice showed that compared with the normal controls, islet morphology was disrupted (indicated by a skewed islet shape), and lipid droplets accumulated in the model group. The number of lipid droplets did not decrease in metformin-treated groups. However, ZSW treatment rescued the aberrant islet morphology and diminished the lipid droplet size in the islets observed in the model group (<xref rid="fig3" ref-type="fig">Fig. 3</xref>f). Although basal insulin levels were high in the model mice, glucose-stimulated insulin secretion was impaired. ZSW treatment significantly increased insulin secretion following glucose administration (<xref rid="fig3" ref-type="fig">Fig. 3</xref>g). TEM of β cells showed that mitochondria in the model group were swollen and distorted, with fewer secretory vesicles. ZSW treatment partially restored mitochondrial structure and increased the number of secretory vesicles (<xref rid="fig3" ref-type="fig">Fig. 3</xref>h).<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>ZishenWan improved insulin sensitivity in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice. (a)</bold> Fasting blood glucose levels of mice during the intervention (<italic toggle="yes">n</italic> = 7). <bold>(b)</bold> Blood glucose levels of mice in the oral glucose tolerance test (OGTT) (<italic toggle="yes">n</italic> = 7). <bold>(c)</bold> Area under the blood glucose-time curve for the OGTT (<italic toggle="yes">n</italic> = 7). <bold>(d)</bold> Fasting serum insulin levels (<italic toggle="yes">n</italic> = 5). <bold>(e)</bold> HOMA-IR scores (<italic toggle="yes">n</italic> = 5). <bold>(f)</bold> Images of H&amp;E staining of pancreatic islets of mice at × 200 magnification. <bold>(g)</bold> Insulin levels at 0 and 30 min in the OGTT (<italic toggle="yes">n</italic> = 6). (h) Transmission electron microscopic observation of pancreatic β cells at × 3000 and × 8000 magnification. ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, compared with the model group. Nor: normal control group; Mod: model group; Met: metformin group; ZSW: ZishenWan group.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.4"><label>3.4</label><title>Epididymal adipose tissue transcriptomics analysis</title><p id="p0145">To further explore the possible mechanisms underlying the therapeutic effects of ZSW in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice, we analyzed the EAT transcriptome (<italic toggle="yes">n</italic> = 4). One sample from the model group was excluded from the final analysis because of its high deviation from the other samples. Principal component analysis showed that the transcriptomic profile of <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice markedly differed from that of normal controls, as evidenced by the high number of identified DEGs (<xref rid="fig4" ref-type="fig">Fig. 4</xref>a–c). KEGG pathway and GO enrichment analyses revealed that the DEGs were mainly associated with lipid metabolism, including cholesterol and lipoprotein synthesis and breakdown, potentially explaining the effects on body weight and serum lipid profile (<xref rid="fig4" ref-type="fig">Fig. 4</xref>d and e). PI3K/AKT signaling regulates critical steps in cell growth, proliferation, and insulin signaling. We identified several DEGs involved in this pathway. Factors upstream of PI3K/AKT were upregulated, whereas p21—a key cell cycle regulator—was significantly downregulated (<xref rid="fig4" ref-type="fig">Fig. 4</xref>f).<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>Results of the epididymal adipose tissue transcriptomics analysis. (a)</bold> Principal component analysis of mRNA expression. (<bold>b)</bold> Summary of the differentially expressed genes (DEGs). <bold>(c)</bold> Venn diagram of the differentially expressed genes. <bold>(d)</bold> KEGG metabolic pathway enrichment for the DEGs between the ZSW and model groups. <bold>(e)</bold> GO biological process enrichment for the DEGs between the ZSW and model groups. <bold>(f)</bold> Enrichment of the DEGs in the KEGG PI3K/AKT signaling pathway map (red: upregulated, dark green: downregulated).</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.5"><label>3.5</label><title>ZSW reduced p21 expression in epididymal adipose tissue of <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice</title><p id="p0150">The transcriptomic results showed that the expression of p21 in the ZSW group was significantly downregulated compared to that in the model group. p21 belongs to the CKI family and regulates cell cycling and apoptosis,<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> both of which are highly related to the size of adipocytes. It is also involved in regulating the metabolic status of the body, including insulin sensitivity and lipid metabolism.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> High expression of p21 is associated with inflammation and lipid accumulation.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> We subsequently validated the expression of the p21-encoding gene (<italic toggle="yes">Cdkn1a</italic>), which was shown to be reduced in the transcriptomic analysis, using qPCR and western blotting. The p21 levels in the EAT were significantly higher in the model group than those in the normal control group, whereas ZSW treatment significantly attenuated this tendency (<xref rid="fig5" ref-type="fig">Fig. 5</xref>a and b). The expression of p21 and F4/80, which are mature macrophage markers in mice, was assessed using immunofluorescence. The results showed that F4/80 expression was induced in areas with strong p21 expression in the model group. However, ZSW treatment reduced the level of F4/80, although not significantly (<xref rid="fig5" ref-type="fig">Fig. 5</xref>c).<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>ZishenWan reduced p21 expression in epididymal adipose tissue of <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice. (a)</bold> The expression of <italic toggle="yes">Cdkn1a</italic> in epididymal adipose tissue (EAT) as detected by qPCR (<italic toggle="yes">n</italic> = 4). <bold>(b)</bold> The protein expression of p21 in EAT (<italic toggle="yes">n=</italic>3). <bold>(c)</bold> Immunofluorescence images of EAT (p21: green, F4/80: red, nucleus: blue) captured at × 200 magnification. Immunofluorescence was quantified as mean fluorescence intensity (<italic toggle="yes">n</italic> = 5). ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, compared with the model group. Nor: normal control group; Mod: model group; ZSW: Zishen Wan group.</p></caption><alt-text id="alttext0040">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec3.6"><label>3.6</label><title>ZSW regulated p21 expression by activating the PI3K/AKT pathway</title><p id="p0155">The transcription of p21 is regulated by PI3K/AKT signaling. Thus, we evaluated the expression levels of PI3K/AKT-encoding genes, as well as the expression of the activated forms of these two proteins. The mRNA levels of <italic toggle="yes">Pik3cb</italic>, <italic toggle="yes">Pik3cd</italic>, <italic toggle="yes">Pik3cg</italic>, and <italic toggle="yes">Akt2</italic> were significantly upregulated in the ZSW group (<xref rid="fig6" ref-type="fig">Fig. 6</xref>a–c). FoxO1 expression did not differ significantly between the model and ZSW groups, although the rate of FoxO1 phosphorylation was much higher in the latter group (<xref rid="fig6" ref-type="fig">Fig. 6</xref>c). Based on the results of the transcriptomic analysis, the mRNA expression levels of genes acting upstream of PI3K/AKT, including two growth factor-encoding genes, <italic toggle="yes">Vegfa</italic> and <italic toggle="yes">Pdgfd</italic>, and two insulin receptor substrate-encoding genes, <italic toggle="yes">Irs1</italic> and <italic toggle="yes">Irs2</italic>, were subsequently validated by qPCR, and the results are shown in <xref rid="fig6" ref-type="fig">Fig. 6</xref>d and e. Taken together, these findings suggest that the diminished expression of p21 in ZSW-treated <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice might be due to activation of the PI3K/AKT pathway.<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>ZSW regulated p21 expression by activating the PI3K/AKT pathway. (a, b)</bold> The expression levels of PI3K-encoding mRNA <bold>(a)</bold> and AKT-encoding mRNA <bold>(b)</bold> in mouse epididymal adipose tissue (EAT) (<italic toggle="yes">n</italic> = 4). <bold>(c)</bold> Western blot analysis of p-PI3K p55, p-AKT, p-FoxO1, and FoxO1 protein expression in mouse EAT (<italic toggle="yes">n</italic> = 3). <bold>(d, e)</bold> The mRNA expression levels of <italic toggle="yes">Vegfa</italic> and <italic toggle="yes">Pdgfd</italic><bold>(d)</bold> and <italic toggle="yes">Irs1</italic> and <italic toggle="yes">Irs2</italic><bold>(e)</bold> in mouse EAT (<italic toggle="yes">n</italic> = 4). ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, compared with the model group. Nor: normal control group; Mod: model group; ZSW: ZishenWan group.</p></caption><alt-text id="alttext0045">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec3.7"><label>3.7</label><title>ZSW enhanced white fat browning and adipocyte apoptosis in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice</title><p id="p0160">The CKI p21 regulates apoptosis and adipogenesis.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Low p21 expression levels have also been shown to be associated with the activation of white fat browning (beige expansion) and the enhancement of thermogenesis, which contribute to energy consumption in white adipose tissue.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> In this study, the levels of UCP1 in brown fat and EAT were evaluated by immunohistochemistry, and the TUNEL assay was used to detect apoptosis in the EAT. The results showed that, compared with the normal control group, UCP1 expression was decreased in the model group but increased after ZSW treatment (<xref rid="fig7" ref-type="fig">Fig. 7</xref>a). When highly expressed, p21 suppresses apoptosis by interacting with apoptosis-related proteins including procaspase-3, caspase-8, and caspase-10.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> TUNEL assay and Western blot analysis demonstrated that reduced p21 levels in the EAT of mice in the ZSW group were associated with increased rates of apoptosis (<xref rid="fig7" ref-type="fig">Fig. 7</xref>b and c).<fig id="fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p><bold>ZishenWan enhanced white fat browning and adipocyte apoptosis in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice. (a)</bold> Immunohistochemical examination of UCP1 expression in brown adipose tissue and epididymal adipose tissue (EAT). Staining intensity was measured as mean optical density (<italic toggle="yes">n</italic> = 5). <bold>(b)</bold> TUNEL staining of EAT (red, TUNEL-positive; blue, nuclei). Immunofluorescence was quantified as mean fluorescence intensity (<italic toggle="yes">n</italic> = 4). <bold>(c)</bold> The expression of caspase-3 in EAT (<italic toggle="yes">n</italic> = 3). <bold>(d)</bold> Diagram of the observed pharmaceutical effects of ZSW in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice. ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, compared with the model group. Nor: normal control group; Mod: model group; ZSW: ZishenWan group.</p></caption><alt-text id="alttext0050">Fig. 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0165">In this study, we investigated the effects of ZSW, a traditional Chinese formula, on genetically obese <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice and explored the underlying mechanisms of its weight-reducing action. We found that ZSW treatment reduced body weight in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice without affecting liver or kidney function, suggesting that it may be a safer alternative compared to some conventional weight loss treatments, which often have adverse side effects. Consistent with previous studies,<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> ZSW also enhanced whole-body insulin sensitivity and improved glucolipid metabolism in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice.</p><p id="p0170">ZSW comprises three traditional Chinese herbs: Zhimu, Huangbo, and Rougui, combined in a ratio of 10:10:1, respectively. Based on early studies of the chemical components of these herbs,<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref> a total of six chemicals were selected and quantified to confirm the quality of the extractions used in this study. All six chemicals were identified in the extracts, with higher levels of mangiferin, timosaponin B-II, berberine, and phellodendrine than cinnamaldehyde and cinnamic acid. This is likely due to the herb ratio in ZSW.</p><p id="p0175">TCM formulas like ZSW are complex and exhibit multi-target, multifunctional, and multi-mechanism effects, which make them potentially effective for managing multifaceted conditions like obesity and diabetes. In our previous study, ZSW restored glucose homeostasis by increasing glycogen synthesis and glycolysis and reducing gluconeogenesis in the liver of <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Since obesity and T2DM involve systemic inflammation and multi-organ dysfunction,<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref> we extended our investigation to understand how ZSW affects adipose tissue using transcriptomic analysis, in order to provide valuable insights into its weight-reducing effects.</p><p id="p0180">White adipose tissue primarily stores excess energy through the synthesis of triglycerides in the cytoplasm and acts as an endocrine organ by secreting adipokines, such as leptin and adiponectin, which regulate whole-body energy homeostasis by controlling food intake, glucose output from the liver, lipolysis, and gluconeogenesis.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Increased fat mass results from adipocyte hyperplasia (increase in cell number) or hypertrophy (increase in cell size). Adipocyte hypertrophy is associated with adipocyte dysfunction and systematic insulin resistance,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> while adipocyte hyperplasia, also known as adipogenesis, is associated with low levels of hypoxic stress and inflammation, potentially leading to “metabolically healthy obesity”.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> However, because the number of adipocytes typically stabilizes after childhood, hypertrophy, rather than hyperplasia, contributes to weight gain in adulthood.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></p><p id="p0185">Our results indicate that ZSW suppresses adipocyte hypertrophy in white adipose tissue. Transcriptomic analysis revealed that p21 was a core regulatory target of ZSW in EAT. p21, also known as p21WAF1/<sup>cip1</sup>, belongs to the CKI family, which regulates the cell cycle by inhibiting CDK activity and interferes with cyclin kinase complexes to arrest the cell cycle at both the G1/S and G2/M transitions.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Additionally, p21 inhibits apoptosis, mainly by suppressing the activity of several caspases, especially caspase-3 and caspase-9.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></p><p id="p0190">In adipogenesis, cytoplasmic triglyceride accumulation occurs at the final stage when adipocytes exit the cell cycle and exhibit mature adipocyte morphology with corresponding metabolic features.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> Large adipocytes are more vulnerable to apoptosis due to increased local hypoxic stress, pro-inflammatory adipokine secretion, and inflammatory cell infiltration.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> In our study, the rate of EAT apoptosis was significantly higher in <italic toggle="yes">db/db</italic> mice than that in <italic toggle="yes">wt/wt</italic> mice, likely due to overnutrition-induced adipocyte hypertrophy. Elevated p21 expression in adipose tissue inhibits the apoptosis of oversized adipocytes and halts the cell cycle, reducing adipocyte turnover.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Which means the accumulation of p21 in adipocytes is associated with senescence-related features, including larger cell size and reduced cell proliferation.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref></p><p id="p0195">In addition to white adipocytes, brown and beige adipocytes play a role in energy metabolism by utilizing energy for thermogenesis.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> These adipocytes are characterized by high expression levels of UCP1, a mitochondrial protein that decreases ATP generation and promotes heat genesis through driving high levels of fatty acid oxidation.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> Beige adipocytes, found in white adipose tissue, can originate from reprogrammed white adipocytes or bipotent preadipocytes.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> The overexpression of p21 has been shown to inhibit beige adipocyte formation, whereas p21 deletion enhances it, likely through a PPARγ co-activator-1α (PGC1α)-dependent mechanism.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> In our study, ZSW treatment increased UCP1 protein expression in both brown and white adipose tissues, indicating that ZSW enhances thermogenesis and energy expenditure in adipocytes.</p><p id="p0200">Cells expressing high levels of p21 were observed to accumulate in adipose tissues in high-fat-diet induced obese mice.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> The clearance of approximately 25 % of these cells in gonadal visceral adipose tissue significantly improved glucose tolerance and whole-body insulin sensitivity, accompanied by a reduction in pro-inflammatory activities. Additionally, the ablation of p21 in white adipose tissue improved insulin sensitivity and reduced obesity in mice fed a high-fat/high-sugar diet, while apoptosis was induced in EAT.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> In our study, ZSW treatment significantly reduced p21 mRNA and protein expression in EAT, accompanied by increased apoptosis, as shown by elevated caspase-3 levels and TUNEL assay. The expression of the macrophage marker F4/80 is upregulated during obesity and thus serves as an indicator of increased macrophage and related inflammatory cell infiltration in adipose tissue.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> The expression of F4/80 tended to increase in the model group and decline in ZSW-treated mice, which suggested that ZSW reduced the inflammatory response in EAT.</p><p id="p0205">The levels of molecules acting upstream of p21 were also examined in this study. PI3K/AKT activation leads to the phosphorylation of the transcription factor FoxO1, which promotes its translocation from the nucleus and diminishes its function. p21 promoter activation is dependent on FoxO1 activity.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> In the present work, ZSW significantly induced the PI3K/AKT signaling pathway in EAT, which may have led to a decrease in p21 expression through the phosphorylation and subsequent inactivation of FoxO1.</p><p id="p0210">Adipose tissue is also an important insulin-targeted organ. Studies have shown that IRS, PI3K, and AKT are three key nodes in insulin signaling,<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> and all three proteins were upregulated in EAT after ZSW treatment. The PI3K/AKT pathway functions at the intersection of metabolic and cell proliferation pathways. PI3K/AKT activation can be induced by receptor tyrosine kinases (RTKs), the Ras superfamily of small GTPases, and G protein-coupled receptors.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Both insulin and growth factors exert their biofunction through binding to RTKs. Well-characterized RTKs include insulin receptors, EGFR, PDGFR, VEGFR, and FGFRs.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Here, ZSW upregulated the mRNA levels of <italic toggle="yes">Irs1</italic>, <italic toggle="yes">Irs2</italic>, <italic toggle="yes">Vegfa</italic>, and <italic toggle="yes">Pdgfd</italic>, important upstream activators of class I PI3K protein activity, leading to the increased phosphorylation of PI3K/AKT, and, consequently, the suppression of p21 expression, which improved insulin sensitivity. Notably, we have previously shown that ZSW significantly activated the PI3K/AKT pathway in the liver,<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> showing that ZSW has a core set of targets irrespective of the tissue type.</p><p id="p0215">This study used a combination of transcriptomics and molecular techniques, including qPCR, immunohistochemistry, and western blotting, to explore the effects of ZSW on obesity. It bridges TCM and modern molecular biology, leveraging the multi-target properties of traditional formulations. To the best of our knowledge, this is the first study to investigate the molecular mechanisms of ZSW in adipose tissue and its role in improving insulin resistance. These findings provide a comprehensive understanding of how ZSW modulates metabolic dysfunction.</p><p id="p0220">This study has few limitations. Although we used the optimal dose identified in previous research, we did not explore whether ZSW has a dose-dependent effect on p21 expression. Future studies should investigate this to better understand the therapeutic potential of ZSW. Additionally, <italic toggle="yes">in vitro</italic> experiments could help clarify the direct effects of ZSW on adipocytes and its molecular mechanisms, offering more detailed insights into its mode of action.</p><p id="p0225">Our findings indicate that ZSW targets p21 to modulate adipocyte function and improve metabolic health. Given that targeting adipocyte apoptosis has been proposed as a potential treatment for obesity,<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> ZSW's ability to reduce p21 expression and promote apoptosis in visceral adipose tissue highlights its potential as a therapeutic agent. Previous studies have evaluated drugs that target p21 in human fat tissue <italic toggle="yes">ex vivo</italic>, showing promising effects.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Collectively, our results provide experimental evidence for the potential benefits of ZSW in treating metabolic disorders.</p></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p id="p0230">This study demonstrated that ZSW reduces obesity and enhances insulin sensitivity in <italic toggle="yes">db</italic>/<italic toggle="yes">db</italic> mice. These effects are likely mediated by the inhibition of p21 expression through the activation of the PI3K/AKT signaling pathway in EAT. By downregulating p21, ZSW promotes adipocyte apoptosis, increases thermogenesis, and suppresses adipocyte hypertrophy, leading to weight loss and improved insulin resistance. These findings suggest that ZSW has promising potential as a therapeutic agent for obesity-related metabolic disorders, offering a multi-target approach to modulate adipose tissue function and metabolic health.</p></sec><sec id="sec6"><title>Author contributions</title><p id="p0235">Y.W. designed the experiment, Y.W. and H.Q. completed the experiment, analyzed data and wrote the manuscript. Z.Q., Y.H., and X.L. helped with the animal experiments. Y.C. helped with the manuscript writing. L.Q. and M.J. reviewed and revised the manuscript. T.L. and L.W. supervised this study. All authors have read and approved the final version of the manuscript.</p></sec><sec id="sec7"><title>Ethics approval and consent to participate</title><p id="p0240">The animal experiments conducted in this study were approved by the Animal Care and Ethics Committee of Beijing University of Chinese Medicine (approval No. BUCM-2023090409-3111) and conformed to internationally recognized principles of laboratory animal use and care.</p></sec><sec id="sec8"><title>Consent for publication</title><p id="p0245">All authors agree to publish this article.</p></sec><sec sec-type="data-availability" id="sec9"><title>Availability of data and materials</title><p id="p0250">The datasets presented in this article could be found in online repository. The raw data from transcriptomics are deposited in Sequence Read Archive database (BioProject No. PRJNA1091037).</p></sec><sec id="sec10"><title>Funding</title><p id="p0255">This research was funded by the <funding-source id="gs1">Creation and Talent Introduction Base of Prevention and Treatment of Diabetes and Its Complications with Traditional Chinese Medicine</funding-source> (Grant No. <award-id award-type="grant" rid="gs1">B20055</award-id>).</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0260">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Wilding</surname><given-names>J.P.H.</given-names></name></person-group><article-title>World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation</article-title><source>Obes Rev</source><volume>18</volume><issue>7</issue><year>2017</year><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1111/obr.12551</pub-id><pub-id pub-id-type="pmid">28489290</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Ruze</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments</article-title><source>Front Endocrinol</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1161521</object-id><pub-id pub-id-type="doi">10.3389/fendo.2023.1161521</pub-id><comment>Published 2023 Apr 21</comment><pub-id pub-id-type="pmcid">PMC10161731</pub-id><pub-id pub-id-type="pmid">37152942</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Tsatsoulis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paschou</surname><given-names>S.A.</given-names></name></person-group><article-title>Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences</article-title><source>Curr Obes Rep</source><volume>9</volume><issue>2</issue><year>2020</year><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s13679-020-00375-0</pub-id><pub-id pub-id-type="pmid">32301039</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Excess body weight: novel insights into its roles in obesity comorbidities</article-title><source>Semin Cancer Biol</source><volume>92</volume><year>2023</year><fpage>16</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2023.03.008</pub-id><pub-id pub-id-type="pmid">36965839</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Klöting</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blüher</surname><given-names>M.</given-names></name></person-group><article-title>Adipocyte dysfunction, inflammation and metabolic syndrome</article-title><source>Rev Endocr Metab Disord</source><volume>15</volume><issue>4</issue><year>2014</year><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1007/s11154-014-9301-0</pub-id><pub-id pub-id-type="pmid">25344447</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Muir</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Neeley</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Adipose tissue fibrosis, hypertrophy, and hyperplasia: correlations with diabetes in human obesity</article-title><source>Obesity</source><volume>24</volume><issue>3</issue><year>2016</year><fpage>597</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1002/oby.21377</pub-id><pub-id pub-id-type="pmid">26916240</pub-id><pub-id pub-id-type="pmcid">PMC4920141</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Cotillard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poitou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Torcivia</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Adipocyte size threshold matters: link with risk of type 2 diabetes and improved insulin resistance after gastric bypass</article-title><source>J Clin Endocrinol Metab</source><volume>99</volume><issue>8</issue><year>2014</year><fpage>E1466</fpage><lpage>E1470</lpage><pub-id pub-id-type="doi">10.1210/jc.2014-1074</pub-id><pub-id pub-id-type="pmid">24780048</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Cancello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Henegar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Viguerie</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss</article-title><source>Diabetes</source><volume>54</volume><issue>8</issue><year>2005</year><fpage>2277</fpage><lpage>2286</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.8.2277</pub-id><pub-id pub-id-type="pmid">16046292</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Hoffstedt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wahrenberg</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity</article-title><source>Diabetologia</source><volume>53</volume><issue>12</issue><year>2010</year><fpage>2496</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1889-3</pub-id><pub-id pub-id-type="pmid">20830466</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Ghaben</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>P.E.</given-names></name></person-group><article-title>Adipogenesis and metabolic health</article-title><source>Nat Rev Mol Cell Biol</source><volume>20</volume><issue>4</issue><year>2019</year><fpage>242</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0093-z</pub-id><pub-id pub-id-type="pmid">30610207</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q.Q.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>M.D.</given-names></name></person-group><article-title>Adipogenesis: from stem cell to adipocyte</article-title><source>Annu Rev Biochem</source><volume>81</volume><year>2012</year><fpage>715</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-052110-115718</pub-id><pub-id pub-id-type="pmid">22463691</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Vermeulen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berneman</surname><given-names>Z.N.</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>D.R.</given-names></name></person-group><article-title>Cell cycle and apoptosis</article-title><source>Cell Prolif</source><volume>36</volume><issue>3</issue><year>2003</year><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2184.2003.00267.x</pub-id><pub-id pub-id-type="pmid">12814432</pub-id><pub-id pub-id-type="pmcid">PMC6496173</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>J.A.</given-names></name></person-group><article-title>Cell cycle development</article-title><source>Dev Cell</source><volume>6</volume><issue>3</issue><year>2004</year><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/s1534-5807(04)00067-x</pub-id><pub-id pub-id-type="pmid">15030756</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hagberg</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>Cascales H.</given-names></name><etal/></person-group><article-title>Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce</article-title><source>Nat Med</source><volume>27</volume><issue>11</issue><year>2021</year><fpage>1941</fpage><lpage>1953</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01501-8</pub-id><pub-id pub-id-type="pmid">34608330</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Rubio-Tomás</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rueda-Robles</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plaza-Díaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Álvarez-Mercado</surname><given-names>A.I.</given-names></name></person-group><article-title>Nutrition and cellular senescence in obesity-related disorders</article-title><source>J Nutr Biochem</source><volume>99</volume><year>2022</year><object-id pub-id-type="publisher-id">108861</object-id><pub-id pub-id-type="doi">10.1016/j.jnutbio.2021.108861</pub-id><pub-id pub-id-type="pmid">34517097</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Zishen Pill alleviates diabetes in Db/db mice via activation of PI3K/AKT pathway in the liver</article-title><source>Chin Med</source><volume>17</volume><issue>1</issue><year>2022</year><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/s13020-022-00683-8</pub-id><comment>Published 2022 Nov 10</comment><pub-id pub-id-type="pmid">36352450</pub-id><pub-id pub-id-type="pmcid">PMC9647929</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name></person-group><article-title>Network pharmacology analysis of ZiShenWan for diabetic nephropathy and experimental verification of its anti-inflammatory mechanism</article-title><source>Drug Des Dev Ther</source><volume>15</volume><year>2021</year><fpage>1577</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S297683</pub-id><comment>Published 2021 Apr 15</comment><pub-id pub-id-type="pmcid">PMC8055297</pub-id><pub-id pub-id-type="pmid">33883881</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.G.</given-names></name></person-group><article-title>Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice</article-title><source>Planta Med</source><volume>78</volume><issue>1</issue><year>2012</year><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1280268</pub-id><pub-id pub-id-type="pmid">22002851</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Bolger</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lohse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Usadel</surname><given-names>B.</given-names></name></person-group><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><issue>15</issue><year>2014</year><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id><pub-id pub-id-type="pmcid">PMC4103590</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langmead</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>S.L.</given-names></name></person-group><article-title>HISAT: a fast spliced aligner with low memory requirements</article-title><source>Nat Methods</source><volume>12</volume><issue>4</issue><year>2015</year><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3317</pub-id><pub-id pub-id-type="pmid">25751142</pub-id><pub-id pub-id-type="pmcid">PMC4655817</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trapnell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Donaghey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rinn</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pachter</surname><given-names>L.</given-names></name></person-group><article-title>Improving RNA-Seq expression estimates by correcting for fragment bias</article-title><source>Genome Biol</source><volume>12</volume><issue>3</issue><year>2011</year><fpage>R22</fpage><pub-id pub-id-type="doi">10.1186/gb-2011-12-3-r22</pub-id><pub-id pub-id-type="pmid">21410973</pub-id><pub-id pub-id-type="pmcid">PMC3129672</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Tissue distribution study of mangiferin after intragastric administration of mangiferin monomer, Rhizoma Anemarrhenae, and Rhizoma Anemarrhenae-Phellodendron decoctions in normal or type 2 diabetic rats by LC-MS/MS</article-title><source>J Chromatogr, B: Anal Technol Biomed Life Sci</source><volume>1122–1123</volume><year>2019</year><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2019.05.019</pub-id><pub-id pub-id-type="pmid">31129356</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.Q.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Identification and pharmacokinetics of saponins in <italic toggle="yes">Rhizoma Anemarrhenae</italic> after oral administration to rats by HPLC-Q-TOF/MS and HPLC-MS/MS</article-title><source>Acta Pharm</source><volume>71</volume><issue>4</issue><year>2021</year><fpage>567</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.2478/acph-2021-0033</pub-id><comment>Published 2021 Apr 3</comment><pub-id pub-id-type="pmid">36651556</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>You</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name></person-group><article-title>Quality evaluation of Phellodendri chinensis Cortex by Fingerprint⁻Chemical pattern</article-title><source>Recognition. Molecules.</source><volume>23</volume><issue>9</issue><year>2018</year><fpage>2307</fpage><pub-id pub-id-type="doi">10.3390/molecules23092307</pub-id><comment>Published 2018 Sep. 10</comment><pub-id pub-id-type="pmid">30201911</pub-id><pub-id pub-id-type="pmcid">PMC6225206</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Comparative analysis of DNA barcoding and HPLC fingerprint to trace species of Phellodendri Cortex, an important traditional Chinese medicine from multiple sources</article-title><source>Biol Pharm Bull</source><volume>39</volume><issue>8</issue><year>2016</year><fpage>1325</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1248/bpb.b16-00210</pub-id><pub-id pub-id-type="pmid">27298183</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Mechanisms for improving hepatic glucolipid metabolism by cinnamic acid and cinnamic aldehyde: an insight provided by multi-omics</article-title><source>Front Nutr</source><volume>8</volume><year>2022</year><object-id pub-id-type="publisher-id">794841</object-id><pub-id pub-id-type="doi">10.3389/fnut.2021.794841</pub-id><comment>Published 2022 Jan 11</comment><pub-id pub-id-type="pmcid">PMC8786797</pub-id><pub-id pub-id-type="pmid">35087857</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Cinnamomum cassia</italic> presl: a review of its traditional uses, phytochemistry, pharmacology and toxicology</article-title><source>Molecules</source><volume>24</volume><issue>19</issue><year>2019</year><fpage>3473</fpage><pub-id pub-id-type="doi">10.3390/molecules24193473</pub-id><comment>Published 2019 Sep. 25</comment><pub-id pub-id-type="pmid">31557828</pub-id><pub-id pub-id-type="pmcid">PMC6804248</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaldis</surname><given-names>P.</given-names></name></person-group><article-title>Cdks, cyclins and CKIs: roles beyond cell cycle regulation</article-title><source>Development</source><volume>140</volume><issue>15</issue><year>2013</year><fpage>3079</fpage><lpage>3093</lpage><pub-id pub-id-type="doi">10.1242/dev.091744</pub-id><pub-id pub-id-type="pmid">23861057</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Roninson</surname><given-names>I.B.</given-names></name></person-group><article-title>Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts</article-title><source>Cancer Lett</source><volume>179</volume><issue>1</issue><year>2002</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/s0304-3835(01)00847-3</pub-id><pub-id pub-id-type="pmid">11880176</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Tinkum</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Marpegan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>H.</given-names></name></person-group><article-title>Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice</article-title><source>J Biol Chem</source><volume>288</volume><issue>39</issue><year>2013</year><fpage>27999</fpage><lpage>28008</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.494328</pub-id><pub-id pub-id-type="pmid">23918930</pub-id><pub-id pub-id-type="pmcid">PMC3784713</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Pezone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Napoli</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Procopio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Avvedimento</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Gabrielli</surname><given-names>A.</given-names></name></person-group><article-title>Inflammation and DNA damage: cause, effect or both</article-title><source>Nat Rev Rheumatol</source><volume>19</volume><issue>4</issue><year>2023</year><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/s41584-022-00905-1</pub-id><pub-id pub-id-type="pmid">36750681</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Grun</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Maurmann</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Scholl</surname><given-names>J.N.</given-names></name><etal/></person-group><article-title>Obesity drives adipose-derived stem cells into a senescent and dysfunctional phenotype associated with P38MAPK/NF-KB axis</article-title><source>Immun Ageing</source><volume>20</volume><issue>1</issue><year>2023</year><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s12979-023-00378-0</pub-id><comment>Published 2023 Oct 11</comment><pub-id pub-id-type="pmid">37821967</pub-id><pub-id pub-id-type="pmcid">PMC10566105</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>S.R.</given-names></name></person-group><article-title>Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis</article-title><source>J Biol Chem</source><volume>274</volume><issue>24</issue><year>1999</year><fpage>17088</fpage><lpage>17097</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.24.17088</pub-id><pub-id pub-id-type="pmid">10358062</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Progenitor-like characteristics in a subgroup of UCP1+ cells within white adipose tissue</article-title><source>Dev Cell</source><volume>56</volume><issue>7</issue><year>2021</year><fpage>985</fpage><lpage>999.e4</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2021.02.018</pub-id><pub-id pub-id-type="pmid">33711247</pub-id><pub-id pub-id-type="pmcid">PMC8026751</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Spohn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>M.C.</given-names></name></person-group><article-title>Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells</article-title><source>Nat Cell Biol</source><volume>3</volume><issue>3</issue><year>2001</year><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/35060032</pub-id><pub-id pub-id-type="pmid">11231573</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Eckel</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Grundy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zimmet</surname><given-names>P.Z.</given-names></name></person-group><article-title>The metabolic syndrome</article-title><source>Lancet</source><volume>365</volume><issue>9468</issue><year>2005</year><fpage>1415</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66378-7</pub-id><pub-id pub-id-type="pmid">15836891</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Olefsky</surname><given-names>J.M.</given-names></name></person-group><article-title>Inflammation and lipid signaling in the etiology of insulin resistance</article-title><source>Cell Metabol</source><volume>15</volume><issue>5</issue><year>2012</year><fpage>635</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.001</pub-id><pub-id pub-id-type="pmcid">PMC4156155</pub-id><pub-id pub-id-type="pmid">22560216</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Hotamisligil</surname><given-names>G.S.</given-names></name></person-group><article-title>Inflammation and metabolic disorders</article-title><source>Nature</source><volume>444</volume><issue>7121</issue><year>2006</year><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/nature05485</pub-id><pub-id pub-id-type="pmid">17167474</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Klöting</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fasshauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Insulin-sensitive obesity</article-title><source>Am J Physiol Endocrinol Metab</source><volume>299</volume><issue>3</issue><year>2010</year><fpage>E506</fpage><lpage>E515</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00586.2009</pub-id><pub-id pub-id-type="pmid">20570822</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wernstedt Asterholm</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kusminski</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Dichotomous effects of VEGF-A on adipose tissue dysfunction</article-title><source>Proc Natl Acad Sci U S A</source><volume>109</volume><issue>15</issue><year>2012</year><fpage>5874</fpage><lpage>5879</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200447109</pub-id><pub-id pub-id-type="pmid">22451920</pub-id><pub-id pub-id-type="pmcid">PMC3326476</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Spalding</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Arner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Westermark</surname><given-names>P.O.</given-names></name><etal/></person-group><article-title>Dynamics of fat cell turnover in humans</article-title><source>Nature</source><volume>453</volume><issue>7196</issue><year>2008</year><fpage>783</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1038/nature06902</pub-id><pub-id pub-id-type="pmid">18454136</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Karimian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>B.</given-names></name></person-group><article-title>Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage</article-title><source>DNA Repair</source><volume>42</volume><year>2016</year><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2016.04.008</pub-id><pub-id pub-id-type="pmid">27156098</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Student</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>R.Y.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>M.D.</given-names></name></person-group><article-title>Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes</article-title><source>J Biol Chem</source><volume>255</volume><issue>10</issue><year>1980</year><fpage>4745</fpage><lpage>4750</lpage><pub-id pub-id-type="pmid">7372608</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Halberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Trujillo</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue</article-title><source>Mol Cell Biol</source><volume>29</volume><issue>16</issue><year>2009</year><fpage>4467</fpage><lpage>4483</lpage><pub-id pub-id-type="doi">10.1128/MCB.00192-09</pub-id><pub-id pub-id-type="pmid">19546236</pub-id><pub-id pub-id-type="pmcid">PMC2725728</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yahagi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance</article-title><source>J Biol Chem</source><volume>283</volume><issue>30</issue><year>2008</year><fpage>21220</fpage><lpage>21229</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801824200</pub-id><pub-id pub-id-type="pmid">18445590</pub-id><pub-id pub-id-type="pmcid">PMC3258954</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gasek</surname><given-names>N.S.</given-names></name><etal/></person-group><article-title>An inducible <italic toggle="yes">p21</italic>-Cre mouse model to monitor and manipulate <italic toggle="yes">p21</italic>-highly-expressing senescent cells <italic toggle="yes">in vivo</italic></article-title><source>Nat Aging</source><volume>1</volume><issue>10</issue><year>2021</year><fpage>962</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00107-6</pub-id><pub-id pub-id-type="pmid">35024619</pub-id><pub-id pub-id-type="pmcid">PMC8746571</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Harms</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seale</surname><given-names>P.</given-names></name></person-group><article-title>Brown and beige fat: development, function and therapeutic potential</article-title><source>Nat Med</source><volume>19</volume><issue>10</issue><year>2013</year><fpage>1252</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1038/nm.3361</pub-id><pub-id pub-id-type="pmid">24100998</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Ricquier</surname><given-names>D.</given-names></name></person-group><article-title>Uncoupling protein 1 of brown adipocytes, the only uncoupler: a historical perspective</article-title><source>Front Endocrinol</source><volume>2</volume><year>2011</year><fpage>85</fpage><pub-id pub-id-type="doi">10.3389/fendo.2011.00085</pub-id><comment>Published 2011 Dec 28</comment><pub-id pub-id-type="pmcid">PMC3355862</pub-id><pub-id pub-id-type="pmid">22649389</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Boström</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jedrychowski</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis</article-title><source>Nature</source><volume>481</volume><issue>7382</issue><year>2012</year><fpage>463</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/nature10777</pub-id><comment>Published 2012 Jan 11</comment><pub-id pub-id-type="pmid">22237023</pub-id><pub-id pub-id-type="pmcid">PMC3522098</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gasek</surname><given-names>N.S.</given-names></name><etal/></person-group><article-title>Targeting p21<sup>Cip1</sup> highly expressing cells in adipose tissue alleviates insulin resistance in obesity [published correction appears in Cell Metab. 2022 Jan 4;34(1):186]</article-title><source>Cell Metabol</source><volume>34</volume><issue>1</issue><year>2022</year><fpage>75</fpage><lpage>89.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.11.002</pub-id><pub-id pub-id-type="pmcid">PMC8732323</pub-id><pub-id pub-id-type="pmid">34813734</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Weisberg</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>McCann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosenbaum</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leibel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>A.W.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Obesity is associated with macrophage accumulation in adipose tissue</article-title><source>J Clin Invest</source><volume>112</volume><issue>12</issue><year>2003</year><fpage>1796</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1172/JCI19246</pub-id><pub-id pub-id-type="pmid">14679176</pub-id><pub-id pub-id-type="pmcid">PMC296995</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Seoane</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Massagué</surname><given-names>J.</given-names></name></person-group><article-title>Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation</article-title><source>Cell</source><volume>117</volume><issue>2</issue><year>2004</year><fpage>211</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(04)00298-3</pub-id><pub-id pub-id-type="pmid">15084259</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Taniguchi</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Emanuelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>C.R.</given-names></name></person-group><article-title>Critical nodes in signalling pathways: insights into insulin action</article-title><source>Nat Rev Mol Cell Biol</source><volume>7</volume><issue>2</issue><year>2006</year><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/nrm1837</pub-id><pub-id pub-id-type="pmid">16493415</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Safaroghli-Azar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanaei</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Pourbagheri-Sigaroodi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bashash</surname><given-names>D.</given-names></name></person-group><article-title>Phosphoinositide 3-kinase (PI3K) classes: from cell signaling to endocytic recycling and autophagy</article-title><source>Eur J Pharmacol</source><volume>953</volume><year>2023</year><object-id pub-id-type="publisher-id">175827</object-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2023.175827</pub-id><pub-id pub-id-type="pmid">37269974</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Targeting adipocyte apoptosis: a novel strategy for obesity therapy</article-title><source>Biochem Biophys Res Commun</source><volume>417</volume><issue>1</issue><year>2012</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.11.158</pub-id><pub-id pub-id-type="pmid">22172945</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Abbreviations</title><p id="p0270">
<def-list><def-item><term id="d0010">AKT</term><def><p id="p0275">protein kinase B</p></def></def-item><def-item><term id="d0015">ALT</term><def><p id="p0280">alanine aminotransferase</p></def></def-item><def-item><term id="d0020">AST</term><def><p id="p0285">aspartate aminotransferase</p></def></def-item><def-item><term id="d0025">AUC</term><def><p id="p0290">area under the blood glucose-time curve</p></def></def-item><def-item><term id="d0030">BMI</term><def><p id="p0295">body mass index</p></def></def-item><def-item><term id="d0035">BUN</term><def><p id="p0300">blood urea nitrogen</p></def></def-item><def-item><term id="d0040">CDKs</term><def><p id="p0305">cyclin-dependent kinases</p></def></def-item><def-item><term id="d0045">CKIs</term><def><p id="p0310">cyclin-dependent kinase inhibitors</p></def></def-item><def-item><term id="d0050">CREA</term><def><p id="p0315">creatinine;</p></def></def-item><def-item><term id="d0055">DEGs</term><def><p id="p0320">differentially expressed genes</p></def></def-item><def-item><term id="d0060">EAT</term><def><p id="p0325">epididymal adipose tissue</p></def></def-item><def-item><term id="d0065">ELSD</term><def><p id="p0330">evaporative light-scattering detector</p></def></def-item><def-item><term id="d0070">FoxO1</term><def><p id="p0335">forkhead box protein O1</p></def></def-item><def-item><term id="d0075">FPKM</term><def><p id="p0340">ragments per kb per million reads</p></def></def-item><def-item><term id="d0080">GO</term><def><p id="p0345">Gene Ontology</p></def></def-item><def-item><term id="d0085">H&amp;E</term><def><p id="p0350">hematoxylin and eosin</p></def></def-item><def-item><term id="d0090">HDL:</term><def><p id="p0355">high-density lipoprotein</p></def></def-item><def-item><term id="d0095">HOMA-IR</term><def><p id="p0360">homeostatic model assessment for insulin resistance</p></def></def-item><def-item><term id="d0100">HPLC</term><def><p id="p0365">high-performance liquid chromatography</p></def></def-item><def-item><term id="d0105">KEGG</term><def><p id="p0370">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term id="d0110">LDL:</term><def><p id="p0375">low-density lipoprotein</p></def></def-item><def-item><term id="d0115">OGTT</term><def><p id="p0380">oral glucose tolerance test</p></def></def-item><def-item><term id="d0120">PGC1α</term><def><p id="p0385">PPAR-γ co-activator-1α</p></def></def-item><def-item><term id="d0125">PI3K</term><def><p id="p0390">phosphoinositide 3-kinase</p></def></def-item><def-item><term id="d0130">RTK</term><def><p id="p0395">receptor tyrosine kinase</p></def></def-item><def-item><term id="d0135">T2DM</term><def><p id="p0400">type 2 diabetes</p></def></def-item><def-item><term id="d0140">TC</term><def><p id="p0405">total cholesterol</p></def></def-item><def-item><term id="d0145">TEM</term><def><p id="p0410">transmission electron microscopy</p></def></def-item><def-item><term id="d0150">TG</term><def><p id="p0415">triglyceride;</p></def></def-item><def-item><term id="d0155">TSA</term><def><p id="p0420">tyramide signal amplification</p></def></def-item><def-item><term id="d0160">TUNEL:</term><def><p id="p0425">terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling</p></def></def-item><def-item><term id="d0165">UCP1</term><def><p id="p0430">uncoupling protein 1; ZSW: ZishenWan</p></def></def-item></def-list>
</p></sec><sec id="appsec2" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0435">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0265">We would like to thank Shanghai OE Biotech for their assistance in transcriptomics analysis.</p></ack><fn-group><fn id="appsec3" fn-type="supplementary-material"><label>Appendix A</label><p id="p0440">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtcme.2025.01.002" id="intref0010">https://doi.org/10.1016/j.jtcme.2025.01.002</ext-link>.</p></fn></fn-group></back></article><article xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Dev Biol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Dev Biol</journal-id><journal-id journal-id-type="pmc-domain-id">2593</journal-id><journal-id journal-id-type="pmc-domain">frontcdb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id><journal-title-group><journal-title>Frontiers in Cell and Developmental Biology</journal-title></journal-title-group><issn pub-type="epub">2296-634X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12909530</article-id><article-id pub-id-type="pmcid-ver">PMC12909530.1</article-id><article-id pub-id-type="pmcaid">12909530</article-id><article-id pub-id-type="pmcaiid">12909530</article-id><article-id pub-id-type="doi">10.3389/fcell.2026.1744305</article-id><article-id pub-id-type="publisher-id">1744305</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Unraveling the complex web: pathogenesis and prevention of gestational diabetes mellitus-related fetal overgrowth</article-title><alt-title alt-title-type="left-running-head">Jiang et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fcell.2026.1744305" ext-link-type="uri">10.3389/fcell.2026.1744305</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Jiang</surname><given-names initials="XY">Xin-Yue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>†</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="DW">Deng-Wang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>†</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2576964"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Duan</surname><given-names initials="T">Tao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="JD">Ji-dong</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2122521"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ren</surname><given-names initials="YP">Yan-Ping</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tan</surname><given-names initials="J">Jun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/596813"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Department of Histology and Embryology, Zunyi Medical University</institution>, <city>Zunyi</city>, <state>Guizhou</state>, <country country="CN">China</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Department of Immunology, Zunyi Medical University</institution>, <city>Zunyi</city>, <state>Guizhou</state>, <country country="CN">China</country>
</aff><author-notes><corresp id="c001">
<label>*</label>Correspondence: Ji-dong Zhang, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:jdzhang0851@163.com">jdzhang0851@163.com</email>; Yan-Ping Ren, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:ypren@foxmail.com">ypren@foxmail.com</email>; Jun Tan, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:juntan_zmu@126.com">juntan_zmu@126.com</email>
</corresp><fn fn-type="equal" id="fn001"><label>†</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-03"><day>03</day><month>2</month><year>2026</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2026</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">506080</issue-id><elocation-id>1744305</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2025</year></date><date date-type="rev-recd"><day>09</day><month>1</month><year>2026</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 00:25:13.357"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 Jiang, Chen, Duan, Zhang, Ren and Tan.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Jiang, Chen, Duan, Zhang, Ren and Tan</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2026-02-03">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcell-14-1744305.pdf"/><abstract><p>Fetal overgrowth, manifesting as large for gestational age or macrosomia, remains a common complication of gestational diabetes mellitus (GDM) with neonatal and long-term metabolic implications. While maternal hyperglycemia is a key driver, evidence describes the role of dysregulated placental nutrient transport involving glucose, amino acids, and lipids mediated by signaling hubs like mTOR, IGF, and AMPK. Beyond traditional metabolic axes, this review explores emerging contributors, including gut microbiota dysbiosis and extracellular vesicle mediated communication, which modulate the environment. We synthesize evidence on fetal vascular adaptations and epigenetic programming underpinning accelerated growth. Clinically, achieving euglycemia often fails to eliminate residual overgrowth risks completely. Management is evolving to integrate advanced ultrasonic markers, such as fetal abdominal fat layer thickness, and pharmacotherapeutic candidates like metformin or pravastatin. However, addressing critical knowledge gaps requires robust longitudinal cohorts and rigorous causal inference to validate complex mechanisms. Furthermore, implementing standardized biomarker protocols remains essential for clinical translation. This review provides a comprehensive framework for precision-based strategies to manage GDM-related fetal overgrowth effectively. Search Strategy. A systematic search of PubMed, Web of Science, and Google Scholar was conducted for literature published up to 2025. The search utilized a combination of the following keywords and their variants: “gestational diabetes mellitus,” “fetal overgrowth,” “macrosomia,” “placental transport,” “insulin resistance,” “mTOR,” “extracellular vesicles,” “microbiome,” and “epigenetics.” Boolean operators (AND, OR) were applied. Priority was given to human clinical studies, meta-analyses, and large cohort studies, with animal and <italic toggle="yes">in vitro</italic> experiments included as mechanistic supplements.</p></abstract><kwd-group><kwd>fetal overgrowth</kwd><kwd>fetal vasculature</kwd><kwd>gestational diabetes mellitus</kwd><kwd>insulin resistance</kwd><kwd>macrosomia</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Science and Technology Support Program of Guizhou Province (QKH-ZK [2023]506; QKH-MS [2025]373); Zunyi City Science and Technology and Big Data Bureau &amp; Zunyi Medical University joint project (HZ [2023]175, HZ [2023]189, [2021]1350-011, [2021]1350-025).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><equation-count count="0"/><ref-count count="208"/><page-count count="24"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Embryonic Development</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Gestational diabetes mellitus (GDM) is currently one of the most common pregnancy-related metabolic disorders, posing significant risks to both maternal and fetal health. Extensive research has shown that GDM significantly increases the incidence of various adverse perinatal outcomes, with fetal overgrowth being the most common and clinically challenging among them (<xref rid="B173" ref-type="bibr">Usta et al., 2017</xref>).</p><p>Fetal overgrowth is a heterogeneous clinical phenotype typically defined as abnormally accelerated intrauterine growth velocity beyond physiological expectations. It is commonly operationalized using two related but distinct clinical definitions: macrosomia and large for gestational age (LGA). Macrosomia is typically defined as an absolute birth weight ≥4,000 g or ≥4,500 g, irrespective of gestational age, whereas LGA refers to a birth weight above the 90th percentile for gestational age and sex (<xref rid="B24" ref-type="bibr">Catalano and Shankar, 2017</xref>). Therefore, in this review, the term fetal overgrowth is used as an umbrella concept, while macrosomia and LGA are applied according to their specific epidemiological definitions.</p><p>In recent years, understanding of the pathogenesis of GDM-related fetal overgrowth has advanced substantially. Fetal growth depends not only on maternal nutrient availability but also on placental transport efficiency (<xref rid="F1" ref-type="fig">Figure 1</xref>) (<xref rid="B151" ref-type="bibr">Sferruzzi-Perri et al., 2023</xref>). The classical Pedersen hypothesis posits that excess maternal glucose in GDM crosses the placenta, induces fetal hyperinsulinemia, and drives overgrowth of insulin-sensitive tissues, resulting in macrosomia (<xref rid="B126" ref-type="bibr">Pedersen, 1954</xref>). Building on this model, subsequent studies have highlighted the contribution of placental lipid transport. Szabo et al. proposed that abnormal maternal-fetal fatty acid transfer in GDM promotes fetal adipocyte differentiation, accelerating adipose tissue expansion and increasing birth weight and later obesity risk (<xref rid="B167" ref-type="bibr">Szabo, 2019</xref>). The prevailing view suggests that maternal-fetal glucose and lipid metabolic disturbances form the core pathological basis of GDM-related fetal overgrowth. These disturbances promote excessive transplacental transport of nutrients such as glucose and lipids, driving abnormal fetal growth (<xref rid="B25" ref-type="bibr">Chagovets et al., 2025</xref>). Importantly, fetal overgrowth reflects not only increased birth weight but also altered body composition, with excessive fat accumulation more strongly associated with adverse perinatal and long-term metabolic outcomes than weight gain alone (<xref rid="B94" ref-type="bibr">Lingwood et al., 2011</xref>; <xref rid="B24" ref-type="bibr">Catalano and Shankar, 2017</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Transport of nutrients closely related to fetal growth in the placenta. The mechanism by which nutrients closely related to fetal growth in the placenta, including fatty acids, amino acids, glucose, and cholesterol, undergo transmembrane transport between maternal blood and fetal capillaries via various transport proteins and receptors on the MVM and BM. Abbreviations: MVM, microvillous plasma membrane; BM, basal plasma membrane; GLUTs, glucose transporters; SNATs, sodium-coupled neutral amino acid transporters; LATs, large neutral amino acid transporters; FATPs, fatty acid transporter proteins; FABP, fatty acid binding protein; TG, triglycerides; LPL, lipoprotein lipase; EL, endothelial lipase; FAT/CD36, fatty acid translocase; FABPpm, plasma membrane fatty acid binding protein; ABCG1, ATP-binding cassette transporter G1; ABCA1, ATP-binding cassette transporter A1; LDLR, low-density lipoprotein receptor; SR-BI, scavenger receptor class B type I; VLDLR, very low-density lipoprotein receptor; FFA, fatty acids; AA, amino acids; TC, total cholesterol; VLDL, very low-density lipoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-14-1744305-g001.jpg"><alt-text content-type="machine-generated">Diagram depicting nutrient transfer across the placenta. Includes structures like GLUTs, FABP, LATs, and receptors like ABCA1 and SR-BI. Shows movement of FFA, AA, glucose, VLDL, LDL, and HDL between maternal blood and fetal capillaries.</alt-text></graphic></fig><p>Epidemiological data indicate that macrosomia occurs in approximately 12% of normal pregnancies but increases to 15%–45% in those complicated by GDM (<xref rid="B77" ref-type="bibr">Kc et al., 2015</xref>). Notably, clinical studies show that fetal overgrowth often persists despite standardized glycemic management and achievement of recommended glucose targets (<xref rid="B103" ref-type="bibr">Mackin et al., 2018</xref>; <xref rid="B59" ref-type="bibr">He et al., 2023</xref>), suggesting that maternal hyperglycemia, although critical, is not the sole determinant of excessive fetal growth.</p><p>Fetal growth in GDM is instead jointly regulated by multiple maternal, placental, and fetal factors, including pre-pregnancy body mass index (BMI), gestational weight gain, fetal sex, parity, and the timing and intensity of glycemic interventions (<xref rid="B102" ref-type="bibr">Luo et al., 2021</xref>; <xref rid="B152" ref-type="bibr">Shaat et al., 2024</xref>; <xref rid="B90" ref-type="bibr">Li et al., 2025</xref>; <xref rid="B104" ref-type="bibr">Maghalian et al., 2025</xref>). These factors act through distinct biological pathways but converge on similar growth phenotypes, complicating causal interpretation. In addition, placental vascular function and growth-related signaling pathways contribute to fetal growth regulation (<xref rid="B41" ref-type="bibr">Díaz Del Moral et al., 2021</xref>; <xref rid="B99" ref-type="bibr">Lorigo and Cairrao, 2022</xref>; <xref rid="B137" ref-type="bibr">Rosario et al., 2023a</xref>), while emerging evidence implicates maternal gut microbiota alterations and extracellular vesicle (EVs) -mediated maternal-fetal communication in GDM-related fetal overgrowth (<xref rid="B171" ref-type="bibr">Tkach and Théry, 2016</xref>; <xref rid="B113" ref-type="bibr">Miko et al., 2022</xref>). Together, these findings extend the traditional glucose-centered framework and help explain why fetal overgrowth may persist despite guideline-compliant glycemic control during pregnancy.</p><p>In summary, GDM-related fetal overgrowth is characterized by a high incidence and a multifactorial etiology, making elucidation of its underlying mechanisms and optimization of intervention strategies of considerable clinical and public health importance. However, the deep molecular mechanisms driving this condition have not yet been fully clarified, and current preventive and therapeutic approaches remain to be further refined. In this review, we systematically synthesize the pathological mechanisms and intervention pathways associated with GDM-related fetal overgrowth, integrate recent advances in the field, and highlight key directions for future research.</p></sec><sec id="s2"><label>2</label><title>Pathogenic mechanisms of GDM-related fetal overgrowth</title><sec id="s2-1"><label>2.1</label><title>Abnormal nutrient transport in the placenta</title><sec id="s2-1-1"><label>2.1.1</label><title>Enhanced placental glucose transport mediated by GLUT1</title><p>In GDM, the sustained maternal hyperglycemic environment promotes increased transplacental glucose transport. This excessive glucose is subsequently converted into adipose tissue deposition in the fetus, ultimately leading to the development of macrosomia (<xref rid="B77" ref-type="bibr">Kc et al., 2015</xref>). This phenomenon occurs because the fetal pancreas is highly sensitive to fluctuations in circulating glucose concentrations. Exposure to hyperglycemia rapidly induces fetal hyperinsulinemia (<xref rid="B193" ref-type="bibr">Yan Y. S. et al., 2023</xref>). Moreover, while the fetus has the intrinsic capacity for gluconeogenesis, this metabolic capability is limited by the delayed expression and activation of phosphoenolpyruvate carboxykinase (PEPCK), an enzyme whose functional activity is typically not observed until the neonatal period (<xref rid="B174" ref-type="bibr">Vargas et al., 2022</xref>). Consequently, the conversion of pyruvate to glucose remains functionally limited before birth, rendering the fetus almost entirely dependent on maternally derived glucose via placental transport during this developmental stage (<xref rid="B145" ref-type="bibr">Santos et al., 2023</xref>). Studies have demonstrated that when maternal blood glucose levels are ≤120 mg/dL, the incidence of macrosomia is approximately 20%. However, this risk rises significantly to 35% when blood glucose levels reach 160 mg/dL (<xref rid="B77" ref-type="bibr">Kc et al., 2015</xref>).</p><p>The placental glucose transport process primarily depends on the GLUT gene family, which comprises 12 members. Among these, GLUT1 serves as the key mediator of glucose transport across the placenta and is predominantly expressed in the syncytiotrophoblast (STB). Under normal physiological conditions, GLUT1 expression on the microvillous membrane is markedly higher than on the basal membrane. During weeks 16–22 and 27–30 of gestation, both the expression levels and transport activity of GLUT1 on the basal membrane are significantly increased (<xref rid="B68" ref-type="bibr">Illsley and Baumann, 2020</xref>). <italic toggle="yes">Ex vivo</italic> and observational studies of human GDM placentas consistently demonstrate increased basal membrane GLUT1 expression, enhanced glucose uptake, and a positive association with fetal birth weight, influenced by maternal pre-pregnancy BMI (<xref rid="B54" ref-type="bibr">Gaither et al., 1999</xref>; <xref rid="B161" ref-type="bibr">Stanirowski et al., 2019</xref>), suggesting that upregulated expression of placental GLUT1 may play a critical role in the pathogenesis of GDM-related fetal overgrowth. Studies demonstrate that antenatal exercise interventions induce significant downregulation of placental GLUT1 expression in GDM pregnancies, concurrently attenuating the disorder’s adverse effects on cardiac, hepatic, and renal organogenesis in offspring (<xref rid="B168" ref-type="bibr">Tang et al., 2024</xref>). Although this protective effect may not be solely attributed to the downregulation of GLUT1, accumulating evidence indicates that maternal hyperglycemia during pregnancy is strongly associated with fetal overgrowth, adverse perinatal outcomes, and even long-term developmental impairments. Therefore, we propose that epigenetic modifications in placental tissue may represent a key regulatory mechanism, exerting long-term influences on offspring metabolic function development through metabolic programming (<xref rid="B129" ref-type="bibr">Picó et al., 2019</xref>). Taken together, the aforementioned human observational studies and <italic toggle="yes">ex vivo</italic> placental experiments consistently indicate a positive association between maternal hyperglycemia, upregulation of placental GLUT1 expression, and fetal birth weight in GDM pregnancies. It is recognized that GLUT1 expression varies with gestational age and maternal pre-pregnancy BMI, both of which may confound the observed associations. Consequently, whether upregulated GLUT1 expression is specifically linked to fetal overgrowth, rather than merely reflecting broader metabolic dysregulation in GDM, remains to be fully elucidated.</p></sec><sec id="s2-1-2"><label>2.1.2</label><title>Abnormal amino acid (AA) transport in the placenta</title><p>Amino acids required for fetal growth and development are primarily utilized in biosynthetic processes such as protein synthesis, carbon storage, and oxidative metabolism, collectively influencing the intrauterine growth rate. The availability of amino acids to the fetus is largely dependent on the placental transport capacity (<xref rid="B176" ref-type="bibr">Vaughan et al., 2017</xref>). The human placenta contains more than 15 AA transport systems, among which Systems A and L are the most functionally characterized. Enhanced activity of these AA transport systems is recognized as a key contributor to fetal overgrowth (<xref rid="B155" ref-type="bibr">Shimada et al., 2024</xref>).</p><p>Placental tissues from women with GDM exhibit significant impairments in amino acid transport function. Increased activity or expression of both System A and System L transporters has been reported in women with GDM and is associated with accelerated fetal growth and fetal overgrowth (<xref rid="B70" ref-type="bibr">Jansson et al., 2006</xref>), and studies using primary human trophoblast cells suggest that insulin may enhance AA transport via activation of the Akt and ERK signaling pathways (<xref rid="B23" ref-type="bibr">Castillo-Castrejon et al., 2019</xref>). These aberrant placental nutrient transport mechanisms result in sustained elevations of multiple AA levels in umbilical cord blood of fetuses from GDM pregnancies, particularly total branched-chain amino acids (BCAAs), leucine, and valine. These AA not only support placental metabolic activities that promote accelerated fetal growth but are also transported across the placenta into the fetal circulation, leading to disrupted BCAAs metabolism. This metabolic disturbance is not limited to the perinatal period but can persist into childhood (<xref rid="B97" ref-type="bibr">Liu et al., 2023</xref>). Abnormalities in BCAAs metabolism are strongly associated with increased cardiac metabolic risk in offspring (<xref rid="B72" ref-type="bibr">Jauhiainen et al., 2021</xref>). Macrosomia, a common complication of GDM, is closely linked to an elevated risk of cardiovascular disease (CVD) in adulthood (<xref rid="B35" ref-type="bibr">Contreras-Duarte et al., 2020</xref>). These findings suggest that enhanced amino acid transport not only promotes excessive fetal growth but also predisposes macrosomia to long-term CVD risks. Overall, human placental studies indicate that the activity of System A and System L transporters is significantly enhanced in placentas from GDM pregnancies, while <italic toggle="yes">in vitro</italic> experiments further demonstrate that insulin can modulate this transport activity. However, important knowledge gaps remain. How the expression and function of System A and System L transporters dynamically change across gestation, and how they are regulated by maternal metabolic characteristics such as maternal BMI, have not yet been systematically investigated. Consequently, whether enhanced placental AA transport serves as a primary driver of fetal overgrowth or represents a compensatory response secondary to maternal metabolic disturbances, and how it dynamically interacts with maternal metabolic states (e.g., insulin resistance and hyperaminoacidemia), remain to be elucidated through longitudinal studies incorporating gestational age stratification and repeated sampling across pregnancy.</p></sec><sec id="s2-1-3"><label>2.1.3</label><title>Enhanced placental free fatty acids (FFA) transport and increased fetal fat accumulation</title><p>FFA play essential roles in fetal development, including neural differentiation and fat accumulation (<xref rid="B48" ref-type="bibr">Duttaroy and Basak, 2021</xref>). In maternal circulation, fatty acids mainly exist as triglycerides (TG), phospholipids, and cholesterol (<xref rid="B44" ref-type="bibr">Du et al., 2024</xref>). From approximately the 12th week of gestation, maternal phospholipid, cholesterol, and TG levels progressively increase due to estrogen stimulation and the development of insulin resistance (<xref rid="B56" ref-type="bibr">Ghio et al., 2011</xref>). During late pregnancy, enhanced adipose tissue lipolysis accelerates fat mobilization, and the release of endogenous FFA, together with dietary fatty acids and increased hepatic TG synthesis, leads to elevated maternal circulating TG concentrations (<xref rid="B47" ref-type="bibr">Duttaroy and Basak, 2020</xref>; <xref rid="B156" ref-type="bibr">Sivan et al., 1999</xref>; <xref rid="B187" ref-type="bibr">Xiang et al., 1999</xref>).</p><p>Although fetal fat has traditionally been considered to derive primarily from glucose conversion, an alternative hypothesis proposes that maternally derived fatty acids transported across the placenta constitute a major source. In GDM, abnormally elevated maternal lipid levels enhance placental fatty acid transport efficiency, increasing both the number and size of fetal adipocytes and promoting fetal overgrowth (<xref rid="B167" ref-type="bibr">Szabo, 2019</xref>). TG cannot cross the syncytiotrophoblast (STB) directly; instead, lipoprotein lipase (LPL) and endothelial lipase (EL) localized on placental microvilli hydrolyze maternal TG into FFA (<xref rid="B26" ref-type="bibr">Chassen and Jansson, 2020</xref>). LPL further hydrolyzes maternal chylomicron triglycerides (CM-TG) and very low-density lipoprotein triglycerides (VLDL-TG), thereby enhancing placental FFA uptake and fetal adipose accumulation. Consistently, placental lipase activity positively correlates with neonatal fat content and maternal TG levels (<xref rid="B60" ref-type="bibr">Heerwagen et al., 2018</xref>). Epidemiological studies show that elevated maternal TG levels in both GDM and non-GDM pregnancies are associated with an increased risk of LGA and macrosomia, with a substantially higher risk observed in women with GDM (<xref rid="B127" ref-type="bibr">Peng et al., 2025</xref>). Compared with normal pregnancies, placentas from women with GDM exhibit increased LPL expression, elevated placental TG content, and higher FFA levels in umbilical cord plasma (<xref rid="B13" ref-type="bibr">Balachandiran et al., 2021b</xref>), while EL expression is further upregulated in obese women with GDM (<xref rid="B55" ref-type="bibr">Gauster et al., 2011</xref>). Enhanced placental LPL and EL activity facilitates the transfer of greater amounts of FFA into the fetal circulation, potentially contributing to GDM-related fetal overgrowth and increasing the risk of macrosomia.</p><p>Placental FFA uptake is mediated by specific fatty acid transporters, including fatty acid transport proteins (FATP), fatty acid translocase (FAT/CD36), plasma membrane fatty acid-binding protein (FABPpm), and intracellular fatty acid-binding proteins (FABP). The expression of these transporters is regulated by fatty acid-activated transcription factors such as PPARs, LXR, RXR, and SREBP-1 (<xref rid="B48" ref-type="bibr">Duttaroy and Basak, 2021</xref>). Compared with placentas from infants with normal birth weight, placentas associated with macrosomia show significantly higher mRNA and protein expression of PPARα, FABPpm, and FAT/CD36 (<xref rid="B120" ref-type="bibr">Ni et al., 2022</xref>). In pregnancies complicated by GDM, dysregulated FABP expression has been linked to excessive fetal lipid accumulation, with placental liver-type fatty acid-binding protein (L-FABP) increased by 64% (<xref rid="B105" ref-type="bibr">Magnusson et al., 2004</xref>) and FABP4 and FABP5 significantly upregulated (<xref rid="B149" ref-type="bibr">Scifres et al., 2011</xref>). In addition to human placental studies, increased placental expression of FABP2 and FABP3 has been reported in rat models of GDM (<xref rid="B114" ref-type="bibr">Mishra and Kumar, 2023</xref>). Elevated glucose levels in placental tissue from GDM pregnancies reduce fatty acid oxidation capacity by approximately 30% while increasing TG accumulation by nearly threefold (<xref rid="B179" ref-type="bibr">Visiedo et al., 2013</xref>). Consistently, macrosomic infants born to women with GDM exhibit higher body fat content than those born to mothers with normal glucose tolerance (<xref rid="B108" ref-type="bibr">Martins et al., 2023</xref>). However, most available evidence is derived from cross-sectional human placental studies, limiting insights into temporal dynamics and regulatory hierarchies of placental lipid transport. Moreover, pre-pregnancy BMI is associated with altered expression of multiple placental fatty acid transport-related genes (<xref rid="B150" ref-type="bibr">Segura et al., 2017</xref>), indicating that maternal obesity and metabolic background factors may interact with these pathways. Overall, current evidence supports a critical regulatory role of placental lipid transport in GDM-related fetal overgrowth, highlighting the need for future studies integrating mechanistic animal models and trophoblast-based systems while controlling for maternal metabolic background.</p></sec><sec id="s2-1-4"><label>2.1.4</label><title>Enhanced placental cholesterol transport</title><p>Cholesterol, as a key structural component of cell membranes and an essential precursor for steroid hormone synthesis, plays an irreplaceable physiological role in fetal growth and development (<xref rid="B27" ref-type="bibr">Chatuphonprasert et al., 2018</xref>). Although the fetus possesses endogenous cholesterol synthesis capacity, prior to 19 weeks of gestation, its cholesterol supply primarily depends on maternal provision (<xref rid="B100" ref-type="bibr">Lu et al., 2022</xref>). The transport of cholesterol from the maternal to fetal circulation relies on ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) located in STB cells and fetal vascular endothelial cells (<xref rid="B1" ref-type="bibr">Aguilera-Olguín and Leiva, 2022</xref>). In addition to direct transport, the placenta also transports cholesterol from the maternal circulation to the fetus by uptake of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density lipoprotein (VLDL) (<xref rid="B186" ref-type="bibr">Winterhager and Gellhaus, 2017</xref>). LDL and HDL in the maternal circulation are taken up by binding to the low-density lipoprotein receptor (LDLR) and scavenger receptor class B type I (SR-BI) on the surface of STB cells, respectively (<xref rid="B1" ref-type="bibr">Aguilera-Olguín and Leiva, 2022</xref>). In normal pregnancies, maternal total cholesterol (TC) and TG levels are positively correlated with neonatal birth weight (<xref rid="B85" ref-type="bibr">Kulkarni et al., 2013</xref>). A mouse model fed a high-cholesterol diet demonstrated that maternal high-cholesterol intake increases placental cholesterol transport efficiency, leading to lipid deposition in the fetal liver and potentially causing fetal growth and developmental abnormalities (<xref rid="B84" ref-type="bibr">Kuentzel et al., 2022</xref>).</p><p>Numerous studies have demonstrated that GDM is strongly associated with maternal lipid metabolism disorders. A meta-analysis revealed that, compared to non-GDM pregnancies, GDM patients exhibit significantly elevated serum TG, TC and LDL levels, while HDL levels are decreased (<xref rid="B63" ref-type="bibr">Hu et al., 2021</xref>). This lipid dysregulation is clearly linked to adverse perinatal outcomes: elevated TG levels during mid-to-late pregnancy are associated with an increased risk of LGA infants, macrosomia, and neonatal complications, whereas higher HDL levels show a negative correlation with the risk of LGA and adverse neonatal outcomes (<xref rid="B154" ref-type="bibr">Shi et al., 2023</xref>). Upregulation of ABCA1 and ABCG1 expression has been observed in human placental endothelial cells isolated from GDM pregnancies (<xref rid="B164" ref-type="bibr">Sun et al., 2018</xref>). The protein expression of placental SR-BI is elevated in normal-weight GDM women compared to both healthy controls and overweight/obese GDM subjects. Meanwhile, both mRNA and protein expression levels of LDLR and very low-density lipoprotein receptor (VLDLR) are significantly increased in the placentas of GDM women, regardless of body weight status (<xref rid="B46" ref-type="bibr">Dubé et al., 2013</xref>; <xref rid="B53" ref-type="bibr">Fruscalzo et al., 2021</xref>). Although the precise mechanisms underlying placental cholesterol and lipoprotein transport in GDM remain incompletely understood, accumulating evidence suggests that disturbances in cholesterol and lipoprotein metabolism may represent a key pathophysiological mechanism contributing to GDM-related fetal overgrowth. It is noteworthy that current research has insufficiently addressed the temporal dynamics of placental cholesterol metabolism, failing to systematically elucidate its regulatory patterns on fetal development across different stages of pregnancy. Additionally, factors such as maternal obesity, dietary structure, and genetic background may influence placental function through pathways like epigenetic modifications, yet existing evidence remains inadequate to unravel the network effects of these complex interactions. Future studies should establish longitudinal research models spanning the entire gestation period, integrating multi-omics technologies and spatial transcriptomics to dynamically dissect the spatiotemporally specific regulatory mechanisms of the placental cholesterol transport system in the pathological progression of GDM.</p></sec></sec><sec id="s2-2"><label>2.2</label><title>Fetal growth-related signaling pathways</title><sec id="s2-2-1"><label>2.2.1</label><title>Regulatory role of the insulin-like growth factor (IGF)</title><p>Numerous studies have demonstrated that the IGF system plays a central regulatory role in bodily growth and development, particularly during embryogenesis, the maintenance of metabolic homeostasis, and fundamental biological processes such as cell proliferation and differentiation, where it performs indispensable functions (<xref rid="B41" ref-type="bibr">Díaz Del Moral et al., 2021</xref>). The ligands of the IGF system include IGF-I, IGF-II, and insulin, which also contribute significantly to placental development through interactions with their specific receptors (<xref rid="B107" ref-type="bibr">Martín-Estal and Castorena-Torres, 2022</xref>).</p><p>Compared with those in normal pregnancies, maternal circulating and fetal serum IGF-I concentrations are markedly elevated in pregnancies complicated by GDM. A human prospective observational cohort study showed that maternal plasma IGF-I levels increased by an average of 55.4% between 24–28 and 32–35 weeks of gestation. Moreover, with every 1 standard deviation increase in maternal circulating IGF-I levels, fetal birth weight increased by 75 g, placental weight increased by 20 g, and the risk of macrosomia rose by 1.91-fold (<xref rid="B101" ref-type="bibr">Luo et al., 2012</xref>). Notably, lncRNA-SNX17 expression is significantly upregulated in placental tissues from pregnancies affected by GDM-induced macrosomia. Further experiments using human trophoblast cell lines have shown that overexpression of lncRNA-SNX17 suppresses miR-517a expression and elevates IGF-I levels, thereby promoting trophoblast cell proliferation (<xref rid="B57" ref-type="bibr">Guiyu et al., 2022</xref>). Furthermore, growth hormone (GH) exerts its effects through the classical GH-insulin-like growth factor-I (GH-IGF-I) axis, influencing pregnancy outcomes in women with GDM. Suppression of the GH-IGF-I axis leads to short stature in offspring, while excessive activation of this axis results in pathological fetal overgrowth (<xref rid="B134" ref-type="bibr">Reynolds et al., 2017</xref>; <xref rid="B30" ref-type="bibr">Chesnokova, 2022</xref>). Observational human studies have shown that maternal serum GH-V concentrations are significantly higher in GDM pregnancies resulting in LGA infants compared to control pregnancies, and maternal IGF-I levels are also markedly elevated in GDM pregnancies (<xref rid="B91" ref-type="bibr">Liao et al., 2017</xref>).</p><p>Additionally, elevated IGF-II levels are also detected in the umbilical cord blood of women with GDM (<xref rid="B181" ref-type="bibr">Wang W. J. et al., 2020</xref>). Evidence from human observational studies and <italic toggle="yes">in vitro</italic> human trophoblast experiments has indicated that the expression levels of the <italic toggle="yes">IGF-II/H19</italic> gene in the umbilical cord blood of GDM patients are significantly correlated with the development of macrosomia. A potential molecular mechanism may involve the maternal hyperglycemic environment, which can alter the methylation status of the <italic toggle="yes">IGF-II</italic> and <italic toggle="yes">H19</italic> gene promoters in trophoblast cells, thereby increasing the expression of <italic toggle="yes">IGF-II/H19</italic> (<xref rid="B162" ref-type="bibr">Su et al., 2016</xref>; <xref rid="B204" ref-type="bibr">Zhang Q. et al., 2022</xref>). Furthermore, studies in GDM mouse models have demonstrated that epigenetic changes in <italic toggle="yes">IGF-II/H19</italic> can be inherited across generations (<xref rid="B42" ref-type="bibr">Ding et al., 2012</xref>). Dysregulation of this epigenetic control mechanism may contribute to fetal overgrowth, with potential transgenerational effects.</p><p>IGF activity is regulated not only by the availability of IGF receptors but also by the insulin-like growth factor-binding protein family (IGFBPs 1–6), which can bind to both IGF-I and IGF-II. In most cases, IGFBPs inhibit the biological actions of IGF through competitive binding mechanisms (<xref rid="B11" ref-type="bibr">Bach, 2018</xref>). IGFBP-7, also known as insulin-like growth factor-binding protein-related protein 1 (IGFBP-rP1), exhibits a higher affinity for insulin than for IGF and has been shown to interact with IGF-1R. IGFBP-rP1 functions as an IGF antagonist by directly binding to the receptor and inhibiting IGF-1R activation (<xref rid="B8" ref-type="bibr">Artico et al., 2021</xref>). Studies have reported that the levels of IGFBP-1, IGFBP-2, IGFBP-3, and IGFBP-rP1 are significantly reduced in the umbilical cord blood from pregnancies complicated by GDM. Moreover, IGFBP-1 and IGFBP-2 show a negative correlation with fetal birth weight (<xref rid="B87" ref-type="bibr">Lappas, 2015</xref>). These findings suggest that fetal overgrowth may result from the downregulation of IGFBP and IGFBP-rP1 expression, which increases IGF bioavailability and consequently accelerates fetal growth and development abnormally. Current evidence linking the IGF system to GDM-related fetal overgrowth is derived primarily from observational human studies demonstrating correlations between circulating or umbilical cord IGF levels and fetal growth outcomes. Although trophoblast cell models indicate that IGF signaling regulates placental gene expression and cellular proliferation, direct mechanistic evidence from animal intervention studies or integrated placental functional models is still lacking to confirm whether IGF actively drives placental nutrient transport and fetal metabolic programming <italic toggle="yes">in vivo</italic>. Therefore, future research should integrate spatially and temporally resolved placental tissue analyses, conditional genetic animal models, and longitudinal clinical cohort data to clarify the specific causal role of IGF signaling in GDM-related fetal overgrowth and its potential translational relevance.</p></sec><sec id="s2-2-2"><label>2.2.2</label><title>mTOR signaling pathway as a central regulator of placental nutrient transport</title><p>The placental mTOR signaling pathway plays a central role in regulating fetal growth (<xref rid="B137" ref-type="bibr">Rosario et al., 2023a</xref>). The mTORC1 signaling pathway primarily promotes protein synthesis through two distinct mechanisms: first, it regulates the function of the eukaryotic initiation factor 4E (eIF4E) by phosphorylating the 4E-binding protein (4E-BP); second, it phosphorylates ribosomal protein S6 kinase 1 (S6K1), which in turn modulates the activity of eIF4B and enhances ribosomal biosynthesis capacity (<xref rid="B123" ref-type="bibr">Panwar et al., 2023</xref>). Placental tissues from macrosomic offspring of GDM mothers exhibited significantly enhanced mTORC1 signaling pathway activity (<xref rid="B147" ref-type="bibr">Sati et al., 2016</xref>). Furthermore, study based on human-derived placental tissues has further demonstrated that phosphorylation levels of the two aforementioned mTORC1 downstream targets (S6K1 and 4EBP-1) exhibit positive correlations with neonatal birth weight (<xref rid="B71" ref-type="bibr">Jansson et al., 2013</xref>). Although no direct evidence currently confirms that the mTORC1 signaling pathway causes macrosomia by promoting protein synthesis, its excessive activation may represent a potential contributing factor to fetal overgrowth.</p><p>As an E3 ubiquitin ligase, neuronal precursor cell expressed developmentally downregulated 4–2 (Nedd4-2) catalyzes protein ubiquitination leading to proteasomal degradation. Using primary human trophoblast models, Rosario F.J et al. first demonstrated a novel regulatory relationship between the mTORC1 signaling pathway and ubiquitination-a common post-translational modification. Their findings revealed that mTORC1 activation suppresses Nedd4-2 expression, thereby reducing ubiquitination of placental AA transporters. This subsequently enhances the transport capacity of SNAT2 and LAT1, ultimately promoting amino acid uptake in trophoblast cells. These discoveries may provide new perspectives for exploring mechanisms underlying fetal overgrowth (<xref rid="B136" ref-type="bibr">Rosario et al., 2016</xref>).</p><p>A human prospective cohort study has demonstrated that reduced AMPK phosphorylation in placental tissue is associated with activation of the mTORC1 signaling pathway, a phenomenon that is significantly linked to fetal overgrowth (<xref rid="B78" ref-type="bibr">Keleher et al., 2020</xref>). Among 50 GDM patients with blood glucose levels maintained within the normal range, 23 delivered macrosomia and 27 delivered infants with normal birth weight. Analyses of placentas from these pregnancies revealed a significant positive correlation between placental IGF-I activity and mTOR signaling pathway activity, as well as a negative correlation between AMPKα phosphorylation levels and fetal birth weight (<xref rid="B153" ref-type="bibr">Shang and Wen, 2018</xref>). Compared with placentas from normal pregnancies, those from GDM pregnancies complicated by LGA infants exhibited lower AMPKα phosphorylation levels and higher mTOR phosphorylation levels (<xref rid="B67" ref-type="bibr">Hung et al., 2021</xref>). In placentas from small-for-gestational-age (SGA) fetuses, LAT1 expression was decreased (<xref rid="B28" ref-type="bibr">Chen et al., 2015</xref>), whereas LAT1 expression was upregulated in LGA placentas. LAT1 is encoded by the <italic toggle="yes">SLC7A5</italic> gene, and studies have shown that overexpression of <italic toggle="yes">SLC7A5</italic> in primary human trophoblast cells not only significantly enhances systemic L-amino acid transport function but also increases systemic A-amino acid transport efficiency by 38%. Furthermore, LAT1 upregulation promotes activation of the mTOR signaling pathway by suppressing AMPK signaling activity (<xref rid="B138" ref-type="bibr">Rosario et al., 2023b</xref>). These findings collectively demonstrate intricate interconnections between the mTOR signaling pathway and fetal growth-regulatory networks, revealing its central regulatory role in governing fetal development (<xref rid="F2" ref-type="fig">Figure 2</xref>). Importantly, dysregulated activation of mTOR-related pathways may constitute the pivotal mechanism underlying GDM-induced fetal overgrowth. However, current evidence on the role of the mTOR signaling pathway in placental function regulation in GDM primarily originates from observational studies or <italic toggle="yes">ex vivo</italic> placental models, which limits interpretability to some extent. It is important to note that placental mTOR pathway activity is highly dependent on dynamic regulation by multiple factors, including maternal nutrient supply, hormonal levels, and oxidative stress. Existing experimental systems struggle to accurately replicate this complex and time-varying physiological environment. Additionally, mTOR signaling is highly sensitive to cellular context, and significant differences may exist across different trophoblast subtypes, developmental stages, and fetal sex. However, these critical variables are often inadequately accounted for in current research. Future studies urgently need to integrate cell-specific genetic models, dynamic functional analyses, and longitudinal study designs spanning different gestational stages to more precisely dissect the specific roles of mTOR signaling in placental adaptive regulation and fetal growth control.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Schematic diagram of mTOR signaling pathway regulation in fetal overgrowth. In patients with GDM, elevated insulin, IGF-I, and leptin promote protein and lipid synthesis by activating the mTOR pathway and enhance the placenta’s transport function for amino acids and glucose, thereby collectively leading to fetal overgrowth. Abbreviations: TSC1, tuberous sclerosis complex 1; TSC2, tuberous sclerosis complex 2; Rheb, ras homolog enriched in brain; AMPK, AMP-activated protein kinase; PDCD4, programmed cell death protein 4; eIF4, eukaryotic translation initiation factor 4; SREBP1, sterol regulatory element-binding protein 1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-14-1744305-g002.jpg"><alt-text content-type="machine-generated">Diagram illustrating the pathway of fetal overgrowth linked to the mTOR signaling pathway. Leptin and Insulin/IGFs activate PI3K and AKT leading to increased glucose transport via GLUT3/4, amino acids transport via SNAT1, LAT1, and SNAT2, and lipid and protein synthesis. These processes contribute to fetal overgrowth as shown in the right portion of the image with a fetus illustration.</alt-text></graphic></fig></sec></sec><sec id="s2-3"><label>2.3</label><title>Placental cellular and vascular dysfunction</title><sec id="s2-3-1"><label>2.3.1</label><title>Imbalance in trophoblast proliferation, autophagy, and apoptosis</title><p>Apoptosis is a naturally occurring process in placental cells and plays a crucial role in placental growth, development, and aging. Maintaining a balance between trophoblast cell apoptosis and proliferation is essential for normal placental development (<xref rid="B188" ref-type="bibr">Xie et al., 2024</xref>). In patients with GDM, an increased number of trophoblast cells and enhanced proliferation activity have been observed in placental tissues, accompanied by a reduction in apoptosis (<xref rid="B45" ref-type="bibr">Duan et al., 2023</xref>), which may contribute to increased placental weight. Elevated placental weight has been significantly associated with the development of LGA infants (<xref rid="B66" ref-type="bibr">Hung et al., 2020</xref>). The epidermal growth factor receptor (EGFR) serves as a key regulator of cell proliferation, human growth and development, and embryogenesis. It is highly expressed in placental tissues and plays a pivotal role in regulating placental growth and development through its involvement in critical physiological processes such as trophoblast cell fusion (<xref rid="B33" ref-type="bibr">Clemente and Bird, 2023</xref>). In mouse experiments, it has been confirmed that after excluding the interference of maternal blood sugar and blood lipids on nutrient supply, EGFR can still significantly promote the proliferation of placental sponge trophoblast cells and lead to an increase in placental volume (<xref rid="B39" ref-type="bibr">Dackor et al., 2009</xref>). Recent studies have identified a positive feedback regulatory loop involving glycoprotein hormone alpha subunit (CGA), EGFR, and transcription factor GATA binding protein 2 (GATA2), which contributes to the pathological proliferation of placentas in GDM-induced macrosomia (<xref rid="B189" ref-type="bibr">Xu et al., 2024</xref>). Moreover, increased expression of proliferating cell nuclear antigen (PCNA) has been observed in placentas associated with GDM-induced macrosomia. <italic toggle="yes">In vitro</italic> studies have demonstrated that a high-glucose environment significantly stimulates trophoblast cell proliferation and activates the phosphorylation of the ERK1/2 signaling pathway. Notably, specific inhibitors of ERK1/2 can effectively suppress this hyperproliferative response induced by high glucose levels (<xref rid="B208" ref-type="bibr">Zheng et al., 2022</xref>). Additionally, elevated expression of FABP4 has been observed in placentas of macrosomic infants born to mothers with GDM. Importantly, FABP4 has been demonstrated to enhance the proliferative and migratory capacities of human trophoblast cells (<xref rid="B191" ref-type="bibr">Yan et al., 2016</xref>; <xref rid="B195" ref-type="bibr">Yang et al., 2020</xref>).</p><p>In addition to pathological proliferation, emerging evidence suggests that the increased placental weight and fetal overgrowth observed in patients with GDM may be attributed to dysregulation of gene expression and protein synthesis related to autophagy and apoptosis in placental tissues. These molecular alterations can impair autophagy and reduce apoptosis in trophoblast cells, ultimately contributing to placental tissue remodeling. A decrease in the levels of autophagy- and apoptosis-related proteins has been observed in placentas from GDM pregnancies complicated by LGA fetuses. <italic toggle="yes">In vitro</italic> cell culture studies have further confirmed that a high-glucose environment can impair autophagy and suppress apoptosis in trophoblast cells (<xref rid="B66" ref-type="bibr">Hung et al., 2020</xref>). MicroRNAs also play a regulatory role in this process. Research using plasma-derived exosomes from GDM patients and trophoblast cell models has revealed that the miR-99 family inhibits autophagy in GDM placental trophoblast cells by upregulating myotubularin-related protein 3 (MTMR3) expression (<xref rid="B95" ref-type="bibr">Liu and Lv, 2025</xref>). Another study revealed that elevated expression of matrix metalloproteinases (MMPs) in the placentas of GDM patients enhances the expression of CSF3R splice variants and activates the PI3K/Akt signaling pathway, thereby reducing trophoblast cell apoptosis (<xref rid="B207" ref-type="bibr">Zhang Y. et al., 2024</xref>). The dual pathological alterations characterized by aberrant proliferation of placental trophoblast cells accompanied by suppressed autophagy and diminished apoptosis may constitute a critical pathogenic mechanism underlying the development of GDM-induced macrosomia. It should be particularly noted that current research on the imbalance of trophoblast proliferation/apoptosis and the development of macrosomia in GDM primarily relies on <italic toggle="yes">in vitro</italic> cell models treated with high glucose or postpartum placental samples. These models struggle to replicate the dynamic microenvironmental changes at the maternal-fetal interface during pregnancy. There is a notable lack of longitudinal studies on the temporal evolution of trophoblast behavior across different stages of pregnancy, making it difficult to determine whether the observed cellular phenotypes represent a persistent pathological state or a stage-specific adaptive response. Future studies should establish three-dimensional placental organoid models capable of simulating the dynamic fluctuations in blood glucose levels during pregnancy, combined with live-cell imaging techniques, to analyze the causal relationship between abnormal trophoblast behavior and fetal growth trajectories in both spatial and temporal dimensions.</p></sec><sec id="s2-3-2"><label>2.3.2</label><title>Abnormal placental angiogenesis and compromised barrier function</title><p>Placental angiogenesis is a tightly regulated dual-phase process governed by the balance between pro-angiogenic and anti-angiogenic factors. Altered placental vascular function can impair fetal development and increase the long-term risk of CVD in offspring (<xref rid="B99" ref-type="bibr">Lorigo and Cairrao, 2022</xref>). This process is dynamically regulated by vascular active factors, particularly vascular endothelial growth factor (VEGF), which plays a central role in placental vascular development, especially during early pregnancy (<xref rid="B65" ref-type="bibr">Huang et al., 2021</xref>). Structural analyses have demonstrated that placentas from women with GDM exhibit enhanced vascular perfusion and maternal-fetal exchange capacity, characterized by increased villous surface area, higher numbers of small villi and villous vessels, increased capillary density, branching, and surface area (<xref rid="B118" ref-type="bibr">Nanobashvili et al., 2018</xref>; <xref rid="B197" ref-type="bibr">Yao et al., 2023</xref>; <xref rid="B115" ref-type="bibr">Moreli et al., 2024</xref>). These structural adaptations may represent a key mechanism contributing to fetal overgrowth in a hyperglycemic intrauterine environment.</p><p>The VEGF family includes VEGF-A, -B, -C, -D, -E, -F, and placental growth factor (PIGF), which exert their effects through VEGF receptor-1 (VEGFR-1/Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4) (<xref rid="B109" ref-type="bibr">Melincovici et al., 2018</xref>). VEGFR-2, predominantly expressed in endothelial cells and their precursors, mediates the major pro-angiogenic effects of VEGF due to its strong tyrosine kinase activity, promoting endothelial proliferation, migration, and vessel formation (<xref rid="B182" ref-type="bibr">Wang X. et al., 2020</xref>). In contrast, VEGFR-1 exhibits high ligand affinity but weak kinase activity, functioning primarily as a negative regulator by competitively binding VEGF-A and limiting VEGFR-2 activation during early vascular development (<xref rid="B65" ref-type="bibr">Huang et al., 2021</xref>). In placentas from women with GDM, Flt-1 mRNA and protein levels are significantly reduced, whereas KDR protein expression is abnormally elevated (<xref rid="B172" ref-type="bibr">Troncoso et al., 2017</xref>). Immunolocalization studies further show that in mild hyperglycemia, VEGF and VEGFR-2 are strongly expressed in endothelial and trophoblast cells, while VEGFR-1 expression remains weak. In contrast, in GDM placentas, VEGFR-1 is strongly expressed in both vascular and trophoblastic cells, whereas VEGF and VEGFR-2 expression is markedly reduced in placental capillary endothelial cells (<xref rid="B130" ref-type="bibr">Pietro et al., 2010</xref>). These findings suggest that intrauterine hyperglycemia initially induces mild hypoxia and compensatory angiogenesis, whereas severe metabolic dysregulation leads to pronounced placental hypoxia and impaired functional capillary formation, although the underlying mechanisms remain incompletely understood (<xref rid="B130" ref-type="bibr">Pietro et al., 2010</xref>).</p><p>In addition to angiogenic signaling, placental barrier integrity is disrupted in GDM patients. Key adhesion and junctional proteins, including vascular endothelial cadherin, β-catenin, occludin, and zonula occludens-1, are significantly downregulated in GDM placentas (<xref rid="B10" ref-type="bibr">Babawale et al., 2000</xref>; <xref rid="B178" ref-type="bibr">Villota et al., 2021</xref>), potentially impairing maternal-fetal substance exchange. Connexin 43 (Cx43), a regulator of monocyte-endothelial adhesion, is markedly upregulated in umbilical vein endothelial cells from GDM pregnancies, activating the PI3K/AKT/NF-κB pathway and increasing ICAM-1 and VCAM-1 expression (<xref rid="B202" ref-type="bibr">Zhang et al., 2021</xref>). This promotes excessive monocyte-endothelial adhesion, amplifies inflammatory signaling, and further aggravates vascular dysfunction (<xref rid="B79" ref-type="bibr">Khambule and George, 2019</xref>), thereby compromising placental barrier integrity and facilitating excessive nutrient transfer to the fetus.</p><p>Insulin also plays a crucial regulatory role in placental vascular biology. It exerts its physiological effects through activation of insulin receptors, which include two subtypes-IR-A and IR-B-both of which are expressed in fetal placental endothelial cells, such as human umbilical vein endothelial cells (HUVECs) and human placental microvascular endothelial cells (hPMECs) (<xref rid="B185" ref-type="bibr">Westermeier et al., 2016</xref>). Activation of the insulin signaling pathway via the PI3K/Akt cascade enhances the expression and activity of endothelial nitric oxide synthase (eNOS), leading to increased production of nitric oxide (NO) (<xref rid="B163" ref-type="bibr">Subiabre et al., 2020</xref>). Current evidence suggests that in HUVECs derived from GDM, both IR-A and IR-B expression levels are significantly elevated, accompanied by enhanced Akt signaling activity, as well as increased eNOS activity and NO synthesis (<xref rid="B184" ref-type="bibr">Westermeier et al., 2015</xref>; <xref rid="B177" ref-type="bibr">Vedika et al., 2023</xref>). eNOS plays a pivotal role in promoting fetal growth and development and enhancing placental perfusion (<xref rid="B83" ref-type="bibr">Krause, 2021</xref>).</p><p>Cellular responses to hypoxia are mediated largely by hypoxia-inducible factor-1 (HIF-1), composed of HIF-1α and HIF-1β, which regulates angiogenesis, glycolysis, and cell proliferation (<xref rid="B196" ref-type="bibr">Yang et al., 2021</xref>). In GDM pregnancies, fetal hyperinsulinemia and insulin-induced eNOS activation increase metabolic demand and oxygen consumption, predisposing the fetus to hypoxia (<xref rid="B40" ref-type="bibr">Desoye and van Poppel, 2015</xref>). Both eNOS activation and hypoxic stress contribute to the stabilization and transcriptional activation of HIF-1, which subsequently upregulates VEGF expression and promotes angiogenesis (<xref rid="B83" ref-type="bibr">Krause, 2021</xref>). In women with GDM, the combined actions of VEGF, insulin signaling, and HIF-1 coordinately regulate placental angiogenesis and barrier function, thereby enhancing nutrient transport to the fetus and influencing both placental and fetal growth and development (<xref rid="F3" ref-type="fig">Figure 3</xref>). However, it remains important to recognize that many of the observed structural and molecular changes-such as enhanced vascular density, upregulated VEGF signaling, and altered junctional protein expression-may represent compensatory adaptations aimed at maintaining adequate nutrient and oxygen delivery under metabolic stress, rather than purely pathological processes. Moreover, most existing studies rely on expression-level analyses of angiogenic factors, adhesion molecules, or signaling components, while direct functional assessments of placental permeability, transendothelial transport capacity, or barrier integrity remain limited. As a result, it is still unclear to what extent these molecular alterations translate into quantitative changes in nutrient flux across the maternal-fetal interface. The frequent coexistence of enhanced angiogenesis with impaired barrier organization further suggests a complex balance between adaptive vascular expansion and compromised structural integrity. Future studies should therefore integrate functional permeability assays, <italic toggle="yes">in vivo</italic> or <italic toggle="yes">ex vivo</italic> placental perfusion models, and quantitative measurements of nutrient transfer to distinguish adaptive angiogenic remodeling from maladaptive barrier disruption. With the continuous advancement of research, progress continues to be made in exploring the molecular mechanisms of GDM-related fetal overgrowth. <xref rid="T1" ref-type="table">Table 1</xref> summarizes the relevant research results in recent years.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Mechanisms underlying the aberrant increase in nutrient transport across the placenta in GDM. In patients with GDM, elevated VEGF and insulin synergize with umbilical cord blood-derived exosomal LRG1 and ECM1 to collectively promote excessive placental vascular proliferation. On the other hand, highly expressed Cx43 in umbilical vein endothelial cells upregulates ICAM-1 and VCAM-1 expression, enhancing abnormal monocyte-endothelial cell adhesion and stimulating the secretion of inflammatory factors IL-6 and TNF-α. Simultaneously, the expression levels of adhesion proteins VE-cadherin, β-catenin, occludin, and ZO-1 in the placenta are significantly reduced. These changes collectively lead to abnormally increased placental vascular permeability. Consequently, the excessive transport of nutrients from the GDM placenta to the fetus accelerates fetal growth. Abbreviations: PI3K, phosphoinositide 3-Kinase; Akt, protein kinase B; HUVECs, human umbilical vein endothelial cells; eNOS, endothelial nitric oxide synthase; HIF-1α, hypoxia-inducible factor 1-Alpha; NF-κB, nuclear factor Kappa-light-chain-enhancer of activated B cells; mTOR, mammalian target of rapamycin; ECM1, extracellular matrix protein 1; LRG1, leucine-rich Alpha-2-Glycoprotein 1; ZO-1, zonula occludens-1; VE-cadherin, vascular endothelial cadherin; VEGF, vascular endothelial growth factor; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcell-14-1744305-g003.jpg"><alt-text content-type="machine-generated">Diagram illustrating placental angiogenesis and increased nutrient transport pathways. It shows interactions between VEGF, insulin, and UCB-Exos leading to vascular changes. Key elements include AKT, PI3K, and mTOR pathways, affecting placental permeability and inflammatory cell recruitment. Intestinal flora seems to influence these processes, impacting HUVECs through signaling molecules like VCAM-1 and IL-6.</alt-text></graphic></fig><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Research of molecular mechanisms associated with GDM-related fetal overgrowth (last 5 years).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Date</th><th align="left" rowspan="1" colspan="1">Model</th><th align="left" rowspan="1" colspan="1">Molecular</th><th align="left" rowspan="1" colspan="1">Signaling pathway</th><th align="left" rowspan="1" colspan="1">Functional effects/Findings</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">GDM women with macrosomia placentas</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">CGA-EGFR-GATA2</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">Promoted STBs proliferation</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B189" ref-type="bibr">Xu et al. (2024)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">GDM women with macrosomia placentas/BeWo cells</td><td align="left" rowspan="1" colspan="1">PCNA↑</td><td align="left" rowspan="1" colspan="1">ERK1/2</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">Promoted trophoblast cell proliferation</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B208" ref-type="bibr">Zheng et al. (2022)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">maternal blood/umbilical cord blood/placentas from GDM women</td><td align="left" rowspan="1" colspan="1">Adiponectin↓, IGF-I↑</td><td align="left" rowspan="1" colspan="1">Insulin/IGF-I</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">Increased GLUT-1 expression</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B12" ref-type="bibr">Balachandiran et al. (2021a)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">GDM women with LGA placenta<styled-content style="color:#1F1F1F">/CTBs</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Beclin-1↓, DRAM↓, M30↓, Cleaved PARP↓, Ki-67↑, Bcl-xL↑, Bak↓, Bad↓</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Decreased autophagic activity and apoptosis in trophoblast cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B66" ref-type="bibr">Hung et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">GDM women with LGA placenta<styled-content style="color:#1F1F1F">/CTBs</styled-content>
</td><td align="left" rowspan="1" colspan="1">p-Akt↑, p-AMPKα↓, p-mTOR↑</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">mTOR</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Promoted protein synthesis, accelerated trophoblast cell proliferation, inhibited apoptosis and autophagy</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B67" ref-type="bibr">Hung et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">GDM women with macrosomia placentas/HTR-8/SVneo cells</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">lncRNA-SNX17↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">MiR-517a/IGF-I</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">Promoted trophoblast cell proliferation</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B57" ref-type="bibr">Guiyu et al. (2022)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2025</td><td align="left" rowspan="1" colspan="1">maternal blood/placentas from GDM women/HFD mouse model</td><td align="left" rowspan="1" colspan="1">Gal-9↑</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">Increased proliferation, decreased apoptosis and impaired autophagy in trophoblast cells</td><td align="left" rowspan="1" colspan="1">
<xref rid="B4" ref-type="bibr">Albuayjan et al. (2025)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">placentas from GDM women</td><td align="left" rowspan="1" colspan="1">LRG1↑, ECM1↑</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">Promoted placental pathological angiogenesis</td><td align="left" rowspan="1" colspan="1">
<xref rid="B197" ref-type="bibr">Yao et al. (2023)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2025</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">maternal blood/placentas from GDM women</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#333333">MiR-99 family↓, MTMR3↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#333333">Inhibited trophoblast autophagy and exacerbated insulin resistance</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B95" ref-type="bibr">Liu and Lv (2025)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">MMPs↑, CSF3R↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">PI3K/Akt</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">Increased proliferation and decreased apoptosis of trophoblast cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B207" ref-type="bibr">Zhang et al. (2024c)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">GDM rat model</td><td align="left" rowspan="1" colspan="1">FABP2↑, FABP3↑, Slc27a3↑</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">Facilitated transfer of LCPUFA to the fetus</td><td align="left" rowspan="1" colspan="1">
<xref rid="B114" ref-type="bibr">Mishra and Kumar (2023)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women</styled-content>/<styled-content style="color:#1B1B1B">HTR-8/SVneo cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">TXNIP-NF-κB-STAT3</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">Accelerated migration and invasion of trophoblast cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B139" ref-type="bibr">Sa et al. (2023)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women</styled-content>/<styled-content style="color:#1B1B1B">GDM mouse model/HUVECs and MUVECs</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">Chemerin↑, VEGF↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">Promoted proliferation, migration and tube formation of umbilical vein endothelial cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B203" ref-type="bibr">Zhang et al. (2022a)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">maternal blood/placentas from GDM women/FpECs</styled-content>
</td><td align="left" rowspan="1" colspan="1">HMOs↑</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">Promoted placental pathological angiogenesis</td><td align="left" rowspan="1" colspan="1">
<xref rid="B62" ref-type="bibr">Hoch et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">GDM-hAMSCs</styled-content>
</td><td align="left" rowspan="1" colspan="1">TGFBR1↑, VEGFA↑, FGFR2↑, SERPINE1↑</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">Enhanced angiogenic capacity of hAMSC</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B81" ref-type="bibr">Klid et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women/FpECAds and HUVECs</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">VEGF↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#212121">Succinate-SUCNR1 axis</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Promoted placental pathological angiogenesis</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B9" ref-type="bibr">Atallah et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Maternal blood<styled-content style="color:#383636">/umbilical cord blood/HTR-8/SVneo cells/GDM mouse model</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#383636">TMAO↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#383636">Inhibited the formation of NETs and enhanced trophoblast cell viability, migration, invasion and angiogenesis</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B93" ref-type="bibr">Lin et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women/HTR-8/SVneo cells/STBs</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#383636">MiR-9↓, MiR-22↓</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Increased expression of GLUT1 and HK2</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B159" ref-type="bibr">Song et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#383636">IMPA1↓, SLC5A11↓, SLC2A13↓</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">Decreased inositol</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B131" ref-type="bibr">Pillai et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women/umbilical cord blood</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">AQP3↓, APN↓</styled-content>
</td><td align="left" rowspan="1" colspan="1">​</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Disordered lipid homeostasis in placenta</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B201" ref-type="bibr">Zhang et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">placentas from GDM women/HTR-8/SVneo cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">Vitronectin↑</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">JNK</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#333333">Insulin resistance increased</styled-content>
</td><td align="left" rowspan="1" colspan="1">
<xref rid="B76" ref-type="bibr">Ju et al. (2024)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1F1F1F">maternal blood/GDM women with macrosomia umbilical cord blood/JEG-3 and HTR8/SVneo cells</styled-content>
</td><td align="left" rowspan="1" colspan="1">Hsa_circ_0024838↑</td><td align="left" rowspan="1" colspan="1">
<styled-content style="color:#1B1B1B">MiR-543/HIF1A axis</styled-content>
</td><td align="left" rowspan="1" colspan="1">Promoted the vitality of trophoblast cells</td><td align="left" rowspan="1" colspan="1">
<xref rid="B98" ref-type="bibr">Liu et al. (2024)</xref>
</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="s3"><label>3</label><title>Gut microbiota and extracellular vesicles: emerging regulators of the maternal-fetal environment and communication</title><sec id="s3-1"><label>3.1</label><title>Regulatory role of gut microbiota</title><p>Recent studies have confirmed that maternal gut microbiota and its metabolites can be transferred to the fetus via the placental route during pregnancy, thereby exerting regulatory effects on fetal growth and development (<xref rid="B113" ref-type="bibr">Miko et al., 2022</xref>). Dysbiosis of the gut microbiota can alter microbial composition, compromise intestinal barrier function, and promote the release of pro-inflammatory cytokines (<xref rid="B49" ref-type="bibr">Edwards et al., 2017</xref>). Importantly, such microbial alterations do not occur in isolation but are closely associated with maternal metabolic abnormalities, including adiposity, hyperglycemia, and insulin resistance (<xref rid="B96" ref-type="bibr">Liu et al., 2019</xref>). This suggests that gut microbiota changes typically arise within the context of systemic metabolic dysregulation rather than as independent events.</p><p>Clinical trials have demonstrated that women with GDM exhibit a reduction in beneficial gut bacterial genera alongside relative enrichment of potentially pathogenic bacteria, accompanied by elevated levels of inflammatory factors such as TNF-α, IL-17, and IL-6 (<xref rid="B43" ref-type="bibr">Ding et al., 2021</xref>). Similar patterns of microbial imbalance have also been observed in neonates born to mothers with GDM. Moreover, transplantation of fecal microbiota from neonates of GDM pregnancies into mice has been shown to induce systemic inflammation and disrupt intestinal barrier integrity in the recipient mice (<xref rid="B64" ref-type="bibr">Hu et al., 2025</xref>), providing mechanistic support for a link between gut microbiota and inflammatory activation. In addition, evidence from GDM mouse models and <italic toggle="yes">in vitro</italic> cell-based experiments indicates that GDM-associated gut microbiota dysbiosis promotes polarization of adipose tissue macrophages toward a pro-inflammatory M1 phenotype, thereby exacerbating insulin resistance (<xref rid="B89" ref-type="bibr">Li et al., 2024</xref>). Collectively, these findings suggest that gut microbiota alterations may indirectly amplify maternal insulin resistance through sustained activation of inflammatory signaling. As insulin resistance worsens, maternal glucose and lipid metabolic homeostasis becomes further disrupted, creating a persistently elevated nutritional exposure for the developing fetus.</p><p>A clinical study has further shown that at 38 weeks of gestation, the abundance of Bilophila is positively associated with LGA. However, this association is markedly attenuated after adjustment for maternal pre-pregnancy BMI and gestational weight gain, indicating that such microbial features may primarily reflect maternal metabolic burden rather than acting as independent drivers of fetal overgrowth. In contrast, genera such as <italic toggle="yes">Acinetobacter</italic> and <italic toggle="yes">Aeromonas</italic> remain stably and negatively associated with LGA after multivariable adjustment (<xref rid="B124" ref-type="bibr">Pašić et al., 2025</xref>), suggesting that they may participate in modulating the fetal growth environment under specific metabolic conditions.</p><p>Interventional studies provide additional supportive evidence. Animal experiments have demonstrated that probiotic supplementation can improve maternal insulin resistance (<xref rid="B142" ref-type="bibr">Salles et al., 2020</xref>). Consistently, clinical studies indicate that probiotic interventions partially ameliorate glucose and lipid metabolic disturbances in women with GDM, leading to reductions in fasting plasma glucose, fasting serum insulin, TC, and hemoglobin A1c (HbA1c) (<xref rid="B117" ref-type="bibr">Mu et al., 2023</xref>). Notably, a randomized controlled trial reported that probiotic supplementation in GDM pregnancies was associated with reduced neonatal birth weight and a lower incidence of macrosomia (<xref rid="B141" ref-type="bibr">Sahhaf Ebrahimi et al., 2019</xref>), suggesting that modulation of gut microbiota may indirectly improve fetal growth outcomes.</p><p>Overall, current evidence supports a role for gut microbiota in the development of GDM-related fetal overgrowth; however, its effects appear to be highly dependent on maternal inflammatory status, the degree of insulin resistance, and the broader metabolic context. Gut microbiota alterations are therefore more likely to function as amplifiers or modulators of maternal metabolic dysfunction rather than as a primary, independent pathogenic trigger. Future studies integrating longitudinal designs, functional experiments, and stratified analyses will be essential to more clearly delineate the indicative versus causal roles of gut microbiota in GDM-related fetal overgrowth and to assess their potential as therapeutic targets.</p></sec><sec id="s3-2"><label>3.2</label><title>Extracellular vesicle-mediated maternal-fetal communication</title><p>EVs are nanoscale membrane-bound particles released by multiple cell types. They contain a variety of bioactive molecules, including proteins, mRNA, and microRNA, and play critical roles in intercellular communication, participating in a wide range of physiological and pathological processes (<xref rid="B171" ref-type="bibr">Tkach and Théry, 2016</xref>). Among them, exosomes are typically defined as small extracellular vesicles (sEVs) with a diameter of less than 150 nm. The terms “exosomes” and “sEVs” are often used interchangeably in the literature.</p><p>During pregnancy, EVs are actively released from diverse maternal and placental tissues, such as adipose tissue, liver, pancreas, skeletal muscle, and the placenta itself. Their concentration, composition, and functional characteristics undergo dynamic shifts in response to gestational age and maternal metabolic health. These regulated changes position EVs as promising candidate biomarkers for a range of pregnancy-related complications (<xref rid="B73" ref-type="bibr">Jayabalan et al., 2017</xref>; <xref rid="B61" ref-type="bibr">Hessvik and Llorente, 2018</xref>; <xref rid="B170" ref-type="bibr">Théry et al., 2018</xref>). In maternal-fetal communication, the placenta plays a pivotal “bidirectional regulatory” role: it not only actively releases EVs into both maternal and fetal circulations but also selectively internalizes maternally derived EVs, thereby mediating the transplacental transfer of maternal or exogenous vesicles into the fetal compartment (<xref rid="B31" ref-type="bibr">Chiarello et al., 2018</xref>; <xref rid="B18" ref-type="bibr">Buca et al., 2020</xref>; <xref rid="B125" ref-type="bibr">Paul et al., 2023</xref>). This unique property provides a structural basis for EV-mediated transmission of maternal metabolic signals to the fetus.</p><p>Previous studies have demonstrated that EVs themselves possess the capacity to regulate metabolic homeostasis. For example, EVs derived from human adipose tissue can induce insulin resistance in hepatocytes and skeletal muscle cells through modulation of the Akt signaling pathway (<xref rid="B82" ref-type="bibr">Kranendonk et al., 2014</xref>), suggesting that EVs may act as carriers of metabolic signals involved in systemic insulin sensitivity regulation. In the context of GDM, both the quantity and functional characteristics of EVs are markedly altered. Clinical studies have shown that during early pregnancy (11–14 weeks of gestation), plasma exosome concentrations in women who subsequently develop GDM are significantly elevated, reaching approximately twofold higher levels observed in normal pregnancies. Further <italic toggle="yes">in vitro</italic> experiments demonstrated that exosomes isolated from the peripheral blood of women with GDM exhibit clear biological activity, capable of inducing the release of pro-inflammatory cytokines from endothelial cells (<xref rid="B144" ref-type="bibr">Salomon et al., 2015</xref>). These findings suggest that, under GDM conditions, EVs may contribute to the amplification of inflammatory signaling, indirectly aggravate maternal insulin resistance, and thereby increase fetal exposure to a hyperglycemic environment.</p><p>In addition, a mechanistic study isolated sEVs from the plasma of healthy pregnant women and women with GDM at 24–28 weeks of gestation and intravenously injected them into late-gestation mice for four consecutive days. The results showed that sEVs derived from GDM pregnancies induced impaired glucose tolerance in pregnant mice, whereas sEVs from healthy pregnancies significantly enhanced glucose-stimulated insulin secretion in pancreatic cells, leading to elevated fasting insulin levels. Notably, this compensatory effect was absent in mice treated with GDM-derived sEVs (<xref rid="B69" ref-type="bibr">James-Allan et al., 2022</xref>). These findings indicate that sEVs may play a specific role in regulating maternal glucose metabolism during pregnancy, and that functional alterations in GDM-derived sEVs may contribute to the development of GDM and indirectly influence fetal growth through changes in the maternal metabolic environment.</p><p>Functionally, both animal and <italic toggle="yes">in vitro</italic> studies further support a potential role for EVs in regulating placental and fetal development. Compared with normal pregnancy, exosomes derived from the umbilical cord blood of GDM pregnancies induced abnormally enhanced placental vascularization in mouse models. This effect was likely associated with enrichment of specific exosomal proteins, particularly leucine-rich α-2 glycoprotein 1 and extracellular matrix protein 1, both of which are closely involved in angiogenic processes (<xref rid="B197" ref-type="bibr">Yao et al., 2023</xref>). These findings suggest that EVs may indirectly alter the fetal nutrient supply environment by modulating placental vascular remodeling.</p><p>Evidence linking EVs to fetal growth outcomes is also accumulating. Studies have shown that among EVs derived from adipose tissue in normal glucose tolerance and GDM groups, 54 miRNAs exhibit significant differential expression. EVs derived from the GDM group markedly promote glucose uptake in trophoblast cells, and further functional analyses revealed that miR-515-5p not only enhances glucose uptake but also suppresses abnormal increases in pro-inflammatory cytokine production in trophoblasts. Mechanistically, <italic toggle="yes">in vivo</italic> administration of EVs derived from normal glucose tolerance adipose tissue and loaded with miR-515-5p into pregnant mice was associated with fetal body weight and blood glucose levels (<xref rid="B74" ref-type="bibr">Jayabalan et al., 2025</xref>), suggesting that specific miRNAs may regulate fetal metabolism and growth through EV-mediated maternal-fetal communication.</p><p>Consistent with these experimental findings, human clinical studies have demonstrated that exosomes isolated from the umbilical cord blood of LGA born to mothers with GDM exhibit significant transcriptomic alterations. Differentially expressed genes were predominantly enriched in biological pathways closely related to growth and metabolism, including the PI3K/Akt signaling pathway, insulin resistance, glycerol metabolism, fatty acid degradation, and the mTOR signaling pathway. Further analysis of peripheral blood exosomes identified growth differentiation factor 3 and lncRNA <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AC006064.4">AC006064.4</ext-link> as potential predictive biomarkers. When assessed at 24–28 weeks of gestation and combined with maternal age, fasting plasma glucose, and 2-h postprandial glucose levels, these biomarkers demonstrated good predictive performance for the occurrence of LGA (<xref rid="B200" ref-type="bibr">Yuan et al., 2022</xref>). Collectively, these findings suggest that the molecular cargo carried by EVs not only reflects maternal metabolic status but may also integrate maternal metabolic signals with placental responses, dynamically contributing to regulatory networks underlying GDM-related fetal overgrowth.</p><p>Taken together, current evidence indicates that EVs involved in GDM-related fetal overgrowth are primarily derived from maternal peripheral blood and umbilical cord blood, with functional cargo dominated by non-coding RNAs and metabolism-related proteins. Functionally, these EVs may indirectly influence fetal growth trajectories by modulating maternal insulin sensitivity, placental vascular remodeling, and key metabolic signaling pathways. However, it should be noted that most studies on EVs remain exploratory, and direct causal evidence linking EVs to GDM-related fetal overgrowth is still limited. Moreover, confounding factors such as maternal BMI, inflammatory status, and gestational age, as well as methodological heterogeneity in EVs isolation and characterization, further constrain their clinical reproducibility as diagnostic or predictive tools. Therefore, although EVs represent a promising avenue for elucidating the mechanisms of GDM-related fetal overgrowth and developing potential biomarkers, their clinical application will require further standardization and rigorous functional validation.</p></sec></sec><sec id="s4"><label>4</label><title>Epigenetic modifications and long-term health risks in GDM-related fetal overgrowth</title><p>The Developmental Origins of Health and Disease (DOHaD) theory posits that exposure to environmental factors during early life, particularly within the intrauterine environment, can shape developmental trajectories and exert long-lasting effects on health outcomes and disease susceptibility later in life (<xref rid="B140" ref-type="bibr">Saffery and Novakovic, 2014</xref>). Early embryonic development is accompanied by extensive and dynamic epigenetic reprogramming (<xref rid="B20" ref-type="bibr">Cantone and Fisher, 2013</xref>); consequently, abnormal metabolic, inflammatory, and hormonal conditions during pregnancy may influence offspring physiological and metabolic phenotypes through intrauterine programming mechanisms (<xref rid="B16" ref-type="bibr">Barker, 1998</xref>; <xref rid="B52" ref-type="bibr">Fernandez-Twinn et al., 2019</xref>). Within this framework, the long-term impact of GDM on fetal development and offspring health has emerged as a major research focus, with accumulating evidence suggesting that its underlying mechanisms are closely linked to metabolic dysregulation and epigenetic alterations (<xref rid="B166" ref-type="bibr">Symonds et al., 2009</xref>).</p><p>Current research has gradually revealed that epigenetic mechanisms play a central role in the regulation of GDM-related fetal growth. Clinical studies have demonstrated that maternal hyperglycemic exposure can induce alterations in placental DNA methylation patterns (<xref rid="B22" ref-type="bibr">Cardenas et al., 2018</xref>), and that these changes are significantly associated with fetal birth weight (<xref rid="B86" ref-type="bibr">Küpers et al., 2019</xref>). Multiple investigations have further identified GDM-specific DNA methylation signatures and proposed their potential utility as molecular biomarkers for monitoring fetal growth status and for the early prediction of fetal overgrowth (<xref rid="B148" ref-type="bibr">Saucedo et al., 2024</xref>). Among these, PPARGC1α has received particular attention. This gene is a key regulator of brown and beige adipose tissue formation and function, and its aberrant methylation has been closely linked to fetal adipose tissue development. Evidence from placental tissues of GDM pregnancies indicates that maternal hyperglycemia is associated with altered PPARGC1α methylation, which may impair fetal adipose tissue development and promote excessive lipid accumulation in late gestation, thereby increasing the risk of neonatal obesity (<xref rid="B37" ref-type="bibr">Côté et al., 2016</xref>). Importantly, dynamic changes in PPARGC1α DNA methylation detected during early childhood have been shown to predict obesity trajectories during adolescence (<xref rid="B32" ref-type="bibr">Clarke-Harris et al., 2014</xref>), suggesting that these early epigenetic alterations are persistent and may represent a key mechanism underlying the elevated long-term metabolic risk observed in infants born LGA to mothers with GDM.</p><p>Beyond metabolic phenotypes, early abnormalities in the cardiovascular system have also been observed in LGA offspring of GDM pregnancies. Epidemiological studies have reported that LGA individuals exhibit a significantly elevated risk of developing CVD and metabolic syndrome (MetS) in adulthood (<xref rid="B17" ref-type="bibr">Boney et al., 2005</xref>; <xref rid="B51" ref-type="bibr">Evagelidou et al., 2010</xref>), although the biological mechanisms remain incompletely understood. Recent clinical evidence has provided novel insights into this association. Cord blood monocytes from neonates born to mothers with GDM display enhanced phagocytic activity and increased adhesive capacity-functional characteristics closely implicated in the pathogenesis of atherosclerosis. Transcriptomic analyses further revealed that CXCL8<sup>+</sup>IL1B<sup>+</sup> monocytes in cord blood from GDM-exposed neonates exhibit gene expression profiles highly similar to those of myeloid cells within coronary atherosclerotic plaques (<xref rid="B199" ref-type="bibr">Yin et al., 2024</xref>), suggesting that intrauterine hyperglycemic exposure may exert long-term effects on offspring cardiovascular health through immune-inflammatory programming. Consistent with these findings, clinical studies have demonstrated early cardiovascular structural remodeling in LGA infants, regardless of maternal GDM status, including increased abdominal aortic intima-media thickness and elevated left ventricular mass. Notably, these abnormalities are not transient but can persist into childhood, as evidenced by sustained carotid intima-media thickness thickening in LGA children aged 8–9 years (<xref rid="B3" ref-type="bibr">Akcakus et al., 2006</xref>; <xref rid="B198" ref-type="bibr">Yapicioglu et al., 2023</xref>). In parallel, lipid metabolic disturbances present at birth-characterized by elevated TC and low-density lipoprotein cholesterol levels-have been shown to persist through early childhood (3–6 years of age) (<xref rid="B92" ref-type="bibr">Lin et al., 2016</xref>). Supporting evidence from animal models further demonstrates that offspring of GDM-exposed dams develop insulin resistance and elevated levels of VLDL in adulthood (<xref rid="B110" ref-type="bibr">Merzouk et al., 2002</xref>). Importantly, aberrant DNA methylation of genes involved in cardiovascular function and lipid metabolism has been detected in the cord blood of LGA neonates (<xref rid="B92" ref-type="bibr">Lin et al., 2016</xref>), indicating that an adverse molecular foundation for cardiovascular health may already be established early in life.</p><p>Taken together, current evidence supports the notion that GDM-related fetal overgrowth and the associated increased risks of cardiovascular disease and metabolic syndrome are closely linked to early-life epigenetic reprogramming. Notably, this process does not appear to be entirely irreversible. Emerging data suggest that modifiable maternal exposures during pregnancy can influence fetal epigenetic states and thereby affect long-term metabolic health in offspring. For instance, maternal exercise interventions have been shown to induce DNA methylation changes in key metabolic regulatory genes, such as POFUT1 and MCEE, in maternal blood, changes that are associated with improved metabolic indicators in neonates (<xref rid="B192" ref-type="bibr">Yan J. et al., 2023</xref>). In addition, maternal dietary composition-particularly the intake of methyl-donor nutrients-has been identified as an important and modifiable determinant of fetal epigenetic patterns. Dietary folate and choline intake have been associated with improved insulin sensitivity and a reduced risk of fetal overgrowth, respectively (<xref rid="B14" ref-type="bibr">Bankole et al., 2022</xref>).</p><p>Overall, epigenetic markers represent a critical and potentially modifiable intermediary linking the intrauterine environment to fetal overgrowth and long-term health outcomes, rather than a fixed genetic endpoint. However, most existing evidence remains associative in nature, and causal relationships between specific epigenetic modifications and long-term metabolic or cardiovascular outcomes have yet to be firmly established. Future studies integrating longitudinal cohort designs, mechanistic experiments, and clinically relevant endpoints will be essential to identify which epigenetic changes are reversible, predictive, and amenable to targeted intervention.</p></sec><sec id="s5"><label>5</label><title>Prevention and management of GDM-related fetal overgrowth</title><sec id="s5-1"><label>5.1</label><title>Early screening and early intervention</title><p>Preventive medicine plays a crucial role in safeguarding the future health of populations. Therefore, the most effective strategy for managing GDM-related fetal overgrowth remains “early screening, early intervention, and early treatment”. Early fetal ultrasound monitoring has been shown to help reduce the incidence of adverse pregnancy outcomes (<xref rid="B7" ref-type="bibr">Antoniou et al., 2022</xref>). At 34 weeks of gestation, if ultrasound examination reveals a fetal abdominal fat layer (FFL) thickness greater than 0.48 cm in women with GDM, the relative risk of delivering a macrosomic infant increases significantly-more than doubling compared to women with FFL thickness ≤0.48 cm, where the incidence of macrosomia is only 16% (<xref rid="B50" ref-type="bibr">Elessawy et al., 2017</xref>). Compared with mothers of non-macrosomic pregnancies, GDM patients with macrosomic pregnancies exhibit significantly increased fetal anterior abdominal wall thickness (FAAWT) between 36 and 39 weeks of gestation. When a cutoff value of FAAWT &gt;6 mm is used for prediction, the sensitivity for detecting macrosomia reaches 87.5%, with a specificity of 75%, a positive predictive value of 40%, and a negative predictive value of 96.9% (<xref rid="B15" ref-type="bibr">Bansal et al., 2023</xref>). In 2020, a study first introduced the concept of combining symphysis-fundal height (SFH) and abdominal circumference (AC) to calculate the integrated symphysial fundal height-abdominal circumference (ISFHAC) index as a predictive indicator of pregnancy outcomes. ISFHAC demonstrates significant predictive value for both normal pregnancies and GDM pregnancies complicated by macrosomia. In GDM pregnancies, when the ISFHAC cutoff is set at 41.7, its sensitivity for predicting macrosomia reaches 75.9%, outperforming traditional indicators such as maternal body mass index, SFH or AC measured alone, and gestational age (<xref rid="B29" ref-type="bibr">Chen et al., 2020</xref>). Taken together, these ultrasound-derived markers provide clinically meaningful information for early identification of fetuses at increased risk of overgrowth in pregnancies complicated by GDM. Earlier detection of excessive fetal adiposity or accelerated growth trajectories allows clinicians to implement timely and targeted management strategies, including intensified glycemic monitoring, earlier initiation or adjustment of medical nutrition therapy, and, when necessary, initiation of pharmacological intervention. Such ultrasound-guided risk stratification supports a more individualized management approach, enabling clinicians to intervene before excessive fetal growth becomes established, rather than relying solely on late-gestational weight estimates or maternal metabolic indices. However, current evidence supporting the clinical utility of these ultrasound parameters is largely derived from observational studies, and their role in guiding specific therapeutic thresholds or intervention algorithms remains to be fully defined. Although these markers clearly enhance risk assessment and clinical vigilance, further prospective studies are needed to determine how their integration into routine GDM management can most effectively inform treatment intensity and timing, and to what extent such strategies translate into sustained improvements in perinatal outcomes.</p><p>GDM screening is typically conducted between weeks 24 and 28 of pregnancy (<xref rid="B194" ref-type="bibr">Yanachkova et al., 2022</xref>), but in pregnant women diagnosed with GDM, approximately 30%–70% may exhibit abnormal blood glucose elevation as early as before week 20 of pregnancy (<xref rid="B165" ref-type="bibr">Sweeting et al., 2024</xref>), suggesting that endocrine dysfunction may already be present in both the mother and fetus during early pregnancy. Although the typical clinical feature of GDM is glucose metabolism abnormalities that appear in the mid-to-late stages of pregnancy, some scholars have pointed out that before the clinical diagnosis of GDM is established, placental development may already be affected by abnormally elevated levels of insulin, IGF, and leptin (<xref rid="B132" ref-type="bibr">Qiu et al., 2005</xref>; <xref rid="B38" ref-type="bibr">D’Anna et al., 2007</xref>). Research indicates that weeks 12–14 of pregnancy may be a critical window period for increased placental sensitivity to maternal insulin, primarily due to high insulin receptor expression in STB cells during early pregnancy, which significantly decreases by term. In early pregnancy, maternal insulin secretion is closely associated with placental weight, which in turn is highly correlated with neonatal birth weight (<xref rid="B121" ref-type="bibr">O’Tierney-Ginn et al., 2015</xref>; <xref rid="B146" ref-type="bibr">Sathasivam et al., 2023</xref>). Research data indicate that compared to women diagnosed with GDM between 22 and 30 weeks of gestation, those diagnosed after 30 weeks have a significantly increased risk of delivering LGA infants (<xref rid="B133" ref-type="bibr">Regnault et al., 2024</xref>). Therefore, compared to interventions implemented in the late stages of pregnancy, initiating intervention protocols in the early stages of pregnancy can effectively reduce the incidence of neonatal hyperlipidemia, macrosomia, LGA, and SGA (<xref rid="B19" ref-type="bibr">Calancie et al., 2025</xref>). Overall, these findings suggest that metabolic dysregulation in GDM begins earlier than its conventional clinical diagnosis, with early pregnancy representing a critical window during which placental insulin sensitivity and endocrine signaling may already shape fetal growth trajectories. This temporal mismatch between early pathophysiology and mid-gestation screening underscores the potential value of earlier risk stratification and timely intervention to mitigate excessive fetal growth and adverse neonatal metabolic outcomes.</p></sec><sec id="s5-2"><label>5.2</label><title>Integrated management through diet and exercise</title><p>GDM-related fetal overgrowth is generally considered to occur within the broader context of impaired maternal metabolic homeostasis during pregnancy, rather than arising from isolated abnormalities in fetal growth signaling. Based on this understanding, clinical and translational studies increasingly recognize that interventions targeting GDM-related fetal overgrowth should not focus solely on glycemic control, but instead aim to improve the overall maternal metabolic environment during pregnancy. Accordingly, recent research has placed greater emphasis on modifiable maternal factors-particularly dietary patterns and lifestyle behaviors-as potential intervention targets for reducing the risk of fetal overgrowth in GDM pregnancies.</p><p>In recent years, an integrated management model known as the 1-day care clinic has been widely established and implemented worldwide (<xref rid="B183" ref-type="bibr">Wang et al., 2022</xref>). Unlike conventional management strategies that primarily focus on glycemic monitoring and individualized follow-up, the 1-day care clinic integrates structured nutritional education, standardized exercise guidance, and scenario-based practical training to enhance pregnant women’s understanding of dietary composition, energy distribution, and appropriate physical activity, while also improving their awareness of GDM-related maternal and neonatal risks. This comprehensive approach facilitates more effective adherence to medical advice and sustained self-management, thereby contributing to improved gestational weight control and mitigation of metabolic disturbances. Clinical studies have demonstrated that this integrated management model not only reduces fasting blood glucose, postprandial glucose, and HbA1c levels, but, importantly, is also associated with a significant reduction in the incidence of macrosomia. These findings suggest that behavior-centered, structured management strategies are both feasible and clinically valuable for reducing the risk of GDM-related fetal overgrowth (<xref rid="B21" ref-type="bibr">Cao et al., 2021</xref>; <xref rid="B183" ref-type="bibr">Wang et al., 2022</xref>; <xref rid="B190" ref-type="bibr">Xu et al., 2025</xref>). Recent studies have shown that the DASH diet has demonstrated significant benefits for weight control and body fat improvement, making it a potential nutritional intervention strategy for GDM. It emphasizes a diet rich in fruits, vegetables, and low-fat dairy products while reducing the intake of saturated fats and total fats (<xref rid="B158" ref-type="bibr">Soltani et al., 2016</xref>). In a recent meta-analysis, 2, 712 pregnant women participated in a randomized controlled trial, indicating that the DASH diet significantly reduced fasting blood glucose and 2hPG levels. In terms of reducing the incidence of macrosomia, the DASH diet not only outperformed the control group but also outperformed the high-fiber diet, antioxidant-enriched diet, and structured exercise groups (<xref rid="B205" ref-type="bibr">Zhang L. et al., 2024</xref>). These findings indicate that the DASH diet represents a highly promising intervention for improving pregnancy outcomes in women with GDM. Such evidence provides practical support for the feasibility of reducing the risk of GDM-related fetal overgrowth through dietary modification and behavioral interventions that improve the maternal metabolic environment. However, it is important to note that current evidence mainly originates from observational studies or integrated intervention trials, making it difficult to disentangle the independent effects of individual intervention components. Moreover, the specific biological mechanisms by which these interventions influence placental function and fetal growth regulation remain to be further elucidated.</p><p>Gestational insulin resistance primarily occurs at the skeletal muscle level, and prenatal exercise interventions-particularly those engaging large muscle groups-can enhance maternal glucose metabolism and improve insulin sensitivity. These physiological benefits contribute to the prevention of GDM, as well as prenatal anxiety and depression, and excessive gestational weight gain (<xref rid="B116" ref-type="bibr">Mottola and Artal, 2016</xref>; <xref rid="B135" ref-type="bibr">Ribeiro et al., 2022</xref>). Numerous studies have demonstrated that regular physical activity provides clear clinical benefits for women with GDM. The currently recommended exercise regimens for GDM patients mainly include two types: aerobic exercise and resistance training (<xref rid="B157" ref-type="bibr">Sklempe Kokic et al., 2018</xref>; <xref rid="B75" ref-type="bibr">Jin et al., 2022</xref>). Research has shown that prenatal exercise interventions can significantly reduce placental expression levels of GLUT-1 in GDM patients, thereby effectively mitigating the adverse developmental effects of GDM on the offspring’s heart, liver, and kidneys (<xref rid="B168" ref-type="bibr">Tang et al., 2024</xref>). Animal studies have further confirmed that exercise during pregnancy can ameliorate metabolic disturbances in GDM mice, increase pancreatic β-cell mass, and help maintain intestinal microbiota homeostasis (<xref rid="B106" ref-type="bibr">Mahizir et al., 2020</xref>). Exercise interventions have also been found to significantly lower the risk of macrosomia in offspring of GDM mothers. Compared with diet management alone, a combination of exercise and dietary intervention is more effective in reducing the incidence of macrosomia among GDM pregnancies (<xref rid="B180" ref-type="bibr">Wang et al., 2015</xref>). Importantly, while prenatal exercise effectively reduces the risk of LGA and macrosomia, it does not elevate the risk of SGA births. Moreover, maternal exercise during pregnancy contributes to long-term protection against chronic metabolic diseases in offspring (<xref rid="B175" ref-type="bibr">Vargas-Terrones et al., 2019</xref>). Therefore, regular exercise, as a fundamental intervention in GDM management, holds significant clinical value in improving both maternal and neonatal outcomes. However, many pregnant women still struggle to maintain consistent exercise routines. Thus, clinical practice should prioritize education and promotion efforts to encourage adherence to prenatal exercise interventions. Current evidence supports prenatal physical activity as an important lifestyle intervention for reducing the risk of fetal overgrowth in pregnancies complicated by GDM. Regular exercise may improve maternal insulin sensitivity and overall metabolic status, thereby indirectly modulating the intrauterine nutritional environment and associating with lower rates of macrosomia and LGA. Compared with dietary intervention alone, combined exercise and dietary management appears to confer more consistent benefits in limiting excessive fetal growth. However, the implementation of exercise interventions in clinical practice remains challenged by suboptimal adherence and heterogeneity in exercise protocols. The optimal type, intensity, and duration of exercise, as well as their differential effects across maternal metabolic backgrounds, require further clarification through larger and more standardized studies.</p></sec><sec id="s5-3"><label>5.3</label><title>Future therapeutic perspectives and translational implications</title><p>Current clinical screening and management of GDM are primarily guided by international recommendations issued by the International Association of Diabetes and Pregnancy Study Groups (IADPSG), the American Diabetes Association (ADA), and the National Institute for Health and Care Excellence (NICE). These guidelines advocate a stepwise, glucose-centered management paradigm, beginning with lifestyle modification and escalating to pharmacological therapy when glycemic targets are not achieved (<xref rid="B111" ref-type="bibr">Metzger et al., 2008</xref>; <xref rid="B112" ref-type="bibr">Metzger et al., 2010</xref>; <xref rid="B119" ref-type="bibr">National Institute for Health and Care Excellence, 2018</xref>; <xref rid="B6" ref-type="bibr">American Diabetes Association Professional Practice Committee, 2024</xref>). While such approaches effectively reduce maternal hyperglycemia, growing clinical evidence indicates that fetal overgrowth-manifesting as macrosomia or LGA-remains common even in pregnancies with apparently well-controlled maternal glucose levels (<xref rid="B103" ref-type="bibr">Mackin et al., 2018</xref>; <xref rid="B59" ref-type="bibr">He et al., 2023</xref>). This observation underscores a critical limitation of glucose-focused management and suggests that mechanisms beyond maternal glycemia, particularly placental metabolic dysregulation and vascular dysfunction, play a decisive role in driving excessive maternofetal nutrient transfer and abnormal fetal growth.</p><p>Within current guidelines, insulin is regarded as the first-line pharmacological therapy for GDM due to its lack of placental transfer. However, barriers related to injection burden, cost, and treatment adherence have prompted continued interest in oral antihyperglycemic agents. Among these, metformin has attracted particular attention not merely for its glucose-lowering efficacy, but for its reproducible association with reduced rates of fetal overgrowth and neonatal hypoglycemia in GDM pregnancies (<xref rid="B143" ref-type="bibr">Salomäki et al., 2013</xref>; <xref rid="B5" ref-type="bibr">Alfadhli, 2015</xref>). Importantly, these clinical benefits often appear disproportionate to improvements in maternal glycemic indices, implying that metformin may exert additional effects through direct modulation of placental function and maternofetal nutrient transport. Nevertheless, because metformin readily crosses the placenta, concerns regarding potential long-term metabolic programming effects in offspring remain unresolved, highlighting the need for careful benefit-risk assessment and patient stratification when prevention of fetal overgrowth is the primary therapeutic objective.</p><p>In this context, emerging therapeutic frameworks are increasingly shifting from exclusive normalization of maternal glucose levels toward mechanism-based interventions that directly target placental dysfunction as a strategy to restrain excessive fetal growth. Beyond its systemic metabolic effects, metformin activates AMPK and suppresses placental mTOR signaling, resulting in downregulation of glucose and amino acid transporters, attenuation of placental inflammation, and limitation of excessive nutrient flux to the fetus-mechanistic actions that closely align with its clinically observed reduction in macrosomia risk (<xref rid="B128" ref-type="bibr">Pérez-Pérez et al., 2008</xref>; <xref rid="B67" ref-type="bibr">Hung et al., 2021</xref>). Concurrently, placental vascular dysfunction and chronic inflammation represent additional, glucose-independent drivers of fetal overgrowth. Hydrophilic statins with low placental permeability, such as pravastatin, have been shown to improve placental endothelial function, restore angiogenic balance, and dampen inflammatory signaling, thereby offering a potential vascular-targeted approach to modulating abnormal fetal growth (<xref rid="B36" ref-type="bibr">Costantine et al., 2016</xref>; <xref rid="B88" ref-type="bibr">Lefkou et al., 2016</xref>; <xref rid="B2" ref-type="bibr">Ahmed et al., 2020</xref>), although direct clinical evidence in GDM remains limited.</p><p>Future therapeutic frameworks should shift toward stratified, mechanism-based precision intervention. For patients who already exhibit placental metabolic hyperactivity or abnormal activation of the mTOR pathway, adjunctive use of placental-modulating agents such as metformin may be considered after comprehensive risk assessment. For patients presenting predominantly with vascular endothelial dysfunction and chronic inflammation, low-dose pravastatin and other vascular-targeted drugs may hold greater therapeutic potential. The successful implementation of such strategies requires establishing a biomarker system for early detection of placental dysfunction, including ultrasound Doppler assessment of placental blood flow and analysis of placenta-specific metabolites via omics technologies, as well as conducting prospective clinical trials with placental function as a core endpoint. Ultimately, building an integrated management model that combines glycemic control, targeted placental modulation, and fetal growth monitoring is expected to more effectively prevent GDM-related fetal overgrowth and may positively influence the long-term health of offspring by improving the intrauterine metabolic environment. Recent and ongoing clinical trials evaluating such stratified approaches are summarized in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Registered clinical trials related to GDM and macrosomia (last 5 years).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Scientific title</th><th align="left" rowspan="1" colspan="1">Study type/Model</th><th align="left" rowspan="1" colspan="1">Study start</th><th align="left" rowspan="1" colspan="1">Target sample size</th><th align="left" rowspan="1" colspan="1">Interventions</th><th align="left" rowspan="1" colspan="1">Outcome evaluation method</th><th align="left" rowspan="1" colspan="1">Registration number</th><th align="left" rowspan="1" colspan="1">Additional information</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Preventive effect of probiotics in GDM</td><td align="left" rowspan="1" colspan="1">Interventional (Randomized clinical trial)</td><td align="left" rowspan="1" colspan="1">2023-10-27</td><td align="left" rowspan="1" colspan="1">334</td><td align="left" rowspan="1" colspan="1">Intervention group: 1 bag of probiotics powder per day<break/>Control group: Placebo 1 bag per day</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: Perform an OGTT at weeks 24–28 of gestation and record perinatal results regarding newborn weight<break/>Secondary outcome measures: The incidence of macrosomia</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06938464">NCT06938464</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Intervention from 12–16 weeks until OGTT at 24–28 weeks<break/>Outcome definition (Macrosomia): Newborn weight &gt;4 kg<break/>Status: Ongoing</td></tr><tr><td align="left" rowspan="1" colspan="1">Influence of triglyceride-glucose (TyG) index and TG/HDL-C ratio on fetal macrosomia</td><td align="left" rowspan="1" colspan="1">Observational Model (Case-Control)</td><td align="left" rowspan="1" colspan="1">2023-01-01</td><td align="left" rowspan="1" colspan="1">302</td><td align="left" rowspan="1" colspan="1">Blood samples were collected from pregnant women in the study and control group between the 28th and 40th weeks of pregnancy</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: The TyG index; The triglyceride to high density lipoprotein cholesterol ratio<break/>Secondary outcome measures: HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06463990">NCT06463990</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Blood collection: 28–40 weeks of pregnancy<break/>Outcome definition (Macrosomia): Per study protocol.: Not specified<break/>Status: Completion</td></tr><tr><td align="left" rowspan="1" colspan="1">Timing of ambulation and infant birth weight in gestational diabetes</td><td align="left" rowspan="1" colspan="1">Interventional (Randomized clinical trial)</td><td align="left" rowspan="1" colspan="1">2022-10-01</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">Experimental group: Participants will be counseled to either complete 20 min of walking after meals<break/>No Intervention group: Participants will be counseled with routine exercise counseling of 30 min of low-impact 5x a week</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: Infant birthweight percentile<break/>Secondary outcome measures: infant birthweight, mode of delivery, fetal macrosomia, neonatal hypoglycemia treatment</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06157684">NCT06157684</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Intervention after GDM diagnosis until delivery<break/>Outcome definition (Macrosomia): Per study protocol<break/>Status: Completion</td></tr><tr><td align="left" rowspan="1" colspan="1">The efficacy of fetal arterial and venous doppler indices in predicting perinatal outcome</td><td align="left" rowspan="1" colspan="1">Observational Model (Case-Crossover)</td><td align="left" rowspan="1" colspan="1">2022-06-15</td><td align="left" rowspan="1" colspan="1">140</td><td align="left" rowspan="1" colspan="1">Diagnostic Test: Fasting blood sugar, 2 h postprandial, HbA1c, Ultrasound and Doppler study</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: The diagnostic value of umbilical artery (UA) Doppler indices and middle cerebral artery (MCA) Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients<break/>Secondary outcome measures: The diagnostic value of cerebroplacental ratio (CPR) and ductus venosus Doppler indices in predicting adverse perinatal outcome among diabetic pregnant patients</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05410080">NCT05410080</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Doppler study within 24 h before pregnancy termination (34–39 weeks)<break/>Outcome definition (Macrosomia): Birth weight &gt;90th percentile for gestational age<break/>Status: Completion</td></tr><tr><td align="left" rowspan="1" colspan="1">The study of biomarker in early diagnosis of GDM by metabolomics</td><td align="left" rowspan="1" colspan="1">Observational Model (Cohort)</td><td align="left" rowspan="1" colspan="1">2022-05-04</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">All subjects had a 5 mL blood sample collected from each subject at each of four time points during pregnancy (6–13 weeks, 24–28 weeks, 36 weeks prior to delivery, and 6 weeks post-delivery)</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: The OGTT test (75 g glucose) was performed between 24 and 28 weeks of gestation</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05733195">NCT05733195</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Blood collection: 6–13 weeks, 24–28 weeks, 36 weeks (pre-delivery), 6 weeks (postpartum)<break/>Outcome definition (Macrosomia): Listed as a GDM-related risk<break/>Status: Completion</td></tr><tr><td align="left" rowspan="1" colspan="1">Strict versus permissive thresholds for initiation of pharmacotherapy in gestational diabetes (START 2)</td><td align="left" rowspan="1" colspan="1">Interventional (Randomized clinical trial)</td><td align="left" rowspan="1" colspan="1">2024-09-01</td><td align="left" rowspan="1" colspan="1">430</td><td align="left" rowspan="1" colspan="1">Drug: Insulin; Strict threshold (two abnormal values or more over a 1-week period) vs. Permissive threshold (50% of values elevated over 1 week)</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: Neonatal composite, including: LGA of neonate defined as birth weight &gt;90th percentile for gestational age using the Fenton growth chart, hypoglycemia, hyperbilirubinemia, stillbirth or neonatal death, birth trauma<break/>Secondary outcome measures: Gestational Age of Birth, APGAR Score, Brachial Plexus Injury, Respiratory distress, Maternal hypoglycemia, Shoulder Dystocia, Obstetric anal sphincter injury (OASIS), Cesarean Delivery, Postpartum hemorrhage, etc.</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06419803">NCT06419803</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Intervention after GDM diagnosis until delivery<break/>Outcome definition (Macrosomia/LGA): Birth weight &gt;90th percentile for gestational age<break/>Status: Ongoing</td></tr><tr><td align="left" rowspan="1" colspan="1">D-chiro inositol in prevention of gestational diabetes mellitus in China</td><td align="left" rowspan="1" colspan="1">Interventional (Randomized clinical trial)</td><td align="left" rowspan="1" colspan="1">2021-01-01</td><td align="left" rowspan="1" colspan="1">291</td><td align="left" rowspan="1" colspan="1">Active comparator: D-chiro inositol 500 mg twice a day<break/>Placebo comparator: Placebo (similar appearance but not containing myo-inositol) 500 mg twice a day</td><td align="left" rowspan="1" colspan="1">Primary outcome measures: The number of cases and incidence of GDM according to OGTT.<break/>Secondary outcome measures: The incidence of macrosomia (macrosomia refers to a newborn weigh more than 4 kg), weight gain during pregnancy, the Caesarean-section incidence</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04801485">NCT04801485</ext-link></td><td align="left" rowspan="1" colspan="1">Gestational time points: Intervention from 12–16 weeks until OGTT at 24–28 weeks<break/>Outcome definition (Macrosomia): Newborn weighs more than 4 kg<break/>Status: Completion</td></tr></tbody></table></table-wrap></sec></sec><sec id="s6"><label>6</label><title>Summary and outlook</title><p>As discussed above, the pathogenesis of GDM-related fetal overgrowth involves multiple interconnected pathophysiological mechanisms. Current research has identified several key components of this process, including enhanced placental nutrient transport and aberrant activation of fetal growth-related signaling pathways, such as the IGF and mTOR pathways. In addition to these classical mechanisms, accumulating evidence indicates that pathological changes-such as abnormal placental angiogenesis, and imbalances in trophoblast cell proliferation and apoptosis-also contribute to fetal overgrowth. Recent advances have further expanded the traditional understanding of this condition, confirming that gut microbiota dysbiosis and EVs-mediated intercellular communication also play significant roles. However, important scientific questions such as how these newly discovered factors interact with classical mechanisms and whether cascade amplification effects exist across systems remain to be further explored. Additionally, epigenetic studies provide new perspectives for understanding the long-term health impacts of macrosomia, suggesting that intrauterine hyperglycemia exposure may be associated with an increased risk of CVD and MetS in adulthood (<xref rid="B92" ref-type="bibr">Lin et al., 2016</xref>; <xref rid="B169" ref-type="bibr">Taschereau et al., 2023</xref>). Recent studies also indicate that intrauterine hyperglycemia leads to reduced fetal fertility and affects fetal sexual differentiation through epigenetic reprogramming (<xref rid="B34" ref-type="bibr">Cong et al., 2025</xref>). However, there is currently no definitive research demonstrating whether GDM-related fetal overgrowth exhibits gender-specific differences or a decline in reproductive capacity. Due to the need for long-term follow-up observations in such studies, the available evidence remains limited. On the other hand, animal models of GDM have relatively homogeneous genetic backgrounds, whereas humans possess highly diverse genetic profiles. It is challenging to replicate the complex genetic background and gene-environment interactions of humans in animal models, which limits the translation of research findings into clinical practice. Nevertheless, in-depth exploration of the transgenerational epigenetic effects of GDM on offspring health holds profound scientific value and clinical significance.</p><p>In clinical practice, early screening and dynamic monitoring of GDM are emphasized as essential strategies. Ultrasonic indicators (such as FFL thickness and ISFHAC) provide crucial evidence for assessing fetal growth trends. Regarding interventions, lifestyle modifications (such as the DASH diet and physical activity during pregnancy) have demonstrated potential in reducing the risk of fetal overgrowth by regulating glucose and lipid metabolism and improving placental function. In the field of pharmacotherapy, metformin has shown promise due to its unique role in enhancing insulin sensitivity and its clinical evidence supporting reductions in the risks of macrosomia and LGA infants. As such, metformin represents a viable alternative to insulin therapy (<xref rid="B58" ref-type="bibr">Guo et al., 2019</xref>; <xref rid="B80" ref-type="bibr">Kirovakov et al., 2024</xref>). Furthermore, mechanism-based intervention strategies offer promising avenues for advancing precision medicine in the management of GDM, although their safety and efficacy require further research validation before widespread clinical application.</p><p>However, the clinical management of GDM still faces significant challenges. Although blood glucose-based interventions have led to notable improvements in maternal metabolic parameters, the incidence of fetal overgrowth remains high, highlighting the limitations of current treatment strategies. This situation arises primarily from two interrelated issues. First, many studies have overly focused on blood glucose control as a singular factor, neglecting the fact that GDM-related fetal overgrowth is a multifactorial pathological process. Contributing factors include maternal pre-pregnancy overweight or obesity, advanced maternal age, and mental health issues during pregnancy (<xref rid="B122" ref-type="bibr">OuYang et al., 2021</xref>; <xref rid="B160" ref-type="bibr">Song et al., 2022</xref>; <xref rid="B206" ref-type="bibr">Zhang T. et al., 2024</xref>)-all of which significantly elevate the risk of fetal overgrowth. Second, fetal overgrowth remains under-prioritized as an adverse clinical outcome in routine clinical practice. To address these challenges, future research must transition from a unidimensional focus on glycemic control to a more comprehensive, integrated approach that considers multiple dimensions, including maternal metabolic status, placental function regulation, and fetal growth signaling pathways. Such a multidisciplinary strategy holds the potential to enable the development of more targeted and effective interventions, ultimately achieving improved outcomes for both mothers and their fetuses.</p></sec></body><back><fn-group><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1093037/overview" ext-link-type="uri">Satoshi Kishigami</ext-link>, University of Yamanashi, Japan</p></fn><fn fn-type="reviewed-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3016805/overview" ext-link-type="uri">Daniel Osmar Suárez Rico</ext-link>, University of Guadalajara, Mexico</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3329458/overview" ext-link-type="uri">Keisuke Nakajima</ext-link>, The University of Tokyo, Japan</p></fn></fn-group><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>XJ: Visualization, Writing – original draft, Writing – review and editing. DC: Investigation, Validation, Visualization, Writing – review and editing. TD: Investigation, Visualization, Writing – original draft. JZ: Funding acquisition, Project administration, Writing – review and editing. YR: Funding acquisition, Project administration, Writing – review and editing. JT: Funding acquisition, Project administration, Writing – original draft.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Aguilera-Olguín</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Leiva</surname><given-names>A.</given-names></name>
</person-group> (<year>2022</year>). <article-title>The LDL receptor: traffic and function in trophoblast cells under normal and pathological conditions</article-title>. <source>Placenta</source>
<volume>127</volume>, <fpage>12</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2022.07.013</pub-id>
<pub-id pub-id-type="pmid">35926304</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Williams</surname><given-names>D. J.</given-names></name>
<name name-style="western"><surname>Cheed</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Middleton</surname><given-names>L. J.</given-names></name>
<name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial</article-title>. <source>BJOG</source>
<volume>127</volume> (<issue>4</issue>), <fpage>478</fpage>–<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1111/1471-0528.16013</pub-id>
<pub-id pub-id-type="pmid">31715077</pub-id>
<pub-id pub-id-type="pmcid">PMC7063986</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Akcakus</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Koklu</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Baykan</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Yikilmaz</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Coskun</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Gunes</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Macrosomic newborns of diabetic mothers are associated with increased aortic intima-media thickness and lipid concentrations</article-title>. <source>Hormone Res.</source>
<volume>67</volume> (<issue>6</issue>), <fpage>277</fpage>–<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1159/000098157</pub-id>
<pub-id pub-id-type="pmid">17191031</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Albuayjan</surname><given-names>H. H. H.</given-names></name>
<name name-style="western"><surname>Watanabe</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Sugawara</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Katsuyama</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Mise</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Oi</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Role of galectin-9 in the development of gestational diabetes mellitus</article-title>. <source>Sci. Rep.</source>
<volume>15</volume> (<issue>1</issue>), <fpage>18981</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-025-03879-8</pub-id>
<pub-id pub-id-type="pmid">40447728</pub-id>
<pub-id pub-id-type="pmcid">PMC12125262</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Alfadhli</surname><given-names>E. M.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Gestational diabetes mellitus</article-title>. <source>Saudi Med. J.</source>
<volume>36</volume> (<issue>4</issue>), <fpage>399</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.15537/smj.2015.4.10307</pub-id>
<pub-id pub-id-type="pmid">25828275</pub-id>
<pub-id pub-id-type="pmcid">PMC4404472</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<collab>American Diabetes Association Professional Practice Committee</collab> (<year>2024</year>). <article-title>15. Management of diabetes in pregnancy: standards of care in Diabetes-2024</article-title>. <source>Diabetes Care</source>
<volume>47</volume> (<issue>Suppl. 1</issue>), <fpage>S282</fpage>–<lpage>S294</lpage>. <pub-id pub-id-type="doi">10.2337/dc24-S015</pub-id>
<pub-id pub-id-type="pmid">38078583</pub-id>
<pub-id pub-id-type="pmcid">PMC10725801</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Antoniou</surname><given-names>M. C.</given-names></name>
<name name-style="western"><surname>Gilbert</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Gross</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Rossel</surname><given-names>J. B.</given-names></name>
<name name-style="western"><surname>Fumeaux</surname><given-names>C. J. F.</given-names></name>
<name name-style="western"><surname>Vial</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Sex-dependent influence of maternal predictors on fetal anthropometry in pregnancies with gestational diabetes mellitus</article-title>. <source>BMC Pregnancy Childbirth</source>
<volume>22</volume> (<issue>1</issue>), <fpage>460</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-022-04767-z</pub-id>
<pub-id pub-id-type="pmid">35650561</pub-id>
<pub-id pub-id-type="pmcid">PMC9158189</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Artico</surname><given-names>L. L.</given-names></name>
<name name-style="western"><surname>Laranjeira</surname><given-names>A. B. A.</given-names></name>
<name name-style="western"><surname>Campos</surname><given-names>L. W.</given-names></name>
<name name-style="western"><surname>Corrêa</surname><given-names>J. R.</given-names></name>
<name name-style="western"><surname>Zenatti</surname><given-names>P. P.</given-names></name>
<name name-style="western"><surname>Carvalheira</surname><given-names>J. B. C.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia</article-title>. <source>Blood Adv.</source>
<volume>5</volume> (<issue>18</issue>), <fpage>3633</fpage>–<lpage>3646</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2020003627</pub-id>
<pub-id pub-id-type="pmid">34438446</pub-id>
<pub-id pub-id-type="pmcid">PMC8945593</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Atallah</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Gindlhuber</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Platzer</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Bärnthaler</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tatzl</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Toller</surname><given-names>W.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>SUCNR1 is expressed in human placenta and mediates angiogenesis: significance in gestational diabetes</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume> (<issue>21</issue>), <fpage>12048</fpage>. <pub-id pub-id-type="doi">10.3390/ijms222112048</pub-id>
<pub-id pub-id-type="pmid">34769478</pub-id>
<pub-id pub-id-type="pmcid">PMC8585094</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Babawale</surname><given-names>M. O.</given-names></name>
<name name-style="western"><surname>Lovat</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mayhew</surname><given-names>T. M.</given-names></name>
<name name-style="western"><surname>Lammiman</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>James</surname><given-names>D. K.</given-names></name>
<name name-style="western"><surname>Leach</surname><given-names>L.</given-names></name>
</person-group> (<year>2000</year>). <article-title>Effects of gestational diabetes on junctional adhesion molecules in human term placental vasculature</article-title>. <source>Diabetologia</source>
<volume>43</volume> (<issue>9</issue>), <fpage>1185</fpage>–<lpage>1196</lpage>. <pub-id pub-id-type="doi">10.1007/s001250051511</pub-id>
<pub-id pub-id-type="pmid">11043866</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bach</surname><given-names>L. A.</given-names></name>
</person-group> (<year>2018</year>). <article-title>IGF-binding proteins</article-title>. <source>J. Mol. Endocrinol.</source>
<volume>61</volume> (<issue>1</issue>), <fpage>T11</fpage>–<lpage>t28</lpage>. <pub-id pub-id-type="doi">10.1530/jme-17-0254</pub-id>
<pub-id pub-id-type="pmid">29255001</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Balachandiran</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bobby</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Dorairajan</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Gladwin</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Vinayagam</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Packirisamy</surname><given-names>R. M.</given-names></name>
</person-group> (<year>2021a</year>). <article-title>Decreased maternal serum adiponectin and increased insulin-like growth factor-1 levels along with increased placental glucose transporter-1 expression in gestational diabetes mellitus: possible role in fetal overgrowth</article-title>. <source>Placenta</source>
<volume>104</volume>, <fpage>71</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2020.11.008</pub-id>
<pub-id pub-id-type="pmid">33285436</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Balachandiran</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bobby</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Dorairajan</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Jacob</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Gladwin</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Vinayagam</surname><given-names>V.</given-names></name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Placental accumulation of triacylglycerols in gestational diabetes mellitus and its association with altered fetal growth are related to the differential expressions of proteins of lipid metabolism</article-title>. <source>Exp. Clin. Endocrinol. Diabetes</source>
<volume>129</volume> (<issue>11</issue>), <fpage>803</fpage>–<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1055/a-1017-3182</pub-id>
<pub-id pub-id-type="pmid">31968385</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bankole</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Winn</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Dietary impacts on gestational diabetes: connection between gut microbiome and epigenetic mechanisms</article-title>. <source>Nutrients</source>
<volume>14</volume> (<issue>24</issue>), <fpage>5269</fpage>. <pub-id pub-id-type="doi">10.3390/nu14245269</pub-id>
<pub-id pub-id-type="pmid">36558427</pub-id>
<pub-id pub-id-type="pmcid">PMC9786016</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bansal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Thukral</surname><given-names>B. B.</given-names></name>
<name name-style="western"><surname>Bagri</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Kanwar</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Khandelwal</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bajaj</surname><given-names>B.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Correlation of fetal anterior abdominal wall thickness and other standard biometric ultrasound measurements to predict fetal macrosomia in gestational diabetes</article-title>. <source>J. Med. Ultrasound</source>
<volume>31</volume> (<issue>1</issue>), <fpage>29</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.4103/jmu.Jmu_57_21</pub-id>
<pub-id pub-id-type="pmid">37180617</pub-id>
<pub-id pub-id-type="pmcid">PMC10173829</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Barker</surname><given-names>D. J.</given-names></name>
</person-group> (<year>1998</year>). <article-title>In utero programming of chronic disease</article-title>. <source>Clin. Sci. (Lond)</source>
<volume>95</volume> (<issue>2</issue>), <fpage>115</fpage>–<lpage>128</lpage>.
<pub-id pub-id-type="pmid">9680492</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Boney</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Tucker</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Vohr</surname><given-names>B. R.</given-names></name>
</person-group> (<year>2005</year>). <article-title>Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus</article-title>. <source>Pediatrics</source>
<volume>115</volume> (<issue>3</issue>), <fpage>e290</fpage>–<lpage>e296</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2004-1808</pub-id>
<pub-id pub-id-type="pmid">15741354</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Buca</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Bologna</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>D’Amico</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Cugini</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Musca</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Febbo</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Extracellular vesicles in feto-maternal crosstalk and pregnancy disorders</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume> (<issue>6</issue>). <pub-id pub-id-type="doi">10.3390/ijms21062120</pub-id>
<pub-id pub-id-type="pmcid">PMC7139847</pub-id><pub-id pub-id-type="pmid">32204473</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Calancie</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>M. O.</given-names></name>
<name name-style="western"><surname>Choi</surname><given-names>W. A.</given-names></name>
<name name-style="western"><surname>Caouette</surname><given-names>J. L.</given-names></name>
<name name-style="western"><surname>McCann</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Nam</surname><given-names>E. Y.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Systematic review of interventions in early pregnancy among pregnant individuals at risk for hyperglycemia</article-title>. <source>Am. J. Obstet. Gynecol. MFM</source>
<volume>7</volume> (<issue>3</issue>), <fpage>101606</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajogmf.2025.101606</pub-id>
<pub-id pub-id-type="pmid">39788428</pub-id>
<pub-id pub-id-type="pmcid">PMC11885049</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cantone</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Fisher</surname><given-names>A. G.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Epigenetic programming and reprogramming during development</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>20</volume> (<issue>3</issue>), <fpage>282</fpage>–<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.2489</pub-id>
<pub-id pub-id-type="pmid">23463313</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cao</surname><given-names>Y. M.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>N. N.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The impact of the one-day clinic diabetes mellitus management model on perinatal outcomes in patients with gestational diabetes mellitus</article-title>. <source>Diabetes Metab. Syndr. Obes.</source>
<volume>14</volume>, <fpage>3533</fpage>–<lpage>3540</lpage>. <pub-id pub-id-type="doi">10.2147/dmso.S316878</pub-id>
<pub-id pub-id-type="pmid">34385828</pub-id>
<pub-id pub-id-type="pmcid">PMC8354338</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cardenas</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Gagné-Ouellet</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Allard</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Brisson</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Perron</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Bouchard</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Placental DNA methylation adaptation to maternal glycemic response in pregnancy</article-title>. <source>Diabetes</source>
<volume>67</volume> (<issue>8</issue>), <fpage>1673</fpage>–<lpage>1683</lpage>. <pub-id pub-id-type="doi">10.2337/db18-0123</pub-id>
<pub-id pub-id-type="pmid">29752424</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Castillo-Castrejon</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
</person-group> (<year>2019</year>). <article-title>No evidence of attenuation of placental insulin-stimulated Akt phosphorylation and amino acid transport in maternal obesity and gestational diabetes mellitus</article-title>. <source>Am. J. Physiol. Endocrinol. Metab.</source>
<volume>317</volume> (<issue>6</issue>), <fpage>E1037</fpage>–<lpage>e1049</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00196.2019</pub-id>
<pub-id pub-id-type="pmid">31573844</pub-id>
<pub-id pub-id-type="pmcid">PMC6962503</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Catalano</surname><given-names>P. M.</given-names></name>
<name name-style="western"><surname>Shankar</surname><given-names>K.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child</article-title>. <source>BMJ</source>
<volume>356</volume>, <fpage>j1</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.j1</pub-id>
<pub-id pub-id-type="pmid">28179267</pub-id>
<pub-id pub-id-type="pmcid">PMC6888512</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chagovets</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Frankevich</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Starodubtseva</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Tokareva</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Derbentseva</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Yuryev</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Early prediction of fetal macrosomia through maternal lipid profiles</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>26</volume> (<issue>3</issue>), <fpage>1149</fpage>. <pub-id pub-id-type="doi">10.3390/ijms26031149</pub-id>
<pub-id pub-id-type="pmid">39940917</pub-id>
<pub-id pub-id-type="pmcid">PMC11818448</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chassen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Complex, coordinated and highly regulated changes in placental signaling and nutrient transport capacity in IUGR</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source>
<volume>1866</volume> (<issue>2</issue>), <fpage>165373</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2018.12.024</pub-id>
<pub-id pub-id-type="pmid">30684642</pub-id>
<pub-id pub-id-type="pmcid">PMC6650384</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chatuphonprasert</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Jarukamjorn</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Ellinger</surname><given-names>I.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Physiology and pathophysiology of steroid biosynthesis, transport and metabolism in the human placenta</article-title>. <source>Front. Pharmacol.</source>
<volume>9</volume>, <fpage>1027</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.01027</pub-id>
<pub-id pub-id-type="pmid">30258364</pub-id>
<pub-id pub-id-type="pmcid">PMC6144938</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Ni</surname><given-names>X.</given-names></name>
</person-group> (<year>2015</year>). <article-title>PPARγ stimulates expression of L-type amino acid and taurine transporters in human placentas: the evidence of PPARγ regulating fetal growth</article-title>. <source>Sci. Rep.</source>
<volume>5</volume>, <fpage>12650</fpage>. <pub-id pub-id-type="doi">10.1038/srep12650</pub-id>
<pub-id pub-id-type="pmid">26227476</pub-id>
<pub-id pub-id-type="pmcid">PMC4521151</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>Z. G.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Y. T.</given-names></name>
<name name-style="western"><surname>Ji</surname><given-names>L. L.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X. L.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X. X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The combination of symphysis-fundal height and abdominal circumference as a novel predictor of macrosomia in GDM and normal pregnancy</article-title>. <source>BMC Pregnancy Childbirth</source>
<volume>20</volume> (<issue>1</issue>), <fpage>461</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-020-03157-7</pub-id>
<pub-id pub-id-type="pmid">32787792</pub-id>
<pub-id pub-id-type="pmcid">PMC7425134</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chesnokova</surname><given-names>V.</given-names></name>
</person-group> (<year>2022</year>). <article-title>The multiple faces of the GH/IGF axis</article-title>. <source>Cells</source>
<volume>11</volume> (<issue>2</issue>), <fpage>217</fpage>. <pub-id pub-id-type="doi">10.3390/cells11020217</pub-id>
<pub-id pub-id-type="pmid">35053333</pub-id>
<pub-id pub-id-type="pmcid">PMC8773948</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chiarello</surname><given-names>D. I.</given-names></name>
<name name-style="western"><surname>Salsoso</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Toledo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Mate</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Vázquez</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Sobrevia</surname><given-names>L.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Foetoplacental communication <italic toggle="yes">via</italic> extracellular vesicles in normal pregnancy and preeclampsia</article-title>. <source>Mol. Asp. Med.</source>
<volume>60</volume>, <fpage>69</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.12.002</pub-id>
<pub-id pub-id-type="pmid">29222068</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Clarke-Harris</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Wilkin</surname><given-names>T. J.</given-names></name>
<name name-style="western"><surname>Hosking</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Pinkney</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Jeffery</surname><given-names>A. N.</given-names></name>
<name name-style="western"><surname>Metcalf</surname><given-names>B. S.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>PGC1α promoter methylation in blood at 5-7 years predicts adiposity from 9 to 14 years (EarlyBird 50)</article-title>. <source>Diabetes</source>
<volume>63</volume> (<issue>7</issue>), <fpage>2528</fpage>–<lpage>2537</lpage>. <pub-id pub-id-type="doi">10.2337/db13-0671</pub-id>
<pub-id pub-id-type="pmid">24622795</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Clemente</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Bird</surname><given-names>I. M.</given-names></name>
</person-group> (<year>2023</year>). <article-title>The epidermal growth factor receptor in healthy pregnancy and preeclampsia</article-title>. <source>J. Mol. Endocrinol.</source>
<volume>70</volume> (<issue>1</issue>), <fpage>e220105</fpage>. <pub-id pub-id-type="doi">10.1530/jme-22-0105</pub-id>
<pub-id pub-id-type="pmid">36197759</pub-id>
<pub-id pub-id-type="pmcid">PMC9742168</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cong</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Intrauterine hyperglycemia impairs mouse primordial germ cell development and fertility by sex-specific epigenetic reprogramming interference</article-title>. <source>Cell Discov.</source>
<volume>11</volume> (<issue>1</issue>), <fpage>74</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-025-00821-0</pub-id>
<pub-id pub-id-type="pmid">40921762</pub-id>
<pub-id pub-id-type="pmcid">PMC12417548</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Contreras-Duarte</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Carvajal</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Garchitorena</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>Subiabre</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fuenzalida</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Cantin</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Gestational diabetes mellitus treatment schemes modify maternal plasma cholesterol levels dependent to women’s weight: possible impact on feto-placental vascular function</article-title>. <source>Nutrients</source>
<volume>12</volume> (<issue>2</issue>). <pub-id pub-id-type="doi">10.3390/nu12020506</pub-id>
<pub-id pub-id-type="pmid">32079298</pub-id>
<pub-id pub-id-type="pmcid">PMC7071311</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Costantine</surname><given-names>M. M.</given-names></name>
<name name-style="western"><surname>Cleary</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hebert</surname><given-names>M. F.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>M. S.</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>L. M.</given-names></name>
<name name-style="western"><surname>Ren</surname><given-names>Z.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial</article-title>. <source>Am. J. Obstet. Gynecol.</source>
<volume>214</volume> (<issue>6</issue>), <fpage>720.e1</fpage>–<lpage>720.e17</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2015.12.038</pub-id>
<pub-id pub-id-type="pmid">26723196</pub-id>
<pub-id pub-id-type="pmcid">PMC4884459</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Côté</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Gagné-Ouellet</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Guay</surname><given-names>S. P.</given-names></name>
<name name-style="western"><surname>Allard</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Houde</surname><given-names>A. A.</given-names></name>
<name name-style="western"><surname>Perron</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>PPARGC1α gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns</article-title>. <source>Clin. Epigenetics</source>
<volume>8</volume>, <fpage>72</fpage>. <pub-id pub-id-type="doi">10.1186/s13148-016-0239-9</pub-id>
<pub-id pub-id-type="pmid">27340502</pub-id>
<pub-id pub-id-type="pmcid">PMC4918074</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>D’Anna</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Baviera</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Cannata</surname><given-names>M. L.</given-names></name>
<name name-style="western"><surname>De Vivo</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Di Benedetto</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Corrado</surname><given-names>F.</given-names></name>
</person-group> (<year>2007</year>). <article-title>Midtrimester amniotic fluid leptin and insulin levels and subsequent gestational diabetes</article-title>. <source>Gynecol. Obstet. Invest</source>
<volume>64</volume> (<issue>2</issue>), <fpage>65</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1159/000099149</pub-id>
<pub-id pub-id-type="pmid">17264515</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dackor</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Threadgill</surname><given-names>D. W.</given-names></name>
</person-group> (<year>2009</year>). <article-title>Placental overgrowth and fertility defects in mice with a hypermorphic allele of epidermal growth factor receptor</article-title>. <source>Mamm. Genome</source>
<volume>20</volume> (<issue>6</issue>), <fpage>339</fpage>–<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1007/s00335-009-9189-2</pub-id>
<pub-id pub-id-type="pmid">19466482</pub-id>
<pub-id pub-id-type="pmcid">PMC8081568</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Desoye</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>van Poppel</surname><given-names>M.</given-names></name>
</person-group> (<year>2015</year>). <article-title>The feto-placental dialogue and diabesity</article-title>. <source>Best. Pract. Res. Clin. Obstet. Gynaecol.</source>
<volume>29</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2014.05.012</pub-id>
<pub-id pub-id-type="pmid">25225059</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Díaz Del Moral</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Benaouicha</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Muñoz-Chápuli</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Carmona</surname><given-names>R.</given-names></name>
</person-group> (<year>2021</year>). <article-title>The insulin-like growth factor signalling pathway in cardiac development and regeneration</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>23</volume> (<issue>1</issue>), <fpage>234</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23010234</pub-id>
<pub-id pub-id-type="pmid">35008660</pub-id>
<pub-id pub-id-type="pmcid">PMC8745665</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ding</surname><given-names>G. L.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>F. F.</given-names></name>
<name name-style="western"><surname>Shu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia</article-title>. <source>Diabetes</source>
<volume>61</volume> (<issue>5</issue>), <fpage>1133</fpage>–<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.2337/db11-1314</pub-id>
<pub-id pub-id-type="pmid">22447856</pub-id>
<pub-id pub-id-type="pmcid">PMC3331740</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Qian</surname><given-names>L.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Systematic review and meta-analysis of the correlation between intestinal flora and gestational diabetes mellitus</article-title>. <source>Ann. Palliat. Med.</source>
<volume>10</volume> (<issue>9</issue>), <fpage>9752</fpage>–<lpage>9764</lpage>. <pub-id pub-id-type="doi">10.21037/apm-21-2061</pub-id>
<pub-id pub-id-type="pmid">34628901</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Du</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Molive</surname><given-names>L. M.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Advances in free fatty acid profiles in gestational diabetes mellitus</article-title>. <source>J. Transl. Med.</source>
<volume>22</volume> (<issue>1</issue>), <fpage>180</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-024-04922-4</pub-id>
<pub-id pub-id-type="pmid">38374136</pub-id>
<pub-id pub-id-type="pmcid">PMC10875910</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name>
</person-group> (<year>2023</year>). <article-title>High glucose and high lipid induced mitochondrial dysfunction in JEG-3 cells through oxidative stress</article-title>. <source>Open Life Sci.</source>
<volume>18</volume> (<issue>1</issue>), <fpage>20220561</fpage>. <pub-id pub-id-type="doi">10.1515/biol-2022-0561</pub-id>
<pub-id pub-id-type="pmid">36816801</pub-id>
<pub-id pub-id-type="pmcid">PMC9922060</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dubé</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Ethier-Chiasson</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Lafond</surname><given-names>J.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Modulation of cholesterol transport by insulin-treated gestational diabetes mellitus in human full-term placenta</article-title>. <source>Biol. Reprod.</source>
<volume>88</volume> (<issue>1</issue>), <fpage>16</fpage>. <pub-id pub-id-type="doi">10.1095/biolreprod.112.105619</pub-id>
<pub-id pub-id-type="pmid">23221398</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Duttaroy</surname><given-names>A. K.</given-names></name>
<name name-style="western"><surname>Basak</surname><given-names>S.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Maternal dietary fatty acids and their roles in human placental development</article-title>. <source>Prostagl. Leukot. Essent. Fat. Acids</source>
<volume>155</volume>, <fpage>102080</fpage>. <pub-id pub-id-type="doi">10.1016/j.plefa.2020.102080</pub-id>
<pub-id pub-id-type="pmid">32120190</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Duttaroy</surname><given-names>A. K.</given-names></name>
<name name-style="western"><surname>Basak</surname><given-names>S.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Maternal fatty acid metabolism in pregnancy and its consequences in the feto-placental development</article-title>. <source>Front. Physiol.</source>
<volume>12</volume>, <fpage>787848</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2021.787848</pub-id>
<pub-id pub-id-type="pmid">35126178</pub-id>
<pub-id pub-id-type="pmcid">PMC8811195</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Edwards</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Cunningham</surname><given-names>S. A.</given-names></name>
<name name-style="western"><surname>Dunlop</surname><given-names>A. L.</given-names></name>
<name name-style="western"><surname>Corwin</surname><given-names>E. J.</given-names></name>
</person-group> (<year>2017</year>). <article-title>The maternal gut microbiome during pregnancy</article-title>. <source>MCN Am. J. Matern. Child. Nurs.</source>
<volume>42</volume> (<issue>6</issue>), <fpage>310</fpage>–<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1097/nmc.0000000000000372</pub-id>
<pub-id pub-id-type="pmid">28787280</pub-id>
<pub-id pub-id-type="pmcid">PMC5648614</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Elessawy</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Harders</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Kleinwechter</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Demandt</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Sheasha</surname><given-names>G. A.</given-names></name>
<name name-style="western"><surname>Maass</surname><given-names>N.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Measurement and evaluation of fetal fat layer in the prediction of fetal macrosomia in pregnancies complicated by gestational diabetes</article-title>. <source>Arch. Gynecol. Obstet.</source>
<volume>296</volume> (<issue>3</issue>), <fpage>445</fpage>–<lpage>453</lpage>. <pub-id pub-id-type="doi">10.1007/s00404-017-4433-6</pub-id>
<pub-id pub-id-type="pmid">28631075</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Evagelidou</surname><given-names>E. N.</given-names></name>
<name name-style="western"><surname>Giapros</surname><given-names>V. I.</given-names></name>
<name name-style="western"><surname>Challa</surname><given-names>A. S.</given-names></name>
<name name-style="western"><surname>Cholevas</surname><given-names>V. K.</given-names></name>
<name name-style="western"><surname>Vartholomatos</surname><given-names>G. A.</given-names></name>
<name name-style="western"><surname>Siomou</surname><given-names>E. C.</given-names></name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Prothrombotic state, cardiovascular, and metabolic syndrome risk factors in prepubertal children born large for gestational age</article-title>. <source>Diabetes Care</source>
<volume>33</volume> (<issue>11</issue>), <fpage>2468</fpage>–<lpage>2470</lpage>. <pub-id pub-id-type="doi">10.2337/dc10-1190</pub-id>
<pub-id pub-id-type="pmid">20724652</pub-id>
<pub-id pub-id-type="pmcid">PMC2963515</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Fernandez-Twinn</surname><given-names>D. S.</given-names></name>
<name name-style="western"><surname>Hjort</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Novakovic</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Ozanne</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Saffery</surname><given-names>R.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Intrauterine programming of obesity and type 2 diabetes</article-title>. <source>Diabetologia</source>
<volume>62</volume> (<issue>10</issue>), <fpage>1789</fpage>–<lpage>1801</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-019-4951-9</pub-id>
<pub-id pub-id-type="pmid">31451874</pub-id>
<pub-id pub-id-type="pmcid">PMC6731191</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Fruscalzo</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Viola</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Orsaria</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Marzinotto</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bulfoni</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Driul</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>STRA6 and placental retinoid metabolism in gestational diabetes mellitus</article-title>. <source>J. Pers. Med.</source>
<volume>11</volume> (<issue>12</issue>), <fpage>1301</fpage>. <pub-id pub-id-type="doi">10.3390/jpm11121301</pub-id>
<pub-id pub-id-type="pmid">34945773</pub-id>
<pub-id pub-id-type="pmcid">PMC8708334</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gaither</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Quraishi</surname><given-names>A. N.</given-names></name>
<name name-style="western"><surname>Illsley</surname><given-names>N. P.</given-names></name>
</person-group> (<year>1999</year>). <article-title>Diabetes alters the expression and activity of the human placental GLUT1 glucose transporter</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>84</volume> (<issue>2</issue>), <fpage>695</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1210/jcem.84.2.5438</pub-id>
<pub-id pub-id-type="pmid">10022440</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gauster</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hiden</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>van Poppel</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Frank</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wadsack</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Hauguel-de Mouzon</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Dysregulation of placental endothelial lipase in obese women with gestational diabetes mellitus</article-title>. <source>Diabetes</source>
<volume>60</volume> (<issue>10</issue>), <fpage>2457</fpage>–<lpage>2464</lpage>. <pub-id pub-id-type="doi">10.2337/db10-1434</pub-id>
<pub-id pub-id-type="pmid">21852675</pub-id>
<pub-id pub-id-type="pmcid">PMC3178285</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ghio</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bertolotto</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Resi</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Volpe</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Di Cianni</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Triglyceride metabolism in pregnancy</article-title>. <source>Adv. Clin. Chem.</source>
<volume>55</volume>, <fpage>133</fpage>–<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1016/b978-0-12-387042-1.00007-1</pub-id>
<pub-id pub-id-type="pmid">22126027</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Guiyu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Quan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Ruochen</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Dan</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Bingnan</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Yuanyua</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>LncRNA-SNX17 promotes HTR-8/SVneo proliferation and invasion through miR-517a/IGF-1 in the placenta of diabetic macrosomia</article-title>. <source>Reprod. Sci.</source>
<volume>29</volume> (<issue>2</issue>), <fpage>596</fpage>–<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1007/s43032-021-00687-z</pub-id>
<pub-id pub-id-type="pmid">34270000</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Comparative efficacy and safety of metformin, glyburide, and insulin in treating gestational diabetes mellitus: a meta-analysis</article-title>. <source>J. Diabetes Res.</source>
<volume>2019</volume>, <fpage>9804708</fpage>. <pub-id pub-id-type="doi">10.1155/2019/9804708</pub-id>
<pub-id pub-id-type="pmid">31781670</pub-id>
<pub-id pub-id-type="pmcid">PMC6875019</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>He</surname><given-names>L. R.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Birth weight and large for gestational age trends in offspring of pregnant women with gestational diabetes mellitus in southern China, 2012-2021</article-title>. <source>Front. Endocrinol. (Lausanne)</source>
<volume>14</volume>, <fpage>1166533</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2023.1166533</pub-id>
<pub-id pub-id-type="pmid">37214242</pub-id>
<pub-id pub-id-type="pmcid">PMC10194652</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Heerwagen</surname><given-names>M. J. R.</given-names></name>
<name name-style="western"><surname>Gumina</surname><given-names>D. L.</given-names></name>
<name name-style="western"><surname>Hernandez</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Van Pelt</surname><given-names>R. E.</given-names></name>
<name name-style="western"><surname>Kramer</surname><given-names>A. W.</given-names></name>
<name name-style="western"><surname>Janssen</surname><given-names>R. C.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Placental lipoprotein lipase activity is positively associated with newborn adiposity</article-title>. <source>Placenta</source>
<volume>64</volume>, <fpage>53</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2018.03.001</pub-id>
<pub-id pub-id-type="pmid">29626981</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hessvik</surname><given-names>N. P.</given-names></name>
<name name-style="western"><surname>Llorente</surname><given-names>A.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Current knowledge on exosome biogenesis and release</article-title>. <source>Cell Mol. Life Sci.</source>
<volume>75</volume> (<issue>2</issue>), <fpage>193</fpage>–<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-017-2595-9</pub-id>
<pub-id pub-id-type="pmid">28733901</pub-id>
<pub-id pub-id-type="pmcid">PMC5756260</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hoch</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Brandl</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Strutz</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Köfeler</surname><given-names>H. C.</given-names></name>
<name name-style="western"><surname>van Poppel</surname><given-names>M. N. M.</given-names></name>
<name name-style="western"><surname>Bode</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Human milk oligosaccharides in cord blood are altered in gestational diabetes and stimulate feto-placental angiogenesis in vitro</article-title>. <source>Nutrients</source>
<volume>13</volume> (<issue>12</issue>), <fpage>4257</fpage>. <pub-id pub-id-type="doi">10.3390/nu13124257</pub-id>
<pub-id pub-id-type="pmid">34959807</pub-id>
<pub-id pub-id-type="pmcid">PMC8705424</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Gillies</surname><given-names>C. L.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Stewart</surname><given-names>Z. A.</given-names></name>
<name name-style="western"><surname>Melford</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Abrams</surname><given-names>K. R.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Association of maternal lipid profile and gestational diabetes mellitus: a systematic review and meta-analysis of 292 studies and 97,880 women</article-title>. <source>EClinicalMedicine</source>
<volume>34</volume>, <fpage>100830</fpage>. <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100830</pub-id>
<pub-id pub-id-type="pmid">33997732</pub-id>
<pub-id pub-id-type="pmcid">PMC8102708</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Gestational diabetes mellitus alters neonatal gut microbiota and increases infection susceptibility</article-title>. <source>Front. Microbiol.</source>
<volume>16</volume>, <fpage>1600325</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2025.1600325</pub-id>
<pub-id pub-id-type="pmid">40625618</pub-id>
<pub-id pub-id-type="pmcid">PMC12233159</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Tan</surname><given-names>C.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Placental angiogenesis in mammals: a review of the regulatory effects of signaling pathways and functional nutrients</article-title>. <source>Adv. Nutr.</source>
<volume>12</volume> (<issue>6</issue>), <fpage>2415</fpage>–<lpage>2434</lpage>. <pub-id pub-id-type="doi">10.1093/advances/nmab070</pub-id>
<pub-id pub-id-type="pmid">34167152</pub-id>
<pub-id pub-id-type="pmcid">PMC8634476</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hung</surname><given-names>T.-H.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>S.-Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>S.-F.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>C.-P.</given-names></name>
<name name-style="western"><surname>Hsieh</surname><given-names>T. T.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Decreased placental apoptosis and autophagy in pregnancies complicated by gestational diabetes with large-for-gestational age fetuses</article-title>. <source>Placenta</source>
<volume>90</volume>, <fpage>27</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2019.12.003</pub-id>
<pub-id pub-id-type="pmid">32056548</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hung</surname><given-names>T. H.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>C. P.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>S. F.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Differential changes in Akt and AMPK phosphorylation regulating mTOR activity in the placentas of pregnancies complicated by fetal growth restriction and gestational diabetes mellitus with large-for-gestational age infants</article-title>. <source>Front. Med. (Lausanne)</source>
<volume>8</volume>, <fpage>788969</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2021.788969</pub-id>
<pub-id pub-id-type="pmid">34938752</pub-id>
<pub-id pub-id-type="pmcid">PMC8685227</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Illsley</surname><given-names>N. P.</given-names></name>
<name name-style="western"><surname>Baumann</surname><given-names>M. U.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Human placental glucose transport in fetoplacental growth and metabolism</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source>
<volume>1866</volume> (<issue>2</issue>), <fpage>165359</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2018.12.010</pub-id>
<pub-id pub-id-type="pmid">30593896</pub-id>
<pub-id pub-id-type="pmcid">PMC6594918</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>James-Allan</surname><given-names>L. B.</given-names></name>
<name name-style="western"><surname>Rosario</surname><given-names>F. J.</given-names></name>
<name name-style="western"><surname>Madi</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Barner</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Lai</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A novel technique using chronic infusion of small extracellular vesicles from gestational diabetes mellitus causes glucose intolerance in pregnant mice</article-title>. <source>Clin. Sci. (Lond)</source>
<volume>136</volume> (<issue>21</issue>), <fpage>1535</fpage>–<lpage>1549</lpage>. <pub-id pub-id-type="doi">10.1042/cs20220484</pub-id>
<pub-id pub-id-type="pmid">36239315</pub-id>
<pub-id pub-id-type="pmcid">PMC9638966</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Cetin</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Desoye</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Radaelli</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ericsson</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Placental transport and metabolism in fetal overgrowth -- a workshop report</article-title>. <source>Placenta</source>
<volume>27</volume> (<issue>Suppl. A</issue>), <fpage>S109</fpage>–<lpage>S113</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2006.01.017</pub-id>
<pub-id pub-id-type="pmid">16542722</pub-id>
</mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jansson</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Rosario</surname><given-names>F. J.</given-names></name>
<name name-style="western"><surname>Gaccioli</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Lager</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jones</surname><given-names>H. N.</given-names></name>
<name name-style="western"><surname>Roos</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>98</volume> (<issue>1</issue>), <fpage>105</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2012-2667</pub-id>
<pub-id pub-id-type="pmid">23150676</pub-id>
<pub-id pub-id-type="pmcid">PMC3537112</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jauhiainen</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Vangipurapu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Laakso</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kuulasmaa</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Kuusisto</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Laakso</surname><given-names>M.</given-names></name>
</person-group> (<year>2021</year>). <article-title>The association of 9 amino acids with cardiovascular events in Finnish men in a 12-Year Follow-up study</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>106</volume> (<issue>12</issue>), <fpage>3448</fpage>–<lpage>3454</lpage>. <pub-id pub-id-type="doi">10.1210/clinem/dgab562</pub-id>
<pub-id pub-id-type="pmid">34346487</pub-id>
<pub-id pub-id-type="pmcid">PMC8634085</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jayabalan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Nuzhat</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Rice</surname><given-names>G. E.</given-names></name>
<name name-style="western"><surname>Zuñiga</surname><given-names>F. A.</given-names></name>
<name name-style="western"><surname>Sobrevia</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Cross talk between adipose tissue and placenta in Obese and gestational diabetes mellitus pregnancies <italic toggle="yes">via</italic> exosomes</article-title>. <source>Front. Endocrinol. (Lausanne)</source>
<volume>8</volume>, <fpage>239</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2017.00239</pub-id>
<pub-id pub-id-type="pmid">29021781</pub-id>
<pub-id pub-id-type="pmcid">PMC5623931</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jayabalan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Lai</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Scholz-Romero</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Razo-Azamar</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ormazabal</surname><given-names>V.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Extracellular vesicle-associated miR-515-5p from adipose tissue regulates placental metabolism and fetal growth in gestational diabetes mellitus</article-title>. <source>Cardiovasc Diabetol.</source>
<volume>24</volume> (<issue>1</issue>), <fpage>205</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-025-02739-z</pub-id>
<pub-id pub-id-type="pmid">40369565</pub-id>
<pub-id pub-id-type="pmcid">PMC12080180</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Effects of the original gymnastics for pregnant women program on glycaemic control and delivery outcomes in women with gestational diabetes mellitus: a randomized controlled trial</article-title>. <source>Int. J. Nurs. Stud.</source>
<volume>132</volume>, <fpage>104271</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijnurstu.2022.104271</pub-id>
<pub-id pub-id-type="pmid">35660387</pub-id>
</mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Kong</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Vitronectin promotes insulin resistance in trophoblast cells by activating JNK in gestational diabetes mellitus</article-title>. <source>Cell Biol. Int</source>. <pub-id pub-id-type="doi">10.1002/cbin.12167</pub-id>
<pub-id pub-id-type="pmid">38654431</pub-id>
</mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kc</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Shakya</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Gestational diabetes mellitus and macrosomia: a literature review</article-title>. <source>Ann. Nutr. Metab.</source>
<volume>66</volume> (<issue>Suppl 2</issue>), <fpage>14</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1159/000371628</pub-id>
<pub-id pub-id-type="pmid">26045324</pub-id>
</mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Keleher</surname><given-names>M. R.</given-names></name>
<name name-style="western"><surname>Erickson</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Kechris</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>I. V.</given-names></name>
<name name-style="western"><surname>Dabelea</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Friedman</surname><given-names>J. E.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Associations between the activity of placental nutrient-sensing pathways and neonatal and postnatal metabolic health: the ECHO healthy start cohort</article-title>. <source>Int. J. Obes. (Lond)</source>
<volume>44</volume> (<issue>11</issue>), <fpage>2203</fpage>–<lpage>2212</lpage>. <pub-id pub-id-type="doi">10.1038/s41366-020-0574-y</pub-id>
<pub-id pub-id-type="pmid">32327723</pub-id>
<pub-id pub-id-type="pmcid">PMC8329931</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Khambule</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>George</surname><given-names>J. A.</given-names></name>
</person-group> (<year>2019</year>). <article-title>The role of inflammation in the development of GDM and the use of markers of inflammation in GDM screening</article-title>. <source>Adv. Exp. Med. Biol.</source>
<volume>1134</volume>, <fpage>217</fpage>–<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-030-12668-1_12</pub-id>
<pub-id pub-id-type="pmid">30919340</pub-id>
</mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kirovakov</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Gyokova</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Hinkova</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Stoilov</surname><given-names>B.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Management of endocrinopathies during pregnancy: a systematic review</article-title>. <source>Cureus</source>
<volume>16</volume> (<issue>9</issue>), <fpage>e70554</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.70554</pub-id>
<pub-id pub-id-type="pmid">39479091</pub-id>
<pub-id pub-id-type="pmcid">PMC11524603</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Klid</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Algaba-Chueca</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Maymó-Masip</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Guarque</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Ballesteros</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Diaz-Perdigones</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The angiogenic properties of human amniotic membrane stem cells are enhanced in gestational diabetes and associate with fetal adiposity</article-title>. <source>Stem Cell Res. Ther.</source>
<volume>12</volume> (<issue>1</issue>), <fpage>608</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-021-02678-y</pub-id>
<pub-id pub-id-type="pmid">34930438</pub-id>
<pub-id pub-id-type="pmcid">PMC8691045</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kranendonk</surname><given-names>M. E.</given-names></name>
<name name-style="western"><surname>Visseren</surname><given-names>F. L.</given-names></name>
<name name-style="western"><surname>van Herwaarden</surname><given-names>J. A.</given-names></name>
<name name-style="western"><surname>Nolte-‘t Hoen</surname><given-names>E. N.</given-names></name>
<name name-style="western"><surname>de Jager</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Wauben</surname><given-names>M. H.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Effect of extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle cells</article-title>. <source>Obesity (Silver Spring)</source>
<volume>22</volume> (<issue>10</issue>), <fpage>2216</fpage>–<lpage>2223</lpage>. <pub-id pub-id-type="doi">10.1002/oby.20847</pub-id>
<pub-id pub-id-type="pmid">25045057</pub-id>
</mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Krause</surname><given-names>B. J.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Novel insights for the role of nitric oxide in placental vascular function during and beyond pregnancy</article-title>. <source>J. Cell Physiol.</source>
<volume>236</volume> (<issue>12</issue>), <fpage>7984</fpage>–<lpage>7999</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.30470</pub-id>
<pub-id pub-id-type="pmid">34121195</pub-id>
</mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kuentzel</surname><given-names>K. B.</given-names></name>
<name name-style="western"><surname>Bradić</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Mihalič</surname><given-names>Z. N.</given-names></name>
<name name-style="western"><surname>Korbelius</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Rainer</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Pirchheim</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Dysregulation of placental lipid hydrolysis by high-fat/high-cholesterol feeding and gestational diabetes mellitus in mice</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>23</volume> (<issue>20</issue>), <fpage>12286</fpage>. <pub-id pub-id-type="doi">10.3390/ijms232012286</pub-id>
<pub-id pub-id-type="pmid">36293139</pub-id>
<pub-id pub-id-type="pmcid">PMC9603336</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kulkarni</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Kumaran</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Rao</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Chougule</surname><given-names>S. D.</given-names></name>
<name name-style="western"><surname>Deokar</surname><given-names>T. M.</given-names></name>
<name name-style="western"><surname>Bhalerao</surname><given-names>A. J.</given-names></name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Maternal lipids are as important as glucose for fetal growth: findings from the Pune maternal nutrition study</article-title>. <source>Diabetes Care</source>
<volume>36</volume> (<issue>9</issue>), <fpage>2706</fpage>–<lpage>2713</lpage>. <pub-id pub-id-type="doi">10.2337/dc12-2445</pub-id>
<pub-id pub-id-type="pmid">23757425</pub-id>
<pub-id pub-id-type="pmcid">PMC3747887</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Küpers</surname><given-names>L. K.</given-names></name>
<name name-style="western"><surname>Monnereau</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Sharp</surname><given-names>G. C.</given-names></name>
<name name-style="western"><surname>Yousefi</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Salas</surname><given-names>L. A.</given-names></name>
<name name-style="western"><surname>Ghantous</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Meta-analysis of epigenome-wide association studies in neonates reveals widespread differential DNA methylation associated with birthweight</article-title>. <source>Nat. Commun.</source>
<volume>10</volume> (<issue>1</issue>), <fpage>1893</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-09671-3</pub-id>
<pub-id pub-id-type="pmid">31015461</pub-id>
<pub-id pub-id-type="pmcid">PMC6478731</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lappas</surname><given-names>M.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Insulin-like growth factor-binding protein 1 and 7 concentrations are lower in obese pregnant women, women with gestational diabetes and their fetuses</article-title>. <source>J. Perinatology</source>
<volume>35</volume> (<issue>1</issue>), <fpage>32</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1038/jp.2014.144</pub-id>
<pub-id pub-id-type="pmid">25078866</pub-id>
</mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lefkou</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Mamopoulos</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Dagklis</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Vosnakis</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Rousso</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Girardi</surname><given-names>G.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy</article-title>. <source>J. Clin. Invest</source>
<volume>126</volume> (<issue>8</issue>), <fpage>2933</fpage>–<lpage>2940</lpage>. <pub-id pub-id-type="doi">10.1172/jci86957</pub-id>
<pub-id pub-id-type="pmid">27454295</pub-id>
<pub-id pub-id-type="pmcid">PMC4966313</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Gut dysbiosis contributes to SCFAs reduction-associated adipose tissue macrophage polarization in gestational diabetes mellitus</article-title>. <source>Life Sci.</source>
<volume>350</volume>, <fpage>122744</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2024.122744</pub-id>
<pub-id pub-id-type="pmid">38810793</pub-id>
</mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Gestational diabetes mellitus: modifier or mediator in the link between pre-pregnancy overweight/obesity and fetal overgrowth?</article-title>
<source>J. Matern Fetal Neonatal Med.</source>
<volume>38</volume> (<issue>1</issue>), <fpage>2561847</fpage>. <pub-id pub-id-type="doi">10.1080/14767058.2025.2561847</pub-id>
<pub-id pub-id-type="pmid">41017647</pub-id>
</mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liao</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Vickers</surname><given-names>M. H.</given-names></name>
<name name-style="western"><surname>Taylor</surname><given-names>R. S.</given-names></name>
<name name-style="western"><surname>Fraser</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>McCowan</surname><given-names>L. M. E.</given-names></name>
<name name-style="western"><surname>Baker</surname><given-names>P. N.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Maternal serum placental growth hormone, insulin-like growth factors and their binding proteins at 20 weeks’ gestation in pregnancies complicated by gestational diabetes mellitus</article-title>. <source>Hormones (Athens)</source>
<volume>16</volume> (<issue>3</issue>), <fpage>282</fpage>–<lpage>290</lpage>. <pub-id pub-id-type="doi">10.14310/horm.2002.1747</pub-id>
<pub-id pub-id-type="pmid">29278514</pub-id>
</mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lin</surname><given-names>X. H.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>D. D.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>J. Y.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>H. T.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Altered DNA methylation in neonates born large-for-gestational-age is associated with cardiometabolic risk in children</article-title>. <source>Oncotarget</source>
<volume>7</volume> (<issue>52</issue>), <fpage>86511</fpage>–<lpage>86521</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13442</pub-id>
<pub-id pub-id-type="pmid">27888796</pub-id>
<pub-id pub-id-type="pmcid">PMC5349931</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The choline metabolite TMAO inhibits NETosis and promotes placental development in GDM of humans and mice</article-title>. <source>Diabetes</source>
<volume>70</volume> (<issue>10</issue>), <fpage>2250</fpage>–<lpage>2263</lpage>. <pub-id pub-id-type="doi">10.2337/db21-0188</pub-id>
<pub-id pub-id-type="pmid">34315726</pub-id>
</mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lingwood</surname><given-names>B. E.</given-names></name>
<name name-style="western"><surname>Henry</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>d’Emden</surname><given-names>M. C.</given-names></name>
<name name-style="western"><surname>Fullerton</surname><given-names>A.-M.</given-names></name>
<name name-style="western"><surname>Mortimer</surname><given-names>R. H.</given-names></name>
<name name-style="western"><surname>Colditz</surname><given-names>P. B.</given-names></name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Determinants of body fat in infants of women with gestational diabetes mellitus differ with fetal sex</article-title>. <source>Diabetes Care</source>
<volume>34</volume> (<issue>12</issue>), <fpage>2581</fpage>–<lpage>2585</lpage>. <pub-id pub-id-type="doi">10.2337/dc11-0728</pub-id>
<pub-id pub-id-type="pmid">21994428</pub-id>
<pub-id pub-id-type="pmcid">PMC3220854</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>S. X.</given-names></name>
<name name-style="western"><surname>Lv</surname><given-names>Y.</given-names></name>
</person-group> (<year>2025</year>). <article-title>MiR-99 family of exosomes targets myotubularin-related protein 3 to regulate autophagy in trophoblast cells and influence insulin resistance</article-title>. <source>J. Physiol. Investig.</source>
<volume>68</volume> (<issue>3</issue>), <fpage>176</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.4103/ejpi.EJPI-D-24-00111</pub-id>
<pub-id pub-id-type="pmid">40358580</pub-id>
</mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>L. L.</given-names></name>
<name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Alterations of Gut microbiota and blood lipidome in gestational diabetes mellitus with hyperlipidemia</article-title>. <source>Front. Physiol.</source>
<volume>10</volume>, <fpage>1015</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2019.01015</pub-id>
<pub-id pub-id-type="pmid">31447702</pub-id>
<pub-id pub-id-type="pmcid">PMC6691352</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>S. Y.</given-names></name>
<name name-style="western"><surname>Eriksson</surname><given-names>J. G.</given-names></name>
<name name-style="western"><surname>Chong</surname><given-names>Y. S.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>Y. S.</given-names></name>
<name name-style="western"><surname>Yap</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Maternal glycemic status during pregnancy and mid-childhood plasma amino acid profiles: findings from a multi-ethnic Asian birth cohort</article-title>. <source>BMC Med.</source>
<volume>21</volume> (<issue>1</issue>), <fpage>472</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-023-03188-9</pub-id>
<pub-id pub-id-type="pmid">38031185</pub-id>
<pub-id pub-id-type="pmcid">PMC10688057</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Gui</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Study on the regulation of trophoblast activity by abnormally expressed hsa_circ_0024838/miR-543/HIF1A in patients with gestational diabetes mellitus</article-title>. <source>Placenta</source>
<volume>151</volume>, <fpage>27</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2024.04.006</pub-id>
<pub-id pub-id-type="pmid">38701658</pub-id>
</mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lorigo</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Cairrao</surname><given-names>E.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Fetoplacental vasculature as a model to study human cardiovascular endocrine disruption</article-title>. <source>Mol. Aspects Med.</source>
<volume>87</volume>, <fpage>101054</fpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2021.101054</pub-id>
<pub-id pub-id-type="pmid">34839931</pub-id>
</mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lu</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Ferriero</surname><given-names>D. M.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Cholesterol in brain development and perinatal brain injury: more than a building block</article-title>. <source>Curr. Neuropharmacol.</source>
<volume>20</volume> (<issue>7</issue>), <fpage>1400</fpage>–<lpage>1412</lpage>. <pub-id pub-id-type="doi">10.2174/1570159x19666211111122311</pub-id>
<pub-id pub-id-type="pmid">34766894</pub-id>
<pub-id pub-id-type="pmcid">PMC9881076</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Luo</surname><given-names>Z.-C.</given-names></name>
<name name-style="western"><surname>Nuyt</surname><given-names>A.-M.</given-names></name>
<name name-style="western"><surname>Delvin</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Audibert</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Girard</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Shatenstein</surname><given-names>B.</given-names></name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Maternal and fetal IGF-I and IGF-II levels, fetal growth, and gestational diabetes</article-title>. <source>J. Clin. Endocrinol. &amp; Metabolism</source>
<volume>97</volume> (<issue>5</issue>), <fpage>1720</fpage>–<lpage>1728</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2011-3296</pub-id>
<pub-id pub-id-type="pmid">22419731</pub-id>
</mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The second pregnancy has no effect in the incidence of macrosomia: a cross-sectional survey in two Western Chinese regions</article-title>. <source>J. Health, Popul. Nutr.</source>
<volume>40</volume> (<issue>1</issue>), <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s41043-021-00244-z</pub-id>
<pub-id pub-id-type="pmid">33849665</pub-id>
<pub-id pub-id-type="pmcid">PMC8045374</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mackin</surname><given-names>S. T.</given-names></name>
<name name-style="western"><surname>Nelson</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Kerssens</surname><given-names>J. J.</given-names></name>
<name name-style="western"><surname>Wood</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Wild</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Colhoun</surname><given-names>H. M.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Diabetes and pregnancy: national trends over a 15 year period</article-title>. <source>Diabetologia</source>
<volume>61</volume> (<issue>5</issue>), <fpage>1081</fpage>–<lpage>1088</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-017-4529-3</pub-id>
<pub-id pub-id-type="pmid">29322220</pub-id>
<pub-id pub-id-type="pmcid">PMC6448996</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Maghalian</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Alizadeh-Dibazari</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Mirghafourvand</surname><given-names>M.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Impact of fetal sex on neonatal outcomes in women with gestational diabetes mellitus: a systematic review and meta-analysis</article-title>. <source>BMC Pregnancy Childbirth</source>
<volume>25</volume> (<issue>1</issue>), <fpage>110</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-025-07250-7</pub-id>
<pub-id pub-id-type="pmid">39901155</pub-id>
<pub-id pub-id-type="pmcid">PMC11792264</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Magnusson</surname><given-names>A. L.</given-names></name>
<name name-style="western"><surname>Waterman</surname><given-names>I. J.</given-names></name>
<name name-style="western"><surname>Wennergren</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
</person-group> (<year>2004</year>). <article-title>Triglyceride hydrolase activities and expression of fatty acid binding proteins in the human placenta in pregnancies complicated by intrauterine growth restriction and diabetes</article-title>. <source>J. Clin. Endocrinol. &amp; Metabolism</source>
<volume>89</volume> (<issue>9</issue>), <fpage>4607</fpage>–<lpage>4614</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2003-032234</pub-id>
<pub-id pub-id-type="pmid">15356070</pub-id>
</mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mahizir</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Briffa</surname><given-names>J. F.</given-names></name>
<name name-style="western"><surname>Wood</surname><given-names>J. L.</given-names></name>
<name name-style="western"><surname>Anevska</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hill-Yardin</surname><given-names>E. L.</given-names></name>
<name name-style="western"><surname>Jefferies</surname><given-names>A. J.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Exercise improves metabolic function and alters the microbiome in rats with gestational diabetes</article-title>. <source>Faseb J.</source>
<volume>34</volume> (<issue>1</issue>), <fpage>1728</fpage>–<lpage>1744</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201901424R</pub-id>
<pub-id pub-id-type="pmid">31914625</pub-id>
</mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Martín-Estal</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Castorena-Torres</surname><given-names>F.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Gestational diabetes mellitus and energy-dense diet: what is the role of the Insulin/IGF axis?</article-title>
<source>Front. Endocrinol. (Lausanne)</source>
<volume>13</volume>, <fpage>916042</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.916042</pub-id>
<pub-id pub-id-type="pmid">35813659</pub-id>
<pub-id pub-id-type="pmcid">PMC9259869</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Martins</surname><given-names>M. G.</given-names></name>
<name name-style="western"><surname>Silver</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Ayoub</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hyland</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Woodside</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Kiss</surname><given-names>A. C. I.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Maternal glucose intolerance during pregnancy affects offspring POMC expression and results in adult metabolic alterations in a sex-dependent manner</article-title>. <source>Front. Endocrinol. (Lausanne)</source>
<volume>14</volume>, <fpage>1189207</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2023.1189207</pub-id>
<pub-id pub-id-type="pmid">37396180</pub-id>
<pub-id pub-id-type="pmcid">PMC10311085</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Melincovici</surname><given-names>C. S.</given-names></name>
<name name-style="western"><surname>Boşca</surname><given-names>A. B.</given-names></name>
<name name-style="western"><surname>Şuşman</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mărginean</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mihu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Istrate</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis</article-title>. <source>Rom. J. Morphol. Embryol.</source>
<volume>59</volume> (<issue>2</issue>), <fpage>455</fpage>–<lpage>467</lpage>.
<pub-id pub-id-type="pmid">30173249</pub-id>
</mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Merzouk</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Madani</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Hichami</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Prost</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Belleville</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>N. A.</given-names></name>
</person-group> (<year>2002</year>). <article-title>Age-related changes in fatty acids in obese offspring of streptozotocin-induced diabetic rats</article-title>. <source>Obes. Res.</source>
<volume>10</volume> (<issue>7</issue>), <fpage>703</fpage>–<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2002.95</pub-id>
<pub-id pub-id-type="pmid">12105294</pub-id>
</mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Metzger</surname><given-names>B. E.</given-names></name>
<name name-style="western"><surname>Lowe</surname><given-names>L. P.</given-names></name>
<name name-style="western"><surname>Dyer</surname><given-names>A. R.</given-names></name>
<name name-style="western"><surname>Trimble</surname><given-names>E. R.</given-names></name>
<name name-style="western"><surname>Chaovarindr</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Coustan</surname><given-names>D. R.</given-names></name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Hyperglycemia and adverse pregnancy outcomes</article-title>. <source>N. Engl. J. Med.</source>
<volume>358</volume> (<issue>19</issue>), <fpage>1991</fpage>–<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0707943</pub-id>
<pub-id pub-id-type="pmid">18463375</pub-id>
</mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Metzger</surname><given-names>B. E.</given-names></name>
<name name-style="western"><surname>Gabbe</surname><given-names>S. G.</given-names></name>
<name name-style="western"><surname>Persson</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Buchanan</surname><given-names>T. A.</given-names></name>
<name name-style="western"><surname>Catalano</surname><given-names>P. A.</given-names></name>
<name name-style="western"><surname>Damm</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2010</year>). <article-title>International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy</article-title>. <source>Diabetes Care</source>
<volume>33</volume> (<issue>3</issue>), <fpage>676</fpage>–<lpage>682</lpage>. <pub-id pub-id-type="doi">10.2337/dc09-1848</pub-id>
<pub-id pub-id-type="pmid">20190296</pub-id>
<pub-id pub-id-type="pmcid">PMC2827530</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Miko</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Csaszar</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bodis</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Kovacs</surname><given-names>K.</given-names></name>
</person-group> (<year>2022</year>). <article-title>The maternal-fetal gut microbiota axis: physiological changes, dietary influence, and modulation possibilities</article-title>. <source>Life (Basel)</source>
<volume>12</volume> (<issue>3</issue>), <fpage>424</fpage>. <pub-id pub-id-type="doi">10.3390/life12030424</pub-id>
<pub-id pub-id-type="pmid">35330175</pub-id>
<pub-id pub-id-type="pmcid">PMC8955030</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mishra</surname><given-names>J. S.</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Placental fatty acid metabolism and transport in a rat model of gestational diabetes mellitus</article-title>. <source>J. Womens Health Dev.</source>
<volume>6</volume> (<issue>2</issue>), <fpage>56</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.26502/fjwhd.2644-288400108</pub-id>
<pub-id pub-id-type="pmid">37288271</pub-id>
<pub-id pub-id-type="pmcid">PMC10246410</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Moreli</surname><given-names>J. B.</given-names></name>
<name name-style="western"><surname>Ferrari</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Ruocco</surname><given-names>A. M. C.</given-names></name>
<name name-style="western"><surname>Santos</surname><given-names>M. G. O.</given-names></name>
<name name-style="western"><surname>Lorenzon</surname><given-names>A. R.</given-names></name>
<name name-style="western"><surname>Carlos</surname><given-names>C. P.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Influence of maternal hyperglycemia on placental capillary distribution</article-title>. <source>Einstein (Sao Paulo)</source>
<volume>22</volume>, <fpage>eAO0583</fpage>. <pub-id pub-id-type="doi">10.31744/einstein_journal/2024AO0583</pub-id>
<pub-id pub-id-type="pmid">39504088</pub-id>
<pub-id pub-id-type="pmcid">PMC11634342</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mottola</surname><given-names>M. F.</given-names></name>
<name name-style="western"><surname>Artal</surname><given-names>R.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Fetal and maternal metabolic responses to exercise during pregnancy</article-title>. <source>Early Hum. Dev.</source>
<volume>94</volume>, <fpage>33</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.earlhumdev.2016.01.008</pub-id>
<pub-id pub-id-type="pmid">26803360</pub-id>
</mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>G.</given-names></name>
</person-group> (<year>2023</year>). <article-title>The effects of probiotics/synbiotics on glucose and lipid metabolism in women with gestational diabetes mellitus: a meta-analysis of randomized controlled trials</article-title>. <source>Nutrients</source>
<volume>15</volume> (<issue>6</issue>), <fpage>1375</fpage>. <pub-id pub-id-type="doi">10.3390/nu15061375</pub-id>
<pub-id pub-id-type="pmid">36986107</pub-id>
<pub-id pub-id-type="pmcid">PMC10056932</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Nanobashvili</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Jack-Roberts</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Bretter</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Jones</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Axen</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Saxena</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Maternal choline and betaine supplementation modifies the placental response to hyperglycemia in mice and human trophoblasts</article-title>. <source>Nutrients</source>
<volume>10</volume> (<issue>10</issue>). <pub-id pub-id-type="doi">10.3390/nu10101507</pub-id>
<pub-id pub-id-type="pmid">30326592</pub-id>
<pub-id pub-id-type="pmcid">PMC6213524</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="book">
<collab>National Institute for Health and Care Excellence</collab> (<year>2018</year>). <source>2018 surveillance of diabetes in pregnancy: management from preconception to the postnatal period (NICE guideline NG3)</source>. <publisher-loc>London</publisher-loc>: <publisher-name>National Institute for Health and Care Excellence</publisher-name>.<pub-id pub-id-type="pmid">31846258</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ni</surname><given-names>L. F.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>C. C.</given-names></name>
<name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>M. M.</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Relationships between placental lipid Activated/transport-related factors and macrosomia in healthy pregnancy</article-title>. <source>Reprod. Sci.</source>
<volume>29</volume> (<issue>3</issue>), <fpage>904</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1007/s43032-021-00755-4</pub-id>
<pub-id pub-id-type="pmid">34750770</pub-id>
</mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>O’Tierney-Ginn</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Presley</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Myers</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Catalano</surname><given-names>P.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Placental growth response to maternal insulin in early pregnancy</article-title>. <source>J. Clin. Endocrinol. &amp; Metabolism</source>
<volume>100</volume> (<issue>1</issue>), <fpage>159</fpage>–<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2014-3281</pub-id>
<pub-id pub-id-type="pmcid">PMC4283005</pub-id><pub-id pub-id-type="pmid">25365315</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>OuYang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Abdulrahman</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>N.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Associations between gestational diabetes and anxiety or depression: a systematic review</article-title>. <source>J. Diabetes Res.</source>
<volume>2021</volume>, <fpage>9959779</fpage>. <pub-id pub-id-type="doi">10.1155/2021/9959779</pub-id>
<pub-id pub-id-type="pmid">34368368</pub-id>
<pub-id pub-id-type="pmcid">PMC8337159</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Panwar</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bhatt</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Tonk</surname><given-names>R. K.</given-names></name>
<name name-style="western"><surname>Azizov</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Raza</surname><given-names>A. S.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease</article-title>. <source>Signal Transduct. Target Ther.</source>
<volume>8</volume> (<issue>1</issue>), <fpage>375</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-023-01608-z</pub-id>
<pub-id pub-id-type="pmid">37779156</pub-id>
<pub-id pub-id-type="pmcid">PMC10543444</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pašić</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Molan</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Pongrac Barlovič</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Starčič Erjavec</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Žgur Bertok</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ambrožič Avguštin</surname><given-names>J.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Maternal gut microbiota in gestational diabetes mellitus and fetal macrosomia: is there an association?</article-title>
<source>Biomedicines</source>
<volume>13</volume> (<issue>12</issue>), <fpage>2941</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines13122941</pub-id>
<pub-id pub-id-type="pmid">41462953</pub-id>
<pub-id pub-id-type="pmcid">PMC12731141</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Paul</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Sultana</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Fisher</surname><given-names>J. J.</given-names></name>
<name name-style="western"><surname>Maiti</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Extracellular vesicles-crucial players in human pregnancy</article-title>. <source>Placenta</source>
<volume>140</volume>, <fpage>30</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2023.07.006</pub-id>
<pub-id pub-id-type="pmid">37531747</pub-id>
</mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pedersen</surname><given-names>J.</given-names></name>
</person-group> (<year>1954</year>). <article-title>Weight and length at birth of infants of diabetic mothers</article-title>. <source>Acta Endocrinol. (Copenh)</source>
<volume>16</volume> (<issue>4</issue>), <fpage>330</fpage>–<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1530/acta.0.0160330</pub-id>
<pub-id pub-id-type="pmid">13206643</pub-id>
</mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Miao</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Impact of maternal lipid profiles on offspring birth size in late pregnancy among women with and without gestational diabetes</article-title>. <source>Lipids Health Dis.</source>
<volume>24</volume> (<issue>1</issue>), <fpage>43</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-025-02458-0</pub-id>
<pub-id pub-id-type="pmid">39930414</pub-id>
<pub-id pub-id-type="pmcid">PMC11809092</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pérez-Pérez</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Maymó</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dueñas</surname><given-names>J. L.</given-names></name>
<name name-style="western"><surname>Goberna</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Calvo</surname><given-names>J. C.</given-names></name>
<name name-style="western"><surname>Varone</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Leptin prevents apoptosis of trophoblastic cells by activation of MAPK pathway</article-title>. <source>Arch. Biochem. Biophys.</source>
<volume>477</volume> (<issue>2</issue>), <fpage>390</fpage>–<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2008.06.015</pub-id>
<pub-id pub-id-type="pmid">18619412</pub-id>
</mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Picó</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Serra</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Rodríguez</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Keijer</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Palou</surname><given-names>A.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Biomarkers of nutrition and health: new tools for new approaches</article-title>. <source>Nutrients</source>
<volume>11</volume> (<issue>5</issue>). <pub-id pub-id-type="doi">10.3390/nu11051092</pub-id>
<pub-id pub-id-type="pmid">31100942</pub-id>
<pub-id pub-id-type="pmcid">PMC6567133</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pietro</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Daher</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Rudge</surname><given-names>M. V.</given-names></name>
<name name-style="western"><surname>Calderon</surname><given-names>I. M.</given-names></name>
<name name-style="western"><surname>Damasceno</surname><given-names>D. C.</given-names></name>
<name name-style="western"><surname>Sinzato</surname><given-names>Y. K.</given-names></name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Vascular endothelial growth factor (VEGF) and VEGF-receptor expression in placenta of hyperglycemic pregnant women</article-title>. <source>Placenta</source>
<volume>31</volume> (<issue>9</issue>), <fpage>770</fpage>–<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2010.07.003</pub-id>
<pub-id pub-id-type="pmid">20674013</pub-id>
</mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pillai</surname><given-names>R. A.</given-names></name>
<name name-style="western"><surname>Islam</surname><given-names>M. O.</given-names></name>
<name name-style="western"><surname>Selvam</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Chu</surname><given-names>A. H. Y.</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>O. C.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Placental inositol reduced in gestational diabetes as glucose alters inositol transporters and IMPA1 enzyme expression</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>106</volume> (<issue>2</issue>), <fpage>e875</fpage>–<lpage>e890</lpage>. <pub-id pub-id-type="doi">10.1210/clinem/dgaa814</pub-id>
<pub-id pub-id-type="pmid">33165596</pub-id>
<pub-id pub-id-type="pmcid">PMC7116629</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Qiu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Vadachkoria</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Meryman</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Frederick</surname><given-names>I. O.</given-names></name>
<name name-style="western"><surname>Williams</surname><given-names>M. A.</given-names></name>
</person-group> (<year>2005</year>). <article-title>Maternal plasma concentrations of IGF-1, IGFBP-1, and C-peptide in early pregnancy and subsequent risk of gestational diabetes mellitus</article-title>. <source>Am. J. Obstet. Gynecol.</source>
<volume>193</volume> (<issue>5</issue>), <fpage>1691</fpage>–<lpage>1697</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2005.04.015</pub-id>
<pub-id pub-id-type="pmid">16260212</pub-id>
</mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Regnault</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Lebreton</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Fosse-Edorh</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Barry</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Olié</surname><given-names>V.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Maternal and neonatal outcomes according to the timing of diagnosis of hyperglycaemia in pregnancy: a nationwide cross-sectional study of 695,912 deliveries in France in 2018</article-title>. <source>Diabetologia</source>
<volume>67</volume> (<issue>3</issue>), <fpage>516</fpage>–<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-023-06066-4</pub-id>
<pub-id pub-id-type="pmid">38182910</pub-id>
<pub-id pub-id-type="pmcid">PMC10844424</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Reynolds</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Perry</surname><given-names>J. K.</given-names></name>
<name name-style="western"><surname>Vickers</surname><given-names>M. H.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Manipulation of the growth hormone-insulin-like growth factor (GH-IGF) axis: a treatment strategy to reverse the effects of early life developmental programming</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>18</volume> (<issue>8</issue>). <pub-id pub-id-type="doi">10.3390/ijms18081729</pub-id>
<pub-id pub-id-type="pmid">28786951</pub-id>
<pub-id pub-id-type="pmcid">PMC5578119</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ribeiro</surname><given-names>M. M.</given-names></name>
<name name-style="western"><surname>Andrade</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Nunes</surname><given-names>I.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Physical exercise in pregnancy: benefits, risks and prescription</article-title>. <source>J. Perinat. Med.</source>
<volume>50</volume> (<issue>1</issue>), <fpage>4</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1515/jpm-2021-0315</pub-id>
<pub-id pub-id-type="pmid">34478617</pub-id>
</mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rosario</surname><given-names>F. J.</given-names></name>
<name name-style="western"><surname>Dimasuay</surname><given-names>K. G.</given-names></name>
<name name-style="western"><surname>Kanai</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Regulation of amino acid transporter trafficking by mTORC1 in primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2</article-title>. <source>Clin. Sci. (Lond)</source>
<volume>130</volume> (<issue>7</issue>), <fpage>499</fpage>–<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1042/cs20150554</pub-id>
<pub-id pub-id-type="pmid">26608079</pub-id>
<pub-id pub-id-type="pmcid">PMC5681479</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rosario</surname><given-names>F. J.</given-names></name>
<name name-style="western"><surname>Chopra</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Biggar</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>M. B.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
</person-group> (<year>2023a</year>). <article-title>Placental remote control of fetal metabolism: trophoblast mTOR signaling regulates liver IGFBP-1 phosphorylation and IGF-1 bioavailability</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>24</volume> (<issue>8</issue>), <fpage>7273</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24087273</pub-id>
<pub-id pub-id-type="pmid">37108437</pub-id>
<pub-id pub-id-type="pmcid">PMC10138459</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rosario</surname><given-names>F. J.</given-names></name>
<name name-style="western"><surname>Urschitz</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
</person-group> (<year>2023b</year>). <article-title>Overexpression of the LAT1 in primary human trophoblast cells increases the uptake of essential amino acids and activates mTOR signaling</article-title>. <source>Clin. Sci. (Lond)</source>
<volume>137</volume> (<issue>21</issue>), <fpage>1651</fpage>–<lpage>1664</lpage>. <pub-id pub-id-type="doi">10.1042/cs20230490</pub-id>
<pub-id pub-id-type="pmid">37861075</pub-id>
<pub-id pub-id-type="pmcid">PMC11654738</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sa</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>D. F.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Jia</surname><given-names>J. C.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>High TXNIP expression accelerates the migration and invasion of the GDM placenta trophoblast</article-title>. <source>BMC Pregnancy Childbirth</source>
<volume>23</volume> (<issue>1</issue>), <fpage>235</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-023-05524-6</pub-id>
<pub-id pub-id-type="pmid">37038114</pub-id>
<pub-id pub-id-type="pmcid">PMC10084645</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Saffery</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Novakovic</surname><given-names>B.</given-names></name>
</person-group> (<year>2014</year>). <article-title>Epigenetics as the mediator of fetal programming of adult onset disease: what is the evidence?</article-title>
<source>Acta Obstet. Gynecol. Scand.</source>
<volume>93</volume> (<issue>11</issue>), <fpage>1090</fpage>–<lpage>1098</lpage>. <pub-id pub-id-type="doi">10.1111/aogs.12431</pub-id>
<pub-id pub-id-type="pmid">24835110</pub-id>
</mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sahhaf Ebrahimi</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Homayouni Rad</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mosen</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Abbasalizadeh</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Tabrizi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Khalili</surname><given-names>L.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Effect of L. acidophilus and B. lactis on blood glucose in women with gestational diabetes mellitus: a randomized placebo-controlled trial</article-title>. <source>Diabetol. Metab. Syndr.</source>
<volume>11</volume>, <fpage>75</fpage>. <pub-id pub-id-type="doi">10.1186/s13098-019-0471-5</pub-id>
<pub-id pub-id-type="pmid">31485272</pub-id>
<pub-id pub-id-type="pmcid">PMC6714347</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Salles</surname><given-names>B. I. M.</given-names></name>
<name name-style="western"><surname>Cioffi</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Ferreira</surname><given-names>S. R. G.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Probiotics supplementation and insulin resistance: a systematic review</article-title>. <source>Diabetol. Metab. Syndr.</source>
<volume>12</volume> (<issue>1</issue>), <fpage>98</fpage>. <pub-id pub-id-type="doi">10.1186/s13098-020-00603-6</pub-id>
<pub-id pub-id-type="pmid">33292434</pub-id>
<pub-id pub-id-type="pmcid">PMC7656736</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Salomäki</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Vähätalo</surname><given-names>L. H.</given-names></name>
<name name-style="western"><surname>Laurila</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Jäppinen</surname><given-names>N. T.</given-names></name>
<name name-style="western"><surname>Penttinen</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Ailanen</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood</article-title>. <source>PLoS One</source>
<volume>8</volume> (<issue>2</issue>), <fpage>e56594</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0056594</pub-id>
<pub-id pub-id-type="pmid">23457588</pub-id>
<pub-id pub-id-type="pmcid">PMC3574083</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Salomon</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Scholz-Romero</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Sarker</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sweeney</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Correa</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation</article-title>. <source>Diabetes</source>
<volume>65</volume> (<issue>3</issue>), <fpage>598</fpage>–<lpage>609</lpage>. <pub-id pub-id-type="doi">10.2337/db15-0966</pub-id>
<pub-id pub-id-type="pmid">26718504</pub-id>
</mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Santos</surname><given-names>E. D.</given-names></name>
<name name-style="western"><surname>Hernández</surname><given-names>M. H.</given-names></name>
<name name-style="western"><surname>Sérazin</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Vialard</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Dieudonné</surname><given-names>M. N.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Human placental adaptive changes in response to maternal obesity: sex specificities</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>24</volume> (<issue>11</issue>), <fpage>9770</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24119770</pub-id>
<pub-id pub-id-type="pmid">37298720</pub-id>
<pub-id pub-id-type="pmcid">PMC10253453</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sathasivam</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Selliah</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sivalingarajah</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Mayorathan</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Munasinghe</surname><given-names>B. M.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Placental weight and its relationship with the birth weight of term infants and body mass index of the mothers</article-title>. <source>J. Int. Med. Res.</source>
<volume>2023</volume> (<issue>5</issue>), <fpage>3000605231172895</fpage>. <pub-id pub-id-type="doi">10.1177/03000605231172895</pub-id>
<pub-id pub-id-type="pmid">37194202</pub-id>
<pub-id pub-id-type="pmcid">PMC10192661</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sati</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Soygur</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Celik-Ozenci</surname><given-names>C.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Expression of mammalian target of Rapamycin and downstream targets in normal and gestational diabetic human term placenta</article-title>. <source>Reprod. Sci.</source>
<volume>23</volume> (<issue>3</issue>), <fpage>324</fpage>–<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1177/1933719115602765</pub-id>
<pub-id pub-id-type="pmid">26335179</pub-id>
</mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Saucedo</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Ferreira-Hermosillo</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Robledo-Clemente</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Díaz-Velázquez</surname><given-names>M. F.</given-names></name>
<name name-style="western"><surname>Valencia-Ortega</surname><given-names>J.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Association of DNA methylation with infant birth weight in women with gestational diabetes</article-title>. <source>Metabolites</source>
<volume>14</volume> (<issue>7</issue>), <fpage>361</fpage>. <pub-id pub-id-type="doi">10.3390/metabo14070361</pub-id>
<pub-id pub-id-type="pmid">39057684</pub-id>
<pub-id pub-id-type="pmcid">PMC11278577</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Scifres</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Nelson</surname><given-names>D. M.</given-names></name>
<name name-style="western"><surname>Sadovsky</surname><given-names>Y.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Fatty acid binding protein 4 regulates intracellular lipid accumulation in human trophoblasts</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>96</volume> (<issue>7</issue>), <fpage>E1083</fpage>–<lpage>E1091</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-2084</pub-id>
<pub-id pub-id-type="pmid">21525163</pub-id>
<pub-id pub-id-type="pmcid">PMC3135200</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Segura</surname><given-names>M. T.</given-names></name>
<name name-style="western"><surname>Demmelmair</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Krauss-Etschmann</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Nathan</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Dehmel</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Padilla</surname><given-names>M. C.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Maternal BMI and gestational diabetes alter placental lipid transporters and fatty acid composition</article-title>. <source>Placenta</source>
<volume>57</volume>, <fpage>144</fpage>–<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2017.07.001</pub-id>
<pub-id pub-id-type="pmid">28864004</pub-id>
</mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sferruzzi-Perri</surname><given-names>A. N.</given-names></name>
<name name-style="western"><surname>Lopez-Tello</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Salazar-Petres</surname><given-names>E.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Placental adaptations supporting fetal growth during normal and adverse gestational environments</article-title>. <source>Exp. Physiol.</source>
<volume>108</volume> (<issue>3</issue>), <fpage>371</fpage>–<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1113/ep090442</pub-id>
<pub-id pub-id-type="pmid">36484327</pub-id>
<pub-id pub-id-type="pmcid">PMC10103877</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shaat</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Akel</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Kristensen</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Nilsson</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Berntorp</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Katsarou</surname><given-names>A.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Analysis of self-monitoring of blood glucose metrics in gestational diabetes mellitus and their association with infants born large for gestational age: a historical observational cohort study of 879 pregnancies</article-title>. <source>Acta Obstetricia Gynecol. Scand.</source>
<volume>104</volume> (<issue>1</issue>), <fpage>109</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1111/aogs.14997</pub-id>
<pub-id pub-id-type="pmid">39445712</pub-id>
<pub-id pub-id-type="pmcid">PMC11683546</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Increased placental IGF-1/mTOR activity in macrosomia born to women with gestational diabetes</article-title>. <source>Diabetes Res. Clin. Pract.</source>
<volume>146</volume>, <fpage>211</fpage>–<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2018.10.017</pub-id>
<pub-id pub-id-type="pmid">30389621</pub-id>
</mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shi</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Association between second- and third-trimester maternal lipid profiles and adverse perinatal outcomes among women with GDM and non-GDM: a retrospective cohort study</article-title>. <source>BMC Pregnancy Childbirth</source>
<volume>23</volume> (<issue>1</issue>), <fpage>318</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-023-05630-5</pub-id>
<pub-id pub-id-type="pmid">37147564</pub-id>
<pub-id pub-id-type="pmcid">PMC10161404</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shimada</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Regulation of placental amino acid transport in health and disease</article-title>. <source>Acta Physiol. (Oxf)</source>
<volume>240</volume> (<issue>7</issue>), <fpage>e14157</fpage>. <pub-id pub-id-type="doi">10.1111/apha.14157</pub-id>
<pub-id pub-id-type="pmid">38711335</pub-id>
<pub-id pub-id-type="pmcid">PMC11162343</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sivan</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Homko</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Reece</surname><given-names>E. A.</given-names></name>
<name name-style="western"><surname>Boden</surname><given-names>G.</given-names></name>
</person-group> (<year>1999</year>). <article-title>Effect of insulin on fat metabolism during and after normal pregnancy</article-title>. <source>Diabetes</source>
<volume>48</volume> (<issue>4</issue>), <fpage>834</fpage>–<lpage>838</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.48.4.834</pub-id>
<pub-id pub-id-type="pmid">10102701</pub-id>
</mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sklempe Kokic</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Ivanisevic</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Biolo</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Simunic</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Kokic</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Pisot</surname><given-names>R.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Combination of a structured aerobic and resistance exercise improves glycaemic control in pregnant women diagnosed with gestational diabetes mellitus. A randomised controlled trial</article-title>. <source>Women Birth</source>
<volume>31</volume> (<issue>4</issue>), <fpage>e232</fpage>–<lpage>e238</lpage>. <pub-id pub-id-type="doi">10.1016/j.wombi.2017.10.004</pub-id>
<pub-id pub-id-type="pmid">29055674</pub-id>
</mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Soltani</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Shirani</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Chitsazi</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>Salehi-Abargouei</surname><given-names>A.</given-names></name>
</person-group> (<year>2016</year>). <article-title>The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials</article-title>. <source>Obes. Rev.</source>
<volume>17</volume> (<issue>5</issue>), <fpage>442</fpage>–<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1111/obr.12391</pub-id>
<pub-id pub-id-type="pmid">26990451</pub-id>
</mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Song</surname><given-names>T. R.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>G. D.</given-names></name>
<name name-style="western"><surname>Chi</surname><given-names>Y. L.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>C. C.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Dysregulated miRNAs contribute to altered placental glucose metabolism in patients with gestational diabetes <italic toggle="yes">via</italic> targeting GLUT1 and HK2</article-title>. <source>Placenta</source>
<volume>105</volume>, <fpage>14</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2021.01.015</pub-id>
<pub-id pub-id-type="pmid">33517149</pub-id>
</mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Song</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Diao</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Pre-pregnancy body mass index and risk of macrosomia and large for gestational age births with gestational diabetes mellitus as a mediator: a prospective cohort study in central China</article-title>. <source>Nutrients</source>
<volume>14</volume> (<issue>5</issue>), <fpage>1072</fpage>. <pub-id pub-id-type="doi">10.3390/nu14051072</pub-id>
<pub-id pub-id-type="pmid">35268050</pub-id>
<pub-id pub-id-type="pmcid">PMC8912482</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Stanirowski</surname><given-names>P. J.</given-names></name>
<name name-style="western"><surname>Szukiewicz</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Pyzlak</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Abdalla</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Sawicki</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Cendrowski</surname><given-names>K.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Analysis of correlations between the placental expression of glucose transporters GLUT-1, GLUT-4 and GLUT-9 and selected maternal and fetal parameters in pregnancies complicated by diabetes mellitus</article-title>. <source>J. Matern. Fetal Neonatal Med.</source>
<volume>32</volume> (<issue>4</issue>), <fpage>650</fpage>–<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1080/14767058.2017.1387897</pub-id>
<pub-id pub-id-type="pmid">28969476</pub-id>
</mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Su</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Alteration in expression and methylation of IGF2/H19 in placenta and umbilical cord blood are associated with macrosomia exposed to intrauterine hyperglycemia</article-title>. <source>PLOS ONE</source>
<volume>11</volume> (<issue>2</issue>), <fpage>e0148399</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0148399</pub-id>
<pub-id pub-id-type="pmid">26840070</pub-id>
<pub-id pub-id-type="pmcid">PMC4739655</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Subiabre</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Villalobos-Labra</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Silva</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Fuentes</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Toledo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Sobrevia</surname><given-names>L.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Role of insulin, adenosine, and adipokine receptors in the foetoplacental vascular dysfunction in gestational diabetes mellitus</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source>
<volume>1866</volume> (<issue>2</issue>), <fpage>165370</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2018.12.021</pub-id>
<pub-id pub-id-type="pmid">30660686</pub-id>
</mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Kopp</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Strutz</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Gali</surname><given-names>C. C.</given-names></name>
<name name-style="western"><surname>Zandl-Lang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fanaee-Danesh</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Gestational diabetes mellitus modulates cholesterol homeostasis in human fetoplacental endothelium</article-title>. <source>Biochim. Biophys. Acta Mol. Cell Biol. Lipids</source>
<volume>1863</volume> (<issue>9</issue>), <fpage>968</fpage>–<lpage>979</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2018.05.005</pub-id>
<pub-id pub-id-type="pmid">29778664</pub-id>
</mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sweeting</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Hannah</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Backman</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Catalano</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Feghali</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Herman</surname><given-names>W. H.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Epidemiology and management of gestational diabetes</article-title>. <source>Lancet</source>
<volume>404</volume> (<issue>10448</issue>), <fpage>175</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(24)00825-0</pub-id>
<pub-id pub-id-type="pmid">38909620</pub-id>
</mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Symonds</surname><given-names>M. E.</given-names></name>
<name name-style="western"><surname>Sebert</surname><given-names>S. P.</given-names></name>
<name name-style="western"><surname>Hyatt</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Budge</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>). <article-title>Nutritional programming of the metabolic syndrome</article-title>. <source>Nat. Rev. Endocrinol.</source>
<volume>5</volume> (<issue>11</issue>), <fpage>604</fpage>–<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2009.195</pub-id>
<pub-id pub-id-type="pmid">19786987</pub-id>
</mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Szabo</surname><given-names>A. J.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Transferred maternal fatty acids stimulate fetal adipogenesis and lead to neonatal and adult obesity</article-title>. <source>Med. Hypotheses</source>
<volume>122</volume>, <fpage>82</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2018.10.022</pub-id>
<pub-id pub-id-type="pmid">30593430</pub-id>
</mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tang</surname><given-names>Y. B.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>L. S.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Y. H.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L. X.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>L. Y.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Effect of exercise during pregnancy on offspring development through ameliorating high glucose and hypoxia in gestational diabetes mellitus</article-title>. <source>World J. Diabetes</source>
<volume>15</volume> (<issue>11</issue>), <fpage>2203</fpage>–<lpage>2219</lpage>. <pub-id pub-id-type="doi">10.4239/wjd.v15.i11.2203</pub-id>
<pub-id pub-id-type="pmid">39582571</pub-id>
<pub-id pub-id-type="pmcid">PMC11580567</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Taschereau</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Thibeault</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Allard</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Juvinao-Quintero</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Perron</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Lutz</surname><given-names>S. M.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Maternal glycemia in pregnancy is longitudinally associated with blood DNAm variation at the FSD1L gene from birth to 5 years of age</article-title>. <source>Clin. Epigenetics</source>
<volume>15</volume> (<issue>1</issue>), <fpage>107</fpage>. <pub-id pub-id-type="doi">10.1186/s13148-023-01524-7</pub-id>
<pub-id pub-id-type="pmid">37386647</pub-id>
<pub-id pub-id-type="pmcid">PMC10308691</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Théry</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Witwer</surname><given-names>K. W.</given-names></name>
<name name-style="western"><surname>Aikawa</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Alcaraz</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>Anderson</surname><given-names>J. D.</given-names></name>
<name name-style="western"><surname>Andriantsitohaina</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines</article-title>. <source>J. Extracell. Vesicles</source>
<volume>7</volume> (<issue>1</issue>), <fpage>1535750</fpage>. <pub-id pub-id-type="doi">10.1080/20013078.2018.1535750</pub-id>
<pub-id pub-id-type="pmid">30637094</pub-id>
<pub-id pub-id-type="pmcid">PMC6322352</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tkach</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Théry</surname><given-names>C.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Communication by extracellular vesicles: where we are and where we need to Go</article-title>. <source>Cell</source>
<volume>164</volume> (<issue>6</issue>), <fpage>1226</fpage>–<lpage>1232</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.01.043</pub-id>
<pub-id pub-id-type="pmid">26967288</pub-id>
</mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Troncoso</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Acurio</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Herlitz</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Aguayo</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Bertoglia</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Guzman-Gutierrez</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1</article-title>. <source>PLoS One</source>
<volume>12</volume> (<issue>8</issue>), <fpage>e0182509</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0182509</pub-id>
<pub-id pub-id-type="pmid">28817576</pub-id>
<pub-id pub-id-type="pmcid">PMC5560693</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Usta</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Usta</surname><given-names>C. S.</given-names></name>
<name name-style="western"><surname>Yildiz</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Ozcaglayan</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Dalkiran</surname><given-names>E. S.</given-names></name>
<name name-style="western"><surname>Savkli</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Frequency of fetal macrosomia and the associated risk factors in pregnancies without gestational diabetes mellitus</article-title>. <source>Pan Afr. Med. J.</source>
<volume>26</volume>, <fpage>62</fpage>. <pub-id pub-id-type="doi">10.11604/pamj.2017.26.62.11440</pub-id>
<pub-id pub-id-type="pmid">28451039</pub-id>
<pub-id pub-id-type="pmcid">PMC5398855</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vargas</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Martins</surname><given-names>I. P.</given-names></name>
<name name-style="western"><surname>Matiusso</surname><given-names>C. C. I.</given-names></name>
<name name-style="western"><surname>Casagrande</surname><given-names>R. A.</given-names></name>
<name name-style="western"><surname>Zara</surname><given-names>C. B.</given-names></name>
<name name-style="western"><surname>Huppes de Souza</surname><given-names>A. C.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Protein restriction during lactation causes transgenerational metabolic dysfunction in adult rat offspring</article-title>. <source>Front. Nutr.</source>
<volume>9</volume>, <fpage>1062116</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2022.1062116</pub-id>
<pub-id pub-id-type="pmid">36704794</pub-id>
<pub-id pub-id-type="pmcid">PMC9872122</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vargas-Terrones</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Nagpal</surname><given-names>T. S.</given-names></name>
<name name-style="western"><surname>Barakat</surname><given-names>R.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Impact of exercise during pregnancy on gestational weight gain and birth weight: an overview</article-title>. <source>Braz J. Phys. Ther.</source>
<volume>23</volume> (<issue>2</issue>), <fpage>164</fpage>–<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjpt.2018.11.012</pub-id>
<pub-id pub-id-type="pmid">30527949</pub-id>
<pub-id pub-id-type="pmcid">PMC6428912</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vaughan</surname><given-names>O. R.</given-names></name>
<name name-style="western"><surname>Rosario</surname><given-names>F. J.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>T. L.</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>T.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Regulation of placental amino acid transport and fetal growth</article-title>. <source>Prog. Mol. Biol. Transl. Sci.</source>
<volume>145</volume>, <fpage>217</fpage>–<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/bs.pmbts.2016.12.008</pub-id>
<pub-id pub-id-type="pmid">28110752</pub-id>
</mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vedika</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>A.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Signature precursor and mature microRNAs in cervical ripening during gestational diabetes mellitus lead to pre-term labor and other impediments in future</article-title>. <source>J. Diabetes Metab. Disord.</source>
<volume>22</volume> (<issue>2</issue>), <fpage>945</fpage>–<lpage>965</lpage>. <pub-id pub-id-type="doi">10.1007/s40200-023-01232-2</pub-id>
<pub-id pub-id-type="pmid">37975145</pub-id>
<pub-id pub-id-type="pmcid">PMC10638342</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Villota</surname><given-names>S. D.</given-names></name>
<name name-style="western"><surname>Toledo-Rodriguez</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Leach</surname><given-names>L.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Compromised barrier integrity of human feto-placental vessels from gestational diabetic pregnancies is related to downregulation of occludin expression</article-title>. <source>Diabetologia</source>
<volume>64</volume> (<issue>1</issue>), <fpage>195</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-020-05290-6</pub-id>
<pub-id pub-id-type="pmid">33001231</pub-id>
<pub-id pub-id-type="pmcid">PMC7716932</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Visiedo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Bugatto</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Sánchez</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Cózar-Castellano</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Bartha</surname><given-names>J. L.</given-names></name>
<name name-style="western"><surname>Perdomo</surname><given-names>G.</given-names></name>
</person-group> (<year>2013</year>). <article-title>High glucose levels reduce fatty acid oxidation and increase triglyceride accumulation in human placenta</article-title>. <source>Am. J. Physiol. Endocrinol. Metab.</source>
<volume>305</volume> (<issue>2</issue>), <fpage>E205</fpage>–<lpage>E212</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00032.2013</pub-id>
<pub-id pub-id-type="pmid">23673156</pub-id>
</mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Exercise intervention during pregnancy can be used to manage weight gain and improve pregnancy outcomes in women with gestational diabetes mellitus</article-title>. <source>BMC Pregnancy Childbirth</source>
<volume>15</volume>, <fpage>255</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-015-0682-1</pub-id>
<pub-id pub-id-type="pmid">26459271</pub-id>
<pub-id pub-id-type="pmcid">PMC4603976</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>W. J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>G. H.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>M. N.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Fetuin-A and fetal growth in gestational diabetes mellitus</article-title>. <source>BMJ Open Diabetes Res. Care</source>
<volume>8</volume> (<issue>1</issue>), <fpage>e000864</fpage>. <pub-id pub-id-type="doi">10.1136/bmjdrc-2019-000864</pub-id>
<pub-id pub-id-type="pmid">32049636</pub-id>
<pub-id pub-id-type="pmcid">PMC7039609</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Bove</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Simone</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Molecular bases of VEGFR-2-Mediated physiological function and pathological role</article-title>. <source>Front. Cell Dev. Biol.</source>
<volume>8</volume>, <fpage>599281</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2020.599281</pub-id>
<pub-id pub-id-type="pmid">33304904</pub-id>
<pub-id pub-id-type="pmcid">PMC7701214</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>Y. M.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>N. N.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y. X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Influence of one-day diabetes mellitus clinic management on blood glucose control and prognosis in patients with gestational diabetes mellitus</article-title>. <source>Gynecol. Endocrinol.</source>
<volume>38</volume> (<issue>4</issue>), <fpage>324</fpage>–<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1080/09513590.2022.2040474</pub-id>
<pub-id pub-id-type="pmid">35188053</pub-id>
</mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Westermeier</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Salomón</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Farías</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Arroyo</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Fuenzalida</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Sáez</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Insulin requires normal expression and signaling of insulin receptor A to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium</article-title>. <source>Faseb J.</source>
<volume>29</volume> (<issue>1</issue>), <fpage>37</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1096/fj.14-254219</pub-id>
<pub-id pub-id-type="pmid">25351985</pub-id>
</mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Westermeier</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Sáez</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Arroyo</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Toledo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Gutiérrez</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Sanhueza</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Insulin receptor isoforms: an integrated view focused on gestational diabetes mellitus</article-title>. <source>Diabetes Metab. Res. Rev.</source>
<volume>32</volume> (<issue>4</issue>), <fpage>350</fpage>–<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1002/dmrr.2729</pub-id>
<pub-id pub-id-type="pmid">26431063</pub-id>
</mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Winterhager</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Gellhaus</surname><given-names>A.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Transplacental nutrient transport mechanisms of intrauterine growth restriction in rodent models and humans</article-title>. <source>Front. Physiol.</source>
<volume>8</volume>, <fpage>951</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.00951</pub-id>
<pub-id pub-id-type="pmid">29230179</pub-id>
<pub-id pub-id-type="pmcid">PMC5711821</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xiang</surname><given-names>A. H.</given-names></name>
<name name-style="western"><surname>Peters</surname><given-names>R. K.</given-names></name>
<name name-style="western"><surname>Trigo</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Kjos</surname><given-names>S. L.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>W. P.</given-names></name>
<name name-style="western"><surname>Buchanan</surname><given-names>T. A.</given-names></name>
</person-group> (<year>1999</year>). <article-title>Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes</article-title>. <source>Diabetes</source>
<volume>48</volume> (<issue>4</issue>), <fpage>848</fpage>–<lpage>854</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.48.4.848</pub-id>
<pub-id pub-id-type="pmid">10102703</pub-id>
</mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Shang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>The crosstalk between cell death and pregnancy related diseases: a narrative review</article-title>. <source>Biomed. &amp; Pharmacother.</source>
<volume>176</volume>, <fpage>116815</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.116815</pub-id>
<pub-id pub-id-type="pmid">38788598</pub-id>
</mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Exploring the molecular underpinnings of macrosomia in gestational diabetes mellitus: the role of EGFR signaling and placental syncytiotrophoblast</article-title>. <source>Life Sci.</source>
<volume>359</volume>, <fpage>123207</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2024.123207</pub-id>
<pub-id pub-id-type="pmid">39489396</pub-id>
</mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Jing</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Qian</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Validation of the clinical efficacy of one-day outpatient management of patients with gestational diabetes mellitus</article-title>. <source>J. Matern. Fetal Neonatal Med.</source>
<volume>38</volume> (<issue>1</issue>), <fpage>2436086</fpage>. <pub-id pub-id-type="doi">10.1080/14767058.2024.2436086</pub-id>
<pub-id pub-id-type="pmid">39617621</pub-id>
</mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Increased expression of fatty acid binding protein 4 in preeclamptic placenta and its relevance to preeclampsia</article-title>. <source>Placenta</source>
<volume>39</volume>, <fpage>94</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2016.01.014</pub-id>
<pub-id pub-id-type="pmid">26992681</pub-id>
</mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Exercise intervention during pregnancy induces DNA methylation alterations in maternal blood and cord blood</article-title>. <source>Chin. Med. J. Engl.</source>
<volume>136</volume> (<issue>13</issue>), <fpage>1624</fpage>–<lpage>1626</lpage>. <pub-id pub-id-type="doi">10.1097/cm9.0000000000002226</pub-id>
<pub-id pub-id-type="pmid">35830266</pub-id>
<pub-id pub-id-type="pmcid">PMC10325741</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yan</surname><given-names>Y. S.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>D. Q.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Y. T.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Long-term outcomes and potential mechanisms of offspring exposed to intrauterine hyperglycemia</article-title>. <source>Front. Nutr.</source>
<volume>10</volume>, <fpage>1067282</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2023.1067282</pub-id>
<pub-id pub-id-type="pmid">37255932</pub-id>
<pub-id pub-id-type="pmcid">PMC10226394</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yanachkova</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Staynova</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Bochev</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Kamenov</surname><given-names>Z.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Potential role of biochemical placentation markers - pregnancy associated plasma protein-A and human chorionic gonadotropin for early gestational diabetes screening - a pilot study</article-title>. <source>Ginekol. Pol.</source>
<volume>93</volume> (<issue>5</issue>), <fpage>405</fpage>–<lpage>409</lpage>. <pub-id pub-id-type="doi">10.5603/GP.a2021.0129</pub-id>
<pub-id pub-id-type="pmid">34541644</pub-id>
</mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Yallampalli</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Fetal macrosomia in a hispanic/latinx predominant cohort and altered expressions of genes related to placental lipid transport and metabolism</article-title>. <source>Int. J. Obes. (Lond)</source>
<volume>44</volume> (<issue>8</issue>), <fpage>1743</fpage>–<lpage>1752</lpage>. <pub-id pub-id-type="doi">10.1038/s41366-020-0610-y</pub-id>
<pub-id pub-id-type="pmid">32494035</pub-id>
<pub-id pub-id-type="pmcid">PMC7387181</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhong</surname><given-names>Z.-F.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>S.-P.</given-names></name>
<name name-style="western"><surname>Vong</surname><given-names>C.-T.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y.-T.</given-names></name>
</person-group> (<year>2021</year>). <article-title>HIF-1: structure, biology and natural modulators</article-title>. <source>Chin. J. Nat. Med.</source>
<volume>19</volume> (<issue>7</issue>), <fpage>521</fpage>–<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(21)60051-1</pub-id>
<pub-id pub-id-type="pmid">34247775</pub-id>
</mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Duan</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Exosome enriched leucine-rich alpha-2-glycoprotein-1 and extracellular matrix protein 1 proteins induce abnormal placental angiogenesis in pregnant mice</article-title>. <source>Placenta</source>
<volume>143</volume>, <fpage>45</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2023.09.008</pub-id>
<pub-id pub-id-type="pmid">37804693</pub-id>
</mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yapicioglu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Seckin</surname><given-names>S. C.</given-names></name>
<name name-style="western"><surname>Yontem</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Yildizdas</surname><given-names>D.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Infants with macrosomia and infants of diabetic mothers have increased carotid artery intima-media thickness in childhood</article-title>. <source>Eur. J. Pediatr.</source>
<volume>182</volume> (<issue>1</issue>), <fpage>203</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1007/s00431-022-04653-y</pub-id>
<pub-id pub-id-type="pmid">36278997</pub-id>
</mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Adverse effects of gestational diabetes mellitus on fetal monocytes revealed by single-cell RNA sequencing</article-title>. <source>iScience</source>
<volume>27</volume> (<issue>1</issue>), <fpage>108637</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2023.108637</pub-id>
<pub-id pub-id-type="pmid">38188508</pub-id>
<pub-id pub-id-type="pmcid">PMC10770529</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Exosomal RNA expression profiles and their prediction performance in patients with gestational diabetes mellitus and macrosomia</article-title>. <source>Front. Endocrinol. (Lausanne)</source>
<volume>13</volume>, <fpage>864971</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.864971</pub-id>
<pub-id pub-id-type="pmid">35547007</pub-id>
<pub-id pub-id-type="pmcid">PMC9082313</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Association between levels of aquaporin 3 in the placenta and adiponectin in the umbilical cord blood with gestational diabetes mellitus and pregnancy outcome</article-title>. <source>Mol. Med. Rep.</source>
<volume>22</volume> (<issue>2</issue>), <fpage>1498</fpage>–<lpage>1506</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2020.11225</pub-id>
<pub-id pub-id-type="pmid">32627013</pub-id>
<pub-id pub-id-type="pmcid">PMC7339817</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hyperglycemia aggravates monocyte-endothelial adhesion in human umbilical vein endothelial cells from women with gestational diabetes mellitus by inducing Cx43 overexpression</article-title>. <source>Ann. Transl. Med.</source>
<volume>9</volume> (<issue>3</issue>), <fpage>234</fpage>. <pub-id pub-id-type="doi">10.21037/atm-19-4738</pub-id>
<pub-id pub-id-type="pmid">33708861</pub-id>
<pub-id pub-id-type="pmcid">PMC7940931</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Chemerin-induced down-regulation of placenta-derived exosomal miR-140-3p and miR-574-3p promotes umbilical vein endothelial cells proliferation, migration, and tube formation in gestational diabetes mellitus</article-title>. <source>Cells</source>
<volume>11</volume> (<issue>21</issue>), <fpage>3457</fpage>. <pub-id pub-id-type="doi">10.3390/cells11213457</pub-id>
<pub-id pub-id-type="pmid">36359855</pub-id>
<pub-id pub-id-type="pmcid">PMC9655594</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Qin</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
</person-group> (<year>2022</year>). <article-title>High glucose increases IGF-2/H19 expression by changing DNA methylation in HTR8/SVneo trophoblast cells</article-title>. <source>Placenta</source>
<volume>118</volume>, <fpage>32</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2021.12.022</pub-id>
<pub-id pub-id-type="pmid">35007927</pub-id>
</mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Tashiro</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>P. J.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Effects of dietary approaches and exercise interventions on gestational diabetes mellitus: a systematic review and bayesian network meta-analysis</article-title>. <source>Adv. Nutr.</source>
<volume>15</volume> (<issue>12</issue>), <fpage>100330</fpage>. <pub-id pub-id-type="doi">10.1016/j.advnut.2024.100330</pub-id>
<pub-id pub-id-type="pmid">39481539</pub-id>
<pub-id pub-id-type="pmcid">PMC11629230</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Risk of adverse pregnancy outcomes in pregnant women with gestational diabetes mellitus by age: a multicentric cohort study in Hebei, China</article-title>. <source>Sci. Rep.</source>
<volume>14</volume> (<issue>1</issue>), <fpage>807</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-49916-2</pub-id>
<pub-id pub-id-type="pmid">38191624</pub-id>
<pub-id pub-id-type="pmcid">PMC10774329</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Bai</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ruan</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Upregulation of MMPs in placentas of patients with gestational diabetes mellitus: involvement of the PI3K/Akt pathway</article-title>. <source>Heliyon</source>
<volume>10</volume> (<issue>12</issue>), <fpage>e32518</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e32518</pub-id>
<pub-id pub-id-type="pmid">39021921</pub-id>
<pub-id pub-id-type="pmcid">PMC11252657</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Association of hyperglycaemia with the placenta of GDM-induced macrosomia with normal pre-pregnancy BMI and the proliferation of trophoblast cells</article-title>. <source>J. Obstet. Gynaecol.</source>
<volume>42</volume> (<issue>6</issue>), <fpage>1759</fpage>–<lpage>1768</lpage>. <pub-id pub-id-type="doi">10.1080/01443615.2022.2036969</pub-id>
<pub-id pub-id-type="pmid">35260025</pub-id>
</mixed-citation></ref></ref-list></back></article><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12909731</article-id><article-id pub-id-type="pmcid-ver">PMC12909731.1</article-id><article-id pub-id-type="pmcaid">12909731</article-id><article-id pub-id-type="pmcaiid">12909731</article-id><article-id pub-id-type="pmid">41572107</article-id><article-id pub-id-type="doi">10.1007/s12672-026-04447-w</article-id><article-id pub-id-type="publisher-id">4447</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A bibliometric and visual analysis of colorectal cancer-diabetes comorbidity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Long</surname><given-names initials="J">Junyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="X">Xuewei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yandong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="Q">Qingyang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Feng</surname><given-names initials="K">Kai</given-names></name><address><email>13848018266@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Baotou Medical College, Inner Mongolia University of Science and Technology, Inner Mongolia, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/044rgx723</institution-id><institution-id institution-id-type="GRID">grid.462400.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0144 9297</institution-id><institution>Tumor Center Department, The First Affiliated Hospital of Baotou Medical College, </institution><institution>Inner Mongolia University of Science and Technology, </institution></institution-wrap>Inner Mongolia, China </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2026</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">503859</issue-id><elocation-id>313</elocation-id><history><date date-type="received"><day>28</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 00:25:13.357"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2026</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12672_2026_Article_4447.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Colorectal cancer (CRC), a leading cause of global cancer-related mortality, exhibits a complex bidirectional relationship with diabetes mellitus (DM). Epidemiological evidence indicates that DM significantly increases the risk of CRC, while CRC progression may exacerbate diabetic complications; however, the underlying mechanisms remain incompletely understood. This study aimed to conduct a bibliometric analysis of the literature on COLORECTAL CANCER-DIABETES comorbidity to identify research trends, collaborative networks, and emerging thematic foci.</p></sec><sec><title>Methods</title><p id="Par2">We performed a comprehensive search in the Web of Science Core Collection (WoSCC) database to retrieve relevant literature. Using analytical and visualization tools, including CiteSpace and VOSviewer, we examined publication trends, major contributing countries and institutions, collaboration networks, and keyword evolution to map the current research landscape in this field.</p></sec><sec><title>Result</title><p id="Par3">Annual publication output on COLORECTAL CANCER-DIABETES comorbidity increased markedly after 2005, reflecting growing recognition of the metabolic-cancer interplay and expanded research funding. The United States and China were the dominant contributors, with Harvard University and Birmingham Women’s Hospital among the most productive institutions. Keyword analysis revealed emerging research clusters such as <italic toggle="yes">“diabetes-associated centrosome amplification</italic>,<italic toggle="yes">” “metformin’s therapeutic potential</italic>,<italic toggle="yes">”</italic> and <italic toggle="yes">“anastomotic leakage.”</italic></p></sec><sec><title>Conclusion</title><p id="Par4">Research on the interplay between colorectal cancer and diabetes is gaining increasing priority. Future efforts should focus on elucidating molecular mechanisms—such as oxidative stress and angiogenesis dysregulation—refining epidemiological models, and translating findings into clinical practice. Developing precision medicine strategies for CRC screening and treatment in diabetic populations, alongside the exploration of novel biomarkers and therapeutic targets, will be essential to improve patient prognosis.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-026-04447-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal cancer</kwd><kwd>Diabetes</kwd><kwd>Bibliometrics</kwd><kwd>Visual analysis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Science+Business Media LLC, part of Springer Nature 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Diabetes mellitus (DM) and colorectal cancer (CRC) are both diseases with high treatment costs that place a heavy financial burden on individuals, society, and the nation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Diabetes is a common chronic disease in the population, mainly characterised by insulin secretion disorders, insulin utilisation disorders or a combination of both deficiencies, and is mainly classified into type 1 diabetes, type 2 diabetes mellitus (T2DM) and gestational diabetes, with T2DM accounting for 90% of the total number of people suffering from the disease [<xref ref-type="bibr" rid="CR3">3</xref>]. Worldwide, diabetes is one of the leading causes of death among adults, and its prevalence and incidence continue to rise. The 9th edition of the International Diabetes Federation (IDF) Atlas shows that the number of people with diabetes is expected to increase to 700 million globally by 2045 [<xref ref-type="bibr" rid="CR4">4</xref>]. Most CRC cases evolve from adenomatous polyps [<xref ref-type="bibr" rid="CR5">5</xref>]. Previous studies have suggested that adenomatous polyps may evolve as neoplastic precursor lesions from cancer stem cells or stem cell-like cells located at the base of the colonic crypts [<xref ref-type="bibr" rid="CR6">6</xref>]. CRC was estimated to be the third most common cause of morbidity (9.6 per cent) and the second most common cause of mortality (9.3 per cent) globally in 2022 [<xref ref-type="bibr" rid="CR7">7</xref>]. The 8th edition of the American Joint Committee on Cancer (AJCC) cancer staging manual suggests that the relative survival rate for patients with stage IV CRC is only about 40% [<xref ref-type="bibr" rid="CR8">8</xref>]. Previous EUROCARE studies on cancer survival analysis in European countries have shown that CRC patients aged 60–69 had an average five-year cumulative relative survival rate of 40% and that the prognosis becomes poorer with increasing age at diagnosis [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par6">A complex bidirectional relationship exists between diabetes and CRC. Diabetes is one of the risk factors for CRC, and CRC may also contribute to the progression of diabetes. Most diabetic patients are associated with an increased incidence of various solid tumours, such as pancreatic cancer, breast cancer, cancers of the hepatobiliary system and CRC. There is a positive correlation between the risk of CRC in patients with diabetes compared to those without diabetes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In addition, studies have shown that CRC patients have a significantly higher risk of developing DM within 5 years of diagnosis compared to non-CRC patients [<xref ref-type="bibr" rid="CR12">12</xref>]. Shared risk factors for both disorders include insulin resistance (IR), hyperglycemia, and hyperinsulinemia [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Prolonged hyperglycemia can seriously damage the function of human organs, and the worse the daily glycaemic control, the more serious the damage to the target organs [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par7">Currently, there is limited bibliometric research output focusing on CRC from the perspective of diabetes, with a notable lack of targeted studies in this area, which warrants further investigation. In 1969, Alan Pritchard defined bibliometrics as a discipline that employs mathematical and statistical methods to analyse scholarly publications [<xref ref-type="bibr" rid="CR16">16</xref>]. As an emerging discipline with extensive application potential, particularly in the field of medical science, the use of CiteSpace enables quantitative analysis of research progress in target domains, thereby providing robust data support for future studies and policy formulation.</p><p id="Par8">This study conducted a bibliometric analysis of research outputs on colorectal cancer-diabetes comorbidity from 1990 to 2024, identified key research hotspots in the field, and provided novel perspectives for subsequent investigations.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Data sources</title><p id="Par9">In the literature search, initially, we selected one of the three major databases, the Web of Science Core Collection (WoSCC), Scopus and Google Scholar, which are the main sources of citation data. Google Scholar provides richer citation results among the three, but its data sources are not all specialised academic journals. Scopus is a newcomer in the field of bibliometric research, but its data content is relatively new. Although WoSCC is not perfect, it is still regarded as the gold standard in the field of bibliometrics [<xref ref-type="bibr" rid="CR16">16</xref>]. Meanwhile, the data analysed by CiteSpace is based on WoSCC data, and the data from other databases need to be converted to WoS data format before they can be analysed, so we finally chose the WoS database as the retrieval source.</p><p id="Par10">On July 10, 2024, we performed a comprehensive literature search in WoSCC database. The primary search terms were “Rectal Neoplasm”, “Colonic Neoplasm” and “Diabetes”, with language restricted to English and publication type limited to Articles. The detailed search strategy is provided in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>. To avoid the impact of database updates, all search results were downloaded within the same day in multiple formats, including plain text, Excel, BibTex, and tab-delimited files. Ultimately, 905 records were identified for analysis. The overall research workflow is schematically illustrated in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par11">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Publications screening flowchart</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e299" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Data analysis and visualization</title><p id="Par12">The retrieved data were imported into CiteSpace (version 6.3.R3), VOSviewer (version 1.6.20), the bibliometrix package in R (version 4.4.0), Scimago Graphica, and the Bibliometric Analysis Online Platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bibliometric.com/">https://bibliometric.com/</ext-link>) to perform analysis of published studies and create visual mapping diagrams. VOSviewer enables knowledge mapping visualisation of large-scale literature data through co-authorship analysis, co-occurrence analysis, and co-citation analysis, representing authors, journals, and related entities [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR19">19</xref>]. CiteSpace was employed to conduct country collaboration mapping, journal co-authorship analysis, reference co-citation analysis, and keyword clustering, thereby identifying developmental trajectories and emerging trends within the research domain [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. We conducted burst detection analysis [<xref ref-type="bibr" rid="CR21">21</xref>] on the references to identify emerging academic trends and novel disciplinary developments, enabling the projection of frontier research directions and potential hotspots [<xref ref-type="bibr" rid="CR22">22</xref>]. The keyword timelines [<xref ref-type="bibr" rid="CR23">23</xref>] delineated temporal ranges of clustered research hotspots, revealing interconnections between distinct thematic concentrations, thereby mapping the evolutionary trajectory of research focuses since the inception of CRC comorbidity studies. Subsequent time-zone maps of keywords demonstrated their chronological distribution patterns, with keyword emergence and evolution elucidating shifts in research themes and trends. An international collaboration network was constructed using the Bibliometric Analysis Online Platform. The historiograph mapping of references was generated using the bibliometrix package in R, which visualizes inter-citation relationships among publications and delineates knowledge dissemination trajectories within the research domain.</p></sec></sec><sec id="Sec5"><title>Results</title><sec id="Sec6"><title>Analysis of annual publications and trends</title><p id="Par13">This study conducted a comprehensive analysis of 905 publications meeting predefined inclusion criteria. Figure <xref rid="Fig2" ref-type="fig">2</xref> displays their annual distribution, revealing a steady increase starting from the late 1990s with accelerated growth after 2005, peaking around 2020. Citation counts peaked in 2012, indicating potential high-impact outputs during this period, followed by a moderate decline in citations after 2018.</p><p id="Par14">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Annual publications and citations</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e348" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec7"><title>Analysis of the trend of countries/regions</title><p id="Par15">The 905 publications originated from 72 countries/regions and 1,605 institutions. The United States (308 articles; average citations per article 98.98; centrality 0.32) dominated in publication volume, followed by China (122 articles; average citations per article 15.66; centrality 0.06), but the latter demonstrated relatively lower citation impact and centrality. New Zealand (40 articles; average citations per article 114.75) exhibited the highest citations per article among the top 10 productive countries, succeeded by the United States and the United Kingdom (Table <xref rid="Tab1" ref-type="table">1</xref>). In our research, the cooperative relationship between countries reveals that the United States and other countries/regions cooperate most closely (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A and B).</p><p id="Par16">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>A</bold> International collaboration network. Automatically removes isolated nodes that do not have cooperative relationships with other countries. <bold>B</bold> Temporal overlay network map of international co-authorship</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e374" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig3_HTML.jpg"/></fig>
</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Top 10 countries/regions in terms of number and centrality of publications related to research on colorectal cancer-diabetes comorbidity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Publications</th><th align="left" colspan="1" rowspan="1">Country/region</th><th align="left" colspan="1" rowspan="1">Average citations</th><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Centrality</th><th align="left" colspan="1" rowspan="1">Country/region</th><th align="left" colspan="1" rowspan="1">Average citations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">308</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">98.98</td><td char="." align="char" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">0.32</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">98.98</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">122</td><td align="left" colspan="1" rowspan="1">China</td><td char="." align="char" colspan="1" rowspan="1">15.66</td><td char="." align="char" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">0.16</td><td align="left" colspan="1" rowspan="1">United Kingdom</td><td char="." align="char" colspan="1" rowspan="1">15.66</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">66</td><td align="left" colspan="1" rowspan="1">Japan</td><td char="." align="char" colspan="1" rowspan="1">29.79</td><td char="." align="char" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">Canada</td><td char="." align="char" colspan="1" rowspan="1">57.58</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td char="." align="char" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">Canada</td><td char="." align="char" colspan="1" rowspan="1">57.58</td><td char="." align="char" colspan="1" rowspan="1">4</td><td char="." align="char" colspan="1" rowspan="1">0.10</td><td align="left" colspan="1" rowspan="1">Saudi Arabia</td><td char="." align="char" colspan="1" rowspan="1">11.29</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">England</td><td char="." align="char" colspan="1" rowspan="1">76.04</td><td char="." align="char" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">France</td><td char="." align="char" colspan="1" rowspan="1">116.55</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td char="." align="char" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">South Korea</td><td char="." align="char" colspan="1" rowspan="1">26.40</td><td char="." align="char" colspan="1" rowspan="1">6</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">Malaysia</td><td char="." align="char" colspan="1" rowspan="1">61.22</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">Netherlands</td><td char="." align="char" colspan="1" rowspan="1">114.75</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td align="left" colspan="1" rowspan="1">Italy</td><td char="." align="char" colspan="1" rowspan="1">49.85</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">Italy</td><td char="." align="char" colspan="1" rowspan="1">49.85</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">Germany</td><td char="." align="char" colspan="1" rowspan="1">110.86</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">Taiwan China</td><td char="." align="char" colspan="1" rowspan="1">35.76</td><td char="." align="char" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">China</td><td char="." align="char" colspan="1" rowspan="1">15.66</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td char="." align="char" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">Spain</td><td char="." align="char" colspan="1" rowspan="1">72.56</td><td char="." align="char" colspan="1" rowspan="1">10</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">Spain</td><td char="." align="char" colspan="1" rowspan="1">72.56</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec8"><title>Analysis of institutions</title><p id="Par18">The analysis revealed less frequent inter-institutional collaborations compared to international collaborations, with Harvard University and the Brigham &amp; Women’s Hospital occupying central positions in the network (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). This phenomenon may be linked to the prominent scholar Edward Giovannucci, who has affiliations with both institutions. The majority of the top 10 institutions by publication volume were located within the United States (Table <xref rid="Tab2" ref-type="table">2</xref>). Notably, Harvard University ranked first with 28 relevant publications, demonstrating leadership in both total citations and average citations per publication.</p><p id="Par19">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Institution collaboration network diagram</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e600" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig4_HTML.jpg"/></fig>
</p><p id="Par20">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Top 10 institutions by publication volume related to research on colorectal cancer-diabetes comorbidity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Organization</th><th align="left" colspan="1" rowspan="1">Country</th><th align="left" colspan="1" rowspan="1">Publications</th><th align="left" colspan="1" rowspan="1">Total citations</th><th align="left" colspan="1" rowspan="1">Average citations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Harvard Univ</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">28</td><td char="." align="char" colspan="1" rowspan="1">12,052</td><td char="." align="char" colspan="1" rowspan="1">430.43</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Brigham &amp; Womens Hosp</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">19</td><td char="." align="char" colspan="1" rowspan="1">4643</td><td char="." align="char" colspan="1" rowspan="1">244.37</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Univ Minnesota</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">18</td><td char="." align="char" colspan="1" rowspan="1">1883</td><td char="." align="char" colspan="1" rowspan="1">104.61</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Univ Calif Los Angeles</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">13</td><td char="." align="char" colspan="1" rowspan="1">2061</td><td char="." align="char" colspan="1" rowspan="1">158.54</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Univ Queensland</td><td align="left" colspan="1" rowspan="1">Australia</td><td char="." align="char" colspan="1" rowspan="1">13</td><td char="." align="char" colspan="1" rowspan="1">2332</td><td char="." align="char" colspan="1" rowspan="1">179.38</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Univ Utah</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">13</td><td char="." align="char" colspan="1" rowspan="1">343</td><td char="." align="char" colspan="1" rowspan="1">26.38</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Mayo Clin</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1">496</td><td char="." align="char" colspan="1" rowspan="1">41.33</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Mem Sloan Kettering Canc Ctr</td><td align="left" colspan="1" rowspan="1">United States</td><td char="." align="char" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1">425</td><td char="." align="char" colspan="1" rowspan="1">35.42</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Sun Yat Sen Univ</td><td align="left" colspan="1" rowspan="1">China</td><td char="." align="char" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1">259</td><td char="." align="char" colspan="1" rowspan="1">21.58</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Univ Toronto</td><td align="left" colspan="1" rowspan="1">Canada</td><td char="." align="char" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1">1360</td><td char="." align="char" colspan="1" rowspan="1">113.33</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec9"><title>Analysis of authors</title><p id="Par21">In past studies, a total of 5389 researchers have contributed in the field of colorectal cancer-diabetes comorbidity. The top three authors with the most publications were Ogino, Shuji (<italic toggle="yes">n</italic> = 6); Meyerhardt, Jeffrey A. (<italic toggle="yes">n</italic> = 5); and Venook, Alan (<italic toggle="yes">n</italic> = 5). The top three most cited authors were Giovannucci, Edward (<italic toggle="yes">n</italic> = 666); Ogino, Shuji (<italic toggle="yes">n</italic> = 406); and Willett, Walter C. (<italic toggle="yes">n</italic> = 262) (Table <xref rid="Tab3" ref-type="table">3</xref>). We used VOSviewer to generate an author collaboration network map in this research field, revealing that Shi, Qian, and Goldberg, Richard M., have maintained active collaborative partnerships in recent years (Fig. <xref rid="Fig5" ref-type="fig">5</xref>A). The co-citation network analysis identified Giovannucci, Edward as occupying the central hub position within the author network (Fig. <xref rid="Fig5" ref-type="fig">5</xref>B).</p><p id="Par22">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>A</bold> Authors collaboration diagram. <bold>B</bold> Cited author co-occurrence map, different colours in (<bold>B</bold>) distinguish different clusters, and the same colour indicates similarity of studies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e811" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig5_HTML.jpg"/></fig>
</p><p id="Par23">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Top 10 authors in terms of publications and citations related to colorectal cancer-diabetes comorbidity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Authors (rank by publications)</th><th align="left" colspan="1" rowspan="1">Publications</th><th align="left" colspan="1" rowspan="1">Average citations</th><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Authors (rank by citations)</th><th align="left" colspan="1" rowspan="1">Citations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Ogino, Shuji</td><td char="." align="char" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">67.6667</td><td char="." align="char" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Giovannucci, Edward</td><td char="." align="char" colspan="1" rowspan="1">666</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Meyerhardt, Jeffrey A.</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">41.4</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Ogino, Shuji</td><td char="." align="char" colspan="1" rowspan="1">406</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Venook, Alan</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">37.4</td><td char="." align="char" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Willett, Walter C.</td><td char="." align="char" colspan="1" rowspan="1">262</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Giovannucci, Edward</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">166.5</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Giovannucci, Edward L.</td><td char="." align="char" colspan="1" rowspan="1">241</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Giovannucci, Edward L.</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">60.25</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Meyerhardt, Jeffrey A.</td><td char="." align="char" colspan="1" rowspan="1">207</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Hantel, Alexander</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">46</td><td char="." align="char" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Venook, Alan</td><td char="." align="char" colspan="1" rowspan="1">187</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Willett, Walter C.</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">65.5</td><td char="." align="char" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Hantel, Alexander</td><td char="." align="char" colspan="1" rowspan="1">184</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Messino, Michael</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">46</td><td char="." align="char" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Mayer, Robert J.</td><td char="." align="char" colspan="1" rowspan="1">184</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Mowat, Rex B.</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">46</td><td char="." align="char" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Messino, Michael</td><td char="." align="char" colspan="1" rowspan="1">184</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Niedzwiecki, Donna</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">46</td><td char="." align="char" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Mowat, Rex B.</td><td char="." align="char" colspan="1" rowspan="1">184</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec10"><title>Analysis of journals and subjects</title><p id="Par24">A total of 513 journals have published articles related to A total of 513 journals have published articles related to colorectal cancer-diabetes comorbidity. PLOS ONE demonstrated the highest publication output (25 publications, IF = 2.9), followed by the INTERNATIONAL JOURNAL OF COLORECTAL DISEASE ranking second (14 publications, IF = 2.5). Interestingly, the most prolific journals were not necessarily the most cited, with PLOS ONE at the bottom of the citation rankings. THE LANCET received the highest citation count (6,785 citations, IF = 98.4). Notably, nearly half of the top-cited journals were classified in the Q1 JCR quartile, indicating substantial academic value within this research field (Table <xref rid="Tab4" ref-type="table">4</xref>). The journal co-citation network (Fig. <xref rid="Fig6" ref-type="fig">6</xref>A) and dual-map overlay diagram (Fig. <xref rid="Fig6" ref-type="fig">6</xref>B) collectively visualise the predominant citation pathways between citing journals and cited journals in this field. The three most prominent coloured paths illustrate citation relationships where journals in the Medicine, Medical, Clinical fields reference publications from both the Health, Nursing, Medicine and Molecular, Biology, Genetics fields, followed by citations from Molecular, Biology, Immunology journals to Molecular, Biology, Genetics literature. This pattern highlights interdisciplinary convergence within the field, demonstrating that modern medical research is increasingly integrating knowledge across multiple specialised disciplines.</p><p id="Par25">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>A</bold> Journal co-citation network. Distinct clusters are differentiated by colour coding, with identical colours indicating similarity in research focus areas. <bold>B</bold> Journal dual-map overlay diagram</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1023" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig6_HTML.jpg"/></fig>
</p><p id="Par26">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Top 10 journals in terms of publications and citations related to colorectal cancer-diabetes comorbidity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Rank</th><th align="left" colspan="4" rowspan="1">Top 10 most productive journals</th><th align="left" colspan="5" rowspan="1">Top 10 most–cited journals</th></tr><tr><th align="left" colspan="1" rowspan="1">Journals</th><th align="left" colspan="1" rowspan="1">Productions</th><th align="left" colspan="1" rowspan="1">JCR</th><th align="left" colspan="1" rowspan="1">IF (2023)</th><th align="left" colspan="1" rowspan="1">Journals</th><th align="left" colspan="1" rowspan="1">Average citations</th><th align="left" colspan="1" rowspan="1">Citations</th><th align="left" colspan="1" rowspan="1">JCR</th><th align="left" colspan="1" rowspan="1">IF (2023)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">PloS One</td><td char="." align="char" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">Q3</td><td char="." align="char" colspan="1" rowspan="1">2.9</td><td align="left" colspan="1" rowspan="1">Lancet</td><td align="left" colspan="1" rowspan="1">1696.25</td><td char="." align="char" colspan="1" rowspan="1">6785</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">98.4</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">International Journal Of Colorectal Disease</td><td char="." align="char" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Q3</td><td char="." align="char" colspan="1" rowspan="1">2.5</td><td align="left" colspan="1" rowspan="1">American Journal Of Clinical Nutrition</td><td align="left" colspan="1" rowspan="1">313.5</td><td char="." align="char" colspan="1" rowspan="1">1881</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">6.5</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Cancer Epidemiology Biomarkers &amp; Prevention</td><td char="." align="char" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Q3</td><td char="." align="char" colspan="1" rowspan="1">3.7</td><td align="left" colspan="1" rowspan="1">JNCI-Journal Of The National Cancer Institute</td><td align="left" colspan="1" rowspan="1">298.25</td><td char="." align="char" colspan="1" rowspan="1">1193</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">99.0</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Diseases Of The Colon &amp; Rectum</td><td char="." align="char" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Q2</td><td char="." align="char" colspan="1" rowspan="1">3.2</td><td align="left" colspan="1" rowspan="1">Journal Of Nutrition</td><td align="left" colspan="1" rowspan="1">248.4</td><td char="." align="char" colspan="1" rowspan="1">1242</td><td align="left" colspan="1" rowspan="1">Q3</td><td align="left" colspan="1" rowspan="1">3.7</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Cancer Causes &amp; Control</td><td char="." align="char" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Q4</td><td char="." align="char" colspan="1" rowspan="1">2.2</td><td align="left" colspan="1" rowspan="1">American Journal Of Epidemiology</td><td align="left" colspan="1" rowspan="1">205.4286</td><td char="." align="char" colspan="1" rowspan="1">1438</td><td align="left" colspan="1" rowspan="1">Q2</td><td align="left" colspan="1" rowspan="1">5</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Scientific Reports</td><td char="." align="char" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Q2</td><td char="." align="char" colspan="1" rowspan="1">3.8</td><td align="left" colspan="1" rowspan="1">Journal Of Clinical Oncology</td><td align="left" colspan="1" rowspan="1">145.7143</td><td char="." align="char" colspan="1" rowspan="1">1020</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">42.1</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Clinical Gastroenterology And Hepatology</td><td char="." align="char" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Q1</td><td char="." align="char" colspan="1" rowspan="1">11.6</td><td align="left" colspan="1" rowspan="1">Clinical Gastroenterology And Hepatology</td><td align="left" colspan="1" rowspan="1">84.1111</td><td char="." align="char" colspan="1" rowspan="1">757</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">11.6</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">American Journal Of Epidemiology</td><td char="." align="char" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Q2</td><td char="." align="char" colspan="1" rowspan="1">5.0</td><td align="left" colspan="1" rowspan="1">Cancer Epidemiology Biomarkers &amp; Prevention</td><td align="left" colspan="1" rowspan="1">72</td><td char="." align="char" colspan="1" rowspan="1">792</td><td align="left" colspan="1" rowspan="1">Q3</td><td align="left" colspan="1" rowspan="1">3.7</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Journal Of Clinical Oncology</td><td char="." align="char" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Q1</td><td char="." align="char" colspan="1" rowspan="1">42.1</td><td align="left" colspan="1" rowspan="1">Diseases Of The Colon &amp; Rectum</td><td align="left" colspan="1" rowspan="1">70</td><td char="." align="char" colspan="1" rowspan="1">700</td><td align="left" colspan="1" rowspan="1">Q2</td><td align="left" colspan="1" rowspan="1">3.2</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Cancer</td><td char="." align="char" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Q2</td><td char="." align="char" colspan="1" rowspan="1">6.1</td><td align="left" colspan="1" rowspan="1">Plos One</td><td align="left" colspan="1" rowspan="1">41.24</td><td char="." align="char" colspan="1" rowspan="1">1031</td><td align="left" colspan="1" rowspan="1">Q3</td><td align="left" colspan="1" rowspan="1">2.9</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec11"><title>Analysis of articles and references</title><p id="Par27">To explore changes in the content of relevant studies over time, we analysed the historical direct citation network of colorectal cancer-diabetes comorbidity references (Fig. <xref rid="Fig7" ref-type="fig">7</xref>A and Supplementary Table S2). Figure <xref rid="Fig7" ref-type="fig">7</xref>B shows the top 19 references with the strongest citation bursts. Among them, Nieves González et al.’s review “2017 update on the relationship between diabetes and CRC: epidemiology, potential molecular mechanisms and therapeutic implications” published in ONCOTARGET (Strength = 7.34) was identified as the reference with the strongest citation burst. And the two most recent high-burst references were both cancer statistical data reports. Table <xref rid="Tab5" ref-type="table">5</xref> listed the top 10 highly cited references. “Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy”, published in Lancet in 2012, was cited 5,268 times [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par28">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p><bold>A</bold> Historical direct citation network. <bold>B</bold> Top 19 references with the strongest citation bursts</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1313" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig7_HTML.jpg"/></fig>
</p><p id="Par29">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Top 10 references in terms of citations related to the research on colorectal cancer-diabetes comorbidity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Title</th><th align="left" colspan="1" rowspan="1">Citation</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Journal</th><th align="left" colspan="1" rowspan="1">JCR</th><th align="left" colspan="1" rowspan="1">IF (2023)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy</td><td char="." align="char" colspan="1" rowspan="1">5268</td><td char="." align="char" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">Lancet</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">98.4</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Lack of exercise is a major cause of chronic diseases</td><td char="." align="char" colspan="1" rowspan="1">1468</td><td char="." align="char" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">Compr Physiol</td><td align="left" colspan="1" rowspan="1">Q2</td><td align="left" colspan="1" rowspan="1">4.2</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Prebiotic effects: metabolic and health benefits</td><td char="." align="char" colspan="1" rowspan="1">1430</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">Br J Nutr</td><td align="left" colspan="1" rowspan="1">Q3</td><td align="left" colspan="1" rowspan="1">3.0</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">The economic burden of physical inactivity: a global analysis of major non-communicable diseases</td><td char="." align="char" colspan="1" rowspan="1">1239</td><td char="." align="char" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Lancet</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">98.4</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Impact of overweight on the risk of developing common chronic diseases during a 10-year period</td><td char="." align="char" colspan="1" rowspan="1">1126</td><td char="." align="char" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">Arch Intern Med</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Current estimates of the economic cost of obesity in the United States</td><td char="." align="char" colspan="1" rowspan="1">844</td><td char="." align="char" colspan="1" rowspan="1">1998</td><td align="left" colspan="1" rowspan="1">Obes Res</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">The relation between different dimensions of alcohol consumption and burden of disease: an overview</td><td char="." align="char" colspan="1" rowspan="1">785</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">Addiction</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">5.2</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth</td><td char="." align="char" colspan="1" rowspan="1">769</td><td char="." align="char" colspan="1" rowspan="1">2007</td><td align="left" colspan="1" rowspan="1">Cancer Res</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">12.5</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Diabetes mellitus and risk of colorectal cancer: a meta-analysis</td><td char="." align="char" colspan="1" rowspan="1">762</td><td char="." align="char" colspan="1" rowspan="1">2005</td><td align="left" colspan="1" rowspan="1">J Natl Cancer Inst</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">9.9</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013</td><td char="." align="char" colspan="1" rowspan="1">743</td><td char="." align="char" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">BMJ</td><td align="left" colspan="1" rowspan="1">Q1</td><td align="left" colspan="1" rowspan="1">93.6</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec12"><title>Analysis of keywords</title><p id="Par30">The keyword co-occurrence network with temporal overlay, generated using VOSviewer, visualises both high-frequency keywords and newly emerged terms in recent years (Fig. <xref rid="Fig8" ref-type="fig">8</xref>A). To mitigate visualization bias caused by excessive frequency dominance, the terms “colon cancer,” “rectal cancer,” and “diabetes” were excluded from this analysis due to their disproportionately high occurrence rates in the dataset. The emergence of new keywords since 2018, including “metformin”, “anastomotic leakage”, “gut microbiota”, and “inflammation”, demonstrates a growing research focus on therapeutic prognosis and molecular biological mechanisms in colorectal cancer-diabetes comorbidity. The keyword time zone map produced by Citespace reveals the variation of high-frequency keywords over time (Fig. <xref rid="Fig8" ref-type="fig">8</xref>B). The keyword timeline map clearly shows the changes in each research hotspot over the time horizon (Fig. <xref rid="Fig8" ref-type="fig">8</xref>C). The timeline map structure included the X-axis representing the publication year and the Y-axis corresponding to the keyword cluster names. The keyword co-occurrence network analysis employing the Log-Likelihood Ratio (LLR) algorithm yielded a modularity (Q) &gt; 0.3, indicating statistically significant clustering, and a silhouette (S) index &gt; 0.7, confirming robust cluster configuration [<xref ref-type="bibr" rid="CR25">25</xref>]. Our dataset demonstrated clustering metrics of Q = 0.4506 and S = 0.7655, aggregating 10 thematic clusters. We observe that in the recent studies mainly focusing on “#0 diabetes-associated centrosome amplification” (Cluster 0), while “#1 economic cost” (Cluster 1), “#2 prospective study” (Cluster 2), and “#3 anastomotic leakage” (Cluster 3) have remained prominent research directions since the 1990s.</p><p id="Par31">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p><bold>A</bold> Keyword co-occurrence network with temporal overlay. <bold>B</bold> Keyword time zone map. <bold>C</bold> Keyword timeline map</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1531" position="float" orientation="portrait" xlink:href="12672_2026_4447_Fig8_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><sec id="Sec14"><title>Research landscape and collaborative networks</title><p id="Par32">To our knowledge, this study represents the first bibliometric analysis in the field of colorectal cancer-diabetes comorbidity, providing essential reference data for researchers intending to explore this field. Since 2005, the number of publications on colorectal cancer-diabetes comorbidity began to trend upward each year, with a peak of about 70 publications in 2020. Citations have likewise been on the rise overall. Beginning in the late 1990s, there were several more significant spikes in citations. In 2010, a consensus report from a joint conference in the field of oncology and diabetes stated that T2DM is a risk factor for breast cancer, CRC, and many other site-specific tumours [<xref ref-type="bibr" rid="CR26">26</xref>]. The global trend in the quantity and impact of publications and citations on colorectal cancer and diabetes has followed a marked upward trajectory, reflecting growing academic interest and the increasing relevance of this research area.</p><p id="Par33">At the national level, both the United States and China show stronger preferences for international collaboration in colorectal cancer-diabetes comorbidity research. China demonstrates remarkable publication volume and recent research activity in this field, making substantial contributions. Over the past 20 years, China has gradually established chronic disease management frameworks and enhanced its universal health insurance system [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Specialized diabetes and cancer surveillance and registration databases have been implemented across all regions. The improvement of these medical systems reveals that China has the basis for evaluating the geographical differences of colorectal cancer diabetes complications, and can carry out multi center research on the mechanism of disease progression in the future.</p><p id="Par34">The top 10 institutions by publication volume - about 80% belong to North America. Harvard University is the most widely published institution in this field, maintaining close collaborations with the Brigham &amp; Women’s Hospital. The cooperation among these global high-level research institutions can effectively promote knowledge exchange and accelerate the output of innovative achievements in this field by sharing their research findings. Therefore, strengthening the cooperation between institutions is very important for the future development of this field. Professor Edward Giovannucci, holding joint appointments at both institutions, has the highest total citations of 666, with an average citation of 166.5, and has pioneered the field of cancer prevention by pointing out that dietary and lifestyle factors greatly influence tumorigenesis. Diet-influenced insulin, insulin-like growth factor-1 (IGF-1) and inflammatory factors can induce tumour development. Insulin is also a mitogen for tumour cell growth in vitro, which induces activation of the proto-oncogene <italic toggle="yes">ras</italic> and sustained activation of the MAPK pathway, ultimately contributing to colorectal carcinogenesis [<xref ref-type="bibr" rid="CR29">29</xref>]. This reveals that exploring dietary differences via diabetes to initiate CRC is a valuable direction for future research.</p><p id="Par35">This field demonstrates robust interdisciplinary integration, primarily spanning medicine, molecular biology, and clinical practice while intersecting with computer science, mathematics, physics, socioeconomics, and education sciences. The current research environment encourages participation from non-biomedical disciplines to promote interdisciplinary collaboration to continuously improve the diverse academic framework.</p></sec><sec id="Sec15"><title>Emerging thematic clusters and their research implications</title><p id="Par36">Keyword clustering analysis identified three prominent and evolving research frontiers, each presenting distinct mechanistic questions and clinical translation opportunities. Diabetes-associated centrosome amplification (CA), anastomotic leakage (AL), and metformin have gained significant attention in recent years and have revealed key areas for future research. Diabetes-associated centrosome amplification has emerged as the most intensively investigated focus in the colorectal cancer–diabetes comorbidity field since 2000, indicating novel mechanistic breakthroughs in pathogenesis elucidation. The sustained academic attention on anastomotic leakage highlights researchers’ extensive clinical trial investigations into postoperative complications among patients with colorectal cancer–diabetes comorbidity. Since 2018, research interest in metformin has increased significantly, reflecting its dual therapeutic potential in glycaemic regulation and modulation of neoplastic pathways.</p><sec id="Sec16"><title>Diabetes-associated centrosome amplification: a mechanistic frontier</title><p id="Par37">Cluster #0 underscores “diabetes-associated centrosome amplification (CA)” as a novel and intense research focus. Theodor Boveri first postulated the potential tumorigenic effects of CA [<xref ref-type="bibr" rid="CR30">30</xref>]. Genetic modification in cellular and animal models has provided compelling evidence demonstrating a causal relationship between CA and both tumorigenesis and metastatic progression [<xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR34">34</xref>]. Taking T2DM as an example, it was found not only to increase the risk of CRC incidence and metastasis rates [<xref ref-type="bibr" rid="CR26">26</xref>], but also to induce CA in cancer-susceptible epithelial cells (e.g., intestinal polyps) and established colorectal carcinoma cells [<xref ref-type="bibr" rid="CR35">35</xref>]. In vitro experimentation demonstrates that chronic exposure of non-neoplastic colonic epithelium to advanced glycation end products (AGEs) initiates tumorigenesis in immunocompromised murine models—an oncogenic process effectively abrogated through pharmacological inhibition or genetic silencing of CA-associated signalling pathways [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. However, critical knowledge gaps persist: the upstream triggers within the diabetic environment (e.g., specific AGEs, oxidative stress species) are not fully defined; the causal role of CA in diabetes-promoted CRC progression in vivo requires further validation; and the translational potential of CA as a biomarker for early detection or as a therapeutic target remains unexplored. Future research should: (i) employ multi-omics approaches to delineate the complete signaling cascade from hyperglycemia to CA; (ii) investigate the clinical utility of CA assessment in polyps or liquid biopsies from diabetic patients for risk stratification.</p></sec><sec id="Sec17"><title>Anastomotic leakage in colorectal cancer-diabetes patients: a clinical challenge</title><p id="Par38">While chemotherapeutic agents, immunotherapies, and molecular-targeted drugs have demonstrated unprecedented progress in CRC, radical surgical resection maintains its gold-standard status for early-stage CRC cases meeting R0 criteria (tumour-free margin ≥ 1 mm histologically confirmed). Standardised surgical protocols for colorectal malignancies, including radical colectomy (RC), low anterior resection (LAR) for rectal cancer, and intersphincteric resection (ISR), necessarily require the implementation of precision anastomotic techniques - encompassing end-to-end, end-to-side, and side-to-side configurations. AL is one of the serious complications that can occur after gastrointestinal surgery, which can have a significant negative impact on the survival and quality of life of postoperative patients [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Prolonged hyperglycemia will result in delayed wound healing, and AL is about three times more likely to occur in patients with T2DM than in those without T2DM [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Fibroblasts and endothelial cells constitute the primary cellular components of granulation tissue [<xref ref-type="bibr" rid="CR41">41</xref>], with fibroblasts mediating wound contraction through matrix deposition [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], while endothelial cells facilitate angiogenesis during the proliferative phase of healing [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Hyperglycemia amplifies intracellular oxidative stress by activating the classical AGE-RAGE axis [<xref ref-type="bibr" rid="CR45">45</xref>] and through atypical interactions between 3-deoxyglucosone (3-DG) and integrins alpha-1/beta-1 (α1β1) [<xref ref-type="bibr" rid="CR46">46</xref>]. Reactive oxygen species (ROS) generated in mitochondria stimulate multiple downstream signalling pathways, including p38/MAPK, Forkhead box protein O1 (FOXO1), and nuclear factor-kappa B (NF-κB) [<xref ref-type="bibr" rid="CR47">47</xref>–<xref ref-type="bibr" rid="CR49">49</xref>]. This cascade triggers inflammatory responses and promotes cellular senescence and apoptosis. The ensuing inflammatory response is accompanied by M1 macrophage polarization, which impairs fibroblasts and inhibits their ability to secrete extracellular matrix (ECM) [<xref ref-type="bibr" rid="CR50">50</xref>]. Concurrently, the presence of ROS and proinflammatory cytokines coincides with increased expression of matrix metalloproteinases (MMPs)—a family of zinc-dependent proteolytic enzymes capable of degrading protein components within the ECM [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. When ECM levels persistently fall below the threshold required for wound healing, fibroblast migration, anchorage, and proliferation become significantly impaired [<xref ref-type="bibr" rid="CR53">53</xref>]. In addition, hyperglycemia impairs the angiogenic function of endothelial cells through ROS-mediated endothelial nitric oxide synthase (e-NOS) inhibition [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>], activation of the AGE-RAGE axis [<xref ref-type="bibr" rid="CR57">57</xref>], and release of pro-inflammatory factors [<xref ref-type="bibr" rid="CR58">58</xref>]. Diabetic wounds are characterized by a chronic low-grade inflammatory state, insufficient ECM deposition, aberrant angiogenesis, and impaired contractile function (reduced α-smooth muscle actin (α-SMA) expression) [<xref ref-type="bibr" rid="CR59">59</xref>]. Elevated levels of tumour necrosis factor-α (TNF-α) and reduced transforming growth factor-β1 (TGF-β1) contribute to an imbalance in repair signalling, promoting apoptosis and increased protease activity [<xref ref-type="bibr" rid="CR59">59</xref>]. These complex pathophysiological processes affect the formation of granulation tissue, which is the key factor of AL after colorectal cancer surgery. Despite this understanding, translational gaps hinder clinical improvement: perioperative glycemic management protocols are not standardized for CRC surgery; reliable predictive biomarkers for AL risk in diabetic patients are lacking; and targeted interventions to improve wound healing in this cohort are underdeveloped. Future studies must prioritize: (i) prospective trials to optimize perioperative glucose control strategies; (ii) discovery and validation of immune-metabolic biomarkers—such as specific MMPs and cytokine profiles—predictive of AL; (iii) development of novel adjunctive therapies, including targeted antioxidants and growth factor applications, to enhance anastomotic healing in patients with diabetes.</p></sec><sec id="Sec18"><title>Metformin in colorectal cancer-diabetes comorbidity: therapeutic promise and uncertainty</title><p id="Par39">Metformin, the first-line oral antihyperglycemic agent for T2DM, exerts its therapeutic effects through mitochondrial respiratory chain complex I/IV inhibition. This bioenergetic interference elevates cellular AMP/ATP ratios, subsequently activating lysosomal AMP-activated protein kinase (AMPK) signalling cascades that coordinate hepatic gluconeogenesis suppression and peripheral glucose uptake enhancement [<xref ref-type="bibr" rid="CR60">60</xref>]. Moreover, its potential cancer-preventive and anti-neoplastic effects have garnered increasing attention in the field of CRC [<xref ref-type="bibr" rid="CR61">61</xref>]. Current evidence reveals two interconnected mechanistic aspects: (1) direct regulation through signalling pathways including mTOR, PI3K/AKT/mTOR (PAM), and K-Ras, and (2) indirect metabolic modulation involving insulin sensitivity and glucose metabolism [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. These dual mechanisms exhibit functional crosstalk rather than operating independently. Buzzai et al. demonstrated that metformin induces energy stress through the AMPK-p53 pathway, forcing tumour cells to undergo metabolic conversion (such as enhanced fatty acid β-oxidation and autophagy), while p53-deficient colon cancer cells undergo apoptosis due to their inability to adapt to this stress [<xref ref-type="bibr" rid="CR64">64</xref>]. However, some studies have reveals less than satisfactory outcomes regarding its protective effects in diabetic patients with CRC [<xref ref-type="bibr" rid="CR65">65</xref>]. The 2016 N0147 trial conducted by the North Central Cancer Treatment Group in the United States revealed no significant differences in disease-free survival (DFS), overall survival (OS), or time to recurrence (TTR) between metformin users and non-users among stage III colon cancer patients undergoing radical resection. This lack of benefit persisted regardless of KRAS or BRAF mutation status or mismatch repair (MMR) proficiency [<xref ref-type="bibr" rid="CR66">66</xref>]. This discrepancy underscores a critical research gap: the lack of predictive biomarkers to identify patient subsets who might benefit from metformin, such as those defined by p53 status, KRAS/BRAF mutations, or metabolic profile. Furthermore, metformin’s interaction with chemotherapy and immunotherapy regimens remains poorly understood. To address these issues, future research directions should include the following: (i) conducting prospective clinical trials stratified by biomarkers (e.g., p53 and MMR status) to resolve efficacy controversies; (ii) performing preclinical and clinical studies evaluating metformin in combination with immunotherapy treatments, given its immunomodulatory potential; (iii) carrying out pharmacokinetic and pharmacodynamic studies to determine whether anticancer effects require doses different from those used for glycemic control.</p></sec></sec><sec id="Sec19"><title>Shifts in research focus: from epidemiology to mechanisms and translation</title><p id="Par40">The temporal analysis of keywords and references reveals a clear paradigm shift. Early research (pre-2000s) was dominated by establishing epidemiological links. Subsequent decades saw a rise in investigating intermediate mechanisms like hyperinsulinemia and Metabolic Syndrome (MetS). Currently, the frontier is characterized by a focus on molecular mechanisms (e.g., CA, gut microbiota) and therapeutic/clinical outcomes (e.g., AL, metformin, survival). This evolution aligns with the broader movement towards precision oncology. However, a significant translational gap remains: few studies integrate patient-derived multi-omics data to personalize risk prediction or treatment for the colorectal cancer-diabetes comorbidity population. Bridging this gap requires interdisciplinary consortia that combine deep phenotyping, molecular profiling, and clinical trial data.</p></sec><sec id="Sec20"><title>Limitation</title><p id="Par41">This study performed a bibliometric analysis of literature on colorectal cancer-diabetes comorbidity. Unlike traditional reviews, this approach offers a clearer visualization of research progress. However, several limitations exist. First, relying solely on the WoSCC database may introduce bias due to incomplete coverage, particularly regarding non-English or regional publications, though WoSCC remains a widely authoritative source. Second, using citation metrics to assess impact is inherently biased: highly cited articles are not always the most rigorous, and significant newer work may lack sufficient citations. Third, keyword clustering and thematic mapping depend on algorithmic parameters and thresholds; varying these settings could alter results, underscoring the sensitivity of such unsupervised methods. Finally, bibliometric analysis is descriptive and correlational—it cannot establish causality or evaluate the scientific validity of findings. While it identifies trends, collaborations, and emerging topics, it does not assess evidence quality. Thus, these conclusions should be complemented by systematic reviews and experimental studies.</p></sec></sec><sec id="Sec21"><title>Conclusion</title><p id="Par42">In this study, we conducted bibliometric and visual analysis with CiteSpace visualisation to map the colorectal cancer-diabetes comorbidity research landscape, which is more intuitively and clearly reflected in the research progress in the target area when compared with traditional narrative reviews. Colorectal cancer-diabetes comorbidity, as an interdisciplinary field of great interest, has research potential in the future.</p></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12672_2026_4447_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher’s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Junyu Long designed bibliometric and visual analysis, performed the literature search and selection, wrote the paper, and revised the manuscript. Xuewei Shi, Yandong Huang, and Qingyang Bai contributed to the review and editing of the paper. Kai Feng contributed to the conceptualization, review, and editing of the paper.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The bibliometric data used in this study were retrieved from the publicly accessible database “Web of Science”, with the search completed on July 10, 2024. The search strategy and inclusion/exclusion criteria are detailed in the MATERIALS AND METHODS section. Due to database license agreements and restrictions on redistribution, the raw bibliometric records cannot be publicly shared. However, all processed data and analysis scripts (e.g., for data cleaning, citation network construction) are available from the corresponding author upon reasonable request via email at [13848018266@163.com](mailto:13848018266@163.com).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par43">The study did not involve humans or animals, so it did not require ethical approval from institutional committees or consent from patient participation.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare no competing interests.</p></notes><notes id="FPar3"><title>Consent to publish</title><p id="Par45">Not applicable.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>CRC</term><def><p id="Par46">Colorectal cancer</p></def></def-item><def-item><term>DM</term><def><p id="Par47">Diabetes mellitus</p></def></def-item><def-item><term>WoSCC</term><def><p id="Par48">The Web of Science Core Collection</p></def></def-item><def-item><term>T2DM</term><def><p id="Par49">Type 2 diabetes mellitus</p></def></def-item><def-item><term>IDF</term><def><p id="Par50">The International Diabetes Federation</p></def></def-item><def-item><term>AJCC</term><def><p id="Par51">The American Joint Committee on Cancer</p></def></def-item><def-item><term>LLR</term><def><p id="Par52">The Log-Likelihood Ratio</p></def></def-item><def-item><term>IGF-1</term><def><p id="Par53">Insulin-like growth factor-1</p></def></def-item><def-item><term>MetS</term><def><p id="Par54">Metabolic Syndrome</p></def></def-item><def-item><term>AL</term><def><p id="Par55">Anastomotic leakage</p></def></def-item><def-item><term>CA</term><def><p id="Par56">Centrosome amplification</p></def></def-item><def-item><term>AGEs</term><def><p id="Par57">Advanced glycation end products</p></def></def-item><def-item><term>RC</term><def><p id="Par58">Radical colectomy</p></def></def-item><def-item><term>LAR</term><def><p id="Par59">Low anterior resection</p></def></def-item><def-item><term>ISR</term><def><p id="Par60">Intersphincteric resection</p></def></def-item><def-item><term>ROS</term><def><p id="Par61">Reactive oxygen species</p></def></def-item><def-item><term>FOXO1</term><def><p id="Par62">Forkhead box protein O1</p></def></def-item><def-item><term>NF-κB</term><def><p id="Par63">Nuclear factor-kappa B</p></def></def-item><def-item><term>ECM</term><def><p id="Par64">Extracellular matrix</p></def></def-item><def-item><term>MMPs</term><def><p id="Par65">Matrix metalloproteinases</p></def></def-item><def-item><term>e-NOS</term><def><p id="Par66">Endothelial nitric oxide synthase</p></def></def-item><def-item><term>α-SMA</term><def><p id="Par67">α-smooth muscle actin</p></def></def-item><def-item><term>TNF-α</term><def><p id="Par68">Tumour necrosis factor-α</p></def></def-item><def-item><term>TGF-β1</term><def><p id="Par69">Transforming growth factor-β1</p></def></def-item><def-item><term>AMPK</term><def><p id="Par70">AMP-activated protein kinase</p></def></def-item><def-item><term>PAM</term><def><p id="Par71">PI3K/AKT/mTOR</p></def></def-item><def-item><term>DFS</term><def><p id="Par72">Disease-free survival</p></def></def-item><def-item><term>OS</term><def><p id="Par73">Overall survival</p></def></def-item><def-item><term>TTR</term><def><p id="Par74">Time to recurrence</p></def></def-item><def-item><term>MMR</term><def><p id="Par75">Mismatch repair</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>H</given-names></name><name name-style="western"><surname>Aubert</surname><given-names>RE</given-names></name><name name-style="western"><surname>Herman</surname><given-names>WH</given-names></name></person-group><article-title>Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><issue>9</issue><fpage>1414</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.2337/diacare.21.9.1414</pub-id><pub-id pub-id-type="pmid">9727886</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.<pub-id pub-id-type="pmid">9727886</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.21.9.1414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klimeck</surname><given-names>L</given-names></name><name name-style="western"><surname>Heisser</surname><given-names>T</given-names></name><name name-style="western"><surname>Hoffmeister</surname><given-names>M</given-names></name><etal/></person-group><article-title>Colorectal cancer: A health and economic problem</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2023</year><volume>66</volume><fpage>101839</fpage><pub-id pub-id-type="doi">10.1016/j.bpg.2023.101839</pub-id><pub-id pub-id-type="pmid">37852707</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Klimeck L, Heisser T, Hoffmeister M, et al. Colorectal cancer: A health and economic problem. Best Pract Res Clin Gastroenterol. 2023;66:101839.<pub-id pub-id-type="pmid">37852707</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpg.2023.101839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ternák</surname><given-names>G</given-names></name><name name-style="western"><surname>Németh</surname><given-names>M</given-names></name><name name-style="western"><surname>Rozanovic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibiotic consumption patterns in European countries might be associated with the prevalence of type 1 and 2 diabetes</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>870465</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.870465</pub-id><pub-id pub-id-type="pmid">35600582</pub-id><pub-id pub-id-type="pmcid">PMC9120822</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ternák G, Németh M, Rozanovic M, et al. Antibiotic consumption patterns in European countries might be associated with the prevalence of type 1 and 2 diabetes. Front Endocrinol (Lausanne). 2022;13:870465.<pub-id pub-id-type="pmid">35600582</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.870465</pub-id><pub-id pub-id-type="pmcid">PMC9120822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Petersohn</surname><given-names>I</given-names></name><name name-style="western"><surname>Salpea</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9(th) edition</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>157</volume><fpage>107843</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2019.107843</pub-id><pub-id pub-id-type="pmid">31518657</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.<pub-id pub-id-type="pmid">31518657</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2019.107843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dekker</surname><given-names>E</given-names></name><name name-style="western"><surname>Tanis</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Vleugels</surname><given-names>JLA</given-names></name><etal/></person-group><source>Colorectal Cancer Lancet</source><year>2019</year><volume>394</volume><issue>10207</issue><fpage>1467</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">31631858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32319-0</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal Cancer Lancet. 2019;394(10207):1467–80.<pub-id pub-id-type="pmid">31631858</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32319-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medema</surname><given-names>JP</given-names></name></person-group><article-title>Cancer stem cells: the challenges ahead</article-title><source>Nat Cell Biol</source><year>2013</year><volume>15</volume><issue>4</issue><fpage>338</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/ncb2717</pub-id><pub-id pub-id-type="pmid">23548926</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013;15(4):338–44.<pub-id pub-id-type="pmid">23548926</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb2717</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.<pub-id pub-id-type="pmid">38572751</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Amin Mb</surname><given-names>ES</given-names></name><name name-style="western"><surname>Greene</surname><given-names>F</given-names></name><etal/></person-group><source>Editors.American joint committee on cancer (AJCC) cancer staging manual</source><year>2017</year><edition>8</edition><publisher-loc>New York</publisher-loc><publisher-name>Springer International</publisher-name></element-citation><mixed-citation id="mc-CR8" publication-type="book">Amin Mb ES, Greene F, editors. Et al., Editors.American joint committee on cancer (AJCC) cancer staging manual. 8th ed. New York: Springer International; 2017.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berrino</surname><given-names>F</given-names></name><name name-style="western"><surname>Gatta</surname><given-names>G</given-names></name><name name-style="western"><surname>Chessa</surname><given-names>E</given-names></name><etal/></person-group><article-title>Introduction: the EUROCARE II study</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>2139</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(98)00334-7</pub-id><pub-id pub-id-type="pmid">10070280</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Berrino F, Gatta G, Chessa E, et al. Introduction: the EUROCARE II study. Eur J Cancer. 1998;34:2139–53. (14 Spec No).<pub-id pub-id-type="pmid">10070280</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0959-8049(98)00334-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Orsini</surname><given-names>N</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>A</given-names></name></person-group><article-title>Diabetes mellitus and risk of colorectal cancer: a meta-analysis</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><issue>22</issue><fpage>1679</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1093/jnci/dji375</pub-id><pub-id pub-id-type="pmid">16288121</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87.<pub-id pub-id-type="pmid">16288121</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/dji375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>L</given-names></name><name name-style="western"><surname>Gui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis</article-title><source>Dig Dis Sci</source><year>2012</year><volume>57</volume><issue>6</issue><fpage>1576</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s10620-012-2055-1</pub-id><pub-id pub-id-type="pmid">22350783</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57(6):1576–85.<pub-id pub-id-type="pmid">22350783</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-012-2055-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Earle</surname><given-names>CC</given-names></name><name name-style="western"><surname>Bae</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Incidence of diabetes in colorectal cancer survivors</article-title><source>J Natl Cancer Inst</source><year>2016</year><volume>108</volume><issue>6</issue><fpage>djv402</fpage><pub-id pub-id-type="doi">10.1093/jnci/djv402</pub-id><pub-id pub-id-type="pmid">26839345</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Singh S, Earle CC, Bae SJ, et al. Incidence of diabetes in colorectal cancer survivors. J Natl Cancer Inst. 2016;108(6):djv402.<pub-id pub-id-type="pmid">26839345</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djv402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YI</given-names></name></person-group><article-title>.Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link?</article-title><source>Nutr Rev</source><year>1998</year><volume>56</volume><issue>9</issue><fpage>275</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1753-4887.1998.tb01765.x</pub-id><pub-id pub-id-type="pmid">9763878</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kim YI. .Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? Nutr Rev. 1998;56(9):275–9.<pub-id pub-id-type="pmid">9763878</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1753-4887.1998.tb01765.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aleksandrova</surname><given-names>K</given-names></name><name name-style="western"><surname>Nimptsch</surname><given-names>K</given-names></name><name name-style="western"><surname>Pischon</surname><given-names>T</given-names></name></person-group><article-title>Influence of obesity and related metabolic alterations on colorectal cancer risk</article-title><source>Curr Nutr Rep</source><year>2013</year><volume>2</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s13668-012-0036-9</pub-id><pub-id pub-id-type="pmid">23396857</pub-id><pub-id pub-id-type="pmcid">PMC3562548</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Aleksandrova K, Nimptsch K, Pischon T. Influence of obesity and related metabolic alterations on colorectal cancer risk. Curr Nutr Rep. 2013;2(1):1–9.<pub-id pub-id-type="pmid">23396857</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13668-012-0036-9</pub-id><pub-id pub-id-type="pmcid">PMC3562548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao Kondapally Seshasai</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaptoge</surname><given-names>S</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diabetes mellitus, fasting glucose, and risk of cause-specific death</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>9</issue><fpage>829</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1008862</pub-id><pub-id pub-id-type="pmid">21366474</pub-id><pub-id pub-id-type="pmcid">PMC4109980</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.<pub-id pub-id-type="pmid">21366474</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1008862</pub-id><pub-id pub-id-type="pmcid">PMC4109980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>DF</given-names></name></person-group><article-title>Walker C K.A descriptive and historical review of bibliometrics with applications to medical sciences</article-title><source>Pharmacotherapy</source><year>2015</year><volume>35</volume><issue>6</issue><fpage>551</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/phar.1586</pub-id><pub-id pub-id-type="pmid">25940769</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Thompson DF. Walker C K.A descriptive and historical review of bibliometrics with applications to medical sciences. Pharmacotherapy. 2015;35(6):551–9.<pub-id pub-id-type="pmid">25940769</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.1586</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022</article-title><source>Hum Vaccin Immunother</source><year>2024</year><volume>20</volume><issue>1</issue><fpage>2335728</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2335728</pub-id><pub-id pub-id-type="pmid">38563136</pub-id><pub-id pub-id-type="pmcid">PMC10989689</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Qu F, Wang G, Wen P, et al. Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022. Hum Vaccin Immunother. 2024;20(1):2335728.<pub-id pub-id-type="pmid">38563136</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2024.2335728</pub-id><pub-id pub-id-type="pmcid">PMC10989689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Eck</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Waltman</surname><given-names>L</given-names></name></person-group><article-title>Software survey: VOSviewer, a computer program for bibliometric mapping</article-title><source>Scientometrics</source><year>2010</year><volume>84</volume><issue>2</issue><fpage>523</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s11192-009-0146-3</pub-id><pub-id pub-id-type="pmid">20585380</pub-id><pub-id pub-id-type="pmcid">PMC2883932</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.<pub-id pub-id-type="pmid">20585380</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11192-009-0146-3</pub-id><pub-id pub-id-type="pmcid">PMC2883932</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Moral-Muñoz JA, Herrera-Viedma E, Santisteban-Espejo A, et al. Software tools for conducting bibliometric analysis in science: an up-to-date review. El Profesional de la Información. 2020;29:1.</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Searching for intellectual turning points: progressive knowledge domain visualization</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><issue>Suppl 1</issue><fpage>5303</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1073/pnas.0307513100</pub-id><pub-id pub-id-type="pmid">14724295</pub-id><pub-id pub-id-type="pmcid">PMC387312</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101(Suppl 1):5303–10.<pub-id pub-id-type="pmid">14724295</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0307513100</pub-id><pub-id pub-id-type="pmcid">PMC387312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>MC</given-names></name><name name-style="western"><surname>Nam</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Mapping scientific landscapes in UMLS research: a scientometric review</article-title><source>J Am Med Inf Assoc</source><year>2020</year><volume>27</volume><issue>10</issue><fpage>1612</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1093/jamia/ocaa107</pub-id><pub-id pub-id-type="pmcid">PMC7647344</pub-id><pub-id pub-id-type="pmid">33059367</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kim MC, Nam S, Wang F, et al. Mapping scientific landscapes in UMLS research: a scientometric review. J Am Med Inf Assoc. 2020;27(10):1612–24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jamia/ocaa107</pub-id><pub-id pub-id-type="pmcid">PMC7647344</pub-id><pub-id pub-id-type="pmid">33059367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Dubin</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MC</given-names></name></person-group><article-title>.Emerging trends and new developments in regenerative medicine: a scientometric update (2000–2014)</article-title><source>Expert Opin Biol Ther</source><year>2014</year><volume>14</volume><issue>9</issue><fpage>1295</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1517/14712598.2014.920813</pub-id><pub-id pub-id-type="pmid">25077605</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chen C, Dubin R, Kim MC. .Emerging trends and new developments in regenerative medicine: a scientometric update (2000–2014). Expert Opin Biol Ther. 2014;14(9):1295–317.<pub-id pub-id-type="pmid">25077605</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2014.920813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis</article-title><source>Pharm Biol</source><year>2024</year><volume>62</volume><issue>1</issue><fpage>499</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1080/13880209.2024.2359105</pub-id><pub-id pub-id-type="pmid">38813803</pub-id><pub-id pub-id-type="pmcid">PMC11141317</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Yuan J, Liu Y, Zhang T, et al. Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis. Pharm Biol. 2024;62(1):499–512.<pub-id pub-id-type="pmid">38813803</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13880209.2024.2359105</pub-id><pub-id pub-id-type="pmcid">PMC11141317</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>IM</given-names></name><name name-style="western"><surname>Shiroma</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lobelo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9838</issue><fpage>219</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61031-9</pub-id><pub-id pub-id-type="pmid">22818936</pub-id><pub-id pub-id-type="pmcid">PMC3645500</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–29.<pub-id pub-id-type="pmid">22818936</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(12)61031-9</pub-id><pub-id pub-id-type="pmcid">PMC3645500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis[J]. Journal of the Association for Information Science and Technology. 2014;65(2):334-351.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Giovannucci E, Harlan D M, Archer M C, et al. Diabetes and Cancer: a Consensus Report[J]. CA: A Cancer Journal for Clinicians. 2010;60(4):207-221.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.20078</pub-id><pub-id pub-id-type="pmid">20554718</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China</article-title><source>Public Health</source><year>2009</year><volume>123</volume><issue>8</issue><fpage>540</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.puhe.2009.06.019</pub-id><pub-id pub-id-type="pmid">19664792</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ren X, Zhang X, Zhang X, et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health. 2009;123(8):540–4.<pub-id pub-id-type="pmid">19664792</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.puhe.2009.06.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S</given-names></name><etal/></person-group><article-title>Facilitators and barriers to chronic non-communicable disease management under family Doctor contracting services in China</article-title><source>Front Med (Lausanne)</source><year>2025</year><volume>12</volume><fpage>1506016</fpage><pub-id pub-id-type="doi">10.3389/fmed.2025.1506016</pub-id><pub-id pub-id-type="pmid">40134919</pub-id><pub-id pub-id-type="pmcid">PMC11932984</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Jiang R, Xin Y, Peng S, et al. Facilitators and barriers to chronic non-communicable disease management under family Doctor contracting services in China. Front Med (Lausanne). 2025;12:1506016.<pub-id pub-id-type="pmid">40134919</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2025.1506016</pub-id><pub-id pub-id-type="pmcid">PMC11932984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giovannucci</surname><given-names>E</given-names></name></person-group><article-title>Insulin and colon cancer</article-title><source>Cancer Causes Control</source><year>1995</year><volume>6</volume><issue>2</issue><fpage>164</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">7749056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00052777</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6(2):164–79.<pub-id pub-id-type="pmid">7749056</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00052777</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boveri</surname><given-names>T</given-names></name></person-group><article-title>Ueber mehrpolige Mitosen Als mittel Zur analyse des Zellkerns</article-title><source>Verh Phys Med Ges Würzburg</source><year>1902</year><volume>35</volume><fpage>67</fpage><lpage>90</lpage></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Boveri T. Ueber mehrpolige Mitosen Als mittel Zur analyse des Zellkerns. Verh Phys Med Ges Würzburg. 1902;35:67–90.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basto</surname><given-names>R</given-names></name><name name-style="western"><surname>Brunk</surname><given-names>K</given-names></name><name name-style="western"><surname>Vinadogrova</surname><given-names>T</given-names></name><etal/></person-group><article-title>Centrosome amplification can initiate tumorigenesis in flies</article-title><source>Cell</source><year>2008</year><volume>133</volume><issue>6</issue><fpage>1032</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.05.039</pub-id><pub-id pub-id-type="pmid">18555779</pub-id><pub-id pub-id-type="pmcid">PMC2653712</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Basto R, Brunk K, Vinadogrova T, et al. Centrosome amplification can initiate tumorigenesis in flies. Cell. 2008;133(6):1032–42.<pub-id pub-id-type="pmid">18555779</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2008.05.039</pub-id><pub-id pub-id-type="pmcid">PMC2653712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>JW</given-names></name><name name-style="western"><surname>Khatamianfar</surname><given-names>V</given-names></name><etal/></person-group><article-title>SKA1 over-expression promotes centriole over-duplication, centrosome amplification and prostate tumourigenesis</article-title><source>J Pathol</source><year>2014</year><volume>234</volume><issue>2</issue><fpage>178</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/path.4374</pub-id><pub-id pub-id-type="pmid">24827423</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Li J, Xuan JW, Khatamianfar V, et al. SKA1 over-expression promotes centriole over-duplication, centrosome amplification and prostate tumourigenesis. J Pathol. 2014;234(2):178–89.<pub-id pub-id-type="pmid">24827423</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>B</given-names></name><name name-style="western"><surname>Boeckx</surname><given-names>B</given-names></name><etal/></person-group><article-title>Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals</article-title><source>Dev Cell</source><year>2017</year><volume>40</volume><issue>3</issue><fpage>313</fpage><lpage>e3225</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.12.022</pub-id><pub-id pub-id-type="pmid">28132847</pub-id><pub-id pub-id-type="pmcid">PMC5296221</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Levine MS, Bakker B, Boeckx B, et al. Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev Cell. 2017;40(3):313–e3225.<pub-id pub-id-type="pmid">28132847</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.devcel.2016.12.022</pub-id><pub-id pub-id-type="pmcid">PMC5296221</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dionne</surname><given-names>LK</given-names></name><name name-style="western"><surname>Shim</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoshi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Centrosome amplification disrupts renal development and causes cystogenesis</article-title><source>J Cell Biol</source><year>2018</year><volume>217</volume><issue>7</issue><fpage>2485</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1083/jcb.201710019</pub-id><pub-id pub-id-type="pmid">29895697</pub-id><pub-id pub-id-type="pmcid">PMC6028550</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dionne LK, Shim K, Hoshi M, et al. Centrosome amplification disrupts renal development and causes cystogenesis. J Cell Biol. 2018;217(7):2485–501.<pub-id pub-id-type="pmid">29895697</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1083/jcb.201710019</pub-id><pub-id pub-id-type="pmcid">PMC6028550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Li YF, Shi LJ, Wang P et al. Binding between ROCK1 and DCTN2 triggers diabetes‑associated centrosome amplification in colon cancer cells. Oncol Rep. 2021;46(1):151.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2021.8102</pub-id><pub-id pub-id-type="pmcid">PMC8185503</pub-id><pub-id pub-id-type="pmid">34080666</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>QQ</given-names></name><etal/></person-group><article-title>Secreted Wnt6 mediates diabetes-associated centrosome amplification via its receptor FZD4</article-title><source>Am J Physiol Cell Physiol</source><year>2020</year><volume>318</volume><issue>1</issue><fpage>C48</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00091.2019</pub-id><pub-id pub-id-type="pmid">31618077</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">He QJ, Wang P, Liu QQ, et al. Secreted Wnt6 mediates diabetes-associated centrosome amplification via its receptor FZD4. Am J Physiol Cell Physiol. 2020;318(1):C48–62.<pub-id pub-id-type="pmid">31618077</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpcell.00091.2019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawler</surname><given-names>J</given-names></name><name name-style="western"><surname>Choynowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>K</given-names></name><etal/></person-group><article-title>Meta-analysis of the impact of postoperative infective complications on oncological outcomes in colorectal cancer surgery</article-title><source>BJS Open</source><year>2020</year><volume>4</volume><issue>5</issue><fpage>737</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1002/bjs5.50302</pub-id><pub-id pub-id-type="pmid">32525280</pub-id><pub-id pub-id-type="pmcid">PMC7528523</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lawler J, Choynowski M, Bailey K, et al. Meta-analysis of the impact of postoperative infective complications on oncological outcomes in colorectal cancer surgery. BJS Open. 2020;4(5):737–47.<pub-id pub-id-type="pmid">32525280</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs5.50302</pub-id><pub-id pub-id-type="pmcid">PMC7528523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koedam</surname><given-names>TWA</given-names></name><name name-style="western"><surname>Bootsma</surname><given-names>BT</given-names></name><name name-style="western"><surname>Deijen</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Oncological outcomes after anastomotic leakage after surgery for colon or rectal cancer: increased risk of local recurrence</article-title><source>Ann Surg</source><year>2022</year><volume>275</volume><issue>2</issue><fpage>e420</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/SLA.0000000000003889</pub-id><pub-id pub-id-type="pmid">32224742</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Koedam TWA, Bootsma BT, Deijen CL, et al. Oncological outcomes after anastomotic leakage after surgery for colon or rectal cancer: increased risk of local recurrence. Ann Surg. 2022;275(2):e420–7.<pub-id pub-id-type="pmid">32224742</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000003889</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golightly</surname><given-names>LK</given-names></name><name name-style="western"><surname>Jones</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hamamura</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy</article-title><source>Pharmacotherapy</source><year>2006</year><volume>26</volume><issue>10</issue><fpage>1421</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1592/phco.26.10.1421</pub-id><pub-id pub-id-type="pmid">16999652</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Golightly LK, Jones MA, Hamamura DH, et al. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy. 2006;26(10):1421–32.<pub-id pub-id-type="pmid">16999652</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.26.10.1421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis</article-title><source>Cancer Commun (Lond)</source><year>2018</year><volume>38</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="pmid">29764483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40880-018-0275-2</pub-id><pub-id pub-id-type="pmcid">PMC5993151</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Yao W, Meng Y, Lu M, et al. Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis. Cancer Commun (Lond). 2018;38(1):14.<pub-id pub-id-type="pmid">29764483</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40880-018-0275-2</pub-id><pub-id pub-id-type="pmcid">PMC5993151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tefft</surname><given-names>JB</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Eyckmans</surname><given-names>J</given-names></name></person-group><article-title>Reconstituting the dynamics of endothelial cells and fibroblasts in wound closure</article-title><source>APL Bioeng</source><year>2021</year><volume>5</volume><issue>1</issue><fpage>016102</fpage><pub-id pub-id-type="doi">10.1063/5.0028651</pub-id><pub-id pub-id-type="pmid">33511324</pub-id><pub-id pub-id-type="pmcid">PMC7817247</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Tefft JB, Chen CS, Eyckmans J. Reconstituting the dynamics of endothelial cells and fibroblasts in wound closure. APL Bioeng. 2021;5(1):016102.<pub-id pub-id-type="pmid">33511324</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1063/5.0028651</pub-id><pub-id pub-id-type="pmcid">PMC7817247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>E</given-names></name><name name-style="western"><surname>Ase</surname><given-names>K</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mechanism of acceleration of wound healing by basic fibroblast growth factor in genetically diabetic mice</article-title><source>Biol Pharm Bull</source><year>1996</year><volume>19</volume><issue>9</issue><fpage>1141</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1248/bpb.19.1141</pub-id><pub-id pub-id-type="pmid">8889031</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Tanaka E, Ase K, Okuda T, et al. Mechanism of acceleration of wound healing by basic fibroblast growth factor in genetically diabetic mice. Biol Pharm Bull. 1996;19(9):1141–8.<pub-id pub-id-type="pmid">8889031</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.19.1141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toyoda</surname><given-names>M</given-names></name><name name-style="western"><surname>Takayama</surname><given-names>H</given-names></name><name name-style="western"><surname>Horiguchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo</article-title><source>FEBS Lett</source><year>2001</year><volume>509</volume><issue>1</issue><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(01)03126-X</pub-id><pub-id pub-id-type="pmid">11734213</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Toyoda M, Takayama H, Horiguchi N, et al. Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett. 2001;509(1):95–100.<pub-id pub-id-type="pmid">11734213</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0014-5793(01)03126-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Warren</surname><given-names>J</given-names></name><etal/></person-group><article-title>Picroliv accelerates epithelialization and angiogenesis in rat wounds</article-title><source>Planta Med</source><year>2007</year><volume>73</volume><issue>3</issue><fpage>251</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1055/s-2007-967119</pub-id><pub-id pub-id-type="pmid">17318779</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Singh AK, Sharma A, Warren J, et al. Picroliv accelerates epithelialization and angiogenesis in rat wounds. Planta Med. 2007;73(3):251–6.<pub-id pub-id-type="pmid">17318779</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2007-967119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giacco</surname><given-names>F</given-names></name><name name-style="western"><surname>Brownlee</surname><given-names>M</given-names></name></person-group><article-title>Oxidative stress and diabetic complications</article-title><source>Circ Res</source><year>2010</year><volume>107</volume><issue>9</issue><fpage>1058</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.223545</pub-id><pub-id pub-id-type="pmid">21030723</pub-id><pub-id pub-id-type="pmcid">PMC2996922</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.<pub-id pub-id-type="pmid">21030723</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.110.223545</pub-id><pub-id pub-id-type="pmcid">PMC2996922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loughlin</surname><given-names>DT</given-names></name><name name-style="western"><surname>Artlett</surname><given-names>CM</given-names></name></person-group><article-title>Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>6</issue><fpage>e11093</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0011093</pub-id><pub-id pub-id-type="pmid">20559423</pub-id><pub-id pub-id-type="pmcid">PMC2885413</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Loughlin DT, Artlett CM. Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4. PLoS ONE. 2010;5(6):e11093.<pub-id pub-id-type="pmid">20559423</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0011093</pub-id><pub-id pub-id-type="pmcid">PMC2885413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siqueira</surname><given-names>MF</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Chehab</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impaired wound healing in mouse models of diabetes is mediated by TNF-alpha dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1)</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><issue>2</issue><fpage>378</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00125-009-1529-y</pub-id><pub-id pub-id-type="pmid">19902175</pub-id><pub-id pub-id-type="pmcid">PMC3130195</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Siqueira MF, Li J, Chehab L, et al. Impaired wound healing in mouse models of diabetes is mediated by TNF-alpha dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1). Diabetologia. 2010;53(2):378–88.<pub-id pub-id-type="pmid">19902175</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-009-1529-y</pub-id><pub-id pub-id-type="pmcid">PMC3130195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivitz</surname><given-names>WI</given-names></name><name name-style="western"><surname>Yorek</surname><given-names>MA</given-names></name></person-group><article-title>.Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities</article-title><source>Antioxid Redox Signal</source><year>2010</year><volume>12</volume><issue>4</issue><fpage>537</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1089/ars.2009.2531</pub-id><pub-id pub-id-type="pmid">19650713</pub-id><pub-id pub-id-type="pmcid">PMC2824521</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sivitz WI, Yorek MA. .Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2010;12(4):537–77.<pub-id pub-id-type="pmid">19650713</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ars.2009.2531</pub-id><pub-id pub-id-type="pmcid">PMC2824521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gloire</surname><given-names>G</given-names></name><name name-style="western"><surname>Legrand-Poels</surname><given-names>S</given-names></name><name name-style="western"><surname>Piette</surname><given-names>J</given-names></name></person-group><article-title>NF-kappaB activation by reactive oxygen species: fifteen years later</article-title><source>Biochem Pharmacol</source><year>2006</year><volume>72</volume><issue>11</issue><fpage>1493</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2006.04.011</pub-id><pub-id pub-id-type="pmid">16723122</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72(11):1493–505.<pub-id pub-id-type="pmid">16723122</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2006.04.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louiselle</surname><given-names>AE</given-names></name><name name-style="western"><surname>Niemiec</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zgheib</surname><given-names>C</given-names></name><etal/></person-group><article-title>Macrophage polarization and diabetic wound healing</article-title><source>Transl Res</source><year>2021</year><volume>236</volume><fpage>109</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2021.05.006</pub-id><pub-id pub-id-type="pmid">34089902</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Louiselle AE, Niemiec SM, Zgheib C, et al. Macrophage polarization and diabetic wound healing. Transl Res. 2021;236:109–16.<pub-id pub-id-type="pmid">34089902</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2021.05.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>M</given-names></name></person-group><article-title>Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective</article-title><source>Pharmacol Res</source><year>2016</year><volume>107</volume><fpage>243</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.03.008</pub-id><pub-id pub-id-type="pmid">27033051</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Chang M. Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective. Pharmacol Res. 2016;107:243–8.<pub-id pub-id-type="pmid">27033051</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2016.03.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagase</surname><given-names>H</given-names></name><name name-style="western"><surname>Visse</surname><given-names>R</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G</given-names></name></person-group><article-title>Structure and function of matrix metalloproteinases and timps</article-title><source>Cardiovasc Res</source><year>2006</year><volume>69</volume><issue>3</issue><fpage>562</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2005.12.002</pub-id><pub-id pub-id-type="pmid">16405877</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and timps. Cardiovasc Res. 2006;69(3):562–73.<pub-id pub-id-type="pmid">16405877</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cardiores.2005.12.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Xue SN, Lei J, Yang C et al. The biological behaviors of rat dermal fibroblasts can be inhibited by high levels of MMP9. Exp Diabetes Res. 2012;2012:494579.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2012/494579</pub-id><pub-id pub-id-type="pmcid">PMC3346983</pub-id><pub-id pub-id-type="pmid">22577368</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooke</surname><given-names>CL</given-names></name><name name-style="western"><surname>Davidge</surname><given-names>ST</given-names></name></person-group><article-title>.Peroxynitrite increases iNOS through NF-kappaB and decreases Prostacyclin synthase in endothelial cells</article-title><source>Am J Physiol Cell Physiol</source><year>2002</year><volume>282</volume><issue>2</issue><fpage>C395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00295.2001</pub-id><pub-id pub-id-type="pmid">11788351</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Cooke CL, Davidge ST. .Peroxynitrite increases iNOS through NF-kappaB and decreases Prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol. 2002;282(2):C395–402.<pub-id pub-id-type="pmid">11788351</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpcell.00295.2001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinhard</surname><given-names>H</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>PK</given-names></name><name name-style="western"><surname>Lajer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><issue>10</issue><fpage>2129</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00125-010-1843-4</pub-id><pub-id pub-id-type="pmid">20607514</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Reinhard H, Jacobsen PK, Lajer M, et al. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia. 2010;53(10):2129–33.<pub-id pub-id-type="pmid">20607514</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-010-1843-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>F</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hydrogen sulfide protects against high Glucose-Induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway</article-title><source>Drug Des Devel Ther</source><year>2020</year><volume>14</volume><fpage>621</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S242521</pub-id><pub-id pub-id-type="pmid">32103904</pub-id><pub-id pub-id-type="pmcid">PMC7027865</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Lin F, Yang Y, Wei S, et al. Hydrogen sulfide protects against high Glucose-Induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway. Drug Des Devel Ther. 2020;14:621–33.<pub-id pub-id-type="pmid">32103904</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S242521</pub-id><pub-id pub-id-type="pmcid">PMC7027865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simons</surname><given-names>M</given-names></name></person-group><article-title>Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed?</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>46</volume><issue>5</issue><fpage>835</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2005.06.008</pub-id><pub-id pub-id-type="pmid">16139133</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Simons M. Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol. 2005;46(5):835–7.<pub-id pub-id-type="pmid">16139133</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2005.06.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingueti</surname><given-names>CP</given-names></name><name name-style="western"><surname>Dusse</surname><given-names>LM</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications</article-title><source>J Diabetes Complications</source><year>2016</year><volume>30</volume><issue>4</issue><fpage>738</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2015.12.018</pub-id><pub-id pub-id-type="pmid">26781070</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Domingueti CP, Dusse LM, Carvalho M, et al. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016;30(4):738–45.<pub-id pub-id-type="pmid">26781070</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2015.12.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>MT</given-names></name><name name-style="western"><surname>Han</surname><given-names>YP</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C</given-names></name><etal/></person-group><article-title>TNF-alpha suppresses alpha-smooth muscle actin expression in human dermal fibroblasts: an implication for abnormal wound healing</article-title><source>J Invest Dermatol</source><year>2007</year><volume>127</volume><issue>11</issue><fpage>2645</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700890</pub-id><pub-id pub-id-type="pmid">17554369</pub-id><pub-id pub-id-type="pmcid">PMC2366884</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Goldberg MT, Han YP, Yan C, et al. TNF-alpha suppresses alpha-smooth muscle actin expression in human dermal fibroblasts: an implication for abnormal wound healing. J Invest Dermatol. 2007;127(11):2645–55.<pub-id pub-id-type="pmid">17554369</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.jid.5700890</pub-id><pub-id pub-id-type="pmcid">PMC2366884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rena</surname><given-names>G</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>DG</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ER</given-names></name></person-group><article-title>.The mechanisms of action of Metformin</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><issue>9</issue><fpage>1577</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4342-z</pub-id><pub-id pub-id-type="pmid">28776086</pub-id><pub-id pub-id-type="pmcid">PMC5552828</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Rena G, Hardie DG, Pearson ER. .The mechanisms of action of Metformin. Diabetologia. 2017;60(9):1577–85.<pub-id pub-id-type="pmid">28776086</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-017-4342-z</pub-id><pub-id pub-id-type="pmcid">PMC5552828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umezawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Higurashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Komiya</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Chemoprevention of colorectal cancer: Past, present, and future</article-title><source>Cancer Sci</source><year>2019</year><volume>110</volume><issue>10</issue><fpage>3018</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/cas.14149</pub-id><pub-id pub-id-type="pmid">31361372</pub-id><pub-id pub-id-type="pmcid">PMC6778640</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Umezawa S, Higurashi T, Komiya Y, et al. Chemoprevention of colorectal cancer: Past, present, and future. Cancer Sci. 2019;110(10):3018–26.<pub-id pub-id-type="pmid">31361372</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.14149</pub-id><pub-id pub-id-type="pmcid">PMC6778640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosato</surname><given-names>V</given-names></name><name name-style="western"><surname>Tavani</surname><given-names>A</given-names></name><name name-style="western"><surname>Gracia-Lavedan</surname><given-names>E</given-names></name><etal/></person-group><article-title>Type 2 Diabetes, antidiabetic Medications, and colorectal cancer risk: two Case-Control studies from Italy and Spain</article-title><source>Front Oncol</source><year>2016</year><volume>6</volume><fpage>210</fpage><pub-id pub-id-type="doi">10.3389/fonc.2016.00210</pub-id><pub-id pub-id-type="pmid">27766252</pub-id><pub-id pub-id-type="pmcid">PMC5052265</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Rosato V, Tavani A, Gracia-Lavedan E, et al. Type 2 Diabetes, antidiabetic Medications, and colorectal cancer risk: two Case-Control studies from Italy and Spain. Front Oncol. 2016;6:210.<pub-id pub-id-type="pmid">27766252</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2016.00210</pub-id><pub-id pub-id-type="pmcid">PMC5052265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>KT</given-names></name><name name-style="western"><surname>Bellows</surname><given-names>CF</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Diabetes mellitus and colorectal cancer prognosis: a meta-analysis</article-title><source>Dis Colon Rectum</source><year>2013</year><volume>56</volume><issue>11</issue><fpage>1304</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1097/DCR.0b013e3182a479f9</pub-id><pub-id pub-id-type="pmid">24105007</pub-id><pub-id pub-id-type="pmcid">PMC3800045</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Mills KT, Bellows CF, Hoffman AE, et al. Diabetes mellitus and colorectal cancer prognosis: a meta-analysis. Dis Colon Rectum. 2013;56(11):1304–19.<pub-id pub-id-type="pmid">24105007</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DCR.0b013e3182a479f9</pub-id><pub-id pub-id-type="pmcid">PMC3800045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buzzai</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RG</given-names></name><name name-style="western"><surname>Amaravadi</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Systemic treatment with the antidiabetic drug Metformin selectively impairs p53-deficient tumor cell growth</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>14</issue><fpage>6745</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4447</pub-id><pub-id pub-id-type="pmid">17638885</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug Metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745–52.<pub-id pub-id-type="pmid">17638885</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-06-4447</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vernieri</surname><given-names>C</given-names></name><name name-style="western"><surname>Galli</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impact of Metformin use and diabetic status during adjuvant Fluoropyrimidine-Oxaliplatin chemotherapy on the outcome of patients with resected colon cancer: A TOSCA study subanalysis</article-title><source>Oncologist</source><year>2019</year><volume>24</volume><issue>3</issue><fpage>385</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2018-0442</pub-id><pub-id pub-id-type="pmid">30606884</pub-id><pub-id pub-id-type="pmcid">PMC6519752</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Vernieri C, Galli F, Ferrari L, et al. Impact of Metformin use and diabetic status during adjuvant Fluoropyrimidine-Oxaliplatin chemotherapy on the outcome of patients with resected colon cancer: A TOSCA study subanalysis. Oncologist. 2019;24(3):385–93.<pub-id pub-id-type="pmid">30606884</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2018-0442</pub-id><pub-id pub-id-type="pmcid">PMC6519752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>PP</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Foster</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Relationship between Metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North central cancer treatment group N0147 (Alliance)</article-title><source>Oncologist</source><year>2016</year><volume>21</volume><issue>12</issue><fpage>1509</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0153</pub-id><pub-id pub-id-type="pmid">27881709</pub-id><pub-id pub-id-type="pmcid">PMC5153338</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Singh PP, Shi Q, Foster NR, et al. Relationship between Metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North central cancer treatment group N0147 (Alliance). Oncologist. 2016;21(12):1509–21.<pub-id pub-id-type="pmid">27881709</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2016-0153</pub-id><pub-id pub-id-type="pmcid">PMC5153338</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12907551</article-id><article-id pub-id-type="pmcid-ver">PMC12907551.1</article-id><article-id pub-id-type="pmcaid">12907551</article-id><article-id pub-id-type="pmcaiid">12907551</article-id><article-id pub-id-type="pmid">41704279</article-id><article-id pub-id-type="doi">10.3389/fphar.2026.1681783</article-id><article-id pub-id-type="publisher-id">1681783</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Mini Review</subject></subj-group></article-categories><title-group><article-title>Repurposing metformin for cardioprotection: mechanisms and therapeutic potential across cardiovascular pathologies</article-title><alt-title alt-title-type="left-running-head">Khinchin et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2026.1681783" ext-link-type="uri">10.3389/fphar.2026.1681783</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Khinchin</surname><given-names initials="J">Julia</given-names></name><xref rid="aff1" ref-type="aff"/><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3086731"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rakoubian</surname><given-names initials="A">Ani</given-names></name><xref rid="aff1" ref-type="aff"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Romano</surname><given-names initials="V">Valentina</given-names></name><xref rid="aff1" ref-type="aff"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ryan</surname><given-names initials="T">Thomas</given-names></name><xref rid="aff1" ref-type="aff"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yarbro</surname><given-names initials="J">Johnathan</given-names></name><xref rid="aff1" ref-type="aff"/><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3114363"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names initials="S">Satoru</given-names></name><xref rid="aff1" ref-type="aff"/><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/743926"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liang</surname><given-names initials="Q">Qiangrong</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/757769"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role></contrib></contrib-group><aff id="aff1">
<institution>Department of Biomedical Sciences, New York Institute of Technology, College of Osteopathic Medicine</institution>, <city>Old Westbury</city>, <state>NY</state>, <country country="US">United States</country>
</aff><author-notes><corresp id="c001">
<label>*</label>Correspondence: Qiangrong Liang, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:qliang03@nyit.edu">qliang03@nyit.edu</email>
</corresp></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-02"><day>02</day><month>2</month><year>2026</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2026</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">506021</issue-id><elocation-id>1681783</elocation-id><history><date date-type="received"><day>07</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>17</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 15:25:12.493"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 Khinchin, Rakoubian, Romano, Ryan, Yarbro, Kobayashi and Liang.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Khinchin, Rakoubian, Romano, Ryan, Yarbro, Kobayashi and Liang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2026-02-02">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-17-1681783.pdf"/><abstract><p>Metformin, a cornerstone therapy for type 2 diabetes mellitus, has emerged as a promising cardioprotective agent with effects that extend well beyond glycemic control. This review synthesizes current evidence on the molecular and cellular mechanisms underlying metformin’s glycemic control and cardiovascular benefits, highlighting both AMPK-dependent and AMPK-independent pathways. We examine its modulation of mitochondrial function, oxidative stress, inflammation, autophagy, and apoptosis across major cardiac conditions, including ischemia/reperfusion injury, heart failure, diabetic cardiomyopathy, and anthracycline-induced cardiotoxicity. By integrating evidence from both preclinical and clinical studies, we evaluate the translational potential of metformin’s pleiotropic actions across specific cardiac pathologies and outline key directions for future research and therapeutic innovation. Together, these insights highlight metformin’s promise in reshaping cardiovascular care beyond its traditional role in diabetes management.</p></abstract><kwd-group><kwd>AMPK</kwd><kwd>anthracycline cardiotoxicity</kwd><kwd>autophagy</kwd><kwd>cardioprotection</kwd><kwd>diabetic cardiomyopathy</kwd><kwd>heart failure</kwd><kwd>ischemia-reperfusion injury</kwd><kwd>metformin</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that financial support was received for this work and/or its publication. SK is supported by NIH grant 1R15HL161737-01A1 and QL is supported by 1R15HL163707-01A1.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="153"/><page-count count="15"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cardiovascular and Smooth Muscle Pharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><label>1</label><title>Metformin: origins, chemical structure, and pharmacokinetic profile</title><p>Metformin is widely recognized as the first-line oral antihyperglycemic agent for the treatment of type 2 diabetes mellitus (T2DM) globally. It is a synthetic biguanide, originally derived from a guanidine compound found in <italic toggle="yes">Galega officinalis</italic>, a medicinal plant historically used to alleviate diabetic symptoms as early as the 18th century (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>). Structurally, metformin consists of two guanidine molecules linked with the loss of ammonia, giving rise to a cationic compound under physiological conditions (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B62" ref-type="bibr">Jones et al., 2022</xref>).</p><p>Initially, metformin attracted limited clinical interest due to its relatively low potency and the need for high doses to achieve therapeutic effects. Earlier biguanides such as phenformin and buformin showed greater potency but were withdrawn from the market due to a high incidence of lactic acidosis (<xref rid="B67" ref-type="bibr">LaMoia and Shulman, 2021</xref>). This risk shifted attention toward metformin, whose milder pharmacologic profile offered a better safety margin and lower propensity for lactic acidosis.</p><p>Pharmacokinetically, metformin is absorbed primarily in the small intestine, with a bioavailability of approximately 50%–60% under fasting conditions (<xref rid="B62" ref-type="bibr">Jones et al., 2022</xref>). Peak plasma concentrations occur 2–3 h after oral administration, and the elimination half-life ranges from 4 to 8.7 h (<xref rid="T1" ref-type="table">Table 1</xref>), depending on the formulation (immediate- vs. extended-release). Metformin is distributed rapidly into various tissues, particularly the liver and gastrointestinal tract, and is excreted unchanged in the urine via active tubular secretion. It is not metabolized by the liver, does not undergo significant protein binding, and its clearance is highly dependent on renal function (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B67" ref-type="bibr">LaMoia and Shulman, 2021</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Pharmacology and mechanistic basis of Metformin’s cardioprotective actions.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Category</th><th align="left" rowspan="1" colspan="1">Details</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Pharmacokinetics</td><td align="left" rowspan="1" colspan="1">Oral bioavailability ∼50–60%; peak plasma 2–3 h; not metabolized, excreted unchanged via kidney (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B62" ref-type="bibr">Jones et al., 2022</xref>; <xref rid="B67" ref-type="bibr">LaMoia and Shulman, 2021</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Safety profile</td><td align="left" rowspan="1" colspan="1">Generally safe; main side-effects are GI-related; rare risk of lactic acidosis, esp. in renal dysfunction (<xref rid="B39" ref-type="bibr">F and roldi, 2024</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Core mechanisms</td><td align="left" rowspan="1" colspan="1">- AMPK activation: Key energy sensor, activated via mitochondrial inhibition (complex I) and PEN2-AXIN-LAMTOR1 complex on lysosome (<xref rid="B83" ref-type="bibr">Ma et al., 2022</xref>; <xref rid="B43" ref-type="bibr">Foretz et al., 2023</xref>; <xref rid="B143" ref-type="bibr">Zhang et al., 2014</xref>)<break/>- Autophagy/mitophagy: AMPK activation, mTORC1 inhibition, ULK1/TFEB modulation; context-dependent (can activate or inhibit autophagy) (<xref rid="B113" ref-type="bibr">Shabkhizan et al., 2025</xref>; <xref rid="B141" ref-type="bibr">Zamanian et al., 2024</xref>; <xref rid="B136" ref-type="bibr">Xiang et al., 2024</xref>; <xref rid="B49" ref-type="bibr">Gu et al., 2017</xref>; <xref rid="B137" ref-type="bibr">Xiao et al., 2017</xref>; <xref rid="B44" ref-type="bibr">Gao et al., 2020</xref>; <xref rid="B129" ref-type="bibr">Wang et al., 2018</xref>; <xref rid="B13" ref-type="bibr">Bhansali et al., 2020</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Redox regulation &amp; metabolism</td><td align="left" rowspan="1" colspan="1">Inhibits mitochondrial GPD2 (affects gluconeogenesis and NADH/NAD + ratio) (<xref rid="B86" ref-type="bibr">Madiraju et al., 2018</xref>; <xref rid="B85" ref-type="bibr">Madiraju et al., 2014</xref>); decreases oxidative stress (<xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>; <xref rid="B98" ref-type="bibr">Osorio-Llanes et al., 2023</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-inflammation</td><td align="left" rowspan="1" colspan="1">Inhibits NLRP3 inflammasome (<xref rid="B144" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B139" ref-type="bibr">Yang et al., 2019</xref>), downregulates IL-6, TNF-α, and CRP, upregulates IL-10 (<xref rid="B4" ref-type="bibr">Almohaimeed et al., 2025</xref>; <xref rid="B139" ref-type="bibr">Yang et al., 2019</xref>; <xref rid="B111" ref-type="bibr">Schulz et al., 2024</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other mechanistic effects</td><td align="left" rowspan="1" colspan="1">Modulates mitochondrial dynamics (e.g., MFN1, MFN2), improves mitochondrial biogenesis, inhibits apoptosis (↓ Bax/Bcl-2, ↓ caspase-3) (<xref rid="B134" ref-type="bibr">Wu, 2023</xref>; <xref rid="B84" ref-type="bibr">Ma et al., 2023</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Controversies/Complexities</td><td align="left" rowspan="1" colspan="1">Effects on autophagy/mitophagy are dose, tissue, and context dependent; AMPK-independent actions are recognized (<xref rid="B138" ref-type="bibr">Xu et al., 2014</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="s2"><label>2</label><title>Mechanistic insights into metformin’s glucose-lowering actions</title><p>Metformin exerts pleiotropic metabolic effects extending beyond glucose control, notably regulating energy metabolism, autophagy, and redox balance. Central to these actions is AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis. AMPK activation by metformin depends on liver kinase B1 (LKB1) and is essential for suppressing hepatic gluconeogenesis (<xref rid="B114" ref-type="bibr">Shaw et al., 2005</xref>). Traditionally, this activation was attributed to inhibition of mitochondrial complex I, which raises the AMP:ATP ratio (<xref rid="B67" ref-type="bibr">LaMoia and Shulman, 2021</xref>; <xref rid="B83" ref-type="bibr">Ma et al., 2022</xref>; <xref rid="B43" ref-type="bibr">Foretz et al., 2023</xref>; <xref rid="B104" ref-type="bibr">Reczek et al., 2024</xref>). However, this occurs primarily at supra-pharmacological concentrations (millimolar), making it unlikely to explain AMPK activation at therapeutic doses (micromolar) (<xref rid="B29" ref-type="bibr">Di Magno et al., 2022</xref>; <xref rid="B42" ref-type="bibr">Fontaine, 2018</xref>; <xref rid="B130" ref-type="bibr">Wang et al., 2019</xref>).</p><p>Recent findings identify an AMP-independent lysosomal mechanism that better accounts for metformin’s effects at clinically relevant concentrations. Through direct binding to presenilin enhancer 2 (PEN2) on the lysosomal membrane, metformin inhibits v-ATPase via interaction with ATP6AP1, triggering recruitment of the AXIN-LKB1 complex to the lysosome (<xref rid="B83" ref-type="bibr">Ma et al., 2022</xref>; <xref rid="B43" ref-type="bibr">Foretz et al., 2023</xref>). This conformational rearrangement allows LKB1 to phosphorylate AMPK locally, independently of cellular energy charge or glucose levels (<xref rid="B143" ref-type="bibr">Zhang et al., 2014</xref>). This PEN2-v-ATPase-Ragulator pathway (<xref rid="F1" ref-type="fig">Figure 1</xref>) links metformin to lysosomal nutrient sensing rather than mitochondrial stress, offering a potentially safer mode of AMPK activation. Although unconfirmed in cardiac tissue, this mechanism may underlie metformin-induced AMPK activation in the heart (<xref rid="B94" ref-type="bibr">Mouli et al., 2025</xref>; <xref rid="B40" ref-type="bibr">Felgueiras et al., 2022</xref>; <xref rid="B126" ref-type="bibr">Vaez et al., 2016</xref>; <xref rid="B106" ref-type="bibr">Saeedi et al., 2008</xref>; <xref rid="B144" ref-type="bibr">Zhang et al., 2020</xref>), where v-ATPase also governs substrate utilization and is implicated in cardiac pathology (<xref rid="B132" ref-type="bibr">Wang et al., 2022</xref>; <xref rid="B25" ref-type="bibr">Chen et al., 2025</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Mechanism by which low-dose Metformin activates AMPK. Clinically relevant concentrations (micromolar) of metformin directly bind to PEN2 on the lysosomal membrane, inducing a conformational change that enables PEN2 to interact with ATP6AP1, an accessory subunit of the lysosomal proton pump v-ATPase, inhibiting its activity. v-ATPase inhibition leads to a conformational change in the v-ATPase-Ragulator complex, facilitating lysosomal translocation of AXIN, which recruits and serves as a scaffold for LKB1. Once recruited to the lysosomal membrane, LKB1 phosphorylates AMPK, leading to its activation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-17-1681783-g001.jpg"><alt-text content-type="machine-generated">Diagram illustrating the activation of AMPK by metformin. Metformin enters the cytosol and interacts with gamma-secretase and PEN2, affecting V-ATPase and Ragulator on the lysosomal membrane. This interaction involves AXIN and LKB1, leading to AMPK activation.</alt-text></graphic></fig><p>While AMPK activation explains many of metformin’s systemic effects, its glucose-lowering action appears to rely more directly on redox modulation of hepatic gluconeogenesis. Metformin inhibits gluconeogenesis from redox-dependent substrates such as lactate and glycerol by targeting mitochondrial glycerol-3-phosphate dehydrogenase (mGPD2), increasing the mitochondrial NADH/NAD<sup>+</sup> ratio and disrupting the glycerol-3-phosphate shuttle (<xref rid="B86" ref-type="bibr">Madiraju et al., 2018</xref>; <xref rid="B85" ref-type="bibr">Madiraju et al., 2014</xref>). Although direct inhibition of mGPD2 remains debated (<xref rid="B29" ref-type="bibr">Di Magno et al., 2022</xref>), metformin likely exerts secondary effects through complex IV inhibition, as shown by elevated hepatic glycerol-3-phosphate and evidence of copper-mediated complex IV modulation (<xref rid="F2" ref-type="fig">Figure 2</xref>) (<xref rid="B68" ref-type="bibr">LaMoia et al., 2022</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Proposed mechanism by which low-dose Metformin reduces hepatic glucose production. Clinically relevant concentrations (micromolar) of metformin inhibit complex IV of the electron transport chain. When complex IV is inhibited, electrons cannot be efficiently transferred to the final electron acceptor, oxygen, causing upstream complexes to become overwhelmed with electrons. The resulting ETC backlog inhibits the activity of GPD2, as GPD2 donates its electrons (from the reduction of FAD to FADH2) to the oxidized form of CoQ10 (ubiquinone, Q) to generate the reduced form (ubiquinol, QH<sub>2</sub>). Indirect inhibition of GPD2 results in reduced conversion of G3P to DHAP, resulting in reduced glycerol-derived gluconeogenesis. Further, impaired GPD2 function disrupts the glycerol-phosphate shuttle, leading to an increased cytosolic redox state (NADH:NAD), which inhibits the activity of LDH, thereby reducing lactate-derived gluconeogenesis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-17-1681783-g002.jpg"><alt-text content-type="machine-generated">Diagram illustrating the biochemical pathway involving glycerol, leading to increased NADH and decreased glucose levels. It highlights GPD1 and GPD2 enzymes in cytosol and mitochondria. Lactate dehydrogenase (LDH) converts lactate to pyruvate. The mitochondrial electron transport chain involves complexes II, III, IV, cytochrome c, and the intermembrane space, affected by metformin. The pathway results in oxygen reduction to water in the mitochondrial matrix. The diagram underscores the cellular role of metformin and its impact on mitochondrial function.</alt-text></graphic></fig><p>Together, these redox and lysosomal pathways allow metformin to suppress hepatic glucose production without broadly impairing mitochondrial respiration. This selective mechanism is especially effective in obesity and advanced T2DM, where enhanced adipose lipolysis increases glycerol flux to the liver (<xref rid="B102" ref-type="bibr">Pu et al., 2020</xref>). Beyond the liver, redox modulation may also contribute to metformin’s cardioprotective effects, particularly under conditions of mitochondrial or metabolic stress (<xref rid="B71" ref-type="bibr">Lewis et al., 2016</xref>).</p></sec><sec id="s3"><label>3</label><title>Metformin as a cardioprotective agent: mechanisms and evidence across diverse cardiac pathologies</title><p>Although widely used as a first-line therapy for type 2 diabetes, metformin exerts beneficial effects that extend well beyond glucose control. In patients with diabetes, metformin therapy is consistently associated with a lower incidence of cardiovascular events compared with sulfonylureas or insulin, even with similar glycemic control (<xref rid="B55" ref-type="bibr">Hong et al., 2013</xref>), although one study reported reductions primarily in all-cause rather than cardiovascular mortality (<xref rid="B12" ref-type="bibr">Bergmark et al., 2019</xref>). In non-diabetic individuals, particularly those with obesity or metabolic syndrome, metformin improves insulin sensitivity, lipid profiles, and body weight (<xref rid="B112" ref-type="bibr">Seifarth et al., 2013</xref>), thereby creating a favorable cardiometabolic milieu that may support downstream cardiovascular protection.</p><p>These benefits arise from several converging mechanisms (<xref rid="T1" ref-type="table">Table 1</xref>). Metformin activates AMPK and related cytoprotective pathways, enhances endothelial function, suppresses inflammation and oxidative stress (<xref rid="B82" ref-type="bibr">Luo et al., 2019</xref>; <xref rid="B95" ref-type="bibr">Mthembu et al., 2025</xref>; <xref rid="B105" ref-type="bibr">Rozier et al., 2021</xref>). It also modulates autophagy via AMPK-mTORC1 and lysosomal regulation (<xref rid="B113" ref-type="bibr">Shabkhizan et al., 2025</xref>; <xref rid="B141" ref-type="bibr">Zamanian et al., 2024</xref>; <xref rid="B136" ref-type="bibr">Xiang et al., 2024</xref>; <xref rid="B49" ref-type="bibr">Gu et al., 2017</xref>; <xref rid="B137" ref-type="bibr">Xiao et al., 2017</xref>; <xref rid="B44" ref-type="bibr">Gao et al., 2020</xref>; <xref rid="B129" ref-type="bibr">Wang et al., 2018</xref>; <xref rid="B13" ref-type="bibr">Bhansali et al., 2020</xref>; <xref rid="B133" ref-type="bibr">Wei et al., 2025</xref>; <xref rid="B81" ref-type="bibr">Lu et al., 2021</xref>). Although autophagy responses may vary by context (<xref rid="B57" ref-type="bibr">Huang et al., 2020</xref>; <xref rid="B127" ref-type="bibr">Van et al., 2023</xref>), the overall effect promotes cellular homeostasis and reduces metabolic stress.</p><p>Clinical studies in non-diabetic cohorts have demonstrated modest vascular and myocardial improvements, but findings remain variable and definitive cardiovascular outcomes trials are still lacking (<xref rid="B72" ref-type="bibr">Lexis et al., 2014</xref>; <xref rid="B101" ref-type="bibr">Preiss et al., 2016</xref>; <xref rid="B100" ref-type="bibr">Preiss et al., 2014</xref>; <xref rid="B60" ref-type="bibr">Jadhav et al., 2006</xref>; <xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>). Thus, despite a strong mechanistic rationale for cardioprotection, metformin’s clinical efficacy likely depends on disease context, timing of intervention, and underlying metabolic status.</p><p>The following sections examine how these core mechanisms translate into condition-specific effects across major cardiovascular pathologies, highlighting how metformin’s multifaceted actions may offer therapeutic value across diverse cardiac settings.</p><sec id="s3-1"><label>3.1</label><title>Metformin and ischemia/reperfusion injury</title><p>Ischemia/reperfusion (I/R) injury is a major contributor to cardiac dysfunction, driven by mitochondrial damage, oxidative stress, inflammation, and cell death upon restoration of blood flow. Metformin demonstrates cardioprotective effects against I/R injury through multiple mechanisms, involving both AMPK dependent and independent pathways (<xref rid="B98" ref-type="bibr">Osorio-Llanes et al., 2023</xref>).</p><sec id="s3-1-1"><label>3.1.1</label><title>Preclinical evidence</title><p>Administration of metformin before ischemia or at reperfusion reduces myocardial injury in diabetic and non-diabetic models without altering blood glucose. During early reperfusion, metformin activates AMPK and promotes endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177(48), effects abolished in AMPK- or eNOS-deficient mice (<xref rid="B50" ref-type="bibr">Gundewar et al., 2009</xref>), confirming pathway dependence. In Langendorff-perfused rat hearts, metformin at reperfusion decreases infarct size, improves ventricular function, and suppresses NLRP3 inflammasome activation, caspase-1 activity, and IL-1β/IL-18 expression; these benefits disappear with AMPK inhibition (<xref rid="B144" ref-type="bibr">Zhang et al., 2020</xref>). At higher doses, metformin confers protection via AMPK-independent inhibition of mitochondrial complex I (<xref rid="B92" ref-type="bibr">Mohsin et al., 2019</xref>).</p><p>Metformin also mimics pharmacologic preconditioning (e.g., sevoflurane) by activating Akt and upregulating anti-apoptotic proteins such as Bcl-xL (<xref rid="B105" ref-type="bibr">Rozier et al., 2021</xref>). In models of metabolic syndrome and coronary artery disease (CAD), chronic metformin therapy reduces cardiomyocyte apoptosis and improves myocardial function under ischemic stress (<xref rid="B119" ref-type="bibr">Stone et al., 2024</xref>).</p></sec><sec id="s3-1-2"><label>3.1.2</label><title>Clinical evidence</title><p>Metformin reduces the risk of rehospitalization for chest pain in hyperglycemic patients with ischemia and no obstructive CAD (<xref rid="B93" ref-type="bibr">Mone et al., 2025</xref>). Observational data further suggest that long-term metformin use lowers the risk of myocardial infarction by approximately 33% (<xref rid="B54" ref-type="bibr">Holman et al., 2008</xref>). Notably, metformin use at the time of acute MI has been associated with higher early cardiovascular risk, whereas initiation after MI confers benefit in patients with type 2 diabetes (<xref rid="B17" ref-type="bibr">Bromage et al., 2019</xref>), indicating that the cardioprotective effects of metformin are timing dependent.</p><p>In contrast, evidence in non-diabetic populations remains inconsistent: some studies report improved vascular function and reduced myocardial ischemia in non-diabetic women treated with metformin (<xref rid="B60" ref-type="bibr">Jadhav et al., 2006</xref>), whereas the GIPS-III trial showed no improvement in left ventricular ejection fraction after myocardial infarction in non-diabetic patients (<xref rid="B72" ref-type="bibr">Lexis et al., 2014</xref>; <xref rid="B52" ref-type="bibr">Hartman et al., 2017</xref>), and the CAMERA trial found no significant regression of carotid intima-media thickness or reduction in vascular inflammation (<xref rid="B101" ref-type="bibr">Preiss et al., 2016</xref>; <xref rid="B100" ref-type="bibr">Preiss et al., 2014</xref>). Collectively, these findings underscore the need for more targeted and adequately powered studies in non-diabetic populations.</p></sec><sec id="s3-1-3"><label>3.1.3</label><title>Mechanistic insights</title><p>Metformin preserves mitochondrial integrity, a key determinant of I/R injury, by stabilizing membrane potential, inhibiting complex I during early reperfusion and preventing mitochondrial permeability transition pore (mPTP) opening, thus limiting ROS generation and apoptosis (<xref rid="B98" ref-type="bibr">Osorio-Llanes et al., 2023</xref>; <xref rid="B92" ref-type="bibr">Mohsin et al., 2019</xref>; <xref rid="B24" ref-type="bibr">Chen et al., 2024</xref>). It further enhances mitochondrial quality control by attenuating ferroptosis and activating the Nur77-IDH1 axis, thereby reducing ROS and promoting cardiomyocyte survival (<xref rid="B135" ref-type="bibr">Wu et al., 2025</xref>). Metformin’s AMPK-dependent actions also extend to cardiopulmonary I/R models, where it reduces oxidative stress, suppresses inflammatory cytokines (TNF-α, IL-1β), and inhibits NF-κB signaling, collectively preserving tissue integrity (<xref rid="B79" ref-type="bibr">Liu et al., 2024</xref>). Reports that metformin may inhibit autophagy (<xref rid="B57" ref-type="bibr">Huang et al., 2020</xref>) highlight the complexity of its regulation of mitochondrial homeostasis and underscore the need for further investigation.</p><p>High-dose metformin treatment to inhibit complex I during early reperfusion protects the aged mouse heart via decreased mitochondrial permeability transition pore opening.</p></sec><sec id="s3-1-4"><label>3.1.4</label><title>Summary</title><p>Collectively, metformin mitigates I/R injury through converging mechanisms including AMPK activation, mitochondrial preservation, suppression of inflammation and oxidative stress, and modulation of regulated cell death, which positions metformin as a multifaceted cardioprotective agent. However, inconsistent clinical outcomes warrant further research to define its role, particularly in non-diabetic populations.</p></sec></sec><sec id="s3-2"><label>3.2</label><title>Metformin and heart failure</title><p>Heart failure (HF) is a clinical syndrome characterized by symptoms and/or signs resulting from structural or functional cardiac abnormalities, confirmed by elevated natriuretic peptide levels or objective evidence of pulmonary or systemic congestion (<xref rid="B15" ref-type="bibr">Bozkurt et al., 2021</xref>). HF remains a leading global cause of morbidity and mortality, driven by reduced cardiac output and progressive ventricular remodeling that compromise quality of life and survival. Increasing evidence suggests that metformin may serve as a promising therapeutic option in HF.</p><sec id="s3-2-1"><label>3.2.1</label><title>Preclinical evidence</title><p>Experimental studies have shown that metformin exerts cardioprotective effects through multiple complementary mechanisms. By activating AMPK, metformin enhances myocardial energy metabolism and mitigates oxidative stress, thereby improving cellular resilience under stress conditions (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B50" ref-type="bibr">Gundewar et al., 2009</xref>; <xref rid="B108" ref-type="bibr">Salvatore et al., 2021</xref>; <xref rid="B74" ref-type="bibr">Li et al., 2020</xref>; <xref rid="B80" ref-type="bibr">Loi et al., 2021</xref>; <xref rid="B23" ref-type="bibr">Chen et al., 2021</xref>). In LPS-induced septic myocardial injury, metformin reverses metabolic disturbances, improves survival and cardiac function, and reduces inflammation, apoptosis, and oxidative stress (<xref rid="B76" ref-type="bibr">Li et al., 2025</xref>). Metabolomic analyses further implicate PI3K/AKT and MMP signaling as key mediators, supporting its therapeutic repurposing potential (<xref rid="B76" ref-type="bibr">Li et al., 2025</xref>).</p></sec><sec id="s3-2-2"><label>3.2.2</label><title>Clinical evidence</title><p>Clinical evidence has increasingly established metformin as safe and potentially beneficial in heart failure (HF). Although its use was previously discouraged because of concerns about lactic acidosis, contemporary data indicate that this risk is minimal with appropriate renal and hepatic monitoring (<xref rid="B103" ref-type="bibr">Rahman and Tuba, 2022</xref>; <xref rid="B59" ref-type="bibr">Inzucchi et al., 2015</xref>; <xref rid="B31" ref-type="bibr">Dziubak et al., 2018</xref>). In small clinical trials, metformin improved antioxidant capacity and left ventricular remodeling in heart failure patients without diabetes (<xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>). Large cohort studies demonstrate the safety of metformin and even suggest survival benefits in patients with moderate renal impairment or advanced HF (<xref rid="B59" ref-type="bibr">Inzucchi et al., 2015</xref>; <xref rid="B89" ref-type="bibr">Masoudi et al., 2005</xref>; <xref rid="B69" ref-type="bibr">Larsen et al., 2020</xref>; <xref rid="B70" ref-type="bibr">Lazarus et al., 2018</xref>). Moreover, observational studies and meta-analyses consistently associate metformin use in patients with type 2 diabetes and HF with significant reductions in major adverse cardiovascular events (MACE), HF-related hospitalizations, cardiovascular mortality, and all-cause mortality (<xref rid="B89" ref-type="bibr">Masoudi et al., 2005</xref>; <xref rid="B2" ref-type="bibr">Aguilar et al., 2011</xref>; <xref rid="B27" ref-type="bibr">Crowley et al., 2017</xref>; <xref rid="B36" ref-type="bibr">Eurich et al., 2007</xref>; <xref rid="B56" ref-type="bibr">Huang and Zhao, 2025</xref>; <xref rid="B9" ref-type="bibr">Bahardoust et al., 2024</xref>). Randomized trials further show that 6 months of metformin therapy reduces oxidative stress, attenuates left ventricular hypertrophy and stiffening, and preserves cardiac function (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>). Notably, benefits extend to non-diabetic HF patients, where metformin enhances antioxidant capacity and prevents increases in left ventricular mass (<xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>).</p></sec><sec id="s3-2-3"><label>3.2.3</label><title>Mechanistic insights</title><p>Metformin’s cardioprotective effects are mediated through several interrelated mechanisms. Activation of AMPK enhances myocardial energy efficiency and reduces oxidative stress, while anti-remodeling actions limit ventricular hypertrophy and fibrosis (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B50" ref-type="bibr">Gundewar et al., 2009</xref>; <xref rid="B108" ref-type="bibr">Salvatore et al., 2021</xref>; <xref rid="B74" ref-type="bibr">Li et al., 2020</xref>; <xref rid="B80" ref-type="bibr">Loi et al., 2021</xref>; <xref rid="B23" ref-type="bibr">Chen et al., 2021</xref>). Through modulation of PI3K/AKT and MMP signaling, metformin exerts anti-inflammatory and anti-apoptotic effects that preserve cardiac structure and function (<xref rid="B76" ref-type="bibr">Li et al., 2025</xref>; <xref rid="B8" ref-type="bibr">Ashayeri Ahmadabad et al., 2025</xref>). Additionally, its ability to correct disturbances in key metabolic pathways enhances overall cardiac resilience under stress (<xref rid="B98" ref-type="bibr">Osorio-Llanes et al., 2023</xref>).</p></sec><sec id="s3-2-4"><label>3.2.4</label><title>Summary</title><p>Metformin is a safe and effective adjunct in HF management, particularly for patients with type 2 diabetes, and shows promise in selected non-diabetic HF populations. Its benefits extend beyond glycemic control, encompassing improved myocardial energetics, reduced oxidative stress, and attenuation of adverse remodeling. These findings support further investigation into metformin’s role as a cardioprotective agent in HF.</p></sec></sec><sec id="s3-3"><label>3.3</label><title>Metformin and diabetic cardiomyopathy</title><p>Diabetic cardiomyopathy (DCM) is a distinct cardiac condition characterized by structural and functional myocardial abnormalities in diabetic patients, independent of coronary artery disease or hypertension (<xref rid="B146" ref-type="bibr">Zhao et al., 2022</xref>). It manifests as impaired contractility, ventricular hypertrophy, and myocardial fibrosis, often progressing to heart failure. With the global rise in diabetes prevalence, interest in metformin’s cardioprotective mechanisms in DCM has intensified.</p><sec id="s3-3-1"><label>3.3.1</label><title>Preclinical evidence</title><p>Preclinical studies demonstrate that metformin protects against diabetic cardiomyopathy (DCM) through multiple complementary mechanisms (<xref rid="B28" ref-type="bibr">Dawood et al., 2022</xref>; <xref rid="B20" ref-type="bibr">Cameron et al., 2016</xref>; <xref rid="B145" ref-type="bibr">Zhao et al., 2021</xref>; <xref rid="B78" ref-type="bibr">Liu et al., 2022</xref>). In animal and cellular models, metformin reduces cardiomyocyte hypertrophy and lactate dehydrogenase release by downregulating HIF-1α and PPAR-γ, implicating the HIF-1α/PPAR-γ axis in limiting pathological growth (<xref rid="B78" ref-type="bibr">Liu et al., 2022</xref>). It also preserves myocardial structure by preventing desmin degradation and attenuating fibrosis via inhibition of the iNOS/mTOR/TIMP-1 pathway, thereby reducing collagen deposition and normalizing cardiac electrical activity (<xref rid="B28" ref-type="bibr">Dawood et al., 2022</xref>). Additionally, metformin activates the PK2/PKR–AKT/GSK3β signaling cascade, enhancing cardiomyocyte survival through Bcl-2 upregulation and reducing hyperglycemia-induced apoptosis and fibrosis (<xref rid="B140" ref-type="bibr">Yang et al., 2020</xref>; <xref rid="B18" ref-type="bibr">Bu et al., 2022</xref>). These findings underscore metformin’s capacity to mitigate structural remodeling and improve myocardial resilience in experimental DCM.</p></sec><sec id="s3-3-2"><label>3.3.2</label><title>Clinical evidence</title><p>Clinical studies support a cardioprotective role for metformin in diabetic cardiomyopathy and related cardiac complications. In the landmark <italic toggle="yes">UK Prospective Diabetes Study (UKPDS)</italic>, metformin use in overweight patients with type 2 diabetes significantly reduced diabetes-related endpoints, myocardial infarction, and all-cause mortality compared with conventional therapy, effects that persisted on long-term follow-up (<xref rid="B32" ref-type="bibr">Anonymous, 1998</xref>). Subsequent meta-analyses and large observational cohorts have consistently shown that metformin use is associated with lower all-cause and cardiovascular mortality and reduced heart failure (HF) incidence in diabetic populations (<xref rid="B27" ref-type="bibr">Crowley et al., 2017</xref>; <xref rid="B66" ref-type="bibr">Lamanna et al., 2011</xref>; <xref rid="B51" ref-type="bibr">Han et al., 2019</xref>). In patients with established HF, metformin therapy has been linked to improved survival and fewer hospitalizations compared with other glucose-lowering agents, supporting its safety and potential benefit even in systolic dysfunction (<xref rid="B2" ref-type="bibr">Aguilar et al., 2011</xref>; <xref rid="B38" ref-type="bibr">Eurich et al., 2013</xref>). Extending these benefits to earlier stages of metabolic disease and aging, a recent clinical study reported that metformin reduced the risk of frailty progression in prefrail older adults with hypertension and prediabetes, a population at high risk for cardiovascular dysfunction (<xref rid="B109" ref-type="bibr">Santulli et al., 2024</xref>). Moreover, small prospective trials demonstrated that metformin reduces left ventricular (LV) mass and improves diastolic function and myocardial energetics, suggesting favorable effects on cardiac remodeling central to DCM pathophysiology (<xref rid="B91" ref-type="bibr">Mohan et al., 2019</xref>). Collectively, these findings indicate that metformin confers both metabolic and direct myocardial benefits, although large randomized trials specifically targeting DCM outcomes are still needed.</p></sec><sec id="s3-3-3"><label>3.3.3</label><title>Mechanistic insight</title><p>Mechanistically, metformin exerts cardioprotection through coordinated regulation of inflammation, metabolism, and oxidative stress. It suppresses IL-6, TNF-α, and CRP while upregulating IL-10, thereby reducing myocardial inflammation (<xref rid="B4" ref-type="bibr">Almohaimeed et al., 2025</xref>; <xref rid="B139" ref-type="bibr">Yang et al., 2019</xref>; <xref rid="B111" ref-type="bibr">Schulz et al., 2024</xref>). Activation of AMPK with concurrent mTOR inhibition dampens NLRP3 inflammasome activity, limits IL-1β–mediated pyroptosis, and restores autophagic flux, effects abolished when AMPK is inhibited (<xref rid="B139" ref-type="bibr">Yang et al., 2019</xref>; <xref rid="B45" ref-type="bibr">Ghazal et al., 2025</xref>). Metformin further enhances oxidative stress resistance via upregulation of Klotho and GDF-15, promoting mitochondrial efficiency and anti-senescence signaling (<xref rid="B142" ref-type="bibr">Zhang et al., 2012</xref>). By improving mitochondrial function and indirectly activating Nrf2, metformin augments antioxidant capacity and contributes to sustained cardiometabolic protection (<xref rid="B95" ref-type="bibr">Mthembu et al., 2025</xref>).</p></sec><sec id="s3-3-4"><label>3.3.4</label><title>Summary</title><p>Metformin demonstrates multifaceted cardioprotective effects in DCM, targeting hypertrophy, fibrosis, inflammation, oxidative stress, and apoptosis through interconnected signaling pathways. These benefits, largely mediated by AMPK activation and modulation of HIF-1α/PPAR-γ, PK2/PKR–AKT/GSK3β, and mTOR/NLRP3 axes, position metformin as a promising therapeutic strategy for preventing and managing DCM. Further clinical trials are warranted to confirm these findings and define its role in routine care.</p></sec></sec><sec id="s3-4"><label>3.4</label><title>Metformin and doxorubicin-induced cardiotoxicity</title><p>Doxorubicin (DOX), a potent anthracycline chemotherapeutic, is widely used in oncology but its clinical utility is limited by dose-dependent cardiotoxicity. The cardiac injury arises from multiple interrelated mechanisms, including oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, iron accumulation, topoisomerase IIβ inhibition, and dysfunctional autophagy/mitophagy (<xref rid="B142" ref-type="bibr">Zhang et al., 2012</xref>; <xref rid="B123" ref-type="bibr">Tadokoro et al., 2020</xref>; <xref rid="B115" ref-type="bibr">Singh et al., 2022</xref>; <xref rid="B14" ref-type="bibr">Bhutani et al., 2025</xref>). Metformin has recently gained attention as a potential cardioprotective agent against DOX-induced cardiac injury. Emerging evidence from preclinical and translational studies suggests that metformin attenuates myocardial damage, preserves cardiac function, and may also enhance DOX’s anticancer efficacy (<xref rid="B115" ref-type="bibr">Singh et al., 2022</xref>; <xref rid="B97" ref-type="bibr">Osataphan et al., 2023</xref>; <xref rid="B58" ref-type="bibr">Huang et al., 2025</xref>; <xref rid="B87" ref-type="bibr">Maghraby et al., 2025</xref>; <xref rid="B34" ref-type="bibr">El-Rayes et al., 2023</xref>).</p><sec id="s3-4-1"><label>3.4.1</label><title>Preclinical evidence</title><p>Extensive preclinical research supports metformin’s cardioprotective role in DOX-induced cardiotoxicity (<xref rid="B115" ref-type="bibr">Singh et al., 2022</xref>; <xref rid="B148" ref-type="bibr">Zilinyi et al., 2018</xref>; <xref rid="B64" ref-type="bibr">Kobashigawa et al., 2014</xref>; <xref rid="B7" ref-type="bibr">Asensio-Lopez et al., 2011</xref>; <xref rid="B3" ref-type="bibr">Ajzashokouhi et al., 2019</xref>; <xref rid="B110" ref-type="bibr">Satyam et al., 2023</xref>; <xref rid="B121" ref-type="bibr">Sun et al., 2024a</xref>; <xref rid="B122" ref-type="bibr">Sun et al., 2024b</xref>). In rodent models, metformin markedly reduces serum markers of myocardial injury, limits cardiac fibrosis, and preserves left-ventricular function (<xref rid="B87" ref-type="bibr">Maghraby et al., 2025</xref>; <xref rid="B110" ref-type="bibr">Satyam et al., 2023</xref>; <xref rid="B121" ref-type="bibr">Sun et al., 2024a</xref>). Meta-analyses and animal studies confirm these benefits, highlighting consistent reductions in oxidative damage, apoptosis, and mitochondrial injury (<xref rid="B87" ref-type="bibr">Maghraby et al., 2025</xref>; <xref rid="B64" ref-type="bibr">Kobashigawa et al., 2014</xref>; <xref rid="B7" ref-type="bibr">Asensio-Lopez et al., 2011</xref>; <xref rid="B121" ref-type="bibr">Sun et al., 2024a</xref>). Metformin has been shown to lower ROS generation, restore mitochondrial membrane potential, and enhance antioxidant defenses through increased glutathione content and reduced malondialdehyde levels, collectively preserving mitochondrial integrity and cardiac function (<xref rid="B87" ref-type="bibr">Maghraby et al., 2025</xref>; <xref rid="B148" ref-type="bibr">Zilinyi et al., 2018</xref>; <xref rid="B6" ref-type="bibr">Argun et al., 2016</xref>). Novel formulations such as mitochondria-targeted metformin nanoparticles further improve mitochondrial morphology, calcium handling, and redox balance without diminishing DOX’s anticancer efficacy (<xref rid="B58" ref-type="bibr">Huang et al., 2025</xref>). Together, these findings underscore metformin’s potential to prevent structural and functional deterioration associated with anthracycline cardiotoxicity.</p></sec><sec id="s3-4-2"><label>3.4.2</label><title>Clinical evidence</title><p>Despite strong preclinical evidence, clinical data on metformin’s cardioprotective effects remain limited and somewhat inconsistent. Small randomized and observational studies in cancer patients have yielded mixed results. A phase II pilot trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02472353">NCT02472353</ext-link>) designed to assess metformin’s effect on LVEF in breast cancer patients receiving DOX was terminated early due to low accrual. Similarly, the addition of metformin to standard breast cancer therapy did not significantly improve invasive disease-free survival (<xref rid="B46" ref-type="bibr">Goodwin et al., 2022</xref>). Although one randomized trial found no measurable change in cardiac function, metformin preserved mitochondrial respiration in peripheral blood mononuclear cells, suggesting a subclinical benefit (<xref rid="B97" ref-type="bibr">Osataphan et al., 2023</xref>). Large cohort data from US cancer survivors indicate that metformin use correlates with a reduced risk of cardiometabolic disease and cardiovascular mortality (<xref rid="B75" ref-type="bibr">Li et al., 2024</xref>), and another clinical study found lower rates of heart failure and mortality among patients receiving both anthracyclines and metformin (<xref rid="B96" ref-type="bibr">Onoue et al., 2023</xref>). Collectively, these findings are encouraging but highlight the need for large-scale, double-blind prospective trials to definitively establish metformin’s cardioprotective efficacy in oncology populations exposed to DOX.</p></sec><sec id="s3-4-3"><label>3.4.3</label><title>Mechanistic insight</title><p>Metformin mitigates DOX-induced cardiotoxicity through both AMPK-dependent and -independent mechanisms. AMPK activation contributes to suppression of ROS generation, preservation of mitochondrial bioenergetics (<xref rid="B140" ref-type="bibr">Yang et al., 2020</xref>), and normalization of autophagy (<xref rid="B148" ref-type="bibr">Zilinyi et al., 2018</xref>). Metformin promotes mitochondrial quality control via AMPK-driven mitochondrial biogenesis (<xref rid="B134" ref-type="bibr">Wu, 2023</xref>; <xref rid="B35" ref-type="bibr">Emelyanova et al., 2021</xref>), enhances PINK1/Parkin-mediated mitophagy, and prevents mitochondrial fragmentation by upregulating fusion proteins MFN1 and MFN2(115). These processes restore ATP production, maintain calcium homeostasis, and stabilize mitochondrial architecture (<xref rid="B87" ref-type="bibr">Maghraby et al., 2025</xref>). In parallel, metformin suppresses apoptosis by reducing the Bax/Bcl-2 ratio and caspase-3 activation (<xref rid="B127" ref-type="bibr">Van et al., 2023</xref>; <xref rid="B22" ref-type="bibr">Chen et al., 2020</xref>) and inhibits pro-inflammatory signaling through NF-κB and cytokines such as TNF-α and IL-6 (<xref rid="B88" ref-type="bibr">Malaekeh-Nikouei et al., 2023</xref>; <xref rid="B41" ref-type="bibr">Feng et al., 2021</xref>; <xref rid="B117" ref-type="bibr">Soraya et al., 2012</xref>). Anti-inflammatory and antioxidant actions also contribute to its synergistic anticancer effects by dampening STAT3-driven tumor-promoting feedback and inhibiting oncogenic pathways including mTOR, PI3K/Akt, and Wnt/β-catenin (<xref rid="B61" ref-type="bibr">Jalali et al., 2024</xref>; <xref rid="B53" ref-type="bibr">Hirsch et al., 2013</xref>; <xref rid="B73" ref-type="bibr">Li et al., 2018</xref>; <xref rid="B5" ref-type="bibr">Amable et al., 2019</xref>). However, the role of AMPK is complex. While AMPK activation by metformin generally confers cardioprotection, some studies report that deletion of the AMPKα2 isoform can actually mitigate DOX-induced injury (<xref rid="B125" ref-type="bibr">Pozzo et al., 2019</xref>), suggesting that different AMPK isoforms may have distinct or even opposing functions. Moreover, the contribution of mitophagy to DOX cardiotoxicity remains debated. Metformin has been shown to inhibit autophagy and mitophagy (<xref rid="B57" ref-type="bibr">Huang et al., 2020</xref>; <xref rid="B127" ref-type="bibr">Van et al., 2023</xref>), reducing DOX-induced cardiomyocyte death. Thus, metformin’s cardioprotective (<xref rid="B148" ref-type="bibr">Zilinyi et al., 2018</xref>; <xref rid="B64" ref-type="bibr">Kobashigawa et al., 2014</xref>; <xref rid="B7" ref-type="bibr">Asensio-Lopez et al., 2011</xref>; <xref rid="B3" ref-type="bibr">Ajzashokouhi et al., 2019</xref>) and antitumor effects (<xref rid="B99" ref-type="bibr">Peng et al., 2017</xref>; <xref rid="B33" ref-type="bibr">El-Ashmawy et al., 2017</xref>; <xref rid="B128" ref-type="bibr">Viollet et al., 2012</xref>; <xref rid="B26" ref-type="bibr">Cho et al., 2013</xref>) likely arise from an integrated network of AMPK-dependent and alternative pathways, warranting further isoform-specific investigation.</p></sec><sec id="s3-4-4"><label>3.4.4</label><title>Summary</title><p>Preclinical studies consistently demonstrate that metformin attenuates DOX-induced cardiotoxicity through coordinated modulation of oxidative stress, mitochondrial dynamics, autophagy, apoptosis, and inflammation. These effects translate into preserved cardiac structure, function, and energetic efficiency in animal models. However, clinical translation remains uncertain due to inconsistent trial outcomes and unresolved mechanistic questions, particularly regarding AMPK isoform-specific roles. Methodological variability among studies, including differences in dosing regimens, timing, and cardiac endpoints, further limits cross-comparison. Future research should emphasize standardized experimental protocols, mechanistic clarification of AMPK signaling, and large-scale randomized trials to establish whether metformin can reliably protect the human heart during anthracycline chemotherapy.</p></sec></sec></sec><sec id="s4"><label>4</label><title>Dose-response and tissue-specific effects of metformin-mediated cardioprotection</title><p>The cardioprotective efficacy of metformin is governed by its unique pharmacokinetic profile and a dose-dependent bifurcation in molecular signaling. As a hydrophilic base, metformin relies on specialized transporters, namely, Organic Cation Transporters (OCT1-3), for cellular entry. While OCT1 is predominantly hepatic, the high expression of OCT3 in the myocardium facilitates tissue penetration and accumulation in cardiomyocytes (<xref rid="B21" ref-type="bibr">Chen et al., 2010</xref>; <xref rid="B116" ref-type="bibr">Solbach et al., 2011</xref>). Once inside the cell, metformin’s positive charge leads to its sequestration within the negatively charged mitochondrial matrix, where it can reach concentrations up to 1,000-fold higher than in the extracellular space (<xref rid="B16" ref-type="bibr">Bridges et al., 2016</xref>). This extensive volume of distribution and lack of plasma protein binding ensure that the heart is a primary site for its pleiotropic effects, though its renal excretion necessitates careful monitoring in heart failure patients to avoid toxicity (<xref rid="B48" ref-type="bibr">Graham et al., 2011</xref>).</p><p>The cardioprotective effects of metformin are both dose-dependent and tissue-specific (<xref rid="T2" ref-type="table">Table 2</xref>). At low doses (≈125 μg/kg), metformin activates AMPK, enhancing endothelial nitric oxide synthase (eNOS) activity, improving vascular function, and reducing myocardial injury (<xref rid="B19" ref-type="bibr">Calvert et al., 2008</xref>). Similar doses improve left ventricular function and survival in heart failure models (<xref rid="B50" ref-type="bibr">Gundewar et al., 2009</xref>). These protective effects occur at concentrations far below those needed for glycemic control, indicating a distinct cardiac mechanism (<xref rid="B147" ref-type="bibr">Zhou et al., 2001</xref>). In contrast, higher concentrations inhibit mitochondrial complex I, thereby reducing oxidative stress and delaying the opening of the mitochondrial permeability transition pore (mPTP), a key event in ischemia-reperfusion injury (<xref rid="B42" ref-type="bibr">Fontaine, 2018</xref>; <xref rid="B149" ref-type="bibr">Zilov et al., 2019</xref>). Thus, metformin’s cardiac actions depend on its local concentration. Lower levels favor AMPK signaling, whereas higher levels exert direct mitochondrial effects. Understanding this dual mechanism underscores the need for dose optimization and precise pharmacokinetic profiling to enhance metformin’s therapeutic potential while minimizing adverse effects in cardiovascular disease management.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Metformin dose &amp; cardioprotection (selected studies).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Model/Species</th><th align="left" rowspan="1" colspan="1">Dose &amp; route</th><th align="left" rowspan="1" colspan="1">Timing/Duration</th><th align="left" rowspan="1" colspan="1">Cardioprotection endpoints</th><th align="left" rowspan="1" colspan="1">Mitochondrial/ROS mechanism</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B19" ref-type="bibr">Calvert et al. (2008)</xref>
</td><td align="left" rowspan="1" colspan="1">Mouse I/R</td><td align="left" rowspan="1" colspan="1">125–250 μg/kg i.v</td><td align="left" rowspan="1" colspan="1">Before ischemia or at reperfusion (acute)</td><td align="left" rowspan="1" colspan="1">↓Infarct size, improved function</td><td align="left" rowspan="1" colspan="1">AMPK activation, eNOS phosphorylation; mitochondrial protection</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B150" ref-type="bibr">Solskov et al. (2008)</xref>
</td><td align="left" rowspan="1" colspan="1">Rat (Langendorff)</td><td align="left" rowspan="1" colspan="1">250 mg/kg oral</td><td align="left" rowspan="1" colspan="1">Single dose, 24h later</td><td align="left" rowspan="1" colspan="1">Protection vs. ischemia <italic toggle="yes">ex vivo</italic>
</td><td align="left" rowspan="1" colspan="1">AMPK activation; mitochondrial energetics</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B151" ref-type="bibr">Kanamori et al. (2019)</xref>
</td><td align="left" rowspan="1" colspan="1">Mouse DCM (δ-sarcoglycan–def.)</td><td align="left" rowspan="1" colspan="1">200 mg/kg/day (pump)</td><td align="left" rowspan="1" colspan="1">4 weeks (chronic)</td><td align="left" rowspan="1" colspan="1">Improved LV function, ↓fibrosis</td><td align="left" rowspan="1" colspan="1">Enhanced autophagy (↑LC3-II)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B152" ref-type="bibr">Cittadini et al. (2012)</xref>
</td><td align="left" rowspan="1" colspan="1">Rat chronic HF (SHHF)</td><td align="left" rowspan="1" colspan="1">100 mg/kg/day (drinking water)</td><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">Prevented CHF development</td><td align="left" rowspan="1" colspan="1">Improved energetics, ↓fibrosis</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B153" ref-type="bibr">Techiryan et al. (2018)</xref>
</td><td align="left" rowspan="1" colspan="1">Swine MI</td><td align="left" rowspan="1" colspan="1">5 mg/kg IV + 1 mg/kg/min infusion</td><td align="left" rowspan="1" colspan="1">At reperfusion</td><td align="left" rowspan="1" colspan="1">No infarct size reduction</td><td align="left" rowspan="1" colspan="1">No mitochondrial benefit</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B35" ref-type="bibr">Emelyanova et al. (2021)</xref>
</td><td align="left" rowspan="1" colspan="1">Human iPSC-CMs</td><td align="left" rowspan="1" colspan="1">≤2.5 mM vs. ≥ 5 mM</td><td align="left" rowspan="1" colspan="1">Acute <italic toggle="yes">in vitro</italic>
</td><td align="left" rowspan="1" colspan="1">Low conc ↑OCR; high conc ↓OCR</td><td align="left" rowspan="1" colspan="1">Biphasic mitochondrial effects via AMPK/complex I</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B154" ref-type="bibr">Bates et al. (2023)</xref>
</td><td align="left" rowspan="1" colspan="1">Aged mouse I/R</td><td align="left" rowspan="1" colspan="1">High dose (reported acute)</td><td align="left" rowspan="1" colspan="1">At reperfusion</td><td align="left" rowspan="1" colspan="1">↓Infarct size, improved recovery</td><td align="left" rowspan="1" colspan="1">Mitochondrial protection in aged heart</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B6" ref-type="bibr">Argun et al. (2016)</xref>
</td><td align="left" rowspan="1" colspan="1">Rat DOX cardiotoxicity</td><td align="left" rowspan="1" colspan="1">50 &amp; 500 mg/kg oral</td><td align="left" rowspan="1" colspan="1">Concurrent with DOX</td><td align="left" rowspan="1" colspan="1">↓Cardiotoxicity markers</td><td align="left" rowspan="1" colspan="1">↓ROS, improved mitochondrial function</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B122" ref-type="bibr">Sun et al. (2024b)</xref>
</td><td align="left" rowspan="1" colspan="1">H9C2 &amp; mouse DOX</td><td align="left" rowspan="1" colspan="1">Various; ∼2.9 mg/kg <italic toggle="yes">in vivo</italic>
</td><td align="left" rowspan="1" colspan="1">Acute &amp; chronic</td><td align="left" rowspan="1" colspan="1">Dose-dependent protection</td><td align="left" rowspan="1" colspan="1">Mitophagy and mitochondrial dynamics</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B91" ref-type="bibr">Mohan et al. (2019)</xref> (MET-REMODEL)</td><td align="left" rowspan="1" colspan="1">Human CAD/LVH (non-diabetic)</td><td align="left" rowspan="1" colspan="1">2000 mg/day oral</td><td align="left" rowspan="1" colspan="1">12 months</td><td align="left" rowspan="1" colspan="1">↓LV mass, improved LVEF</td><td align="left" rowspan="1" colspan="1">Metabolic/Mitochondrial remodeling</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B151" ref-type="bibr">Kanamori et al. (2019)</xref>, <xref rid="B136" ref-type="bibr">Xiang et al. (2024)</xref>, <xref rid="B139" ref-type="bibr">Yang et al. (2019)</xref> (rodent diabetic CM)</td><td align="left" rowspan="1" colspan="1">Mouse/Rat diabetic CM</td><td align="left" rowspan="1" colspan="1">100–300 mg/kg/day</td><td align="left" rowspan="1" colspan="1">Weeks–months</td><td align="left" rowspan="1" colspan="1">↑LV function, ↓fibrosis</td><td align="left" rowspan="1" colspan="1">↓ROS, improved mitochondria &amp; mitophagy</td></tr></tbody></table></table-wrap></sec><sec id="s5"><label>5</label><title>Metformin’s safety profile and clinical considerations</title><p>Metformin is generally well tolerated, with gastrointestinal symptoms (nausea, diarrhea, metallic taste, flatulence) being the most common adverse effects; these can be minimized by taking the drug with meals (<xref rid="B39" ref-type="bibr">F and roldi, 2024</xref>). Long-term use may also reduce vitamin B12 absorption, warranting periodic monitoring during extended therapy (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B124" ref-type="bibr">Top et al., 2022</xref>). In addition to these well-recognized effects, emerging experimental evidence suggests that metformin may influence systemic metabolism beyond classical peripheral targets. For example, combined administration of metformin and the thiamine antagonist amprolium altered free amino acid metabolism in the rat brain, leading to changes in behavior and heart rate, highlighting potential central and autonomic effects under conditions of metabolic stress or drug interaction (<xref rid="B47" ref-type="bibr">Graf et al., 2024</xref>). Given its expanding role in cardiometabolic disease, renal function and heart failure status must guide clinical use. Metformin is contraindicated at eGFR &lt;30 mL/min/1.73 m<sup>2</sup> and should be dose-adjusted or avoided when eGFR is 30–44 mL/min (<xref rid="B77" ref-type="bibr">Lipska et al., 2011</xref>; <xref rid="B107" ref-type="bibr">Salpeter et al., 2010</xref>). Although once avoided in congestive heart failure, current evidence supports its safety and potential benefit in stable CHF, with discontinuation advised during acute decompensation (<xref rid="B2" ref-type="bibr">Aguilar et al., 2011</xref>; <xref rid="B36" ref-type="bibr">Eurich et al., 2007</xref>; <xref rid="B11" ref-type="bibr">Benes et al., 2022</xref>; <xref rid="B131" ref-type="bibr">Wang et al., 2021</xref>; <xref rid="B37" ref-type="bibr">Eurich et al., 2009</xref>).</p><p>The most serious but rare complication is metformin-associated lactic acidosis (MALA), typically occurring in the setting of renal impairment and mechanistically linked to mitochondrial complex I inhibition (<xref rid="B30" ref-type="bibr">Dutta et al., 2023</xref>; <xref rid="B48" ref-type="bibr">Graham et al., 2011</xref>; <xref rid="B147" ref-type="bibr">Zhou et al., 2001</xref>). Although exceedingly uncommon (∼0.03 cases per 1,000 patient-years), MALA carries a high mortality rate (∼50%) (<xref rid="B11" ref-type="bibr">Benes et al., 2022</xref>; <xref rid="B131" ref-type="bibr">Wang et al., 2021</xref>). It most often develops with renal or hepatic failure, severe heart failure, sepsis, or excessive alcohol use, underscoring the need for close monitoring and immediate discontinuation if signs of metabolic acidosis emerge (<xref rid="B10" ref-type="bibr">Bailey and Turner, 1996</xref>; <xref rid="B118" ref-type="bibr">Stades et al., 2004</xref>; <xref rid="B65" ref-type="bibr">Lalau and Race, 2001</xref>). Because conventional formulations are limited by poor bioavailability, gastrointestinal intolerance, and suboptimal tissue targeting, innovative drug delivery systems, such as nanoparticles, pH-responsive hydrogels, and microneedles, are being developed to enhance therapeutic efficacy, reduce adverse effects, and improve patient adherence (<xref rid="B120" ref-type="bibr">Sulong et al., 2025</xref>). For example, metformin-loaded nanoparticles attenuate hyperglycemia-associated oxidative stress and promote eNOS phosphorylation in vascular endothelial cells (<xref rid="B90" ref-type="bibr">Mohamed et al., 2024</xref>), supporting the feasibility of nanoparticle-based drug delivery strategies.</p></sec><sec id="s6"><label>6</label><title>Summary and future perspectives</title><p>Metformin, traditionally a first-line therapy for type 2 diabetes, is increasingly recognized as a pleiotropic cardiometabolic agent. Its cardiovascular benefits arise through dose- and tissue-dependent mechanisms: low concentrations predominantly activate AMPK to enhance endothelial function and reduce myocardial injury (<xref rid="B19" ref-type="bibr">Calvert et al., 2008</xref>), while higher concentrations inhibit mitochondrial complex I to limit oxidative stress and delay mPTP opening (<xref rid="B42" ref-type="bibr">Fontaine, 2018</xref>; <xref rid="B149" ref-type="bibr">Zilov et al., 2019</xref>). These mechanistic distinctions highlight the need for optimized dosing and improved pharmacokinetic understanding. Clinically, metformin is well tolerated, with gastrointestinal symptoms and vitamin B12 deficiency representing the most common adverse effects (<xref rid="B39" ref-type="bibr">F and roldi, 2024</xref>; <xref rid="B124" ref-type="bibr">Top et al., 2022</xref>). The rare occurrence of metformin-associated lactic acidosis underscores the importance of renal function-guided prescriptions (<xref rid="B77" ref-type="bibr">Lipska et al., 2011</xref>; <xref rid="B107" ref-type="bibr">Salpeter et al., 2010</xref>).</p><p>Across cardiovascular contexts, metformin demonstrates broad protective effects (<xref rid="T3" ref-type="table">Table 3</xref>). It attenuates ischemia/reperfusion injury by suppressing NLRP3 inflammasome and apoptosis, mitigating ferroptosis via Nur77-IDH1 signaling (<xref rid="B144" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B119" ref-type="bibr">Stone et al., 2024</xref>; <xref rid="B135" ref-type="bibr">Wu et al., 2025</xref>), and mimicking ischemic preconditioning (<xref rid="B105" ref-type="bibr">Rozier et al., 2021</xref>). In heart failure and diabetic cardiomyopathy, metformin reduces oxidative stress, fibrosis, and adverse remodeling through coordinated AMPK-dependent and independent pathways (<xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>; <xref rid="B78" ref-type="bibr">Liu et al., 2022</xref>; <xref rid="B140" ref-type="bibr">Yang et al., 2020</xref>). Metformin also shows promise against doxorubicin-induced cardiotoxicity, though variability in preclinical models calls for standardized approaches (<xref rid="B115" ref-type="bibr">Singh et al., 2022</xref>; <xref rid="B148" ref-type="bibr">Zilinyi et al., 2018</xref>; <xref rid="B64" ref-type="bibr">Kobashigawa et al., 2014</xref>; <xref rid="B7" ref-type="bibr">Asensio-Lopez et al., 2011</xref>; <xref rid="B3" ref-type="bibr">Ajzashokouhi et al., 2019</xref>; <xref rid="B110" ref-type="bibr">Satyam et al., 2023</xref>; <xref rid="B121" ref-type="bibr">Sun et al., 2024a</xref>; <xref rid="B122" ref-type="bibr">Sun et al., 2024b</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Cardioprotective and Therapeutic Effects of Metformin Across cardiac pathologies.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Population/Disease</th><th align="left" rowspan="1" colspan="1">Key effects &amp; evidence</th><th align="left" rowspan="1" colspan="1">Proposed mechanisms</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Non-diabetic (general)</td><td align="left" rowspan="1" colspan="1">Weight loss, improved lipid/insulin profile, some anti-atherosclerotic effects (e.g., CAMERA trial), mild improvements in cardiac function (<xref rid="B100" ref-type="bibr">Preiss et al., 2014</xref>)</td><td align="left" rowspan="1" colspan="1">AMPK, PEN2-lysosome signaling (<xref rid="B83" ref-type="bibr">Ma et al., 2022</xref>), anti-inflammatory, insulin modulation</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular disease</td><td align="left" rowspan="1" colspan="1">Slows atherosclerosis progression; reduces vascular thickening; improves myocardial ischemia (in some non-diabetic trials); reduces MI risk in diabetics (<xref rid="B54" ref-type="bibr">Holman et al., 2008</xref>)</td><td align="left" rowspan="1" colspan="1">Energetic remodeling, endothelial effects, anti-inflammation</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart failure</td><td align="left" rowspan="1" colspan="1">Reduced all-cause mortality in diabetics with HF; improves LV hypertrophy, oxidative stress, and systolic/diastolic function; cautious use due to lactic acidosis risks (<xref rid="B63" ref-type="bibr">Kamel et al., 2024</xref>; <xref rid="B108" ref-type="bibr">Salvatore et al., 2021</xref>)</td><td align="left" rowspan="1" colspan="1">AMPK activation, improved bioenergetics, anti-fibrosis mechanisms</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetic cardiomyopathy</td><td align="left" rowspan="1" colspan="1">↓ heart weight/body weight ratio, suppresses hypertrophy, preserves structure, modulates fibrosis and anti-apoptotic pathways</td><td align="left" rowspan="1" colspan="1">PK2/PKR/AKT/GSK3β axis, iNOS/mTOR/TIMP-1 axis, AMPK-dependent/independent mechanisms (<xref rid="B28" ref-type="bibr">Dawood et al., 2022</xref>; <xref rid="B140" ref-type="bibr">Yang et al., 2020</xref>; <xref rid="B18" ref-type="bibr">Bu et al., 2022</xref>)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemia-reperfusion injury</td><td align="left" rowspan="1" colspan="1">↓ NLRP3 inflammasome, ↓apoptosis &amp; ferroptosis, ↓ infarct size; mimics ischemic preconditioning (<xref rid="B144" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B105" ref-type="bibr">Rozier et al., 2021</xref>; <xref rid="B119" ref-type="bibr">Stone et al., 2024</xref>)</td><td align="left" rowspan="1" colspan="1">Activates Akt, ↑ Bcl-xL, reduces ROS (<xref rid="B105" ref-type="bibr">Rozier et al., 2021</xref>; <xref rid="B119" ref-type="bibr">Stone et al., 2024</xref>), ↑ Nur77-IDH1 (57)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemotherapy-induced cardiotoxicity (e.g., Doxorubicin)</td><td align="left" rowspan="1" colspan="1">Mitigates structural/functional damage (preclinical); effect on autophagy/mitophagy is controversial</td><td align="left" rowspan="1" colspan="1">PINK1/Parkin pathways, mitochondrial preservation (<xref rid="B84" ref-type="bibr">Ma et al., 2023</xref>), AMPK (complex role)</td></tr><tr><td align="left" rowspan="1" colspan="1">Limitation/Uncertainties</td><td align="left" rowspan="1" colspan="1">Mixed results in non-diabetic CVD and oncology trials, context-dependent autophagy/AMPK effects, need for more targeted studies</td><td align="left" rowspan="1" colspan="1">​</td></tr></tbody></table></table-wrap><p>Despite strong evidence in diabetic populations, results in non-diabetic individuals remain inconsistent. Trials such as CAMERA and GIPS-III suggest slowed atherosclerosis progression or improved post–myocardial infarction remodeling, whereas others show no clear cardiovascular benefit. As summarized in <xref rid="T4" ref-type="table">Table 4</xref>, preclinical and clinical studies support cardioprotective effects of metformin across diverse cardiac conditions, but large, rigorously designed trials are needed to define its role beyond metabolic indications. Ongoing studies, including VA-IMPACT (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02915198">NCT02915198</ext-link>) for secondary prevention in patients with prediabetes and atherosclerotic cardiovascular disease and emerging trials in atrial fibrillation (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05878535">NCT05878535</ext-link>), will be critical. If consistent benefits are confirmed, metformin could be considered as adjunct therapy for high-risk non-diabetic patients; until then, its use should remain confined to established metabolic indications.</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Metformin’s cardioprotective effects: preclinical and clinical evidence.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">Condition</th><th align="center" rowspan="1" colspan="1">Preclinical evidence</th><th align="center" rowspan="1" colspan="1">Clinical evidence</th><th align="center" rowspan="1" colspan="1">Strength of evidence</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Ischemia-reperfusion injury</td><td align="left" rowspan="1" colspan="1">Robust animal studies show ↓ infarct size, improved LV remodeling via AMPK-eNOS activation, mitochondrial protection, anti-oxidative effects</td><td align="left" rowspan="1" colspan="1">Beneficial in diabetic patients (<xref rid="B93" ref-type="bibr">Mone et al., 2025</xref>; <xref rid="B54" ref-type="bibr">Holman et al., 2008</xref>; <xref rid="B17" ref-type="bibr">Bromage et al., 2019</xref>); inconsistent in nondiabetic patients: GIPS-III trial (<xref rid="B72" ref-type="bibr">Lexis et al., 2014</xref>; <xref rid="B52" ref-type="bibr">Hartman et al., 2017</xref>) and Camera trial (<xref rid="B101" ref-type="bibr">Preiss et al., 2016</xref>; <xref rid="B100" ref-type="bibr">Preiss et al., 2014</xref>)</td><td align="left" rowspan="1" colspan="1">Low to moderate</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart failure</td><td align="left" rowspan="1" colspan="1">Animal models: improved LV function, ↓ oxidative stress, ↑ AMPK signaling</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05177588">NCT05177588</ext-link>- Metformin add-on in non-diabetic HFrEF; meta-analysis of 15 RCTs in T2DM + CHF shows mortality benefit (RR ≈ 0.72)</td><td align="left" rowspan="1" colspan="1">Low to moderate</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetic cardiomyopathy</td><td align="left" rowspan="1" colspan="1">Strong mechanistic rationale; animal studies show improved myocardial structure/function, ↓ fibrosis, ↑ mitochondrial efficiency</td><td align="left" rowspan="1" colspan="1">No large RCTs; ongoing observational studies (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05958706">NCT05958706</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05915260">NCT05915260</ext-link>)</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1">Doxorubicin cardiotoxicity</td><td align="left" rowspan="1" colspan="1">Consistent protective effects in animal models (↓ oxidative stress, apoptosis, improved mitochondrial dynamics); meta-analysis confirms reliability</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02472353">NCT02472353</ext-link>- Pilot RCT in breast cancer patients; RCT in 143 patients during DOX therapy showed mitochondrial protection but no significant troponin/LVEF benefit</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr></tbody></table></table-wrap><p>Looking ahead, several research priorities will shape the future of metformin in cardiovascular medicine. First, clarifying the isoform-specific roles of AMPK, particularly AMPKα1 versus AMPKα2 in distinct cardiac cell types, is essential for understanding the context-dependent nature of metformin’s effects. Tissue-specific genetic models, single-cell transcriptomics, and proteomic approaches will be critical for defining these pathways. Equally important is expanding investigation into alternative AMPK activation mechanisms, such as the PEN2-dependent lysosomal pathway, which may offer safer therapeutic avenues for patients at risk of mitochondrial dysfunction or lactic acidosis.</p><p>Secondly, metformin’s context-dependent regulation of autophagy and mitophagy remains an area of notable uncertainty. Divergent findings across studies reflect variations in dosing, model systems, disease context, and timing. Advanced tools, including <italic toggle="yes">in vivo</italic> autophagy/mitophagy reporters, high-resolution mitochondrial imaging, and integrative multi-omics, are needed to resolve these discrepancies and identify key downstream mediators such as NLRP3, the Nur77-IDH1 axis, and regulators of ferroptosis and pyroptosis.</p><p>Finally, success in clinical translation will depend on innovative delivery strategies and refined dosing paradigms (<xref rid="B120" ref-type="bibr">Sulong et al., 2025</xref>). Cardiac-targeted nanoparticles, low-dose pulses, or intermittent regimens could enhance bioavailability and efficacy while reducing systemic exposure and toxicity. Standardization of preclinical models, especially for doxorubicin cardiotoxicity, will be essential for reconciling inconsistencies in proposed mechanisms.</p><p>In summary, metformin’s expanding cardiometabolic profile suggests potential to reshape cardiovascular disease management. Beyond glucose lowering, metformin exerts pleiotropic effects that include endothelial protection, preservation of mitochondrial function, modulation of redox homeostasis, suppression of inflammation, attenuation of fibrosis, and regulation of autophagy (<xref rid="T1" ref-type="table">Table 1</xref>). These actions confer metabolic and cardioprotective benefits in both diabetic and non-diabetic populations and support its candidacy as a broad-spectrum cardioprotective agent. However, despite strong mechanistic and translational evidence, clinical outcomes in non-diabetic cohorts remain inconsistent. Ongoing trials, together with large, well-controlled studies, will be essential to determine whether these mechanistic benefits translate into meaningful cardiovascular risk reduction across diverse patient populations.</p></sec></body><back><fn-group><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/45372/overview" ext-link-type="uri">Mojgan Rastegar</ext-link>, University of Manitoba, Canada</p></fn><fn fn-type="reviewed-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1773955/overview" ext-link-type="uri">Mahmoud Sabra</ext-link>, Assiut University, Egypt</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3141116/overview" ext-link-type="uri">Linda Piras</ext-link>, Sapienza University of Rome, Italy</p></fn></fn-group><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>JK: Writing – original draft. AR: Writing – original draft. VR: Writing – original draft. TR: Writing – original draft. JY: Visualization, Writing – review and editing. SK: Visualization, Writing – review and editing, Validation. QL: Validation, Writing – review and editing, Conceptualization, Funding acquisition, Methodology, Resources, Supervision.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declared that generative AI was used in the creation of this manuscript. We used Microsoft Copilot to improve the English clarity and editing of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Aguilar</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Bozkurt</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Ramasubbu</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Deswal</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Metformin use and mortality in ambulatory patients with diabetes and heart failure</article-title>. <source>Circ. Heart Failure</source>
<volume>4</volume> (<issue>1</issue>), <fpage>53</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.110.952556</pub-id>
<pub-id pub-id-type="pmid">20952583</pub-id>
<pub-id pub-id-type="pmcid">PMC3046634</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ajzashokouhi</surname><given-names>A. H.</given-names></name>
<name name-style="western"><surname>Bostan</surname><given-names>H. B.</given-names></name>
<name name-style="western"><surname>Jomezadeh</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Hayes</surname><given-names>A. W.</given-names></name>
<name name-style="western"><surname>Karimi</surname><given-names>G.</given-names></name>
</person-group> (<year>2019</year>). <article-title>A review on the cardioprotective mechanisms of metformin against doxorubicin</article-title>. <source>Hum. and Experimental Toxicology</source>, <volume>39</volume> (<issue>3</issue>), <fpage>237</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1177/0960327119888277</pub-id>
<pub-id pub-id-type="pmid">31735071</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Almohaimeed</surname><given-names>G. M.</given-names></name>
<name name-style="western"><surname>Alonazi</surname><given-names>A. S.</given-names></name>
<name name-style="western"><surname>Alshammari</surname><given-names>T. K.</given-names></name>
<name name-style="western"><surname>Bin Dayel</surname><given-names>A. F.</given-names></name>
<name name-style="western"><surname>Alghibiwi</surname><given-names>H. K.</given-names></name>
<name name-style="western"><surname>Alamin</surname><given-names>M. A.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Metformin-mediated protection against immunosenescence in diabetic cardiomyopathy: the potential roles of GDF-15 and klotho proteins</article-title>. <source>Int. Immunopharmacol.</source>
<volume>153</volume>, <fpage>114530</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2025.114530</pub-id>
<pub-id pub-id-type="pmid">40139098</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Amable</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Martinez-Leon</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Picco</surname><given-names>M. E.</given-names></name>
<name name-style="western"><surname>Di Siervi</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Davio</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Rozengurt</surname><given-names>E.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metformin inhibits beta-catenin phosphorylation on Ser-552 through an AMPK/PI3K/Akt pathway in colorectal cancer cells</article-title>. <source>Int. J. Biochem. Cell Biol.</source>
<volume>112</volume>, <fpage>88</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2019.05.004</pub-id>
<pub-id pub-id-type="pmid">31082618</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Argun</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Uzum</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Sonmez</surname><given-names>M. F.</given-names></name>
<name name-style="western"><surname>Ozyurt</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Derya</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Cilenk</surname><given-names>K. T.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats</article-title>. <source>Anatol. J. Cardiol.</source>
<volume>16</volume> (<issue>4</issue>), <fpage>234</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.5152/akd.2015.6185</pub-id>
<pub-id pub-id-type="pmid">26642465</pub-id>
<pub-id pub-id-type="pmcid">PMC5368431</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Asensio-Lopez</surname><given-names>M. C.</given-names></name>
<name name-style="western"><surname>Lax</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Pascual-Figal</surname><given-names>D. A.</given-names></name>
<name name-style="western"><surname>Valdes</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Sanchez-Mas</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>51</volume> (<issue>10</issue>), <fpage>1861</fpage>–<lpage>1871</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.08.015</pub-id>
<pub-id pub-id-type="pmid">21907790</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ashayeri Ahmadabad</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Mohammadi Panah</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ghasemnejad-Berenji</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Ghojavand</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ghasemnejad-Berenji</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Khezri</surname><given-names>M. R.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases</article-title>. <source>Naunyn Schmiedeb. Arch. Pharmacol.</source>
<volume>398</volume> (<issue>2</issue>), <fpage>1035</fpage>–<lpage>1055</lpage>. <pub-id pub-id-type="doi">10.1007/s00210-024-03358-3</pub-id>
<pub-id pub-id-type="pmid">39225830</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bahardoust</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mousavi</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Yariali</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Haghmoradi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hadaegh</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Khalili</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis</article-title>. <source>J. Diabetes Metab. Disord.</source>
<volume>23</volume> (<issue>1</issue>), <fpage>27</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1007/s40200-023-01309-y</pub-id>
<pub-id pub-id-type="pmid">38932855</pub-id>
<pub-id pub-id-type="pmcid">PMC11196519</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bailey</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>Turner</surname><given-names>R. C.</given-names></name>
</person-group> (<year>1996</year>). <article-title>Metformin</article-title>. <source>N. Engl. J. Med.</source>
<volume>334</volume> (<issue>9</issue>), <fpage>574</fpage>–<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199602293340906</pub-id>
<pub-id pub-id-type="pmid">8569826</pub-id>
</mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bates</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Krause-Hauch</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Fatmi</surname><given-names>M. K.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Acute, high dose metformin therapy at reperfusion decreases infarct size in the high-risk aging heart</article-title>. <source>Aging Dis.</source>
<volume>14</volume> (<issue>5</issue>), <fpage>1488</fpage>–<lpage>1491</lpage>.
<pub-id pub-id-type="pmid">37196121</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2023.0205</pub-id><pub-id pub-id-type="pmcid">PMC10529738</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Benes</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Kotrc</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kroupova</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Wohlfahrt</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kovar</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Franekova</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)</article-title>. <source>Sci. Reports</source>
<volume>12</volume> (<issue>1</issue>), <fpage>13038</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-17327-4</pub-id>
<pub-id pub-id-type="pmid">35906276</pub-id>
<pub-id pub-id-type="pmcid">PMC9338272</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bergmark</surname><given-names>B. A.</given-names></name>
<name name-style="western"><surname>Bhatt</surname><given-names>D. L.</given-names></name>
<name name-style="western"><surname>McGuire</surname><given-names>D. K.</given-names></name>
<name name-style="western"><surname>Cahn</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mosenzon</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Steg</surname><given-names>P. G.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial</article-title>. <source>Circulation</source>
<volume>140</volume> (<issue>12</issue>), <fpage>1004</fpage>–<lpage>1014</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.040144</pub-id>
<pub-id pub-id-type="pmid">31362530</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bhansali</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bhansali</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Dhawan</surname><given-names>V.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Metformin promotes mitophagy in mononuclear cells: a potential <italic toggle="yes">in vitro</italic> model for unraveling metformin's mechanism of action</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>1463</volume> (<issue>1</issue>), <fpage>23</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.14141</pub-id>
<pub-id pub-id-type="pmid">31225649</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bhutani</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Varzideh</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Wilson</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kansakar</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Jankauskas</surname><given-names>S. S.</given-names></name>
<name name-style="western"><surname>Santulli</surname><given-names>G.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Doxorubicin-induced cardiotoxicity: a comprehensive update</article-title>. <source>J. Cardiovasc Dev. Dis.</source>
<volume>12</volume> (<issue>6</issue>), <fpage>207</fpage>. <pub-id pub-id-type="doi">10.3390/jcdd12060207</pub-id>
<pub-id pub-id-type="pmid">40558642</pub-id>
<pub-id pub-id-type="pmcid">PMC12193598</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bozkurt</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Coats</surname><given-names>A. J. S.</given-names></name>
<name name-style="western"><surname>Tsutsui</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Abdelhamid</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Adamopoulos</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Albert</surname><given-names>N.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European Society of Cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association</article-title>. <source>Eur. Journal Heart Failure</source>
<volume>23</volume> (<issue>3</issue>), <fpage>352</fpage>–<lpage>380</lpage>. <pub-id pub-id-type="doi">10.1002/ejhf.2115</pub-id>
<pub-id pub-id-type="pmid">33605000</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bridges</surname><given-names>H. R.</given-names></name>
<name name-style="western"><surname>Sirvio</surname><given-names>V. A.</given-names></name>
<name name-style="western"><surname>Agip</surname><given-names>A. N.</given-names></name>
<name name-style="western"><surname>Hirst</surname><given-names>J.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase</article-title>. <source>BMC Biol.</source>
<volume>14</volume>, <fpage>65</fpage>. <pub-id pub-id-type="doi">10.1186/s12915-016-0287-9</pub-id>
<pub-id pub-id-type="pmid">27506389</pub-id>
<pub-id pub-id-type="pmcid">PMC4977651</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bromage</surname><given-names>D. I.</given-names></name>
<name name-style="western"><surname>Godec</surname><given-names>T. R.</given-names></name>
<name name-style="western"><surname>Pujades-Rodriguez</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Gonzalez-Izquierdo</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Denaxas</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Hemingway</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study</article-title>. <source>Cardiovasc Diabetol.</source>
<volume>18</volume> (<issue>1</issue>), <fpage>168</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-019-0972-4</pub-id>
<pub-id pub-id-type="pmid">31815634</pub-id>
<pub-id pub-id-type="pmcid">PMC6900858</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>A. F.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms</article-title>. <source>J. Cellular Molecular Medicine</source>
<volume>26</volume> (<issue>19</issue>), <fpage>4886</fpage>–<lpage>4903</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.17519</pub-id>
<pub-id pub-id-type="pmid">36052760</pub-id>
<pub-id pub-id-type="pmcid">PMC9549498</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Calvert</surname><given-names>J. W.</given-names></name>
<name name-style="western"><surname>Gundewar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jha</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Greer</surname><given-names>J. J.</given-names></name>
<name name-style="western"><surname>Bestermann</surname><given-names>W. H.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling</article-title>. <source>Diabetes</source>
<volume>57</volume> (<issue>3</issue>), <fpage>696</fpage>–<lpage>705</lpage>. <pub-id pub-id-type="doi">10.2337/db07-1098</pub-id>
<pub-id pub-id-type="pmid">18083782</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cameron</surname><given-names>A. R.</given-names></name>
<name name-style="western"><surname>Morrison</surname><given-names>V. L.</given-names></name>
<name name-style="western"><surname>Levin</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Mohan</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Forteath</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Beall</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Anti-inflammatory effects of metformin irrespective of diabetes status</article-title>. <source>Circ. Res.</source>
<volume>119</volume> (<issue>5</issue>), <fpage>652</fpage>–<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308445</pub-id>
<pub-id pub-id-type="pmid">27418629</pub-id>
<pub-id pub-id-type="pmcid">PMC4990459</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Pawlikowski</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Schlessinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>More</surname><given-names>S. S.</given-names></name>
<name name-style="western"><surname>Stryke</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Johns</surname><given-names>S. J.</given-names></name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin</article-title>. <source>Pharmacogenet Genomics.</source>
<volume>20</volume> (<issue>11</issue>), <fpage>687</fpage>–<lpage>699</lpage>. <pub-id pub-id-type="doi">10.1097/FPC.0b013e32833fe789</pub-id>
<pub-id pub-id-type="pmid">20859243</pub-id>
<pub-id pub-id-type="pmcid">PMC2976715</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Modulatory effect of metformin on cardiotoxicity induced by doxorubicin via the MAPK and AMPK pathways</article-title>. <source>Life Sci.</source>
<volume>249</volume>, <fpage>117498</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117498</pub-id>
<pub-id pub-id-type="pmid">32142765</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Lesnefsky</surname><given-names>E. J.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Chronic metformin treatment decreases cardiac injury during ischemia-reperfusion by attenuating endoplasmic reticulum stress with improved mitochondrial function</article-title>. <source>Aging</source>
<volume>13</volume> (<issue>6</issue>), <fpage>7828</fpage>–<lpage>7845</lpage>. <pub-id pub-id-type="doi">10.18632/aging.202858</pub-id>
<pub-id pub-id-type="pmid">33746115</pub-id>
<pub-id pub-id-type="pmcid">PMC8034968</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Slotabec</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>J. D.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>High-dose metformin treatment to inhibit complex I during early reperfusion protects the aged mouse heart via decreased mitochondrial permeability transition pore opening</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>392</volume> (<issue>3</issue>), <fpage>100529</fpage>. <pub-id pub-id-type="doi">10.1016/j.jpet.2024.100529</pub-id>
<pub-id pub-id-type="pmid">39969273</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>Y. Y.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C. X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>H. X.</given-names></name>
<name name-style="western"><surname>Wen</surname><given-names>S. Y.</given-names></name>
</person-group> (<year>2025</year>). <article-title>The emerging roles of vacuolar-type ATPase-Dependent lysosomal acidification in cardiovascular disease</article-title>. <source>Biomolecules</source>
<volume>15</volume> (<issue>4</issue>), <fpage>525</fpage>. <pub-id pub-id-type="doi">10.3390/biom15040525</pub-id>
<pub-id pub-id-type="pmid">40305271</pub-id>
<pub-id pub-id-type="pmcid">PMC12024769</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cho</surname><given-names>S. Y.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H. J.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H. J.</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>D. B.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Sohn</surname><given-names>E. J.</given-names></name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Activation of AMP-activated protein kinase alpha and extracelluar signal-regulated kinase mediates CB-PIC-Induced apoptosis in hypoxic SW620 colorectal cancer cells</article-title>. <source>Evi.-Based Complement. Alternat. Med.</source>
<volume>2013</volume>, <fpage>974313</fpage>. <pub-id pub-id-type="doi">10.1155/2013/974313</pub-id>
<pub-id pub-id-type="pmid">23589723</pub-id>
<pub-id pub-id-type="pmcid">PMC3622407</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Cittadini</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Napoli</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Monti</surname><given-names>M. G.</given-names></name>
<name name-style="western"><surname>Rea</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Longobardi</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Netti</surname><given-names>P. A.</given-names></name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Metformin prevents the development of chronic heart failure in the SHHF rat model</article-title>. <source>Diabetes.</source>
<volume>61</volume> (<issue>4</issue>), <fpage>944</fpage>–<lpage>953</lpage>.
<pub-id pub-id-type="pmid">22344560</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db11-1132</pub-id><pub-id pub-id-type="pmcid">PMC3314362</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Crowley</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>Diamantidis</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>McDuffie</surname><given-names>J. R.</given-names></name>
<name name-style="western"><surname>Cameron</surname><given-names>C. B.</given-names></name>
<name name-style="western"><surname>Stanifer</surname><given-names>J. W.</given-names></name>
<name name-style="western"><surname>Mock</surname><given-names>C. K.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review</article-title>. <source>Ann. Intern Med.</source>
<volume>166</volume> (<issue>3</issue>), <fpage>191</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.7326/M16-1901</pub-id>
<pub-id pub-id-type="pmid">28055049</pub-id>
<pub-id pub-id-type="pmcid">PMC5293600</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dawood</surname><given-names>A. F.</given-names></name>
<name name-style="western"><surname>Alzamil</surname><given-names>N. M.</given-names></name>
<name name-style="western"><surname>Hewett</surname><given-names>P. W.</given-names></name>
<name name-style="western"><surname>Momenah</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Dallak</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kamar</surname><given-names>S. S.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Metformin protects against diabetic cardiomyopathy: an association between desmin-sarcomere injury and the iNOS/mTOR/TIMP-1 fibrosis axis</article-title>. <source>Biomedicines</source>
<volume>10</volume> (<issue>5</issue>), <fpage>984</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines10050984</pub-id>
<pub-id pub-id-type="pmid">35625721</pub-id>
<pub-id pub-id-type="pmcid">PMC9139128</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Di Magno</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Di Pastena</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Bordone</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Coni</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Canettieri</surname><given-names>G.</given-names></name>
</person-group> (<year>2022</year>). <article-title>The mechanism of action of biguanides: new answers to a complex question</article-title>. <source>Cancers (Basel)</source>
<volume>14</volume> (<issue>13</issue>), <fpage>3220</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14133220</pub-id>
<pub-id pub-id-type="pmid">35804992</pub-id>
<pub-id pub-id-type="pmcid">PMC9265089</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>R. B.</given-names></name>
<name name-style="western"><surname>Singhal</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Dutta</surname><given-names>S. B.</given-names></name>
<name name-style="western"><surname>Bansal</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Metformin: a review of potential mechanism and therapeutic utility beyond diabetes</article-title>. <source>Drug Des. Devel Ther.</source>
<volume>17</volume>, <fpage>1907</fpage>–<lpage>1932</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S409373</pub-id>
<pub-id pub-id-type="pmid">37397787</pub-id>
<pub-id pub-id-type="pmcid">PMC10312383</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dziubak</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Wojcicka</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Wojtak</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Beltowski</surname><given-names>J.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Metabolic effects of metformin in the failing heart</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>19</volume> (<issue>10</issue>). <pub-id pub-id-type="doi">10.3390/ijms19102869</pub-id>
<pub-id pub-id-type="pmid">30248910</pub-id>
<pub-id pub-id-type="pmcid">PMC6213955</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<collab>Anonymous</collab> (<year>1998</year>). <article-title>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK prospective diabetes study (UKPDS) group</article-title>. <source>Lancet</source>. <volume>352</volume>(<issue>9131</issue>):<fpage>854</fpage>–<lpage>865</lpage>.
<pub-id pub-id-type="pmid">9742977</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>El-Ashmawy</surname><given-names>N. E.</given-names></name>
<name name-style="western"><surname>Khedr</surname><given-names>N. F.</given-names></name>
<name name-style="western"><surname>El-Bahrawy</surname><given-names>H. A.</given-names></name>
<name name-style="western"><surname>Abo Mansour</surname><given-names>H. E.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway</article-title>. <source>Tumour Biol.</source>
<volume>39</volume> (<issue>5</issue>), <fpage>1010428317692235</fpage>. <pub-id pub-id-type="doi">10.1177/1010428317692235</pub-id>
<pub-id pub-id-type="pmid">28459206</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>El-Rayes</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Nadler</surname><given-names>M. B.</given-names></name>
<name name-style="western"><surname>Abdel-Qadir</surname><given-names>H.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Metformin to prevent anthracycline cardiotoxicity? That would be sweet</article-title>. <source>JACC CardioOncol</source>
<volume>5</volume> (<issue>5</issue>), <fpage>683</fpage>–<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaccao.2023.07.004</pub-id>
<pub-id pub-id-type="pmid">37969641</pub-id>
<pub-id pub-id-type="pmcid">PMC10635862</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Emelyanova</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Bosnjak</surname><given-names>Z. J.</given-names></name>
<name name-style="western"><surname>Kress</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Warner</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Biphasic effect of metformin on human cardiac energetics</article-title>. <source>Transl. Res.</source>
<volume>229</volume>, <fpage>5</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.trsl.2020.10.002</pub-id>
<pub-id pub-id-type="pmid">33045408</pub-id>
<pub-id pub-id-type="pmcid">PMC10655614</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Eurich</surname><given-names>D. T.</given-names></name>
<name name-style="western"><surname>McAlister</surname><given-names>F. A.</given-names></name>
<name name-style="western"><surname>Blackburn</surname><given-names>D. F.</given-names></name>
<name name-style="western"><surname>Majumdar</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Tsuyuki</surname><given-names>R. T.</given-names></name>
<name name-style="western"><surname>Varney</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review</article-title>. <source>BMJ</source>
<volume>335</volume> (<issue>7618</issue>), <fpage>497</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.39314.620174.80</pub-id>
<pub-id pub-id-type="pmid">17761999</pub-id>
<pub-id pub-id-type="pmcid">PMC1971204</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Eurich</surname><given-names>D. T.</given-names></name>
<name name-style="western"><surname>Tsuyuki</surname><given-names>R. T.</given-names></name>
<name name-style="western"><surname>Majumdar</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>McAlister</surname><given-names>F. A.</given-names></name>
<name name-style="western"><surname>Lewanczuk</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Shibata</surname><given-names>M. C.</given-names></name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality</article-title>. <source>Trials</source>
<volume>10</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.1186/1745-6215-10-12</pub-id>
<pub-id pub-id-type="pmid">19203392</pub-id>
<pub-id pub-id-type="pmcid">PMC2644685</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Eurich</surname><given-names>D. T.</given-names></name>
<name name-style="western"><surname>Weir</surname><given-names>D. L.</given-names></name>
<name name-style="western"><surname>Majumdar</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Tsuyuki</surname><given-names>R. T.</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>J. A.</given-names></name>
<name name-style="western"><surname>Tjosvold</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients</article-title>. <source>Circ. Heart Failure</source>
<volume>6</volume> (<issue>3</issue>), <fpage>395</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.112.000162</pub-id>
<pub-id pub-id-type="pmid">23508758</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Froldi</surname><given-names>G.</given-names></name>
</person-group> (<year>2024</year>). <article-title>View on metformin: antidiabetic and pleiotropic effects, pharmacokinetics, side effects, and sex-related differences</article-title>. <source>Pharm. (Basel).</source>
<volume>17</volume> (<issue>4</issue>), <fpage>478</fpage>. <pub-id pub-id-type="doi">10.3390/ph17040478</pub-id>
<pub-id pub-id-type="pmid">38675438</pub-id>
<pub-id pub-id-type="pmcid">PMC11054066</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Felgueiras</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Neto</surname><given-names>A. C.</given-names></name>
<name name-style="western"><surname>Rodrigues</surname><given-names>A. R.</given-names></name>
<name name-style="western"><surname>Gouveia</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Almeida</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Neves</surname><given-names>D.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Anti-oxidant effect of metformin through AMPK/SIRT1/PGC-1alpha/SIRT3-independent GPx1 expression in the heart of mice with endometriosis</article-title>. <source>Horm. Mol. Biol. Clin. Investig.</source>
<volume>43</volume> (<issue>4</issue>), <fpage>405</fpage>–<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1515/hmbci-2022-0039</pub-id>
<pub-id pub-id-type="pmid">35796227</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Ni</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Little</surname><given-names>P. J.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Metformin, macrophage dysfunction and atherosclerosis</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>, <fpage>682853</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.682853</pub-id>
<pub-id pub-id-type="pmid">34163481</pub-id>
<pub-id pub-id-type="pmcid">PMC8215340</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Fontaine</surname><given-names>E.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences</article-title>. <source>Front. Endocrinol. (Lausanne)</source>
<volume>9</volume>, <fpage>753</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2018.00753</pub-id>
<pub-id pub-id-type="pmid">30619086</pub-id>
<pub-id pub-id-type="pmcid">PMC6304344</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Foretz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Guigas</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Viollet</surname><given-names>B.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Metformin: update on mechanisms of action and repurposing potential</article-title>. <source>Nat. Rev. Endocrinol.</source>
<volume>19</volume> (<issue>8</issue>), <fpage>460</fpage>–<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1038/s41574-023-00833-4</pub-id>
<pub-id pub-id-type="pmid">37130947</pub-id>
<pub-id pub-id-type="pmcid">PMC10153049</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>W. S.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X. O.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>S. Y.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Metformin induces autophagy via the AMPK-mTOR signaling pathway in human hepatocellular carcinoma cells</article-title>. <source>Cancer Manag. Res.</source>
<volume>12</volume>, <fpage>5803</fpage>–<lpage>5811</lpage>. <pub-id pub-id-type="doi">10.2147/CMAR.S257966</pub-id>
<pub-id pub-id-type="pmid">32765083</pub-id>
<pub-id pub-id-type="pmcid">PMC7371564</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ghazal</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Tschumperlin</surname><given-names>D. J.</given-names></name>
<name name-style="western"><surname>Pereira</surname><given-names>N. L.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Cardiac fibrosis in the multi-omics era: implications for heart failure</article-title>. <source>Circ. Res.</source>
<volume>136</volume> (<issue>7</issue>), <fpage>773</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.124.325402</pub-id>
<pub-id pub-id-type="pmid">40146800</pub-id>
<pub-id pub-id-type="pmcid">PMC11949229</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Goodwin</surname><given-names>P. J.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>B. E.</given-names></name>
<name name-style="western"><surname>Gelmon</surname><given-names>K. A.</given-names></name>
<name name-style="western"><surname>Whelan</surname><given-names>T. J.</given-names></name>
<name name-style="western"><surname>Ennis</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Lemieux</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial</article-title>. <source>JAMA</source>
<volume>327</volume> (<issue>20</issue>), <fpage>1963</fpage>–<lpage>1973</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2022.6147</pub-id>
<pub-id pub-id-type="pmid">35608580</pub-id>
<pub-id pub-id-type="pmcid">PMC9131745</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Graf</surname><given-names>A. V.</given-names></name>
<name name-style="western"><surname>Artiukhov</surname><given-names>A. V.</given-names></name>
<name name-style="western"><surname>Solovjeva</surname><given-names>O. N.</given-names></name>
<name name-style="western"><surname>Ksenofontov</surname><given-names>A. L.</given-names></name>
<name name-style="western"><surname>Bunik</surname><given-names>V. I.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Combined administration of metformin and amprolium to rats affects metabolism of free amino acids in the brain, altering behavior, and heart rate</article-title>. <source>Biochem. (Mosc).</source>
<volume>89</volume> (<issue>10</issue>), <fpage>1692</fpage>–<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.1134/S0006297924100043</pub-id>
<pub-id pub-id-type="pmid">39523110</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Graham</surname><given-names>G. G.</given-names></name>
<name name-style="western"><surname>Punt</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Arora</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Day</surname><given-names>R. O.</given-names></name>
<name name-style="western"><surname>Doogue</surname><given-names>M. P.</given-names></name>
<name name-style="western"><surname>Duong</surname><given-names>J. K.</given-names></name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Clinical pharmacokinetics of metformin</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>50</volume> (<issue>2</issue>), <fpage>81</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.2165/11534750-000000000-00000</pub-id>
<pub-id pub-id-type="pmid">21241070</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gu</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>S. L.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>J. S.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells</article-title>. <source>Am. J. Transl. Res.</source>
<volume>9</volume> (<issue>9</issue>), <fpage>4071</fpage>–<lpage>4082</lpage>.
<pub-id pub-id-type="pmid">28979682</pub-id>
<pub-id pub-id-type="pmcid">PMC5622251</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gundewar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Calvert</surname><given-names>J. W.</given-names></name>
<name name-style="western"><surname>Jha</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Toedt-Pingel</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Ji</surname><given-names>S. Y.</given-names></name>
<name name-style="western"><surname>Nunez</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure</article-title>. <source>Circ. Res.</source>
<volume>104</volume> (<issue>3</issue>), <fpage>403</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.190918</pub-id>
<pub-id pub-id-type="pmid">19096023</pub-id>
<pub-id pub-id-type="pmcid">PMC2709761</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis</article-title>. <source>Cardiovasc Diabetol.</source>
<volume>18</volume> (<issue>1</issue>), <fpage>96</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-019-0900-7</pub-id>
<pub-id pub-id-type="pmid">31362743</pub-id>
<pub-id pub-id-type="pmcid">PMC6668189</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hartman</surname><given-names>M. H. T.</given-names></name>
<name name-style="western"><surname>Prins</surname><given-names>J. K. B.</given-names></name>
<name name-style="western"><surname>Schurer</surname><given-names>R. A. J.</given-names></name>
<name name-style="western"><surname>Lipsic</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Lexis</surname><given-names>C. P. H.</given-names></name>
<name name-style="western"><surname>van der Horst-Schrivers</surname><given-names>A. N. A.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT</article-title>. <source>Clin. Research Cardiology</source>
<volume>106</volume> (<issue>12</issue>), <fpage>939</fpage>–<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1007/s00392-017-1140-z</pub-id>
<pub-id pub-id-type="pmid">28755285</pub-id>
<pub-id pub-id-type="pmcid">PMC5696505</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hirsch</surname><given-names>H. A.</given-names></name>
<name name-style="western"><surname>Iliopoulos</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Struhl</surname><given-names>K.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>110</volume> (<issue>3</issue>), <fpage>972</fpage>–<lpage>977</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1221055110</pub-id>
<pub-id pub-id-type="pmid">23277563</pub-id>
<pub-id pub-id-type="pmcid">PMC3549132</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Holman</surname><given-names>R. R.</given-names></name>
<name name-style="western"><surname>Paul</surname><given-names>S. K.</given-names></name>
<name name-style="western"><surname>Bethel</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Matthews</surname><given-names>D. R.</given-names></name>
<name name-style="western"><surname>Neil</surname><given-names>H. A.</given-names></name>
</person-group> (<year>2008</year>). <article-title>10-year follow-up of intensive glucose control in type 2 diabetes</article-title>. <source>N. Engl. J. Med.</source>
<volume>359</volume> (<issue>15</issue>), <fpage>1577</fpage>–<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0806470</pub-id>
<pub-id pub-id-type="pmid">18784090</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Lai</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Lv</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Effects of metformin <italic toggle="yes">versus</italic> glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease</article-title>. <source>Diabetes Care</source>
<volume>36</volume> (<issue>5</issue>), <fpage>1304</fpage>–<lpage>1311</lpage>. <pub-id pub-id-type="doi">10.2337/dc12-0719</pub-id>
<pub-id pub-id-type="pmid">23230096</pub-id>
<pub-id pub-id-type="pmcid">PMC3631843</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis</article-title>. <source>Endocrine</source>
<volume>87</volume> (<issue>2</issue>), <fpage>436</fpage>–<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1007/s12020-024-04025-6</pub-id>
<pub-id pub-id-type="pmid">39277567</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>K. Y.</given-names></name>
<name name-style="western"><surname>Que</surname><given-names>J. Q.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>Z. S.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>Y. W.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Y. Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Metformin suppresses inflammation and apoptosis of myocardiocytes by inhibiting autophagy in a model of ischemia-reperfusion injury</article-title>. <source>Int. Journal Biological Sciences</source>
<volume>16</volume> (<issue>14</issue>), <fpage>2559</fpage>–<lpage>2579</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.40823</pub-id>
<pub-id pub-id-type="pmid">32792857</pub-id>
<pub-id pub-id-type="pmcid">PMC7415420</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Mitigating doxorubicin-induced cardiotoxicity and enhancing anti-tumor efficacy with a metformin-integrated self-assembled nanomedicine</article-title>. <source>Adv. Sci. (Weinh)</source>
<volume>12</volume> (<issue>17</issue>), <fpage>e2415227</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202415227</pub-id>
<pub-id pub-id-type="pmid">40052211</pub-id>
<pub-id pub-id-type="pmcid">PMC12061326</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Inzucchi</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Bergenstal</surname><given-names>R. M.</given-names></name>
<name name-style="western"><surname>Buse</surname><given-names>J. B.</given-names></name>
<name name-style="western"><surname>Diamant</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ferrannini</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Nauck</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes</article-title>. <source>Diabetes Care</source>
<volume>38</volume> (<issue>1</issue>), <fpage>140</fpage>–<lpage>149</lpage>. <pub-id pub-id-type="doi">10.2337/dc14-2441</pub-id>
<pub-id pub-id-type="pmid">25538310</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jadhav</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ferrell</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Greer</surname><given-names>I. A.</given-names></name>
<name name-style="western"><surname>Petrie</surname><given-names>J. R.</given-names></name>
<name name-style="western"><surname>Cobbe</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Sattar</surname><given-names>N.</given-names></name>
</person-group> (<year>2006</year>). <article-title>Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>48</volume> (<issue>5</issue>), <fpage>956</fpage>–<lpage>963</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2006.04.088</pub-id>
<pub-id pub-id-type="pmid">16949486</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jalali</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Fakhari</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Sepehr</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Zafari</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Sarajar</surname><given-names>B. O.</given-names></name>
<name name-style="western"><surname>Sarihi</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Synergistic anticancer effects of doxorubicin and metformin combination therapy: a systematic review</article-title>. <source>Transl. Oncol.</source>
<volume>45</volume>, <fpage>101946</fpage>. <pub-id pub-id-type="doi">10.1016/j.tranon.2024.101946</pub-id>
<pub-id pub-id-type="pmid">38636389</pub-id>
<pub-id pub-id-type="pmcid">PMC11040171</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jones</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ionescu</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Walker</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Wagle</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Kovacevic</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Chester</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Biguanide pharmaceutical formulations and the applications of bile acid-based nano delivery in chronic medical conditions</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>23</volume> (<issue>2</issue>), <fpage>836</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23020836</pub-id>
<pub-id pub-id-type="pmid">35055022</pub-id>
<pub-id pub-id-type="pmcid">PMC8775521</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kamel</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Ismail</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Abdel</surname><given-names>H. G.</given-names></name>
<name name-style="western"><surname>Sabry</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Farid</surname><given-names>S.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Effect of metformin on oxidative stress and left ventricular geometry in nondiabetic heart failure patients: a randomized controlled trial</article-title>. <source>Metab. Syndr. Relat. Disord.</source>
<volume>22</volume> (<issue>1</issue>), <fpage>49</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1089/met.2023.0164</pub-id>
<pub-id pub-id-type="pmid">37816240</pub-id>
</mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kanamori</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Naruse</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Yoshida</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Minatoguchi</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Kawaguchi</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metformin enhances autophagy and provides cardioprotection in delta-sarcoglycan deficiency-induced dilated cardiomyopathy</article-title>. <source>Circ. Heart Fail.</source>
<volume>12</volume> (<issue>4</issue>), <fpage>e005418</fpage>.
<pub-id pub-id-type="pmid">30922066</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCHEARTFAILURE.118.005418</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kobashigawa</surname><given-names>L. C.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Y. C.</given-names></name>
<name name-style="western"><surname>Padbury</surname><given-names>J. F.</given-names></name>
<name name-style="western"><surname>Tseng</surname><given-names>Y. T.</given-names></name>
<name name-style="western"><surname>Yano</surname><given-names>N.</given-names></name>
</person-group> (<year>2014</year>). <article-title>Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an <italic toggle="yes">in vitro</italic> study</article-title>. <source>PloS One</source>
<volume>9</volume> (<issue>8</issue>), <fpage>e104888</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0104888</pub-id>
<pub-id pub-id-type="pmid">25127116</pub-id>
<pub-id pub-id-type="pmcid">PMC4134245</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lalau</surname><given-names>J. D.</given-names></name>
<name name-style="western"><surname>Race</surname><given-names>J. M.</given-names></name>
</person-group> (<year>2001</year>). <article-title>Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis</article-title>. <source>Diabetes Obes. Metab.</source>
<volume>3</volume> (<issue>3</issue>), <fpage>195</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1046/j.1463-1326.2001.00128.x</pub-id>
<pub-id pub-id-type="pmid">11412284</pub-id>
</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lamanna</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Monami</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Marchionni</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Mannucci</surname><given-names>E.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials</article-title>. <source>Diabetes Obes. Metab.</source>
<volume>13</volume> (<issue>3</issue>), <fpage>221</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01349.x</pub-id>
<pub-id pub-id-type="pmid">21205121</pub-id>
</mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>LaMoia</surname><given-names>T. E.</given-names></name>
<name name-style="western"><surname>Shulman</surname><given-names>G. I.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Cellular and molecular mechanisms of metformin action</article-title>. <source>Endocr. Rev.</source>
<volume>42</volume> (<issue>1</issue>), <fpage>77</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1210/endrev/bnaa023</pub-id>
<pub-id pub-id-type="pmid">32897388</pub-id>
<pub-id pub-id-type="pmcid">PMC7846086</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>LaMoia</surname><given-names>T. E.</given-names></name>
<name name-style="western"><surname>Butrico</surname><given-names>G. M.</given-names></name>
<name name-style="western"><surname>Kalpage</surname><given-names>H. A.</given-names></name>
<name name-style="western"><surname>Goedeke</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Hubbard</surname><given-names>B. T.</given-names></name>
<name name-style="western"><surname>Vatner</surname><given-names>D. F.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>119</volume> (<issue>10</issue>), <fpage>e2122287119</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2122287119</pub-id>
<pub-id pub-id-type="pmid">35238637</pub-id>
<pub-id pub-id-type="pmcid">PMC8916010</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Larsen</surname><given-names>A. H.</given-names></name>
<name name-style="western"><surname>Jessen</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Norrelund</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Tolbod</surname><given-names>L. P.</given-names></name>
<name name-style="western"><surname>Harms</surname><given-names>H. J.</given-names></name>
<name name-style="western"><surname>Feddersen</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes</article-title>. <source>Eur. Journal Heart Failure</source>
<volume>22</volume> (<issue>9</issue>), <fpage>1628</fpage>–<lpage>1637</lpage>. <pub-id pub-id-type="doi">10.1002/ejhf.1656</pub-id>
<pub-id pub-id-type="pmid">31863557</pub-id>
</mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lazarus</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Shin</surname><given-names>J. I.</given-names></name>
<name name-style="western"><surname>Sang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Alexander</surname><given-names>G. C.</given-names></name>
<name name-style="western"><surname>Secora</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study</article-title>. <source>JAMA Intern Med.</source>
<volume>178</volume> (<issue>7</issue>), <fpage>903</fpage>–<lpage>910</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2018.0292</pub-id>
<pub-id pub-id-type="pmid">29868840</pub-id>
<pub-id pub-id-type="pmcid">PMC6145716</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lewis</surname><given-names>A. J.</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>J. J.</given-names></name>
<name name-style="western"><surname>McCallum</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Rider</surname><given-names>O. J.</given-names></name>
<name name-style="western"><surname>Neubauer</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Heather</surname><given-names>L. C.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Assessment of metformin-induced changes in cardiac and hepatic Redox State using Hyperpolarized[1-13C]Pyruvate</article-title>. <source>Diabetes</source>
<volume>65</volume> (<issue>12</issue>), <fpage>3544</fpage>–<lpage>3551</lpage>. <pub-id pub-id-type="doi">10.2337/db16-0804</pub-id>
<pub-id pub-id-type="pmid">27561726</pub-id>
</mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lexis</surname><given-names>C. P.</given-names></name>
<name name-style="western"><surname>van der Horst</surname><given-names>I. C.</given-names></name>
<name name-style="western"><surname>Lipsic</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Wieringa</surname><given-names>W. G.</given-names></name>
<name name-style="western"><surname>de Boer</surname><given-names>R. A.</given-names></name>
<name name-style="western"><surname>van den Heuvel</surname><given-names>A. F.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial</article-title>. <source>JAMA</source>
<volume>311</volume> (<issue>15</issue>), <fpage>1526</fpage>–<lpage>1535</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2014.3315</pub-id>
<pub-id pub-id-type="pmid">24687169</pub-id>
</mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhi</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>You</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>J. Q.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Metformin synergistically suppress tumor growth with doxorubicin and reverse drug resistance by inhibiting the expression and function of P-glycoprotein in MCF7/ADR cells and xenograft models</article-title>. <source>Oncotarget</source>
<volume>9</volume> (<issue>2</issue>), <fpage>2158</fpage>–<lpage>2174</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.23187</pub-id>
<pub-id pub-id-type="pmid">29416762</pub-id>
<pub-id pub-id-type="pmcid">PMC5788630</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Minczuk</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Massey</surname><given-names>J. C.</given-names></name>
<name name-style="western"><surname>Howell</surname><given-names>N. L.</given-names></name>
<name name-style="western"><surname>Roy</surname><given-names>R. J.</given-names></name>
<name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Metformin improves cardiac metabolism and function, and prevents left ventricular hypertrophy in spontaneously hypertensive rats</article-title>. <source>J. Am. Heart Assoc.</source>
<volume>9</volume> (<issue>7</issue>), <fpage>e015154</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.119.015154</pub-id>
<pub-id pub-id-type="pmid">32248762</pub-id>
<pub-id pub-id-type="pmcid">PMC7428616</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Lv</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study</article-title>. <source>BMC Med.</source>
<volume>22</volume> (<issue>1</issue>), <fpage>269</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-024-03484-y</pub-id>
<pub-id pub-id-type="pmid">38926749</pub-id>
<pub-id pub-id-type="pmcid">PMC11210152</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Fang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Novel applications of metformin in the treatment of septic myocardial injury based on metabolomics and network pharmacology</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>986</volume>, <fpage>177141</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2024.177141</pub-id>
<pub-id pub-id-type="pmid">39566813</pub-id>
</mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lipska</surname><given-names>K. J.</given-names></name>
<name name-style="western"><surname>Bailey</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>Inzucchi</surname><given-names>S. E.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Use of metformin in the setting of mild-to-moderate renal insufficiency</article-title>. <source>Diabetes Care</source>
<volume>34</volume> (<issue>6</issue>), <fpage>1431</fpage>–<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.2337/dc10-2361</pub-id>
<pub-id pub-id-type="pmid">21617112</pub-id>
<pub-id pub-id-type="pmcid">PMC3114336</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Metformin attenuates cardiac hypertrophy <italic toggle="yes">via</italic> the HIF-1alpha/PPAR-gamma signaling pathway in high-fat diet rats</article-title>. <source>Front. Pharmacology</source>
<volume>13</volume>, <fpage>919202</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.919202</pub-id>
<pub-id pub-id-type="pmid">35833024</pub-id>
<pub-id pub-id-type="pmcid">PMC9271627</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Metformin attenuates lung ischemia-reperfusion injury and necroptosis through AMPK pathway in type 2 diabetic recipient rats</article-title>. <source>BMC Pulm. Med.</source>
<volume>24</volume> (<issue>1</issue>), <fpage>237</fpage>. <pub-id pub-id-type="doi">10.1186/s12890-024-03056-z</pub-id>
<pub-id pub-id-type="pmid">38745191</pub-id>
<pub-id pub-id-type="pmcid">PMC11094932</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Loi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Kramar</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Laborde</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Marsal</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Pizzinat</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Cussac</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Metformin attenuates postinfarction myocardial fibrosis and inflammation in mice</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume> (<issue>17</issue>), <fpage>9393</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22179393</pub-id>
<pub-id pub-id-type="pmid">34502314</pub-id>
<pub-id pub-id-type="pmcid">PMC8430638</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>
</person-group> (<year>2021</year>). <article-title>The effects of metformin on autophagy</article-title>. <source>Biomed. and Pharmacotherapy = Biomedecine and Pharmacotherapie</source>
<volume>137</volume>, <fpage>111286</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111286</pub-id>
<pub-id pub-id-type="pmid">33524789</pub-id>
</mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Das</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management</article-title>. <source>Cardiovasc Diabetol.</source>
<volume>18</volume> (<issue>1</issue>), <fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-019-0860-y</pub-id>
<pub-id pub-id-type="pmid">31029144</pub-id>
<pub-id pub-id-type="pmcid">PMC6486984</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ma</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Low-dose metformin targets the lysosomal AMPK pathway through PEN2</article-title>. <source>Nature</source>
<volume>603</volume> (<issue>7899</issue>), <fpage>159</fpage>–<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-04431-8</pub-id>
<pub-id pub-id-type="pmid">35197629</pub-id>
<pub-id pub-id-type="pmcid">PMC8891018</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Metformin collaborates with PINK1/Mfn2 overexpression to prevent cardiac injury by improving mitochondrial function</article-title>. <source>Biol. (Basel).</source>
<volume>12</volume> (<issue>4</issue>), <fpage>582</fpage>. <pub-id pub-id-type="doi">10.3390/biology12040582</pub-id>
<pub-id pub-id-type="pmid">37106782</pub-id>
<pub-id pub-id-type="pmcid">PMC10135998</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Madiraju</surname><given-names>A. K.</given-names></name>
<name name-style="western"><surname>Erion</surname><given-names>D. M.</given-names></name>
<name name-style="western"><surname>Rahimi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X. M.</given-names></name>
<name name-style="western"><surname>Braddock</surname><given-names>D. T.</given-names></name>
<name name-style="western"><surname>Albright</surname><given-names>R. A.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase</article-title>. <source>Nature</source>
<volume>510</volume> (<issue>7506</issue>), <fpage>542</fpage>–<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1038/nature13270</pub-id>
<pub-id pub-id-type="pmid">24847880</pub-id>
<pub-id pub-id-type="pmcid">PMC4074244</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Madiraju</surname><given-names>A. K.</given-names></name>
<name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Perry</surname><given-names>R. J.</given-names></name>
<name name-style="western"><surname>Rahimi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X. M.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Metformin inhibits gluconeogenesis via a redox-dependent mechanism <italic toggle="yes">in vivo</italic>
</article-title>. <source>Nat. Med.</source>
<volume>24</volume> (<issue>9</issue>), <fpage>1384</fpage>–<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0125-4</pub-id>
<pub-id pub-id-type="pmid">30038219</pub-id>
<pub-id pub-id-type="pmcid">PMC6129196</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Maghraby</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>El-Baz</surname><given-names>M. A. H.</given-names></name>
<name name-style="western"><surname>Hassan</surname><given-names>A. M. A.</given-names></name>
<name name-style="western"><surname>Abd-Elghaffar</surname><given-names>S. K.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>A. S.</given-names></name>
<name name-style="western"><surname>Sabra</surname><given-names>M. S.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Metformin alleviates doxorubicin-induced cardiotoxicity via preserving mitochondrial dynamics balance and calcium homeostasis</article-title>. <source>Appl. Biochem. Biotechnol.</source>
<volume>197</volume> (<issue>4</issue>), <fpage>2713</fpage>–<lpage>2733</lpage>. <pub-id pub-id-type="doi">10.1007/s12010-024-05141-9</pub-id>
<pub-id pub-id-type="pmid">39792339</pub-id>
<pub-id pub-id-type="pmcid">PMC11985558</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Malaekeh-Nikouei</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Shokri-Naei</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Karbasforoushan</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bahari</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Baradaran Rahimi</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Heidari</surname><given-names>R.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Metformin beyond an anti-diabetic agent: a comprehensive and mechanistic review on its effects against natural and chemical toxins</article-title>. <source>Biomed. and Pharmacotherapy = Biomedecine and Pharmacotherapie</source>
<volume>165</volume>, <fpage>115263</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2023.115263</pub-id>
<pub-id pub-id-type="pmid">37541178</pub-id>
</mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Masoudi</surname><given-names>F. A.</given-names></name>
<name name-style="western"><surname>Inzucchi</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Havranek</surname><given-names>E. P.</given-names></name>
<name name-style="western"><surname>Foody</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Krumholz</surname><given-names>H. M.</given-names></name>
</person-group> (<year>2005</year>). <article-title>Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study</article-title>. <source>Circulation</source>
<volume>111</volume> (<issue>5</issue>), <fpage>583</fpage>–<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000154542.13412.B1</pub-id>
<pub-id pub-id-type="pmid">15699279</pub-id>
</mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mohamed</surname><given-names>H. A.</given-names></name>
<name name-style="western"><surname>Mohamed</surname><given-names>N. A.</given-names></name>
<name name-style="western"><surname>Macasa</surname><given-names>S. S.</given-names></name>
<name name-style="western"><surname>Basha</surname><given-names>H. K.</given-names></name>
<name name-style="western"><surname>Adan</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Crovella</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Metformin-loaded nanoparticles reduce hyperglycemia-associated oxidative stress and induce eNOS phosphorylation in vascular endothelial cells</article-title>. <source>Sci. Reports</source>
<volume>14</volume> (<issue>1</issue>), <fpage>30870</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-81427-6</pub-id>
<pub-id pub-id-type="pmid">39730492</pub-id>
<pub-id pub-id-type="pmcid">PMC11681025</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mohan</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Al-Talabany</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>McKinnie</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Mordi</surname><given-names>I. R.</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>J. S. S.</given-names></name>
<name name-style="western"><surname>Gandy</surname><given-names>S. J.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial</article-title>. <source>Eur. Heart Journal</source>
<volume>40</volume> (<issue>41</issue>), <fpage>3409</fpage>–<lpage>3417</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehz203</pub-id>
<pub-id pub-id-type="pmid">30993313</pub-id>
<pub-id pub-id-type="pmcid">PMC6823615</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mohsin</surname><given-names>A. A.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Quan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Rousselle</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Maceyka</surname><given-names>M. W.</given-names></name>
<name name-style="western"><surname>Samidurai</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Mitochondrial complex I inhibition by metformin limits reperfusion injury</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>369</volume> (<issue>2</issue>), <fpage>282</fpage>–<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.118.254300</pub-id>
<pub-id pub-id-type="pmid">30846619</pub-id>
<pub-id pub-id-type="pmcid">PMC6474909</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mone</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Varzideh</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Rainone</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kansakar</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Jankauskas</surname><given-names>S. S.</given-names></name>
<name name-style="western"><surname>Salemme</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Beneficial effects of metformin treatment in hyperglycaemic patients affected by ischaemia with no obstructive coronary artery</article-title>. <source>Cardiovasc Res.</source>
<volume>121</volume> (<issue>4</issue>), <fpage>532</fpage>–<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvae269</pub-id>
<pub-id pub-id-type="pmid">39786492</pub-id>
<pub-id pub-id-type="pmcid">PMC12054629</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Moulin</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Blachot-Minassian</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Kneppers</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Paradis</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bultot</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Metformin protects the heart against chronic intermittent hypoxia through AMPK-dependent phosphorylation of HIF-1alpha</article-title>. <source>FEBS J.</source>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.70110</pub-id><pub-id pub-id-type="pmid">40364612</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mthembu</surname><given-names>S. X. H.</given-names></name>
<name name-style="western"><surname>Mazibuko-Mbeje</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Ziqubu</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Silvestri</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Orlando</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Nkambule</surname><given-names>B. B.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Pharmacological activation of Nrf2: cardioprotective effects of statins and metformin against dyslipidemia-induced oxidative stress</article-title>. <source>Atherosclerosis</source>
<volume>409</volume>, <fpage>120474</fpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2025.120474</pub-id>
<pub-id pub-id-type="pmid">40834569</pub-id>
</mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Onoue</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Lefebvre</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Denduluri</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Carver</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The association of metformin with heart failure in patients with diabetes mellitus receiving anthracycline chemotherapy</article-title>. <source>JACC CardioOncol</source>
<volume>5</volume> (<issue>5</issue>), <fpage>674</fpage>–<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaccao.2023.05.013</pub-id>
<pub-id pub-id-type="pmid">37969650</pub-id>
<pub-id pub-id-type="pmcid">PMC10635887</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Osataphan</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Phrommintikul</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Leemasawat</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Somwangprasert</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Apaijai</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Suksai</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial</article-title>. <source>Sci. Reports</source>
<volume>13</volume> (<issue>1</issue>), <fpage>12759</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-40061-4</pub-id>
<pub-id pub-id-type="pmid">37550350</pub-id>
<pub-id pub-id-type="pmcid">PMC10406870</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Osorio-Llanes</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Villamizar-Villamizar</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Ospino Guerra</surname><given-names>M. C.</given-names></name>
<name name-style="western"><surname>Diaz-Ariza</surname><given-names>L. A.</given-names></name>
<name name-style="western"><surname>Castiblanco-Arroyave</surname><given-names>S. C.</given-names></name>
<name name-style="western"><surname>Medrano</surname><given-names>L.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Effects of metformin on Ischemia/reperfusion injury: new evidence and mechanisms</article-title>. <source>Pharm. (Basel).</source>
<volume>16</volume> (<issue>8</issue>), <fpage>1121</fpage>. <pub-id pub-id-type="doi">10.3390/ph16081121</pub-id>
<pub-id pub-id-type="pmid">37631036</pub-id>
<pub-id pub-id-type="pmcid">PMC10459572</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Darko</surname><given-names>K. O.</given-names></name>
<name name-style="western"><surname>Tao</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>C.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Combination of metformin with chemotherapeutic drugs <italic toggle="yes">via</italic> different molecular mechanisms</article-title>. <source>Cancer Treatment Reviews</source>
<volume>54</volume>, <fpage>24</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2017.01.005</pub-id>
<pub-id pub-id-type="pmid">28161619</pub-id>
</mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pozzo</surname><given-names>J. D.</given-names></name>
<name name-style="western"><surname>Mehta</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Kobayashi</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Liang</surname><given-names>Q.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Unexpected role of adenosine-monophosphate activated protein kinase in doxorubicin cardiotoxicity and metformin-mediated cardioprotection</article-title>. <source>J. Cardiac Fail</source>. <volume>25</volume> (<issue>8</issue>), <fpage>S2</fpage>.</mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Preiss</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Lloyd</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Ford</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>McMurray</surname><given-names>J. J.</given-names></name>
<name name-style="western"><surname>Holman</surname><given-names>R. R.</given-names></name>
<name name-style="western"><surname>Welsh</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial</article-title>. <source>Lancet Diabetes Endocrinol.</source>
<volume>2</volume> (<issue>2</issue>), <fpage>116</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(13)70152-9</pub-id>
<pub-id pub-id-type="pmid">24622715</pub-id>
</mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Preiss</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Welsh</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sattar</surname><given-names>N.</given-names></name>
</person-group> (<year>2016</year>). <article-title>Metformin therapy and circulating NT-proBNP levels: the CAMERA trial</article-title>. <source>Diabetes Care</source>
<volume>39</volume> (<issue>8</issue>), <fpage>e114</fpage>–<lpage>e115</lpage>. <pub-id pub-id-type="doi">10.2337/dc16-0887</pub-id>
<pub-id pub-id-type="pmid">27271181</pub-id>
</mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pu</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Gan</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Ba</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huo</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Effects of metformin in obesity treatment in different populations: a meta-analysis</article-title>. <source>Ther. Adv. Endocrinol. Metab.</source>
<volume>11</volume>, <fpage>2042018820926000</fpage>. <pub-id pub-id-type="doi">10.1177/2042018820926000</pub-id>
<pub-id pub-id-type="pmid">32499908</pub-id>
<pub-id pub-id-type="pmcid">PMC7243386</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rahman</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Tuba</surname><given-names>S.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Lactic acidosis associated with metformin in patients with diabetic kidney disease</article-title>. <source>Med. Arch.</source>
<volume>76</volume> (<issue>4</issue>), <fpage>297</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.5455/medarh.2022.76.297-300</pub-id>
<pub-id pub-id-type="pmid">36313954</pub-id>
<pub-id pub-id-type="pmcid">PMC9559667</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Reczek</surname><given-names>C. R.</given-names></name>
<name name-style="western"><surname>Chakrabarty</surname><given-names>R. P.</given-names></name>
<name name-style="western"><surname>D'Alessandro</surname><given-names>K. B.</given-names></name>
<name name-style="western"><surname>Sebo</surname><given-names>Z. L.</given-names></name>
<name name-style="western"><surname>Grant</surname><given-names>R. A.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Metformin targets mitochondrial complex I to lower blood glucose levels</article-title>. <source>Sci. Adv.</source>
<volume>10</volume> (<issue>51</issue>), <fpage>eads5466</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.ads5466</pub-id>
<pub-id pub-id-type="pmid">39693440</pub-id>
<pub-id pub-id-type="pmcid">PMC11654692</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rozier</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Paul</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Madji Hounoum</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Villa</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Mhaidly</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Chiche</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Pharmacological preconditioning protects from ischemia/reperfusion-induced apoptosis by modulating Bcl-xL expression through a ROS-dependent mechanism</article-title>. <source>FEBS J.</source>
<volume>288</volume> (<issue>11</issue>), <fpage>3547</fpage>–<lpage>3569</lpage>. <pub-id pub-id-type="doi">10.1111/febs.15675</pub-id>
<pub-id pub-id-type="pmid">33340237</pub-id>
</mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Saeedi</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Parsons</surname><given-names>H. L.</given-names></name>
<name name-style="western"><surname>Wambolt</surname><given-names>R. B.</given-names></name>
<name name-style="western"><surname>Paulson</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Dyck</surname><given-names>J. R.</given-names></name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source>
<volume>294</volume> (<issue>6</issue>), <fpage>H2497</fpage>–<lpage>H2506</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00873.2007</pub-id>
<pub-id pub-id-type="pmid">18375721</pub-id>
</mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Salpeter</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Greyber</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Pasternak</surname><given-names>G. A.</given-names></name>
<name name-style="western"><surname>Salpeter</surname><given-names>E. E.</given-names></name>
</person-group> (<year>2010</year>). <article-title>Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus</article-title>. <source>Cochrane Database Syst. Rev.</source>
<volume>2010</volume> (<issue>4</issue>), <fpage>CD002967</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD002967</pub-id>
<pub-id pub-id-type="pmid">12804446</pub-id>
</mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Salvatore</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Galiero</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Caturano</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Vetrano</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Rinaldi</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Coviello</surname><given-names>F.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Effects of metformin in heart failure: from pathophysiological rationale to clinical evidence</article-title>. <source>Biomolecules</source>
<volume>11</volume> (<issue>12</issue>), <fpage>1834</fpage>. <pub-id pub-id-type="doi">10.3390/biom11121834</pub-id>
<pub-id pub-id-type="pmid">34944478</pub-id>
<pub-id pub-id-type="pmcid">PMC8698925</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Santulli</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Visco</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Varzideh</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Guerra</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Kansakar</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Gasperi</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Prediabetes increases the risk of frailty in prefrail older adults with hypertension: beneficial effects of metformin</article-title>. <source>Hypertension</source>
<volume>81</volume> (<issue>7</issue>), <fpage>1637</fpage>–<lpage>1643</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.124.23087</pub-id>
<pub-id pub-id-type="pmid">38752357</pub-id>
<pub-id pub-id-type="pmcid">PMC11170724</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Satyam</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Bairy</surname><given-names>L. K.</given-names></name>
<name name-style="western"><surname>Shetty</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sainath</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Bharati</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>A. Z.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Metformin and dapagliflozin attenuate doxorubicin-induced acute cardiotoxicity in Wistar rats: an electrocardiographic, biochemical, and histopathological approach</article-title>. <source>Cardiovasc Toxicol.</source>
<volume>23</volume> (<issue>2</issue>), <fpage>107</fpage>–<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1007/s12012-023-09784-8</pub-id>
<pub-id pub-id-type="pmid">36790727</pub-id>
<pub-id pub-id-type="pmcid">PMC9950216</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Schulz</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Reuter</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Navarrete Santos</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bitter</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Rehm</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Schlitt</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Major adverse cardiovascular events: the importance of serum levels and haplotypes of the anti-inflammatory cytokine interleukin 10</article-title>. <source>Biomolecules</source>
<volume>14</volume> (<issue>8</issue>), <fpage>979</fpage>. <pub-id pub-id-type="doi">10.3390/biom14080979</pub-id>
<pub-id pub-id-type="pmid">39199367</pub-id>
<pub-id pub-id-type="pmcid">PMC11353162</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Seifarth</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Schehler</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Schneider</surname><given-names>H. J.</given-names></name>
</person-group> (<year>2013</year>). <article-title>Effectiveness of metformin on weight loss in non-diabetic individuals with obesity</article-title>. <source>Exp. Clin. Endocrinol. Diabetes</source>
<volume>121</volume> (<issue>1</issue>), <fpage>27</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1055/s-0032-1327734</pub-id>
<pub-id pub-id-type="pmid">23147210</pub-id>
</mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shabkhizan</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Avci</surname><given-names>C. B.</given-names></name>
<name name-style="western"><surname>Haiaty</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Moslehian</surname><given-names>M. S.</given-names></name>
<name name-style="western"><surname>Sadeghsoltani</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Bazmani</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Metformin exerted tumoricidal effects on colon cancer tumoroids <italic toggle="yes">via</italic> the regulation of autophagy pathway</article-title>. <source>Stem Cell Res. Ther.</source>
<volume>16</volume> (<issue>1</issue>), <fpage>45</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-025-04174-z</pub-id>
<pub-id pub-id-type="pmid">39901295</pub-id>
<pub-id pub-id-type="pmcid">PMC11792360</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shaw</surname><given-names>R. J.</given-names></name>
<name name-style="western"><surname>Lamia</surname><given-names>K. A.</given-names></name>
<name name-style="western"><surname>Vasquez</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Koo</surname><given-names>S. H.</given-names></name>
<name name-style="western"><surname>Bardeesy</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Depinho</surname><given-names>R. A.</given-names></name>
<etal/>
</person-group> (<year>2005</year>). <article-title>The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin</article-title>. <source>Science</source>
<volume>310</volume> (<issue>5754</issue>), <fpage>1642</fpage>–<lpage>1646</lpage>. <pub-id pub-id-type="doi">10.1126/science.1120781</pub-id>
<pub-id pub-id-type="pmid">16308421</pub-id>
<pub-id pub-id-type="pmcid">PMC3074427</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Nicol</surname><given-names>A. T.</given-names></name>
<name name-style="western"><surname>DelPozzo</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Demystifying the relationship between metformin, AMPK, and doxorubicin cardiotoxicity</article-title>. <source>Front. Cardiovascular Medicine</source>
<volume>9</volume>, <fpage>839644</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.839644</pub-id>
<pub-id pub-id-type="pmid">35141304</pub-id>
<pub-id pub-id-type="pmcid">PMC8818847</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Solbach</surname><given-names>T. F.</given-names></name>
<name name-style="western"><surname>Grube</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fromm</surname><given-names>M. F.</given-names></name>
<name name-style="western"><surname>Zolk</surname><given-names>O.</given-names></name>
</person-group> (<year>2011</year>). <article-title>Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization</article-title>. <source>J. Cardiovasc Pharmacol.</source>
<volume>58</volume> (<issue>4</issue>), <fpage>409</fpage>–<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1097/FJC.0b013e3182270783</pub-id>
<pub-id pub-id-type="pmid">21697722</pub-id>
</mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Solskov</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Lofgren</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Kristiansen</surname><given-names>S. B.</given-names></name>
<name name-style="western"><surname>Jessen</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Pold</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Nielsen</surname><given-names>T. T.</given-names></name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration</article-title>. <source>Basic Clin. Pharmacol. Toxicol.</source>
<volume>103</volume> (<issue>1</issue>), <fpage>82</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.111</pub-id>
<pub-id pub-id-type="pmid">18484962</pub-id>
</mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Soraya</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Farajnia</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Khani</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Rameshrad</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Khorrami</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Banani</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Short-term treatment with metformin suppresses toll like receptors (TLRs) activity in isoproterenol-induced myocardial infarction in rat: are AMPK and TLRs connected?</article-title>
<source>Int. Immunopharmacol.</source>
<volume>14</volume> (<issue>4</issue>), <fpage>785</fpage>–<lpage>791</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2012.10.014</pub-id>
<pub-id pub-id-type="pmid">23122726</pub-id>
</mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Stades</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Heikens</surname><given-names>J. T.</given-names></name>
<name name-style="western"><surname>Erkelens</surname><given-names>D. W.</given-names></name>
<name name-style="western"><surname>Holleman</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Hoekstra</surname><given-names>J. B.</given-names></name>
</person-group> (<year>2004</year>). <article-title>Metformin and lactic acidosis: cause or coincidence? A review of case reports</article-title>. <source>J. Intern Med.</source>
<volume>255</volume> (<issue>2</issue>), <fpage>179</fpage>–<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2796.2003.01271.x</pub-id>
<pub-id pub-id-type="pmid">14746555</pub-id>
</mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Stone</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Sabe</surname><given-names>S. A.</given-names></name>
<name name-style="western"><surname>Harris</surname><given-names>D. D.</given-names></name>
<name name-style="western"><surname>Broadwin</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kant</surname><given-names>R. J.</given-names></name>
<name name-style="western"><surname>Kanuparthy</surname><given-names>M.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Metformin preconditioning augments cardiac perfusion and performance in a large animal model of chronic coronary artery disease</article-title>. <source>Ann. Surg.</source>
<volume>280</volume> (<issue>4</issue>), <fpage>547</fpage>–<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0000000000006437</pub-id>
<pub-id pub-id-type="pmid">39041226</pub-id>
</mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sulong</surname><given-names>N. A.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>V. S.</given-names></name>
<name name-style="western"><surname>Fei</surname><given-names>C. C.</given-names></name>
<name name-style="western"><surname>Johan</surname><given-names>M. R.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Exploring multifaceted roles of metformin in therapeutic applications, mechanistic insights, and innovations in drug delivery systems across biological contexts: a systematic review</article-title>. <source>Drug Deliv. Transl. Res.</source>
<volume>15</volume> (<issue>11</issue>), <fpage>4043</fpage>–<lpage>4066</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-025-01903-y</pub-id>
<pub-id pub-id-type="pmid">40555912</pub-id>
</mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sun</surname><given-names>M. L.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>X. H.</given-names></name>
</person-group> (<year>2024a</year>). <article-title>Reliability of Metformin's protective effects against doxorubicin-induced cardiotoxicity: a meta-analysis of animal studies</article-title>. <source>Front. Pharmacology</source>
<volume>15</volume>, <fpage>1435866</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2024.1435866</pub-id>
<pub-id pub-id-type="pmid">39175538</pub-id>
<pub-id pub-id-type="pmcid">PMC11338926</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sun</surname><given-names>M. L.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhen</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2024b</year>). <article-title>Metformin-mediated protection against doxorubicin-induced cardiotoxicity</article-title>. <source>Biomed. Pharmacother.</source>
<volume>180</volume>, <fpage>117535</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.117535</pub-id>
<pub-id pub-id-type="pmid">39405911</pub-id>
</mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tadokoro</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ide</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Deguchi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Ikeda</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Okabe</surname><given-names>K.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity</article-title>. <source>JCI Insight</source>
<volume>5</volume> (<issue>9</issue>). <pub-id pub-id-type="doi">10.1172/jci.insight.132747</pub-id>
<pub-id pub-id-type="pmid">32376803</pub-id>
<pub-id pub-id-type="pmcid">PMC7253028</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Techiryan</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Weil</surname><given-names>B. R.</given-names></name>
<name name-style="western"><surname>Palka</surname><given-names>B. A.</given-names></name>
<name name-style="western"><surname>Canty</surname><given-names>J. M.</given-names><suffix>Jr.</suffix></name>
</person-group> (<year>2018</year>). <article-title>Effect of intracoronary metformin on myocardial infarct size in Swine</article-title>. <source>Circ. Res.</source>
<volume>123</volume> (<issue>8</issue>), <fpage>986</fpage>–<lpage>995</lpage>.
<pub-id pub-id-type="pmid">30355033</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.118.313341</pub-id><pub-id pub-id-type="pmcid">PMC6207210</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Top</surname><given-names>W. M. C.</given-names></name>
<name name-style="western"><surname>Kooy</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Stehouwer</surname><given-names>C. D. A.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia</article-title>. <source>Pharm. (Basel)</source>
<volume>15</volume> (<issue>3</issue>), <fpage>312</fpage>. <pub-id pub-id-type="doi">10.3390/ph15030312</pub-id>
<pub-id pub-id-type="pmid">35337110</pub-id>
<pub-id pub-id-type="pmcid">PMC8951049</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vaez</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Najafi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Rameshrad</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Toutounchi</surname><given-names>N. S.</given-names></name>
<name name-style="western"><surname>Garjani</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Barar</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2016</year>). <article-title>AMPK activation by metformin inhibits local innate immune responses in the isolated rat heart by suppression of TLR 4-related pathway</article-title>. <source>Int. Immunopharmacol.</source>
<volume>40</volume>, <fpage>501</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2016.10.002</pub-id>
<pub-id pub-id-type="pmid">27756052</pub-id>
</mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Van</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hahn</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Silverstein</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Metformin inhibits autophagy, mitophagy and antagonizes doxorubicin-induced cardiomyocyte death</article-title>. <source>Int. J. Drug Discov. Pharmacol.</source>
<volume>2</volume> (<issue>1</issue>), <fpage>5</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.53941/ijddp.0201004</pub-id>
<pub-id pub-id-type="pmid">38487671</pub-id>
<pub-id pub-id-type="pmcid">PMC10939033</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Viollet</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Guigas</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Sanz Garcia</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Leclerc</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Foretz</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Andreelli</surname><given-names>F.</given-names></name>
</person-group> (<year>2012</year>). <article-title>Cellular and molecular mechanisms of metformin: an overview</article-title>. <source>Clin. Sci. (Lond).</source>
<volume>122</volume> (<issue>6</issue>), <fpage>253</fpage>–<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1042/CS20110386</pub-id>
<pub-id pub-id-type="pmid">22117616</pub-id>
<pub-id pub-id-type="pmcid">PMC3398862</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Yan</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Mi</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways</article-title>. <source>J. Experimental and Clinical Cancer Research CR</source>
<volume>37</volume> (<issue>1</issue>), <fpage>63</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0731-5</pub-id>
<pub-id pub-id-type="pmid">29554968</pub-id>
<pub-id pub-id-type="pmcid">PMC5859411</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>An</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Sesaki</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metformin improves mitochondrial respiratory activity through activation of AMPK</article-title>. <source>Cell Rep.</source>
<volume>29</volume> (<issue>6</issue>), <fpage>1511</fpage>–<lpage>23 e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.09.070</pub-id>
<pub-id pub-id-type="pmid">31693892</pub-id>
<pub-id pub-id-type="pmcid">PMC6866677</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Min</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yuan</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name>
</person-group> (<year>2021</year>). <article-title>The association between metformin treatment and outcomes in type 2 diabetes mellitus patients with heart failure with preserved ejection fraction: a retrospective study</article-title>. <source>Front. Cardiovascular Medicine</source>
<volume>8</volume>, <fpage>648212</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2021.648212</pub-id>
<pub-id pub-id-type="pmid">33778026</pub-id>
<pub-id pub-id-type="pmcid">PMC7994337</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Nabben</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Neumann</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Luiken</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Glatz</surname><given-names>J. F. C.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Endosomal v-ATPase as a sensor determining myocardial substrate preference</article-title>. <source>Metabolites</source>
<volume>12</volume> (<issue>7</issue>), <fpage>579</fpage>. <pub-id pub-id-type="doi">10.3390/metabo12070579</pub-id>
<pub-id pub-id-type="pmid">35888703</pub-id>
<pub-id pub-id-type="pmcid">PMC9316095</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Meng</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Guan</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Metformin activates autophagy and inhibits apoptosis and fetal heart abnormalities <italic toggle="yes">via</italic> the Dnmt3l/Usp18/STAT1 pathway</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>1005</volume>, <fpage>177997</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2025.177997</pub-id>
<pub-id pub-id-type="pmid">40738360</pub-id>
</mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity</article-title>. <source>Exp. Biol. Med. (Maywood)</source>
<volume>248</volume> (<issue>18</issue>), <fpage>1556</fpage>–<lpage>1565</lpage>. <pub-id pub-id-type="doi">10.1177/15353702231191178</pub-id>
<pub-id pub-id-type="pmid">37750221</pub-id>
<pub-id pub-id-type="pmcid">PMC10676127</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Jiao</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name>
</person-group> (<year>2025</year>). <article-title>Metformin attenuates myocardial ischemia/reperfusion-induced ferroptosis through the upregulation of Nur77-mediated IDH1</article-title>. <source>Biochim. Biophys. Acta Mol. Cell Res.</source>
<volume>1872</volume> (<issue>4</issue>), <fpage>119934</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2025.119934</pub-id>
<pub-id pub-id-type="pmid">40096893</pub-id>
</mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xiang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Effects of exercise, metformin, and combination treatments on type 2 diabetic mellitus-induced muscle atrophy in db/db mice: crosstalk between autophagy and the proteasome</article-title>. <source>J. Physiol. Biochem.</source>
<volume>80</volume> (<issue>1</issue>), <fpage>235</fpage>–<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1007/s13105-023-01001-y</pub-id>
<pub-id pub-id-type="pmid">38112970</pub-id>
</mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Gaertner</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Morresi-Hauf</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Genzel</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Duell</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ullrich</surname><given-names>A.</given-names></name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Metformin triggers autophagy to attenuate drug-induced apoptosis in NSCLC cells, with minor effects on tumors of diabetic patients</article-title>. <source>Neoplasia</source>
<volume>19</volume> (<issue>5</issue>), <fpage>385</fpage>–<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1016/j.neo.2017.02.011</pub-id>
<pub-id pub-id-type="pmid">28391030</pub-id>
<pub-id pub-id-type="pmcid">PMC5384889</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Fassett</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Metformin protects against systolic overload-induced heart failure independent of AMP-activated protein kinase alpha2</article-title>. <source>Hypertension</source>
<volume>63</volume> (<issue>4</issue>), <fpage>723</fpage>–<lpage>728</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.113.02619</pub-id>
<pub-id pub-id-type="pmid">24420540</pub-id>
<pub-id pub-id-type="pmcid">PMC4026291</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Meng</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xian</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Che</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metformin inhibits the NLRP3 inflammasome via AMPK/mTOR-dependent effects in diabetic cardiomyopathy</article-title>. <source>Int. Journal Biological Sciences</source>
<volume>15</volume> (<issue>5</issue>), <fpage>1010</fpage>–<lpage>1019</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.29680</pub-id>
<pub-id pub-id-type="pmid">31182921</pub-id>
<pub-id pub-id-type="pmcid">PMC6535781</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Zha</surname><given-names>W.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Metformin ameliorates diabetic cardiomyopathy by activating the PK2/PKR pathway</article-title>. <source>Front. Physiol.</source>
<volume>11</volume>, <fpage>425</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2020.00425</pub-id>
<pub-id pub-id-type="pmid">32508669</pub-id>
<pub-id pub-id-type="pmcid">PMC7252307</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zamanian</surname><given-names>M. Y.</given-names></name>
<name name-style="western"><surname>Golmohammadi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yumashev</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Hjazi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Toama</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>AbdRabou</surname><given-names>M. A.</given-names></name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Effects of metformin on cancers in experimental and clinical studies: focusing on autophagy and AMPK/mTOR signaling pathways</article-title>. <source>Cell Biochem. Funct.</source>
<volume>42</volume> (<issue>4</issue>), <fpage>e4071</fpage>. <pub-id pub-id-type="doi">10.1002/cbf.4071</pub-id>
<pub-id pub-id-type="pmid">38863255</pub-id>
</mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Bawa-Khalfe</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>L. S.</given-names></name>
<name name-style="western"><surname>Lyu</surname><given-names>Y. L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L. F.</given-names></name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Identification of the molecular basis of doxorubicin-induced cardiotoxicity</article-title>. <source>Nat. Med.</source>
<volume>18</volume> (<issue>11</issue>), <fpage>1639</fpage>–<lpage>1642</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2919</pub-id>
<pub-id pub-id-type="pmid">23104132</pub-id>
</mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>C. S.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y. L.</given-names></name>
<etal/>
</person-group> (<year>2014</year>). <article-title>The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism</article-title>. <source>Cell Metab.</source>
<volume>20</volume> (<issue>3</issue>), <fpage>526</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.06.014</pub-id>
<pub-id pub-id-type="pmid">25002183</pub-id>
</mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Hua</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway</article-title>. <source>Aging</source>
<volume>12</volume> (<issue>23</issue>), <fpage>24270</fpage>–<lpage>24287</lpage>. <pub-id pub-id-type="doi">10.18632/aging.202143</pub-id>
<pub-id pub-id-type="pmid">33232283</pub-id>
<pub-id pub-id-type="pmcid">PMC7762510</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Metformin decreased myocardial fibrosis and apoptosis in hyperhomocysteinemia -induced cardiac hypertrophy</article-title>. <source>Curr. Res. Transl. Med.</source>
<volume>69</volume> (<issue>1</issue>), <fpage>103270</fpage>. <pub-id pub-id-type="doi">10.1016/j.retram.2020.103270</pub-id>
<pub-id pub-id-type="pmid">33268288</pub-id>
</mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Pang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Diabetic cardiomyopathy: clinical phenotype and practice</article-title>. <source>Front. Endocrinol. (Lausanne)</source>
<volume>13</volume>, <fpage>1032268</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.1032268</pub-id>
<pub-id pub-id-type="pmid">36568097</pub-id>
<pub-id pub-id-type="pmcid">PMC9767955</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Myers</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Fenyk-Melody</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Role of AMP-activated protein kinase in mechanism of metformin action</article-title>. <source>J. Clinical Investigation</source>
<volume>108</volume> (<issue>8</issue>), <fpage>1167</fpage>–<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1172/JCI13505</pub-id>
<pub-id pub-id-type="pmid">11602624</pub-id>
<pub-id pub-id-type="pmcid">PMC209533</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zilinyi</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Czompa</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Czegledi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Gajtko</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Pituk</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Lekli</surname><given-names>I.</given-names></name>
<etal/>
</person-group> (<year>2018</year>). <article-title>The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy</article-title>. <source>Molecules</source>
<volume>23</volume> (<issue>5</issue>). <pub-id pub-id-type="doi">10.3390/molecules23051184</pub-id>
<pub-id pub-id-type="pmid">29762537</pub-id>
<pub-id pub-id-type="pmcid">PMC6100061</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zilov</surname><given-names>A. V.</given-names></name>
<name name-style="western"><surname>Abdelaziz</surname><given-names>S. I.</given-names></name>
<name name-style="western"><surname>AlShammary</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Al Zahrani</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Amir</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Assaad Khalil</surname><given-names>S. H.</given-names></name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Mechanisms of action of metformin with special reference to cardiovascular protection</article-title>. <source>Diabetes Metab. Res. Rev.</source>
<volume>35</volume> (<issue>7</issue>), <fpage>e3173</fpage>. <pub-id pub-id-type="doi">10.1002/dmrr.3173</pub-id>
<pub-id pub-id-type="pmid">31021474</pub-id>
<pub-id pub-id-type="pmcid">PMC6851752</pub-id></mixed-citation></ref></ref-list><sec id="s12"><title>Glossary</title><def-list><def-item><term id="G1-fphar.2026.1681783">
T2DM
</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term id="G2-fphar.2026.1681783">
AMPK
</term><def><p>AMP-activated protein kinase</p></def></def-item><def-item><term id="G3-fphar.2026.1681783">
LKB1
</term><def><p>liver kinase B1</p></def></def-item><def-item><term id="G4-fphar.2026.1681783">
ETC
</term><def><p>electron transport chain</p></def></def-item><def-item><term id="G5-fphar.2026.1681783">
mTOR
</term><def><p>mammalian of mechanistic target of rapamycin</p></def></def-item><def-item><term id="G6-fphar.2026.1681783">
TFEB
</term><def><p>Transcription Factor EB</p></def></def-item><def-item><term id="G7-fphar.2026.1681783">
eNOS
</term><def><p>endothelial nitric oxide synthase</p></def></def-item><def-item><term id="G8-fphar.2026.1681783">
PEN2
</term><def><p>presenilin enhancer 2</p></def></def-item><def-item><term id="G9-fphar.2026.1681783">
mGPD2
</term><def><p>mitochondrial glycerol-3-phosphate dehydrogenase</p></def></def-item><def-item><term id="G10-fphar.2026.1681783">
G3P
</term><def><p>glycerol-3-phosphate</p></def></def-item><def-item><term id="G11-fphar.2026.1681783">
DHAP
</term><def><p>dihydroxyacetone phosphate</p></def></def-item><def-item><term id="G12-fphar.2026.1681783">
ULK
</term><def><p>unc-51 like autophagy activating kinase</p></def></def-item><def-item><term id="G13-fphar.2026.1681783">
LV
</term><def><p>left ventricle</p></def></def-item><def-item><term id="G14-fphar.2026.1681783">
LVEF
</term><def><p>Left Ventricular Ejection Fraction</p></def></def-item><def-item><term id="G15-fphar.2026.1681783">
CAD
</term><def><p>coronary artery disease</p></def></def-item><def-item><term id="G16-fphar.2026.1681783">
AMI
</term><def><p>acute myocardial infarction</p></def></def-item><def-item><term id="G17-fphar.2026.1681783">
STEMI
</term><def><p>ST-Elevation Myocardial Infarction</p></def></def-item><def-item><term id="G18-fphar.2026.1681783">
I/R
</term><def><p>ischemia-reperfusion</p></def></def-item><def-item><term id="G19-fphar.2026.1681783">
NLRP3
</term><def><p>NLR Family Pyrin Domain Containing 3</p></def></def-item><def-item><term id="G20-fphar.2026.1681783">
ROS
</term><def><p>reactive oxygen species</p></def></def-item><def-item><term id="G21-fphar.2026.1681783">
mPTP
</term><def><p>mitochondrial permeability transition pore</p></def></def-item><def-item><term id="G22-fphar.2026.1681783">
LPS
</term><def><p>Lipopolysaccharide</p></def></def-item><def-item><term id="G23-fphar.2026.1681783">
MMP
</term><def><p>matrix metalloproteinase</p></def></def-item><def-item><term id="G24-fphar.2026.1681783">
TIMP-1
</term><def><p>Tissue Inhibitor of Metalloproteinases-1</p></def></def-item><def-item><term id="G25-fphar.2026.1681783">
HF
</term><def><p>Heart failure</p></def></def-item><def-item><term id="G26-fphar.2026.1681783">
DCM
</term><def><p>Diabetic cardiomyopathy</p></def></def-item><def-item><term id="G27-fphar.2026.1681783">
LDH
</term><def><p>lactate dehydrogenase</p></def></def-item><def-item><term id="G28-fphar.2026.1681783">
PPARγ
</term><def><p>peroxisome-proliferator-activated receptor γ</p></def></def-item><def-item><term id="G29-fphar.2026.1681783">
PGC-1α
</term><def><p>PPARγ co-activator-1α</p></def></def-item><def-item><term id="G30-fphar.2026.1681783">
GDF-15
</term><def><p>growth differentiation factor 15</p></def></def-item><def-item><term id="G31-fphar.2026.1681783">
PK2
</term><def><p>Prokineticin 2</p></def></def-item><def-item><term id="G32-fphar.2026.1681783">
PKR1/2
</term><def><p>prokineticin receptor1/2</p></def></def-item><def-item><term id="G33-fphar.2026.1681783">
GSK3B
</term><def><p>Glycogen synthase kinase-3 beta</p></def></def-item><def-item><term id="G34-fphar.2026.1681783">
TNF-α
</term><def><p>Tumor Necrosis Factor alpha</p></def></def-item><def-item><term id="G35-fphar.2026.1681783">
CRP
</term><def><p>C-reactive protein</p></def></def-item><def-item><term id="G36-fphar.2026.1681783">
DOX
</term><def><p>doxorubicin</p></def></def-item><def-item><term id="G37-fphar.2026.1681783">
IL-6
</term><def><p>Interleukin 6</p></def></def-item><def-item><term id="G38-fphar.2026.1681783">
PINK1
</term><def><p>phosphatase and tensin homolog (PTEN)–induced putative kinase 1</p></def></def-item><def-item><term id="G39-fphar.2026.1681783">
Mfn1/2
</term><def><p>Mitofusins1/2</p></def></def-item><def-item><term id="G40-fphar.2026.1681783">
GLP-1
</term><def><p>glucagon-like peptide-1</p></def></def-item><def-item><term id="G41-fphar.2026.1681783">
SGLT1
</term><def><p>sodium-glucose cotransporter 1</p></def></def-item><def-item><term id="G42-fphar.2026.1681783">
RCT
</term><def><p>Randomized Controlled Trial</p></def></def-item></def-list></sec></back></article><article xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">670</journal-id><journal-id journal-id-type="pmc-domain">frontneurosci</journal-id><journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1662-4548</issn><issn pub-type="epub">1662-453X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12909493</article-id><article-id pub-id-type="pmcid-ver">PMC12909493.1</article-id><article-id pub-id-type="pmcaid">12909493</article-id><article-id pub-id-type="pmcaiid">12909493</article-id><article-id pub-id-type="doi">10.3389/fnins.2026.1760558</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Mini Review</subject></subj-group></article-categories><title-group><article-title>Insulin resistance in cerebral small vessel disease: a mini review</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Su</surname><given-names initials="C">Chen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>†</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1879029"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Cui</surname><given-names initials="Z">Zhigang</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>†</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Guo</surname><given-names initials="J">Junhong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1814268"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib></contrib-group><aff id="aff1"><label>1</label><institution>First Clinical Medical College, Shanxi Medical University</institution>, <city>Taiyuan</city>, <country country="cn">China</country></aff><aff id="aff2"><label>2</label><institution>Department of Neurology, First Hospital of Shanxi Medical University</institution>, <city>Taiyuan</city>, <country country="cn">China</country></aff><aff id="aff3"><label>3</label><institution>Department of Neurology, The Third People's Hospital of Datong</institution>, <city>Datong</city>, <state>Shanxi</state>, <country country="cn">China</country></aff><author-notes><corresp id="c001"><label>*</label>Correspondence: Junhong Guo, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:neuroguo@163.com">neuroguo@163.com</email></corresp><fn fn-type="equal" id="fn0001"><label>†</label><p>These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-03"><day>03</day><month>2</month><year>2026</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2026</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">506445</issue-id><elocation-id>1760558</elocation-id><history><date date-type="received"><day>04</day><month>12</month><year>2025</year></date><date date-type="rev-recd"><day>15</day><month>1</month><year>2026</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 00:25:13.357"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 Su, Cui and Guo.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Su, Cui and Guo</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2026-02-03">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fnins-20-1760558.pdf"/><abstract><p>Cerebral small vessel disease (CSVD) is a leading cause of stroke and vascular cognitive impairment, but its metabolic determinants are not fully understood. Emerging evidence indicates that insulin resistance (IR) plays a crucial role in CSVD through vascular, inflammatory, and oxidative mechanisms. Higher IR levels may be associated with greater burdens of white matter hyperintensities, lacunes, cerebral microbleeds, and enlarged perivascular spaces. Mechanistic studies suggest that IR impairs endothelial nitric oxide signaling, disrupts the blood–brain barrier, promotes vascular remodeling, and alters astrocytic aquaporin-4 polarization, which together aggravate both ischemic and hemorrhagic microvascular injury. Clinically, IR represents a modifiable target, and interventions that reduce IR, including the use of pioglitazone, metformin, glucagon-like peptide-1 receptor agonists, physical activity, and dietary modification, may help slow CSVD progression. This mini review summarizes current epidemiological and mechanistic evidence linking IR to CSVD and highlights the potential of metabolic regulation as a strategy to prevent or mitigate small-vessel–related brain injury.</p></abstract><kwd-group><kwd>blood–brain barrier</kwd><kwd>cerebral small vessel disease</kwd><kwd>endothelial dysfunction</kwd><kwd>insulin resistance</kwd><kwd>treatment</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Shanxi Province Basic Research Program [grant number 202303021212373].</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="78"/><page-count count="8"/><word-count count="6659"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neuroenergetics and Brain Health</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>Cerebral small vessel disease (CSVD) encompasses a group of pathological processes affecting the small arteries, arterioles, venules, and capillaries of the brain (<xref rid="ref69" ref-type="bibr">Wardlaw et al., 2019</xref>). The characteristic imaging features include white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), enlarged perivascular spaces (EPVS), and brain atrophy (<xref rid="ref68" ref-type="bibr">Wardlaw et al., 2013</xref>). CSVD is highly prevalent in the elderly population and has been recognized as a major contributor to stroke, cognitive decline, gait disturbances, and late-life depression (<xref rid="ref47" ref-type="bibr">Ostergaard et al., 2016</xref>; <xref rid="ref58" ref-type="bibr">Su et al., 2022</xref>; <xref rid="ref11" ref-type="bibr">Castello et al., 2022</xref>). With the global demographic shift toward aging societies, the burden of CSVD is expected to increase substantially, making the identification of modifiable risk factors and the elucidation of underlying mechanisms of paramount importance.</p><p>Insulin resistance (IR), defined as a diminished sensitivity of peripheral tissues to insulin, represents a key metabolic abnormality that underlies type 2 diabetes and metabolic syndrome (<xref rid="ref40" ref-type="bibr">Lee et al., 2022</xref>). Beyond its established role in cardiovascular disease, IR has recently gained attention as a potential contributor to cerebrovascular pathology (<xref rid="ref64" ref-type="bibr">Tian et al., 2022</xref>; <xref rid="ref21" ref-type="bibr">Frosch et al., 2017</xref>). While extensive research has focused on the link between IR and large-vessel atherosclerosis (<xref rid="ref51" ref-type="bibr">Reardon et al., 2018</xref>), emerging evidence suggests that IR may also play a critical role in microvascular injury and, consequently, in the pathogenesis of CSVD (<xref rid="ref45" ref-type="bibr">Nam et al., 2020</xref>; <xref rid="ref62" ref-type="bibr">Teng et al., 2022</xref>). Notably, these effects may occur independently of overt diabetes, highlighting IR as an early and potentially modifiable risk factor (<xref rid="ref72" ref-type="bibr">Wu et al., 2022</xref>).</p><p>Despite growing interest, the relationship between IR and CSVD remains insufficiently explored. Most existing studies have focused on diabetic populations or metabolic syndrome as a whole, while fewer have specifically addressed IR. Moreover, diverse surrogate indices have been used to quantify IR, which complicates comparisons across studies and limits clinical translation. This review aims to summarize current evidence linking IR with CSVD, discuss potential mechanisms, evaluate different IR indices, and highlight the clinical implications for prevention and management.</p></sec><sec id="sec2"><label>2</label><title>Assessment of IR</title><p>The hyperinsulinemic–euglycemic clamp is the gold standard for assessing IR but is impractical for large studies (<xref rid="ref17" ref-type="bibr">Delai et al., 2022</xref>; <xref rid="ref36" ref-type="bibr">Kim, 2009</xref>). Therefore, several surrogate indices have been developed using routine biochemical parameters. The homeostasis model assessment of insulin resistance (HOMA-IR) is the most commonly used, though it depends on fasting insulin assays (<xref rid="ref4" ref-type="bibr">Anoop et al., 2021</xref>; <xref rid="ref37" ref-type="bibr">Kosmas et al., 2024</xref>; <xref rid="ref2" ref-type="bibr">Aliyu et al., 2025</xref>). It is calculated as fasting insulin (μU/mL) × fasting glucose (mmol/L) divided by 22.5. The triglyceride-glucose (TyG) index, calculated from fasting triglycerides and glucose, has gained popularity as a simple and reliable alternative that correlates well with clamp results and predicts metabolic and vascular outcomes (<xref rid="ref55" ref-type="bibr">Son et al., 2022</xref>; <xref rid="ref70" ref-type="bibr">Wu et al., 2021</xref>). It is defined as the natural logarithm of [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Other indices, including the metabolic score for insulin resistance (METS-IR) and the quantitative insulin sensitivity check index (QUICKI), also provide feasible measures of insulin sensitivity (<xref rid="ref7" ref-type="bibr">Bello-Chavolla et al., 2018</xref>; <xref rid="ref54" ref-type="bibr">Skrha et al., 2004</xref>). Among these, the TyG index appears particularly suitable for CSVD research because it is simple, reproducible, and applicable in large-scale epidemiological settings.</p></sec><sec id="sec3"><label>3</label><title>Relationship between IR and imaging findings of CSVD</title><sec id="sec4"><label>3.1</label><title>White matter hyperintensities</title><p>WMH are hyperintense lesions on T2-weighted or fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI), located in periventricular and deep white matter, and represent chronic ischemic injury of presumed vascular origin (<xref rid="ref68" ref-type="bibr">Wardlaw et al., 2013</xref>). Multiple cross-sectional studies have demonstrated that IR is positively associated with WMH burden. In a Korean cohort of over 2,600 individuals, the TyG index showed a dose–response association with WMH volume, outperforming HOMA-IR in multivariable models (<xref rid="ref45" ref-type="bibr">Nam et al., 2020</xref>). Similarly, in Japanese non-diabetic stroke patients, higher HOMA-IR independently predicted severe WMH grades (<xref rid="ref34" ref-type="bibr">Katsumata et al., 2010</xref>). In the Maastricht Study, WMH volumes increased progressively from normoglycemia to prediabetes and type 2 diabetes, highlighting that metabolic dysfunction contributes to white matter injury even before overt diabetes develops (<xref rid="ref65" ref-type="bibr">van Agtmaal et al., 2018</xref>). Nevertheless, prospective evidence is less consistent: in the Atherosclerosis Risk in Communities cohort, baseline IR score did not significantly predict 10-year WMH progression after full adjustment (<xref rid="ref16" ref-type="bibr">Dearborn et al., 2015</xref>). The IR score was constructed via principal components analysis to capture combined effects of central obesity and insulin resistance, based on key variables like body mass index, waist measures, insulin, and HOMA-IR. Overall, a potential relationship between IR and WMH has been reported in cross-sectional studies, but longitudinal evidence remains limited or inconclusive.</p></sec><sec id="sec5"><label>3.2</label><title>Lacunes</title><p>Lacunes are defined as round or ovoid, cerebrospinal fluid-filled cavities (3–15 mm in diameter) in the deep gray or white matter, reflecting the chronic sequelae of small subcortical infarcts (<xref rid="ref68" ref-type="bibr">Wardlaw et al., 2013</xref>). Both cross-sectional and longitudinal data support a robust association between IR and lacunes. In the cohort of non-diabetic adults, higher IR was significantly associated with lacunes, with mediation analyses showing that 30–40% of the effect was explained by elevated blood pressure (<xref rid="ref76" ref-type="bibr">Zhou et al., 2024</xref>). In a large community-based cohort of nondiabetic adults in southeastern China, lower HOMA-IR was independently associated with a higher prevalence of lacunes and greater total CSVD burden (<xref rid="ref77" ref-type="bibr">Zhou et al., 2022</xref>). Longitudinally, a cohort demonstrated that an IR composite score predicted incident lacunes over a decade, even when WMH progression was not significantly associated (<xref rid="ref16" ref-type="bibr">Dearborn et al., 2015</xref>). Together, these findings suggest that IR may be an important risk factor for lacunes, potentially acting both directly and through its association with hypertension.</p></sec><sec id="sec6"><label>3.3</label><title>Cerebral microbleeds</title><p>CMBs appear as small hypointense lesions on T2-weighted or susceptibility-weighted MRI, reflecting hemosiderin deposits from prior microhemorrhage (<xref rid="ref68" ref-type="bibr">Wardlaw et al., 2013</xref>). The evidence linking IR to CMBs is limited but emerging. A hospital-based study in older Chinese CSVD patients found that individuals in the highest HOMA-IR quartile had more than double the odds of CMBs compared with the lowest quartile, independent of age, blood pressure, and lipids (<xref rid="ref41" ref-type="bibr">Li et al., 2023</xref>). In contrast, the Maastricht Study, conducted in a middle-aged community sample, found no significant association between prediabetes or diabetes and CMBs prevalence (<xref rid="ref65" ref-type="bibr">van Agtmaal et al., 2018</xref>). These discrepancies may reflect differences in population risk profiles, lesion burden, and imaging sensitivity. Importantly, the distribution of CMBs reflects distinct pathologies. Deep CMBs, located in the basal ganglia, thalamus, or brainstem, are linked to hypertensive arteriopathy. Lobar CMBs, found in cortical and subcortical areas, are more typical of cerebral amyloid angiopathy (CAA) (<xref rid="ref38" ref-type="bibr">Kuo et al., 2024</xref>). Current evidence suggests that IR may preferentially contribute to deep CMBs through mechanisms related to vascular remodeling and endothelial dysfunction in the context of metabolic syndrome (<xref rid="ref24" ref-type="bibr">Hayden, 2024</xref>). However, most existing studies do not distinguish between deep and lobar lesions. Failure to account for this anatomical heterogeneity may obscure mechanistic links and dilute observed associations. Future longitudinal studies with topographic stratification of CMBs are needed to clarify whether IR specifically contributes to hypertensive-type microangiopathy versus amyloid-related vascular injury.</p></sec><sec id="sec7"><label>3.4</label><title>Enlarged perivascular spaces</title><p>EPVS are small, linear or ovoid fluid-filled structures along penetrating vessels, visible on T2-weighted MRI, and reflect impaired interstitial fluid clearance and microvascular dysfunction (<xref rid="ref68" ref-type="bibr">Wardlaw et al., 2013</xref>). Emerging evidence implicates IR in EPVS burden. In a study of 235 non-diabetic Chinese older adults, higher HOMA-IR values were independently associated with a greater likelihood of moderate-to-severe basal ganglia EPVS, even after adjustment for conventional vascular risk factors (<xref rid="ref71" ref-type="bibr">Wu et al., 2020</xref>). Another study using the TyG index showed significant associations with moderate-to-severe EPVS, particularly in the centrum semiovale (<xref rid="ref9" ref-type="bibr">Cai et al., 2022</xref>). Although regional differences were noted, current studies suggest a potential link between IR and perivascular dysfunction. However, the evidence is limited, predominantly cross-sectional, and requires confirmation in longitudinal studies across diverse populations.</p></sec><sec id="sec8"><label>3.5</label><title>Global CSVD burden</title><p>Composite CSVD scores integrate WMH, lacunes, CMBs, and EPVS, offering a holistic measure of microvascular injury. Studies consistently report that insulin-resistant individuals have higher total CSVD scores. In a Chinese cohort of 156 non-diabetic adults, IR was significantly associated with greater CSVD burden, with a dose-dependent relationship between HOMA-IR levels and total CSVD score (<xref rid="ref73" ref-type="bibr">Yang et al., 2019</xref>). In a larger cohort, IR was similarly linked to higher CSVD scores, with mediation analyses showing that 40–50% of the effect was explained by blood pressure (<xref rid="ref76" ref-type="bibr">Zhou et al., 2024</xref>). These findings imply that IR may contribute to diffuse cerebral microvascular injury, potentially affecting multiple lesion types rather than a single marker.</p><p>Taken together, IR appears to be associated with multiple MRI features of CSVD, with the most consistent evidence for lacunes and EPVS. The link to CMBs and WMH is supported by preliminary studies but remains less conclusive (<xref rid="tab1" ref-type="table">Table 1</xref>). Importantly, IR correlates with higher global CSVD burden, reinforcing its role as a systemic risk factor for diffuse microvascular injury. While part of this effect is mediated by hypertension and obesity, consistent independent associations suggest direct microvascular effects of IR. Longitudinal and interventional studies are needed to establish causality and to evaluate whether reducing IR can slow CSVD progression.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Key studies examining the association between IR and CSVD imaging markers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" char="×" rowspan="1" colspan="1">Study</th><th align="char" valign="top" char="×" rowspan="1" colspan="1">Study design</th><th align="char" valign="top" char="×" rowspan="1" colspan="1">Metabolic exposure</th><th align="char" valign="top" char="×" rowspan="1" colspan="1">CSVD marker(s)</th><th align="char" valign="top" char="×" rowspan="1" colspan="1">Main findings</th></tr></thead><tbody><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref45" ref-type="bibr">Nam et al. (2020)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">TyG index</td><td align="left" valign="top" rowspan="1" colspan="1">WMH</td><td align="left" valign="top" rowspan="1" colspan="1">Higher TyG index was associated with WMH volume</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref34" ref-type="bibr">Katsumata et al. (2010)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="left" valign="top" rowspan="1" colspan="1">WMH</td><td align="left" valign="top" rowspan="1" colspan="1">Higher IR was associated with greater WMH severity</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref65" ref-type="bibr">van Agtmaal et al. (2018)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">OGTT</td><td align="left" valign="top" rowspan="1" colspan="1">WMH, CMBs</td><td align="left" valign="top" rowspan="1" colspan="1">Prediabetes and T2DM were associated with greater WMH burden, but not CMBs</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref16" ref-type="bibr">Dearborn et al. (2015)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Longitudinal</td><td align="left" valign="top" rowspan="1" colspan="1">IR score</td><td align="left" valign="top" rowspan="1" colspan="1">WMH, Lacunes</td><td align="left" valign="top" rowspan="1" colspan="1">IR score was associated with lacunes but not WMH progression</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref76" ref-type="bibr">Zhou et al. (2024)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="left" valign="top" rowspan="1" colspan="1">Lacunes, WMH, Global CSVD burden</td><td align="left" valign="top" rowspan="1" colspan="1">Blood pressure partially mediated the association between IR and lacunes, WMH, and CSVD total burden</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref77" ref-type="bibr">Zhou et al. (2022)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR, Insulin sensitivity index (ISI<sub>0,120</sub>)</td><td align="left" valign="top" rowspan="1" colspan="1">Lacunes, WMH, Global CSVD burden</td><td align="left" valign="top" rowspan="1" colspan="1">Higher IR was associated with greater lacunes, WMH, and CSVD total burden</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref41" ref-type="bibr">Li et al. (2023)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="left" valign="top" rowspan="1" colspan="1">CMBs</td><td align="left" valign="top" rowspan="1" colspan="1">IR was associated with presence and burden of CMBs</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref71" ref-type="bibr">Wu et al. (2020)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="left" valign="top" rowspan="1" colspan="1">EPVS</td><td align="left" valign="top" rowspan="1" colspan="1">Higher IR was independently associated with EPVS burden</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref9" ref-type="bibr">Cai et al. (2022)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">TyG index</td><td align="left" valign="top" rowspan="1" colspan="1">EPVS</td><td align="left" valign="top" rowspan="1" colspan="1">Elevated TyG index was associated with increased EPVS</td></tr><tr><td align="left" valign="top" char="×" rowspan="1" colspan="1">
<xref rid="ref73" ref-type="bibr">Yang et al. (2019)</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="left" valign="top" rowspan="1" colspan="1">Global CSVD burden</td><td align="left" valign="top" rowspan="1" colspan="1">IR was an independent risk factor for total CSVD burden</td></tr></tbody></table><table-wrap-foot><p>CMBs, cerebral microbleeds; CSVD, cerebral small vessel disease; EPVS, enlarged perivascular spaces; HOMA-IR, homeostasis model assessment of insulin resistance; IR, insulin resistance; TyG, triglyceride-glucose; OGTT, oral glucose tolerance test; WMH, white matter hyperintensities.</p></table-wrap-foot></table-wrap></sec></sec><sec id="sec9"><label>4</label><title>Pathophysiological mechanisms linking IR and CSVD</title><p>IR influences CSVD through a multifactorial network of interrelated mechanisms. These include endothelial dysfunction, blood–brain barrier (BBB) disruption, vascular remodeling via hypertension, chronic inflammation and oxidative stress, impaired glymphatic clearance, and neurovascular unit (NVU) dysfunction involving glial activation (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Each of these processes contributes to the development of hallmark CSVD features such as WMH, lacunes, CMBs, and EPVS.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Mechanistic pathways linking insulin resistance to cerebral small vessel disease and potential interventions. <bold>(A)</bold> Insulin resistance may promote CSVD via endothelial dysfunction, BBB disruption, inflammation, vascular remodeling, impaired clearance, and glial activation. <bold>(B)</bold> Both pharmacologic and lifestyle interventions targeting insulin resistance show potential to mitigate CSVD-related brain injury through diverse mechanisms and evidence levels.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fnins-20-1760558-g001.jpg"><alt-text content-type="machine-generated">Diagram titled "Insulin resistance" with two main sections. A) Shows insulin resistance linked to endothelial dysfunction, hypertension, blood-brain barrier disruption, inflammation, glial activation, and impaired clearance. B) Lists interventions like medication and lifestyle changes targeting insulin resistance, detailing mechanisms, outcomes, and evidence levels, mentioning various studies such as RCT and observational studies.</alt-text></graphic></fig><sec id="sec10"><label>4.1</label><title>Endothelial dysfunction and impaired nitric oxide signaling</title><p>In healthy endothelium, insulin signaling activates the PI3K–Akt pathway, stimulating nitric oxide (NO) production and vasodilation (<xref rid="ref26" ref-type="bibr">Hernandez-Resendiz et al., 2015</xref>). In IR, this pathway is selectively impaired, while the MAPK pathway remains active, leading to diminished NO bioavailability, increased endothelin-1 release, and heightened vasoconstriction (<xref rid="ref50" ref-type="bibr">Quinones et al., 2005</xref>; <xref rid="ref6" ref-type="bibr">Bai et al., 2022</xref>). Clinical studies link higher HOMA-IR or TyG index to reduced flow-mediated dilation and elevated circulating markers of endothelial injury (<xref rid="ref78" ref-type="bibr">Zhu et al., 2024</xref>; <xref rid="ref8" ref-type="bibr">Berezin et al., 2016</xref>). Experimental data further show that IR diminishes endothelial NO synthase (eNOS) activity, resulting in microvascular rarefaction and impaired cerebral autoregulation (<xref rid="ref32" ref-type="bibr">Katakam et al., 2012</xref>; <xref rid="ref10" ref-type="bibr">Carter et al., 2023</xref>). These abnormalities reduce perfusion in vulnerable white matter regions, predisposing to WMH and lacunes formation.</p></sec><sec id="sec11"><label>4.2</label><title>Blood–brain barrier disruption</title><p>The BBB maintains brain homeostasis through tight junctions between endothelial cells (<xref rid="ref5" ref-type="bibr">Ashby and Mack, 2021</xref>). IR-related endothelial dysfunction destabilizes these junctions by reducing NO signaling, increasing oxidative stress, and upregulating matrix metalloproteinases (MMP)(<xref rid="ref3" ref-type="bibr">Alshammari et al., 2024</xref>; <xref rid="ref13" ref-type="bibr">Chen et al., 2025</xref>; <xref rid="ref15" ref-type="bibr">de Aquino et al., 2018</xref>). Dynamic MRI studies demonstrate increased BBB permeability in IR and diabetic patients, even before overt CSVD lesions appear (<xref rid="ref14" ref-type="bibr">Chen et al., 2021</xref>; <xref rid="ref56" ref-type="bibr">Starr et al., 2003</xref>; <xref rid="ref75" ref-type="bibr">Zhang et al., 2019</xref>). Disrupted barriers permit extravasation of plasma proteins and inflammatory mediators, which accumulate in perivascular spaces, exacerbate white matter injury, and promote CMBs formation (<xref rid="ref31" ref-type="bibr">Jia et al., 2024</xref>). IR-related BBB impairment therefore contributes to both ischemic and hemorrhagic CSVD manifestations.</p></sec><sec id="sec12"><label>4.3</label><title>Hypertension and vascular remodeling</title><p>IR is closely linked to hypertension via sympathetic activation, sodium retention, and vascular stiffness (<xref rid="ref53" ref-type="bibr">Sinha and Haque, 2022</xref>). Chronic hyperinsulinemia augments renin-angiotensin-aldosterone system (RAAS) activity and enhances vascular smooth muscle growth, promoting arteriolosclerosis and lipohyalinosis (<xref rid="ref61" ref-type="bibr">Tanaka, 2020</xref>). Pathological remodeling narrows the lumen of penetrating arterioles, leading to chronic hypoperfusion and increased risk of vessel rupture (<xref rid="ref33" ref-type="bibr">Katsi et al., 2024</xref>). Epidemiological mediation analyses confirm that blood pressure partially explains the association between IR and CSVD burden, particularly lacunes and WMH (<xref rid="ref76" ref-type="bibr">Zhou et al., 2024</xref>). Thus, IR-driven hypertension acts as both a mediator and amplifier of microvascular pathology.</p></sec><sec id="sec13"><label>4.4</label><title>Inflammation and oxidative stress</title><p>IR represents a state of chronic low-grade inflammation characterized by elevated tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP)(<xref rid="ref60" ref-type="bibr">Suren Garg et al., 2023</xref>). These mediators activate NF-κB signaling in endothelial cells, increasing adhesion molecule expression and leukocyte infiltration (<xref rid="ref44" ref-type="bibr">Menon et al., 2023</xref>). Concurrently, oxidative stress from mitochondrial ROS and advanced glycation end-products (AGEs) damages vessel walls, uncouples eNOS, and promotes demyelination (<xref rid="ref30" ref-type="bibr">Ji et al., 2022</xref>; <xref rid="ref22" ref-type="bibr">Haase et al., 2024</xref>; <xref rid="ref19" ref-type="bibr">Deng et al., 2018</xref>; <xref rid="ref25" ref-type="bibr">He et al., 2019</xref>). Clinical data indicate that inflammatory biomarkers, including TNF-α, IL-6, and CRP, are positively correlated with CSVD lesion load (<xref rid="ref74" ref-type="bibr">Zhang et al., 2022</xref>). Experimental studies further demonstrate that antioxidants ameliorate white matter damage in diabetic animal models (<xref rid="ref67" ref-type="bibr">Wang et al., 2019</xref>; <xref rid="ref28" ref-type="bibr">Infante-Garcia and Garcia-Alloza, 2019</xref>). Together, inflammation and oxidative stress provide a unifying mechanism for WMH progression, lacune formation, and microvascular fragility underlying CMBs (<xref rid="ref66" ref-type="bibr">Wan et al., 2023</xref>).</p></sec><sec id="sec14"><label>4.5</label><title>Impaired glymphatic and perivascular clearance</title><p>The glymphatic system removes interstitial solutes via perivascular pathways (<xref rid="ref27" ref-type="bibr">Iliff et al., 2012</xref>). IR impairs this system through multiple mechanisms. It causes arterial stiffening that reduces perivascular pulsatility, promotes vascular wall thickening that narrows perivascular channels, and induces astrocytic dysfunction that disturbs aquaporin-4 (AQP-4) polarization (<xref rid="ref43" ref-type="bibr">Meng et al., 2023</xref>; <xref rid="ref48" ref-type="bibr">Ozkan et al., 2023</xref>). Rodent models of diabetes demonstrate slowed interstitial clearance and cognitive decline (<xref rid="ref18" ref-type="bibr">Deng et al., 2024</xref>), while human studies reveal associations between IR indices and increased EPVS burden (<xref rid="ref71" ref-type="bibr">Wu et al., 2020</xref>; <xref rid="ref9" ref-type="bibr">Cai et al., 2022</xref>). Impaired clearance leads to accumulation of metabolic wastes such as amyloid-β, further damaging vessel walls and aggravating CSVD pathology (<xref rid="ref39" ref-type="bibr">Lee et al., 2024</xref>).</p></sec><sec id="sec15"><label>4.6</label><title>Glial activation and neurovascular unit dysfunction</title><p>The NVU coordinates neuronal activity with vascular responses. IR disrupts this system by inducing astrocytic gliosis, microglial activation, and pericyte degeneration (<xref rid="ref23" ref-type="bibr">Hayden, 2019</xref>). Microglia in insulin-resistant states adopt a pro-inflammatory phenotype, releasing cytokines and proteases that injure myelin and endothelium (<xref rid="ref59" ref-type="bibr">Sun and Mi, 2025</xref>; <xref rid="ref29" ref-type="bibr">Jackson et al., 2020</xref>). Astrocytic dysfunction impairs gliovascular coupling, reducing adaptive vasodilation in response to neuronal demand (<xref rid="ref42" ref-type="bibr">Masamoto et al., 2015</xref>). These changes result in chronic hypoperfusion, demyelination, and progressive WMH. Functional imaging studies corroborate impaired cerebrovascular reactivity in individuals with IR (<xref rid="ref12" ref-type="bibr">Chantler et al., 2015</xref>), linking NVU dysfunction to cognitive decline in CSVD.</p><p>Taken together, IR exerts a multifaceted impact on the cerebral microvasculature. Endothelial dysfunction, BBB breakdown, hypertension, inflammation, impaired clearance, and glial activation converge to drive CSVD pathology. These mechanisms act synergistically, creating a self-perpetuating cycle of vascular injury. Future studies should focus on disentangling direct versus indirect effects of IR, clarifying longitudinal causal pathways, and evaluating whether interventions that reduce IR can prevent or mitigate CSVD progression.</p></sec></sec><sec id="sec16"><label>5</label><title>Potential intervention strategies</title><p>Given the converging epidemiological and mechanistic evidence that IR contributes to the burden of CSVD, the clinical implications of these findings deserve attention. Recognition of IR as a modifiable metabolic abnormality provides opportunities for both risk stratification and therapeutic intervention in patients with CSVD (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p><p>Targeting IR pharmacologically represents a promising therapeutic approach. A large randomized controlled trial showed that pioglitazone reduced recurrent vascular events in non-diabetic patients with IR after ischemic stroke, supporting the therapeutic potential of targeting metabolic dysfunction in cerebrovascular disease (<xref rid="ref35" ref-type="bibr">Kernan et al., 2016</xref>). Long-term metformin use has been linked to lower CSVD burden and better post-stroke outcomes in patients with CSVD, though causal effects remain to be validated in randomized trials (<xref rid="ref63" ref-type="bibr">Teng et al., 2021</xref>; <xref rid="ref1" ref-type="bibr">Akiyama et al., 2024</xref>). Glucagon-like peptide-1 receptor agonists, which improve metabolic control and reduce stroke incidence in large outcome trials, offer another promising class with potential cerebrovascular benefits (<xref rid="ref57" ref-type="bibr">Stefanou et al., 2024</xref>). Although these agents have not yet been specifically validated for CSVD, their pleiotropic effects, including improvement of endothelial function, reduction of inflammation, and mitigation of vascular risk, make them attractive candidates for future investigations.</p><p>Lifestyle interventions remain the cornerstone of IR management and may indirectly protect the cerebral microvasculature. Aerobic exercise reduces IR, enhances cerebrovascular reactivity, and has been linked to healthier white matter integrity (<xref rid="ref49" ref-type="bibr">Pani et al., 2022</xref>). Adherence to Mediterranean-style diets correlates with lower white matter lesion volumes and improved microstructural connectivity, likely via anti-inflammatory and antioxidative effects (<xref rid="ref52" ref-type="bibr">Samuelsson et al., 2023</xref>). Sustained weight loss reduces IR and may modestly attenuate lesion progression (<xref rid="ref20" ref-type="bibr">Espeland et al., 2016</xref>). Multidomain approaches, as tested in the Finnish Geriatric Intervention Study, integrate diet, exercise, and vascular risk management, and have shown cognitive benefits in at-risk populations, suggesting potential applicability to CSVD prevention (<xref rid="ref46" ref-type="bibr">Ngandu et al., 2015</xref>).</p></sec><sec id="sec17"><label>6</label><title>Limitations and interpretation of current evidence</title><p>Despite accumulating evidence linking IR to CSVD, several important limitations should be considered when interpreting current findings. First, CSVD represents a heterogeneous spectrum of imaging phenotypes, including WMH, lacunes, CMBs, and EPVS, which may reflect partially distinct underlying pathophysiological processes. Associations observed for one CSVD marker may not necessarily generalize to others, and pooling these phenotypes may obscure marker-specific relationships.</p><p>Second, most available studies are cross-sectional in design, limiting causal inference. Although longitudinal data suggest that IR may precede progression of certain CSVD features, these findings remain inconsistent and are vulnerable to residual confounding. In particular, hypertension and obesity frequently coexist with IR and may act as important confounders or mediators, especially for deep perforator-related lesions. Disentangling the independent contribution of IR from these closely related vascular risk factors remains challenging.</p><p>Third, interventional evidence linking improvement of IR to changes in CSVD imaging outcomes is scarce. While pharmacological and lifestyle interventions targeting IR have demonstrated benefits on vascular events and cognitive outcomes, dedicated trials incorporating CSVD imaging endpoints are largely lacking. As a result, current conclusions regarding therapeutic modulation of CSVD through IR should be viewed as hypothesis-generating rather than definitive.</p><p>Overall, these limitations underscore the need for well-designed longitudinal studies and interventional trials with standardized CSVD imaging outcomes to clarify causal pathways and clinical relevance.</p></sec><sec id="sec18"><label>7</label><title>Conclusion and outlook</title><p>IR is an emerging and potentially modifiable contributor to CSVD. Based on current evidence, the following points summarize key insights:</p><p>While most evidence linking IR to CSVD is cross-sectional, emerging studies suggest associations across multiple imaging markers.</p><p>IR may influence CSVD through endothelial dysfunction, inflammation, and impaired vascular homeostasis.</p><p>Its modifiable nature makes IR a potential target for interventions aiming to preserve brain health.</p><p>Longitudinal and interventional studies with neuroimaging endpoints are needed to clarify causal pathways and therapeutic value.</p></sec></body><back><fn-group><fn fn-type="edited-by" id="fn0002"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1107090/overview" ext-link-type="uri">Rita Machado De Olivera</ext-link>, New University of Lisbon, Portugal</p></fn><fn fn-type="reviewed-by" id="fn0003"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3010617/overview" ext-link-type="uri">Vanessa Estato</ext-link>, Oswaldo Cruz Foundation (Fiocruz), Brazil</p></fn></fn-group><sec sec-type="author-contributions" id="sec19"><title>Author contributions</title><p>CS: Conceptualization, Investigation, Software, Validation, Visualization, Writing – original draft. ZC: Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – original draft. JG: Funding acquisition, Supervision, Validation, Writing – review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec20"><title>Conflict of interest</title><p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec21"><title>Generative AI statement</title><p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec22"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akiyama</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Yamashiro</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ninomiya</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Uemura</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hattori</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ihara</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Neuroprotective effects of oral metformin before stroke on cerebral small-vessel disease</article-title>. <source>J. Neurol. Sci.</source>
<volume>456</volume>:<fpage>122812</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2023.122812</pub-id>, <pub-id pub-id-type="pmid">38043334</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aliyu</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Toor</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Abdalhakam</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Elrayess</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Abou Samra</surname><given-names>A. B.</given-names></name>
<name name-style="western"><surname>Albagha</surname><given-names>O. M. E.</given-names></name></person-group> (<year>2025</year>). <article-title>Evaluating indices of insulin resistance and estimating the prevalence of insulin resistance in a large biobank cohort</article-title>. <source>Front Endocrinol (Lausanne)</source>
<volume>16</volume>:<fpage>1591677</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fendo.2025.1591677</pub-id>, <pub-id pub-id-type="pmid">40421243</pub-id>
<pub-id pub-id-type="pmcid">PMC12104043</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshammari</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Alshehri</surname><given-names>A. O.</given-names></name>
<name name-style="western"><surname>Alqahtani</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>M. R.</given-names></name>
<name name-style="western"><surname>Bakhrebah</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Alasmari</surname><given-names>F.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Increased permeability of the blood-brain barrier in a diabetic mouse model (Lepr(db)(/db) mice)</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>25</volume>:<fpage>7768</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25147768</pub-id>, <pub-id pub-id-type="pmid">39063010</pub-id>
<pub-id pub-id-type="pmcid">PMC11276738</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anoop</surname><given-names>S. S.</given-names></name>
<name name-style="western"><surname>Dasgupta</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Rebekah</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Jose</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Inbakumari</surname><given-names>M. P.</given-names></name>
<name name-style="western"><surname>Finney</surname><given-names>G.</given-names></name>
<etal/></person-group>. (<year>2021</year>). <article-title>Lipid accumulation product (LAP) as a potential index to predict risk of insulin resistance in young, non-obese Asian Indian males from southern India: observations from hyperinsulinemic-euglycemic clamp studies</article-title>. <source>BMJ Open Diabetes Res. Care</source>
<volume>9</volume>:<fpage>e002414</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjdrc-2021-002414</pub-id>, <pub-id pub-id-type="pmid">34531243</pub-id>
<pub-id pub-id-type="pmcid">PMC8449941</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashby</surname><given-names>J. W.</given-names></name>
<name name-style="western"><surname>Mack</surname><given-names>J. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Endothelial control of cerebral blood flow</article-title>. <source>Am. J. Pathol.</source>
<volume>191</volume>, <fpage>1906</fpage>–<lpage>1916</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2021.02.023</pub-id>, <pub-id pub-id-type="pmid">33713686</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Advances in the role of endothelial cells in cerebral small vessel disease</article-title>. <source>Front. Neurol.</source>
<volume>13</volume>:<fpage>861714</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2022.861714</pub-id>, <pub-id pub-id-type="pmid">35481273</pub-id>
<pub-id pub-id-type="pmcid">PMC9035937</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bello-Chavolla</surname><given-names>O. Y.</given-names></name>
<name name-style="western"><surname>Almeda-Valdes</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Gomez-Velasco</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Viveros-Ruiz</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Cruz-Bautista</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Romo-Romo</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2018</year>). <article-title>METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes</article-title>. <source>Eur. J. Endocrinol.</source>
<volume>178</volume>, <fpage>533</fpage>–<lpage>544</lpage>. doi: <pub-id pub-id-type="doi">10.1530/EJE-17-0883</pub-id>, <pub-id pub-id-type="pmid">29535168</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berezin</surname><given-names>A. E.</given-names></name>
<name name-style="western"><surname>Kremzer</surname><given-names>A. A.</given-names></name>
<name name-style="western"><surname>Cammarota</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Zulli</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Petrovic</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Martell-Claros</surname><given-names>N.</given-names></name>
<etal/></person-group>. (<year>2016</year>). <article-title>Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure</article-title>. <source>Clin. Chem. Lab. Med.</source>
<volume>54</volume>, <fpage>1259</fpage>–<lpage>1267</lpage>. doi: <pub-id pub-id-type="doi">10.1515/cclm-2015-0605</pub-id><pub-id pub-id-type="pmid">26656612</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>The triglyceride glucose index is a risk factor for enlarged perivascular space</article-title>. <source>Front. Neurol.</source>
<volume>13</volume>:<fpage>782286</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2022.782286</pub-id>, <pub-id pub-id-type="pmid">35185759</pub-id>
<pub-id pub-id-type="pmcid">PMC8854364</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>K. J.</given-names></name>
<name name-style="western"><surname>Ward</surname><given-names>A. T.</given-names></name>
<name name-style="western"><surname>Kellawan</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Harrell</surname><given-names>J. W.</given-names></name>
<name name-style="western"><surname>Peltonen</surname><given-names>G. L.</given-names></name>
<name name-style="western"><surname>Roberts</surname><given-names>G. S.</given-names></name>
<etal/></person-group>. (<year>2023</year>). <article-title>Reduced basal macrovascular and microvascular cerebral blood flow in young adults with metabolic syndrome: potential mechanisms</article-title>. <source>J. Appl. Physiol. (1985)</source>
<volume>135</volume>, <fpage>94</fpage>–<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1152/japplphysiol.00688.2022</pub-id>, <pub-id pub-id-type="pmid">37199780</pub-id>
<pub-id pub-id-type="pmcid">PMC10292973</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castello</surname><given-names>J. P.</given-names></name>
<name name-style="western"><surname>Pasi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kubiszewski</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Abramson</surname><given-names>J. R.</given-names></name>
<name name-style="western"><surname>Charidimou</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kourkoulis</surname><given-names>C.</given-names></name>
<etal/></person-group>. (<year>2022</year>). <article-title>Cerebral small vessel disease and depression among intracerebral hemorrhage survivors</article-title>. <source>Stroke</source>
<volume>53</volume>, <fpage>523</fpage>–<lpage>531</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.121.035488</pub-id>, <pub-id pub-id-type="pmid">34587793</pub-id>
<pub-id pub-id-type="pmcid">PMC8792169</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chantler</surname><given-names>P. D.</given-names></name>
<name name-style="western"><surname>Shrader</surname><given-names>C. D.</given-names></name>
<name name-style="western"><surname>Tabone</surname><given-names>L. E.</given-names></name>
<name name-style="western"><surname>d'Audiffret</surname><given-names>A. C.</given-names></name>
<name name-style="western"><surname>Huseynova</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Brooks</surname><given-names>S. D.</given-names></name>
<etal/></person-group>. (<year>2015</year>). <article-title>Cerebral cortical microvascular rarefaction in metabolic syndrome is dependent on insulin resistance and loss of nitric oxide bioavailability</article-title>. <source>Microcirculation</source>
<volume>22</volume>, <fpage>435</fpage>–<lpage>445</lpage>. doi: <pub-id pub-id-type="doi">10.1111/micc.12209</pub-id>, <pub-id pub-id-type="pmid">26014499</pub-id>
<pub-id pub-id-type="pmcid">PMC4551443</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Zeng</surname><given-names>D.</given-names></name>
<etal/></person-group>. (<year>2025</year>). <article-title>Mesenchymal stem cells restore endothelial integrity and alleviate emotional impairments in a diabetic mouse model via inhibition of MMP-9 activity</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>26</volume>:<fpage>3355</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms26073355</pub-id>, <pub-id pub-id-type="pmid">40244194</pub-id>
<pub-id pub-id-type="pmcid">PMC11989596</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y. C.</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>B. Z.</given-names></name>
<name name-style="western"><surname>Shu</surname><given-names>Y. C.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>Y. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Spatiotemporal dynamics of cerebral vascular permeability in type 2 diabetes-related cerebral Microangiopathy</article-title>. <source>Front Endocrinol (Lausanne)</source>
<volume>12</volume>:<fpage>805637</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fendo.2021.805637</pub-id>, <pub-id pub-id-type="pmid">35087478</pub-id>
<pub-id pub-id-type="pmcid">PMC8786705</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Aquino</surname><given-names>C. C.</given-names></name>
<name name-style="western"><surname>Leitao</surname><given-names>R. A.</given-names></name>
<name name-style="western"><surname>Oliveira Alves</surname><given-names>L. A.</given-names></name>
<name name-style="western"><surname>Coelho-Santos</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Guerrant</surname><given-names>R. L.</given-names></name>
<name name-style="western"><surname>Ribeiro</surname><given-names>C. F.</given-names></name>
<etal/></person-group>. (<year>2018</year>). <article-title>Effect of hypoproteic and high-fat diets on hippocampal blood-brain barrier permeability and oxidative stress</article-title>. <source>Front. Nutr.</source>
<volume>5</volume>:<fpage>131</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2018.00131</pub-id>, <pub-id pub-id-type="pmid">30687711</pub-id>
<pub-id pub-id-type="pmcid">PMC6333637</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dearborn</surname><given-names>J. L.</given-names></name>
<name name-style="western"><surname>Schneider</surname><given-names>A. L.</given-names></name>
<name name-style="western"><surname>Sharrett</surname><given-names>A. R.</given-names></name>
<name name-style="western"><surname>Mosley</surname><given-names>T. H.</given-names></name>
<name name-style="western"><surname>Bezerra</surname><given-names>D. C.</given-names></name>
<name name-style="western"><surname>Knopman</surname><given-names>D. S.</given-names></name>
<etal/></person-group>. (<year>2015</year>). <article-title>Obesity, insulin resistance, and incident small vessel disease on magnetic resonance imaging: atherosclerosis risk in communities study</article-title>. <source>Stroke</source>
<volume>46</volume>, <fpage>3131</fpage>–<lpage>3136</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.115.010060</pub-id>, <pub-id pub-id-type="pmid">26451022</pub-id>
<pub-id pub-id-type="pmcid">PMC4624467</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delai</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Gomes</surname><given-names>P. M.</given-names></name>
<name name-style="western"><surname>Foss-Freitas</surname><given-names>M. C.</given-names></name>
<name name-style="western"><surname>Elias</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Antonini</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Castro</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2022</year>). <article-title>Hyperinsulinemic-Euglycemic clamp strengthens the insulin resistance in nonclassical congenital adrenal hyperplasia</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>107</volume>, <fpage>e1106</fpage>–<lpage>e1116</lpage>. doi: <pub-id pub-id-type="doi">10.1210/clinem/dgab767</pub-id>, <pub-id pub-id-type="pmid">34693966</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Chronic sleep fragmentation impairs brain interstitial clearance in young wildtype mice</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>44</volume>, <fpage>1515</fpage>–<lpage>1531</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0271678X241230188</pub-id>, <pub-id pub-id-type="pmid">38639025</pub-id>
<pub-id pub-id-type="pmcid">PMC11418708</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>T. T.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>X. L.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>X. Y.</given-names></name>
<etal/></person-group>. (<year>2018</year>). <article-title>Irisin alleviates advanced glycation end products-induced inflammation and endothelial dysfunction via inhibiting ROS-NLRP3 Inflammasome signaling</article-title>. <source>Inflammation</source>
<volume>41</volume>, <fpage>260</fpage>–<lpage>275</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10753-017-0685-3</pub-id>, <pub-id pub-id-type="pmid">29098483</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espeland</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Erickson</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Neiberg</surname><given-names>R. H.</given-names></name>
<name name-style="western"><surname>Jakicic</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Wadden</surname><given-names>T. A.</given-names></name>
<name name-style="western"><surname>Wing</surname><given-names>R. R.</given-names></name>
<etal/></person-group>. (<year>2016</year>). <article-title>Brain and white matter Hyperintensity volumes after 10 years of random assignment to lifestyle intervention</article-title>. <source>Diabetes Care</source>
<volume>39</volume>, <fpage>764</fpage>–<lpage>771</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc15-2230</pub-id>, <pub-id pub-id-type="pmid">27208378</pub-id>
<pub-id pub-id-type="pmcid">PMC4839171</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frosch</surname><given-names>O. H.</given-names></name>
<name name-style="western"><surname>Yau</surname><given-names>P. L.</given-names></name>
<name name-style="western"><surname>Osorio</surname><given-names>R. S.</given-names></name>
<name name-style="western"><surname>Rusinek</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Storey</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Convit</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Insulin resistance among obese middle-aged is associated with decreased cerebrovascular reactivity</article-title>. <source>Neurology</source>
<volume>89</volume>, <fpage>249</fpage>–<lpage>255</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000004110</pub-id>, <pub-id pub-id-type="pmid">28615420</pub-id>
<pub-id pub-id-type="pmcid">PMC5513815</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haase</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kuhbandner</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Muhleck</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Gisevius</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Freudenstein</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Hirschberg</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Dietary galactose exacerbates autoimmune neuroinflammation via advanced glycation end product-mediated neurodegeneration</article-title>. <source>Front. Immunol.</source>
<volume>15</volume>:<fpage>1367819</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2024.1367819</pub-id>, <pub-id pub-id-type="pmid">39185426</pub-id>
<pub-id pub-id-type="pmcid">PMC11341352</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>M. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Type 2 diabetes mellitus increases the risk of late-onset Alzheimer's disease: ultrastructural remodeling of the neurovascular unit and diabetic gliopathy</article-title>. <source>Brain Sci.</source>
<volume>9</volume>:<fpage>262</fpage>. doi: <pub-id pub-id-type="doi">10.3390/brainsci9100262</pub-id>, <pub-id pub-id-type="pmid">31569571</pub-id>
<pub-id pub-id-type="pmcid">PMC6826500</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>M. R.</given-names></name></person-group> (<year>2024</year>). <article-title>Cerebral microbleeds associate with brain endothelial cell activation-dysfunction and blood-brain barrier dysfunction/disruption with increased risk of hemorrhagic and ischemic stroke</article-title>. <source>Biomedicine</source>
<volume>12</volume>:<fpage>1463</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biomedicines12071463</pub-id>, <pub-id pub-id-type="pmid">39062035</pub-id>
<pub-id pub-id-type="pmcid">PMC11274519</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2019</year>). <article-title>Doxorubicin induces Endotheliotoxicity and mitochondrial dysfunction via ROS/eNOS/NO pathway</article-title>. <source>Front. Pharmacol.</source>
<volume>10</volume>:<fpage>1531</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2019.01531</pub-id>, <pub-id pub-id-type="pmid">31998130</pub-id>
<pub-id pub-id-type="pmcid">PMC6965327</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez-Resendiz</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Palma-Flores</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>De Los Santos</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Roman-Anguiano</surname><given-names>N. G.</given-names></name>
<name name-style="western"><surname>Flores</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>de la Pena</surname><given-names>A.</given-names></name>
<etal/></person-group>. (<year>2015</year>). <article-title>Reduction of no-reflow and reperfusion injury with the synthetic 17beta-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade</article-title>. <source>Basic Res. Cardiol.</source>
<volume>110</volume>:<fpage>1</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00395-015-0464-y</pub-id>, <pub-id pub-id-type="pmid">25589055</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliff</surname><given-names>J. J.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Plogg</surname><given-names>B. A.</given-names></name>
<name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Gundersen</surname><given-names>G. A.</given-names></name>
<etal/></person-group>. (<year>2012</year>). <article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta</article-title>. <source>Sci. Transl. Med.</source>
<volume>4</volume>:<fpage>147ra111</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.3003748</pub-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id><pub-id pub-id-type="pmid">22896675</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Infante-Garcia</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Garcia-Alloza</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Review of the effect of natural compounds and extracts on neurodegeneration in animal models of diabetes mellitus</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>20</volume>:<fpage>2533</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms20102533</pub-id>, <pub-id pub-id-type="pmid">31126031</pub-id>
<pub-id pub-id-type="pmcid">PMC6566911</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Dumanli</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>M. H.</given-names></name>
<name name-style="western"><surname>Fagan</surname><given-names>S. C.</given-names></name>
<name name-style="western"><surname>Ergul</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Microglia knockdown reduces inflammation and preserves cognition in diabetic animals after experimental stroke</article-title>. <source>J. Neuroinflammation</source>
<volume>17</volume>:<fpage>137</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-020-01815-3</pub-id>, <pub-id pub-id-type="pmid">32345303</pub-id>
<pub-id pub-id-type="pmcid">PMC7189436</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Niu</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Qu</surname><given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>Trimethylamine N-oxide promotes demyelination in spontaneous hypertension rats through enhancing pyroptosis of oligodendrocytes</article-title>. <source>Front. Aging Neurosci.</source>
<volume>14</volume>:<fpage>963876</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2022.963876</pub-id>, <pub-id pub-id-type="pmid">36072486</pub-id>
<pub-id pub-id-type="pmcid">PMC9441869</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Sole-Guardia</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Kiliaan</surname><given-names>A. J.</given-names></name></person-group> (<year>2024</year>). <article-title>Blood-brain barrier pathology in cerebral small vessel disease</article-title>. <source>Neural Regen. Res.</source>
<volume>19</volume>, <fpage>1233</fpage>–<lpage>1240</lpage>. doi: <pub-id pub-id-type="doi">10.4103/1673-5374.385864</pub-id>, <pub-id pub-id-type="pmid">37905869</pub-id>
<pub-id pub-id-type="pmcid">PMC11467932</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katakam</surname><given-names>P. V.</given-names></name>
<name name-style="western"><surname>Snipes</surname><given-names>J. A.</given-names></name>
<name name-style="western"><surname>Steed</surname><given-names>M. M.</given-names></name>
<name name-style="western"><surname>Busija</surname><given-names>D. W.</given-names></name></person-group> (<year>2012</year>). <article-title>Insulin-induced generation of reactive oxygen species and uncoupling of nitric oxide synthase underlie the cerebrovascular insulin resistance in obese rats</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>32</volume>, <fpage>792</fpage>–<lpage>804</lpage>. doi: <pub-id pub-id-type="doi">10.1038/jcbfm.2011.181</pub-id>, <pub-id pub-id-type="pmid">22234336</pub-id>
<pub-id pub-id-type="pmcid">PMC3345912</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsi</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Mavroudis</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Liatakis</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Konstantinos</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Tsioufis</surname><given-names>K.</given-names></name></person-group> (<year>2024</year>). <article-title>Exploring the relationship between hypertension and cerebral microvascular disease</article-title>. <source>Diseases</source>
<volume>12</volume>:<fpage>266</fpage>. doi: <pub-id pub-id-type="doi">10.3390/diseases12110266</pub-id>, <pub-id pub-id-type="pmid">39589940</pub-id>
<pub-id pub-id-type="pmcid">PMC11592893</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katsumata</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Otori</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Nishiyama</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Okubo</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Nishiyama</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Nagayama</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2010</year>). <article-title>Correlation between insulin resistance and white matter lesions among non-diabetic patients with ischemic stroke</article-title>. <source>Neurol. Res.</source>
<volume>32</volume>, <fpage>743</fpage>–<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.1179/016164109X12608733393755</pub-id>, <pub-id pub-id-type="pmid">20223079</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kernan</surname><given-names>W. N.</given-names></name>
<name name-style="western"><surname>Viscoli</surname><given-names>C. M.</given-names></name>
<name name-style="western"><surname>Furie</surname><given-names>K. L.</given-names></name>
<name name-style="western"><surname>Young</surname><given-names>L. H.</given-names></name>
<name name-style="western"><surname>Inzucchi</surname><given-names>S. E.</given-names></name>
<name name-style="western"><surname>Gorman</surname><given-names>M.</given-names></name>
<etal/></person-group>. (<year>2016</year>). <article-title>Pioglitazone after ischemic stroke or transient ischemic attack</article-title>. <source>N. Engl. J. Med.</source>
<volume>374</volume>, <fpage>1321</fpage>–<lpage>1331</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1506930</pub-id>, <pub-id pub-id-type="pmid">26886418</pub-id>
<pub-id pub-id-type="pmcid">PMC4887756</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J. K.</given-names></name></person-group> (<year>2009</year>). <article-title>Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity <italic toggle="yes">in vivo</italic></article-title>. <source>Methods Mol. Biol.</source>
<volume>560</volume>, <fpage>221</fpage>–<lpage>238</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-59745-448-3_15</pub-id>, <pub-id pub-id-type="pmid">19504253</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosmas</surname><given-names>C. E.</given-names></name>
<name name-style="western"><surname>Sourlas</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Oikonomakis</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Zoumi</surname><given-names>E.-A.</given-names></name>
<name name-style="western"><surname>Papadimitriou</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kostara</surname><given-names>C. E.</given-names></name></person-group> (<year>2024</year>). <article-title>Biomarkers of insulin sensitivity/resistance</article-title>. <source>J. Int. Med. Res.</source>
<volume>52</volume>:<fpage>03000605241285550</fpage>. doi: <pub-id pub-id-type="doi">10.1177/03000605241285550</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>P. Y.</given-names></name>
<name name-style="western"><surname>Tsai</surname><given-names>H. H.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>B. C.</given-names></name>
<name name-style="western"><surname>Chiang</surname><given-names>P. T.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y. F.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Differences in lobar microbleed topography in cerebral amyloid angiopathy and hypertensive arteriopathy</article-title>. <source>Sci. Rep.</source>
<volume>14</volume>:<fpage>3774</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-54243-1</pub-id>, <pub-id pub-id-type="pmid">38355951</pub-id>
<pub-id pub-id-type="pmcid">PMC10866968</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>D. H.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>E. C.</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>S. W.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>M. R.</given-names></name>
<name name-style="western"><surname>Oh</surname><given-names>J. S.</given-names></name></person-group> (<year>2024</year>). <article-title>Pathogenesis of cerebral small vessel disease: role of the Glymphatic system dysfunction</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>25</volume>:<fpage>8752</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25168752</pub-id>, <pub-id pub-id-type="pmid">39201439</pub-id>
<pub-id pub-id-type="pmcid">PMC11354389</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S. H.</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>S. Y.</given-names></name>
<name name-style="western"><surname>Choi</surname><given-names>C. S.</given-names></name></person-group> (<year>2022</year>). <article-title>Insulin resistance: from mechanisms to therapeutic strategies</article-title>. <source>Diabetes Metab. J.</source>
<volume>46</volume>, <fpage>15</fpage>–<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.4093/dmj.2021.0280</pub-id>, <pub-id pub-id-type="pmid">34965646</pub-id>
<pub-id pub-id-type="pmcid">PMC8831809</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name></person-group> (<year>2023</year>). <article-title>Correlation between insulin resistance and cerebral microbleeds among Chinese patients with cerebral small vessel disease</article-title>. <source>J. Clin. Neurosci.</source>
<volume>111</volume>, <fpage>1</fpage>–<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jocn.2023.02.018</pub-id>, <pub-id pub-id-type="pmid">37032584</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masamoto</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Unekawa</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Toriumi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Takuwa</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Kawaguchi</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2015</year>). <article-title>Unveiling astrocytic control of cerebral blood flow with optogenetics</article-title>. <source>Sci. Rep.</source>
<volume>5</volume>:<fpage>11455</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep11455</pub-id>, <pub-id pub-id-type="pmid">26076820</pub-id>
<pub-id pub-id-type="pmcid">PMC4468581</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhuang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name>
<etal/></person-group>. (<year>2023</year>). <article-title>Function and therapeutic value of astrocytes in diabetic cognitive impairment</article-title>. <source>Neurochem. Int.</source>
<volume>169</volume>:<fpage>105591</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuint.2023.105591</pub-id>, <pub-id pub-id-type="pmid">37543309</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menon</surname><given-names>S. N.</given-names></name>
<name name-style="western"><surname>Zerin</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Ezewudo</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Simon</surname><given-names>N. P.</given-names></name>
<name name-style="western"><surname>Menon</surname><given-names>S. N.</given-names></name>
<name name-style="western"><surname>Daniel</surname><given-names>M. L.</given-names></name>
<etal/></person-group>. (<year>2023</year>). <article-title>Neflamapimod inhibits endothelial cell activation, adhesion molecule expression, leukocyte attachment and vascular inflammation by inhibiting p38 MAPKalpha and NF-kappaB signaling</article-title>. <source>Biochem. Pharmacol.</source>
<volume>214</volume>:<fpage>115683</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2023.115683</pub-id><pub-id pub-id-type="pmid">37429422</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>K. W.</given-names></name>
<name name-style="western"><surname>Kwon</surname><given-names>H. M.</given-names></name>
<name name-style="western"><surname>Jeong</surname><given-names>H. Y.</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>J. H.</given-names></name>
<name name-style="western"><surname>Kwon</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Jeong</surname><given-names>S. M.</given-names></name></person-group> (<year>2020</year>). <article-title>High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study</article-title>. <source>Cardiovasc. Diabetol.</source>
<volume>19</volume>:<fpage>53</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12933-020-01031-6</pub-id>, <pub-id pub-id-type="pmid">32375783</pub-id>
<pub-id pub-id-type="pmcid">PMC7201807</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngandu</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Lehtisalo</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Solomon</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Levalahti</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Ahtiluoto</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Antikainen</surname><given-names>R.</given-names></name>
<etal/></person-group>. (<year>2015</year>). <article-title>A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial</article-title>. <source>Lancet</source>
<volume>385</volume>, <fpage>2255</fpage>–<lpage>2263</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60461-5</pub-id>, <pub-id pub-id-type="pmid">25771249</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostergaard</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Engedal</surname><given-names>T. S.</given-names></name>
<name name-style="western"><surname>Moreton</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Hansen</surname><given-names>M. B.</given-names></name>
<name name-style="western"><surname>Wardlaw</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Dalkara</surname><given-names>T.</given-names></name>
<etal/></person-group>. (<year>2016</year>). <article-title>Cerebral small vessel disease: capillary pathways to stroke and cognitive decline</article-title>. <source>J. Cereb. Blood Flow Metab.</source>
<volume>36</volume>, <fpage>302</fpage>–<lpage>325</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0271678X15606723</pub-id>, <pub-id pub-id-type="pmid">26661176</pub-id>
<pub-id pub-id-type="pmcid">PMC4759673</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozkan</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Cetin-Tas</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Sekerdag</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Yigit</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Shomalizadeh</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Sapanci</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2023</year>). <article-title>Hyperglycemia with or without insulin resistance triggers different structural changes in brain microcirculation and perivascular matrix</article-title>. <source>Metab. Brain Dis.</source>
<volume>38</volume>, <fpage>307</fpage>–<lpage>321</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11011-022-01100-7</pub-id><pub-id pub-id-type="pmid">36305999</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pani</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Eikenes</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Reitlo</surname><given-names>L. S.</given-names></name>
<name name-style="western"><surname>Stensvold</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Wisloff</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Haberg</surname><given-names>A. K.</given-names></name></person-group> (<year>2022</year>). <article-title>Effects of a 5-year exercise intervention on white matter microstructural Organization in Older Adults. A generation 100 substudy</article-title>. <source>Front. Aging Neurosci.</source>
<volume>14</volume>:<fpage>859383</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2022.859383</pub-id>, <pub-id pub-id-type="pmid">35847676</pub-id>
<pub-id pub-id-type="pmcid">PMC9278017</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinones</surname><given-names>M. J.</given-names></name>
<name name-style="western"><surname>Nicholas</surname><given-names>S. B.</given-names></name>
<name name-style="western"><surname>Lyon</surname><given-names>C. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Insulin resistance and the endothelium</article-title>. <source>Curr. Diab. Rep.</source>
<volume>5</volume>, <fpage>246</fpage>–<lpage>253</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11892-005-0018-z</pub-id>, <pub-id pub-id-type="pmid">16033673</pub-id>
</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reardon</surname><given-names>C. A.</given-names></name>
<name name-style="western"><surname>Lingaraju</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Schoenfelt</surname><given-names>K. Q.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Jacobs-El</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2018</year>). <article-title>Obesity and insulin resistance promote atherosclerosis through an IFNγ-regulated macrophage protein network</article-title>. <source>Cell Rep.</source>
<volume>23</volume>, <fpage>3021</fpage>–<lpage>3030</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.010</pub-id>, <pub-id pub-id-type="pmid">29874587</pub-id>
<pub-id pub-id-type="pmcid">PMC6082182</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samuelsson</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Marseglia</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Lindberg</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Westman</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Pereira</surname><given-names>J. B.</given-names></name>
<name name-style="western"><surname>Shams</surname><given-names>S.</given-names></name>
<etal/></person-group>. (<year>2023</year>). <article-title>Associations between dietary patterns and dementia-related neuroimaging markers</article-title>. <source>Alzheimers Dement.</source>
<volume>19</volume>, <fpage>4629</fpage>–<lpage>4640</lpage>. doi: <pub-id pub-id-type="doi">10.1002/alz.13048</pub-id>, <pub-id pub-id-type="pmid">36960849</pub-id>
</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Haque</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Insulin resistance is cheerfully hitched with hypertension</article-title>. <source>Life (Basel)</source>
<volume>12</volume>:<fpage>564</fpage>. doi: <pub-id pub-id-type="doi">10.3390/life12040564</pub-id>, <pub-id pub-id-type="pmid">35455055</pub-id>
<pub-id pub-id-type="pmcid">PMC9028820</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skrha</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Haas</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Sindelka</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Prazny</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Widimsky</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Cibula</surname><given-names>D.</given-names></name>
<etal/></person-group>. (<year>2004</year>). <article-title>Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>89</volume>, <fpage>135</fpage>–<lpage>141</lpage>. doi: <pub-id pub-id-type="doi">10.1210/jc.2002-030024</pub-id>, <pub-id pub-id-type="pmid">14715840</pub-id>
</mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>D. H.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H. S.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>Y. J.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>J. H.</given-names></name></person-group> (<year>2022</year>). <article-title>Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome</article-title>. <source>Nutr. Metab. Cardiovasc. Dis.</source>
<volume>32</volume>, <fpage>596</fpage>–<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.numecd.2021.11.017</pub-id>, <pub-id pub-id-type="pmid">35090800</pub-id>
</mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Wardlaw</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Ferguson</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>MacLullich</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Deary</surname><given-names>I. J.</given-names></name>
<name name-style="western"><surname>Marshall</surname><given-names>I.</given-names></name></person-group> (<year>2003</year>). <article-title>Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source>
<volume>74</volume>, <fpage>70</fpage>–<lpage>76</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.74.1.70</pub-id>, <pub-id pub-id-type="pmid">12486269</pub-id>
<pub-id pub-id-type="pmcid">PMC1738177</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanou</surname><given-names>M. I.</given-names></name>
<name name-style="western"><surname>Theodorou</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Malhotra</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Aguiar de Sousa</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Katan</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Palaiodimou</surname><given-names>L.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>Eur. Stroke J.</source>
<volume>9</volume>, <fpage>530</fpage>–<lpage>539</lpage>. doi: <pub-id pub-id-type="doi">10.1177/23969873241234238</pub-id>, <pub-id pub-id-type="pmid">38400569</pub-id>
<pub-id pub-id-type="pmcid">PMC11418422</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>Association of Cerebral Small Vessel Disease with Gait and Balance Disorders</article-title>. <source>Front. Aging Neurosci.</source>
<volume>14</volume>:<fpage>834496</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2022.834496</pub-id>, <pub-id pub-id-type="pmid">35875801</pub-id>
<pub-id pub-id-type="pmcid">PMC9305071</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mi</surname><given-names>W.</given-names></name></person-group> (<year>2025</year>). <article-title>Microglial insulin resistance drives neurodegeneration</article-title>. <source>Trends Endocrinol. Metab.</source>
<volume>36</volume>, <fpage>696</fpage>–<lpage>698</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tem.2025.06.006</pub-id>, <pub-id pub-id-type="pmid">40610268</pub-id>
</mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suren Garg</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kushwaha</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Dubey</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Gupta</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Association between obesity, inflammation and insulin resistance: insights into signaling pathways and therapeutic interventions</article-title>. <source>Diabetes Res. Clin. Pract.</source>
<volume>200</volume>:<fpage>110691</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.diabres.2023.110691</pub-id>, <pub-id pub-id-type="pmid">37150407</pub-id>
</mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Improving obesity and blood pressure</article-title>. <source>Hypertens. Res.</source>
<volume>43</volume>, <fpage>79</fpage>–<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41440-019-0348-x</pub-id>, <pub-id pub-id-type="pmid">31649313</pub-id>
</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2022</year>). <article-title>Triglyceride glucose index is associated with cerebral small vessel disease burden and cognitive impairment in elderly patients with type 2 diabetes mellitus</article-title>. <source>Front Endocrinol (Lausanne)</source>
<volume>13</volume>:<fpage>970122</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fendo.2022.970122</pub-id>, <pub-id pub-id-type="pmid">35992100</pub-id>
<pub-id pub-id-type="pmcid">PMC9390881</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Qi</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name>
<etal/></person-group>. (<year>2021</year>). <article-title>Long-term use of metformin is associated with reduced risk of cognitive impairment with alleviation of cerebral small vessel disease burden in patients with type 2 diabetes</article-title>. <source>Front. Aging Neurosci.</source>
<volume>13</volume>:<fpage>773797</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2021.773797</pub-id>, <pub-id pub-id-type="pmid">34776938</pub-id>
<pub-id pub-id-type="pmcid">PMC8589019</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>
<etal/></person-group>. (<year>2022</year>). <article-title>Insulin resistance mediates obesity-related risk of cardiovascular disease: a prospective cohort study</article-title>. <source>Cardiovasc. Diabetol.</source>
<volume>21</volume>:<fpage>289</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12933-022-01729-9</pub-id>, <pub-id pub-id-type="pmid">36564775</pub-id>
<pub-id pub-id-type="pmcid">PMC9789633</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Agtmaal</surname><given-names>M. J. M.</given-names></name>
<name name-style="western"><surname>Houben</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>de Wit</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Henry</surname><given-names>R. M. A.</given-names></name>
<name name-style="western"><surname>Schaper</surname><given-names>N. C.</given-names></name>
<name name-style="western"><surname>Dagnelie</surname><given-names>P. C.</given-names></name>
<etal/></person-group>. (<year>2018</year>). <article-title>Prediabetes is associated with structural brain abnormalities: the Maastricht study</article-title>. <source>Diabetes Care</source>
<volume>41</volume>, <fpage>2535</fpage>–<lpage>2543</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc18-1132</pub-id><pub-id pub-id-type="pmid">30327356</pub-id>
</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Dandu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>H.</given-names></name>
<etal/></person-group>. (<year>2023</year>). <article-title>Plasma inflammatory biomarkers in cerebral small vessel disease: a review</article-title>. <source>CNS Neurosci. Ther.</source>
<volume>29</volume>, <fpage>498</fpage>–<lpage>515</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cns.14047</pub-id>, <pub-id pub-id-type="pmid">36478511</pub-id>
<pub-id pub-id-type="pmcid">PMC9873530</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Zacharek</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Landschoot-Ward</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Chopp</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>
<etal/></person-group>. (<year>2019</year>). <article-title>ApoA-I mimetic peptide reduces vascular and white matter damage after stroke in Type-2 diabetic mice</article-title>. <source>Front. Neurosci.</source>
<volume>13</volume>:<fpage>1127</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2019.01127</pub-id>, <pub-id pub-id-type="pmid">31708728</pub-id>
<pub-id pub-id-type="pmcid">PMC6823666</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardlaw</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>E. E.</given-names></name>
<name name-style="western"><surname>Biessels</surname><given-names>G. J.</given-names></name>
<name name-style="western"><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Fazekas</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Frayne</surname><given-names>R.</given-names></name>
<etal/></person-group>. (<year>2013</year>). <article-title>Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration</article-title>. <source>Lancet Neurol.</source>
<volume>12</volume>, <fpage>822</fpage>–<lpage>838</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70124-8</pub-id>, <pub-id pub-id-type="pmid">23867200</pub-id>
<pub-id pub-id-type="pmcid">PMC3714437</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardlaw</surname><given-names>J. M.</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Dichgans</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Small vessel disease: mechanisms and clinical implications</article-title>. <source>Lancet Neurol.</source>
<volume>18</volume>, <fpage>684</fpage>–<lpage>696</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(19)30079-1</pub-id>, <pub-id pub-id-type="pmid">31097385</pub-id>
</mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T. D.</given-names></name>
<name name-style="western"><surname>Fawzy</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Brigham</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>McCormack</surname><given-names>M. C.</given-names></name>
<name name-style="western"><surname>Rosas</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Villareal</surname><given-names>D. T.</given-names></name>
<etal/></person-group>. (<year>2021</year>). <article-title>Association of triglyceride-glucose index and lung health: a population-based study</article-title>. <source>Chest</source>
<volume>160</volume>, <fpage>1026</fpage>–<lpage>1034</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chest.2021.03.056</pub-id>, <pub-id pub-id-type="pmid">33839084</pub-id>
<pub-id pub-id-type="pmcid">PMC8449007</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhong</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Insulin resistance is independently associated with enlarged perivascular space in the basal ganglia in nondiabetic healthy elderly population</article-title>. <source>Am. J. Alzheimers Dis. Other Dement.</source>
<volume>35</volume>:<fpage>1533317520912126</fpage>. doi: <pub-id pub-id-type="doi">10.1177/1533317520912126</pub-id>, <pub-id pub-id-type="pmid">32180437</pub-id>
<pub-id pub-id-type="pmcid">PMC10624068</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Association of triglyceride-glucose index with ischemic stroke recurrence in nondiabetic patients with small vessel occlusion: a multicenter hospital-based prospective cohort study</article-title>. <source>Cardiovasc. Diabetol.</source>
<volume>21</volume>:<fpage>250</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12933-022-01693-4</pub-id>, <pub-id pub-id-type="pmid">36397084</pub-id>
<pub-id pub-id-type="pmcid">PMC9673408</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name>
<etal/></person-group>. (<year>2019</year>). <article-title>Insulin resistance is a risk factor for overall cerebral small vessel disease burden in old nondiabetic healthy adult population</article-title>. <source>Front. Aging Neurosci.</source>
<volume>11</volume>:<fpage>127</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2019.00127</pub-id>, <pub-id pub-id-type="pmid">31249520</pub-id>
<pub-id pub-id-type="pmcid">PMC6582254</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D. D.</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Mu</surname><given-names>J. Y.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>Y. M.</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Han</surname><given-names>F.</given-names></name>
<etal/></person-group>. (<year>2022</year>). <article-title>Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study</article-title>. <source>Stroke Vasc Neurol</source>
<volume>7</volume>, <fpage>302</fpage>–<lpage>309</lpage>. doi: <pub-id pub-id-type="doi">10.1136/svn-2021-001102</pub-id>, <pub-id pub-id-type="pmid">35260438</pub-id>
<pub-id pub-id-type="pmcid">PMC9453831</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C. E.</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>S. M.</given-names></name>
<name name-style="western"><surname>Uiterwijk</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Backes</surname><given-names>W. H.</given-names></name>
<name name-style="western"><surname>Jansen</surname><given-names>J. F. A.</given-names></name>
<name name-style="western"><surname>Jeukens</surname><given-names>C.</given-names></name>
<etal/></person-group>. (<year>2019</year>). <article-title>Blood-brain barrier leakage in relation to white matter hyperintensity volume and cognition in small vessel disease and normal aging</article-title>. <source>Brain Imaging Behav.</source>
<volume>13</volume>, <fpage>389</fpage>–<lpage>395</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11682-018-9855-7</pub-id>, <pub-id pub-id-type="pmid">29572621</pub-id>
<pub-id pub-id-type="pmcid">PMC6486901</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Jing</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Blood pressure partially mediated the Association of Insulin Resistance and Cerebral Small Vessel Disease: a community-based study</article-title>. <source>J. Am. Heart Assoc.</source>
<volume>13</volume>:<fpage>e031723</fpage>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.123.031723</pub-id>, <pub-id pub-id-type="pmid">38390815</pub-id>
<pub-id pub-id-type="pmcid">PMC10944068</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Jing</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Cai</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name>
<etal/></person-group>. (<year>2022</year>). <article-title>Insulin resistance based on postglucose load measure is associated with prevalence and burden of cerebral small vessel disease</article-title>. <source>BMJ Open Diabetes Res. Care</source>
<volume>10</volume>:<fpage>e002897</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjdrc-2022-002897</pub-id>, <pub-id pub-id-type="pmid">36220196</pub-id>
<pub-id pub-id-type="pmcid">PMC9557259</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H. H.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y. C.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>L. C.</given-names></name>
<name name-style="western"><surname>Luo</surname><given-names>H. Y.</given-names></name>
<name name-style="western"><surname>Zong</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y. H.</given-names></name>
<etal/></person-group>. (<year>2024</year>). <article-title>Novel inflammatory and insulin resistance indices provide a clue in cerebral amyloid angiopathy</article-title>. <source>Sci. Rep.</source>
<volume>14</volume>:<fpage>11474</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-62280-z</pub-id>, <pub-id pub-id-type="pmid">38769356</pub-id>
<pub-id pub-id-type="pmcid">PMC11106308</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Diabetes</journal-id><journal-id journal-id-type="pmc-domain-id">1498</journal-id><journal-id journal-id-type="pmc-domain">wjd</journal-id><journal-id journal-id-type="publisher-id">WJD</journal-id><journal-title-group><journal-title>World Journal of Diabetes</journal-title></journal-title-group><issn pub-type="epub">1948-9358</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12897518</article-id><article-id pub-id-type="pmcid-ver">PMC12897518.1</article-id><article-id pub-id-type="pmcaid">12897518</article-id><article-id pub-id-type="pmcaiid">12897518</article-id><article-id pub-id-type="pmid">41696095</article-id><article-id pub-id-type="doi">10.4239/wjd.v17.i2.113992</article-id><article-id pub-id-type="other">jWJD.v17.i2.eid113992</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Basic Study</subject></subj-group></article-categories><title-group><article-title>Neuroprotective potential of a plant-based intervention in diabetic neuropathy: Biochemical and behavioral insights from a streptozotocin-induced rat model</article-title><alt-title>Kausar MA <italic toggle="yes">et al.</italic> Plant-based neuroprotection in DN rats</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kausar</surname><given-names initials="MA">Mohd Adnan</given-names></name><aff>Department of Biochemistry, College of Medicine, University of Ha’il, Hail 53962, Saudi Arabia. <email>ma.kausar@uoh.edu.sa</email></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parveen</surname><given-names initials="K">Kehkashan</given-names></name><aff>Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, Delhi, India</aff><aff>Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anwar</surname><given-names initials="S">Sadaf</given-names></name><aff>Department of Biochemistry, College of Medicine, University of Ha’il, Hail 53962, Saudi Arabia</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="YS">Yusuf Saleem</given-names></name><aff>Department of Anatomy, College of Medicine, University of Ha’il, Hail 53962, Saudi Arabia</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saleh</surname><given-names initials="AA">Ayman A</given-names></name><aff>Department of Pathology, College of Medicine, University of Ha’il, Hail 53962, Saudi Arabia</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmed</surname><given-names initials="MAA">Mai Ali Abdelfattah</given-names></name><aff>Department of Pediatrics, College of Medicine, University of Ha’il, Hail 53962, Saudi Arabia</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names initials="WA">Waseem Ahmad</given-names></name><aff>Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parvez</surname><given-names initials="S">Suhel</given-names></name><aff>Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, Delhi, India</aff></contrib></contrib-group><author-notes><fn><p>Author contributions: Kausar MA and Anwar S did conceptualization; Parveen K and Saleh AA contributed to methodology; Parvez S, Parveen K, Ahmed MAA, and Siddiqui WA did validation; Ahmed MAA contributed to formal analysis; Parveen K and Khan YS contributed to data curation; Parveen K and Kausar MA contributed to original draft preparation; Parvez S, Saleh AA, Siddiqui WA, and Khan YS did review and editing; Parveen K and Anwar S contributed to visualization; Parvez S, Siddiqui WA, and Kausar MA contributed to supervision; Anwar S and Kausar MA contributed to project administration; Kausar MA contributed to funding acquisition; Parvez S and Siddiqui WA contributed to resources. All authors have read and approved the submitted version.</p><p>Supported by Scientific Research Deanship at University of Ha’il, Saudi Arabia, No. RG-24082.</p><p>Corresponding author: Mohd Adnan Kausar, PhD, Professor, Department of Biochemistry, College of Medicine, University of Ha’il, University City-Hail, Al Khitah Street, Hail 53962, Saudi Arabia. <email>ma.kausar@uoh.edu.sa</email></p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>15</day><month>2</month><year>2026</year></pub-date><volume>17</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">507567</issue-id><elocation-id>113992</elocation-id><history><date date-type="received"><day>10</day><month>9</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>15</day><month>02</month><year>2026</year></date></event><event event-type="pmc-released-under-embargo"><date><day>13</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-16 15:25:13.347"><day>16</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/Licenses/by-nc/4.0/</uri></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="wjd-17-2-113992.pdf"/><abstract><sec><title>BACKGROUND</title><p>Diabetic neuropathy is a neurodegenerative complication of diabetes mellitus that occurs due to various factors, with oxidative stress, neuroinflammation and neurotrophic signalling impairment being the major causes.</p></sec><sec><title>AIM</title><p>To evaluate the neuroprotective effects of a polyherbal extract (PHE) prepared from <italic toggle="yes">Citrullus colocynthis</italic>, <italic toggle="yes">Curcuma longa</italic>, and <italic toggle="yes">Myristica fragrans</italic> in diabetic rats.</p></sec><sec><title>METHODS</title><p>Type 2 diabetes was induced in rats with a single intraperitoneal injection of streptozotocin, and those with fasting blood glucose levels of &gt; 250 mg/dL were included for further studies. The animals were categorised into five groups: Control, diabetic, diabetic + PHE, control + PHE and diabetic + metformin. These treatments were administered orally for 8 weeks. Behavioral tests comprised the hot plate, tail-flick, acetone drop and rotarod tests. Serum glucose, insulin, glycosylated haemoglobin and lipid profile analyses were performed, along with oxidative stress (malondialdehyde, reduced glutathione, superoxide dismutase, catalase and glutathione-S-transferase) and pro-inflammatory (tumour necrosis factor-α and interleukin-6) markers. Neurotrophic factors were measured, and the pancreas, liver and sciatic nerve were histologically examined.</p></sec><sec><title>RESULTS</title><p>This study demonstrated that PHE exerts a significant metabolic regulatory effect in streptozotocin-induced diabetic rat models. PHE treatment led to a marked reduction of 30.17% in fasting blood glucose levels, indicating potent antihyperglycemic activity, and also restored the lipid profile, enhanced antioxidant defenses, and reduced neuroinflammation. Serum insulin levels were significantly increased in diabetic rats receiving PHE, suggesting potential stimulation or preservation of pancreatic β-cells. Furthermore, behavioral impairments and histological damage were notably reversed following PHE administration.</p></sec><sec><title>CONCLUSION</title><p>The PHE derived from <italic toggle="yes">Curcuma longa, Myristica fragrans</italic>, and <italic toggle="yes">Citrullus colocynthis</italic> mitigates diabetic neuropathy through synergistic chemical-biological interactions targeting key mediators of oxidative stress and inflammation. These findings support the need for comprehensive evaluation of this formulation as a potential therapeutic candidate. This study enhances the current understanding of integrative approaches for managing chronic diabetic complications and provides further evidence supporting the therapeutic potential of plant-based compounds.</p></sec></abstract><kwd-group><kwd>Diabetes</kwd><kwd>Polyherbal extract</kwd><kwd>Oxidative stress</kwd><kwd>Inflammation</kwd><kwd>Neurotrophic factors</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<bold>Core Tip:</bold> Diabetic neuropathy represents the primary complication of diabetes, characterized by oxidative stress, inflammation, and impaired neurotrophic signaling. In streptozotocin-induced diabetic rats, a polyherbal extract derived from <italic toggle="yes">Curcuma longa, Myristica fragrans,</italic> and <italic toggle="yes">Citrullus colocynthis</italic> significantly enhanced metabolic parameters, improved lipid profile and promoted antioxidant defense, and neurobehavioral outcomes. It reversed behavioral impairments and histological damage by lowering hyperglycemia, raising insulin levels, and reducing neuroinflammation and oxidative stress. These findings demonstrate the neuroprotective qualities of polyherbal extract and encourage more research into plant-based remedies for diabetic neuropathy.</p><sec><title>INTRODUCTION</title><p>Diabetic neuropathy (DN) is a prevalent and painful complication of diabetes mellitus (DM) that affects approximately 50% of individuals with diabetes globally[<xref rid="B1" ref-type="bibr">1</xref>]. With progressive neuronal damage, signals are sent to nerve tissues in the pain sub-syndrome of neural disorders, resulting in numbness and impaired motor functions, thereby drastically affecting the quality of life. The pathogenesis of DN is multifaceted and involves oxidative stress, inflammation and dyslipoproteinaemia, all of which aggravate neuronal injury and dysfunction[<xref rid="B2" ref-type="bibr">2</xref>-<xref rid="B4" ref-type="bibr">4</xref>].</p><p>One of the most significant mechanisms in DN is oxidative stress, which is caused by the excessive generation of reactive oxygen species (ROS) under hyperglycaemic conditions[<xref rid="B5" ref-type="bibr">5</xref>]. The generation of ROS, along with reactive nitrogen species, overwhelms all endogenous antioxidant systems, including glutathione-S-transferase (GST), reduced glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD), leading to lipid peroxidation (LPO) and consequently cellular damage, evidenced by an increase in malondialdehyde (MDA) levels. These parameters can be improved by enhancing antioxidant defences, thus ameliorating oxidative damage and normalising neuronal function in diabetic models[<xref rid="B6" ref-type="bibr">6</xref>]. Furthermore, interleukin-1β (IL-1β) and tumour necrosis factor-alpha (TNF-α) are pro-inflammatory mediators associated with the chronic inflammatory process, aggravating neuronal degeneration <italic toggle="yes">via</italic> apoptosis and demyelination[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Dyslipidaemia, which usually co-exists with type 2 diabetes, is often ignored in DN. Lipid profile alterations, marked by increased triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and decreased high-density lipoprotein cholesterol (HDL-C) levels, result in peripheral nerve and endothelial dysfunction, fatty infiltration into Schwann cells and an augmented oxidative burden. These lipid disturbances compromise the vascular supply to nerves, contributing to the onset and severity of DN[<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Moreover, alterations in lipid profile interfere with the expression and action of neurotrophic factors in patients with diabetes, specifically brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are essential for neuronal survival, axonal growth and synaptic plasticity. NGF and BDNF may halt nerve damage and trigger functional recovery; thus, their deficiency in patients with diabetes appears to be correlated with sensory loss and impairment of nerve regeneration[<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>]. Recently, meta-analyses demonstrated that serum BDNF is considerably diminished in patients with type 2 diabetes having complications such as retinopathy and cognitive impairments[<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>]. Decreased NGF levels have also been linked to advancing DN[<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Considering the multifaceted nature of DN, therapeutic agents that can target several pathological pathways simultaneously have attracted immense research attention. Polyherbal formulations containing various medicinal plants with complementary pharmacological properties are promising candidates for therapeutic applications. Such formulations can potentially act synergistically and enhance the therapeutic effects while minimising the side effects. This approach is important because current pharmacotherapies have limitations, providing only symptomatic relief and failing to address the underlying disease. Therefore, the search for herbal medications continues to attract immense attention. Phytochemicals endowed with antioxidant, anti-inflammatory, lipid-modulating and neuroprotective activities are currently being investigated as multi-targeted agents for tackling DN[<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B15" ref-type="bibr">15</xref>]. In this study, a polyherbal extract (PHE) composed of three medicinally important plants, <italic toggle="yes">Citrullus colocynthis</italic> (<italic toggle="yes">C. colocynthis</italic>, bitter apple), <italic toggle="yes">Curcuma longa</italic> (<italic toggle="yes">C. longa</italic>, Turmeric) and, both the aril and nut of <italic toggle="yes">Myristica fragrans</italic> (<italic toggle="yes">M. fragrans</italic>, nutmeg and mace), was evaluated to explore the combined effects of its bioactive constituents and therapeutic properties. These plants have traditionally been used in Ayurvedic medicine owing to their anti-inflammatory, antioxidant and anti-diabetic properties.</p><p>
<italic toggle="yes">C. colocynthis</italic> (bitter apple) has been shown to exhibit hypoglycaemic and neuroprotective properties in diabetic models, and its phenolic and flavonoid constituents act as antioxidants and anti-inflammatory agents, ameliorating the metabolic and neural complications of DM[<xref rid="B16" ref-type="bibr">16</xref>]. <italic toggle="yes">C. longa</italic> (turmeric), a well-known source of curcumin, displays robust anti-inflammatory and antioxidant activity <italic toggle="yes">via</italic> the nuclear factor kappa B (NF-κB) pathway and the enhancement of the natural antioxidant system and neurotrophic factors such as BDNF[<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B19" ref-type="bibr">19</xref>]. <italic toggle="yes">M. fragrans</italic> (nutmeg) has been used traditionally owing to its neurotonic and anxiolytic effects[<xref rid="B20" ref-type="bibr">20</xref>]. Recent studies have shown that bioactive compounds can improve antioxidant defences and modulate neurotransmission, which are useful for nerve repair and regeneration[<xref rid="B21" ref-type="bibr">21</xref>-<xref rid="B23" ref-type="bibr">23</xref>].</p><p>To determine the effect of PHE on DN, a streptozotocin (STZ)-induced diabetic rat model was used. This study evaluated the manifestations of DN <italic toggle="yes">via</italic> behavioral tests; serum biochemical analyses; determination of oxidative stress markers, pro-inflammatory cytokines and neurotrophic factors; and histopathological examination of the liver, pancreas and sciatic nerve. Thus, this study aimed to elucidate the multifaceted effects of PHE and provide insights into the complex mechanisms by which it exerts its neuroprotective effects.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><p>STZ (Cat# S0130), metformin (Met, PHR1084-dia500MG), β-nicotinamide adenine dinucleotide 2’-phosphate reduced (Cat# N7505), thiobarbituric acid (Cat#T5500) and 1-chloro-2,4-dinitrobenzene (Cat#237329) were procured from Sigma-Aldrich, St. Louis, MO, United States. Other chemicals and reagents were of analytical grade.</p><sec><title>Plant preparation and ethanolic extraction</title><p>A fresh sample of <italic toggle="yes">C. colocynthis</italic> fruit, <italic toggle="yes">C. longa</italic> rhizome and <italic toggle="yes">M. fragrans</italic> (aril and nut) were procured from Herbal Garden, Jamia Hamdard. Botanical identification of each sample was done by the Taxonomist in Department of Botany, Jamia Hamdard, New Delhi, and voucher specimens were submitted for future reference. After being cleaned, the plant materials were dried and ground into a powder form with an electric grinder. Based on the results of the anti-diabetic pilot study performed in our laboratory, equal weights of each powdered plant part (1:1:1:1, w/w) were mixed. The coarse powder was then extracted for 3 days using Soxhlet equipment with ethanol. The extract was cooled and filtered to remove the leftover portions. Subsequently, concentrated extracts were dried using a low-pressure evaporator. The extracts were stored in an airtight bottle. PHE was dissolved using proper proportions in normal saline for the study.</p></sec><sec><title>Quality control and chemical standardisation</title><p>The PHE, employed throughout the study, was previously characterised using gas chromatography-mass spectrometry (GC-MS) by our group. The chromatographic fingerprint confirmed the presence of major bioactive constituents. The GC-MS spectra were reproducible across replicate analyses, validating batch-to-batch consistency and qualitative standardisation of the extract. Aliquots from this analytically characterised batch were used in this study to ensure experimental reproducibility.</p></sec><sec><title>Animals</title><p>This study was conducted using adult male Wistar rats (total 35) aged 7 weeks and weighing 150-200 g. To avoid hormonal fluctuations caused by the oestrus cycle in females that alter glucose metabolism, oxidative stress markers, and pain perception thresholds, male rats were exclusively selected. This approach ensured experimental consistency across biochemical and behavioral parameters. Standard laboratory settings were employed to house the rats, which included a 12-hour light/dark cycle, a controlled temperature of 25 °C and unrestricted access to water and a standard pellet diet.</p></sec><sec><title>Acute toxicity study</title><p>According to Organisation for Economic Co-operation and Development recommendations, the acute toxicity of PHE was examined using male Wistar rats weighing 130-140 g to determine the dose. Before the experiment, the animals were fasted for 6-8 hours. PHE was given <italic toggle="yes">via</italic> both intraperitoneal (i.p.) and oral routes at different dosages to assess safety. The LD50 was determined using the Miller and Tainter formula. PHE did not cause mortality even at a high dose of 2000 mg/kg orally, which is the route used for subsequent efficacy studies. Therefore, based on standard pharmacological conventions, 1/10<sup>th</sup> of the maximum non-lethal dose (200 mg/kg) was adopted as the effective working dose for this study[<xref rid="B24" ref-type="bibr">24</xref>]. Moreover, this dose aligns well with earlier reports confirming the biological efficacy of individual components, including <italic toggle="yes">C. longa</italic>, <italic toggle="yes">M. fragrans</italic> and <italic toggle="yes">C. colocynthis</italic>, in rodent models of diabetes[<xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref>]. Additionally, a preliminary pilot trial in our laboratory (100, 200, and 400 mg/kg) confirmed that 200 mg/kg consistently caused significant antihyperglycemic and behavioral improvements, with no observable signs of toxicity or stress responses, and was therefore selected for this study.</p></sec><sec><title>Experimental design</title><p>Blood glucose levels were measured in all animals before the administration of STZ. The animals whose blood glucose levels ranged from 70 to 100 mg/dL, as determined using the glucose oxidase-peroxidase method blood glucose diagnostic kit (Accurex<sup>®</sup>, India), were included in the study. STZ at a dose of 55 mg/kg was dissolved in citrate buffer and administered intraperitoneally to induce diabetes[<xref rid="B27" ref-type="bibr">27</xref>]. The blood glucose level was measured 72 hours after STZ administration. For DN investigation, animals with blood glucose levels &gt; 250 mg/dL were classified as diabetic. Previous studies, as well as experimental trials from our laboratory, served as the basis for the dosages and treatment plans.</p><p>Following the induction of diabetes, five groups with an equal number of rats (<italic toggle="yes">n</italic> = 7) were established. Control (C) group: Administered single i.p. injection of citrate buffer only; diabetic (D) group: Received a single dose of STZ (55 mg/kg body weight; i.p.) and no treatment; D + PHE: Treated with PHE orally (200 mg/kg body weight) starting from the 1<sup>st</sup> week; C + PHE: Included as negative control and received only PHE orally (200 mg/kg body weight); D + Met group: Included as a positive control and treated with Met orally (300 mg/kg body weight) starting from the 1<sup>st</sup> week. The treatment regimen was followed for 8 weeks. Body weights were recorded at weeks 0 and 8 after STZ administration.</p></sec><sec><title>Behavior test for validation of DN rats</title><p>After 8 weeks, behavioral parameters were analysed using the acetone drop, hot plate, tail-flick and rotarod tests.</p></sec><sec><title>Sample collection and tissue preparation</title><p>At the end of the experiment, the rats were anesthetized (<italic toggle="yes">e.g.</italic>, ketamine 80 mg/kg + xylazine 10 mg/kg, intraperitoneally) and their hearts were punctured using a sterile 5 mL syringe fitted with a 21-gauge needle to extract blood. Approximately 4-5 mL of whole blood was withdrawn from each rat. As this was a terminal collection, no repeated blood draws were performed. The collected blood was used for biochemical analysis. After blood collection, the animals were euthanized using CO<sub>2</sub> inhaler system available in the animal house facility. The sciatic nerve was excised and stored at -80 °C until further use. The liver and pancreas were excised swiftly from different experimental groups, along with the sciatic nerve, for histopathological analysis.</p></sec><sec><title>Behavioral assessment</title><p>
<bold>Acetone drop test:</bold> Acetone (100 μL) was applied to the plantar region of the right hind paw, and the chilling sensation was monitored for 1 minute[<xref rid="B28" ref-type="bibr">28</xref>].</p><p>
<bold>Hot plate test:</bold> With a 10-second cut-off time, the right hind paw of the rat was placed on a hot plate and maintained at 52 °C ± 2 °C. A heat hyperalgesic reaction was noted when the right hind limb was quickly withdrawn.</p><p>
<bold>Tail-flick test:</bold> A modified version of the protocol of D’Amour and Smith[<xref rid="B29" ref-type="bibr">29</xref>] was used to perform this test. The tail was immersed in a beaker containing water maintained at 65 °C ± 5 °C. Tail-flick latency was recorded to measure the temperature sensitivity of the rats. The prompt removal of the tail from the plantar device indicated the onset of neuropathic pain. A period of 10 seconds was set as the cut-off for this experiment.</p><p>
<bold>Rotarod test:</bold> Before sacrificing the rats, the rotarod test was performed using the Omni Rotor (Omnitech Electronics, Inc., Columbus, OH, United States) to determine motor impairment, as described previously[<xref rid="B30" ref-type="bibr">30</xref>]. The equipment featured a revolving rod with a 75-mm diameter, divided into four compartments, allowing for the simultaneous testing of four animals. The time spent by each animal was recorded, with a 5-minute gap, for a maximum duration of 180 seconds for each trial throughout the three trials. The time from 0.1 seconds to the rat falling to the ground was automatically recorded by the device. The cut-off limit was set at 180 seconds, and the pace was maintained at 10 revolutions per minute. The mean time of the three trials for which the rat remained on the rotating rod was used to calculate the score.</p></sec><sec><title>Determination of metabolic panel markers</title><p>Serum glucose concentration was estimated at the end of the study using the glucose oxidase-peroxidase method with a commercially available kit (Crest Biosystems, Goa, India). Serum insulin level was measured using an enzyme-linked immunosorbent assay (ELISA) kit (Ultra-Sensitive Rat Insulin ELISA kit, Crystal Chem Inc., IL, United States). A diagnostic kit (ELK Biotech, Wuhan, China) was employed to perform the glycosylated haemoglobin (HbA1c) analysis using the cation-exchange method.</p></sec><sec><title>Lipid profiling</title><p>TG, TC, LDL-C and HDL-C were part of the lipid profile assessed using enzymatic kits (Agappe Diagnostics Ltd., Kerala, India). Friedewald’s equation was used to calculate the concentrations of LDL-C and very LDL-C.</p></sec><sec><title>Assessment of oxidative stress in the sciatic nerve</title><p>
<bold>Estimation of LPO level:</bold> MDA, a product of LPO, was determined in the sciatic nerve homogenate to estimate LPO indirectly[<xref rid="B31" ref-type="bibr">31</xref>]. The procedure involved mixing 0.1 mL of the homogenate with 1.5 mL of thiobarbituric acid (0.8%), 0.2 mL of sodium dodecyl sulphate (8.1%) and 1.5 mL of acetic acid (20%, pH 3.5) and then incubating the mixture for 1 hour at 100 °C. After adding 1 mL of distilled water and 5 mL of n-butanol: Pyridine (15:1, v/v), the blend was centrifuged for 10 minutes at 3000 × <italic toggle="yes">g</italic>. Following the removal of the organic layer, the absorbance was measured at 532 nm using a Shimadzu UV-1900 spectrophotometer. With a molar extinction coefficient of 9.6 × 10<sup>3</sup> M<sup>-1</sup>·cm<sup>-1</sup>, the amount of MDA generated in each sample was represented as nmol of MDA produced h<sup>-1</sup>·mg<sup>-1</sup> of protein.</p><p>
<bold>Assay of GSH:</bold> 5,5’-dithiobis (2-nitrobenzoic acid) was used to estimate the total GSH content utilising the procedure of Gherghel <italic toggle="yes">et al</italic>[<xref rid="B32" ref-type="bibr">32</xref>].</p><p>
<bold>Assay of GST activity:</bold> The approach of Habig and Jakoby[<xref rid="B33" ref-type="bibr">33</xref>] was used to calculate GST activity. The reaction mixture comprised 1.0 mmol/L 1-chloro-2,4-dinitrobenzene, 0.1 mL of post-mitochondrial supernatant (PMS) and 3.0 mL of 0.1 M phosphate buffer (pH 7.4). The reading was taken at 340 nm using a Shimadzu UV-1900 spectrophotometer. The molar extinction value of 9.6 × 10<sup>3</sup> M<sup>-1</sup>·cm<sup>-1</sup> was employed to calculate the activity, which is the number of 1-chloro-2,4-dinitrobenzene conjugates created/minute/mg.</p><p>
<bold>Assay of SOD and CAT activity:</bold> SOD activity was assessed using a standard protocol[<xref rid="B34" ref-type="bibr">34</xref>]<italic toggle="yes">.</italic> For instance, pyrogallol (24 mmol/L in 10 mmol/L HCl) and Tris-HCl buffer (50 mmol/L, pH 8.5) (25 μL and 2.875 mL, respectively) were mixed with 0.1 mL of PMS (10%). The absorbance was read at 420 nm to calculate SOD activity, which was then represented in units of mg<sup>-1</sup> protein. The quantity that prevented the oxidation of 50% pyrogallol was considered as one unit of the enzyme. The Claiborne method was used to measure the CAT activity[<xref rid="B35" ref-type="bibr">35</xref>]. The procedure involved adding 0.1 mL of PMS (10%) to 1.9 mL of phosphate buffer (0.05 M, pH 7.0) and 1 mL of hydrogen peroxide (0.019 M). The readings were obtained at 240 nm. A molar extinction coefficient of 43.6 M<sup>-1</sup>·cm<sup>-1</sup> was then used to estimate CAT activity as nmol H<sub>2</sub>O<sub>2</sub> consumed minute<sup>-1</sup>·mg<sup>-1</sup> protein.</p></sec><sec><title>Inflammatory marker analysis</title><p>As directed by the manufacturer, IL-β and TNF-α levels were measured using a commercial ELISA kit (RayBiotech, GA, United States).</p></sec><sec><title>Examination of neuron-specific markers</title><p>To elucidate the neuroprotective mechanisms, neuron-specific markers, including BDNF and NGF, were measured in the serum and the sciatic nerve tissue using a commercial ELISA kit (RayBiotech, GA, United States) according to the manufacturer’s instructions. Their levels in the sciatic nerve homogenates were normalized to total protein content and expressed as (pg/mg protein).</p></sec><sec><title>Histological analysis of the liver, pancreas and sciatic nerve</title><p>The liver, pancreas and sciatic nerve tissues were preserved in 10% buffered formalin for histopathological processing. The tissues were washed, enclosed in paraffin blocks, sliced into 3-4 μm-thick sections and stained with haematoxylin and eosin for histopathological examination. After mounting the tissue sections in DPX mountant and performing two 2-minute xylene washes, the slides were viewed and analysed under a bright-field microscope. For morphometric analysis, hepatic steatosis was assessed semi-quantitatively as a percentage of steatosis. Pancreatic islet counts and diameters were measured using the ImageJ software in five randomly selected 10 × fields per section. Sciatic nerve damage was graded blindly by the pathologist on a 0-3 scale (0 = none, 1 = mild, 2 = moderate, 3 = severe), reflecting axonal and myelin alterations.</p></sec><sec><title>Statistical analysis</title><p>For analysis purposes, the statistical programme SPSS 23 was utilised. For multiple comparisons, the Tukey-Kramer <italic toggle="yes">post-hoc</italic> test was performed after analysis of variance, and <italic toggle="yes">P</italic> &lt; 0.05 was considered statistically significant. Accordingly, the mean ± SEM was used to present the data.</p></sec></sec><sec><title>RESULTS</title><sec><title>Phytochemical characterization</title><p>GC-MS analysis of the PHE showed a characteristic chemical fingerprint consistent with our latest dataset[<xref rid="B36" ref-type="bibr">36</xref>]. The profile indicated the presence of bioactive constituents (<italic toggle="yes">e.g.</italic>, tetradecanoic acid, myristic acid TMS derivative and phenolic derivatives) known for their antioxidant, anti-inflammatory and neuroprotective properties. A representative GC-MS chromatogram and the list of major compounds, as shown in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://f6publishing.blob.core.windows.net/96a3aeb6-1861-429d-9ffa-8999cc2c5e00/113992-supplementary-material.pdf">Supplementary Figure 1</uri> and <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://f6publishing.blob.core.windows.net/96a3aeb6-1861-429d-9ffa-8999cc2c5e00/113992-supplementary-material.pdf">Supplementary Table 1</uri>, confirm the consistent and reproducible nature of the extract used in this study.</p></sec><sec><title>Body weight</title><p>Experimental timeline is shown in <xref rid="F1" ref-type="fig">Figure 1</xref>. At week 0, the body weights of different groups did not differ significantly (<xref rid="T1" ref-type="table">Table 1</xref>). By week 8, however, a significant loss of body weight was observed in the diabetic group, confirming diabetes-induced weight loss (from 185.6 ± 5.2 g to 155.6 ± 6.5 g; <italic toggle="yes">P</italic> &lt; 0.05). In contrast, diabetic + PHE group rats exhibited a significant increase in body weight (from 188.4 ± 5.8 g to 220.7 ± 7.4 g; <italic toggle="yes">P</italic> &lt; 0.05), indicating the potential ameliorating effect of PHE treatment. The diabetic + Met group also exhibited a slight increase in body weight (from 198.7 ± 4.5 g to 210.5 ± 5.8 g; <italic toggle="yes">P</italic> &lt; 0.05). The body weight of the diabetic + PHE group increased by 41.84% compared with the untreated diabetic group, while that of diabetic + Met animals increased by 35.28%. Interestingly, the control and control + PHE groups exhibited normal physiological weight gain, confirming that PHE is non-toxic to non-diabetic animals.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>Experimental timeline.</bold> A: Polyherbal extract treatment in diabetic neuropathy; B: The exposed sciatic nerve. STZ: Streptozotocin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g001.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>The effect of polyherbal extract treatment on body weight of control and experimental groups, mean ± SEM</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1">
<bold>Groups</bold>
</td><td colspan="2" rowspan="1">
<bold>Body weight<xref rid="T1FN1" ref-type="table-fn">1</xref> (g)</bold>
<hr/>
</td></tr><tr><td rowspan="1" colspan="1">
<bold>Week 0</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Week 8</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">195.4 ± 6.0</td><td rowspan="1" colspan="1">245.3 ± 7.7 (-3.70%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic</td><td rowspan="1" colspan="1">185.6 ± 5.2 (-5.02%)</td><td rowspan="1" colspan="1">155.6 ± 6.5<xref rid="T1FNa" ref-type="table-fn">a</xref> (-36.57%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic + PHE</td><td rowspan="1" colspan="1">188.4 ± 5.8 (+1.51%)</td><td rowspan="1" colspan="1">220.7 ± 7.4<xref rid="T1FNd" ref-type="table-fn">d</xref> (+41.84%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic + Met</td><td rowspan="1" colspan="1">198.7 ± 4.5 (+7.06%)</td><td rowspan="1" colspan="1">210.5 ± 5.8<xref rid="T1FNd" ref-type="table-fn">d</xref> (+35.28%)</td></tr><tr><td rowspan="1" colspan="1">Control + PHE</td><td rowspan="1" colspan="1">189.7 ± 5.6 (-2.92 %)</td><td rowspan="1" colspan="1">238.6 ± 6.9 (-2.73%)</td></tr></tbody></table><table-wrap-foot><fn id="T1FN1"><label>1</label><p>The diabetic groups treated with polyherbal extract or metformin showed increased in body weight compared to the untreated diabetic group. Values in parentheses indicate percentage increase (+) or decrease (-) as compared with the control or the diabetic group.</p></fn><fn id="T1FNa"><label>a</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> the control group.</p></fn><fn id="T1FNd"><label>d</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group.</p></fn><fn><p>PHE: Polyherbal extract; Met: Metformin.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Effect of PHE treatment on behavioral parameters</title><p>The rats with STZ-induced diabetes developed DN, which was confirmed by behavioral studies.</p></sec><sec><title>Acetone drop test</title><p>The diabetic rats exhibited a significant increase in withdrawal responses (3.32 ± 0.26 seconds) compared with the control group (1.61 ± 0.14 seconds), indicating that they had developed sensitivity to cold stimuli as a result of neuropathic pain. Nonetheless, PHE treatment reversed the cold-induced nociceptive behavior in diabetic rats (2.71 ± 0.16 seconds, <italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic), signifying a moderate yet statistically significant analgesic action. A similar response was observed with the control drug Met (2.67 ± 0.10 seconds; <italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic), a well-known anti-diabetic drug with neuroprotective properties (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Control + PHE (1.82 ± 0.12 seconds) did not significantly differ from the untreated control, confirming that PHE does not evoke an adverse sensory response in healthy animals.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>Effects on behavioral tests.</bold> A: Acetone drop test; B: Hot plate test; C: Tail-flick test; D: Rotarod test. Data are expressed as mean ± SEM (<italic toggle="yes">n</italic> = 7). <sup>a</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control group, <sup>b</sup><italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> control group, <sup>c</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> control group, <sup>d</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group. Met: Metformin; PHE: Polyherbal extract.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g002.jpg"/></fig></sec><sec><title>Hot plate test</title><p>This test was performed to determine the thermal nociceptive threshold, which indicates the sensory function and pain perception often impaired in DN. Latency to nociceptive response was markedly reduced in diabetic rats (4.85 ± 0.22 seconds) compared with the control group (5.81 ± 0.12 seconds; <italic toggle="yes">P</italic> &lt; 0.01), demonstrating enhanced sensitivity to thermal stimuli and nerve dysfunction induced by diabetes (<xref rid="F2" ref-type="fig">Figure 2B</xref>). Nevertheless, PHE application significantly increased the pain threshold in diabetic animals, with an increase in latency to 5.98 ± 0.27 seconds (<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic), thus indicating substantial recovery of sensory function. This effect was comparable and possibly slightly higher to that of the Met-treated diabetic group (5.16 ± 0.18 seconds; <italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic), which approached normal values. The control + PHE group (5.72 ± 0.21 seconds) and the untreated control group did not vary significantly, demonstrating that PHE does not interfere with normal pain perception and thereby asserting its safety in non-diabetic animals.</p></sec><sec><title>Tail-flick test</title><p>This test evaluated spinal reflex nociceptive responses induced by nociception, indicating the integrity of peripheral and spinal sensory pathways. Diabetic rats displayed a significant decrease in response latency (6.93 ± 0.34 seconds) compared with the control (8.21 ± 0.25 seconds; <italic toggle="yes">P</italic> &lt; 0.05), with severe thermal hyperalgesia and sensory function deficits that are typical of DN. However, treatment with PHE elevated the tail-flick latency to 7.64 ± 0.38 seconds and exerted a clear protective effect on pain thresholds and spinal reflex pathways (<xref rid="F2" ref-type="fig">Figure 2C</xref>). The control + PHE group (7.92 ± 0.29 seconds) exhibited response latencies within the range of the untreated control group, confirming that PHE did not adversely affect normal nociceptive responses.</p></sec><sec><title>Rotarod test</title><p>The rotarod test assessed motor coordination and balance, functions often compromised during DN. The major finding was that the diabetic rats fell significantly earlier than those in the control group (latency to fall: 156.25 ± 4.8 seconds <italic toggle="yes">vs</italic> 170.15 ± 5.6 seconds; <italic toggle="yes">P</italic> &lt; 0.05), indicating disruptions in neuromuscular activity and coordination. However, treatment with PHE enhanced motor performance, with diabetic rats achieving a latency of 161.45 ± 4.7 seconds, establishing the protective effect of the extract on neuromuscular integrity. This performance compared favorably with that of Met-treated diabetic rats (163.15 ± 5.2 seconds), which also demonstrated improved motor function (<xref rid="F2" ref-type="fig">Figure 2D</xref>). The control + PHE group maintained latency times (170.25 ± 3.9 seconds) similar to those of untreated control animals, implying that the extract does not impair normal motor activity.</p></sec><sec><title>Effect of PHE treatment on the metabolic panel</title><p>At the end of 8 weeks, the diabetic group exhibited considerably elevated blood glucose levels (284.4 ± 5.1 mg/dL), confirming hyperglycaemia. Nonetheless, PHE treatment significantly reduced blood glucose levels in the diabetic animals, as indicated by the following comparison: Diabetic + PHE: 198.6 ± 4.9 mg/dL; <italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> the diabetic group. A decrease in blood glucose level was observed in the diabetic + Met group (168.3 ± 4.1 mg/dL; <italic toggle="yes">P</italic> &lt; 0.05) owing to the well-known hypoglycaemic action of the drug. PHE treatment lowered the fasting blood glucose (FBG) level by 30.17% and Met by 40.82% relative to the diabetic group. The control + PHE group exhibited only a slight increase (23.96%) compared with the control group, providing additional evidence for the safety of the extract. Induction of diabetes resulted in lower serum insulin levels (<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control), indicative of beta-cell dysfunction. Both the Met and PHE groups demonstrated significantly increased insulin levels compared with the diabetic group. The PHE group exhibited a greater increase in insulin levels, suggesting the protective or stimulatory effect of the extract on pancreatic β-cell function. The control + PHE group did not display any substantial deviations from the control group. Concentrations of HbA1c increased substantially in the diabetic rats (<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control) owing to prolonged exposure to hyperglycaemia. However, treatment with both PHE and Met significantly decreased HbA1c levels (<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic), with PHE and Met achieving reductions of 18.99% and 25.32% respectively. The control + PHE group displayed normal HbA1c levels, with only a 4.08% increase compared with the control group (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>The effect of polyherbal extract treatment on blood glucose, insulin and haemoglobin level of control and experimental groups, mean ± SEM</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Groups<xref rid="T2FN1" ref-type="table-fn">1</xref></bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Blood glucose (mg/dL)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Insulin (ng/mL)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Haemoglobin (%)</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">96.4 ± 3.6</td><td rowspan="1" colspan="1">3.8 ± 0.65</td><td rowspan="1" colspan="1">4.9 ± 0.61</td></tr><tr><td rowspan="1" colspan="1">Diabetic</td><td rowspan="1" colspan="1">284.4 ± 5.1<xref rid="T2FNa" ref-type="table-fn">a</xref> (+195.02%)</td><td rowspan="1" colspan="1">0.68 ± 0.36<xref rid="T2FNa" ref-type="table-fn">a</xref> (-82.11%)</td><td rowspan="1" colspan="1">7.9 ± 0.52<xref rid="T2FNa" ref-type="table-fn">a</xref> (+61.22%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic + PHE</td><td rowspan="1" colspan="1">198.6 ± 4.9<xref rid="T2FNd" ref-type="table-fn">d</xref> (-30.17%)</td><td rowspan="1" colspan="1">2.8 ± 0.46<xref rid="T2FNd" ref-type="table-fn">d</xref> (+311.76%)</td><td rowspan="1" colspan="1">6.4 ± 0.71<xref rid="T2FNd" ref-type="table-fn">d</xref> (-18.99%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic + Met</td><td rowspan="1" colspan="1">168.3 ± 4.1<xref rid="T2FNd" ref-type="table-fn">d</xref> (-40.82%)</td><td rowspan="1" colspan="1">3.1 ± 0.69<xref rid="T2FNd" ref-type="table-fn">d</xref> (+355.88%)</td><td rowspan="1" colspan="1">5.9 ± 0.41<xref rid="T2FNd" ref-type="table-fn">d</xref> (-25.32%)</td></tr><tr><td rowspan="1" colspan="1">Control + PHE</td><td rowspan="1" colspan="1">119.5 ± 4.6 (+23.96%)</td><td rowspan="1" colspan="1">3.4 ± 0.67 (-10.53 %)</td><td rowspan="1" colspan="1">5.1 ± 0.56 (+4.08%)</td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><label>1</label><p>The diabetic group showed a significant increase in fasting blood glucose and glycosylated haemoglobin with a significant decrease in insulin compared with the control group. Polyherbal extract treatment significantly augmented these parameters in the diabetic + polyherbal extract group compared with the diabetic group. Values in parentheses indicate percentage increase (+) or decrease (-) as compared with the control or the diabetic group.</p></fn><fn id="T2FNa"><label>a</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control group.</p></fn><fn id="T2FNd"><label>d</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group.</p></fn><fn><p>PHE: Polyherbal extract; Met: Metformin.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Effect of PHE treatment on lipid profile</title><p>Diabetic rats exhibited significant dyslipidaemia in the form of increased TC, TG and LDL-C and decreased HDL-C (<italic toggle="yes">P</italic> &lt; 0.01 to <italic toggle="yes">P</italic> &lt; 0.001, compared with the control) levels. However, both Met and PHE treatment rectified these abnormalities. PHE significantly reduced TC, TG and LDL-C levels (<italic toggle="yes">P</italic> &lt; 0.05 to <italic toggle="yes">P</italic> &lt; 0.01) and increased HDL-C levels (<italic toggle="yes">P</italic> &lt; 0.01 compared with the diabetic group). These effects indicate that PHE modulates lipid levels favorably under diabetic conditions (<xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>The effect of polyherbal extract treatment on lipid profile of control and experimental groups, mean ± SEM</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Groups/parameters<xref rid="T3FN1" ref-type="table-fn">1</xref></bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Total cholesterol (mg/dL)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Triglycerides (mg/dL)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>High-density lipoprotein cholesterol (mg/dL)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Low-density lipoprotein cholesterol (mg/dL)</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Very low-density lipoprotein cholesterol (mg/dL)</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">125.33 ± 3.2</td><td rowspan="1" colspan="1">98.57 ± 4.3</td><td rowspan="1" colspan="1">58.62 ± 1.9</td><td rowspan="1" colspan="1">47.0 ± 2.3</td><td rowspan="1" colspan="1">19.71 ± 1.8</td></tr><tr><td rowspan="1" colspan="1">Diabetic</td><td rowspan="1" colspan="1">288.75 ± 4.7<xref rid="T3FNc" ref-type="table-fn">c</xref> (+130.39%)</td><td rowspan="1" colspan="1">187.05 ± 5.3<xref rid="T3FNb" ref-type="table-fn">b</xref> (+89.776%)</td><td rowspan="1" colspan="1">27.34 ± 1.6<xref rid="T3FNb" ref-type="table-fn">b</xref> (-53.36%)</td><td rowspan="1" colspan="1">224.0 ± 4.6<xref rid="T3FNc" ref-type="table-fn">c</xref> (+376.59%)</td><td rowspan="1" colspan="1">37.41 ± 1.9<xref rid="T3FNb" ref-type="table-fn">b</xref> (+89.80%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic + PHE</td><td rowspan="1" colspan="1">178.44 ± 3.9<xref rid="T3FNe" ref-type="table-fn">e</xref> (-38.20%)</td><td rowspan="1" colspan="1">158.34 ± 5.2<xref rid="T3FNd" ref-type="table-fn">d</xref> (-15.35%)</td><td rowspan="1" colspan="1">42.33 ± 2.4<xref rid="T3FNe" ref-type="table-fn">e</xref> (+54.83%)</td><td rowspan="1" colspan="1">104.4 ± 3.8<xref rid="T3FNe" ref-type="table-fn">e</xref> (-53.39%)</td><td rowspan="1" colspan="1">31.67 ± 1.6<xref rid="T3FNd" ref-type="table-fn">d</xref> (-15.34%)</td></tr><tr><td rowspan="1" colspan="1">Diabetic + Met</td><td rowspan="1" colspan="1">148.42 ± 4.2<xref rid="T3FNf" ref-type="table-fn">f</xref> (-48.59%)</td><td rowspan="1" colspan="1">139.22 ± 4.9<xref rid="T3FNd" ref-type="table-fn">d</xref> (-25.57%)</td><td rowspan="1" colspan="1">48.78 ± 2.9<xref rid="T3FNe" ref-type="table-fn">e</xref> (+78.42%)</td><td rowspan="1" colspan="1">71.8 ± 3.2<xref rid="T3FNf" ref-type="table-fn">f</xref> (-67.95%)</td><td rowspan="1" colspan="1">27.84 ± 1.7<xref rid="T3FNd" ref-type="table-fn">d</xref> (-25.58%)</td></tr><tr><td rowspan="1" colspan="1">Control + PHE</td><td rowspan="1" colspan="1">130.65 ± 3.3 (+4.24%)</td><td rowspan="1" colspan="1">119.76 ± 4.4 (+21.49%)</td><td rowspan="1" colspan="1">52.65 ± 3.1 (-10.18%)</td><td rowspan="1" colspan="1">54.1 ± 3.1 (+15.11%)</td><td rowspan="1" colspan="1">23.92 ± 2.1 (+21.36%)</td></tr></tbody></table><table-wrap-foot><fn id="T3FN1"><label>1</label><p>The diabetic group showed a significant increase in total cholesterol, triglycerides, low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol with a significant decrease in high-density lipoprotein cholesterol compared with the control group. Polyherbal extract treatment significantly augmented these parameters in the diabetic + polyherbal extract group compared with the diabetic group. Values in parentheses indicate percentage increase (+) or decrease (-) as compared with the control or the diabetic group.</p></fn><fn id="T3FNb"><label>b</label><p>
<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> control group.</p></fn><fn id="T3FNc"><label>c</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control group.</p></fn><fn id="T3FNd"><label>d</label><p>
<italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic group.</p></fn><fn id="T3FNe"><label>e</label><p>
<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> diabetic group.</p></fn><fn id="T3FNf"><label>f</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group.</p></fn><fn><p>PHE: Polyherbal extract; Met: Metformin.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Effect of PHE treatment on MDA and GSH levels</title><p>MDA is a well-known biomarker of LPO and oxidative stress. The diabetic group showed a significant increase in MDA levels (2.6 ± 0.06 nmol/mg protein) compared with the control group (0.88 ± 0.09 nmol/mg protein; <italic toggle="yes">P</italic> &lt; 0.001), possibly reflecting an increased level of oxidative stress resulting from metabolic disorders associated with diabetes. Treatment with PHE significantly reduced the MDA levels in diabetic rats to 1.86 ± 0.07 nmol/mg protein (<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group), suggesting a strong antioxidant and free-radical scavenging activity (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Diabetic rats treated with Met exhibited more profound reductions in MDA levels (1.68 ± 0.08 nmol/mg protein; <italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> the diabetic group), suggesting a significant mitigation of oxidative stress. The control + PHE group (0.83 ± 0.10 nmol/mg protein) exhibited MDA levels similar to those of the untreated control, indicating that PHE does not increase LPO under normal physiological conditions. GSH is a major intracellular antioxidant that protects cells from oxidative damage. A marked depletion of GSH levels was observed in the diabetic group (4.83 ± 0.32 μmol/mg protein) compared with the control group (7.14 ± 0.31 μmol/mg protein; <italic toggle="yes">P</italic> &lt; 0.001). Nonetheless, treatment with PHE moderately restored GSH levels to 5.42 ± 0.30 μmol/mg protein (<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> the diabetic group) in diabetic rats, indicating partial restoration of antioxidant capacity (<xref rid="F3" ref-type="fig">Figure 3B</xref>). The Met-treated diabetic group showed a slightly higher GSH level (5.88 ± 0.29 μmol/mg protein; <italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group), indicating better restoration of the redox balance. The GSH levels in control + PHE rats (7.99 ± 0.33 μmol/mg protein) were almost the same as those in untreated controls, indicating that PHE administration, on its own, does not interfere with redox homeostasis under normal conditions.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>
<bold>Effect of polyherbal extract supplementation.</bold> A: On the malondialdehyde (MDA) level. The diabetic group showed a significant increase in the MDA level compared with the control group. Polyherbal extract (PHE) supplementation significantly decreased the MDA level in the diabetic + PHE group compared with the diabetic group; B: On the reduced glutathione (GSH) level. The diabetic group showed a significant decrease in the GSH content compared with the control group. PHE supplementation significantly increased the GSH content in the diabetic + PHE group compared with the diabetic group. Data are expressed as mean ± SEM (<italic toggle="yes">n</italic> = 7). <sup>c</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> control group, <sup>d</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group, <sup>e</sup><italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> diabetic group, <sup>f</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic group. Met: Metformin; PHE: Polyherbal extract; MDA: Malondialdehyde.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g003.jpg"/></fig></sec><sec><title>Effect of PHE treatment on antioxidant enzymes</title><p>
<bold>GST activity:</bold> GST plays a pivotal role in detoxification by conjugating GSH with toxic electrophilic compounds. In this study, the diabetic group exhibited significantly impaired GST activity (2.91 ± 0.22 U/mg protein) compared with the control (5.23 ± 0.21 U/mg protein; <italic toggle="yes">P</italic> &lt; 0.001), reflecting reduced enzymatic antioxidant defence under hyperglycaemic conditions. Treatment with PHE significantly increased the GST to 3.87 ± 0.17 U/mg protein (<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group), indicating the restoration of antioxidant enzyme function. Slightly higher GST activity (4.13 ± 0.14 U/mg protein) was observed in Met-treated diabetic groups compared with PHE (<italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic), confirming the effectiveness of standard anti-diabetic treatment in restoring enzymatic antioxidant capacity (<xref rid="F4" ref-type="fig">Figure 4A</xref>). In the control + PHE group, GST levels (5.31 ± 0.19 U/mg protein) were similar to those in the untreated control, suggesting that PHE plays a non-toxic and possibly supportive role under physiological conditions.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p>
<bold>The diabetic group exhibited significant alterations in the activities of antioxidant enzymes (glutathione-S-transferase, superoxide dismutase, and catalase) compared with the control group.</bold> A: Glutathione-S-transferase; B: Superoxide dismutase; C: Catalase. The administration of polyherbal extract significantly attenuated the activities of these enzymes in the diabetic + polyherbal extract group compared with the diabetic group. <sup>c</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> control group, <sup>d</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group, <sup>e</sup><italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> diabetic group, and <sup>f</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic group. CDNB: 1-Chloro-2,4-dinitrobenzene; Met: Metformin; PHE: Polyherbal extract.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g004.jpg"/></fig><p>
<bold>SOD and CAT activities:</bold> SOD is a major antioxidant enzyme that scavenges superoxide radicals, thereby protecting cells from oxidative injury. The SOD activity was significantly reduced in diabetic animals (4.43 ± 0.26 U/mg protein) compared with the control (6.82 ± 0.30 U/mg protein; <italic toggle="yes">P</italic> &lt; 0.001), indicating impaired enzymatic defence against oxidative stress. Treatment with PHE significantly increased the SOD activity in diabetic rats to 5.71 ± 0.23 U/mg protein (<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> diabetic), indicating partial restoration of the antioxidant enzyme function (<xref rid="F4" ref-type="fig">Figure 4B</xref>). The Met-treated diabetic group exhibited slightly higher levels of SOD (5.83 ± 0.29 U/mg protein) than the PHE-treated group (<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group), asserting the role of the drug in the effective recovery of redox homeostasis. The SOD activity of the control + PHE group was similar to that of untreated control rats (7.12 ± 0.31 U/mg protein), indicating that the extract does not disrupt normal antioxidant enzyme function on its own but may assist in maintaining redox balance.</p><p>The CAT activity was significantly reduced under diabetic conditions compared with control conditions (diabetic: 33.6 ± 2.2 U/mg protein; 50.3 ± 1.9 U/mg protein; <italic toggle="yes">P</italic> &lt; 0.001). Nonetheless, treatment with PHE significantly increased CAT levels (38.65 ± 1.6 U/mg protein; <italic toggle="yes">P</italic> &lt; 0.05). The restoration of CAT activity was more pronounced in the case of Met treatment (40.66 ± 2.1 U/mg protein; <italic toggle="yes">P</italic> &lt; 0.01), with values approaching normal levels. The control + PHE group (49.67 ± 2.5 U/mg protein) did not differ from the control group, signifying that PHE does not alter CAT activity under non-diabetic conditions (<xref rid="F4" ref-type="fig">Figure 4C</xref>).</p></sec><sec><title>Effect of PHE on TNF-α and IL-1β markers in diabetic rats</title><p>Compared with the control group (TNF-α = 30.67 ± 1.6 pg/mL), the level of TNF-α was significantly increased in the diabetic group (73.66 ± 2.7 pg/mL), indicating generalised inflammation due to hyperglycaemia. However, the administration of PHE resulted in a marked decrease in TNF-α levels (53.84 ± 2.4 pg/mL), signifying its anti-inflammatory effect (<xref rid="F5" ref-type="fig">Figure 5A</xref>). Furthermore, similar reductions were observed in TNF-α levels in Met-treated diabetic rats (44.37 ± 2.3 pg/mL), confirming its anti-inflammatory activity. The control + PHE group (34.58 ± 2.1 pg/mL) did not differ significantly from the control group, implying that PHE does not promote inflammation in non-diabetic rats. Moreover, IL-1β level was significantly elevated in diabetic animals (205.66 ± 4.8 pg/mL) compared with the control group (90.54 ± 3.9 pg/mL, <italic toggle="yes">P</italic> &lt; 0.001), showing a strong inflammatory response associated with the pathology of diabetes. Nonetheless, PHE treatment led to a significant decrease in the IL-1β level in diabetic animals (157.43 ± 4.4 pg/mL, <italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group), suggesting a potent anti-inflammatory effect. Met also decreased the IL-1β level in the Met-administered group (146.87 ± 4.7 pg/mL, <italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic), which agrees with its well-established anti-inflammatory function. The control + PHE group (95.33 ± 4.1 pg/mL) did not vary significantly from the control group, confirming that PHE does not alter the IL-1β level under normoglycemic conditions (<xref rid="F5" ref-type="fig">Figure 5B</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>Figure 5</label><caption><p>
<bold>Effects of polyherbal extract on the protein expression of pro-inflammatory cytokines.</bold> A: Tumour necrosis factor-α; B: Interleukin-1β. The diabetic group exhibited a significant decrease in tumour necrosis factor-α and interleukin-1β levels compared with the control group. The administration of polyherbal extract significantly attenuated the activities of these markers in the diabetic + polyherbal extract group compared with the diabetic group. Data are expressed as mean ± SEM (<italic toggle="yes">n</italic> = 7). <sup>c</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> control group, <sup>e</sup><italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> diabetic group, <sup>f</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic group. Met: Metformin; PHE: Polyherbal extract; TNF-α: Tumour necrosis factor-α; IL-1β: Interleukin-1β.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g005.jpg"/></fig></sec><sec><title>Effect of PHE on neuro-specific biomarker levels in diabetic rats</title><p>Diabetic rats exhibited significantly lower levels of BDNF in both the serum and the sciatic nerve (13.65 ± 0.9 pg/mL and 11.66 ± 0.78 pg/mg protein, respectively) compared with the control rats (20.43 ± 1.1 pg/mL in the serum and 22.98 ± 0.99 pg/mg protein in the sciatic nerve), indicating diabetes-induced neural impairment (<italic toggle="yes">P</italic> &lt; 0.001). Nevertheless, PHE administration significantly improved the BDNF levels in both the serum and the sciatic nerve (17.78 ± 0.91 pg/mL and 15.84 ± 0.86 pg/mg protein, respectively), demonstrating a partial protective effect (<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group; <xref rid="F6" ref-type="fig">Figure 6A</xref>). Treatment with Met also significantly restored the level of this biomarker in both the serum and the sciatic nerve (16.46 ± 0.95 pg/mL and 15.12 ± 0.89 pg/mg protein, respectively) (<italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> the diabetic group), supporting its efficacy. Moreover, the levels in the control + PHE group (20.53 ± 0.87 pg/mL in the serum and 21.96 ± 0.91 pg/mg protein in the sciatic nerve) did not differ significantly compared with the control group (<italic toggle="yes">P</italic> &lt; 0.05), proving that PHE does not alter the levels of this biomarker in healthy animals. In addition, the levels of NGF were diminished in diabetic rats in both the serum and the sciatic nerve (600.16 ± 13.99 pg/mL and 987.86 ± 15.33 pg/mg protein, respectively) compared with the control group (876.76 ± 12.87 pg/mL and 1708.32 ± 18.21 pg/mg protein, respectively) suggesting oxidative or neurotrophic damage associated with diabetes (<italic toggle="yes">P</italic> &lt; 0.01). However, treatment with PHE significantly increased the biomarker levels in both the serum and the sciatic nerve (706.65 ± 13.87 pg/mL and 1297.64 ± 15.92 pg/mg protein, respectively), demonstrating a significant restoration (<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> the diabetic group; <xref rid="F6" ref-type="fig">Figure 6B</xref>). The control + PHE group did not show a significant variation from the control group (<italic toggle="yes">P</italic> &lt; 0.05), suggesting that PHE does not affect baseline biomarker levels in non-diabetic animals.</p><fig position="float" id="F6" orientation="portrait"><label>Figure 6</label><caption><p>
<bold>Effects of polyherbal extract on the protein expression of the neuron-specific markers in the serum and sciatic nerve tissue.</bold> A: Brain-derived neurotrophic factor; B: Nerve growth factor. The diabetic group experienced a significant reduction in the levels of brain-derived neurotrophic factor and nerve growth factor compared with the control group. However, the administration of polyherbal extract significantly ameliorated their levels in the diabetic + polyherbal extract group compared with the diabetic group. Data are expressed as mean ± SEM (<italic toggle="yes">n</italic> = 7). <sup>a</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control group, <sup>b</sup><italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> control group, <sup>c</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> control group, <sup>d</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group, <sup>e</sup><italic toggle="yes">P</italic> &lt; 0.01 <italic toggle="yes">vs</italic> diabetic group. Met: Metformin; PHE: Polyherbal extract; BDNF: Brain-derived neurotrophic factor; NGF: Nerve growth factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g006.jpg"/></fig></sec><sec><title>Histopathological findings</title><p>Histopathological examination of liver tissues from control animals revealed normal, trabecular-arranged hepatocytes with polygonal shapes, without any signs of cellular disintegration, pyknosis, apoptosis, or central vein congestion. The cytoplasm was clear, and normal/round/oval nuclei were noted. No inflammatory infiltrate or congestion was evident in the central vein. However, when sections from the diabetic group were studied, considerable hepatocyte damage was observed, characterised by high cellular density, dense cytoplasm and significant fatty changes, with a higher steatosis percentage (<xref rid="F7" ref-type="fig">Figure 7</xref>) and vacuolation. Pyknosis and central vein congestion, along with inflammatory infiltrates, were seen. Sections from diabetic + PHE rats showed mild to moderate histological damage to the liver tissue. The hepatocytes were slightly damaged, with mild vacuolation and pyknosis. Moderate fatty changes and congestion were evident, accompanied by a decrease in steatosis percentage. Sections from diabetic + Met animals indicated normal hepatocytes. Mild histological damage to liver tissues was noted, with minimal alterations in characteristics such as congestion, fatty changes, vacuolation, pyknosis and inflammatory infiltrates. The sections from control + PHE rats exhibited a normal histological appearance (<xref rid="F7" ref-type="fig">Figure 7</xref>).</p><fig position="float" id="F7" orientation="portrait"><label>Figure 7</label><caption><p>
<bold>Histopathological changes in the rat liver tissue after 8 weeks of polyherbal extract treatment, with semi-quantitative data as steatosis percentage.</bold> A: Control. No evidence of cellular disintegration, pyknosis, apoptosis, central vein congestion or nuclear morphology was found (green arrow). Furthermore, the sections exhibited normal and trabecular-arranged hepatocytes, which were polygonal in shape (indicated by the blue arrow). The cytoplasm was clear, and the nuclei were normal/round/oval; no fatty changes, inflammatory infiltrates or congestion in the central vein were observed; B: Diabetic. The section showed significantly damaged hepatocytes (indicated by the blue arrow). High cellular density, dense cytoplasm and significant fatty changes (yellow arrow) and vacuolation (purple arrow) were seen. Pyknosis (black arrow) and central vein congestion (green arrow), along with inflammatory infiltrates (orange arrow), were seen. The micromorphological characteristics were suggestive of severe hepatic toxicity; C: Diabetic + polyherbal extract. The section showed mild to moderate histological damage to the liver tissue. Moderate congestion was seen (green arrow). The section showed mildly damaged hepatocytes (blue arrow), mild vacuolation (purple arrow), mild pyknosis (black arrow), moderate fatty changes (yellow arrow) and moderate inflammatory infiltrates (orange arrow); D: Diabetic + metformin. The section showed mild histological damage to the liver tissue. Minimal congestion was seen (green arrow). The section showed normal hepatocytes (indicated by the blue arrow). Minimal fatty changes (yellow arrow), minimal vacuolation (purple arrow) and minimal pyknosis (black arrow) along with minimal inflammatory infiltrates (orange arrow) were seen; E: Control + polyherbal extract. The section showed the normal histological appearance of the liver tissue. No evidence of cellular disintegration, pyknosis, apoptosis, central vein congestion or nuclear morphology was found (green arrow). The section also showed normal and trabecular-arranged hepatocytes, which were polygonal in shape (indicated by the blue arrow). The cytoplasm was clear, and the nuclei were normal/round/oval; no fatty changes, inflammatory infiltrates or congestion in the central vein were seen (haematoxylin and eosin, 400 ×; scale bar 50 μm); F: Semi-quantitative analysis of hepatic steatosis percentage in different experimental groups. <sup>c</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> control group, <sup>d</sup><italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group, <sup>f</sup><italic toggle="yes">P</italic> &lt; 0.001 <italic toggle="yes">vs</italic> diabetic group. Met: Metformin; PHE: Polyherbal extract.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g007.jpg"/></fig><p>The haematoxylin and eosin-stained sections from the control group showed normal histological attributes of the pancreatic tissue. The islets of Langerhans appeared normal, with no evidence of cellular disintegration or atrophy. Furthermore, normal pyramidal acidophilic pancreatic acini were seen, with no congestion or haemorrhage. The diabetic group demonstrated considerable distortions in the pancreatic lobules and cellular disintegration in the islets of Langerhans, along with haemorrhage. Marked pyknosis was observed in the beta cells, and the pancreatic acini were atrophic, exhibiting substantial disintegration and fibrotic changes. The diabetic + PHE group displayed moderately damaged pancreatic lobules, characterised by cellular disintegration in the islets of Langerhans. Mild pyknosis was seen in the beta cells. The diabetic + Met group showed mild to moderate damage to pancreatic lobules and cellular disintegration in the islets of Langerhans. Moderate pyknosis was seen in the beta cells, with no congestion or haemorrhage. The control + PHE group presented normal histological attributes of the pancreatic tissue (<xref rid="F8" ref-type="fig">Figure 8</xref>).</p><fig position="float" id="F8" orientation="portrait"><label>Figure 8</label><caption><p>
<bold>Effect of polyherbal extract treatment on the pancreas section.</bold> A: Control. The sections showed normal histological attributes of the pancreatic tissue. The islets of Langerhans appeared normal, with no evidence of cellular disintegration, pyknosis or atrophic changes in the beta cells (indicated by the green arrow). In addition, normal pyramidal acidophilic pancreatic acini were seen (yellow arrow). No congestion or haemorrhage was found; B: Diabetic. The sections showed significantly distorted pancreatic lobules and cellular disintegration in the islets of Langerhans (orange arrow), along with haemorrhage (green arrow). Marked pyknosis was seen in the beta cells (yellow arrow). Pancreatic acini were atrophic and significantly disintegrated (blue arrow) and fibrotic (black arrow); C: Diabetic + polyherbal extract. The sections showed moderately damaged pancreatic lobules and cellular disintegration in the islets of Langerhans (orange arrow). Healthy beta cells were represented by the green arrow. Mild pyknosis was seen in the beta cells (black arrow). No congestion or haemorrhage was found; D: Diabetic + metformin. The sections showed mild to moderate damaged pancreatic lobules and cellular disintegration in the islets of Langerhans (orange arrow). Healthy beta cells were represented by the green arrow. Moderate pyknosis was observed in the beta cells (indicated by the black arrow). No congestion or haemorrhage was found; E: Polyherbal extract. The sections showed normal histological attributes of the pancreatic tissue. The islets of Langerhans appeared normal, with no evidence of cellular disintegration, pyknosis or atrophic changes in the beta cells (green arrow). Moreover, normal pyramidal acidophilic pancreatic acini were seen (yellow arrow). No congestion or haemorrhage was found (magnification 400 ×; scale bar 50 μm).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g008.jpg"/></fig><p>Sections from the control group possessed normal histopathological attributes of the sciatic nerve. Healthy or intact perineural sheath and intact epineurium were seen, along with healthy and intact axon and myelin sheath. The sections from the diabetic group exhibited significantly damaged histopathological attributes of the sciatic nerve. Severely damaged paraneural sheath, with highly affected sub-paraneural compartment and epineurium, was seen. At high power, significantly damaged and distorted axons and myelin sheaths were observed. The diabetic + PHE group exhibited mildly damaged and distorted features and myelin sheath. The diabetic + Met group showed mildly damaged histopathological attributes of the sciatic nerve and myelin sheath. Sections from the control + PHE group displayed healthy and intact axons and myelin sheaths (<xref rid="F9" ref-type="fig">Figure 9</xref>). Semi-quantitative evaluation corroborated the qualitative histopathological observations. As shown in <xref rid="T4" ref-type="table">Table 4</xref>, diabetic rats exhibited a significant reduction in islet number and diameter, along with higher sciatic nerve lesion scores, which were ameliorated by PHE and Met treatments (<italic toggle="yes">P</italic> &lt; 0.05).</p><fig position="float" id="F9" orientation="portrait"><label>Figure 9</label><caption><p>
<bold>Histopathological results.</bold> A: Control. Healthy and intact axon (green arrow) and myelin (orange arrow); B: Diabetic. Significantly damaged and distorted axon (green arrow) and myelin (orange arrow); C: Diabetic + polyherbal extract. Mildly damaged and distorted axon (green arrow) and myelin (orange arrow); D: Diabetic + metformin: Mildly damaged and distorted axon (green arrow) and myelin (orange arrow); E: Control + polyherbal extract: Healthy and intact axon (green arrow) and myelin (orange arrow) (400 ×, scale bar 50 μm).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="wjd-17-2-113992-g009.jpg"/></fig><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Effect of polyherbal extract on quantitative histopathological changes in the pancreas and sciatic nerve tissue, mean ± SEM</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">
<bold>Groups</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Number of islets, 10 × field</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Diameter of the islet</bold>
<hr/>
</td><td rowspan="1" colspan="1">
<bold>Sciatic nerve damage score</bold>
<hr/>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">6.33 ± 0.29</td><td rowspan="1" colspan="1">163.62 ± 12.71</td><td rowspan="1" colspan="1">0.0 ± 0.0</td></tr><tr><td rowspan="1" colspan="1">Diabetic</td><td rowspan="1" colspan="1">3.7 ± 0.32<xref rid="T4FNa" ref-type="table-fn">a</xref></td><td rowspan="1" colspan="1">95.83 ± 5.10<xref rid="T4FNa" ref-type="table-fn">a</xref></td><td rowspan="1" colspan="1">2.85 ± 0.16<xref rid="T4FNa" ref-type="table-fn">a</xref></td></tr><tr><td rowspan="1" colspan="1">Diabetic+ PHE</td><td rowspan="1" colspan="1">4.6 ± 0.42<xref rid="T4FNd" ref-type="table-fn">d</xref></td><td rowspan="1" colspan="1">145.81 ± 6.32<xref rid="T4FNd" ref-type="table-fn">d</xref></td><td rowspan="1" colspan="1">1.62 ± 0.23<xref rid="T4FNd" ref-type="table-fn">d</xref></td></tr><tr><td rowspan="1" colspan="1">Diabetic + Met</td><td rowspan="1" colspan="1">4.9 ± 0.52<xref rid="T4FNd" ref-type="table-fn">d</xref></td><td rowspan="1" colspan="1">140.22 ± 6.72<xref rid="T4FNd" ref-type="table-fn">d</xref></td><td rowspan="1" colspan="1">1.59 ± 0.24<xref rid="T4FNd" ref-type="table-fn">d</xref></td></tr><tr><td rowspan="1" colspan="1">Control + PHE</td><td rowspan="1" colspan="1">5.89 ± 0.37</td><td rowspan="1" colspan="1">156.47 ± 8.90</td><td rowspan="1" colspan="1">0.12 ± 0.02</td></tr></tbody></table><table-wrap-foot><fn id="T4FNa"><label>a</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> control group.</p></fn><fn id="T4FNd"><label>d</label><p>
<italic toggle="yes">P</italic> &lt; 0.05 <italic toggle="yes">vs</italic> diabetic group.</p></fn><fn><p>PHE: Polyherbal extract; Met: Metformin.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec><title>DISCUSSION</title><p>This study was aimed at evaluating the activity of PHE, which comprised <italic toggle="yes">C. longa, M. fragrans</italic> and <italic toggle="yes">C. colocynthis</italic>, for the amelioration of DN in STZ-induced Wistar rats. DN is a common complication of DM that inflicts organ damage owing to inflammation, oxidative stress and neuronal injury. Existing pharmacological options are limited, offer little success and are associated with severe side effects. Hence, better rehabilitation options are sought. In this study, PHE was hypothesised to ameliorate oxidative stress, inflammation and neuronal damage and improve behavioral and histopathological outcomes in DN.</p><p>Pain perception, locomotor activity and behavioral patterns in the PHE-treated rats were consistent with known reports on the individual components of PHE. <italic toggle="yes">C. longa</italic>, containing the bioactive compound curcumin, has long been used for its anti-inflammatory and neuroprotective properties. Previous studies have demonstrated curcumin’s ability to attenuate neuropathic pain in diabetic rats <italic toggle="yes">via</italic> its anti-inflammatory and antioxidant properties[<xref rid="B6" ref-type="bibr">6</xref>]. Moreover, the anti-inflammatory and neuroprotective activities of <italic toggle="yes">M. fragrans</italic> are well established. Earlier study[<xref rid="B37" ref-type="bibr">37</xref>] noted that nutmeg extract can significantly reduce nociceptive behavior in chronic pain models, possibly by inhibiting pro-inflammatory mediators such as cyclooxygenase-2 and TNF-α. Nutmeg has also been shown to enhance pain threshold levels in a DN clinical trial[<xref rid="B38" ref-type="bibr">38</xref>]. In addition, <italic toggle="yes">C. colocynthis</italic> has been reported to be beneficial in treating neuropathic pain. According to Ostovar <italic toggle="yes">et al</italic>[<xref rid="B16" ref-type="bibr">16</xref>], <italic toggle="yes">C. colocynthis</italic> extract decreased pain perception and increased motor activity in diabetic animals by modulating pain pathways and mitigating oxidative stress. The combined action of the three herbs may result in enhanced pain relief and improved motor function, which can be attributed to their synergistic effects on inflammation and oxidative stress.</p><p>Our study established that PHE exerts a profound metabolic regulatory effect on STZ-administered diabetic rat models. The pronounced decrease in FBG following PHE treatment suggests its potent anti-hyperglycaemic activity. The 30.17% drop in FBG compared with the diabetic group indicates promising potential for therapeutic efficacy, although it is slightly less than that of the reference standard Met. This glucose-lowering effect is potentially attributable to the bioactive constituents, which have been previously reported to enhance insulin-sensitising action, glucose uptake and preservation of β-cell integrity[<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>].</p><p>Serum insulin levels were significantly elevated in diabetic rats receiving PHE, signifying possible stimulation or preservation of pancreatic β-cells. This finding corroborates past reports stating that the active constituent from <italic toggle="yes">C. longa</italic> could prevent STZ-induced cell apoptosis and improve insulin secretion[<xref rid="B41" ref-type="bibr">41</xref>,<xref rid="B42" ref-type="bibr">42</xref>]. Similarly, <italic toggle="yes">M. fragrans</italic> has been shown to regenerate pancreatic activity in various experimental models owing to its insulinotropic effect[<xref rid="B43" ref-type="bibr">43</xref>]. In contrast, <italic toggle="yes">C. colocynthis</italic> has been proven to promote insulin release against insulin resistance by influencing the signalling pathways of its major precursors[<xref rid="B44" ref-type="bibr">44</xref>]. Collectively, the improved insulin profile, together with a reduction in HbA1c level (18.99% reduction), asserts the ability of PHE to mediate long-term glycaemic control, a hallmark aim when treating DN. HbA1c is an established measure of chronic hyperglycaemia, and its declining level is linked to a lowering of the risk for developing microvascular complications such as neuropathy[<xref rid="B45" ref-type="bibr">45</xref>].</p><p>Dyslipidaemia is known to contribute to neuronal injury in diabetes <italic toggle="yes">via</italic> augmented oxidative stress, altered endothelial function and inflammation[<xref rid="B46" ref-type="bibr">46</xref>]. Apart from its glucose-lowering activity, PHE was able to reduce the levels of serum lipids in diabetic rats. The marked reductions in TC, TG and LDL-C, along with an elevation in HDL-C, are all markers of potent dyslipidaemic activity. Moreover, PHE could provide neuroprotection on a secondary basis by diminishing metabolic stressors that mediate DN development <italic toggle="yes">via</italic> normalisation of the lipid parameters, consistent with previous studies[<xref rid="B47" ref-type="bibr">47</xref>].</p><p>Another important mechanism in DN is the increased generation of ROS, causing oxidative stress, which in turn leads to neuronal damage and dysfunction. Oxidative stress can also cause damage to lipids, proteins and DNA, ultimately leading to neuroinflammation and axonal degeneration. Our study demonstrated a significant attenuation of oxidative stress markers (MDA and GSH) and an increase in antioxidant enzyme activities (SOD, GST and CAT) in PHE-treated rats. The modulation of oxidative stress markers and the strengthening of the antioxidant status of rats observed in this research may be attributed to the efficacy of individual herbs in mitigating oxidative injury, as demonstrated in previous studies[<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B48" ref-type="bibr">48</xref>-<xref rid="B50" ref-type="bibr">50</xref>].</p><p>Chronic inflammation serves as bedrock on which the condition of DN develops and progresses. The activation of pro-inflammatory cytokines (TNF-α and IL-1β) maintains the pluripotent inflammatory state that causes neuronal damage and death. In our study, PHE treatment significantly reduced the levels of inflammatory cytokines, confirming its strong anti-inflammatory potential attributed to the presence of phytoconstituents in individual components[<xref rid="B51" ref-type="bibr">51</xref>]. Curcumin, nutmeg and <italic toggle="yes">C. colocynthis</italic> reported from known literature interfere with the signalling pathways leading to inflammation, particularly by inhibiting the NF-κB pathway, the master regulator of inflammation[<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>]. Additionally, curcumin has been shown to inhibit the activation of inducible nitric oxide synthase, thereby reducing the production of nitric oxide, a key mediator of neuroinflammation. The observed anti-inflammatory response of PHE may involve possible contributions from bioactive constituents reported in these plants, although specific active agents within PHE remain to be investigated.</p><p>NGF and BDNF are well-defined neurotrophic factors that play a critical role in neuronal survival, differentiation and synaptic plasticity. Particularly, their expression is of immense significance in peripheral nerve regeneration and in thwarting neuronal damage under pathological conditions such as DN[<xref rid="B54" ref-type="bibr">54</xref>,<xref rid="B55" ref-type="bibr">55</xref>]. In this study, a significant reduction was observed in NGF and BDNF levels in DN rats, which corresponded with earlier reports showing that chronic hyperglycaemia down-regulates neurotrophic support and accelerates neuronal degeneration[<xref rid="B11" ref-type="bibr">11</xref>]. Restoration of neurotrophic factors is likely due to the bioactive constituents reported in <italic toggle="yes">C. longa, M. fragrans</italic> and <italic toggle="yes">C. colocynthis</italic>, which exert neuroprotective effects <italic toggle="yes">via</italic> antioxidant, anti-inflammatory and mitochondria-supportive pathways[<xref rid="B56" ref-type="bibr">56</xref>-<xref rid="B58" ref-type="bibr">58</xref>]. For instance, curcumin, among other phytochemicals, has been reported to up-regulate BDNF and NGF expression in various models of neurological damage and to enhance axonal regeneration and synaptic repair[<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B59" ref-type="bibr">59</xref>].</p><p>Nerve regeneration and myelination are crucial pathways in recovering from DN. The histopathological results obtained in this study demonstrated that PHE treatment significantly ameliorated nerve morphology, reduced axonal degeneration and enhanced myelination in treated rats. Curcumin has been shown to promote nerve regeneration in DN models by stimulating the phosphoinositide 3-kinases/protein kinase B pathway, which is involved in cell survival, proliferation and regeneration. Moreover, curcumin up-regulates the expression of neurotrophic factors such as BDNF[<xref rid="B60" ref-type="bibr">60</xref>] and promotes the activity of oligodendrocyte precursor cells while propelling the synthesis of myelin basic protein to enhance myelination[<xref rid="B61" ref-type="bibr">61</xref>]. Nutmeg possibly contributed to the improved histopathological outcomes noted in our study by stimulating myelination and nerve repair[<xref rid="B23" ref-type="bibr">23</xref>]. Extracts of <italic toggle="yes">C. colocynthis</italic> have been shown to enhance nerve repair by increasing the expression of NGFs and improving the morphology of nerve fibres[<xref rid="B62" ref-type="bibr">62</xref>]. The collective action of these constituents, as observed in previous literature, may be responsible for the improvements, although the exact molecular mechanism remains to be determined.</p><p>In addition to the <italic toggle="yes">in vivo</italic> behavioral, biochemical and histopathological assessments, our earlier work, involving GC-MS profiling and in silico docking studies, has provided reproducibility and key mechanistic insights into the therapeutic action of the examined PHE on DN. GC-MS profiling identified major compounds and ensured batch-to-batch chemical consistency. Absolute quantification of markers, such as curcumin, cucurbitacin B and myristicin, is planned for subsequent studies. Docking studies further revealed that aldose reductase (AR) interacts strongly with (4-isopropyl-1,6-dimethyl-1,2,3,4-tetrahydronaphthalene;1S,2R)-2-(4-allyl-2,6-dimethoxyphenoxy)-1-(3,4,5-trimethoxyphenyl)-1-propanol; (S)-5-allyl-2-((1-(3,4-dimethoxyphenyl)propan-2-yl)oxy)-1,3-dimethoxybenzene and plays a vital role in the disability mechanism of DN[<xref rid="B36" ref-type="bibr">36</xref>]. The over-activation of AR causes the accumulation of sorbitol in nerve fibres, leading to oxidative stress and nerve damage. AR inhibition by these phytochemicals appears to be a crucial mechanism in attenuating oxidative and inflammatory damage[<xref rid="B63" ref-type="bibr">63</xref>]. This finding aligns with the <italic toggle="yes">in vivo</italic> results from the current investigation in which rats treated with PHE displayed decreased MDA levels, improved antioxidant markers and reduced levels of pro-inflammatory cytokines, correlating with an improved behavioral outcome. This multi-system action, against oxidative stress, inflammation and AR activity, underscores the synergistic potential of PHE and finds an important translation into a multi-component therapeutic candidate against DN.</p><sec><title>Limitations and future directions</title><p>These results, although promising, have some limitations. The study was conducted exclusively in male rats to minimise hormonal variability; however, it is recognised that sex differences exist in oxidative stress and neuropathic progression, and female cohorts should be included in future studies to validate and extend the present findings. Furthermore, the pharmacokinetics of PHE and those of its components are worth exploring as a method to understand their bioavailability and optimal dosage for therapeutic use. Lastly, further studies are required to investigate the molecular mechanisms underlying the synergistic effects of these herbs, including signal transduction pathways (NF-κB, phosphoinositide 3-kinases/protein kinase B and AR pathways) that contribute to neuroinflammation and oxidative stress. Future studies would be conducted using targeted molecular techniques to address this issue.</p></sec></sec><sec><title>CONCLUSION</title><p>To summarise, the PHE from <italic toggle="yes">C. longa</italic>, <italic toggle="yes">M. fragrans</italic> and <italic toggle="yes">C. colocynthis</italic> has significant therapeutic potential in alleviating certain behavioral, biochemical and histopathological features of DN in STZ-induced rats. Individual herbal components are known to exhibit antioxidant, anti-inflammatory and neuroprotective effects; however, the observed impacts most likely resulted from synergistic interactions in PHE. These findings support the use of PHE as a potential natural treatment for DN and, quite rightly, warrant clinical consideration for further research. Thus, this study provides additional evidence for the use of plant-based compounds and contributes to the existing knowledge on the integrative approach for managing chronic diabetic complications.</p></sec></body><back><fn-group><fn><p>
<bold>Institutional animal care and use committee statement:</bold> All experimental procedures involving animals were approved by the Institutional Animal Ethics Committee of Jamia Hamdard, No. 86/1871.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflict-of-interest statement:</bold> All the authors report no relevant conflicts of interest for this article.</p></fn><fn><p>
<bold>ARRIVE guidelines statement:</bold> The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.</p></fn><fn><p>
<bold>Provenance and peer review:</bold> Unsolicited article; Externally peer reviewed.</p></fn><fn><p>
<bold>Peer-review model:</bold> Single blind</p></fn><fn><p>
<bold>Corresponding Author's Membership in Professional Societies:</bold> Biotechnology Society of India.</p></fn><fn><p>
<bold>Specialty type:</bold> Endocrinology and metabolism</p></fn><fn><p>
<bold>Country of origin:</bold> Saudi Arabia</p></fn><fn><p>
<bold>Peer-review report’s classification</bold>
</p></fn><fn><p>
<bold>Scientific Quality:</bold> Grade B, Grade B, Grade B, Grade B</p></fn><fn><p>
<bold>Novelty:</bold> Grade B, Grade B, Grade B</p></fn><fn><p>
<bold>Creativity or Innovation:</bold> Grade B, Grade B, Grade B</p></fn><fn><p>
<bold>Scientific Significance:</bold> Grade B, Grade B, Grade B</p></fn><fn><p>
<bold>P-Reviewer:</bold> Liu ZY, MD, China; Pappachan JM, MD, FRCP, MRCP, Professor, Senior Researcher, United Kingdom; Zeng HM, MD, Affiliate Associate Professor, Chief Nurse, China <bold>S-Editor:</bold> Wu S <bold>L-Editor:</bold> A <bold>P-Editor:</bold> Zhao S</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Akbar</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Subhan</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Akbar</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Habib</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Shahbaz</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Wadood</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Salman</surname><given-names>S</given-names></name>
</person-group><article-title>Targeting Anti-Inflammatory Pathways to Treat Diabetes-Induced Neuropathy by 6-Hydroxyflavanone</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><fpage>2552</fpage><pub-id pub-id-type="pmid">37299516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu15112552</pub-id><pub-id pub-id-type="pmcid">PMC10255489</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Callaghan</surname><given-names>BC</given-names></name>
<name name-style="western"><surname>Cheng</surname><given-names>HT</given-names></name>
<name name-style="western"><surname>Stables</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>AL</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name>
</person-group><article-title>Diabetic neuropathy: clinical manifestations and current treatments</article-title><source>Lancet Neurol</source><year>2012</year><volume>11</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">22608666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(12)70065-0</pub-id><pub-id pub-id-type="pmcid">PMC4254767</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vincent</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Callaghan</surname><given-names>BC</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>AL</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name>
</person-group><article-title>Diabetic neuropathy: cellular mechanisms as therapeutic targets</article-title><source>Nat Rev Neurol</source><year>2011</year><volume>7</volume><fpage>573</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">21912405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2011.137</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name>
<name name-style="western"><surname>Nave</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Jensen</surname><given-names>TS</given-names></name>
<name name-style="western"><surname>Bennett</surname><given-names>DLH</given-names></name>
</person-group><article-title>New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain</article-title><source>Neuron</source><year>2017</year><volume>93</volume><fpage>1296</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">28334605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2017.02.005</pub-id><pub-id pub-id-type="pmcid">PMC5400015</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sheethal</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Ratheesh</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Svenia</surname><given-names>P Jose</given-names></name>
<name name-style="western"><surname>Sandya</surname><given-names>S</given-names></name>
</person-group><article-title>Effect of Glutathione Enriched Polyherbal Formulation on Streptozotocin Induced Diabetic Model by Regulating Oxidative Stress and PKC Pathway</article-title><source>Pharmacogn Res</source><year>2023</year><volume>15</volume><fpage>347</fpage><lpage>355</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kaur</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Kishore</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Farooq</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Kajal</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Agrawal</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Mannan</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>TG</given-names></name>
</person-group><article-title>Cucurbita pepo seeds improve peripheral neuropathy in diabetic rats by modulating the inflammation and oxidative stress in rats</article-title><source>Environ Sci Pollut Res Int</source><year>2023</year><volume>30</volume><fpage>85910</fpage><lpage>85919</lpage><pub-id pub-id-type="pmid">37400700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11356-023-28339-6</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Obrosova</surname><given-names>IG</given-names></name>
</person-group><article-title>Diabetes and the peripheral nerve</article-title><source>Biochim Biophys Acta</source><year>2009</year><volume>1792</volume><fpage>931</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">19061951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2008.11.005</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pop-Busui</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Boulton</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name>
<name name-style="western"><surname>Bril</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Freeman</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Malik</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Sosenko</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Ziegler</surname><given-names>D</given-names></name>
</person-group><article-title>Diabetic Neuropathy: A Position Statement by the American Diabetes Association</article-title><source>Diabetes Care</source><year>2017</year><volume>40</volume><fpage>136</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">27999003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc16-2042</pub-id><pub-id pub-id-type="pmcid">PMC6977405</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wiggin</surname><given-names>TD</given-names></name>
<name name-style="western"><surname>Sullivan</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Pop-Busui</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Amato</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sima</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name>
</person-group><article-title>Elevated triglycerides correlate with progression of diabetic neuropathy</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>1634</fpage><lpage>1640</lpage><pub-id pub-id-type="pmid">19411614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db08-1771</pub-id><pub-id pub-id-type="pmcid">PMC2699859</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Anand</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Terenghi</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Warner</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Kopelman</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Williams-Chestnut</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Sinicropi</surname><given-names>DV</given-names></name>
</person-group><article-title>The role of endogenous nerve growth factor in human diabetic neuropathy</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">8640566</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm0696-703</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Fernyhough</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Roy</surname><given-names>Chowdhury SK</given-names></name>
<name name-style="western"><surname>Schmidt</surname><given-names>RE</given-names></name>
</person-group><article-title>Mitochondrial stress and the pathogenesis of diabetic neuropathy</article-title><source>Expert Rev Endocrinol Metab</source><year>2010</year><volume>5</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">20729997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/eem.09.55</pub-id><pub-id pub-id-type="pmcid">PMC2924887</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Moosaie</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Mohammadi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Saghazadeh</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Dehghani</surname><given-names>Firouzabadi F</given-names></name>
<name name-style="western"><surname>Rezaei</surname><given-names>N</given-names></name>
</person-group><article-title>Brain-derived neurotrophic factor in diabetes mellitus: A systematic review and meta-analysis</article-title><source>PLoS One</source><year>2023</year><volume>18</volume><fpage>e0268816</fpage><pub-id pub-id-type="pmid">36787304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0268816</pub-id><pub-id pub-id-type="pmcid">PMC9928073</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>He</surname><given-names>WL</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>FX</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>BX</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>RR</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>LP</given-names></name>
</person-group><article-title>Serum brain-derived neurotrophic factor levels in type 2 diabetes mellitus patients and its association with cognitive impairment: A meta-analysis</article-title><source>PLoS One</source><year>2024</year><volume>19</volume><fpage>e0297785</fpage><pub-id pub-id-type="pmid">38648255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0297785</pub-id><pub-id pub-id-type="pmcid">PMC11034647</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>K</surname><given-names>U VR</given-names></name>
<name name-style="western"><surname>Siddiqi</surname><given-names>SS</given-names></name>
<name name-style="western"><surname>Debbarman</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Mukherjee</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Akhtar</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Waris</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Thacker</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Shaista</surname></name>
</person-group><article-title>Serum Brain-Derived Neurotrophic Factor: An Emerging Marker for Diabetic Retinopathy</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e74153</fpage><pub-id pub-id-type="pmid">39712817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.74153</pub-id><pub-id pub-id-type="pmcid">PMC11663298</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lakshmi</surname><given-names>SGVJ</given-names></name>
</person-group><article-title>Antidiabetic and Anti-neuropathic Activities of Hydroalcoholic Polyherbal Extract in Wistar Rats</article-title><source>Trop J Nat Prod Res</source><year>2023</year><volume>7</volume><fpage>3881</fpage><lpage>3886</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ostovar</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Akbari</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Anbardar</surname><given-names>MH</given-names></name>
<name name-style="western"><surname>Iraji</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Salmanpour</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hafez</surname><given-names>Ghoran S</given-names></name>
<name name-style="western"><surname>Heydari</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Shams</surname><given-names>M</given-names></name>
</person-group><article-title>Effects of Citrullus colocynthis L. in a rat model of diabetic neuropathy</article-title><source>J Integr Med</source><year>2020</year><volume>18</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">31874814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.joim.2019.12.002</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Aggarwal</surname><given-names>BB</given-names></name>
<name name-style="western"><surname>Harikumar</surname><given-names>KB</given-names></name>
</person-group><article-title>Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases</article-title><source>Int J Biochem Cell Biol</source><year>2009</year><volume>41</volume><fpage>40</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">18662800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biocel.2008.06.010</pub-id><pub-id pub-id-type="pmcid">PMC2637808</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Narwal</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Prakash</surname><given-names>O</given-names></name>
</person-group><article-title>α-glucosidase inhibitors from plants: A natural approach to treat diabetes</article-title><source>Pharmacogn Rev</source><year>2011</year><volume>5</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">22096315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0973-7847.79096</pub-id><pub-id pub-id-type="pmcid">PMC3210010</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kandezi</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Mohammadi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Ghaffari</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gholami</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Motaghinejad</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Safari</surname><given-names>S</given-names></name>
</person-group><article-title>Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways</article-title><source>Int J Mol Cell Med</source><year>2020</year><volume>9</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">32832482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22088/IJMCM.BUMS.9.1.1</pub-id><pub-id pub-id-type="pmcid">PMC7422850</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sultan</surname><given-names>MT</given-names></name>
<name name-style="western"><surname>Saeed</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Raza</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Ilyas</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Sadiq</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Musarrat</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Afzaal</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hussain</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Raza</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Al</surname><given-names>Jbawi E</given-names></name>
</person-group><article-title>Nutritional and therapeutic potential of nutmeg (<italic toggle="yes">Myristica fragrans</italic>): A concurrent review</article-title><source>Cogent Food Agric</source><year>2023</year><volume>9</volume><fpage>2279701</fpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Veerendrakumar</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Gayathri</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Priya</surname><given-names>VV</given-names></name>
<name name-style="western"><surname>Selvaraj</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Kavitha</surname><given-names>S</given-names></name>
</person-group><article-title>Evaluation of Antioxidant and Protease-inhibitory Potential of Ethanolic Extract of Myristica fragrans (Nutmeg)</article-title><source>J Pharm Res Int</source><year>2021</year><volume>33</volume><fpage>263</fpage><lpage>270</lpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Al-Quraishy</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Dkhil</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Abdel-Gaber</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Zrieq</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Hafez</surname><given-names>TA</given-names></name>
<name name-style="western"><surname>Mubaraki</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Abdel</surname><given-names>Moneim AE</given-names></name>
</person-group><article-title>Myristica fragrans seed extract reverses scopolamine-induced cortical injury via stimulation of HO-1 expression in male rats</article-title><source>Environ Sci Pollut Res Int</source><year>2020</year><volume>27</volume><fpage>12395</fpage><lpage>12404</lpage><pub-id pub-id-type="pmid">31993909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11356-020-07686-8</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ghorbanian</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Ghasemi-Kasman</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Hashemian</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gorji</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Gol</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Feizi</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Kazemi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Ashrafpour</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Moghadamnia</surname><given-names>AA</given-names></name>
</person-group><article-title>Myristica Fragrans Houtt Extract Attenuates Neuronal Loss and Glial Activation in Pentylenetetrazol-Induced Kindling Model</article-title><source>Iran J Pharm Res</source><year>2019</year><volume>18</volume><fpage>812</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">31531064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22037/ijpr.2019.1100670</pub-id><pub-id pub-id-type="pmcid">PMC6706727</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Chopra</surname><given-names>K</given-names></name>
</person-group><article-title>Fundamentals of experimental pharmacology</article-title><source>Indian J Pharmacol</source><year>2020</year><volume>52</volume><fpage>443</fpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kalva</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Fatima</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Raghunandan</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Samreen</surname><given-names>S</given-names></name>
</person-group><article-title>Insulinomimetic Effect of Citrullus Colocynthis Roots in STZ Challenged Rat Model</article-title><source>Iran J Pharm Sci</source><year>2018</year><volume>14</volume><fpage>49</fpage><lpage>66</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rai</surname><given-names>PK</given-names></name>
<name name-style="western"><surname>Jaiswal</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Mehta</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Rai</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Watal</surname><given-names>G</given-names></name>
</person-group><article-title>Effect of Curcuma longa freeze dried rhizome powder with milk in STZ induced diabetic rats</article-title><source>Indian J Clin Biochem</source><year>2010</year><volume>25</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">23105906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12291-010-0032-z</pub-id><pub-id pub-id-type="pmcid">PMC3453095</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Morrow</surname><given-names>TJ</given-names></name>
</person-group><article-title>Animal models of painful diabetic neuropathy: the STZ rat model</article-title><source>Curr Protoc Neurosci</source><year>2004</year><fpage>Chapter 9: Unit 9.18</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/0471142301.ns0918s29</pub-id><pub-id pub-id-type="pmid">18428614</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Choi</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Jang</surname><given-names>BH</given-names></name>
<name name-style="western"><surname>Youn</surname><given-names>DY</given-names></name>
<name name-style="western"><surname>Ryu</surname><given-names>WH</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>CO</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>ID</given-names></name>
</person-group><article-title>Selective diagnosis of diabetes using Pt-functionalized WO3 hemitube networks as a sensing layer of acetone in exhaled breath</article-title><source>Anal Chem</source><year>2013</year><volume>85</volume><fpage>1792</fpage><lpage>1796</lpage><pub-id pub-id-type="pmid">23252728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ac303148a</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>D’amour</surname><given-names>FE</given-names></name>
<name name-style="western"><surname>Smith</surname><given-names>DL</given-names></name>
</person-group><article-title>A Method For Determining Loss of Pain Sensation</article-title><source>J Pharmacol Exp Ther</source><year>1941</year><volume>72</volume><fpage>74</fpage><lpage>79</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Andrabi</surname><given-names>SS</given-names></name>
<name name-style="western"><surname>Parvez</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tabassum</surname><given-names>H</given-names></name>
</person-group><article-title>Progesterone induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in rats</article-title><source>Dis Model Mech</source><year>2017</year><volume>10</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">28363987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.025692</pub-id><pub-id pub-id-type="pmcid">PMC5482998</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ohkawa</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Ohishi</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Yagi</surname><given-names>K</given-names></name>
</person-group><article-title>Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction</article-title><source>Anal Biochem</source><year>1979</year><volume>95</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">36810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0003-2697(79)90738-3</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Gherghel</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Griffiths</surname><given-names>HR</given-names></name>
<name name-style="western"><surname>Hilton</surname><given-names>EJ</given-names></name>
<name name-style="western"><surname>Cunliffe</surname><given-names>IA</given-names></name>
<name name-style="western"><surname>Hosking</surname><given-names>SL</given-names></name>
</person-group><article-title>Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">15728543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.04-0777</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Habig</surname><given-names>WH</given-names></name>
<name name-style="western"><surname>Jakoby</surname><given-names>WB</given-names></name>
</person-group><article-title>Assays for differentiation of glutathione S-transferases</article-title><source>Methods Enzymol</source><year>1981</year><volume>77</volume><fpage>398</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">7329316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0076-6879(81)77053-8</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Marklund</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Marklund</surname><given-names>G</given-names></name>
</person-group><article-title>Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase</article-title><source>Eur J Biochem</source><year>1974</year><volume>47</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">4215654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1432-1033.1974.tb03714.x</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Greenwald</surname><given-names>RA</given-names></name>
</person-group><comment>Handbook of Methods for Oxygen Radical Research. 1<sup>st</sup> ed. Boca Raton: CRC Press, 1985: 467</comment></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kausar</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Anwar</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Elagib</surname><given-names>HM</given-names></name>
<name name-style="western"><surname>Parveen</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Hussain</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Najm</surname><given-names>MZ</given-names></name>
<name name-style="western"><surname>Nair</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kar</surname><given-names>S</given-names></name>
</person-group><article-title>GC-MS Profiling of Ethanol-Extracted Polyherbal Compounds from Medicinal Plant (Citrullus colocynthis, Curcuma longa, and Myristica fragrans): In Silico and Analytical Insights into Diabetic Neuropathy Therapy via Targeting the Aldose Reductase</article-title><source>Curr Issues Mol Biol</source><year>2025</year><volume>47</volume><fpage>75</fpage><pub-id pub-id-type="pmid">39996796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb47020075</pub-id><pub-id pub-id-type="pmcid">PMC11854889</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>WK</given-names></name>
<name name-style="western"><surname>Tao</surname><given-names>SS</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>TT</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>YS</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>XJ</given-names></name>
<name name-style="western"><surname>Tang</surname><given-names>HB</given-names></name>
<name name-style="western"><surname>Cong</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>FL</given-names></name>
<name name-style="western"><surname>Wan</surname><given-names>CJ</given-names></name>
</person-group><article-title>Nutmeg oil alleviates chronic inflammatory pain through inhibition of COX-2 expression and substance P release in vivo</article-title><source>Food Nutr Res</source><year>2016</year><volume>60</volume><fpage>30849</fpage><pub-id pub-id-type="pmid">27121041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3402/fnr.v60.30849</pub-id><pub-id pub-id-type="pmcid">PMC4848392</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Motilal</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Maharaj</surname><given-names>RG</given-names></name>
</person-group><article-title>Nutmeg extracts for painful diabetic neuropathy: a randomized, double-blind, controlled study</article-title><source>J Altern Complement Med</source><year>2013</year><volume>19</volume><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">23098698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/acm.2012.0016</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rahimi</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Nikfar</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Larijani</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Abdollahi</surname><given-names>M</given-names></name>
</person-group><article-title>A review on the role of antioxidants in the management of diabetes and its complications</article-title><source>Biomed Pharmacother</source><year>2005</year><volume>59</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">16081237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2005.07.002</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ghauri</surname><given-names>AO</given-names></name>
<name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Rehman</surname><given-names>T</given-names></name>
</person-group><article-title>In vitro and in vivo anti-diabetic activity of Citrullus colocynthis pulpy flesh with seeds hydro-ethanolic extract</article-title><source>J Complement Integr Med</source><year>2020</year><volume>17</volume><fpage>/j/jcim.2020.17.issue</fpage><lpage>2/jcim</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jcim-2018-0228</pub-id><pub-id pub-id-type="pmid">31971913</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Arulmozhi</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Kurian</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Veeranjaneyulu</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Bodhankar</surname><given-names>SL</given-names></name>
</person-group><article-title>Antidiabetic and Antihyperlipidemic Effects of <italic toggle="yes">Myristica fragrans</italic>. in Animal Models</article-title><source>Pharm Biol</source><year>2007</year><volume>45</volume><fpage>64</fpage><lpage>68</lpage></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jain</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Rains</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Jones</surname><given-names>K</given-names></name>
</person-group><article-title>Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels</article-title><source>Free Radic Biol Med</source><year>2006</year><volume>41</volume><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">16781457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2006.03.008</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Broadhurst</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Polansky</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Anderson</surname><given-names>RA</given-names></name>
</person-group><article-title>Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro</article-title><source>J Agric Food Chem</source><year>2000</year><volume>48</volume><fpage>849</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">10725162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jf9904517</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Huseini</surname><given-names>HF</given-names></name>
<name name-style="western"><surname>Darvishzadeh</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Heshmat</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Jafariazar</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Raza</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Larijani</surname><given-names>B</given-names></name>
</person-group><article-title>The clinical investigation of Citrullus colocynthis (L.) schrad fruit in treatment of Type II diabetic patients: a randomized, double blind, placebo-controlled clinical trial</article-title><source>Phytother Res</source><year>2009</year><volume>23</volume><fpage>1186</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">19170143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ptr.2754</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><article-title> Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>837</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">9742976</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Vincent</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Russell</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Low</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name>
</person-group><article-title>Oxidative stress in the pathogenesis of diabetic neuropathy</article-title><source>Endocr Rev</source><year>2004</year><volume>25</volume><fpage>612</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">15294884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2003-0019</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Opazo-Ríos</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Mas</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Marín-Royo</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Mezzano</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gómez-Guerrero</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Moreno</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Egido</surname><given-names>J</given-names></name>
</person-group><article-title>Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>2632</fpage><pub-id pub-id-type="pmid">32290082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21072632</pub-id><pub-id pub-id-type="pmcid">PMC7177360</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhao</surname><given-names>WC</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Liao</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>WX</given-names></name>
<name name-style="western"><surname>He</surname><given-names>WY</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>HB</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>CX</given-names></name>
</person-group><article-title>Curcumin ameliorated diabetic neuropathy partially by inhibition of NADPH oxidase mediating oxidative stress in the spinal cord</article-title><source>Neurosci Lett</source><year>2014</year><volume>560</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">24370596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2013.12.019</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Patel</surname><given-names>SS</given-names></name>
<name name-style="western"><surname>Acharya</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ray</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Agrawal</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Raghuwanshi</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Jain</surname><given-names>P</given-names></name>
</person-group><article-title>Cellular and molecular mechanisms of curcumin in prevention and treatment of disease</article-title><source>Crit Rev Food Sci Nutr</source><year>2020</year><volume>60</volume><fpage>887</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">30632782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408398.2018.1552244</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pashapoor</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Mashhadyrafie</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Mortazavi</surname><given-names>P</given-names></name>
</person-group><article-title>Ameliorative effect of Myristica fragrans (nutmeg) extract on oxidative status and histology of pancreas in alloxan induced diabetic rats</article-title><source>Folia Morphol (Warsz)</source><year>2020</year><volume>79</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">31063201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5603/FM.a2019.0052</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>DB</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>HY</given-names></name>
<name name-style="western"><surname>Hou</surname><given-names>WG</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>YS</given-names></name>
</person-group><article-title>Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model</article-title><source>Int J Med Sci</source><year>2013</year><volume>10</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">23471081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.5224</pub-id><pub-id pub-id-type="pmcid">PMC3590595</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Le</surname><given-names>TT</given-names></name>
<name name-style="western"><surname>Tran</surname><given-names>SH</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>SW</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>SH</given-names></name>
</person-group><article-title>Furan Acids from Nutmeg and Their Neuroprotective and Anti-neuroinflammatory Activities</article-title><source>J Agric Food Chem</source><year>2025</year><volume>73</volume><fpage>11080</fpage><lpage>11093</lpage><pub-id pub-id-type="pmid">40278862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.5c02528</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Esmaealzadeh</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Miri</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Mavaddat</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Peyrovinasab</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ghasemi</surname><given-names>Zargar S</given-names></name>
<name name-style="western"><surname>Sirous</surname><given-names>Kabiri S</given-names></name>
<name name-style="western"><surname>Razavi</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Abdolghaffari</surname><given-names>AH</given-names></name>
</person-group><article-title>The regulating effect of curcumin on NF-κB pathway in neurodegenerative diseases: a review of the underlying mechanisms</article-title><source>Inflammopharmacology</source><year>2024</year><volume>32</volume><fpage>2125</fpage><lpage>2151</lpage><pub-id pub-id-type="pmid">38769198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10787-024-01492-1</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Terenghi</surname><given-names>G</given-names></name>
</person-group><article-title>Peripheral nerve regeneration and neurotrophic factors</article-title><source>J Anat</source><year>1999</year><volume>194 (Pt 1)</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">10227662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1469-7580.1999.19410001.x</pub-id><pub-id pub-id-type="pmcid">PMC1467889</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Siniscalco</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Giordano</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Rossi</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Maione</surname><given-names>S</given-names></name>
<name name-style="western"><surname>de</surname><given-names>Novellis V</given-names></name>
</person-group><article-title>Role of neurotrophins in neuropathic pain</article-title><source>Curr Neuropharmacol</source><year>2011</year><volume>9</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">22654713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157015911798376208</pub-id><pub-id pub-id-type="pmcid">PMC3263449</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Al-Qahtani</surname><given-names>WH</given-names></name>
<name name-style="western"><surname>Dinakarkumar</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Arokiyaraj</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Saravanakumar</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Rajabathar</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Arjun</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Gayathri</surname><given-names>PK</given-names></name>
<name name-style="western"><surname>Nelson</surname><given-names>Appaturi J</given-names></name>
</person-group><article-title>Phyto-chemical and biological activity of Myristica fragrans, an ayurvedic medicinal plant in Southern India and its ingredient analysis</article-title><source>Saudi J Biol Sci</source><year>2022</year><volume>29</volume><fpage>3815</fpage><lpage>3821</lpage><pub-id pub-id-type="pmid">35844361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sjbs.2022.02.043</pub-id><pub-id pub-id-type="pmcid">PMC9280313</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kapoor</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kaur</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Sharma</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Kaur</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Batra</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Rani</surname><given-names>J</given-names></name>
</person-group><article-title>Citrullus colocynthis an Important Plant in Indian Traditional System of Medicine</article-title><source>Pharmacogn Rev</source><year>2021</year><volume>14</volume><fpage>22</fpage><lpage>27</lpage></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sevindik</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Uysal</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Sevindik</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Krupodorova</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Koçer</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Ünal</surname><given-names>O</given-names></name>
</person-group><article-title>Citrullus colocynthis (Bitter-apple): a comprehensive review on general properties, biological activities, phenolic and chemical contents</article-title><source>Not Sci Biol</source><year>2024</year><volume>16</volume><fpage>12202</fpage></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>WX</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>ZQ</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>AL</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>YY</given-names></name>
<name name-style="western"><surname>Hong</surname><given-names>QX</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>GF</given-names></name>
</person-group><article-title>Curcumin Ameliorates the Experimental Diabetic Peripheral Neuropathy through Promotion of NGF Expression in Rats</article-title><source>Chem Biodivers</source><year>2022</year><volume>19</volume><fpage>e202200029</fpage><pub-id pub-id-type="pmid">35538560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbdv.202200029</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zamanian</surname><given-names>MY</given-names></name>
<name name-style="western"><surname>Alsaab</surname><given-names>HO</given-names></name>
<name name-style="western"><surname>Golmohammadi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Yumashev</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Jabba</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Abid</surname><given-names>MK</given-names></name>
<name name-style="western"><surname>Joshi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Alawadi</surname><given-names>AH</given-names></name>
<name name-style="western"><surname>Jafer</surname><given-names>NS</given-names></name>
<name name-style="western"><surname>Kianifar</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Obakiro</surname><given-names>SB</given-names></name>
</person-group><article-title>NF-κB pathway as a molecular target for curcumin in diabetes mellitus treatment: Focusing on oxidative stress and inflammation</article-title><source>Cell Biochem Funct</source><year>2024</year><volume>42</volume><fpage>e4030</fpage><pub-id pub-id-type="pmid">38720663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbf.4030</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Gao</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>
</person-group><article-title>Curcumin enhances the proliferation and myelinization of Schwann cells through Runx2 to repair sciatic nerve injury</article-title><source>Neurosci Lett</source><year>2022</year><volume>770</volume><fpage>136391</fpage><pub-id pub-id-type="pmid">34902518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neulet.2021.136391</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Qin</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ling</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Rong</surname><given-names>W</given-names></name>
</person-group><article-title>Citrullus colocynthis (L.) Schrad.: A Promising Pharmaceutical Resource for Multiple Diseases</article-title><source>Molecules</source><year>2023</year><volume>28</volume><fpage>6221</fpage><pub-id pub-id-type="pmid">37687049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28176221</pub-id><pub-id pub-id-type="pmcid">PMC10488440</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tang</surname><given-names>WH</given-names></name>
<name name-style="western"><surname>Martin</surname><given-names>KA</given-names></name>
<name name-style="western"><surname>Hwa</surname><given-names>J</given-names></name>
</person-group><article-title>Aldose reductase, oxidative stress, and diabetic mellitus</article-title><source>Front Pharmacol</source><year>2012</year><volume>3</volume><fpage>87</fpage><pub-id pub-id-type="pmid">22582044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2012.00087</pub-id><pub-id pub-id-type="pmcid">PMC3348620</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data sharing statement</title><p>All data supporting the findings of this study are included within the main text and <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://f6publishing.blob.core.windows.net/96a3aeb6-1861-429d-9ffa-8999cc2c5e00/113992-supplementary-material.pdf">Supplementary material</uri> of the article.</p></sec></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12908829</article-id><article-id pub-id-type="pmcid-ver">PMC12908829.1</article-id><article-id pub-id-type="pmcaid">12908829</article-id><article-id pub-id-type="pmcaiid">12908829</article-id><article-id pub-id-type="pmid">41686569</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000047562</article-id><article-id pub-id-type="publisher-id">MD-D-25-16242</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>5400</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-4123-890X</contrib-id><name name-style="western"><surname>Mai</surname><given-names initials="T">Tingting</given-names></name><degrees>MM</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Endocrinology, Heyuan People’s Hospital, Heyuan, Guangdong Province, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Tingting Mai, Department of Endocrinology, Heyuan People’s Hospital, Heyuan 517000, Guangdong Province, China (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="maitingting1@163.com">maitingting1@163.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>13</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2026</year></pub-date><volume>105</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">507770</issue-id><elocation-id>e47562</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2025</year></date><date date-type="rev-recd"><day>12</day><month>1</month><year>2026</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>17</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-17 10:25:14.483"><day>17</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-105-e47562.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-105-e47562.pdf"/><abstract><p>Durable glycemic control remains challenging in patients with type 2 diabetes mellitus inadequately controlled with metformin alone. Liraglutide, a glucagon-like peptide-1 receptor agonist, has been proposed as a beneficial add-on therapeutic option. This retrospective study included adults with type 2 diabetes mellitus treated between March 2021 and March 2025. Patients were divided into a combination group receiving liraglutide plus metformin and a control group receiving metformin alone. Glycemic parameters and safety outcomes were assessed at baseline and after 6 months of treatment. Statistical comparisons were conducted using Welch <italic toggle="yes">t</italic> test and Chi-square or Fisher exact test. A total of 207 patients were analyzed. Compared with metformin monotherapy, combination therapy achieved greater reductions in glycated hemoglobin (‐1.8 ± 0.9% vs ‐1.3 ± 0.8%; <italic toggle="yes">P</italic> &lt; .001), fasting and postprandial plasma glucose, fasting insulin, and homeostasis model assessment of insulin resistance. The proportion achieving composite glycemic targets was higher in the combination group (76.5% vs 57.9%; <italic toggle="yes">P</italic> = .006). Adverse event incidence and treatment discontinuation did not differ significantly between groups. Liraglutide add-on therapy provided superior glycemic improvement compared with metformin alone and demonstrated acceptable safety and tolerability.</p></abstract><kwd-group><kwd>glucagon-like peptide-1 receptor agonist</kwd><kwd>glycated hemoglobin</kwd><kwd>insulin resistance</kwd><kwd>liraglutide</kwd><kwd>metformin</kwd><kwd>type 2 diabetes mellitus</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Type 2 diabetes mellitus (T2DM) remains a major global public health burden, with steadily increasing prevalence, accelerated disease progression, and substantial long-term complications despite advances in screening, pharmacologic therapeutics, and individualized risk management strategies. International epidemiological analyses indicate that the continuous rise in T2DM incidence is strongly associated with obesogenic nutritional patterns, sedentary lifestyle, population aging, as well as metabolic and inflammatory dysregulation, resulting in significant healthcare expenditure and premature disability-adjustedlife years loss worldwide.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> Glycemic control remains the core therapeutic objective in T2DM management because chronic hyperglycemia contributes to microvascular and macrovascular complications, including diabetic nephropathy, neuropathy, retinopathy, cardiomyopathy, and cerebrovascular events, and achieving persistent glycemic normalization confers substantial long-term clinical benefit. Metformin is recognized as first-line pharmacotherapy for T2DM based on its robust efficacy, safety, weight neutrality, and affordability. However, a substantial proportion of patients fail to achieve sustained glycemic control with metformin monotherapy, especially in real-world clinical care where metabolic heterogeneity, progressive β-cell dysfunction, and declining insulin secretory capacity are common. For this population, rational second-line combination strategies are required. In recent guidelines and consensus statements, glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide, are increasingly recommended as preferred combination therapy due to their glucose-dependent insulinotropic effect, suppression of glucagon overproduction, beneficial effects on body weight, low intrinsic hypoglycemia risk, and favorable cardiometabolic profile.<sup>[<xref rid="R3" ref-type="bibr">3</xref>–<xref rid="R5" ref-type="bibr">5</xref>]</sup></p><p>Recent high-quality trials and real-world evidence have demonstrated that GLP-1RA add-on therapy enhances glycated hemoglobin (HbA1c) reduction and improves postprandial glucose excursions more effectively than traditional drug intensification approaches while minimizing the need for additional glucose-lowering agents and excessive polypharmacy.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Additionally, GLP-1RA therapy exerted beneficial effects on insulin resistance, metabolic efficiency, satiety signaling, gastrointestinal hormone regulation, and systemic inflammatory stress response, all of which are increasingly recognized as key contributors to metabolic disease progression and cardiometabolic risk trajectories. The weight-modulation and cardiovascular protection observed in GLP-1RA class studies further support their integration into contemporary T2DM treatment paradigms, particularly in subpopulations with high cardiometabolic vulnerability.<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> Despite evidence supporting the superiority of GLP-1RAs over traditional escalation pathways such as sulfonylureas or insulin in selected clinical scenarios, comparative data directly evaluating liraglutide plus metformin versus metformin monotherapy in routine, non-trial practice conditions remain relatively limited, particularly in real-world East Asian cohorts, where insulin resistance profiles, β-cell reserve, and dose–response characteristics may differ from Western populations. Furthermore, treatment intensification patterns and safety signals under real practice conditions require additional evaluation to guide rational regimen selection and refine personalized pharmacologic management strategies. Therefore, further clinical research examining real-world therapeutic effectiveness, metabolic benefit, and tolerability is necessary to provide stronger evidence for optimized stepwise pharmacotherapy in T2DM.</p><p>The present study focuses on evaluating glycemic improvement, insulin resistance reduction, treatment intensification needs, and short-term safety outcomes in patients with T2DM receiving liraglutide plus metformin combination therapy compared with metformin monotherapy. Findings generated from clinically relevant populations may provide important implications for clinical decision-making, real-world treatment selection, and evidence-based refinement of individualized T2DM therapeutic pathways.</p></sec><sec sec-type="methods"><title>2. Methods</title><sec><title>2.1. Study design</title><p>This study was approved by the Ethics Committee of Heyuan People’s Hospital. The present study was designed as a retrospective including patients with type 2 diabetes mellitus who received treatment at our institution between March 2021 and March 2025. Eligible participants were adults with a confirmed diagnosis of type 2 diabetes mellitus based on standard clinical and laboratory criteria and had complete baseline and follow-up clinical data. Exclusion criteria included patients with type 1 diabetes mellitus, gestational diabetes, acute metabolic decompensation at presentation, severe hepatic or renal dysfunction, active malignancy, severe cardiovascular or cerebrovascular events within the preceding 3 months, or those who discontinued therapy or had missing outcome data. According to the therapeutic regimen received, patients were stratified into the observation group, in which individuals received combination therapy with liraglutide and metformin, and the control group, in which patients were treated with metformin alone. All study procedures were performed in compliance with the ethical principles outlined in the Declaration of Helsinki, and protocol approval was obtained from the Institutional Medical Ethics Committee. Written informed consent was obtained from all participants.</p></sec><sec><title>2.2. Treatment protocols</title><p>Patients in the observation group received combination therapy consisting of subcutaneous liraglutide in addition to oral metformin. Liraglutide was initiated at a dose of 0.6 mg once daily and titrated to 1.2 to 1.8 mg once daily based on glycemic response and individual tolerability. Metformin was administered at a total daily dose of 1500 to 2000 mg, divided into 2 or 3 doses, with dose adjustments performed according to gastrointestinal tolerance and renal function indicators. Antidiabetic therapy was maintained continuously throughout the treatment course, and follow-up evaluations were conducted at predetermined clinical visits.</p><p>Patients in the control group received metformin monotherapy. The initial metformin dose was 500 mg 2 to 3 times daily, and treatment could be escalated to a total daily dose of 1500 to 2000 mg according to efficacy and tolerability, following the same strategy of dosing adjustment and safety monitoring as in the observation group. No glucagon-like peptide-1 receptor agonists or other glucose-lowering agents with similar mechanisms of action were used during the treatment period in this group.</p><p>For both groups, lifestyle counseling based on standardized diabetes management recommendations, including dietary guidance, exercise recommendations, and self-monitoring of blood glucose, was provided as routine clinical care and was not considered part of the study intervention. Continuous clinical monitoring, adverse event screening, and laboratory assessments were performed in accordance with institutional clinical practice standards.</p></sec><sec><title>2.3. Data collection and follow-up</title><p>Clinical data were obtained retrospectively through extraction from the hospital electronic medical record system. Baseline demographic characteristics, clinical history, medication records, anthropometric parameters, laboratory indicators, and comorbidities were collected at treatment initiation. Laboratory parameters included HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting insulin concentration, lipid metabolic indicators, and renal function parameters. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the formula: HOMA-IR = fasting insulin (μU/mL) × fasting glucose (mmol/L)/22.5. Information on antidiabetic drug dosage, dose modification, initiation of additional glucose-lowering medication, and treatment-related adverse events was also recorded. All laboratory tests were performed in the institutional clinical laboratory using standardized biochemical testing methods and validated automated instruments. All enrolled patients were followed continuously for a total treatment duration of 6 months. Follow-up assessments were conducted at predetermined time points through outpatient clinical visits, electronic medical record review, and additional telephone contact when needed. Glycemic indices, metabolic parameters, and medication usage were reassessed during follow-up, and treatment safety and tolerability outcomes were continuously monitored. Final endpoint data were collected at the completion of the 6-month follow-up to ensure consistent and comparable outcome evaluation across both treatment groups.</p><p>Given the retrospective and non-randomized design of this study, several measures were implemented to minimize potential bias and confounding. First, baseline demographic and clinical characteristics were systematically compared between groups to assess initial comparability. Second, uniform inclusion and exclusion criteria were applied, and all patients were followed over an identical 6-month period to reduce time-related bias. Third, laboratory measurements were performed using standardized methods in a single institutional laboratory.</p><p>Nevertheless, residual confounding related to unmeasured factors such as lifestyle adherence, socioeconomic status, and physician prescribing preference cannot be fully excluded. These limitations may affect causal inference, and the results should therefore be interpreted as associative rather than definitive evidence of treatment superiority.</p></sec><sec><title>2.4. Statistical analysis</title><p>All statistical analyses were performed using Statistical Package for the Social Sciences software version 28.0 (IBM Corp., Armonk) and R statistical software version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were examined for normality using the Shapiro–Wilk test. Normally distributed data were expressed as mean ± standard deviation. Comparisons between the 2 treatment groups were conducted using Welch <italic toggle="yes">t</italic> test to account for potential variance heterogeneity. Categorical variables were presented as frequencies and percentages, and intergroup comparisons were performed using the Chi-square test or Fisher exact test when expected frequencies were less than 5. Treatment effect was evaluated by calculating within-group changes (end of follow-up minus baseline), and between-group differences in mean changes were compared using Welch <italic toggle="yes">t</italic> test. Ninety-five percent confidence intervals were calculated for effect estimates. Missing data were handled using complete case analysis. Statistical significance was defined as a two-sided <italic toggle="yes">P</italic> value &lt;.05.</p></sec></sec><sec sec-type="results"><title>3. Results</title><sec><title>3.1. Baseline characteristics</title><p>In total, 207 patients were enrolled, including 81 patients in the observation group and 126 patients in the control group. Baseline demographic and clinical characteristics were comparable between the 2 groups. The mean age was 56.1 ± 8.4 years in the observation group and 56.8 ± 8.3 years in the control group (<italic toggle="yes">P</italic> = .557). Body mass index showed similar distribution between groups (28.3 ± 3.6 kg/m<sup>2</sup> vs 28.1 ± 3.5 kg/m<sup>2</sup>, <italic toggle="yes">P</italic> = .693). Parameters reflecting diabetes severity were also balanced, including HbA1c (8.7 ± 1.2% vs 8.8 ± 1.3%, <italic toggle="yes">P</italic> = .571), fasting plasma glucose (9.9 ± 2.0 mmol/L vs 10.1 ± 2.1 mmol/L, <italic toggle="yes">P</italic> = .491), and HOMA-IR (7.0 ± 3.2 vs 7.2 ± 3.4, <italic toggle="yes">P</italic> = .669). Blood pressure, lipid profiles, and renal function indicators such as estimated glomerular filtration rate (85.9 ± 18.9 mL/min/1.73 m<sup>2</sup> vs 84.7 ± 19.6 mL/min/1.73 m<sup>2</sup>, <italic toggle="yes">P</italic> = .660) were also not statistically different between the 2 cohorts. Likewise, the distribution of sex, hypertension, dyslipidemia, and current smoking status did not differ significantly (all <italic toggle="yes">P</italic> &gt; .05). These results demonstrate that baseline metabolic conditions and cardiovascular risk factors were balanced across groups prior to treatment initiation (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of the study population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Observation (n = 81)</th><th align="center" rowspan="1" colspan="1">Control (n = 126)</th><th align="center" rowspan="1" colspan="1">Test statistic</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (yr)</td><td align="center" rowspan="1" colspan="1">56.1 ± 8.4</td><td align="center" rowspan="1" colspan="1">56.8 ± 8.3</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.59</td><td align="center" rowspan="1" colspan="1">.557</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">28.3 ± 3.6</td><td align="center" rowspan="1" colspan="1">28.1 ± 3.5</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = 0.39</td><td align="center" rowspan="1" colspan="1">.693</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of T2DM (yr)</td><td align="center" rowspan="1" colspan="1">8.2 ± 4.4</td><td align="center" rowspan="1" colspan="1">8.0 ± 4.5</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = 0.32</td><td align="center" rowspan="1" colspan="1">.752</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">8.7 ± 1.2</td><td align="center" rowspan="1" colspan="1">8.8 ± 1.3</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.57</td><td align="center" rowspan="1" colspan="1">.571</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">9.9 ± 2.0</td><td align="center" rowspan="1" colspan="1">10.1 ± 2.1</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.69</td><td align="center" rowspan="1" colspan="1">.491</td></tr><tr><td align="left" rowspan="1" colspan="1">Postprandial plasma glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">12.8 ± 2.8</td><td align="center" rowspan="1" colspan="1">13.0 ± 2.9</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.50</td><td align="center" rowspan="1" colspan="1">.621</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting insulin (μU/mL)</td><td align="center" rowspan="1" colspan="1">16.2 ± 6.1</td><td align="center" rowspan="1" colspan="1">15.8 ± 6.3</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = 0.46</td><td align="center" rowspan="1" colspan="1">.649</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">7.0 ± 3.2</td><td align="center" rowspan="1" colspan="1">7.2 ± 3.4</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.43</td><td align="center" rowspan="1" colspan="1">.669</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mm Hg)</td><td align="center" rowspan="1" colspan="1">134.6 ± 14.8</td><td align="center" rowspan="1" colspan="1">135.1 ± 15.2</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.24</td><td align="center" rowspan="1" colspan="1">.814</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mm Hg)</td><td align="center" rowspan="1" colspan="1">80.9 ± 8.2</td><td align="center" rowspan="1" colspan="1">81.1 ± 8.5</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.17</td><td align="center" rowspan="1" colspan="1">.866</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.15 ± 0.92</td><td align="center" rowspan="1" colspan="1">2.20 ± 0.95</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.38</td><td align="center" rowspan="1" colspan="1">.706</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">5.02 ± 0.96</td><td align="center" rowspan="1" colspan="1">5.06 ± 0.98</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.29</td><td align="center" rowspan="1" colspan="1">.772</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.08 ± 0.23</td><td align="center" rowspan="1" colspan="1">1.06 ± 0.22</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = 0.62</td><td align="center" rowspan="1" colspan="1">.535</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C (mmol/L)</td><td align="center" rowspan="1" colspan="1">3.05 ± 0.82</td><td align="center" rowspan="1" colspan="1">3.10 ± 0.85</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −0.42</td><td align="center" rowspan="1" colspan="1">.673</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">85.9 ± 18.9</td><td align="center" rowspan="1" colspan="1">84.7 ± 19.6</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = 0.44</td><td align="center" rowspan="1" colspan="1">.660</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, n (%)</td><td align="center" rowspan="1" colspan="1">45 (55.6)</td><td align="center" rowspan="1" colspan="1">68 (54.0)</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 0.05</td><td align="center" rowspan="1" colspan="1">.823</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="center" rowspan="1" colspan="1">39 (48.1)</td><td align="center" rowspan="1" colspan="1">63 (50.0)</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 0.07</td><td align="center" rowspan="1" colspan="1">.795</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia, n (%)</td><td align="center" rowspan="1" colspan="1">44 (54.3)</td><td align="center" rowspan="1" colspan="1">71 (56.3)</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 0.08</td><td align="center" rowspan="1" colspan="1">.774</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking, n (%)</td><td align="center" rowspan="1" colspan="1">21 (25.9)</td><td align="center" rowspan="1" colspan="1">28 (22.2)</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 0.37</td><td align="center" rowspan="1" colspan="1">.541</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>eGFR = estimated glomerular filtration rate, HbA1c = glycated hemoglobin, HDL-C = high-density lipoprotein cholesterol, HOMA-IR = homeostasis model assessment of insulin resistance, LDL-C = low-density lipoprotein cholesterol, T2DM = type 2 diabetes mellitus.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.2. Comparative analysis of HbA1c reduction between liraglutide plus metformin combination therapy and metformin monotherapy</title><p>A significant improvement in HbA1c levels was observed in both groups, but the magnitude of reduction was greater in patients receiving liraglutide combined with metformin. HbA1c decreased from 8.7 ± 1.2% to 6.9 ± 0.8% in the observation group and from 8.8 ± 1.3% to 7.5 ± 0.9% in the control group. The mean HbA1c reduction was ‐1.8 ± 0.9% and ‐1.3 ± 0.8% in the observation and control groups, respectively. The between-group difference in the mean change was ‐0.50% (95% confidence interval [CI], ‐0.74 to ‐0.26), and this difference was statistically significant (<italic toggle="yes">t</italic> = ‐4.07, <italic toggle="yes">P</italic> &lt; .001) (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Change in glycated hemoglobin (HbA1c) from baseline to end of follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">Observation (n = 81)</th><th align="center" rowspan="1" colspan="1">Control (n = 126)</th><th align="center" rowspan="1" colspan="1">Between-group comparison</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">HbA1c at baseline, % (mean ± SD)</td><td align="center" rowspan="1" colspan="1">8.7 ± 1.2</td><td align="center" rowspan="1" colspan="1">8.8 ± 1.3</td><td align="center" rowspan="1" colspan="1">–</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c at end of follow-up, % (mean ± SD)</td><td align="center" rowspan="1" colspan="1">6.9 ± 0.8</td><td align="center" rowspan="1" colspan="1">7.5 ± 0.9</td><td align="center" rowspan="1" colspan="1">–</td></tr><tr><td align="left" rowspan="1" colspan="1">Within-group change, % (mean ± SD)</td><td align="center" rowspan="1" colspan="1">‐1.8 ± 0.9</td><td align="center" rowspan="1" colspan="1">‐1.3 ± 0.8</td><td align="center" rowspan="1" colspan="1">–</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean difference in change (Obs ‐ Ctrl), % (95% CI)</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">‐0.50 (‐0.74 to ‐0.26)</td></tr><tr><td align="left" rowspan="1" colspan="1">Welch <italic toggle="yes">t</italic> test for change</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1"><italic toggle="yes">t</italic> = −4.07, <italic toggle="yes">P</italic> &lt; .001</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI = confidence interval, HbA1c = glycated hemoglobin, SD = standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.3. Comparative assessment of glucose metabolic parameters and achievement of composite glycemic control targets</title><p>From baseline to study end, both groups exhibited improvements across glycemic indices, with consistently larger mean reductions in the observation group. FPG decreased by ‐3.0 ± 1.6 mmol/L in the observation group versus ‐2.5 ± 1.5 mmol/L in the control group (mean difference in change, ‐0.50 mmol/L; 95% CI, ‐0.94 to ‐0.06; Welch <italic toggle="yes">t</italic> = ‐2.25; <italic toggle="yes">P</italic> = .026). PPG declined by ‐4.1 ± 2.2 mmol/L versus ‐3.4 ± 2.1 mmol/L, respectively (mean difference, ‐0.70 mmol/L; 95% CI, ‐1.30 to ‐0.10; Welch <italic toggle="yes">t</italic> = ‐2.27; <italic toggle="yes">P</italic> = .024). Fasting insulin fell by ‐3.7 ± 3.6 μU/mL in the observation group and ‐2.0 ± 3.4 μU/mL in the control group (mean difference, ‐1.70 μU/mL; 95% CI, ‐2.68 to ‐0.72; Welch <italic toggle="yes">t</italic> = −3.39; <italic toggle="yes">P</italic> &lt; .001). HOMA-IR decreased by ‐2.7 ± 2.0 versus ‐1.8 ± 2.1 (mean difference, ‐0.90; 95% CI, ‐1.47 to ‐0.33; Welch <italic toggle="yes">t</italic> = −3.10; <italic toggle="yes">P</italic> = .002). The composite glycemic target was achieved by 76.5% in the observation group and 57.9% in the control group, yielding an absolute risk difference of 18.6% (χ<sup>2</sup> = 7.53; <italic toggle="yes">P</italic> = .006) (Table <xref rid="T3" ref-type="table">3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Comparative changes in glycemic and insulin resistance parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Baseline (mean ± SD)</th><th align="center" rowspan="1" colspan="1">End (mean ± SD)</th><th align="center" rowspan="1" colspan="1">Change (end − base)</th><th align="center" rowspan="1" colspan="1">MD in change (Obs − Ctrl)</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">Test</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">FPG (mmol/L)</td><td align="center" rowspan="1" colspan="1">Observation (n = 81)</td><td align="center" rowspan="1" colspan="1">9.9 ± 2.0</td><td align="center" rowspan="1" colspan="1">6.9 ± 1.1</td><td align="center" rowspan="1" colspan="1">‐3.0 ± 1.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control (n = 126)</td><td align="center" rowspan="1" colspan="1">10.1 ± 2.1</td><td align="center" rowspan="1" colspan="1">7.6 ± 1.2</td><td align="center" rowspan="1" colspan="1">‐2.5 ± 1.5</td><td align="center" rowspan="1" colspan="1">‐0.50</td><td align="center" rowspan="1" colspan="1">‐0.94 to ‐0.06</td><td align="center" rowspan="1" colspan="1">Welch <italic toggle="yes">t</italic> = −2.25</td><td align="center" rowspan="1" colspan="1">.026</td></tr><tr><td align="left" rowspan="2" colspan="1">PPG (mmol/L)</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">12.8 ± 2.8</td><td align="center" rowspan="1" colspan="1">8.7 ± 1.6</td><td align="center" rowspan="1" colspan="1">‐4.1 ± 2.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">13.0 ± 2.9</td><td align="center" rowspan="1" colspan="1">9.6 ± 1.8</td><td align="center" rowspan="1" colspan="1">‐3.4 ± 2.1</td><td align="center" rowspan="1" colspan="1">‐0.70</td><td align="center" rowspan="1" colspan="1">‐1.30 to ‐0.10</td><td align="center" rowspan="1" colspan="1">Welch <italic toggle="yes">t</italic> = −2.27</td><td align="center" rowspan="1" colspan="1">.024</td></tr><tr><td align="left" rowspan="2" colspan="1">Fasting insulin (μU/mL)</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">16.2 ± 6.1</td><td align="center" rowspan="1" colspan="1">12.5 ± 5.3</td><td align="center" rowspan="1" colspan="1">−3.7 ± 3.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">15.8 ± 6.3</td><td align="center" rowspan="1" colspan="1">13.8 ± 5.8</td><td align="center" rowspan="1" colspan="1">‐2.0 ± 3.4</td><td align="center" rowspan="1" colspan="1">‐1.70</td><td align="center" rowspan="1" colspan="1">‐2.68 to ‐0.72</td><td align="center" rowspan="1" colspan="1">Welch <italic toggle="yes">t</italic> = −3.39</td><td align="center" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td align="left" rowspan="2" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">7.0 ± 3.2</td><td align="center" rowspan="1" colspan="1">4.3 ± 2.2</td><td align="center" rowspan="1" colspan="1">−2.7 ± 2.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">7.2 ± 3.4</td><td align="center" rowspan="1" colspan="1">5.4 ± 2.5</td><td align="center" rowspan="1" colspan="1">−1.8 ± 2.1</td><td align="center" rowspan="1" colspan="1">−0.90</td><td align="center" rowspan="1" colspan="1">−1.47 to −0.33</td><td align="center" rowspan="1" colspan="1">Welch <italic toggle="yes">t</italic> = −3.10</td><td align="center" rowspan="1" colspan="1">.002</td></tr><tr><td align="left" rowspan="2" colspan="1">Composite glycemic target</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">62/81 (76.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">73/126 (57.9%)</td><td align="center" rowspan="1" colspan="1">+18.6%</td><td align="center" rowspan="1" colspan="1">–</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 7.53</td><td align="center" rowspan="1" colspan="1">.006</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CI = confidence interval, FPG = fasting plasma glucose, HbA1c = glycated hemoglobin, HOMA-IR = homeostasis model assessment of insulin resistance, PPG = postprandial plasma glucose, SD = standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.4. Comparative evaluation of medication adjustment, adverse events, and treatment discontinuation</title><p>The safety and tolerability assessment showed that the proportion of patients requiring the initiation of an additional glucose-lowering medication was significantly lower in the observation group compared with the control group (7.4% vs 19.8%; χ<sup>2</sup> = 5.99, <italic toggle="yes">P</italic> = .014). The incidence of treatment-related adverse events was comparable between groups, with 22.2% in the observation group and 17.5% in the control group, and no statistically significant difference was detected (χ<sup>2</sup> = 0.72, <italic toggle="yes">P</italic> = .397). Discontinuation due to intolerance occurred infrequently in both cohorts, with 4.9% in the observation group and 1.6% in the control group, and the difference was not statistically significant (Fisher exact <italic toggle="yes">P</italic> = .212) (Table <xref rid="T4" ref-type="table">4</xref>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Safety and tolerability outcomes during follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Value</th><th align="center" rowspan="1" colspan="1">Effect/test</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Initiation of additional glucose-lowering medication, n/N (%)</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">6/81 (7.4)</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 5.99</td><td align="center" rowspan="1" colspan="1">.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">25/126 (19.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Any treatment-related AE, n/N (%)</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">18/81 (22.2)</td><td align="center" rowspan="1" colspan="1">χ<sup>2</sup> = 0.72</td><td align="center" rowspan="1" colspan="1">.397</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">22/126 (17.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Discontinuation due to intolerance, n/N (%)</td><td align="center" rowspan="1" colspan="1">Observation</td><td align="center" rowspan="1" colspan="1">4/81 (4.9)</td><td align="center" rowspan="1" colspan="1">Fisher exact</td><td align="center" rowspan="1" colspan="1">.212</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">2/126 (1.6)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>The present retrospective analysis demonstrated that, over a 6-month treatment period, liraglutide added to metformin achieved greater improvements in glycemic control than metformin alone while maintaining a comparable safety profile. The combination regimen was associated with a larger reduction in HbA1c (between-group mean difference in change, −0.50%; 95% CI, ‐0.74 to ‐0.26; <italic toggle="yes">P</italic> &lt; .001) alongside superior improvements in secondary glycemic indices, including fasting plasma glucose, postprandial plasma glucose, fasting insulin, and HOMA-IR. In parallel, a higher proportion of patients in the combination group reached the prespecified composite glycemic target. Requirements for treatment intensification were lower in the combination group, whereas the incidence of treatment-related adverse events and discontinuation due to intolerance did not differ significantly between groups. Collectively, these findings support the incremental glycemic benefits of GLP-1RA add-on therapy to metformin under routine clinical care conditions and indicate that such benefits can be achieved without an excess safety burden over 6 months. Contemporary guideline statements that prioritize GLP-1RAs as effective options after metformin (particularly when weight reduction and low hypoglycemia risk are desired) are consistent with these observations.</p><p>Mechanistically, the observed superiority of the combination regimen in reducing HbA1c and postprandial glycemia is congruent with the known pharmacology of GLP-1RAs: enhancement of glucose-dependent insulin secretion, suppression of inappropriate glucagon secretion, delayed gastric emptying, and consequent mitigation of postprandial excursions. Current standards synthesize these effects into treatment algorithms that recommend GLP-1RA therapy when additional glucose lowering beyond metformin is needed, especially in individuals for whom weight management and avoidance of hypoglycemia are priorities.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> Our data showing greater reductions in fasting insulin and HOMA-IR further suggest an improvement in insulin sensitivity and/or reduced insulin demand, aligning with recent evidence that GLP-1RA therapy favorably modulates metabolic efficiency. The magnitude of HbA1c reduction observed with liraglutide add-on in this cohort falls within the range reported for the GLP-1RA class in recent clinical literature. Although variability arises from baseline HbA1c, dose titration, adherence, and background therapies, our between-group difference in HbA1c change (−0.50%) is directionally consistent with the incremental benefit expected when adding a GLP-1RA to metformin versus continuing metformin alone. These class-consistenteffects are reflected in recent guidance and comparative analyses that position GLP-1RAs among the preferred add-on options after metformin.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup></p><p>The improvements in fasting insulin and HOMA-IR provide internal coherence to the primary glycemic findings. While HOMA-IR is an indirect index and subject to physiological and assay variability, the greater reduction observed with liraglutide add-on may indicate decreased insulin requirements owing to enhanced incretin-mediated insulin efficiency and reduced glucagon drive. Recent syntheses have also reported anti-inflammatoryand metabolic benefits with GLP-1RA therapy, which could contribute to improved whole-body insulin sensitivity over intermediate time horizons, though such pathways were not directly measured in this study.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref>]</sup> The safety profile observed here aligns with recent real-world and clinical-trial experience. The rates of “any treatment-related adverse event” did not differ significantly between groups over 6 months, and discontinuations due to intolerance were infrequent. Contemporary real-world effectiveness studies evaluating once-daily liraglutide add-on therapy similarly report acceptable tolerability with gastrointestinal events as the most common adverse effects and low discontinuation rates, supporting the generalizability of our findings to routine practice.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></p><p>Our findings accord with and extend recent evidence regarding the glycemic efficacy and tolerability of GLP-1RAs added to metformin. The 2024 and 2025 updates of the American Diabetes Association Standards of Care summarize high-qualitydata showing that GLP-1RAs produce clinically meaningful HbA1c reductions, favorably affect postprandial glucose, and promote weight loss with a low risk of hypoglycemia; they are recommended as preferred add-on therapy to metformin in many clinical scenarios, including individuals prioritizing weight reduction or those at high cardiovascular risk. The present analysis reproduces the incremental HbA1c benefit of GLP-1RA add-on over 6 months and demonstrates concordant improvements across FPG, PPG, and HOMA-IR. Beyond guidelines, recent comparative and real-world reports provide complementary context.<sup>[<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>]</sup> A 2023 network meta-analysis comparing multiple GLP-1RAs confirmed class-wide reductions in HbA1c and body weight without an increased incidence of hypoglycemia relative to comparators, supporting their positioning as effective glucose-lowering therapies with ancillary metabolic benefits. Real-world cohorts evaluating liraglutide add-on regimens have further documented clinically relevant HbA1c reductions and acceptable tolerability profiles across diverse practice settings. Our data are consistent with these observations, although the present study was not designed to quantify weight change or gastrointestinal adverse-event subtypes.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> In addition, emerging analyses underscore that the glycemic and metabolic gains with GLP-1RAs translate into treatment de-intensification in some patients, reflected by reduced need for therapy escalation. In our cohort, the initiation of additional glucose-lowering medication was significantly less frequent with liraglutide plus metformin than with metformin alone, mirroring recent clinical practice insights that GLP-1RA add-on can reduce downstream intensification, at least over intermediate follow-up. Taken together, the current results are directionally aligned with contemporary comparative effectiveness research and guideline-driven care pathways, reinforcing the role of GLP-1RA add-on to metformin as a rational strategy for patients requiring additional glycemic control.</p><p>Beyond statistical significance, the present study demonstrates a clinically meaningful incremental reduction in HbA1c of 0.50% with liraglutide add-on therapy compared with metformin alone. Importantly, this benefit was consistently supported by parallel improvements in fasting and postprandial glucose, fasting insulin levels, and HOMA-IR, suggesting a coherent metabolic effect rather than an isolated glycemic change. The reduced need for additional glucose-lowering medications observed in the combination group further underscores the potential of liraglutide to delay treatment intensification in routine practice, which may translate into simplified therapeutic regimens and improved long-term adherence.</p><p>For clinicians managing adults with type 2 diabetes inadequately controlled on metformin, adding liraglutide offers incremental HbA1c reduction and broader glycemic improvements without excess adverse events over 6 months. The higher achievement of composite glycemic targets and the lower need for treatment intensification observed in this study suggest potential to simplify regimens and delay escalation, consistent with American Diabetes Association recommendations that favor GLP-1RAs when additional efficacy with weight neutrality/benefit and low hypoglycemia risk is desired. Patient selection should consider gastrointestinal tolerability, injection preference, and access, but the net clinical profile supports routine consideration of GLP-1RA add-on after metformin. This study has several strengths. First, it reflects real-world practice over a uniform 6-month treatment horizon with standardized laboratory testing, allowing consistent ascertainment of primary and secondary glycemic outcomes. Second, the dataset captured multiple domains of glucose metabolism (HbA1c, FPG, PPG, fasting insulin, and HOMA-IR) and clinically relevant endpoints (composite glycemic targets, treatment intensification, and adverse events), enabling convergent assessment of therapeutic effectiveness and tolerability. Third, both treatment groups were comparable at baseline across demographic, metabolic, and comorbidity profiles, reducing confounding by indication at study entry.</p><p>Several limitations merit consideration. The retrospective, nonrandomized design is susceptible to residual confounding and selection bias despite baseline balance; unmeasured factors (e.g., diet quality, physical activity, medication adherence, socioeconomic determinants) may have influenced outcomes. The follow-up was limited to 6 months; durability of glycemic benefit and long-term safety, including cardiovascular and renal outcomes, were not evaluated. Weight change, gastrointestinal adverse-event subtypes, and hypoglycemia incidence were not systematically adjudicated, limiting comparisons with trials that include these endpoints. Finally, single-center data may constrain generalizability across health systems with different prescribing patterns and formularies. Prospective randomized studies or pragmatic trials with longer follow-up and broader outcome capture would strengthen causal inference and external validity.</p></sec><sec sec-type="conclusions"><title>5. Conclusions</title><p>In this retrospective study, liraglutide combined with metformin produced greater improvements in HbA1c, glucose metabolism parameters, and glycemic target achievement compared with metformin monotherapy, without increasing adverse event incidence. These findings suggest that liraglutide add-on therapy may offer enhanced glycemic benefit with acceptable tolerability in patients with type 2 diabetes inadequately controlled with metformin alone.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Tingting Mai.</p><p><bold>Data curation:</bold> Tingting Mai.</p><p><bold>Formal analysis:</bold> Tingting Mai.</p><p><bold>Funding acquisition:</bold> Tingting Mai.</p><p><bold>Investigation:</bold> Tingting Mai.</p><p><bold>Writing – original draft:</bold> Tingting Mai.</p><p><bold>Writing – review &amp; editing:</bold> Tingting Mai.</p></sec></body><back><fn-group><fn fn-type="abbr"><p><def-list><title>Abbreviations:</title><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>FPG</term><def><p>fasting plasma glucose</p></def></def-item><def-item><term>GLP-1RA</term><def><p>glucagon-like peptide-1 receptor agonist</p></def></def-item><def-item><term>HbA1c</term><def><p>glycated hemoglobin</p></def></def-item><def-item><term>HOMA-IR</term><def><p>homeostasis model assessment of insulin resistance</p></def></def-item><def-item><term>PPG</term><def><p>postprandial plasma glucose</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="other"><p>The author has no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></fn><fn fn-type="other"><p>How to cite this article: Mai T. Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study. Medicine 2026;105:7(e47562).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>. <article-title>Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.</article-title>
<source>Ir J Med Sci</source>. <year>2023</year>;<volume>192</volume>:<fpage>2809</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">37036569</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11845-023-03337-2</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsen</surname><given-names>LV</given-names></name><name name-style="western"><surname>Flint</surname><given-names>A</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>AK</given-names></name><name name-style="western"><surname>Ingwersen</surname><given-names>SH</given-names></name></person-group>. <article-title>Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics.</article-title>
<source>Clin Pharmacokinet</source>. <year>2016</year>;<volume>55</volume>:<fpage>657</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">26597252</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0343-6</pub-id><pub-id pub-id-type="pmcid">PMC4875959</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capehorn</surname><given-names>MS</given-names></name><name name-style="western"><surname>Catarig</surname><given-names>AM</given-names></name><name name-style="western"><surname>Furberg</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).</article-title>
<source>Diabetes Metab</source>. <year>2020</year>;<volume>46</volume>:<fpage>100</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">31539622</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabet.2019.101117</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaman</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bain</surname><given-names>SC</given-names></name><name name-style="western"><surname>Bakris</surname><given-names>GL</given-names></name><etal/></person-group>. <article-title>Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER.</article-title>
<source>Circulation</source>. <year>2022</year>;<volume>145</volume>:<fpage>575</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">34903039</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.121.055459</pub-id><pub-id pub-id-type="pmcid">PMC8860212</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bendotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Montefusco</surname><given-names>L</given-names></name><name name-style="western"><surname>Lunati</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>The anti-inflammatory and immunological properties of GLP-1 receptor agonists.</article-title>
<source>Pharmacol Res</source>. <year>2022</year>;<volume>182</volume>:<fpage>106320</fpage>.<pub-id pub-id-type="pmid">35738455</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2022.106320</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayaniyil</surname><given-names>S</given-names></name><name name-style="western"><surname>Lozano-Ortega</surname><given-names>G</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>HA</given-names></name><etal/></person-group>. <article-title>A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus.</article-title>
<source>Diabetes Ther</source>. <year>2016</year>;<volume>7</volume>:<fpage>27</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">26886440</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13300-016-0155-1</pub-id><pub-id pub-id-type="pmcid">PMC4801811</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ard</surname><given-names>J</given-names></name><name name-style="western"><surname>Fitch</surname><given-names>A</given-names></name><name name-style="western"><surname>Fruh</surname><given-names>S</given-names></name><name name-style="western"><surname>Herman</surname><given-names>L</given-names></name></person-group>. <article-title>Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists.</article-title>
<source>Adv Ther</source>. <year>2021</year>;<volume>38</volume>:<fpage>2821</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">33977495</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-021-01710-0</pub-id><pub-id pub-id-type="pmcid">PMC8189979</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousef</surname><given-names>CC</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Matar</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Liraglutide effects on glycemic control and weight in patients with type 2 diabetes mellitus: a real-world, observational study and brief narrative review.</article-title>
<source>Diabetes Res Clin Pract</source>. <year>2021</year>;<volume>177</volume>:<fpage>108871</fpage>.<pub-id pub-id-type="pmid">34052248</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.108871</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.</article-title>
<source>Prim Care Diabetes</source>. <year>2023</year>;<volume>17</volume>:<fpage>460</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">37541792</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pcd.2023.07.006</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>EH</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chou</surname><given-names>TS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TH</given-names></name></person-group>. <article-title>A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists.</article-title>
<source>Medicina (Kaunas)</source>. <year>2024</year>;<volume>60</volume>:<fpage>357</fpage>.<pub-id pub-id-type="pmid">38541083</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medicina60030357</pub-id><pub-id pub-id-type="pmcid">PMC10972401</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegegne</surname><given-names>BA</given-names></name><name name-style="western"><surname>Adugna</surname><given-names>A</given-names></name><name name-style="western"><surname>Yenet</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents.</article-title>
<source>Front Endocrinol (Lausanne)</source>. <year>2024</year>;<volume>15</volume>:<fpage>1440456</fpage>.<pub-id pub-id-type="pmid">39493778</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2024.1440456</pub-id><pub-id pub-id-type="pmcid">PMC11527681</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis.</article-title>
<source>Diabetes Obes Metab</source>. <year>2025</year>;<volume>27</volume>:<fpage>3607</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">40230207</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.16366</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karagiannis</surname><given-names>T</given-names></name><name name-style="western"><surname>Avgerinos</surname><given-names>I</given-names></name><name name-style="western"><surname>Liakos</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.</article-title>
<source>Diabetologia</source>. <year>2022</year>;<volume>65</volume>:<fpage>1251</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">35579691</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-022-05715-4</pub-id><pub-id pub-id-type="pmcid">PMC9112245</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sodhi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rezaeianzadeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Kezouh</surname><given-names>A</given-names></name><name name-style="western"><surname>Etminan</surname><given-names>M</given-names></name></person-group>. <article-title>Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.</article-title>
<source>JAMA</source>. <year>2023</year>;<volume>330</volume>:<fpage>1795</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">37796527</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.19574</pub-id><pub-id pub-id-type="pmcid">PMC10557026</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>AB</given-names></name><name name-style="western"><surname>Renström</surname><given-names>F</given-names></name><name name-style="western"><surname>Aczél</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study.</article-title>
<source>Obes Surg</source>. <year>2023</year>;<volume>33</volume>:<fpage>1017</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">36765019</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11695-023-06484-8</pub-id><pub-id pub-id-type="pmcid">PMC9918402</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group>. <article-title>Clinical efficacy and safety of liraglutide and dapagliflozin on glucose and lipid metabolism and insulin function in patients with type 2 diabetes mellitus.</article-title>
<source>Altern Ther Health Med</source>. <year>2024</year>;<volume>30</volume>:<fpage>144</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">38294744</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group>. <article-title>Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.</article-title>
<source>Front Endocrinol (Lausanne)</source>. <year>2023</year>;<volume>14</volume>:<fpage>1244432</fpage>.<pub-id pub-id-type="pmid">37701904</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1244432</pub-id><pub-id pub-id-type="pmcid">PMC10493284</pub-id></mixed-citation></ref></ref-list></back></article><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Biol Chem</journal-id><journal-id journal-id-type="pmc-domain-id">567</journal-id><journal-id journal-id-type="pmc-domain">jbc</journal-id><journal-title-group><journal-title>The Journal of Biological Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12906186</article-id><article-id pub-id-type="pmcid-ver">PMC12906186.1</article-id><article-id pub-id-type="pmcaid">12906186</article-id><article-id pub-id-type="pmcaiid">12906186</article-id><article-id pub-id-type="pmid">41539566</article-id><article-id pub-id-type="doi">10.1016/j.jbc.2026.111159</article-id><article-id pub-id-type="pii">S0021-9258(26)00029-3</article-id><article-id pub-id-type="publisher-id">111159</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Metformin suppresses PPARδ-driven CD47 transcription to enhance macrophage phagocytosis in lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Cui</surname><given-names initials="Q">Qian</given-names></name></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Wang</surname><given-names initials="H">Huijie</given-names></name></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Yu</surname><given-names initials="H">Hongxu</given-names></name></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yinghan</given-names></name></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yelei</given-names></name></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Shi</surname><given-names initials="J">Juanjuan</given-names></name></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Hou</surname><given-names initials="Y">Yongzhong</given-names></name><email>houyz@ujs.edu.cn</email><xref rid="cor1" ref-type="corresp">∗</xref></contrib><aff id="aff1">School of Life Science, Jiangsu University, Zhenjiang, Jiangsu Province, People's Republic of China</aff></contrib-group><author-notes><corresp id="cor1"><label>∗</label>For correspondence: Yongzhong Hou <email>houyz@ujs.edu.cn</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>13</day><month>1</month><year>2026</year></pub-date><volume>302</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">507031</issue-id><elocation-id>111159</elocation-id><history><date date-type="received"><day>6</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>7</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>15</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-15 10:25:14.707"><day>15</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2026 The Authors</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Metformin, an activator of AMP kinase, influences critical cellular processes, including proliferation, metabolism, inflammation, and immunity. However, its specific impact on macrophage-mediated phagocytosis of tumor cells remains poorly characterized. Our study demonstrates that metformin treatment substantially decreases both CD47 protein and mRNA levels in lung cancer cells. This reduction stems from metformin's suppression of CD47 gene transcription. Consequently, metformin enhances macrophage phagocytic activity against cancer cells. <italic toggle="yes">In vivo</italic> analyses using a tumor implantation model revealed that metformin impedes tumor immune escape. This effect correlates with diminished CD47 expression within tumors and heightened macrophage phagocytosis. Furthermore, combining metformin with an anti-CD47 antibody synergistically augmented antitumor immunotherapy efficacy. Mechanistically, metformin attenuates peroxisome proliferator–activated receptor delta–mediated CD47 transcriptional activation and subsequent gene expression. These results elucidate a novel mechanism by which metformin counteracts tumor immune evasion.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>metformin</kwd><kwd>CD47</kwd><kwd>PPARδ</kwd><kwd>phagocytosis</kwd><kwd>immune evasion</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0040">AMPK</term><def><p>AMP-activated protein kinase</p></def></def-item><def-item><term id="kwrd0050">CFSE</term><def><p>carboxyfluorescein succinimidyl ester</p></def></def-item><def-item><term id="kwrd0060">LLC</term><def><p>Lewis lung carcinoma</p></def></def-item><def-item><term id="kwrd0070">PD-1</term><def><p>programmed cell death protein 1</p></def></def-item><def-item><term id="kwrd0080">PD-L1</term><def><p>programmed cell death ligand 1</p></def></def-item><def-item><term id="kwrd0090">PPARδ</term><def><p>peroxisome proliferator–activated receptor delta</p></def></def-item><def-item><term id="kwrd0100">SIRPα</term><def><p>signal regulatory protein α</p></def></def-item></def-list><notes><p id="misc0010">Reviewed by members of the JBC Editorial Board. Edited by Paul Shapiro</p></notes></front><body><p id="p0010">Metformin, a synthetic biguanide, is widely regarded as a foundational therapy for type 2 diabetes and ranks among the most commonly prescribed medications worldwide (<xref rid="bib1" ref-type="bibr">1</xref>). In addition to its well-established glucose-lowering effects, metformin exhibits a significant role in protection against tumor development (<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>). Clinically, metformin use is associated with reduced cancer incidence and improved outcomes in colorectal, pancreatic, hepatocellular, breast, and lung cancer (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>), underscoring its potential as an antineoplastic agent. The AMP-activated protein kinase (AMPK) serves as a primary target of metformin, functioning as a central sensor of cellular energy status (<xref rid="bib8" ref-type="bibr">8</xref>). Metformin-induced AMPK activation restrains cancer cell proliferation and tumor growth (<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>). Importantly, metformin also modulates tumor immunology. It can reduce programmed cell death ligand 1 (PD-L1) expression on cancer cells, thereby augmenting T cell–mediated cytotoxicity (<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>). This positions metformin as a modulator of cancer immune evasion, although its full immunomodulatory potential remains incompletely characterized.</p><p id="p0015">Cancer immune evasion is orchestrated through multiple, nonredundant checkpoint systems. While the programmed cell death protein 1 (PD-1)–PD-L1 axis constitutes a dominant “don't find me” signal impairing adaptive T-cell immunity, the CD47–signal regulatory protein α (SIRPα) axis represents a crucial “don't eat me” signal that dampens innate immune responses (<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>). CD47, frequently overexpressed in lung cancer and other solid tumors, binds to SIRPα on macrophages, thereby suppressing phagocytic clearance and facilitating immune escape (<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>). The transcriptional regulation of CD47 is governed by several factors, including Myc, NF-κB, hypoxia-inducible factor 1, and nuclear respiratory factor 1 (<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). Notably, the nuclear receptor peroxisome proliferator–activated receptor delta (PPARδ), encoded by the <italic toggle="yes">PPARD</italic> gene, has been identified as a direct transcriptional activator of CD47. Ligand-mediated activation of PPARδ leads to increased CD47 expression, which consequently inhibits macrophage phagocytosis (<xref rid="bib21" ref-type="bibr">21</xref>). PPARδ activity is itself regulated by AMPK (<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>). Specifically, AMPK can directly bind to PPARδ and induce its phosphorylation, an action that inhibits PPARδ′s transcriptional activity and suppresses colorectal cancer cell proliferation. Furthermore, the AMPK agonist metformin enhances this inhibitory process (<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib35" ref-type="bibr">35</xref>). Although PPARδ is established as a transcriptional activator of CD47 (<xref rid="bib21" ref-type="bibr">21</xref>), the potential involvement of the AMPK–PPARδ axis in CD47-mediated immune escape remains unexplored. Here, we found that metformin–AMPK–PPARδ pathway inhibited CD47-mediated tumor immune escape.</p><sec id="sec1"><title>Results</title><sec id="sec1.1"><title>Metformin suppresses CD47 membrane expression</title><p id="p0020">To evaluate metformin's effect on CD47 regulation, four lung cancer cell lines (H520, H1975, H1299, and Lewis lung carcinoma [LLC]) were treated with 30 mM metformin for different durations. Immunoblotting analysis demonstrated a time-dependent attenuation of total CD47 protein (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">A</italic>). Dose–course experiments further established progressive CD47 reduction over treatment duration (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">B</italic>). Flow cytometric quantification confirmed a significant reduction of membrane-localized CD47 in all tested cell lines (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">C</italic>). These findings collectively indicate that metformin, as an AMPK activator, downregulates surface CD47 expression in lung cancer cells.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p><bold>Metformin reduces CD47 protein expression.</bold><italic toggle="yes">A</italic>, cells were treated with 30 mM metformin for the indicated times. Western blot analysis was performed, and the blots were quantified (mean ± SD, n = 3). <italic toggle="yes">B</italic>, cells were treated with metformin (0, 5, 10, and 30 mM) for 6 h. Cell lysates were analyzed by Western blot, and blots were quantified (mean ± SD, n = 3). <italic toggle="yes">C</italic>, surface CD47 expression was analyzed by flow cytometry in cells treated with 30 mM metformin for 6 h. Median fluorescence intensity (MFI) values are shown as mean ± SD (n = 3). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at p &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p><bold>Metformin inhibits CD47 expression at the transcriptional level.</bold><italic toggle="yes">A</italic>, quantitative PCR analysis showing reduced CD47 mRNA levels in cells treated with 30 mM metformin for 6 h. Data represent mean ± SD (n = 3). <italic toggle="yes">B</italic>, luciferase reporter assay of CD47 promoter activity. Cells cotransfected with pGL3-CD47-lu and Ptk-RL plasmids for 48 h were treated with 30 mM metformin for 6 h. Data represent mean ± SD (n = 3). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec1.2"><title>Metformin transcriptionally represses CD47 expression</title><p id="p0025">Building on the observed CD47 protein suppression, we investigated transcriptional regulation as a potential mechanism. Quantitative PCR analysis revealed a decrease in CD47 mRNA levels in lung cancer cells (H520, H1975, H1299, and LLC), following treatment with 30 mM metformin (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">A</italic>). This transcriptional inhibition was further corroborated by luciferase reporter assays, showing significant attenuation of CD47 promoter activity following metformin exposure (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">B</italic>). Collectively, these data establish transcriptional repression as the primary mechanism through which metformin downregulates CD47 expression.</p></sec><sec id="sec1.3"><title>Metformin potentiates macrophage phagocytic function</title><p id="p0030">The CD47–SIRPα checkpoint axis suppresses macrophage-mediated phagocytosis by transmitting “don't eat me” signals (<xref rid="bib22" ref-type="bibr">22</xref>). Given our findings that metformin transcriptionally represses CD47 in lung cancer cells, we investigated its functional impact on immune evasion. To assess whether CD47 downregulation reverses phagocytic inhibition, macrophages were cocultured with lung cancer cells pretreated with metformin. Quantitative phagocytosis assays revealed an increase in macrophage engulfment of metformin-exposed tumor cells <italic toggle="yes">versus</italic> controls (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>). This demonstrates that metformin-induced CD47 suppression functionally antagonizes the CD47–SIRPα axis, thereby enhancing immunophagocytic clearance of lung cancer cells.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p><bold>Metformin potentiates macrophage phagocytic function.</bold><italic toggle="yes">A</italic>, flow cytometry analysis of phagocytosis in macrophages cocultured with target cells preexposed to 30 mM metformin or control (6 h). The percent of phagocytosis was quantified. Data represent mean ± SD (n = 3). <italic toggle="yes">B</italic>, CFSE-labeled target cells and anti–CD11b-stained macrophages were analyzed after coculture with metformin-treated targets (30 mM, 6 h). Phagocytic activity was assayed by immunofluorescence. The scale bars represent 50 μm. More than 100 cells were scored (mean ± SD, n = 4). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001. CFSE, carboxyfluorescein succinimidyl ester.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec1.4"><title>Metformin inhibits tumor immune evasion <italic toggle="yes">via</italic> suppression of CD47</title><p id="p0035">Cancer cells evade macrophage phagocytosis by expressing CD47 (<xref rid="bib22" ref-type="bibr">22</xref>). To assess whether metformin counteracts this immune evasion mechanism by reducing CD47 levels, we utilized a subcutaneous murine lung tumor model. Compared with saline-treated controls, metformin-treated mice exhibited significantly slower tumor progression and lower terminal tumor mass (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>). Analysis of tumors by Western blot demonstrated that metformin administration effectively lowered CD47 expression (<xref rid="fig4" ref-type="fig">Fig. 4</xref><italic toggle="yes">C</italic>). Concurrently, we observed a substantial increase in F4/80<sup>+</sup> macrophage infiltration within the tumors (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic>), which was associated with heightened phagocytic activity.<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p><bold>Metformin blocks tumor immune escape <italic toggle="yes">in vivo</italic>.</bold><italic toggle="yes">A</italic>–<italic toggle="yes">D</italic>, subcutaneous LLC tumor–bearing C57BL/6 mice received metformin treatment. Tumor volume, tumor weight, and body weight were measured (mean ± SD; n = 5). <italic toggle="yes">E</italic>, multiplex immunofluorescence staining of tumor sections showing CK19 (tumor) and F4/80 (macrophage) levels. The scale bars represent 20 μm. Phagocytic activity was assayed by immunofluorescence. More than 100 cells were scored (mean ± SD; n = 5). <italic toggle="yes">F</italic>, CD47 protein levels in tumor lysates by immunoblotting with quantitative analysis (mean ± SD; n = 5). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001. LLC, Lewis lung carcinoma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec1.5"><title>Metformin exhibits additive effects with the CD47 antibody on antitumor immunity</title><p id="p0040">Capitalizing on the observation that metformin impedes tumor immune evasion, we explored its capacity to enhance the effectiveness of immunotherapy. In a murine tumor model, animals were treated with metformin alone, anti-CD47 antibody alone, or both agents combined. Metformin monotherapy curbed tumor growth and reduced the end-point tumor mass. However, the combined regimen achieved significantly greater suppression of tumor progression and final mass than either single-agent treatment (<xref rid="fig5" ref-type="fig">Fig. 5</xref>, <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic>). Immunofluorescence assessment further showed that tumors from the combination group had markedly increased infiltration of F4/80<sup>+</sup> macrophages compared with those treated solely with anti-CD47 antibody (<xref rid="fig5" ref-type="fig">Fig. 5</xref><italic toggle="yes">C</italic>). These findings indicate that metformin exhibits additive effects with the CD47 antibody on antitumor immunity.<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p><bold>Metformin exhibits additive effects with the CD47 antibody on antitumor immunity.</bold><italic toggle="yes">A</italic>–<italic toggle="yes">C</italic>, C57BL/6 mice with subcutaneously implanted LLC cells (2 × 10<sup>5</sup>) received metformin monotherapy, anti-CD47 monotherapy, or combination therapy. Tumor volume, tumor weight, and body weight were measured (mean ± SD; n = 5). <italic toggle="yes">D</italic>, multiplex immunofluorescence staining of tumor sections showing CK19 (tumor) and F4/80 (macrophage) levels. The scale bars represent 20 μm. Phagocytic activity was assayed by immunofluorescence. More than 100 cells were scored (mean ± SD; n = 5). <italic toggle="yes">E</italic>, immunoblot-based quantification of CD47 protein in tumor lysates (mean ± SD; n = 5). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001. LLC, Lewis lung carcinoma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec1.6"><title>Metformin suppresses CD47 expression dependent on PPARδ</title><p id="p0045">Our previous investigation suggested that PPARδ induces CD47 expression (<xref rid="bib36" ref-type="bibr">36</xref>). Metformin downregulates CD47 expression, but its dependence on PPARδ remained undetermined. To investigate this mechanism, we overexpressed PPARδ in H520 cells and treated them with metformin. Western blot analysis showed that overexpressed PPARδ increased CD47 expression, which was reversed by metformin (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">A</italic>). Similarly, overexpressed PPARδ increased CD47 gene expression and transcriptional activity, which was reduced by metformin treatment (<xref rid="fig6" ref-type="fig">Fig. 6</xref>, <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic>). Metformin treatment had a more significant effect (<xref rid="fig6" ref-type="fig">Fig. 6</xref>, <italic toggle="yes">D</italic>–<italic toggle="yes">F</italic>, <xref rid="appsec1" ref-type="sec">Fig S1</xref>), which was consistent with the results from PPARδ-knockout H520 cells generated by CRISPR–Cas9 (<xref rid="fig6" ref-type="fig">Fig. 6</xref>, <italic toggle="yes">G</italic>–<italic toggle="yes">I</italic>). These findings suggest that metformin decreases CD47 expression in a PPARδ-dependent manner.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p><bold>Metformin downregulates CD47 <italic toggle="yes">via</italic> a PPARδ-dependent pathway.</bold><italic toggle="yes">A</italic>, H520 cells were transfected with pcDNA3 (control) or pcDNA3-FLAG-PPARδ. After 48 h, cells were treated with or without 30 mM metformin for 6 h. Western blot analysis and blot quantification were performed (mean ± SD, n = 3). <italic toggle="yes">B</italic>, H520 cells were transfected with pcDNA3 (control) or pcDNA3-FLAG-PPARδ. After 48 h, cells were treated with or without 30 mM metformin for 6 h. Quantitative PCR analysis was performed (mean ± SD, n = 3). <italic toggle="yes">C</italic>, H520 cells transfected with the indicated plasmids were exposed to vehicle or 30 mM metformin for 6 h. Luciferase reporter assay was performed (mean ± SD, n = 3). <italic toggle="yes">D</italic>, H520 cells were transfected with control siRNA or PPARδ siRNA. After 48 h, cells were treated with or without 30 mM metformin for 6 h. Western blot and quantification were performed (mean ± SD, n = 3). <italic toggle="yes">E</italic>, H520 cells were transfected with control siRNA or PPARδ siRNA. After 48 h, cells were treated with or without 30 mM metformin for 6 h. Quantitative PCR analysis was performed (mean ± SD, n = 3). <italic toggle="yes">F</italic>, H520 cells were transfected with control siRNA or PPARδ siRNA together with reporter plasmids as indicated. After 48 h, cells were treated with or without 30 mM metformin for 6 h. Luciferase reporter assay was performed (mean ± SD, n = 3). <italic toggle="yes">G</italic>, WT and PPARδ-knockout H520 cells were treated with 30 mM metformin for 6 h. Western blot and quantification were performed (mean ± SD, n = 3). <italic toggle="yes">H</italic>, WT and PPARδ-knockout H520 cells were treated with 30 mM metformin for 6 h. Quantitative PCR analysis was performed (mean ± SD, n = 3). <italic toggle="yes">I</italic>, WT and PPARδ-knockout H520 cells transfected with reporter plasmids as indicated were treated with or without 30 mM metformin for 6 h after 48 h. Luciferase reporter assay was performed (mean ± SD, n = 3). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001. PPARδ, peroxisome proliferator–activated receptor delta.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec1.7"><title>Metformin inhibits CD47 expression <italic toggle="yes">via</italic> the AMPK–PPARδ pathway</title><p id="p0050">Previous investigations show that metformin facilitates AMPK-mediated phosphorylation of the PPARδ S50 residue, leading to inhibition of PPARδ activity (<xref rid="bib13" ref-type="bibr">13</xref>). To further determine the effect of the PPARδ phosphomimetic mutant (S50E) on CD47 expression, PPARδ-deficient (PPARδ<sup>−/−</sup>) H520 cells were reconstituted with either WT PPARδ or the S50E mutant. The results showed that although overexpression of PPARδ increased CD47 expression, the PPARδ–S50E mutant reversed this effect (<xref rid="fig7" ref-type="fig">Fig. 7</xref><italic toggle="yes">A</italic>). Similarly, PPARδ promoted CD47 gene expression and increased its transcriptional activity, whereas the PPARδ–S50E mutant reversed this effect (<xref rid="fig7" ref-type="fig">Fig. 7</xref>, <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic>). To assess the effect of the PPARδ–S50E mutant on macrophage phagocytosis, macrophages were cocultured with H520 cells that had been reconstituted with either WT PPARδ or the S50E mutant. The results revealed that overexpression of PPARδ inhibited phagocytosis, but the S50E mutant reversed this effect (<xref rid="fig7" ref-type="fig">Fig. 7</xref><italic toggle="yes">D</italic>). These findings suggest that metformin inhibits CD47 expression <italic toggle="yes">via</italic> the AMPK–PPARδ pathway.<fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p><bold>PPARδ phosphomimetic mutant (S50E) loses CD47 induction capacity.</bold><italic toggle="yes">A</italic>, Western blot analysis of CD47 protein expression in WT or PPARδ-deficient (PPARδ<sup>−/−</sup>) H520 cells re-expressing either PPARδ or the S50E mutant. Quantified CD47 protein levels are shown as mean ± SD (n = 3). <italic toggle="yes">B</italic>, quantitative PCR analysis of CD47 mRNA levels in WT or PPARδ<sup>−/−</sup> H520 cells re-expressing PPARδ or the S50E mutant. Data are presented as mean ± SD (n = 3). <italic toggle="yes">C</italic>, luciferase reporter assay measuring CD47 promoter activity in WT or PPARδ<sup>−/−</sup> H520 cells re-expressing PPARδ or the S50E mutant. Data are presented as mean ± SD (n = 3). <italic toggle="yes">D</italic>, phagocytosis assay: CFSE-labeled WT or PPARδ<sup>−/−</sup> H520 cells re-expressing PPARδ or the S50E mutant were cocultured with macrophages (CD11b). Phagocytic activity was assayed by immunofluorescence. The scale bars represent 50 μm. More than 100 cells were scored; data are presented as mean ± SD (n = 4). A paired Student's t test was used for comparison between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparison among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.05, ∗∗<italic toggle="yes">p</italic> &lt; 0.01, ∗∗∗&lt;0.001,∗∗∗∗&lt;0.0001. CFSE, carboxyfluorescein succinimidyl ester; PPARδ, peroxisome proliferator–activated receptor delta.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p></sec></sec><sec id="sec2"><title>Discussion</title><p id="p0055">The host immune system possesses inherent antitumor capabilities when activated (<xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>). However, the immune checkpoint protein PD-L1, acting as a “don't find me” signal, binds PD-1 on T cells to promote immunosuppression in cancer (<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib39" ref-type="bibr">39</xref>). Beyond the established role of adaptive immune checkpoints like PD-1–PD-L1 in cancer immunotherapy, innate immune checkpoints, particularly the SIRPα–CD47 axis, are crucial regulators of tumor immune surveillance (<xref rid="bib22" ref-type="bibr">22</xref>). CD47, a glycoprotein frequently overexpressed on cancer cells, engages SIRPα on phagocytes. This interaction delivers an inhibitory “don't eat me” signal, suppressing phagocytosis (<xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>). The elevated CD47 levels observed in tumors are transcriptionally regulated by factors, including NF-κB, HIF, Myc, and PPARδ (<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>). Consequently, reducing CD47 expression disrupts this signal, enhancing macrophage phagocytosis of cancer cells and thereby inhibiting tumor immune escape (<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib36" ref-type="bibr">36</xref>). Metformin—primarily used for diabetes—is accumulating evidence for exhibiting anticancer effects across various malignancies (<xref rid="bib44" ref-type="bibr">44</xref>), alongside targeted therapies and immunotherapy (<xref rid="bib45" ref-type="bibr">45</xref>). Metformin activates AMPK, which subsequently triggers phosphorylation of PD-L1 at serine-195. This phosphorylation impairs PD-L1 glycosylation and targets it for endoplasmic reticulum–associated protein degradation (<xref rid="bib16" ref-type="bibr">16</xref>). Consequently, metformin augments antitumor immunotherapy efficacy (<xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>). In this study, our results demonstrated that treatment with the AMPK agonist metformin significantly decreased CD47 expression. This decrease, in turn, increased macrophage phagocytosis of cancer cells. This study revealed a novel role of metformin on the macrophage phagocytosis in the tumor microenvironment by reducing CD47 expression.</p><p id="p0060">Numerous studies suggest that metformin treatment affects T-cell activity by reprogramming tumor-specific T-cell metabolism (<xref rid="bib48" ref-type="bibr">48</xref>) and reducing PD-L1 expression (<xref rid="bib16" ref-type="bibr">16</xref>). This consequently enhances the host adaptive immunity, which in turn blocks tumor immune escape and effectively enhances antitumor immunotherapy (<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>). Our study also provides insight into the effect of metformin on innate immune checkpoints (the SIRPα–CD47 axis).</p><p id="p0065">PPARδ, a member of the PPAR family (<xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>), is activated by fatty acids and their derivatives. This receptor participates in mucosal inflammation and malignant transformation (<xref rid="bib51" ref-type="bibr">51</xref>) with aberrant expression or activation driving metastatic progression and tumorigenesis (<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref>, <xref rid="bib59" ref-type="bibr">59</xref>). Upon activation, PPARδ binds peroxisome proliferator response elements in target gene promoters to regulate transcription (<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>). AMPK, a conserved metabolic sensor in eukaryotes, responds to ATP depletion by modulating cellular and organismal metabolism (<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib64" ref-type="bibr">64</xref>), critically regulating cell growth and metabolic pathways (<xref rid="bib11" ref-type="bibr">11</xref>). Metformin activates AMPK, which phosphorylates PPARδ. This phosphorylation event inhibits PPARδ′s transcriptional activity—reducing glucose/glutamine uptake and suppressing cancer cell proliferation and tumor growth (<xref rid="bib13" ref-type="bibr">13</xref>). Notably, our prior work demonstrated that PPARδ activation upregulates CD47 transcription, inhibiting macrophage phagocytosis (<xref rid="bib36" ref-type="bibr">36</xref>). Conversely, PPARδ antagonism suppresses CD47 expression, promoting phagocytosis and limiting tumor immune escape (<xref rid="bib21" ref-type="bibr">21</xref>). In this study, PPARδ overexpression elevated CD47 levels—an effect abrogated by metformin. Similarly, PPARδ overexpression inhibited phagocytosis, whereas the phospho-mimicking mutant PPARδ–S50E failed to upregulate CD47. These findings align with AMPK-mediated phosphorylation of PPARδ at Ser50, suppressing its transcriptional function (<xref rid="bib13" ref-type="bibr">13</xref>) and suggest that metformin decreases CD47 expression in a PPARδ-dependent manner.</p><p id="p0070">In conclusion, this study demonstrates that metformin treatment enhances macrophage phagocytosis by reducing CD47 expression in a PPARδ-dependent manner in lung cancer cells, thereby inhibiting tumor immune escape. These findings reveal a potential immunotherapy strategy.</p></sec><sec id="sec3"><title>Experimental procedures</title><sec id="sec3.1"><title>Antibodies, reagents, and plasmids</title><p id="p0075">The primary antibodies recognizing tubulin, PPARδ, CK19, and CD47 were derived from Proteintech. PE-labeled CD11b and FITC-labeled CD47 antibodies, as well as matching PE-IgG and FITC-IgG isotype controls, were all obtained from Elabscience. Jackson ImmunoResearch provided the secondary antibodies. PPARδ siRNA was purchased from Sangon Biotec. Sense: A1GUUUGAAUUUGCUGUCAAGU; antisense: UUGACAGCAAAUUCAAACUUA. In addition, the metformin (MedChemExpress) and a protease inhibitor cocktail (Yeasen) were used. PPARδ and PPARδ–S50E were described previously (<xref rid="bib13" ref-type="bibr">13</xref>). pGl3-CD47-lu, pRL-TK plasmids were described previously (<xref rid="bib36" ref-type="bibr">36</xref>).</p></sec><sec id="sec3.2"><title>Cell culture</title><p id="p0080">The human cancer cell lines utilized in this study (H1975, H1299, H520, and THP-1) and the murine cancer cell line LLC were procured from the National Collection of Authenticated Cell Cultures. PPARδ knockout H520 cells were described (<xref rid="bib36" ref-type="bibr">36</xref>). Prior to experimentation, each line underwent authentication <italic toggle="yes">via</italic> short tandem repeat analysis and was verified as mycoplasma negative. Cultivation media consisted of RPMI1640 for THP-1 and LLC cells, and Dulbecco's modified Eagle's medium for H1975, H520, and H1299 cells. All media formulations contained 10% fetal bovine serum (Gibco). Plasmid transfections were performed using polyethylenimine.</p></sec><sec id="sec3.3"><title>Western blot analysis</title><p id="p0085">Cells were washed twice with ice-cold PBS and centrifuged to form pellets. Cell lysis was conducted using a buffer composed of 50 mM Tris–HCl (pH 7.4), 250 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM DTT, and protease inhibitor cocktail. After centrifugation to clarify lysates, supernatants were harvested. Equal protein quantities were separated by SDS-PAGE and subsequently transferred electrophoretically onto nitrocellulose membranes. Membranes were probed with primary antibodies overnight at 4 °C. Following three washes with PBS with Tween-20, horseradish peroxidase–conjugated anti-mouse/rabbit, immunoreactive bands were visualized by enhanced chemiluminescence substrate exposure, and chemiluminescent signals were recorded. Quantitative analysis of band intensities was carried out with ImageJ (NIH) software.</p></sec><sec id="sec3.4"><title>Analysis of surface CD47 levels by flow cytometry</title><p id="p0090">Cells were treated with either dimethyl sulfoxide (vehicle control) or 30 mM metformin for 6 h. Post-treatment, cells were washed three times with PBS and subjected to surface staining using FITC-conjugated anti-CD47 antibody with parallel isotype control (IgG) on ice for 1 h. After three additional PBS washes to remove unbound antibodies, cellular fluorescence was quantified on a CytoFLEX flow cytometer.</p></sec><sec id="sec3.5"><title>Immunofluorescence</title><p id="p0095">Tumor specimens from mice were fixed by immersion in 10% neutral-buffered formalin. After paraffin embedding, consecutive 5 μm tissue sections were cut. Deparaffinized sections underwent heat-induced antigen retrieval in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6.0) for 20 min to unmask epitopes. Following three PBS washes, nonspecific binding sites were blocked with 1% bovine serum albumin in PBS. Primary antibodies targeting CK19 or F4/80 were applied for overnight immunostaining at 4 °C. Sections were then incubated with fluorescence-conjugated secondary antibodies. Finally, antibody-labeled tissues were imaged under a fluorescence microscope. The phagocytic index, defined as the number of ingested CK19-labeled cancer cells per 100 F4/80-positive macrophages, was quantified using ImageJ.</p></sec><sec id="sec3.6"><title>Quantitative real-time PCR analysis</title><p id="p0100">H1975, H520, and H1299 cells were treated with 30 mM metformin for 6 h. Total RNA was extracted and reverse transcribed into complementary DNA using HiScript III RT SuperMix (Vazyme). CD47 mRNA expression was quantified with ChamQ Universal SYBR qPCR Master Mix (Vazyme), normalized to β-actin as endogenous control. Relative gene expression <italic toggle="yes">versus</italic> dimethyl sulfoxide vehicle control was calculated <italic toggle="yes">via</italic> the 2<sup>-ΔΔCt</sup> method.</p></sec><sec id="sec3.7"><title>Phagocytosis assay</title><p id="p0105">THP-1 monocytes were polarized into macrophages by 5-day incubation with 100 ng/ml phorbol 12-myristate 13-acetate. Cancer cells were fluorescently labeled with carboxyfluorescein succinimidyl ester (CFSE; Solarbio) and washed three times with PBS. Labeled cancer cells (4 × 10<sup>5</sup>) were cocultured with macrophages (1 × 10<sup>5</sup>) at a 4:1 effector-to-target ratio in serum-free medium for 4 h to assess engulfment capacity. For phagocytosis analysis by flow cytometry, harvested cells were labeled with CD11b antibody (1:500 dilution) and subjected to flow cytometry. The phagocytosis percentage was defined as the proportion of CD11b<sup>+</sup>CFSE<sup>+</sup> cells (Q1) among all CFSE<sup>+</sup> cancer cells (Q1 + Q2). In the fluorescence microscopy assay, cells were similarly stained with CD11b antibody (1:500 dilution) and visualized under a fluorescence microscope. The phagocytic index, defined as the number of ingested CFSE-labeled cancer cells per 100 CD11b-positive macrophages, was quantified using ImageJ.</p></sec><sec id="sec3.8"><title>Luciferase reporter assay for CD47 transcriptional activity</title><p id="p0110">To assess CD47 promoter activity, cells were cotransfected with a CD47-luciferase reporter plasmid (pGL3-CD47-luc) and a Renilla luciferase control plasmid (pTK-RL) for 48 h. Following transfection, the cells were treated with metformin. In a separate experiment, the same plasmids were transfected into WT or PPARδ<sup>−/−</sup> H520 cells that were re-expressing either PPARδ or the S50E mutant. Subsequently, cell lysates were prepared and analyzed using a dual-luciferase reporter assay kit (GN201-01; YPH Biotech) following the manufacturer's protocol. Firefly luciferase activity was normalized to Renilla luciferase activity for each sample to determine relative CD47 promoter–driven transcription.</p></sec><sec id="sec3.9"><title>Subcutaneous tumor xenograft model</title><p id="p0115">To establish tumor xenografts, male C57BL/6 mice (5 weeks old) were subcutaneously inoculated with LLC cells (1 × 10<sup>5</sup> cells per mouse). Following tumor engraftment after 7 days, mice were randomly assigned to four treatment groups (n = 5 per group): group 1 (vehicle): received vehicle control (saline); group 2 (metformin): administered metformin (10 mg/kg/day) <italic toggle="yes">via</italic> intraperitoneal injection; group 3 (anti-CD47): treated with anti-CD47 monoclonal antibody (100 μg per mouse) <italic toggle="yes">via</italic> intratumoral injection; and group 4 (combination): Received both metformin and anti-CD47 monoclonal antibody at the doses specified above. Tumor size was monitored regularly using digital calipers. Tumor volume was calculated using the formula: volume (mm<sup>3</sup>) = 0.5 × length × width<sup>2</sup>. All animal experiments were conducted in accordance with protocols approved by the Jiangsu University Animal Care Committee (approval no.: 20180053). Mice were obtained from the Animal Center of Jiangsu University.</p></sec><sec id="sec3.10"><title>Statistical analysis</title><p id="p0120">Data analysis was performed using GraphPad Prism software (Dotmatics, version 10.1.2). Continuous variables are presented as mean ± SD. Statistical comparisons were conducted as follows:</p><p id="p0125">A paired Student's <italic toggle="yes">t</italic> test was used for comparisons between two related groups. One-way ANOVA or two-way ANOVA was selected based on the number of independent variables in the experimental design for comparisons among three or more groups: statistical significance thresholds were set at <italic toggle="yes">p</italic> &lt; 0.05, ∗<italic toggle="yes">p</italic> &lt; 0.01, and ∗∗<italic toggle="yes">p</italic> &lt; 0.001.</p></sec></sec><sec sec-type="data-availability" id="sec4"><title>Data availability</title><p id="p0130">All data will be shared upon request to <email>houyz@ujs.edu.com</email>.</p></sec><sec sec-type="supplementary-material" id="sec5"><title>Supporting information</title><p id="p0135">This article contains <xref rid="appsec1" ref-type="sec">supporting information</xref>.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflict of interest</title><p id="p0140">The authors declare that they have no conflicts of interest with the contents of this article.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Schernthaner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schernthaner</surname><given-names>G.H.</given-names></name></person-group><article-title>The right place for metformin today</article-title><source>Diabetes Res. Clin. Pract.</source><volume>159</volume><year>2020</year><object-id pub-id-type="publisher-id">107946</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2019.107946</pub-id><pub-id pub-id-type="pmid">31778746</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zha</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lash</surname><given-names>G.E.</given-names></name><etal/></person-group><article-title>Metformin in gynecological disorders: pathogenic insights and therapeutic implications</article-title><source>Front. Pharmacol.</source><volume>16</volume><year>2025</year><object-id pub-id-type="publisher-id">1526709</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1526709</pub-id><pub-id pub-id-type="pmcid">PMC12052884</pub-id><pub-id pub-id-type="pmid">40331195</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Petrasca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hambly</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Pender</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Mac Mahon</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa</article-title><source>Br. J. Dermatol.</source><volume>189</volume><year>2023</year><fpage>730</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">37648653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bjd/ljad305</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Decensi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puntoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cazzaniga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gennari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonanni</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis</article-title><source>Cancer Prev. Res. (Phila)</source><volume>3</volume><year>2010</year><fpage>1451</fpage><lpage>1461</lpage><pub-id pub-id-type="pmid">20947488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-10-0157</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Rada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krzywon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lazaris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Metrakos</surname><given-names>P.</given-names></name></person-group><article-title>A retrospective study on the role of metformin in colorectal cancer liver metastases</article-title><source>Biomedicines</source><volume>11</volume><year>2023</year><fpage>731</fpage><pub-id pub-id-type="pmid">36979711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11030731</pub-id><pub-id pub-id-type="pmcid">PMC10045020</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Polychronopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abdelgadir</surname><given-names>O.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cowell</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Messiah</surname><given-names>S.E.</given-names></name><etal/></person-group><article-title>Effects of metformin on cancer survival among men diagnosed with advanced prostate cancer treated with androgen-deprivation therapy: emulating a target trial</article-title><source>Cancers (Basel)</source><volume>17</volume><year>2025</year><fpage>3579</fpage><pub-id pub-id-type="pmid">41228370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers17213579</pub-id><pub-id pub-id-type="pmcid">PMC12609103</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xinke</surname><given-names>W.</given-names></name></person-group><article-title>Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013-2023)</article-title><source>Front. Pharmacol.</source><volume>15</volume><year>2024</year><object-id pub-id-type="publisher-id">1388253</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1388253</pub-id><pub-id pub-id-type="pmcid">PMC11347356</pub-id><pub-id pub-id-type="pmid">39193327</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Lage</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dieguez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vidal-Puig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>M.</given-names></name></person-group><article-title>AMPK: a metabolic gauge regulating whole-body energy homeostasis</article-title><source>Trends Mol. Med.</source><volume>14</volume><year>2008</year><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">18977694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2008.09.007</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Hardie</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Hawley</surname><given-names>S.A.</given-names></name></person-group><article-title>AMPK: a nutrient and energy sensor that maintains energy homeostasis</article-title><source>Nat. Rev. Mol. Cel. Biol.</source><volume>13</volume><year>2012</year><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm3311</pub-id><pub-id pub-id-type="pmcid">PMC5726489</pub-id><pub-id pub-id-type="pmid">22436748</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fenyk-Melody</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Role of AMP-activated protein kinase in mechanism of metformin action</article-title><source>J. Clin. Invest.</source><volume>108</volume><year>2001</year><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">11602624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI13505</pub-id><pub-id pub-id-type="pmcid">PMC209533</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Mihaylova</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>R.J.</given-names></name></person-group><article-title>The AMPK signalling pathway coordinates cell growth, autophagy and metabolism</article-title><source>Nat. Cell Biol.</source><volume>13</volume><year>2011</year><fpage>1016</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">21892142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb2329</pub-id><pub-id pub-id-type="pmcid">PMC3249400</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Hardie</surname><given-names>D.G.</given-names></name></person-group><article-title>Molecular pathways: is AMPK a friend or a foe in cancer?</article-title><source>Clin. Cancer Res.</source><volume>21</volume><year>2015</year><fpage>3836</fpage><lpage>3840</lpage><pub-id pub-id-type="pmid">26152739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-14-3300</pub-id><pub-id pub-id-type="pmcid">PMC4558946</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>AMPK phosphorylates PPARdelta to mediate its stabilization, inhibit glucose and glutamine uptake and colon tumor growth</article-title><source>J. Biol. Chem.</source><volume>297</volume><year>2021</year><object-id pub-id-type="publisher-id">100954</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2021.100954</pub-id><pub-id pub-id-type="pmcid">PMC8397901</pub-id><pub-id pub-id-type="pmid">34270958</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.X.</given-names></name><name name-style="western"><surname>Choy</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Priyadarshini</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q.H.</given-names></name><etal/></person-group><article-title>FOXO-regulated DEAF1 controls muscle regeneration through autophagy</article-title><source>Autophagy</source><volume>20</volume><year>2024</year><fpage>2632</fpage><lpage>2654</lpage><pub-id pub-id-type="pmid">38963021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2024.2374693</pub-id><pub-id pub-id-type="pmcid">PMC11587838</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>PD-L1 degradation pathway and immunotherapy for cancer</article-title><source>Cell Death Dis.</source><volume>11</volume><year>2020</year><fpage>955</fpage><pub-id pub-id-type="pmid">33159034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-03140-2</pub-id><pub-id pub-id-type="pmcid">PMC7648632</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.O.</given-names></name><etal/></person-group><article-title>Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1</article-title><source>Mol. Cell</source><volume>71</volume><year>2018</year><fpage>606</fpage><lpage>620.e7</lpage><pub-id pub-id-type="pmid">30118680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2018.07.030</pub-id><pub-id pub-id-type="pmcid">PMC6786495</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Ubiquitination of CD47 regulates innate anti-tumor immune response</article-title><source>Adv. Sci. (Weinh)</source><volume>12</volume><year>2025</year><object-id pub-id-type="publisher-id">e2412205</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202412205</pub-id><pub-id pub-id-type="pmcid">PMC11792004</pub-id><pub-id pub-id-type="pmid">39665172</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Inhibition of CK2/ING4 pathway facilitates non-small cell lung cancer immunotherapy</article-title><source>Adv. Sci. (Weinh)</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">e2304068</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202304068</pub-id><pub-id pub-id-type="pmcid">PMC10700192</pub-id><pub-id pub-id-type="pmid">37870169</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Che</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>TBB inhibits CK2/PD-L1/EGFR pathway-mediated tumor progression</article-title><source>Eur. J. Pharmacol.</source><volume>999</volume><year>2025</year><object-id pub-id-type="publisher-id">177689</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2025.177689</pub-id><pub-id pub-id-type="pmid">40311835</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PPARalpha phosphorylation regulates colorectal tumor immune escape</article-title><source>J. Biol. Chem.</source><volume>300</volume><year>2024</year><object-id pub-id-type="publisher-id">107447</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2024.107447</pub-id><pub-id pub-id-type="pmcid">PMC11259715</pub-id><pub-id pub-id-type="pmid">38844134</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>PPARdelta antagonist inhibited CD47 expression and phagocytosis</article-title><source>J. Cell. Biochem.</source><volume>126</volume><year>2025</year><object-id pub-id-type="publisher-id">e30685</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.30685</pub-id><pub-id pub-id-type="pmid">39632616</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>CD47/SIRPalpha pathway mediates cancer immune escape and immunotherapy</article-title><source>Int. J. Biol. Sci.</source><volume>17</volume><year>2021</year><fpage>3281</fpage><lpage>3287</lpage><pub-id pub-id-type="pmid">34512146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.60782</pub-id><pub-id pub-id-type="pmcid">PMC8416724</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Kharitonenkov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sures</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>A.</given-names></name></person-group><article-title>A family of proteins that inhibit signalling through tyrosine kinase receptors</article-title><source>Nature</source><volume>386</volume><year>1997</year><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">9062191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/386181a0</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Seiffert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rappold</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brugger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kanz</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47</article-title><source>Blood</source><volume>94</volume><year>1999</year><fpage>3633</fpage><lpage>3643</lpage><pub-id pub-id-type="pmid">10572074</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lagenaur</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>V.</given-names></name></person-group><article-title>Integrin-associated protein is a ligand for the P84 neural adhesion molecule</article-title><source>J. Biol. Chem.</source><volume>274</volume><year>1999</year><fpage>559</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">9872987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.274.2.559</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Do</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.N.</given-names></name><etal/></person-group><article-title>MYC regulates the antitumor immune response through CD47 and PD-L1</article-title><source>Science</source><volume>352</volume><year>2016</year><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">26966191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aac9935</pub-id><pub-id pub-id-type="pmcid">PMC4940030</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Betancur</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Yiu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Khameneh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zarnegar</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer</article-title><source>Nat. Commun.</source><volume>8</volume><year>2017</year><object-id pub-id-type="publisher-id">14802</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms14802</pub-id><pub-id pub-id-type="pmcid">PMC5382276</pub-id><pub-id pub-id-type="pmid">28378740</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bullen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Samanta</surname><given-names>D.</given-names></name><etal/></person-group><article-title>HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>112</volume><year>2015</year><fpage>E6215</fpage><lpage>E6223</lpage><pub-id pub-id-type="pmid">26512116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1520032112</pub-id><pub-id pub-id-type="pmcid">PMC4653179</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Satoh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kawana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y.</given-names></name></person-group><article-title>Pathway analysis of ChIP-Seq-based NRF1 target genes suggests a logical hypothesis of their involvement in the pathogenesis of neurodegenerative diseases</article-title><source>Gene Regul. Syst. Bio.</source><volume>7</volume><year>2013</year><fpage>139</fpage><lpage>152</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/GRSB.S13204</pub-id><pub-id pub-id-type="pmcid">PMC3825669</pub-id><pub-id pub-id-type="pmid">24250222</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Down-regulation of AMPK/PPARdelta signalling promotes endoplasmic reticulum stress-induced endothelial dysfunction in adult rat offspring exposed to maternal diabetes</article-title><source>Cardiovasc. Res.</source><volume>118</volume><year>2022</year><fpage>2304</fpage><lpage>2316</lpage><pub-id pub-id-type="pmid">34415333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvab280</pub-id><pub-id pub-id-type="pmcid">PMC9890455</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Omentin-1 protects against high glucose-induced endothelial dysfunction via the AMPK/PPARdelta signaling pathway</article-title><source>Biochem. Pharmacol.</source><volume>174</volume><year>2020</year><object-id pub-id-type="publisher-id">113830</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2020.113830</pub-id><pub-id pub-id-type="pmid">32001235</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Manio</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujitani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fushiki</surname><given-names>T.</given-names></name></person-group><article-title>Combined pharmacological activation of AMPK and PPARdelta potentiates the effects of exercise in trained mice</article-title><source>Physiol. Rep.</source><volume>4</volume><year>2016</year><object-id pub-id-type="publisher-id">e12625</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14814/phy2.12625</pub-id><pub-id pub-id-type="pmcid">PMC4823600</pub-id><pub-id pub-id-type="pmid">26997622</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Baik</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.M.</given-names></name></person-group><article-title>BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARdelta-dependent pathway in mice</article-title><source>Diabetologia</source><volume>58</volume><year>2015</year><fpage>2096</fpage><lpage>2105</lpage><pub-id pub-id-type="pmid">26105792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-015-3663-z</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Narkar</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Downes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Embler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Banayo</surname><given-names>E.</given-names></name><etal/></person-group><article-title>AMPK and PPARdelta agonists are exercise mimetics</article-title><source>Cell</source><volume>134</volume><year>2008</year><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">18674809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2008.06.051</pub-id><pub-id pub-id-type="pmcid">PMC2706130</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>Metformin inhibits PPARdelta agonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells</article-title><source>Eur. J. Pharmacol.</source><volume>857</volume><year>2019</year><object-id pub-id-type="publisher-id">172425</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2019.172425</pub-id><pub-id pub-id-type="pmid">31150647</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>GW501516 facilitated tumor immune escape by inhibiting phagocytosis</article-title><source>Eur. J. Pharmacol.</source><volume>995</volume><year>2025</year><object-id pub-id-type="publisher-id">177418</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2025.177418</pub-id><pub-id pub-id-type="pmid">39993702</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Balkwill</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name></person-group><article-title>Inflammation and cancer: back to Virchow?</article-title><source>Lancet</source><volume>357</volume><year>2001</year><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">11229684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(00)04046-0</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mlecnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bindea</surname><given-names>G.</given-names></name><name name-style="western"><surname>Angell</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lagorce</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Towards the introduction of the 'Immunoscore' in the classification of malignant tumours</article-title><source>J. Pathol.</source><volume>232</volume><year>2014</year><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">24122236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4287</pub-id><pub-id pub-id-type="pmcid">PMC4255306</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Topalian</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity</article-title><source>Curr. Opin. Immunol.</source><volume>24</volume><year>2012</year><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">22236695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2011.12.009</pub-id><pub-id pub-id-type="pmcid">PMC3319479</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>W.A.</given-names></name></person-group><article-title>Integrin-associated protein (CD47) and its ligands</article-title><source>Trends Cell Biol.</source><volume>11</volume><year>2001</year><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">11306274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0962-8924(00)01906-1</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Yanagita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Motegi</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Daniwijaya</surname><given-names>E.W.</given-names></name><etal/></person-group><article-title>Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy</article-title><source>JCI Insight</source><volume>2</volume><year>2017</year><object-id pub-id-type="publisher-id">e89140</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.89140</pub-id><pub-id pub-id-type="pmcid">PMC5214103</pub-id><pub-id pub-id-type="pmid">28097229</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.Y.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>I.L.</given-names></name></person-group><article-title>Phagocytosis checkpoints as new targets for cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><volume>19</volume><year>2019</year><fpage>568</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">31462760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0183-z</pub-id><pub-id pub-id-type="pmcid">PMC7002027</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.M.</given-names></name></person-group><article-title>Alpha-Pal/NRF-1 regulates the promoter of the human integrin-associated protein/CD47 gene</article-title><source>J. Biol. Chem.</source><volume>279</volume><year>2004</year><fpage>14542</fpage><lpage>14550</lpage><pub-id pub-id-type="pmid">14747477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M309825200</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Kirtonia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics</article-title><source>Semin. Cancer Biol.</source><volume>68</volume><year>2021</year><fpage>258</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">32380233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2020.04.006</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Benjamin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Haslam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>V.</given-names></name></person-group><article-title>Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: a systematic review and meta-analysis of randomized trials</article-title><source>Cancer Med.</source><volume>13</volume><year>2024</year><object-id pub-id-type="publisher-id">e7049</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.7049</pub-id><pub-id pub-id-type="pmcid">PMC10943275</pub-id><pub-id pub-id-type="pmid">38491813</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name></person-group><article-title>Metformin enhances PD-L1 inhibitor efficacy in ovarian cancer by modulating the immune microenvironment and RBMS3 expression</article-title><source>FASEB J.</source><volume>39</volume><year>2025</year><object-id pub-id-type="publisher-id">e70705</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202500906R</pub-id><pub-id pub-id-type="pmid">40471105</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mitigating doxorubicin-induced cardiotoxicity and enhancing anti-tumor efficacy with a metformin-integrated self-assembled nanomedicine</article-title><source>Adv. Sci. (Weinh)</source><volume>12</volume><year>2025</year><object-id pub-id-type="publisher-id">e2415227</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202415227</pub-id><pub-id pub-id-type="pmcid">PMC12061326</pub-id><pub-id pub-id-type="pmid">40052211</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Bahrambeigi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shafiei-Irannejad</surname><given-names>V.</given-names></name></person-group><article-title>Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin</article-title><source>Biochem. Pharmacol.</source><volume>174</volume><year>2020</year><object-id pub-id-type="publisher-id">113787</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2019.113787</pub-id><pub-id pub-id-type="pmid">31884044</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>60704</fpage><lpage>60709</lpage><pub-id pub-id-type="pmid">28948004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.19610</pub-id><pub-id pub-id-type="pmcid">PMC5601172</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>Dual function of activated PPARgamma by ligands on tumor growth and immunotherapy</article-title><source>Med. Oncol.</source><volume>41</volume><year>2024</year><fpage>114</fpage><pub-id pub-id-type="pmid">38619661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12032-024-02363-z</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>PPARdelta signaling regulates colorectal cancer</article-title><source>Curr. Pharm. Des.</source><volume>21</volume><year>2015</year><fpage>2956</fpage><lpage>2959</lpage><pub-id pub-id-type="pmid">26004416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612821666150514104035</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Vogelstein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kinzler</surname><given-names>K.W.</given-names></name></person-group><article-title>PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs</article-title><source>Cell</source><volume>99</volume><year>1999</year><fpage>335</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">10555149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(00)81664-5</pub-id><pub-id pub-id-type="pmcid">PMC3779681</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>F.J.</given-names></name></person-group><article-title>Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)</article-title><source>Drug Discov. Today Dis. Mech.</source><volume>8</volume><year>2011</year><fpage>e85</fpage><lpage>e93</lpage><pub-id pub-id-type="pmid">22611424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ddmec.2011.11.002</pub-id><pub-id pub-id-type="pmcid">PMC3352671</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>PPARdelta promotes tumor progression via activation of Glut1 and SLC1-A5 transcription</article-title><source>Carcinogenesis</source><volume>38</volume><year>2017</year><fpage>748</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">28419191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgx035</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moussalli</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Manyam</surname><given-names>G.C.</given-names></name><etal/></person-group><article-title>Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-delta/beta overexpression</article-title><source>J. Natl. Cancer Inst.</source><volume>106</volume><year>2014</year><object-id pub-id-type="publisher-id">dju052</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/dju052</pub-id><pub-id pub-id-type="pmcid">PMC3982893</pub-id><pub-id pub-id-type="pmid">24681603</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Hollingshead</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Borland</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Billin</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Willson</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>J.M.</given-names></name></person-group><article-title>Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms</article-title><source>Carcinogenesis</source><volume>29</volume><year>2008</year><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">17893232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgm209</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Peraza</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Billin</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Willson</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kennett</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis</article-title><source>Cancer Res.</source><volume>66</volume><year>2006</year><fpage>4394</fpage><lpage>4401</lpage><pub-id pub-id-type="pmid">16618765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-05-4277</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Blazanin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bility</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Khozoie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B.H.</given-names></name><etal/></person-group><article-title>PPARbeta/delta promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling</article-title><source>Oncogene</source><volume>33</volume><year>2014</year><fpage>5348</fpage><lpage>5359</lpage><pub-id pub-id-type="pmid">24213576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2013.477</pub-id><pub-id pub-id-type="pmcid">PMC4017002</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Foreman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Palkar</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Borland</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Functional characterization of peroxisome proliferator-activated receptor-beta/delta expression in colon cancer</article-title><source>Mol. Carcinog.</source><volume>50</volume><year>2011</year><fpage>884</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">21400612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mc.20757</pub-id><pub-id pub-id-type="pmcid">PMC3482838</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Michalik</surname><given-names>L.</given-names></name><name name-style="western"><surname>Desvergne</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wahli</surname><given-names>W.</given-names></name></person-group><article-title>Peroxisome-proliferator-activated receptors and cancers: complex stories</article-title><source>Nat. Rev. Cancer</source><volume>4</volume><year>2004</year><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">14708026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1254</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chadee</surname><given-names>K.</given-names></name></person-group><article-title>PPARgamma is an E3 ligase that induces the degradation of NFkappaB/p65</article-title><source>Nat. Commun.</source><volume>3</volume><year>2012</year><fpage>1300</fpage><pub-id pub-id-type="pmid">23250430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms2270</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>PPARgamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability</article-title><source>Oncogene</source><volume>33</volume><year>2014</year><fpage>5619</fpage><lpage>5625</lpage><pub-id pub-id-type="pmid">24292674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2013.504</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name></person-group><article-title>PPARgamma against tumors by different signaling pathways</article-title><source>Onkologie</source><volume>36</volume><year>2013</year><fpage>598</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">24107916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000355328</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Hardie</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Schaffer</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Brunet</surname><given-names>A.</given-names></name></person-group><article-title>AMPK: an energy-sensing pathway with multiple inputs and outputs</article-title><source>Trends Cell Biol.</source><volume>26</volume><year>2016</year><fpage>190</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">26616193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2015.10.013</pub-id><pub-id pub-id-type="pmcid">PMC5881568</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supporting information</title><p id="p0155">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplemental Figure S1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0145">This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (grant nos.: <award-id award-type="grant" rid="gs1">82172979</award-id> and <award-id award-type="grant" rid="gs1">82573810</award-id>).</p><sec id="sec6"><title>Author contributions</title><p id="p0150">Y. H. conceptualization; Q. C., H. W., H. Y., Y. L., and Y. W. investigation; J. S. writing–original draft; Y. H. project administration.</p></sec></ack></back></article><article article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiooncology</journal-id><journal-id journal-id-type="iso-abbrev">Cardiooncology</journal-id><journal-id journal-id-type="pmc-domain-id">3801</journal-id><journal-id journal-id-type="pmc-domain">cardioon</journal-id><journal-title-group><journal-title>Cardio-oncology</journal-title></journal-title-group><issn pub-type="epub">2057-3804</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12910814</article-id><article-id pub-id-type="pmcid-ver">PMC12910814.1</article-id><article-id pub-id-type="pmcaid">12910814</article-id><article-id pub-id-type="pmcaiid">12910814</article-id><article-id pub-id-type="pmid">41578414</article-id><article-id pub-id-type="doi">10.1186/s40959-025-00412-8</article-id><article-id pub-id-type="publisher-id">412</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Diabetes and cancer: therapeutic implications</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fay</surname><given-names initials="S">Stavros</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bayshtok</surname><given-names initials="G">Gabriella</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamo</surname><given-names initials="CE">Carine E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Butler</surname><given-names initials="J">Javed</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bloom</surname><given-names initials="M">Michelle</given-names></name><address><email>Michelle.Bloom@nyulangone.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0190ak572</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution>Department of Chemistry, </institution><institution>New York University, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0190ak572</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution>New York University Grossman School of Medicine, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.530858.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2034 655X</institution-id><institution>Baylor Scott and White Research Institute, </institution></institution-wrap>Dallas, TX USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/044pcn091</institution-id><institution-id institution-id-type="GRID">grid.410721.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0407</institution-id><institution>University of Mississippi Medical Center, </institution></institution-wrap>Jackson, MS USA </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">504595</issue-id><elocation-id>30</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 10:25:12.893"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2026</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40959_2025_Article_412.pdf"/><abstract id="Abs1" abstract-type="structured"><sec><title>Background</title><p id="Par1">The growing coexistence of diabetes and cancer contributes substantially to global morbidity and mortality. Beyond the independent burden of each disease, their intersection introduces unique challenges, particularly in cardiovascular risk. Patients with diabetes, especially those with underlying diabetic cardiomyopathy (DbCM), are at increased risk for cancer therapy-related cardiac dysfunction (CTRCD). Yet, the interplay between DbCM and CTRCD remains underexplored despite clear evidence of overlapping mechanisms and heightened vulnerability in this population.</p></sec><sec><title>Main text</title><p id="Par2">DbCM and CTRCD share key pathophysiologic features, including oxidative stress, mitochondrial dysfunction, inflammation, fibrosis, and impaired calcium handling, which collectively reducing myocardial reserve during cancer therapy. Even in patients without overt DbCM, diabetes management complicates cancer care by influencing treatment tolerance and outcomes. Antidiabetic agents exert pleiotropic effects on both cardiac and oncologic pathways: insulin may worsen remodeling and potentially amplify tumorigenic signaling, whereas metformin and sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrate promise for cardioprotection and modulation of cancer therapy responses. This review synthesizes the current evidence on shared pathobiology, highlights drug-drug interactions that may exacerbate cardiotoxicity and discusses therapeutic opportunities that could improve patient outcomes.</p></sec><sec><title>Conclusions</title><p id="Par3">Understanding the intersection of diabetes and cancer is essential for reducing cardiac complications in this high-risk population. Integrated management strategies should prioritize early risk stratification, interdisciplinary collaboration, and judicious selection of antidiabetic therapies with cardioprotective potential. Research gaps remain in defining optimal monitoring protocols, refining pharmacologic strategies, and developing tailored guidelines. Addressing these gaps is critical to advancing cardio-oncology care and improving survivorship for patients living with both diabetes and cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetic Cardiomyopathy (DbCM)</kwd><kwd>Cancer Therapy-Related Cardiac Dysfunction (CTRCD)</kwd><kwd>Cardio-oncology</kwd><kwd>Cardiotoxicity</kwd><kwd>Diabetes</kwd><kwd>Cancer</kwd><kwd>Pharmacologic Interactions</kwd><kwd>Insulin</kwd><kwd>Adiposity</kwd><kwd>Sodium-glucose cotransporter-2 (SGLT2) inhibitor (SGLT2i)</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>KL2TR001446</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© BioMed Central Ltd., part of Springer Nature 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par49">Diabetes and cancer contribute significantly to morbidity, mortality, and healthcare burden globally [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>], and a growing number of patients are living with both conditions [<xref ref-type="bibr" rid="CR6">6</xref>]. Patients with diabetes are considered to be particularly at high risk for the development of cancer therapy related to cardiac toxicity with a spectrum of cancer therapeutics, especially those with diabetic cardiomyopathy (DbCM). Diabetes therapies may predispose patients with cancer to increased cardiac complications. Conversely, through complex mechanisms, other diabetes therapies might be clinically beneficial in this patient population [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par50">Comorbid diabetes affects the care of patients with cancer, particularly as it relates to cardiovascular complications [<xref ref-type="bibr" rid="CR8">8</xref>]. Cancer therapy-related cardiac dysfunction (CTRCD) has emerged as a major focus in oncology [<xref ref-type="bibr" rid="CR9">9</xref>], and many cancer therapies are associated with cardiotoxic effects [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. CTRCD, typically defined as a decline in left ventricular (LV) systolic function, limits the ability to complete potentially curative cancer therapy and contributes substantially to morbidity and mortality during treatment and survivorship [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The presence of traditional cardiac risk factors further amplifies the risk of potential cardiac toxicities [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par51">Diabetes is associated with increased cardiovascular risk [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and may exert direct effects on myocardial structure and function, with subsequent development of DbCM [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. The presence of DbCM predisposes patients to myocardial vulnerability when additional stressors such as potentially cardiotoxic cancer therapies are introduced [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Both DbCM and CTRCD involve shared pathways [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par52">Glucose-lowering agents such as metformin, sodium-glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exert pleiotropic effects that influence pathways involved in cell growth, angiogenesis, inflammation, and myocardial remodeling [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). Conversely, insulin and sulfonylureas may promote tumor progression or interfere with metabolic stress responses during therapy [<xref ref-type="bibr" rid="CR77">77</xref>–<xref ref-type="bibr" rid="CR80">80</xref>]. This review synthesizes current knowledge regarding the interactions between diabetes and cancer therapies, highlighting areas of synergy and conflict between metabolic and oncologic pharmacotherapy, explores shared pathophysiology between DbCM and CTRCD, and identifies key gaps in knowledge that must be addressed to optimize care for this growing population of high-risk patients (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<list list-type="bullet"><list-item><p id="Par53">Diabetes and cancer frequently co-occur, amplifying cardiovascular risk and increasing vulnerability to CTRCD, especially in those with DbCM</p></list-item><list-item><p id="Par54">Both DbCM and CTRCD share overlapping pathophysiologic mechanisms, and diabetes therapies can either worsen or mitigate cardiac complications in cancer patients.</p></list-item><list-item><p id="Par55">This review examines the interplay between diabetes, cancer therapy, and cardiotoxicity, highlighting therapeutic synergies, conflicts, and critical gaps in current management strategies.</p></list-item></list></p><p id="Par56">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Mechanisms and cardiac implications of diabetes and cancer therapies in the context of DbCM</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Agent</th><th align="left" colspan="1" rowspan="1">Mechanism of Action</th><th align="left" colspan="1" rowspan="1">Relevance to DbCM Pathophysiology</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Insulin</td><td align="left" colspan="1" rowspan="1">Activates PI3K/Akt and MAPK/ERK pathways; promotes glucose uptake and cellular growth [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" colspan="1" rowspan="1"><p>May exacerbate fibrosis, lipid accrual, and oxidative stress;</p><p>[<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Metformin</td><td align="left" colspan="1" rowspan="1">Activates AMPK; inhibits hepatic gluconeogenesis and mTOR signaling [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" colspan="1" rowspan="1">Reduces myocardial fibrosis, oxidative stress, and improves mitochondrial function; [<xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SGLT2 Inhibitors</td><td align="left" colspan="1" rowspan="1">Inhibits renal glucose reabsorption; reduces preload/afterload; modulates mitochondrial and inflammatory pathways [<xref ref-type="bibr" rid="CR46">46</xref>–<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left" colspan="1" rowspan="1">SGLT2 inhibitors reduce heart-failure hospitalization [<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GLP-1 Receptor Agonists</td><td align="left" colspan="1" rowspan="1">Activates GLP-1 receptors; enhances insulin secretion, delays gastric emptying, reduces appetite [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left" colspan="1" rowspan="1">Emerging evidence for anti-inflammatory and cardioprotective effects [<xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DPP-4 Inhibitors</td><td align="left" colspan="1" rowspan="1">Inhibits DPP-4 enzyme; prolongs activity of incretin hormones; increases insulin release, decreases glucagon [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left" colspan="1" rowspan="1">Limited data may offer mild cardiometabolic benefits</td></tr><tr><td align="left" colspan="1" rowspan="1">Anthracyclines</td><td align="left" colspan="1" rowspan="1">Intercalates DNA and inhibits topoisomerase II; generates ROS, causing cellular damage [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left" colspan="1" rowspan="1">Known to cause irreversible cardiotoxicity through oxidative stress and mitochondrial damage [<xref ref-type="bibr" rid="CR61">61</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Trastuzumab (HER2-targeted therapy)</td><td align="left" colspan="1" rowspan="1">Inhibits HER2 receptor signaling, disrupting cell proliferation and survival pathways [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left" colspan="1" rowspan="1">Reversible cardiotoxicity; interferes with cardiac HER2 survival signaling [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Radiation Therapy</td><td align="left" colspan="1" rowspan="1">Damages DNA and promotes fibrosis through ionizing radiation [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left" colspan="1" rowspan="1">Leads to fibrosis, vascular damage, and accelerated atherosclerosis [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Immune Checkpoint Inhibitors</td><td align="left" colspan="1" rowspan="1">Blocks PD-1/PD-L1 or CTLA-4 to activate T-cell mediated anti-tumor immunity [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left" colspan="1" rowspan="1">Can trigger immune-mediated myocarditis and pericarditis, especially in predisposed individuals [<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tyrosine Kinase Inhibitors</td><td align="left" colspan="1" rowspan="1">Inhibits kinase pathways involved in tumor growth, angiogenesis, and survival [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left" colspan="1" rowspan="1">Associated with hypertension, arrhythmia, and ventricular dysfunction [<xref ref-type="bibr" rid="CR72">72</xref>–<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr></tbody></table><table-wrap-foot><p>This table summarizes the mechanisms of action of commonly used diabetic therapies and oncologic therapies, highlighting potential implications for DbCM</p></table-wrap-foot></table-wrap>
</p><p id="Par57">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The complex interplay between diabetes and cancer. This illustration demonstrates the complex and overlapping pathophysiologic mechanisms linking diabetic cardiomyopathy and cancer therapy-related cardiac dysfunction, additionally highlighting commonly used diabetes therapies and their potential influence of cardiac outcomes in patients also undergoing cancer therapy. The central roles of fibrosis, oxidative stress, and mitochondrial dysfunction are emphasized as shared drivers of myocardial injury. The diagram underscores the importance of these overlapping pathways when managing patients with diabetes undergoing cancer therapy</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40959_2025_412_Fig1_HTML.jpg"/></fig>
</p><sec id="Sec2"><title>Pathophysiologic Overlap Between Diabetic Cardiomyopathy and Cancer Therapy-Related Cardiac Dysfunction</title><sec id="Sec3"><title>Diabetic Cardiomyopathy</title><p id="Par58">DbCM is defined as myocardial dysfunction in patients with diabetes in the absence of overt coronary disease, valvular disease, or hypertension [<xref ref-type="bibr" rid="CR81">81</xref>]. Often subclinical in early stages, DbCM leads to diastolic dysfunction, impaired ventricular compliance, and eventually to clinical heart failure (HF) [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. DbCM is characterized histologically by interstitial and perivascular fibrosis, myocardial lipid accumulation, and microvascular rarefaction [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. At the molecular level, it is driven by a constellation of processes including hyperglycemia, insulin resistance, mitochondrial dysfunction, increased reactive oxygen species (ROS) generation, and activation of profibrotic signaling cascades such as the transforming growth factor-beta (TGF-β) and nuclear factor-kappa B (NF-κB) pathways [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR84">84</xref>–<xref ref-type="bibr" rid="CR89">89</xref>]. Inflammation, oxidative stress, advanced glycation end products (AGEs), and abnormal calcium handling all contribute to myocardial stiffening, altered conduction, and apoptosis [<xref ref-type="bibr" rid="CR90">90</xref>–<xref ref-type="bibr" rid="CR93">93</xref>].</p></sec></sec><sec id="Sec4"><title>Cancer Therapy-Related Cardiac Dysfunction</title><p id="Par59">CTRCD represents a heterogeneous spectrum of myocardial injury arising from exposure to anticancer agents [<xref ref-type="bibr" rid="CR9">9</xref>]. Although diverse in presentation, these toxicities share overlapping molecular and pathophysiologic pathways that impair myocardial contractility and reserve. Among the most extensively studied are anthracyclines, which produce cumulative, dose-dependent, and often irreversible cardiomyopathy through oxidative stress, mitochondrial injury, and interference with topoisomerase IIβ [<xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. Human epidermal growth factor receptor 2 (HER2)-targeted therapies such as trastuzumab typically induce a reversible decline in cardiac function, reflecting transient disruption of HER2-mediated survival signaling within cardiomyocytes [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR66">66</xref>]. Immune checkpoint inhibitors (ICIs), which enhance antitumor immunity by blocking inhibitory pathways such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), may lead to myocarditis or subclinical inflammatory injury through aberrant activation of cytotoxic T cells [<xref ref-type="bibr" rid="CR68">68</xref>], whereas tyrosine kinase inhibitors (TKIs) impair mitochondrial energetics and promote apoptotic cell death by disrupting pro-survival kinase cascades [<xref ref-type="bibr" rid="CR70">70</xref>]. Radiation therapy contributes to a more insidious pattern of endothelial damage, microvascular dysfunction, and progressive fibrosis that may culminate in ischemic or restrictive phenotypes [<xref ref-type="bibr" rid="CR94">94</xref>]. Together, these therapies highlight the diverse yet intersecting mechanisms that define the CTRCD continuum.</p><p id="Par60">Beyond individual agents, synergistic cardiotoxicity emerges with modern combination regimens. For example, there is an increased incidence of CTRCD in patients treated with both anthracyclines and trastuzumab, with preclinical data suggesting that HER2 blockade increases susceptibility to anthracycline-induced injury [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Treatment protocols modeled after KEYNOTE-522, which pair anthracyclines with ICIs in triple-negative breast cancer, demonstrate that cardiac injury may be amplified through oxidative and immune-mediated mechanisms [<xref ref-type="bibr" rid="CR73">73</xref>]. Regimens combining vascular endothelial growth factor inhibitors with ICIs, commonly used in renal and lung cancers, can compound endothelial dysfunction and promote hypertensive remodeling [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Furthermore, combinations of HER2-targeted agents with taxanes or platinum-based cytotoxics, which are now used in esophageal, gastric, and gynecologic malignancies, may exacerbate mitochondrial stress and impair contractile reserve [<xref ref-type="bibr" rid="CR76">76</xref>]. Although systematic data remain limited, these emerging patterns underscore the importance of monitoring cardiac function and considering potential cardiovascular risks when administering combination regimens.</p></sec><sec id="Sec5"><title>Shared Molecular Mechanisms Between DbCM and CTRCD</title><p id="Par61">A growing body of evidence suggests that DbCM and CTRCD share several molecular pathways that contribute to cardiac injury [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR34">34</xref>]. At the cellular level, both diabetes and certain cancer therapies promote elevated intracellular ROS levels, leading to oxidative stress secondary to lipid peroxidation, protein damage, and mitochondrial DNA injury [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Mitochondrial dysfunction and impaired ATP production are central features of both DbCM and CTRCD, contributing to an energy-starved myocardium and contractile dysfunction [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Inflammation and cytokine signaling in diabetes mirrors inflammatory cascades activated by certain cancer therapies and lead to endothelial dysfunction and myocardial fibrosis, e.g., ICIs (Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Both DbCM and CTRCD demonstrate myocardial interstitial fibrosis and extracellular matrix remodeling due to enhanced collagen and fibronectin deposition in the interstitium predisposing to stiffening of the ventricular wall and impaired compliance [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Abnormalities in calcium handling are a hallmark of both diabetes and chemotherapy-related cardiac injury. Impaired sarcoplasmic reticulum calcium uptake reduced sarcoplasmic/endoplasmic Reticulum Ca2 + -ATPase 2a (SERCA2a) activity, and increased intracellular calcium contribute to impaired relaxation and arrhythmogenesis. Autophagy, apoptosis, and disruption of normal autophagic flux and increased cardiomyocyte apoptosis are seen in both DbCM and CTRCD [<xref ref-type="bibr" rid="CR104">104</xref>].</p><p id="Par62">Beyond these canonical pathways, adipose-cardiac crosstalk has emerged as a unifying driver of metabolic cardiomyopathy and a plausible amplifier of cancer-therapy susceptibility. In states of visceral adiposity, expansion and dysfunction of adipose tissue remodel the secretome toward a pro-inflammatory, pro-fibrotic adipokine profile (increases in levels of leptin, resistin, RBP4; relative decreases in adiponectin) that promotes endothelial dysfunction, sodium retention, microvascular inflammation, myocardial steatosis, and interstitial fibrosis: features shared by DbCM and prevalent in heart failure with preserved ejection fraction (HFpEF) phenotypes [<xref ref-type="bibr" rid="CR105">105</xref>–<xref ref-type="bibr" rid="CR109">109</xref>]. The “adipokine hypothesis” reframes diabetes-associated cardiomyopathy as a disease of adipose signaling rather than hyperglycemia, with adiposity functioning as a modifiable risk factor that shapes myocardial biology and treatment response [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. These insights intersect with cardio-oncology because adipokine-driven metaflammation and lipotoxic stress can plausibly lower the threshold for CTRCD, particularly in patients with obesity and diabetes receiving cardiotoxic regimens [<xref ref-type="bibr" rid="CR107">107</xref>–<xref ref-type="bibr" rid="CR109">109</xref>].</p><p id="Par63">Closely linked to adipokine signaling is innate immune activation. Pattern-recognition receptors, especially toll-like receptor 2/toll-like receptor 4 (TLR2/TLR4), sense damage- and pathogen-associated molecular patterns arising from hyperglycemia, lipid peroxidation, and mitochondrial injury; they prime NF-κB-dependent transcription of pro-interleukin-1 beta and nucleotide-binding and leucine-rich repeat-containing receptor (NLR) family pyrin domain containing 3 (NLRP3) components in cardiomyocytes and immune cells [<xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR112">112</xref>]. Anthracyclines and other antineoplastic agents add a second hit, mitochondrial ROS, iron dysregulation, and damage-associated molecular patterns release, that intensifies innate immune signaling and maladaptive remodeling [<xref ref-type="bibr" rid="CR112">112</xref>]. Thus, DbCM and CTRCD share two-signal logic: metabolic priming (TLR-NF-κB) plus therapy-induced danger cues.</p><p id="Par64">At the convergence of these pathways lies the NLRP3 inflammasome, increasingly recognized in both DbCM and cardio-oncology. NLRP3 activation (via ROS-thioredoxin-interacting protein (TXNIP), ion flux, or mitochondrial DNA) promotes caspase-1 activation, interleukin-1 beta/interleukin-18 maturation, and pyroptosis, driving fibrosis and systolic/diastolic cardiac dysfunction [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. Preclinical and translational reports implicate doxorubicin in triggering NLRP3 signaling in the heart, while metabolic disease provides the primed background [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. In this primed milieu, convergent adipose-cardiac and innate immune pathways create a self-reinforcing loop that lowers the threshold for cardiotoxic remodeling. The NLRP3 inflammasome links metabolic stress to caspase-1/gasdermin-D-mediated pyroptosis and Interleukin-1 beta/Interleukin-18 (IL-1β/IL-18) signaling in the heart [<xref ref-type="bibr" rid="CR115">115</xref>]. At the same time, epicardial adipose tissue (EAT), a depot that shares microcirculation with the myocardium, undergoes expansion and inflammatory remodeling. Activated EAT releases paracrine and vasocrine mediators that drive microvascular inflammation, fibroblast activation, and diastolic stiffening, producing an HFpEF-like phenotype [<xref ref-type="bibr" rid="CR116">116</xref>]. Finally, EAT-derived extracellular vesicles and microRNAs provide a mechanistic conduit through which adiposity reprograms myocardial redox balance and matrix pathways [<xref ref-type="bibr" rid="CR117">117</xref>]. In parallel, trained innate immune memory at hematopoietic and tissue-resident macrophage levels sustains NF-κB/inflammasome tone, amplifying injury responses once anthracyclines or other cardiotoxic regimens are introduced [<xref ref-type="bibr" rid="CR118">118</xref>]. Together, these axes (inflammasome-pyroptosis, EAT-EV signaling, and innate immune reprogramming) offer a contemporary framework for why metabolic comorbidity magnifies susceptibility to CTRCD and suggest intermediate phenotypes (EAT burden, IL-1 family cytokines, EV-miRNA signatures) for risk stratification [<xref ref-type="bibr" rid="CR115">115</xref>–<xref ref-type="bibr" rid="CR119">119</xref>].</p><p id="Par65">
<list list-type="bullet"><list-item><p id="Par66">DbCM is characterized by diastolic dysfunction, fibrosis, lipid accumulation, and mitochondrial dysfunction driven by hyperglycemia, oxidative stress, and profibrotic signaling.</p></list-item><list-item><p id="Par67">CTRCD results from various cancer therapies and involves oxidative stress, mitochondrial injury, immune activation, and fibrotic remodeling.</p></list-item><list-item><p id="Par68">DbCM and CTRCD share molecular pathways including increased ROS, mitochondrial dysfunction, inflammation, fibrosis, calcium handling abnormalities, and apoptosis, increasing myocardial vulnerability.</p></list-item></list>
</p></sec></sec><sec id="Sec6"><title>Clinical Implications</title><p id="Par69">A patient with diabetes undergoing cancer therapy may have impaired baseline myocardial reserve, increased propensity toward myocardial injury, and a reduced ability to recover from cardiac insult [<xref ref-type="bibr" rid="CR11">11</xref>]. These patients are characterized by higher rates of comorbidities and report more severe scores for pain and for poorer general well-being [<xref ref-type="bibr" rid="CR120">120</xref>]. The additive effect of cancer therapy on an already compromised cardiac substrate necessitates a heightened identification of baseline risk and a carefully tailored surveillance and monitoring strategy. A comprehensive baseline assessment of cardiac function and reserve, through assessments such as transthoracic echocardiography with strain and/or cardiopulmonary stress testing, and quantification of myocardial fibrosis through cardiovascular magnetic resonance imaging (CMRI) might help identify subclinical DbCM and stratify patients for early intervention. While not well characterized, baseline assessment for the presence of ischemic coronary disease should be considered as part of risk stratification [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. However, these strategies remain underutilized. The shared pathophysiology of diabetes and cancer (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) lends itself to targeted interventions that might mitigate risk.</p></sec><sec id="Sec7"><title>Insulin and Insulin Analogues</title><p id="Par70">Insulin resistance and hyperinsulinemia contribute to maladaptive myocardial changes such as lipid accumulation, oxidative stress, and mitochondrial dysfunction [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Chronic hyperinsulinemia activates the renin-angiotensin aldosterone system, sympathetic nervous system, and profibrotic signaling, and animal studies have shown that insulin can exacerbate myocardial fibrosis and impair mitochondrial bioenergetics [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. Insulin exerts its effects through phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and rat sarcoma/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) pathways. While the former promotes metabolic functions, the latter may drive mitogenic and growth-promoting signals, raising concerns about oncogenic potential with high insulin exposure (See Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par71">Epidemiologic studies have reported increased cancer incidence- particularly breast, colorectal, and pancreatic-in patients using insulin, especially long-acting analogues like insulin glargine. These findings are thought to stem from insulin’s ability to stimulate insulin-like growth factor 1 (IGF-1) pathways, which support tumor growth [<xref ref-type="bibr" rid="CR127">127</xref>–<xref ref-type="bibr" rid="CR131">131</xref>]. However, many studies are limited by confounding factors such as disease severity, and results remain mixed. Despite the lack of definitive evidence, concerns about mitogenic effects in insulin-treated cancer patients have prompted ongoing investigation into the safest insulin regimens for this population [<xref ref-type="bibr" rid="CR132">132</xref>].</p><sec id="Sec8"><title>Insulin Interactions with Cancer Therapies</title><p id="Par72">Insulin may interfere with cancer therapy by activating pathways such as PI3K/Akt, potentially reducing the efficacy of targeted treatments like PI3K or mammalian target of rapamycin (mTOR) inhibitors [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. Hyperinsulinemia has been demonstrated to independently enhance tumor growth and significantly increase cancer mortality risk, even in nonobese individuals without diabetes [<xref ref-type="bibr" rid="CR135">135</xref>]. It may also increase susceptibility to CTRCD through effects like ROS amplification, fibrosis, endothelial dysfunction, mitochondrial dysfunction, metabolic dysfunction, and pro-inflammatory signaling [<xref ref-type="bibr" rid="CR136">136</xref>–<xref ref-type="bibr" rid="CR141">141</xref>]. Though insulin-treated patients show higher cardiovascular risk and mortality, this may reflect more severe underlying disease rather than a direct causal effect [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR142">142</xref>].</p></sec></sec><sec id="Sec9"><title>Metformin</title><p id="Par73">Metformin is a first-line agent for the treatment of type 2 diabetes [<xref ref-type="bibr" rid="CR143">143</xref>]. Beyond glucose lowering, metformin has garnered interest for its pleiotropic benefits, including potential to reduce cancer risk, attenuate cardiovascular disease progression, and modulate key molecular pathways involved in DbCM and CTRCD (See Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR36">36</xref>]. It inhibits hepatic gluconeogenesis and improves peripheral insulin sensitivity, lowering plasma glucose without causing hypoglycemia. On a molecular level, metformin activates adenosine monophosphate (AMP)-activated protein kinase (AMPK), which regulates cellular metabolism, mitochondrial biogenesis, autophagy, and oxidative stress. AMPK activation also inhibits the mTOR pathway, potentially limiting tumor progression by reducing proliferation, angiogenesis, and resistance to apoptosis [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR42">42</xref>]. This activation enhances endothelial function, promotes fatty acid oxidation, and decreases fibrosis and inflammation-effects that help preserve myocardial energy balance during physiologic stress such as cancer therapy [<xref ref-type="bibr" rid="CR43">43</xref>–<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par74">Metformin may function as a cancer therapy by exerting both direct anti-tumor effects on cancer cells and indirect systemic effects through modulation of glucose and insulin metabolism, ultimately reducing cancer risk and mortality [<xref ref-type="bibr" rid="CR144">144</xref>]. However, results from clinical trials remain mixed, with some early-phase studies suggesting benefit, while larger randomized trials have failed to consistently confirm these findings [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. In parallel, metformin has demonstrated multiple mechanisms of cardiac protection in both animal and human studies, including reduced myocardial fibrosis, improved diastolic function, enhanced mitochondrial efficiency, and decreased oxidative stress [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>]. Its use has been associated with improved ventricular function and reduced HF hospitalizations in patients with diabetes, and it has shown potential to reverse features of metabolic cardiomyopathy in preclinical models [<xref ref-type="bibr" rid="CR149">149</xref>].</p><p id="Par75">Metformin has emerged as a promising adjuvant to conventional chemotherapeutic regimens, with evidence suggesting it can enhance treatment efficacy, overcome resistance, and reduce required drug doses, making its interaction with cancer therapies an important area of investigation. [<xref ref-type="bibr" rid="CR150">150</xref>] Metformin may enhance the effectiveness of chemotherapy and radiation by improving pathological response rates, particularly in patients with higher BMI or triple-positive breast cancer histology [<xref ref-type="bibr" rid="CR151">151</xref>]. Metformin use in patients with diabetes receiving anthracyclines was associated with a significantly reduced risk of CTRCD and lower mortality, suggesting a protective effect against cardiotoxicity [<xref ref-type="bibr" rid="CR152">152</xref>]. The ability of metformin to reduce myocardial inflammation, prevent mitochondrial damage, and limit fibrotic remodeling may confer added protection in the presence of cancer therapy-related oxidative stress and metabolic strain [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. It should be noted that metformin is contraindicated in patients with advanced renal impairment due to the risk of lactic acidosis [<xref ref-type="bibr" rid="CR153">153</xref>, <xref ref-type="bibr" rid="CR154">154</xref>].</p></sec><sec id="Sec10"><title>Glucagon-like Peptide-1 Receptor Agonists</title><p id="Par76">GLP-1 RAs stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, delay gastric emptying, and reduce appetite [<xref ref-type="bibr" rid="CR54">54</xref>]. The cardioprotective potential of GLP-1 RAs has gained attention due to their benefits in reducing major adverse cardiovascular events, including HF [<xref ref-type="bibr" rid="CR155">155</xref>]. GLP-1 RAs may help mitigate the cardiovascular side effects of cancer therapies by reducing oxidative stress, inflammation, apoptosis, and endothelial dysfunction, while supporting autophagy and mitochondrial function [<xref ref-type="bibr" rid="CR156">156</xref>]. Studies suggest that GLP-1 RAs may help attenuate fibrosis, a key pathologic feature in both DbCM and CTRCD. The role for GLP-1 RAs in CTRCD remains largely unknown [<xref ref-type="bibr" rid="CR157">157</xref>]. Given the ability of the agents to reduce oxidative stress and improve remodeling, GLP-1 RAs are an attractive therapeutic target for cardiac protection during cancer therapy, though oncology-specific trials are limited [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>].</p><p id="Par77">Recent randomized trials in HFpEF extend this rationale and clarify the cardiometabolic-inflammatory mechanisms by which GLP-1 RAs may improve patient-centered outcomes. In the Semaglutide in Patients with Heart Failure With Preserved Ejectin Fraction and Obesity (STEP-HFpEF) Trial, semaglutide produced larger improvements in symptoms and physical limitations, greater gains in exercise capacity, and marked weight reduction, alongside substantial anti-inflammatory effects and superiority on a hierarchical composite [<xref ref-type="bibr" rid="CR158">158</xref>]. Parallel findings were confirmed in Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 DM (STEP-HFpEF DM) Trial, where semaglutide again improved symptoms, exercise capacity, weight, and inflammation, with fewer serious adverse events than placebo [<xref ref-type="bibr" rid="CR159">159</xref>]. Complementing these studies, the Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) trial showed that semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with obesity and established atherosclerotic cardiovascular disease without diabetes. Follow-up analyses also found fewer heart-failure-related events, including hospitalizations or urgent visits requiring intravenous therapy [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par78">Collectively this data indicates that GLP-1 RAs can modify the HFpEF phenotype by reducing adiposity and systemic inflammation and by improving functional capacity and health status, thereby reshaping the cardiometabolic-inflammatory axis central to HFpEF. Although older liraglutide trials in HFrEF were neutral or raised safety signals, underscoring phenotype-specific effects, the STEP-HFpEF program suggests that in patients with obesity (with or without diabetes), semaglutide favorably affects pathways that overlap with those implicated in CTRCD vulnerability (e.g. low-grade inflammation, endothelial dysfunction, and adverse remodeling) [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. From a therapeutic-implications standpoint, GLP-1 RAs may be reasonable adjuncts for patients with obesity/diabetes who are undergoing potentially cardiotoxic cancer therapies, not as anti-cancer agents themselves but rather as cardiometabolic conditioners that could reduce symptom burden and inflammatory stress.</p><p id="Par79">Emerging dual incretin co-agonists (GLP-1/glucose-dependent insulinotropic polypeptide) share many of the cardiometabolic and anti-inflammatory benefits observed with GLP-1 RAs and may further potentiate these effects through combined incretin pathway activation. Early data suggest similar weight-lowering and metabolic benefits in populations with obesity or diabetes, but cardio-oncology evidence remains preliminary [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]. Dedicated cardio-oncology trials are now needed to test these translational hypotheses.</p><sec id="Sec11"><title>Dipeptidyl Peptidase-4 Inhibitors</title><p id="Par80">Dipeptidyl peptidase-4 (DPP-4) inhibitors act by inhibiting the DPP-4 enzyme responsible for degrading incretin hormones like GLP-1. By inhibiting DPP-4, they prolong the action of GLP-1, leading to improved insulin secretion and reduced glucagon levels [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. DPP-4 inhibitors may offer benefits in cancer populations by improving glycemic control while also exerting anti-inflammatory and vascular protective effects, which could help reduce cardiovascular complications during cancer therapy [<xref ref-type="bibr" rid="CR161">161</xref>]. DPP-4 inhibitors suppress inflammatory pathways such as NF-κB, mitogen-activated protein kinase (MAPK), and cytokine signaling, lowering C-reactive protein (CRP) and other mediators, thereby targeting mechanisms like oxidative stress, endothelial dysfunction, and fibrosis that contribute to both DbCM and CTRCD [<xref ref-type="bibr" rid="CR162">162</xref>]. While they may offer benefits in terms of endothelial protection and glycemic control, their direct impact on cardiotoxicity, especially in the context of cancer therapy, has not been sufficiently investigated (See Table <xref rid="Tab2" ref-type="table">2</xref> for potential interactions and concerns when combining diabetes medications with specific cancer therapies).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Drug–drug interaction of diabetes and cancer therapies: risks and considerations for clinical management</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Diabetes Medication</th><th align="left" colspan="1" rowspan="1">Cancer Therapy/Class</th><th align="left" colspan="1" rowspan="1">Mechanism and Clinical Implications</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Metformin</td><td align="left" colspan="1" rowspan="1">Tyrosine Kinase Inhibitors (TKIs) (e.g., imatinib, sunitinib)</td><td align="left" colspan="1" rowspan="1">TKIs may impair renal tubular secretion and reduce metformin clearance, increasing the risk of lactic acidosis if renal function is compromised; renal monitoring is advised [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Anthracyclines (e.g., doxorubicin)</td><td align="left" colspan="1" rowspan="1">No direct pharmacokinetic interaction. Metformin may exert cardioprotective and anti-inflammatory effects, potentially mitigating anthracycline-induced cardiotoxicity [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin</td><td align="left" colspan="1" rowspan="1">Immune Checkpoint Inhibitors (ICIs) (e.g., nivolumab, pembrolizumab)</td><td align="left" colspan="1" rowspan="1">ICIs can trigger immune-mediated β-cell destruction, resulting in new-onset type 1 diabetes or diabetic ketoacidosis (DKA); insulin requirements may fluctuate with systemic inflammation [<xref ref-type="bibr" rid="CR160">160</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SGLT2 Inhibitors</td><td align="left" colspan="1" rowspan="1">Immune Checkpoint Inhibitors (ICIs)</td><td align="left" colspan="1" rowspan="1">Additive DKA risk due to immune-mediated metabolic stress or reduced oral intake. Monitor for ketosis during acute illness [<xref ref-type="bibr" rid="CR161">161</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Cytotoxic Chemotherapy (e.g., platinum agents, taxanes)</td><td align="left" colspan="1" rowspan="1">Overlapping risk of volume depletion, renal injury, and euglycemic DKA from chemotherapy-related vomiting or diarrhea. SGLT2 inhibitors should be held during acute illness or dehydration [<xref ref-type="bibr" rid="CR161">161</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GLP-1 Receptor Agonists</td><td align="left" colspan="1" rowspan="1">Tyrosine Kinase Inhibitors (TKIs)</td><td align="left" colspan="1" rowspan="1">Overlapping gastrointestinal toxicity (nausea, vomiting) can limit tolerance. Monitor hydration and consider dose adjustment if severe symptoms occur [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Anthracyclines/TKIs</td><td align="left" colspan="1" rowspan="1">Both classes may rarely cause pancreatitis or cardiac dysfunction; concurrent use warrants caution in patients with heart failure or QT interval prolongation [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]</td></tr></tbody></table><table-wrap-foot><p>This table outlines potential side effects and/or potential protective effects when using common diabetes medications alongside various cancer therapies. Most diabetes medications have minimal CYP3A4 or P450 metabolism, reducing the likelihood of significant drug-drug interactions with cancer therapies</p></table-wrap-foot></table-wrap></p><p id="Par81">Moreover, DPP-4 functions as an adipokine released predominantly from visceral adipocytes, where it promotes insulin resistance and low-grade inflammation: linking adipose dysfunction to cardiometabolic injury [<xref ref-type="bibr" rid="CR46">46</xref>]. Clinically, sitagliptin has been associated with reduction in EAT thickness over 24 weeks in adults with T2D on metformin, with EAT change correlating with visceral fat rather than hemoglobin A1c (HbA1c) [<xref ref-type="bibr" rid="CR47">47</xref>]. Complementing this, the randomized ASSET Study found comparable (no significant between-group differences) in pericardial/epicardial fat and myocardial triglyceride content over 12 weeks with sitagliptin versus empagliflozin by MRI, situating DPP-4 inhibition squarely within the adiposity-cardiac fat axis [<xref ref-type="bibr" rid="CR48">48</xref>]. Together, these data support positioning DPP-4 inhibitors within an adiposity-centered framework (adipokine signaling, EAT phenotypes) relevant to cardiometabolic vulnerability.</p></sec><sec id="Sec12"><title>SGLT2 inhibitors</title><p id="Par82">SGLT2is (e.g., empagliflozin, dapagliflozin, canagliflozin) reduce renal glucose and sodium reabsorption, producing glycosuria and natriuresis with modest blood pressure and weight reductions. Beyond hemodynamics, SGLT2 inhibition favorably remodels myocardial energetics (increasing ketone utilization and mitochondrial redox capacity), attenuates oxidative stress, and exerts anti-inflammatory and antifibrotic effects that may be relevant to CTRCD [<xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR53">53</xref>]. Mechanistically, benefits are linked to shifts in substrate utilization toward ketone oxidation, reduced intracellular sodium and calcium (via putative Na^ +/H^ + exchanger-1 modulation), AMPK/Sirtuin 1 (SIRT1)/Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC-1α) signaling, and suppression of NLRP3 inflammasome pathways [<xref ref-type="bibr" rid="CR50">50</xref>–<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par83">Across HF phenotypes (reduced and preserved ejection fraction) and regardless of diabetes status, SGLT2is reduce HF hospitalization and improve patient-reported quality of life and functional capacity, while also providing kidney protection [<xref ref-type="bibr" rid="CR163">163</xref>–<xref ref-type="bibr" rid="CR165">165</xref>]. These class effects and their pleiotropic mechanisms make SGLT2is foundational agents in cardio-oncology when tolerated, particularly in patients at risk for CTRCD or with established HF.</p><p id="Par84">Preclinical and translational studies demonstrate that SGLT2is limit anthracycline cardiotoxicity by preserving mitochondrial function, reducing oxidative stress and apoptosis, and improving myocardial energetics [<xref ref-type="bibr" rid="CR164">164</xref>]. Large-animal data further show empagliflozin prevents anthracycline-induced LV dysfunction on serial cardiovascular MRI [<xref ref-type="bibr" rid="CR165">165</xref>]. Clinically, retrospective cohorts in patients with diabetes and cancer report lower risks of incident CTRCD, HF hospitalizations, and all-cause mortality with SGLT2i use compared with matched controls receiving potentially cardiotoxic therapy [<xref ref-type="bibr" rid="CR166">166</xref>–<xref ref-type="bibr" rid="CR168">168</xref>]. A prospective case–control pilot, Use of EMPAgliflozin in the Prevention of CARDiotoxicity (EMPACARD-PILOT), found empagliflozin, started one week before anthracyclines in high-risk patients, was associated with a reduced incidence of CTRCD and smaller declines in global longitudinal strain/left ventricular ejection fraction without safety signals, supporting evaluation in randomized trials [<xref ref-type="bibr" rid="CR169">169</xref>, <xref ref-type="bibr" rid="CR170">170</xref>].</p><p id="Par85">Current meta-analyses of randomized trials do not show an overall increase in incident cancer with SGLT2is; no consistent association with breast or bladder cancer has been observed. A possible signal for renal cancer has appeared in some analyses and pharmacovigilance datasets, warranting vigilance and longer follow-up [<xref ref-type="bibr" rid="CR171">171</xref>, <xref ref-type="bibr" rid="CR172">172</xref>]. Emerging observational work in breast cancer suggests potential mortality benefits of SGLT2is vs DPP-4 inhibitors, but data remain hypothesis-generating [<xref ref-type="bibr" rid="CR172">172</xref>].</p><p id="Par86">SGLT2is also map onto the adiposity-cardiac fat framework: a 2024 network meta-analysis found SGLT2is reduced EAT thickness more than placebo and other therapies in patients with dysmetabolism [<xref ref-type="bibr" rid="CR173">173</xref>]. Human imaging corroborates this, with dapagliflozin lowering EAT thickness and epicardial glucose uptake over follow-up in type 2 diabetes [<xref ref-type="bibr" rid="CR174">174</xref>]. Mechanistically, SGLT2is attenuate NLRP3 inflammasome activity and downstream IL-1β/IL-18 signaling in cardiometabolic tissues, aligning their effects with adiposity-driven inflammation rather than glucose alone [<xref ref-type="bibr" rid="CR175">175</xref>]. Together, these data situate SGLT2 inhibition within an adiposity/inflammasome paradigm that is relevant to myocardial vulnerability.</p></sec><sec id="Sec13"><title>Peri‑operative Management of Antidiabetic Therapy in Patients with Cancer</title><p id="Par87">As part of oncologic management, patients may undergo surgery, making perioperative management of antidiabetic medications essential to mitigate metabolic and cardiovascular risks. Oral agents such as metformin should be withheld at least 24 h prior to surgery and for 48 h postoperatively in patients with renal impairment to reduce the risk of lactic acidosis, while SGLT2is should be discontinued at least 72 h before surgery due to the risk of euglycemic ketoacidosis. Insulin regimens require careful adjustment with frequent glucose monitoring to maintain stable perioperative glycemia and avoid both hypoglycemic and hyperglycemic complications [<xref ref-type="bibr" rid="CR176">176</xref>].</p></sec><sec id="Sec14"><title>Hormonal Therapy-induced Metabolic Dysfunction and Potential Mitigation Strategies</title><p id="Par88">Androgen-deprivation therapy (ADT) has been shown to disrupt metabolic homeostasis by promoting insulin resistance, dyslipidemia, increased adiposity, and loss of lean body mass [<xref ref-type="bibr" rid="CR67">67</xref>]. These changes overlap with mechanisms driving DbCM, suggesting increased vulnerability to cardiotoxicity, particularly in patients with preexisting diabetes or when combined with other cardiotoxic agents. Strategies to prevent or mitigate these adverse effects are therefore of growing clinical interest.</p><p id="Par89">Antidiabetic agents, such as metformin, SGLT2is, and GLP-1-RAs, have emerged as potential interventions, though clinical evidence is still limited. Studies investigating metformin in patients receiving ADT show modest improvements in metabolic parameters but no clear impact on metabolic syndrome or survival outcomes [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. Currently, the Investigation of GLP1-Receptor Agonists in Men with Prostate cancer taking Androgen Deprivation Therapy (GAINPCCONTROL) trial is investigating GLP-1 RAs in this population to evaluate whether metabolic modulation can prevent ADT-induced weight gain, insulin resistance, and dyslipidemia [<xref ref-type="bibr" rid="CR178">178</xref>]. Meanwhile, SGLT2is have shown early promise, with observational data suggesting reduced cardiovascular events in men with prostate cancer and diabetes on hormone therapy [<xref ref-type="bibr" rid="CR179">179</xref>].</p><p id="Par90">Although these studies were not designed specifically to evaluate cardiotoxicity, they provide early proof-of-concept that metabolic interventions may reduce hormone therapy-associated cardiometabolic risk. Key gaps remain, including long-term cardiovascular outcomes, optimal timing of interventions relative to hormone therapy initiation, and direct measures of myocardial injury or remodeling. These findings support enhanced metabolic monitoring and targeted mitigation strategies to reduce susceptibility to CTRCD in patients receiving ADT.</p></sec><sec id="Sec15"><title>Management of Patients with Diabetes Undergoing Cancer Therapy</title><sec id="Sec16"><title>Lack of Guidelines</title><p id="Par91">Currently, there is limited guidance for managing diabetes in patients undergoing cancer therapy, despite their heightened vulnerability to CTRCD. Standardized protocols for risk assessment, therapy selection, and cardiac monitoring in this population are lacking. Enhanced cardiac monitoring, such as echocardiography and biomarkers like high-sensitivity troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP), is essential, though optimal timing and frequency remain unclear [<xref ref-type="bibr" rid="CR180">180</xref>]. Interdisciplinary collaboration can support early detection and personalized initiation of cardioprotective therapies.</p></sec></sec></sec><sec id="Sec17"><title>Clinical Implications and Future Directions</title><sec id="Sec18"><title>Interdisciplinary Collaboration for Tailored Patient Care</title><p id="Par92">Given the shared pathophysiology between DbCM and CTRCD (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), it is critical to implement interdisciplinary collaboration between oncology, cardiology, endocrinology, and primary care clinicians with the inclusion of a pharmacist. Clinicians must regularly assess cardiac risk factors in patients with cancer and diabetes and incorporate early cardiac screening into the oncology care pathway. Intensive multidisciplinary follow-up during and post-therapy should focus on identification of subclinical cardiac dysfunction and provide opportunities for early intervention. (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Multidisciplinary strategies for future care in patients with diabetes and cancer. This schematic illustrates a holistic, patient-centered model for managing coexisting diabetes and cancer, emphasizing interdisciplinary collaboration, optimized pharmacologic treatment, early risk stratification, tailored clinical guidelines, and long-term survivorship planning</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40959_2025_412_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec19"><title>Optimized Pharmacological Management</title><p id="Par93">The increasing recognition of the interplay between diabetes and oncologic therapeutics underscores the need for personalized pharmacological management. When feasible, potentially beneficial therapies such as SGLT2i and metformin should be prioritized over other diabetes agents due to their potential cardioprotective effects (Table <xref rid="Tab1" ref-type="table">1</xref>). For patients at risk of cardiotoxicity, particularly those undergoing chemotherapy or radiation therapy, these medications may mitigate cardiac risk and improve myocardial function. In high-risk populations when feasible, agents with potential cardiac toxicity should be minimized or avoided. Clinical guidelines should be updated to reflect these insights and provide clear recommendations for diabetes management in patients with cancer, integrating cardiovascular safety into treatment plans. Pharmacy colleagues should be regularly engaged in discussions regarding therapeutic strategies.</p></sec><sec id="Sec20"><title>Early Risk Stratification and Personalized Care Plans</title><p id="Par94">Early risk stratification is critical for managing patients with both diabetes and cancer. Assessing patient history, cardiovascular risk factors, and cancer treatment type can help identify those at highest risk for CTRCD. Risk assessment tools tailored to this population can guide personalized care plans, monitoring schedules, and interventions. Routine echocardiography, cardiac biomarkers, and, when appropriate, CMRI, or functional testing should be used to detect subclinical cardiac dysfunction and optimize care.</p></sec><sec id="Sec21"><title>Refining Clinical Guidelines for Managing Diabetes in Patients with Cancer</title><p id="Par95">Current clinical guidelines specifically for the management of diabetes and cancer therapy-related cardiotoxicity are limited. It is imperative that the development of guidelines for pharmacologic management, cardiac monitoring, and therapy adjustments be developed for the diabetic population of patients with cancer. Existing guidelines from agencies such as the American Diabetes Association (ADA), American Society of Clinical Oncology (ASCO), and International Cardio-Oncology Society could be leveraged to tailor current guidance to this complex population.</p></sec><sec id="Sec22"><title>Long-term Survivorship and Prevention</title><p id="Par96">For patients with diabetes and cancer, the longitudinal management of cardiovascular health should be a central focus, particularly as these patients transition into cancer survivorship. While post cancer therapy cardiac surveillance is currently underutilized, long-term monitoring of the diabetic population is of particular importance given their high risk for cardiac toxicity over time. Lifestyle interventions, including dietary counseling, physical activity, and structured exercise programs should be incorporated into survivorship programs to mitigate cardiovascular risk. The implementation of patient education programs focused on healthy lifestyle choices for post-cancer treatment is essential to reducing HF and other cardiovascular complications in this complex and vulnerable population.<list list-type="bullet"><list-item><p id="Par97">There is a lack of standardized guidelines for managing diabetes in patients with cancer, necessitating improved cardiac risk assessment, monitoring, and interdisciplinary care.</p></list-item><list-item><p id="Par98">Early risk stratification and personalized care plans, including prioritization of cardioprotective agents like SGLT2i and metformin, are essential to mitigate CTRCD risk.</p></list-item><list-item><p id="Par99">Long-term survivorship care with ongoing cardiac surveillance, lifestyle interventions, and patient education is critical to reduce cardiovascular complications in this high-risk population.</p></list-item></list></p></sec><sec id="Sec23"><title>Conclusions — Toward Metabolic Cardioprotection in Cancer Care</title><p id="Par100">Diabetes and cancer converge at the myocardial level through shared pathways of injury, including oxidative stress, myocardial dysfunction, and interstitial fibrosis. The complexity of these interactions is further amplified by adiposity-driven and innate-immune circuits (EAT expansion, inflammasome activation, trained immunity). Within this framework, cardio-oncology care must extend beyond the avoidance of or attention to cardiotoxic cancer therapies with instead a focus on the cardiometabolic milieu. Contemporary glucose-lowering therapies differ meaningfully in this regard. Metformin, SGLT2is, and GLP-1 RAs tend to favor myocardial energetics, vascular health, weight loss, and inflammatory tone, whereas insulin and sulfonylureas may, in specific contexts, augment metabolic stress and require careful titration. Early risk stratification, deliberate medication selection, and coordinated management among oncology, cardiology, endocrinology, pharmacy, and primary care can protect cardiac function without compromising cancer efficacy. The field now needs oncology-specific randomized trials that test cardiometabolic strategies (e.g., GLP-1 RAs/SGLT2is) for prevention and treatment of CTRCD, harmonized cardio-oncology end points, and pragmatic pathways that embed ketone monitoring, volume and renal surveillance, and survivorship follow-up incorporated into routine care. Bridging DbCM and CTRCD in this way shifts the discipline from reaction to prevention: aligning cancer cure with durable cardiovascular health.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DbCM</term><def><p id="Par4">Diabetic Cardiomyopathy</p></def></def-item><def-item><term>CTRCD</term><def><p id="Par5">Cancer Therapy-Related Cardiac Dysfunction</p></def></def-item><def-item><term>SGLT2i</term><def><p id="Par6">Sodium-glucose Cotransporter 2 inhibitor</p></def></def-item><def-item><term>LV</term><def><p id="Par7">Left Ventricle</p></def></def-item><def-item><term>SGLT2</term><def><p id="Par8">Sodium-glucose Cotransporter-2</p></def></def-item><def-item><term>GLP-1</term><def><p id="Par9">Glucagon-like Peptide 1</p></def></def-item><def-item><term>GLP-1 Ras</term><def><p id="Par10">Glucagon-like Peptide-1 Receptor Agonists</p></def></def-item><def-item><term>HF</term><def><p id="Par11">Heart Failure</p></def></def-item><def-item><term>ROS</term><def><p id="Par12">Reactive Oxygen Species</p></def></def-item><def-item><term>TGF-β</term><def><p id="Par13">Transforming Growth Factor-beta</p></def></def-item><def-item><term>NF-κB</term><def><p id="Par14">Nuclear Factor-kappa B</p></def></def-item><def-item><term>AGEs</term><def><p id="Par15">Advanced Glycation End Products</p></def></def-item><def-item><term>HER2</term><def><p id="Par16">Human Epidermal Growth Factor Receptor 2</p></def></def-item><def-item><term>ICIs</term><def><p id="Par17">Immune Checkpoint Inhibitors</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par18">Programmed Death-Ligand 1</p></def></def-item><def-item><term>CTLA-4</term><def><p id="Par19">Cytotoxic T-Lymphocyte Antigen 4</p></def></def-item><def-item><term>TKIs</term><def><p id="Par20">Tyrosine Kinase Inhibitors</p></def></def-item><def-item><term>SERCA2a</term><def><p id="Par21">Sarcoplasmic/Endoplasmic Reticulum Ca2 + -ATPase 2a</p></def></def-item><def-item><term>HfpEF</term><def><p id="Par22">Heart Failure with Preserved Ejection Fraction</p></def></def-item><def-item><term>TLR2</term><def><p id="Par23">Toll-like Receptor 2</p></def></def-item><def-item><term>TLR4</term><def><p id="Par24">Toll-like Receptor 4</p></def></def-item><def-item><term>NLR</term><def><p id="Par25">Nucleotide-binding and Leucine-rich Repeat receptors</p></def></def-item><def-item><term>NLRP3</term><def><p id="Par26">NLR family pyrin domain containing 3</p></def></def-item><def-item><term>TXNIP</term><def><p id="Par27">Thioredoxin-interacting Protein</p></def></def-item><def-item><term>IL-1β/IL-18</term><def><p id="Par28">Interleukin-1 beta/Interleukin-18</p></def></def-item><def-item><term>EAT</term><def><p id="Par29">Epicardial Adipose Tissue</p></def></def-item><def-item><term>CMRI</term><def><p id="Par30">Cardiovascular Magnetic Resonance Imaging</p></def></def-item><def-item><term>PI3K/Akt</term><def><p id="Par31">Phosphoinositide 3-Kinase/Protein Kinase B</p></def></def-item><def-item><term>Ras/Raf</term><def><p id="Par32">Rat Sarcoma/Rapidly Accelerated Fibrosarcoma</p></def></def-item><def-item><term>Ras/Raf/MEK/ERK</term><def><p id="Par33">Rat Sarcoma/Rapidly Accelerated Fibrosarcoma/Extracellular Signal-Regulated Kinase</p></def></def-item><def-item><term>IGF-1</term><def><p id="Par34">Insulin-like Growth Factor 1</p></def></def-item><def-item><term>mTOR</term><def><p id="Par35">Mammalian Target of Rapamycin</p></def></def-item><def-item><term>AMP</term><def><p id="Par36">Adenosine Monophosphate</p></def></def-item><def-item><term>AMPK</term><def><p id="Par37">AMP-activated protein kinase</p></def></def-item><def-item><term>DPP-4</term><def><p id="Par38">Dipeptidyl peptidase-4</p></def></def-item><def-item><term>MAPK</term><def><p id="Par39">Mitogen-activated Protein Kinase</p></def></def-item><def-item><term>CRP</term><def><p id="Par40">C-reactive protein</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par41">Hemoglobin A1c</p></def></def-item><def-item><term>SIRT1</term><def><p id="Par42">Sirtuin 1</p></def></def-item><def-item><term>PGC-1α</term><def><p id="Par43">Peroxisome proliferator-activated receptor-γ coactivator 1-α</p></def></def-item><def-item><term>NT-proBNP</term><def><p id="Par44">N-terminal pro-B-type Natriuretic Peptide</p></def></def-item><def-item><term>ADA</term><def><p id="Par45">American Diabetes Association</p></def></def-item><def-item><term>ASCO</term><def><p id="Par46">American Society of Clinical Oncology</p></def></def-item><def-item><term>PD-1</term><def><p id="Par47">Programmed Cell Death Protein 1</p></def></def-item><def-item><term>DKA</term><def><p id="Par48">Diabetic Ketoacidosis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher’s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Clinical trial registration</title><p id="Par101">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>SF conceptualized the manuscript. SF and GB investigated. SF,GB, CEH, JB, and MB designed methodology. SF GB and MB managed the project. MB supervised. SF GB CEH, JB and MB aided in visualization. SF and GB wrote the original draft. All authors reviewed and edited.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>CEH is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through Grant Award Number KL2TR001446.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Available upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par102">Not applicable.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par103">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par104">Javed Butler is a consultant to Abbott, Adaptyx, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Bearing, CVRx, Cytokinetics, Edwards, Element Science, Faraday, Foundry, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muka</surname><given-names>T</given-names></name><name name-style="western"><surname>Imo</surname><given-names>D</given-names></name><name name-style="western"><surname>Jaspers</surname><given-names>L</given-names></name><name name-style="western"><surname>Colpani</surname><given-names>V</given-names></name><name name-style="western"><surname>Chaker</surname><given-names>L</given-names></name><name name-style="western"><surname>van der Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Mendis</surname><given-names>S</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>R</given-names></name><name name-style="western"><surname>Bramer</surname><given-names>WM</given-names></name><name name-style="western"><surname>Falla</surname><given-names>A</given-names></name><name name-style="western"><surname>Pazoki</surname><given-names>R</given-names></name><name name-style="western"><surname>Franco</surname><given-names>OH</given-names></name></person-group><article-title>The global impact of non-communicable diseases on healthcare spending and national income: a systematic review</article-title><source>Eur J Epidemiol</source><year>2015</year><volume>30</volume><issue>4</issue><fpage>251</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1007/s10654-014-9984-2</pub-id><pub-id pub-id-type="pmid">25595318</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol. 2015;30(4):251–77. 10.1007/s10654-014-9984-2.<pub-id pub-id-type="pmid">25595318</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10654-014-9984-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hacker</surname><given-names>K</given-names></name></person-group><article-title>The burden of chronic disease</article-title><source>Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>112</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.mayocpiqo.2023.08.005</pub-id><pub-id pub-id-type="pmcid">PMC10830426</pub-id><pub-id pub-id-type="pmid">38304166</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hacker K. The burden of chronic disease. Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes. 2024;8(1):112–9. 10.1016/j.mayocpiqo.2023.08.005.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocpiqo.2023.08.005</pub-id><pub-id pub-id-type="pmcid">PMC10830426</pub-id><pub-id pub-id-type="pmid">38304166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>MAB</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>MJ</given-names></name><name name-style="western"><surname>King</surname><given-names>JK</given-names></name><name name-style="western"><surname>Govender</surname><given-names>RD</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>H</given-names></name><name name-style="western"><surname>Al</surname><given-names>KJ</given-names></name></person-group><article-title>epidemiology of type 2 diabetes - global burden of disease and forecasted trends</article-title><source>J Epidemiol Glob Health</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.2991/jegh.k.191028.001</pub-id><pub-id pub-id-type="pmid">32175717</pub-id><pub-id pub-id-type="pmcid">PMC7310804</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11. 10.2991/jegh.k.191028.001. (PMID:32175717;PMCID:PMC7310804).<pub-id pub-id-type="pmid">32175717</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2991/jegh.k.191028.001</pub-id><pub-id pub-id-type="pmcid">PMC7310804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. 10.3322/caac.21834.<pub-id pub-id-type="pmid">38572751</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F</given-names></name><name name-style="western"><surname>Lin</surname><given-names>R</given-names></name></person-group><article-title>Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021</article-title><source>J Hematol Oncol</source><year>2024</year><volume>17</volume><issue>1</issue><fpage>119</fpage><pub-id pub-id-type="doi">10.1186/s13045-024-01640-8</pub-id><pub-id pub-id-type="pmid">39614359</pub-id><pub-id pub-id-type="pmcid">PMC11607901</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wu Z, Xia F, Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021. J Hematol Oncol. 2024;17(1):119. 10.1186/s13045-024-01640-8.<pub-id pub-id-type="pmid">39614359</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-024-01640-8</pub-id><pub-id pub-id-type="pmcid">PMC11607901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurney</surname><given-names>J</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>J</given-names></name><name name-style="western"><surname>Teng</surname><given-names>A</given-names></name><name name-style="western"><surname>Krebs</surname><given-names>J</given-names></name><name name-style="western"><surname>Koea</surname><given-names>J</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cancer and diabetes co-occurrence: a national study with 44 million person-years of follow-up</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><issue>28</issue><fpage>e0276913</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0276913</pub-id><pub-id pub-id-type="pmid">36441693</pub-id><pub-id pub-id-type="pmcid">PMC9704677</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gurney J, Stanley J, Teng A, Krebs J, Koea J, Lao C, et al. Cancer and diabetes co-occurrence: a national study with 44 million person-years of follow-up. PLoS One. 2022;17(28):e0276913. 10.1371/journal.pone.0276913.<pub-id pub-id-type="pmid">36441693</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0276913</pub-id><pub-id pub-id-type="pmcid">PMC9704677</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name><name name-style="western"><surname>Qu</surname><given-names>S</given-names></name></person-group><article-title>The relationship between diabetes mellitus and cancers and its underlying mechanisms</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>800995</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.800995</pub-id><pub-id pub-id-type="pmid">35222270</pub-id><pub-id pub-id-type="pmcid">PMC8873103</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Zhu B, Qu S. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol (Lausanne). 2022;13:800995. 10.3389/fendo.2022.800995.<pub-id pub-id-type="pmid">35222270</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.800995</pub-id><pub-id pub-id-type="pmcid">PMC8873103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Yeh HC, Golozar A, Brancati FL. Cancer and Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 29. PMID: 33651571.<pub-id pub-id-type="pmid">33651571</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>MW</given-names></name><name name-style="western"><surname>Hamo</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>D</given-names></name><name name-style="western"><surname>Ky</surname><given-names>B</given-names></name><name name-style="western"><surname>Nohria</surname><given-names>A</given-names></name><name name-style="western"><surname>Baer</surname><given-names>L</given-names></name><name name-style="western"><surname>Skopicki</surname><given-names>H</given-names></name><name name-style="western"><surname>Lenihan</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gheorghiade</surname><given-names>M</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name></person-group><article-title>Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging</article-title><source>Circ Heart Fail</source><year>2016</year><volume>9</volume><issue>1</issue><fpage>e002661</fpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.115.002661</pub-id><pub-id pub-id-type="pmid">26747861</pub-id><pub-id pub-id-type="pmcid">PMC4709035</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661. 10.1161/CIRCHEARTFAILURE.115.002661.<pub-id pub-id-type="pmid">26747861</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCHEARTFAILURE.115.002661</pub-id><pub-id pub-id-type="pmcid">PMC4709035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>IE</given-names></name><name name-style="western"><surname>Taveras Alam</surname><given-names>S</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>GA</given-names></name><name name-style="western"><surname>Sancassani</surname><given-names>R</given-names></name></person-group><article-title>Cancer therapy-related cardiac dysfunction: an overview for the clinician</article-title><source>Clin Med Insights Cardiol</source><year>2019</year><volume>29</volume><issue>13</issue><fpage>1179546819866445</fpage><pub-id pub-id-type="doi">10.1177/1179546819866445</pub-id><pub-id pub-id-type="pmcid">PMC6664629</pub-id><pub-id pub-id-type="pmid">31384135</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;29(13):1179546819866445. 10.1177/1179546819866445.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1179546819866445</pub-id><pub-id pub-id-type="pmcid">PMC6664629</pub-id><pub-id pub-id-type="pmid">31384135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Lenihan</surname><given-names>D</given-names></name><name name-style="western"><surname>Armenian</surname><given-names>S</given-names></name><name name-style="western"><surname>Barac</surname><given-names>A</given-names></name><name name-style="western"><surname>Blaes</surname><given-names>A</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>D</given-names></name><name name-style="western"><surname>Carver</surname><given-names>J</given-names></name><name name-style="western"><surname>Dent</surname><given-names>S</given-names></name><name name-style="western"><surname>Ky</surname><given-names>B</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></name><name name-style="western"><surname>López-Fernández</surname><given-names>T</given-names></name><name name-style="western"><surname>Fradley</surname><given-names>MG</given-names></name><name name-style="western"><surname>Ganatra</surname><given-names>S</given-names></name><name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>JD</given-names></name><name name-style="western"><surname>Minotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Lang</surname><given-names>NN</given-names></name><name name-style="western"><surname>Liu</surname><given-names>JE</given-names></name><name name-style="western"><surname>Neilan</surname><given-names>TG</given-names></name><name name-style="western"><surname>Nohria</surname><given-names>A</given-names></name><name name-style="western"><surname>O'Quinn</surname><given-names>R</given-names></name><name name-style="western"><surname>Pusic</surname><given-names>I</given-names></name><name name-style="western"><surname>Porter</surname><given-names>C</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>KL</given-names></name><name name-style="western"><surname>Ruddy</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Thavendiranathan</surname><given-names>P</given-names></name><name name-style="western"><surname>Valent</surname><given-names>P</given-names></name></person-group><article-title>Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement</article-title><source>Eur Heart J</source><year>2022</year><volume>43</volume><issue>31</issue><fpage>280</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab674</pub-id><pub-id pub-id-type="pmid">34904661</pub-id><pub-id pub-id-type="pmcid">PMC8803367</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(31):280–99. 10.1093/eurheartj/ehab674.<pub-id pub-id-type="pmid">34904661</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehab674</pub-id><pub-id pub-id-type="pmcid">PMC8803367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>MW</given-names></name><name name-style="western"><surname>Vo</surname><given-names>JB</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>JE</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>AM</given-names></name><name name-style="western"><surname>Nohria</surname><given-names>A</given-names></name><name name-style="western"><surname>Deswal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America</article-title><source>J Card Fail</source><year>2025</year><volume>31</volume><issue>2</issue><fpage>415</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2024.08.045</pub-id><pub-id pub-id-type="pmid">39419165</pub-id><pub-id pub-id-type="pmcid">PMC12317758</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, et al. Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail. 2025;31(2):415–55. 10.1016/j.cardfail.2024.08.045.<pub-id pub-id-type="pmid">39419165</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cardfail.2024.08.045</pub-id><pub-id pub-id-type="pmcid">PMC12317758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamo</surname><given-names>CE</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>MW</given-names></name></person-group><article-title>Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy</article-title><source>Clin Med Insights Cardiol</source><year>2015</year><volume>9</volume><issue>Suppl 2</issue><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.4137/CMC.S19704</pub-id><pub-id pub-id-type="pmid">26309419</pub-id><pub-id pub-id-type="pmcid">PMC4525792</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Hamo CE, Bloom MW. Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy. Clin Med Insights Cardiol. 2015;9(Suppl 2):47–51. 10.4137/CMC.S19704.<pub-id pub-id-type="pmid">26309419</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/CMC.S19704</pub-id><pub-id pub-id-type="pmcid">PMC4525792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>M</given-names></name><name name-style="western"><surname>Budd</surname><given-names>GT</given-names></name><name name-style="western"><surname>Tang</surname><given-names>WHW</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Shah</surname><given-names>C</given-names></name><name name-style="western"><surname>Moudgil</surname><given-names>R</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>Z</given-names></name><name name-style="western"><surname>Watson</surname><given-names>C</given-names></name><name name-style="western"><surname>Cho</surname><given-names>L</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanj</surname><given-names>M</given-names></name><name name-style="western"><surname>Kapadia</surname><given-names>S</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>B</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>L</given-names></name><name name-style="western"><surname>Collier</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name></person-group><article-title>Cardiac risk stratification in cancer patients: a longitudinal patient-patient network analysis</article-title><source>PLoS Med</source><year>2021</year><volume>18</volume><issue>8</issue><fpage>e1003736</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1003736</pub-id><pub-id pub-id-type="pmid">34339408</pub-id><pub-id pub-id-type="pmcid">PMC8366997</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hou Y, Zhou Y, Hussain M, Budd GT, Tang WHW, Abraham J, et al. Cardiac risk stratification in cancer patients: a longitudinal patient-patient network analysis. PLoS Med. 2021;18(8):e1003736. 10.1371/journal.pmed.1003736.<pub-id pub-id-type="pmid">34339408</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1003736</pub-id><pub-id pub-id-type="pmcid">PMC8366997</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omland</surname><given-names>T</given-names></name><name name-style="western"><surname>Heck</surname><given-names>SL</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>G</given-names></name></person-group><article-title>The role of cardioprotection in cancer therapy cardiotoxicity</article-title><source>JACC: CardioOncology</source><year>2022</year><volume>4</volume><issue>1</issue><fpage>19</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2022.01.101</pub-id><pub-id pub-id-type="pmid">35492815</pub-id><pub-id pub-id-type="pmcid">PMC9040117</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity. JACC: CardioOncology. 2022;4(1):19–37. 10.1016/j.jaccao.2022.01.101.<pub-id pub-id-type="pmid">35492815</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaccao.2022.01.101</pub-id><pub-id pub-id-type="pmcid">PMC9040117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martín-Timón</surname><given-names>I</given-names></name><name name-style="western"><surname>Sevillano-Collantes</surname><given-names>C</given-names></name><name name-style="western"><surname>Segura-Galindo</surname><given-names>A</given-names></name><name name-style="western"><surname>Del Cañizo-Gómez</surname><given-names>FJ</given-names></name></person-group><article-title>Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?</article-title><source>World J Diabetes</source><year>2014</year><volume>5</volume><issue>4</issue><fpage>444</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.4239/wjd.v5.i4.444</pub-id><pub-id pub-id-type="pmid">25126392</pub-id><pub-id pub-id-type="pmcid">PMC4127581</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444–70. 10.4239/wjd.v5.i4.444.<pub-id pub-id-type="pmid">25126392</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4239/wjd.v5.i4.444</pub-id><pub-id pub-id-type="pmcid">PMC4127581</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bays</surname><given-names>HE</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>A</given-names></name><name name-style="western"><surname>German</surname><given-names>C</given-names></name><name name-style="western"><surname>Satish</surname><given-names>P</given-names></name><name name-style="western"><surname>Iluyomade</surname><given-names>A</given-names></name><name name-style="western"><surname>Dudum</surname><given-names>R</given-names></name><name name-style="western"><surname>Thakkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Rifai</surname><given-names>MA</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A</given-names></name><name name-style="western"><surname>Thobani</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Saiegh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Sheth</surname><given-names>S</given-names></name><name name-style="western"><surname>Toth</surname><given-names>PP</given-names></name></person-group><article-title>Ten things to know about ten cardiovascular disease risk factors - 2022</article-title><source>Am J Prev Cardiol</source><year>2022</year><volume>10</volume><fpage>100342</fpage><pub-id pub-id-type="doi">10.1016/j.ajpc.2022.100342</pub-id><pub-id pub-id-type="pmid">35517870</pub-id><pub-id pub-id-type="pmcid">PMC9061634</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Bays HE, Kulkarni A, German C, Satish P, Iluyomade A, Dudum R, et al. Ten things to know about ten cardiovascular disease risk factors - 2022. Am J Prev Cardiol. 2022;10:100342. 10.1016/j.ajpc.2022.100342.<pub-id pub-id-type="pmid">35517870</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpc.2022.100342</pub-id><pub-id pub-id-type="pmcid">PMC9061634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habib</surname><given-names>SL</given-names></name><name name-style="western"><surname>Rojna</surname><given-names>M</given-names></name></person-group><article-title>Diabetes and risk of cancer</article-title><source>ISRN Oncol</source><year>2013</year><volume>2013</volume><fpage>583786</fpage><pub-id pub-id-type="doi">10.1155/2013/583786</pub-id><pub-id pub-id-type="pmid">23476808</pub-id><pub-id pub-id-type="pmcid">PMC3582053</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol. 2013;2013:583786. 10.1155/2013/583786.<pub-id pub-id-type="pmid">23476808</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/583786</pub-id><pub-id pub-id-type="pmcid">PMC3582053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dąbrowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Szymańska-Garbacz</surname><given-names>E</given-names></name><name name-style="western"><surname>Miszczyszyn</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dereziński</surname><given-names>T</given-names></name><name name-style="western"><surname>Czupryniak</surname><given-names>L</given-names></name></person-group><article-title>Risk factors for cancer development in type 2 diabetes: a retrospective case-control study</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>785</fpage><pub-id pub-id-type="doi">10.1186/s12885-016-2836-6</pub-id><pub-id pub-id-type="pmid">27724912</pub-id><pub-id pub-id-type="pmcid">PMC5057369</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Dąbrowski M, Szymańska-Garbacz E, Miszczyszyn Z, Dereziński T, Czupryniak L. Risk factors for cancer development in type 2 diabetes: a retrospective case-control study. BMC Cancer. 2016;16(1):785. 10.1186/s12885-016-2836-6.<pub-id pub-id-type="pmid">27724912</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-016-2836-6</pub-id><pub-id pub-id-type="pmcid">PMC5057369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvatore</surname><given-names>T</given-names></name><name name-style="western"><surname>Pafundi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Galiero</surname><given-names>R</given-names></name><name name-style="western"><surname>Albanese</surname><given-names>G</given-names></name><name name-style="western"><surname>Di Martino</surname><given-names>A</given-names></name><name name-style="western"><surname>Caturano</surname><given-names>A</given-names></name><etal/></person-group><article-title>The diabetic cardiomyopathy: the contributing pathophysiological mechanisms</article-title><source>Front Med</source><year>2021</year><volume>8</volume><fpage>695792</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.695792</pub-id><pub-id pub-id-type="pmcid">PMC8279779</pub-id><pub-id pub-id-type="pmid">34277669</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Salvatore T, Pafundi PC, Galiero R, Albanese G, Di Martino A, Caturano A, et al. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms. Front Med. 2021;8:695792. 10.3389/fmed.2021.695792.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.695792</pub-id><pub-id pub-id-type="pmcid">PMC8279779</pub-id><pub-id pub-id-type="pmid">34277669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dillmann</surname><given-names>WH</given-names></name></person-group><article-title>Diabetic cardiomyopathy</article-title><source>Circ Res</source><year>2019</year><volume>124</volume><fpage>1160</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.314665</pub-id><pub-id pub-id-type="pmid">30973809</pub-id><pub-id pub-id-type="pmcid">PMC6578576</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Dillmann WH. Diabetic cardiomyopathy. Circ Res. 2019;124:1160–2. 10.1161/CIRCRESAHA.118.314665.<pub-id pub-id-type="pmid">30973809</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.118.314665</pub-id><pub-id pub-id-type="pmcid">PMC6578576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>G</given-names></name><name name-style="western"><surname>Whaley-Connell</surname><given-names>A</given-names></name><name name-style="western"><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease</article-title><source>Diabetologia</source><year>2018</year><volume>61</volume><issue>1</issue><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4390-4</pub-id><pub-id pub-id-type="pmid">28776083</pub-id><pub-id pub-id-type="pmcid">PMC5720913</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61(1):21–8. 10.1007/s00125-017-4390-4.<pub-id pub-id-type="pmid">28776083</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-017-4390-4</pub-id><pub-id pub-id-type="pmcid">PMC5720913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>MT</given-names></name><name name-style="western"><surname>Fung</surname><given-names>K</given-names></name><name name-style="western"><surname>Aung</surname><given-names>N</given-names></name><name name-style="western"><surname>Sanghvi</surname><given-names>MM</given-names></name><name name-style="western"><surname>Chadalavada</surname><given-names>S</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Changes in cardiac morphology and function in individuals with diabetes mellitus: the UK Biobank cardiovascular magnetic resonance substudy</article-title><source>Circ Cardiovasc Imaging</source><year>2019</year><volume>12</volume><issue>9</issue><fpage>e009476</fpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.119.009476</pub-id><pub-id pub-id-type="pmid">31522551</pub-id><pub-id pub-id-type="pmcid">PMC7099857</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jensen MT, Fung K, Aung N, Sanghvi MM, Chadalavada S, Paiva JM, et al. Changes in cardiac morphology and function in individuals with diabetes mellitus: the UK Biobank cardiovascular magnetic resonance substudy. Circ Cardiovasc Imaging. 2019;12(9):e009476. 10.1161/CIRCIMAGING.119.009476.<pub-id pub-id-type="pmid">31522551</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCIMAGING.119.009476</pub-id><pub-id pub-id-type="pmcid">PMC7099857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segar</surname><given-names>MW</given-names></name><name name-style="western"><surname>Khan</surname><given-names>MS</given-names></name><name name-style="western"><surname>Patel</surname><given-names>KV</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>WHW</given-names></name><name name-style="western"><surname>Vaduganathan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>78</volume><issue>19</issue><fpage>1587</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.08.020</pub-id><pub-id pub-id-type="pmid">34649696</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Segar MW, Khan MS, Patel KV, Butler J, Tang WHW, Vaduganathan M, et al. Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults. J Am Coll Cardiol. 2021;78(19):1587–98. 10.1016/j.jacc.2021.08.020.<pub-id pub-id-type="pmid">34649696</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2021.08.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>RH</given-names></name><name name-style="western"><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Basic mechanisms of diabetic heart disease</article-title><source>Circ Res</source><year>2020</year><volume>126</volume><issue>11</issue><fpage>1501</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.315913</pub-id><pub-id pub-id-type="pmid">32437308</pub-id><pub-id pub-id-type="pmcid">PMC7251974</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501–25. 10.1161/CIRCRESAHA.120.315913.<pub-id pub-id-type="pmid">32437308</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.120.315913</pub-id><pub-id pub-id-type="pmcid">PMC7251974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions</article-title><source>Cell Death Discov</source><year>2023</year><volume>9</volume><fpage>256</fpage><pub-id pub-id-type="doi">10.1038/s41420-023-01553-4</pub-id><pub-id pub-id-type="pmid">37479697</pub-id><pub-id pub-id-type="pmcid">PMC10362058</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Huo JL, Feng Q, Pan S, Fu WJ, Liu Z, Liu Z. Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. Cell Death Discov. 2023;9:256. 10.1038/s41420-023-01553-4.<pub-id pub-id-type="pmid">37479697</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01553-4</pub-id><pub-id pub-id-type="pmcid">PMC10362058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Geest</surname><given-names>B</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>M</given-names></name></person-group><article-title>Role of oxidative stress in diabetic cardiomyopathy</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><issue>4</issue><fpage>784</fpage><pub-id pub-id-type="doi">10.3390/antiox11040784</pub-id><pub-id pub-id-type="pmid">35453469</pub-id><pub-id pub-id-type="pmcid">PMC9030255</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">De Geest B, Mishra M. Role of oxidative stress in diabetic cardiomyopathy. Antioxidants. 2022;11(4):784. 10.3390/antiox11040784.<pub-id pub-id-type="pmid">35453469</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11040784</pub-id><pub-id pub-id-type="pmcid">PMC9030255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>ML</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CW</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>SS</given-names></name></person-group><article-title>Signaling pathways related to oxidative stress in diabetic cardiomyopathy</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>907757</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.907757</pub-id><pub-id pub-id-type="pmid">35784531</pub-id><pub-id pub-id-type="pmcid">PMC9240190</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Peng ML, Fu Y, Wu CW, Zhang Y, Ren H, Zhou SS. Signaling pathways related to oxidative stress in diabetic cardiomyopathy. Front Endocrinol (Lausanne). 2022;13:907757. 10.3389/fendo.2022.907757.<pub-id pub-id-type="pmid">35784531</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.907757</pub-id><pub-id pub-id-type="pmcid">PMC9240190</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Rajasekaran</surname><given-names>NS</given-names></name><name name-style="western"><surname>Abel</surname><given-names>ED</given-names></name><name name-style="western"><surname>Bugger</surname><given-names>H</given-names></name></person-group><article-title>Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy</article-title><source>Free Radic Biol Med</source><year>2021</year><volume>169</volume><fpage>317</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.03.046</pub-id><pub-id pub-id-type="pmid">33910093</pub-id><pub-id pub-id-type="pmcid">PMC8285002</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Byrne NJ, Rajasekaran NS, Abel ED, Bugger H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. Free Radic Biol Med. 2021;169:317–42. 10.1016/j.freeradbiomed.2021.03.046.<pub-id pub-id-type="pmid">33910093</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2021.03.046</pub-id><pub-id pub-id-type="pmcid">PMC8285002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oakes</surname><given-names>SA</given-names></name></person-group><article-title>Endoplasmic reticulum stress signaling in cancer cells</article-title><source>Am J Pathol</source><year>2020</year><volume>190</volume><issue>5</issue><fpage>934</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2020.01.010</pub-id><pub-id pub-id-type="pmid">32112719</pub-id><pub-id pub-id-type="pmcid">PMC7237829</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Oakes SA. Endoplasmic reticulum stress signaling in cancer cells. Am J Pathol. 2020;190(5):934–46. 10.1016/j.ajpath.2020.01.010.<pub-id pub-id-type="pmid">32112719</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpath.2020.01.010</pub-id><pub-id pub-id-type="pmcid">PMC7237829</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kropski</surname><given-names>JA</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>TS</given-names></name></person-group><article-title>Endoplasmic reticulum stress in the pathogenesis of fibrotic disease</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><issue>1</issue><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1172/JCI93560</pub-id><pub-id pub-id-type="pmid">29293089</pub-id><pub-id pub-id-type="pmcid">PMC5749533</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kropski JA, Blackwell TS. Endoplasmic reticulum stress in the pathogenesis of fibrotic disease. J Clin Invest. 2018;128(1):64–73. 10.1172/JCI93560.<pub-id pub-id-type="pmid">29293089</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI93560</pub-id><pub-id pub-id-type="pmcid">PMC5749533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>JD</given-names></name><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><name name-style="western"><surname>Tew</surname><given-names>KD</given-names></name></person-group><article-title>Oxidative stress in cancer</article-title><source>Cancer Cell</source><year>2020</year><volume>10</volume><fpage>167</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.06.001</pub-id><pub-id pub-id-type="pmcid">PMC7439808</pub-id><pub-id pub-id-type="pmid">32649885</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;10:167–97. 10.1016/j.ccell.2020.06.001.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.06.001</pub-id><pub-id pub-id-type="pmcid">PMC7439808</pub-id><pub-id pub-id-type="pmid">32649885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arfin</surname><given-names>S</given-names></name><name name-style="western"><surname>Jha</surname><given-names>NK</given-names></name><name name-style="western"><surname>Jha</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kesari</surname><given-names>KK</given-names></name><name name-style="western"><surname>Ruokolainen</surname><given-names>J</given-names></name><name name-style="western"><surname>Roychoudhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Rathi</surname><given-names>B</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D</given-names></name></person-group><article-title>Oxidative stress in cancer cell metabolism</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><issue>5</issue><fpage>642</fpage><pub-id pub-id-type="doi">10.3390/antiox10050642</pub-id><pub-id pub-id-type="pmid">33922139</pub-id><pub-id pub-id-type="pmcid">PMC8143540</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, et al. Oxidative stress in cancer cell metabolism. Antioxidants. 2021;10(5):642. 10.3390/antiox10050642.<pub-id pub-id-type="pmid">33922139</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox10050642</pub-id><pub-id pub-id-type="pmcid">PMC8143540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jelic</surname><given-names>MD</given-names></name><name name-style="western"><surname>Mandic</surname><given-names>AD</given-names></name><name name-style="western"><surname>Maricic</surname><given-names>SM</given-names></name><name name-style="western"><surname>Srdjenovic</surname><given-names>BU</given-names></name></person-group><article-title>Oxidative stress and its role in cancer</article-title><source>J Cancer Res Ther</source><year>2021</year><volume>17</volume><issue>1</issue><fpage>22</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4103/jcrt.JCRT_862_16</pub-id><pub-id pub-id-type="pmid">33723127</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. J Cancer Res Ther. 2021;17(1):22–8. 10.4103/jcrt.JCRT_862_16.<pub-id pub-id-type="pmid">33723127</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/jcrt.JCRT_862_16</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giraldo-Gonzalez</surname><given-names>GC</given-names></name><name name-style="western"><surname>Roman-Gonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Cañas</surname><given-names>F</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>A</given-names></name></person-group><article-title>Molecular mechanisms of type 2 diabetes-related heart disease and therapeutic insights</article-title><source>Int J Mol Sci</source><year>2025</year><volume>26</volume><issue>10</issue><fpage>4548</fpage><pub-id pub-id-type="doi">10.3390/ijms26104548</pub-id><pub-id pub-id-type="pmid">40429692</pub-id><pub-id pub-id-type="pmcid">PMC12111323</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Giraldo-Gonzalez GC, Roman-Gonzalez A, Cañas F, Garcia A. Molecular mechanisms of type 2 diabetes-related heart disease and therapeutic insights. Int J Mol Sci. 2025;26(10):4548. 10.3390/ijms26104548.<pub-id pub-id-type="pmid">40429692</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26104548</pub-id><pub-id pub-id-type="pmcid">PMC12111323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>S</given-names></name><name name-style="western"><surname>Shah</surname><given-names>RB</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>S</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>SB</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>S</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S</given-names></name><name name-style="western"><surname>Haque</surname><given-names>M</given-names></name></person-group><article-title>Metformin: a review of potential mechanism and therapeutic utility beyond diabetes</article-title><source>Drug Des Devel Ther</source><year>2023</year><volume>26</volume><issue>17</issue><fpage>1907</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S409373</pub-id><pub-id pub-id-type="pmcid">PMC10312383</pub-id><pub-id pub-id-type="pmid">37397787</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, et al. Metformin: a review of potential mechanism and therapeutic utility beyond diabetes. Drug Des Devel Ther. 2023;26(17):1907–32. 10.2147/DDDT.S409373. (PMID:37397787;PMCID:PMC10312383).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S409373</pub-id><pub-id pub-id-type="pmcid">PMC10312383</pub-id><pub-id pub-id-type="pmid">37397787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>TKC</given-names></name><name name-style="western"><surname>Dao</surname><given-names>XD</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>DV</given-names></name><name name-style="western"><surname>Luu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Bui</surname><given-names>TMH</given-names></name><name name-style="western"><surname>Le</surname><given-names>TH</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>HT</given-names></name><name name-style="western"><surname>Le</surname><given-names>TN</given-names></name><name name-style="western"><surname>Hosaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TTT</given-names></name></person-group><article-title>Insulin signaling and its application</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>17</volume><issue>14</issue><fpage>1226655</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1226655</pub-id><pub-id pub-id-type="pmcid">PMC10469844</pub-id><pub-id pub-id-type="pmid">37664840</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Le TKC, Dao XD, Nguyen DV, Luu DH, Bui TMH, Le TH, et al. Insulin signaling and its application. Front Endocrinol (Lausanne). 2023;17(14):1226655. 10.3389/fendo.2023.1226655. (PMID:37664840;PMCID:PMC10469844).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1226655</pub-id><pub-id pub-id-type="pmcid">PMC10469844</pub-id><pub-id pub-id-type="pmid">37664840</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miki</surname><given-names>T</given-names></name><name name-style="western"><surname>Yuda</surname><given-names>S</given-names></name><name name-style="western"><surname>Kouzu</surname><given-names>H</given-names></name><name name-style="western"><surname>Miura</surname><given-names>T</given-names></name></person-group><article-title>Diabetic cardiomyopathy: pathophysiology and clinical features</article-title><source>Heart Fail Rev</source><year>2013</year><volume>18</volume><issue>2</issue><fpage>149</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1007/s10741-012-9313-3</pub-id><pub-id pub-id-type="pmid">22453289</pub-id><pub-id pub-id-type="pmcid">PMC3593009</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18(2):149–66. 10.1007/s10741-012-9313-3.<pub-id pub-id-type="pmid">22453289</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10741-012-9313-3</pub-id><pub-id pub-id-type="pmcid">PMC3593009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanamori</surname><given-names>H</given-names></name><name name-style="western"><surname>Naruse</surname><given-names>G</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>A</given-names></name><name name-style="western"><surname>Minatoguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Morphological characteristics in diabetic cardiomyopathy associated with autophagy</article-title><source>J Cardiol</source><year>2021</year><volume>77</volume><issue>1</issue><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2020.05.009</pub-id><pub-id pub-id-type="pmid">32907780</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kanamori H, Naruse G, Yoshida A, Minatoguchi S, Watanabe T, Kawaguchi T, et al. Morphological characteristics in diabetic cardiomyopathy associated with autophagy. J Cardiol. 2021;77(1):30–40. 10.1016/j.jjcc.2020.05.009.<pub-id pub-id-type="pmid">32907780</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jjcc.2020.05.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaMoia</surname><given-names>TE</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>Cellular and molecular mechanisms of metformin action</article-title><source>Endocr Rev</source><year>2021</year><volume>42</volume><issue>1</issue><fpage>77</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1210/endrev/bnaa023</pub-id><pub-id pub-id-type="pmid">32897388</pub-id><pub-id pub-id-type="pmcid">PMC7846086</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77–96. 10.1210/endrev/bnaa023.<pub-id pub-id-type="pmid">32897388</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/endrev/bnaa023</pub-id><pub-id pub-id-type="pmcid">PMC7846086</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rena</surname><given-names>G</given-names></name><name name-style="western"><surname>Hardie</surname><given-names>DG</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ER</given-names></name></person-group><article-title>The mechanisms of action of metformin</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><issue>9</issue><fpage>1577</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4342-z</pub-id><pub-id pub-id-type="pmid">28776086</pub-id><pub-id pub-id-type="pmcid">PMC5552828</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85. 10.1007/s00125-017-4342-z.<pub-id pub-id-type="pmid">28776086</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-017-4342-z</pub-id><pub-id pub-id-type="pmcid">PMC5552828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>YR</given-names></name><name name-style="western"><surname>Danelisen</surname><given-names>I</given-names></name></person-group><article-title>Molecular mechanisms of action of metformin: latest advances and therapeutic implications</article-title><source>Clin Exp Med</source><year>2023</year><volume>23</volume><issue>7</issue><fpage>2941</fpage><lpage>2951</lpage><pub-id pub-id-type="doi">10.1007/s10238-023-01051-y</pub-id><pub-id pub-id-type="pmid">37016064</pub-id><pub-id pub-id-type="pmcid">PMC10072049</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Zhu H, Jia Z, Li YR, Danelisen I. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. Clin Exp Med. 2023;23(7):2941–51. 10.1007/s10238-023-01051-y.<pub-id pub-id-type="pmid">37016064</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01051-y</pub-id><pub-id pub-id-type="pmcid">PMC10072049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ling</surname><given-names>P</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><issue>9</issue><fpage>9376</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.7150/thno.64706</pub-id><pub-id pub-id-type="pmid">34646376</pub-id><pub-id pub-id-type="pmcid">PMC8490502</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X, et al. Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics. 2021;11(9):9376–96. 10.7150/thno.64706.<pub-id pub-id-type="pmid">34646376</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.64706</pub-id><pub-id pub-id-type="pmcid">PMC8490502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X</given-names></name><name name-style="western"><surname>Wan</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metformin and fibrosis: a review of existing evidence and mechanisms</article-title><source>J Diabetes Res</source><year>2021</year><volume>2021</volume><fpage>6673525</fpage><pub-id pub-id-type="doi">10.1155/2021/6673525</pub-id><pub-id pub-id-type="pmid">34007848</pub-id><pub-id pub-id-type="pmcid">PMC8102119</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Wu M, Xu H, Liu J, Tan X, Wan S, Guo M, et al. Metformin and fibrosis: a review of existing evidence and mechanisms. J Diabetes Res. 2021;2021:6673525. 10.1155/2021/6673525.<pub-id pub-id-type="pmid">34007848</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/6673525</pub-id><pub-id pub-id-type="pmcid">PMC8102119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristófi</surname><given-names>R</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>JW</given-names></name></person-group><article-title>Metformin as an anti-inflammatory agent: a short review</article-title><source>J Endocrinol</source><year>2021</year><volume>251</volume><issue>2</issue><fpage>R11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1530/JOE-21-0194</pub-id><pub-id pub-id-type="pmid">34463292</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kristófi R, Eriksson JW. Metformin as an anti-inflammatory agent: a short review. J Endocrinol. 2021;251(2):R11-22. 10.1530/JOE-21-0194.<pub-id pub-id-type="pmid">34463292</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JOE-21-0194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barchetta</surname><given-names>I</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>MG</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 (DPP4) as a novel adipokine: role in metabolism and fat homeostasis</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><issue>9</issue><fpage>2306</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10092306</pub-id><pub-id pub-id-type="pmid">36140405</pub-id><pub-id pub-id-type="pmcid">PMC9496088</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Barchetta I, Cavallo MG. Dipeptidyl peptidase 4 (DPP4) as a novel adipokine: role in metabolism and fat homeostasis. Biomedicines. 2022;10(9):2306. 10.3390/biomedicines10092306.<pub-id pub-id-type="pmid">36140405</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10092306</pub-id><pub-id pub-id-type="pmcid">PMC9496088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lima-Martínez</surname><given-names>MM</given-names></name><name name-style="western"><surname>Paoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodney</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study</article-title><source>Endocrine</source><year>2016</year><volume>51</volume><issue>3</issue><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1007/s12020-015-0710-y</pub-id><pub-id pub-id-type="pmid">26233684</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Lima-Martínez MM, Paoli M, Rodney M, et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine. 2016;51(3):448–55. 10.1007/s12020-015-0710-y.<pub-id pub-id-type="pmid">26233684</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-015-0710-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hiruma</surname><given-names>S</given-names></name><name name-style="western"><surname>Shigiyama</surname><given-names>F</given-names></name><name name-style="western"><surname>Hisatake</surname><given-names>S</given-names></name><etal/></person-group><article-title>A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study</article-title><source>Cardiovasc Diabetol</source><year>2021</year><volume>20</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s12933-021-01228-3</pub-id><pub-id pub-id-type="pmid">33530982</pub-id><pub-id pub-id-type="pmcid">PMC7852076</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20:32. 10.1186/s12933-021-01228-3.<pub-id pub-id-type="pmid">33530982</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-021-01228-3</pub-id><pub-id pub-id-type="pmcid">PMC7852076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolski</surname><given-names>F</given-names></name><name name-style="western"><surname>Mączewski</surname><given-names>M</given-names></name></person-group><article-title>Cardiac fibrosis: mechanistic discoveries linked to SGLT2 inhibitors</article-title><source>Pharmaceuticals (Basel)</source><year>2025</year><volume>18</volume><issue>3</issue><fpage>313</fpage><pub-id pub-id-type="doi">10.3390/ph18030313</pub-id><pub-id pub-id-type="pmid">40143092</pub-id><pub-id pub-id-type="pmcid">PMC11944955</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Rolski F, Mączewski M. Cardiac fibrosis: mechanistic discoveries linked to SGLT2 inhibitors. Pharmaceuticals (Basel). 2025;18(3):313. 10.3390/ph18030313.<pub-id pub-id-type="pmid">40143092</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph18030313</pub-id><pub-id pub-id-type="pmcid">PMC11944955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goedeke</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gaspar</surname><given-names>RC</given-names></name><name name-style="western"><surname>Nasiri</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts</article-title><source>J Clin Invest</source><year>2024</year><volume>134</volume><issue>24</issue><fpage>e176708</fpage><pub-id pub-id-type="doi">10.1172/JCI176708</pub-id><pub-id pub-id-type="pmid">39680452</pub-id><pub-id pub-id-type="pmcid">PMC11645152</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024;134(24):e176708. 10.1172/JCI176708.<pub-id pub-id-type="pmid">39680452</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI176708</pub-id><pub-id pub-id-type="pmcid">PMC11645152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>992937</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.992937</pub-id><pub-id pub-id-type="pmid">36589841</pub-id><pub-id pub-id-type="pmcid">PMC9797675</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yang L, Zhang X, Wang Q. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol (Lausanne). 2022;13:992937. 10.3389/fendo.2022.992937.<pub-id pub-id-type="pmid">36589841</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.992937</pub-id><pub-id pub-id-type="pmcid">PMC9797675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karakasis</surname><given-names>P</given-names></name><name name-style="western"><surname>Theofilis</surname><given-names>P</given-names></name><name name-style="western"><surname>Vlachakis</surname><given-names>PK</given-names></name><name name-style="western"><surname>Apostolos</surname><given-names>A</given-names></name><name name-style="western"><surname>Milaras</surname><given-names>N</given-names></name><name name-style="western"><surname>Ktenopoulos</surname><given-names>N</given-names></name><etal/></person-group><article-title>SGLT2 inhibitors and cardiac fibrosis: a comprehensive review</article-title><source>Curr Probl Cardiol</source><year>2025</year><volume>50</volume><issue>10</issue><fpage>103149</fpage><pub-id pub-id-type="doi">10.1016/j.cpcardiol.2025.103149</pub-id><pub-id pub-id-type="pmid">40769233</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Karakasis P, Theofilis P, Vlachakis PK, Apostolos A, Milaras N, Ktenopoulos N, et al. SGLT2 inhibitors and cardiac fibrosis: a comprehensive review. Curr Probl Cardiol. 2025;50(10):103149. 10.1016/j.cpcardiol.2025.103149.<pub-id pub-id-type="pmid">40769233</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpcardiol.2025.103149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>HY</given-names></name><name name-style="western"><surname>Barajas-Martinez</surname><given-names>H</given-names></name><name name-style="western"><surname>Antzelevitch</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name></person-group><article-title>The potential anti-arrhythmic effect of SGLT2 inhibitors</article-title><source>Cardiovasc Diabetol</source><year>2024</year><volume>23</volume><issue>1</issue><fpage>252</fpage><pub-id pub-id-type="doi">10.1186/s12933-024-02312-0</pub-id><pub-id pub-id-type="pmid">39010053</pub-id><pub-id pub-id-type="pmcid">PMC11251349</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Duan HY, Barajas-Martinez H, Antzelevitch C, Hu D. The potential anti-arrhythmic effect of SGLT2 inhibitors. Cardiovasc Diabetol. 2024;23(1):252. 10.1186/s12933-024-02312-0.<pub-id pub-id-type="pmid">39010053</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-024-02312-0</pub-id><pub-id pub-id-type="pmcid">PMC11251349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamed</surname><given-names>K</given-names></name><name name-style="western"><surname>Alosaimi</surname><given-names>MN</given-names></name><name name-style="western"><surname>Ali</surname><given-names>BA</given-names></name><name name-style="western"><surname>Alghamdi</surname><given-names>A</given-names></name><name name-style="western"><surname>Alkhashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Alkhaldi</surname><given-names>SS</given-names></name><name name-style="western"><surname>Altowarqi</surname><given-names>NA</given-names></name><name name-style="western"><surname>Alzahrani</surname><given-names>H</given-names></name><name name-style="western"><surname>Alshehri</surname><given-names>AM</given-names></name><name name-style="western"><surname>Alkhaldi</surname><given-names>RK</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>KW</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>NH</given-names></name><name name-style="western"><surname>Alhulayfi</surname><given-names>HF</given-names></name><name name-style="western"><surname>Sharifi</surname><given-names>SY</given-names></name><name name-style="western"><surname>Dighriri</surname><given-names>IM</given-names></name></person-group><article-title>Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review</article-title><source>Cureus</source><year>2024</year><volume>16</volume><issue>9</issue><fpage>e68390</fpage><pub-id pub-id-type="doi">10.7759/cureus.68390</pub-id><pub-id pub-id-type="pmid">39355484</pub-id><pub-id pub-id-type="pmcid">PMC11444311</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024;16(9):e68390. 10.7759/cureus.68390. (<bold>PMID:39355484;PMCID:PMC11444311</bold>).<pub-id pub-id-type="pmid">39355484</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.68390</pub-id><pub-id pub-id-type="pmcid">PMC11444311</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lincoff</surname><given-names>AM</given-names></name><name name-style="western"><surname>Brown-Frandsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Colhoun</surname><given-names>HM</given-names></name><name name-style="western"><surname>Deanfield</surname><given-names>J</given-names></name><name name-style="western"><surname>Emerson</surname><given-names>SS</given-names></name><name name-style="western"><surname>Esbjerg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>24</issue><fpage>2221</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2307563</pub-id><pub-id pub-id-type="pmid">37952131</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–32. 10.1056/NEJMoa2307563. (PMID: 37952131).<pub-id pub-id-type="pmid">37952131</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2307563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taqueti</surname><given-names>VR</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LJ</given-names></name></person-group><article-title>Semaglutide and cardiovascular outcomes</article-title><source>N Engl J Med</source><year>2024</year><volume>390</volume><issue>8</issue><fpage>766</fpage><pub-id pub-id-type="doi">10.1056/NEJMc2400414</pub-id><pub-id pub-id-type="pmid">38381682</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Taqueti VR, Shaw LJ. Semaglutide and cardiovascular outcomes. N Engl J Med. 2024;390(8):766. 10.1056/NEJMc2400414. (PMID: 38381682).<pub-id pub-id-type="pmid">38381682</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2400414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorsal</surname><given-names>A</given-names></name><name name-style="western"><surname>Kistorp</surname><given-names>C</given-names></name><name name-style="western"><surname>Holmager</surname><given-names>P</given-names></name><name name-style="western"><surname>Tougaard</surname><given-names>RS</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>R</given-names></name><name name-style="western"><surname>Hänselmann</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of liraglutide… (LIVE) in stable chronic heart failure with and without diabetes: a randomized, placebo-controlled trial</article-title><source>Eur J Heart Fail</source><year>2017</year><volume>19</volume><issue>1</issue><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1002/ejhf.657</pub-id><pub-id pub-id-type="pmid">27790809</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide… (LIVE) in stable chronic heart failure with and without diabetes: a randomized, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77. 10.1002/ejhf.657. (PMID: 27790809).<pub-id pub-id-type="pmid">27790809</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejhf.657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kong</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>KF</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JJ</given-names></name></person-group><article-title>DPP4 as a potential candidate in cardiovascular disease</article-title><source>J Inflamm Res</source><year>2022</year><volume>16</volume><issue>15</issue><fpage>5457</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.2147/JIR.S380285</pub-id><pub-id pub-id-type="pmcid">PMC9488155</pub-id><pub-id pub-id-type="pmid">36147690</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Chen SY, Kong XQ, Zhang KF, Luo S, Wang F, Zhang JJ. DPP4 as a potential candidate in cardiovascular disease. J Inflamm Res. 2022;16(15):5457–69. 10.2147/JIR.S380285.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S380285</pub-id><pub-id pub-id-type="pmcid">PMC9488155</pub-id><pub-id pub-id-type="pmid">36147690</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomovic</surname><given-names>K</given-names></name><name name-style="western"><surname>Lazarevic</surname><given-names>J</given-names></name><name name-style="western"><surname>Kocic</surname><given-names>G</given-names></name><name name-style="western"><surname>Deljanin-Ilic</surname><given-names>M</given-names></name><name name-style="western"><surname>Anderluh</surname><given-names>M</given-names></name><name name-style="western"><surname>Smelcerovic</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection</article-title><source>Med Res Rev</source><year>2019</year><volume>39</volume><issue>1</issue><fpage>404</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/med.21513</pub-id><pub-id pub-id-type="pmid">29806214</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Tomovic K, Lazarevic J, Kocic G, Deljanin-Ilic M, Anderluh M, Smelcerovic A. Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection. Med Res Rev. 2019;39(1):404–22. 10.1002/med.21513.<pub-id pub-id-type="pmid">29806214</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21513</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marinello</surname><given-names>J</given-names></name><name name-style="western"><surname>Delcuratolo</surname><given-names>M</given-names></name><name name-style="western"><surname>Capranico</surname><given-names>G</given-names></name></person-group><article-title>Anthracyclines as topoisomerase II poisons: from early studies to new perspectives</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>11</issue><fpage>3480</fpage><pub-id pub-id-type="doi">10.3390/ijms19113480</pub-id><pub-id pub-id-type="pmid">30404148</pub-id><pub-id pub-id-type="pmcid">PMC6275052</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Marinello J, Delcuratolo M, Capranico G. Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci. 2018;19(11):3480. 10.3390/ijms19113480.<pub-id pub-id-type="pmid">30404148</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19113480</pub-id><pub-id pub-id-type="pmcid">PMC6275052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardinale</surname><given-names>D</given-names></name><name name-style="western"><surname>Iacopo</surname><given-names>F</given-names></name><name name-style="western"><surname>Cipolla</surname><given-names>CM</given-names></name></person-group><article-title>Cardiotoxicity of anthracyclines</article-title><source>Front Cardiovasc Med</source><year>2020</year><volume>18</volume><issue>7</issue><fpage>26</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2020.00026</pub-id><pub-id pub-id-type="pmcid">PMC7093379</pub-id><pub-id pub-id-type="pmid">32258060</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;18(7):26. 10.3389/fcvm.2020.00026.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2020.00026</pub-id><pub-id pub-id-type="pmcid">PMC7093379</pub-id><pub-id pub-id-type="pmid">32258060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrasco</surname><given-names>R</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>RL</given-names></name><name name-style="western"><surname>Gormaz</surname><given-names>JG</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>M</given-names></name><name name-style="western"><surname>Thavendiranathan</surname><given-names>P</given-names></name></person-group><article-title>Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: effects of preventive strategies</article-title><source>Oxid Med Cell Longev</source><year>2021</year><volume>2021</volume><issue>1</issue><fpage>8863789</fpage><pub-id pub-id-type="doi">10.1155/2021/8863789</pub-id><pub-id pub-id-type="pmid">33574985</pub-id><pub-id pub-id-type="pmcid">PMC7857913</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Carrasco R, Castillo RL, Gormaz JG, Carrillo M, Thavendiranathan P. Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: effects of preventive strategies. Oxid Med Cell Longev. 2021;2021(1):8863789. 10.1155/2021/8863789.<pub-id pub-id-type="pmid">33574985</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8863789</pub-id><pub-id pub-id-type="pmcid">PMC7857913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Understanding anthracycline cardiotoxicity from mitochondrial aspect</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>811406</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.811406</pub-id><pub-id pub-id-type="pmid">35211017</pub-id><pub-id pub-id-type="pmcid">PMC8861498</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Huang J, Wu R, Chen L, Yang Z, Yan D, Li M. Understanding anthracycline cardiotoxicity from mitochondrial aspect. Front Pharmacol. 2022;13:811406. 10.3389/fphar.2022.811406.<pub-id pub-id-type="pmid">35211017</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.811406</pub-id><pub-id pub-id-type="pmcid">PMC8861498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eaton</surname><given-names>H</given-names></name><name name-style="western"><surname>Timm</surname><given-names>KN</given-names></name></person-group><article-title>Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment?</article-title><source>Cardio-Oncology</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s40959-023-00172-3</pub-id><pub-id pub-id-type="pmid">37098605</pub-id><pub-id pub-id-type="pmcid">PMC10127350</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Eaton H, Timm KN. Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment? Cardio-Oncology. 2023;9(1):22. 10.1186/s40959-023-00172-3.<pub-id pub-id-type="pmid">37098605</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40959-023-00172-3</pub-id><pub-id pub-id-type="pmcid">PMC10127350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dempsey</surname><given-names>N</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>A</given-names></name><name name-style="western"><surname>Dabas</surname><given-names>N</given-names></name><name name-style="western"><surname>Kropotova</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lippman</surname><given-names>M</given-names></name><name name-style="western"><surname>Bishopric</surname><given-names>NH</given-names></name></person-group><article-title>Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.</article-title><source>Breast Cancer Res Treat</source><year>2021</year><volume>188</volume><issue>1</issue><fpage>21</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s10549-021-06280-x</pub-id><pub-id pub-id-type="pmid">34115243</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21–36. 10.1007/s10549-021-06280-x.<pub-id pub-id-type="pmid">34115243</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-021-06280-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>SS</given-names></name><name name-style="western"><surname>Khalique</surname><given-names>OK</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>H</given-names></name></person-group><article-title>Trastuzumab-induced cardiotoxicity: when and how much should we worry?</article-title><source>JCO Oncol Pract</source><year>2024</year><volume>20</volume><issue>8</issue><fpage>1055</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1200/OP.23.00816</pub-id><pub-id pub-id-type="pmid">38662969</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Zheng H, Mahmood SS, Khalique OK, Zhan H. Trastuzumab-induced cardiotoxicity: when and how much should we worry? JCO Oncol Pract. 2024;20(8):1055–63. 10.1200/OP.23.00816. (Epub 2024 Apr 25 PMID: 38662969).<pub-id pub-id-type="pmid">38662969</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/OP.23.00816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>JR</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>MS</given-names></name><name name-style="western"><surname>Morgans</surname><given-names>AK</given-names></name><name name-style="western"><surname>Brown</surname><given-names>JD</given-names></name><name name-style="western"><surname>Meijers</surname><given-names>WC</given-names></name><name name-style="western"><surname>Freiberg</surname><given-names>MS</given-names></name><name name-style="western"><surname>Salem</surname><given-names>JE</given-names></name><name name-style="western"><surname>Beckman</surname><given-names>JA</given-names></name><name name-style="western"><surname>Moslehi</surname><given-names>JJ</given-names></name></person-group><article-title>Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2020</year><volume>40</volume><issue>3</issue><fpage>e55</fpage><lpage>e64</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313046</pub-id><pub-id pub-id-type="pmid">31969015</pub-id><pub-id pub-id-type="pmcid">PMC7047549</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40(3):e55–64. 10.1161/ATVBAHA.119.313046.<pub-id pub-id-type="pmid">31969015</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.119.313046</pub-id><pub-id pub-id-type="pmcid">PMC7047549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="other">Becker RC. Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management. J Thromb Thrombolysis. 2025. 10.1007/s11239-025-03146-7. Epub ahead of print. PMID: 40673965.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11239-025-03146-7</pub-id><pub-id pub-id-type="pmcid">PMC12740968</pub-id><pub-id pub-id-type="pmid">40673965</pub-id></mixed-citation></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillessen</surname><given-names>S</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>L</given-names></name><name name-style="western"><surname>James</surname><given-names>ND</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>A</given-names></name><name name-style="western"><surname>El-Taji</surname><given-names>O</given-names></name><name name-style="western"><surname>Abdel-Aty</surname><given-names>H</given-names></name><name name-style="western"><surname>Adler</surname><given-names>AI</given-names></name><name name-style="western"><surname>Amos</surname><given-names>C</given-names></name><name name-style="western"><surname>Attard</surname><given-names>G</given-names></name><name name-style="western"><surname>Varughese</surname><given-names>M</given-names></name><name name-style="western"><surname>Gale</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>S</given-names></name><name name-style="western"><surname>Srihari</surname><given-names>N</given-names></name><name name-style="western"><surname>Birtle</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Cross</surname><given-names>W</given-names></name><name name-style="western"><surname>Dearnaley</surname><given-names>DP</given-names></name><name name-style="western"><surname>Din</surname><given-names>O</given-names></name><name name-style="western"><surname>Dutey-Magni</surname><given-names>P</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>DC</given-names></name><name name-style="western"><surname>Gilson</surname><given-names>C</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S</given-names></name><name name-style="western"><surname>Grist</surname><given-names>E</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>U</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Jain</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jeyasangar</surname><given-names>G</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R</given-names></name><name name-style="western"><surname>Kayani</surname><given-names>M</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RE</given-names></name><name name-style="western"><surname>Malik</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mason</surname><given-names>MD</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>D</given-names></name><name name-style="western"><surname>McAlpine</surname><given-names>C</given-names></name><name name-style="western"><surname>Macnair</surname><given-names>A</given-names></name><name name-style="western"><surname>Millman</surname><given-names>R</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C</given-names></name><name name-style="western"><surname>Padden-Modi</surname><given-names>M</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>O</given-names></name><name name-style="western"><surname>Parker</surname><given-names>C</given-names></name><name name-style="western"><surname>Rush</surname><given-names>H</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>R</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>S</given-names></name><name name-style="western"><surname>Tanguay</surname><given-names>JS</given-names></name><name name-style="western"><surname>Turco</surname><given-names>F</given-names></name><name name-style="western"><surname>Williams</surname><given-names>P</given-names></name><name name-style="western"><surname>Sydes</surname><given-names>MR</given-names></name><name name-style="western"><surname>Parmar</surname><given-names>MKB</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LC</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>NW</given-names></name><collab>STAMPEDE investigators</collab></person-group><article-title>Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.</article-title><source>Lancet Oncol</source><year>2025</year><volume>26</volume><issue>8</issue><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(25)00231-1</pub-id><pub-id pub-id-type="pmid">40639383</pub-id><pub-id pub-id-type="pmcid">PMC12303861</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, et al. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. Lancet Oncol. 2025;26(8):1018–30. 10.1016/S1470-2045(25)00231-1.<pub-id pub-id-type="pmid">40639383</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(25)00231-1</pub-id><pub-id pub-id-type="pmcid">PMC12303861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kerkelä</surname><given-names>R</given-names></name><name name-style="western"><surname>Force</surname><given-names>T</given-names></name></person-group><article-title>Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics</article-title><source>Circulation</source><year>2008</year><volume>1</volume><issue>1</issue><fpage>84</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.776831</pub-id><pub-id pub-id-type="pmcid">PMC2735334</pub-id><pub-id pub-id-type="pmid">18591451</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;1(1):84–95. 10.1161/CIRCULATIONAHA.108.776831.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.108.776831</pub-id><pub-id pub-id-type="pmcid">PMC2735334</pub-id><pub-id pub-id-type="pmid">18591451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Yakout IA, Gallab MM, Mohamed DA, Hamdar H, I Ibrahim S, Mohamed A, Abdelshafi A, Abd-ElGawad M. Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: A systematic review and meta-analysis. Semin Oncol. 2024<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.seminoncol.2024.10.001</pub-id><pub-id pub-id-type="pmid">39547874</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozcelik</surname><given-names>C</given-names></name><name name-style="western"><surname>Erdmann</surname><given-names>B</given-names></name><name name-style="western"><surname>Pilz</surname><given-names>B</given-names></name><name name-style="western"><surname>Wettschureck</surname><given-names>N</given-names></name><name name-style="western"><surname>Britsch</surname><given-names>S</given-names></name><name name-style="western"><surname>Hübner</surname><given-names>N</given-names></name><name name-style="western"><surname>Chien</surname><given-names>KR</given-names></name><name name-style="western"><surname>Birchmeier</surname><given-names>C</given-names></name><name name-style="western"><surname>Garratt</surname><given-names>AN</given-names></name></person-group><article-title>Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><issue>13</issue><fpage>8880</fpage><lpage>8885</lpage><pub-id pub-id-type="doi">10.1073/pnas.122249299</pub-id><pub-id pub-id-type="pmid">12072561</pub-id><pub-id pub-id-type="pmcid">PMC124392</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880–5. 10.1073/pnas.122249299.<pub-id pub-id-type="pmid">12072561</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.122249299</pub-id><pub-id pub-id-type="pmcid">PMC124392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmid</surname><given-names>P</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name><name name-style="western"><surname>Pusztai</surname><given-names>L</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>H</given-names></name><name name-style="western"><surname>Kümmel</surname><given-names>S</given-names></name><name name-style="western"><surname>Bergh</surname><given-names>J</given-names></name><name name-style="western"><surname>Denkert</surname><given-names>C</given-names></name><name name-style="western"><surname>Park</surname><given-names>YH</given-names></name><name name-style="western"><surname>Hui</surname><given-names>R</given-names></name><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Foukakis</surname><given-names>T</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>F</given-names></name><name name-style="western"><surname>Untch</surname><given-names>M</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L</given-names></name><name name-style="western"><surname>Karantza</surname><given-names>V</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Aktan</surname><given-names>G</given-names></name><name name-style="western"><surname>Dent</surname><given-names>R</given-names></name><name name-style="western"><surname>O'Shaughnessy</surname><given-names>J</given-names></name><collab>KEYNOTE-522 Investigators</collab></person-group><article-title>Pembrolizumab for early triple-negative breast cancer</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>9</issue><fpage>810</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910549</pub-id><pub-id pub-id-type="pmid">32101663</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. 10.1056/NEJMoa1910549. (PMID: 32101663).<pub-id pub-id-type="pmid">32101663</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1910549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Penkov</surname><given-names>K</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Rini</surname><given-names>B</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>MT</given-names></name><name name-style="western"><surname>Venugopal</surname><given-names>B</given-names></name><name name-style="western"><surname>Kollmannsberger</surname><given-names>C</given-names></name><name name-style="western"><surname>Negrier</surname><given-names>S</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JL</given-names></name><name name-style="western"><surname>Vasiliev</surname><given-names>A</given-names></name><name name-style="western"><surname>Miller</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Gurney</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></name><name name-style="western"><surname>Bedke</surname><given-names>J</given-names></name><name name-style="western"><surname>Alekseev</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>M</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>PB</given-names></name><name name-style="western"><surname>Chudnovsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Fowst</surname><given-names>C</given-names></name><name name-style="western"><surname>Hariharan</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>di Pietro</surname><given-names>A</given-names></name><name name-style="western"><surname>Choueiri</surname><given-names>TK</given-names></name></person-group><article-title>Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title><source>N Engl J Med</source><year>2019</year><pub-id pub-id-type="doi">10.1056/NEJMoa1816047</pub-id><pub-id pub-id-type="pmid">30779531</pub-id><pub-id pub-id-type="pmcid">PMC6716603</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019. 10.1056/NEJMoa1816047.<pub-id pub-id-type="pmid">30779531</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1816047</pub-id><pub-id pub-id-type="pmcid">PMC6716603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makunts</surname><given-names>T</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>IM</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>IV</given-names></name><etal/></person-group><article-title>Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>17324</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-96467-5</pub-id><pub-id pub-id-type="pmid">34462476</pub-id><pub-id pub-id-type="pmcid">PMC8405813</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Makunts T, Saunders IM, Cohen IV, et al. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep. 2021;11:17324. 10.1038/s41598-021-96467-5.<pub-id pub-id-type="pmid">34462476</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-96467-5</pub-id><pub-id pub-id-type="pmcid">PMC8405813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name><name name-style="western"><surname>Feyereislova</surname><given-names>A</given-names></name><name name-style="western"><surname>Chung</surname><given-names>HC</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Sawaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Lordick</surname><given-names>F</given-names></name><name name-style="western"><surname>Ohtsu</surname><given-names>A</given-names></name><name name-style="western"><surname>Omuro</surname><given-names>Y</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Aprile</surname><given-names>G</given-names></name><name name-style="western"><surname>Kulikov</surname><given-names>E</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J</given-names></name><name name-style="western"><surname>Lehle</surname><given-names>M</given-names></name><name name-style="western"><surname>Rüschoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name></person-group><article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9742</issue><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61121-X</pub-id><pub-id pub-id-type="pmid">20728210</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. 10.1016/S0140-6736(10)61121-X. (Erratum. In: Lancet. 2010 Oct 16;376(9749):1302).<pub-id pub-id-type="pmid">20728210</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61121-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>KS</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>S</given-names></name><name name-style="western"><surname>Adegoke</surname><given-names>EO</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Role of insulin in health and disease: an update</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>12</issue><fpage>6403</fpage><pub-id pub-id-type="doi">10.3390/ijms22126403</pub-id><pub-id pub-id-type="pmid">34203830</pub-id><pub-id pub-id-type="pmcid">PMC8232639</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of insulin in health and disease: an update. Int J Mol Sci. 2021;22(12):6403. 10.3390/ijms22126403.<pub-id pub-id-type="pmid">34203830</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22126403</pub-id><pub-id pub-id-type="pmcid">PMC8232639</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasello</surname><given-names>G</given-names></name><name name-style="western"><surname>Urso</surname><given-names>L</given-names></name><name name-style="western"><surname>Conte</surname><given-names>P</given-names></name><name name-style="western"><surname>Favaretto</surname><given-names>A</given-names></name></person-group><article-title>Effects of sulfonylureas on tumor growth: a review of the literature</article-title><source>Oncologist</source><year>2013</year><volume>18</volume><issue>10</issue><fpage>1118</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2013-0177</pub-id><pub-id pub-id-type="pmid">24043597</pub-id><pub-id pub-id-type="pmcid">PMC3805154</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Pasello G, Urso L, Conte P, Favaretto A. Effects of sulfonylureas on tumor growth: a review of the literature. Oncologist. 2013;18(10):1118–25. 10.1634/theoncologist.2013-0177.<pub-id pub-id-type="pmid">24043597</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2013-0177</pub-id><pub-id pub-id-type="pmcid">PMC3805154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leitner</surname><given-names>BP</given-names></name><name name-style="western"><surname>Siebel</surname><given-names>S</given-names></name><name name-style="western"><surname>Akingbesote</surname><given-names>ND</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Perry</surname><given-names>RJ</given-names></name></person-group><article-title>Insulin and cancer: a tangled web</article-title><source>Biochem J</source><year>2022</year><volume>479</volume><issue>5</issue><fpage>583</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1042/BCJ20210134</pub-id><pub-id pub-id-type="pmid">35244142</pub-id><pub-id pub-id-type="pmcid">PMC9022985</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Leitner BP, Siebel S, Akingbesote ND, Zhang X, Perry RJ. Insulin and cancer: a tangled web. Biochem J. 2022;479(5):583–607. 10.1042/BCJ20210134.<pub-id pub-id-type="pmid">35244142</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BCJ20210134</pub-id><pub-id pub-id-type="pmcid">PMC9022985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawakita</surname><given-names>E</given-names></name><name name-style="western"><surname>Kanasaki</surname><given-names>K</given-names></name></person-group><article-title>Cancer biology in diabetes update: focusing on antidiabetic drugs</article-title><source>J Diabetes Investig</source><year>2024</year><volume>15</volume><issue>5</issue><fpage>525</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/jdi.14152</pub-id><pub-id pub-id-type="pmid">38456597</pub-id><pub-id pub-id-type="pmcid">PMC11060166</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Kawakita E, Kanasaki K. Cancer biology in diabetes update: focusing on antidiabetic drugs. J Diabetes Investig. 2024;15(5):525–40. 10.1111/jdi.14152.<pub-id pub-id-type="pmid">38456597</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdi.14152</pub-id><pub-id pub-id-type="pmcid">PMC11060166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boudina</surname><given-names>S</given-names></name><name name-style="western"><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Diabetic cardiomyopathy, causes and effects</article-title><source>Rev Endocr Metab Disord</source><year>2010</year><volume>11</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s11154-010-9131-7</pub-id><pub-id pub-id-type="pmid">20180026</pub-id><pub-id pub-id-type="pmcid">PMC2914514</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11(1):31–9. 10.1007/s11154-010-9131-7.<pub-id pub-id-type="pmid">20180026</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11154-010-9131-7</pub-id><pub-id pub-id-type="pmcid">PMC2914514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolajević Starčević</surname><given-names>J</given-names></name><name name-style="western"><surname>Janić</surname><given-names>M</given-names></name><name name-style="western"><surname>Šabovič</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms responsible for diastolic dysfunction in diabetes mellitus patients</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>5</issue><fpage>1197</fpage><pub-id pub-id-type="doi">10.3390/ijms20051197</pub-id><pub-id pub-id-type="pmid">30857271</pub-id><pub-id pub-id-type="pmcid">PMC6429211</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Nikolajević Starčević J, Janić M, Šabovič M. Molecular mechanisms responsible for diastolic dysfunction in diabetes mellitus patients. Int J Mol Sci. 2019;20(5):1197. 10.3390/ijms20051197.<pub-id pub-id-type="pmid">30857271</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20051197</pub-id><pub-id pub-id-type="pmcid">PMC6429211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teupe</surname><given-names>C</given-names></name><name name-style="western"><surname>Rosak</surname><given-names>C</given-names></name></person-group><article-title>Diabetic cardiomyopathy and diastolic heart failure - difficulties with relaxation</article-title><source>Diabetes Res Clin Pract</source><year>2012</year><volume>97</volume><issue>2</issue><fpage>185</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2012.03.008</pub-id><pub-id pub-id-type="pmid">22502812</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Teupe C, Rosak C. Diabetic cardiomyopathy and diastolic heart failure - difficulties with relaxation. Diabetes Res Clin Pract. 2012;97(2):185–94. 10.1016/j.diabres.2012.03.008.<pub-id pub-id-type="pmid">22502812</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2012.03.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>G</given-names></name><name name-style="western"><surname>DeMarco</surname><given-names>VG</given-names></name><name name-style="western"><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy</article-title><source>Nat Rev Endocrinol</source><year>2016</year><volume>12</volume><issue>3</issue><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2015.216</pub-id><pub-id pub-id-type="pmid">26678809</pub-id><pub-id pub-id-type="pmcid">PMC4753054</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144–53. 10.1038/nrendo.2015.216.<pub-id pub-id-type="pmid">26678809</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrendo.2015.216</pub-id><pub-id pub-id-type="pmcid">PMC4753054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>C</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name><name name-style="western"><surname>Dostal</surname><given-names>DE</given-names></name><name name-style="western"><surname>White</surname><given-names>MF</given-names></name><name name-style="western"><surname>Baker</surname><given-names>KM</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name></person-group><article-title>Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38α MAPK during insulin resistance</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><issue>11</issue><fpage>3887</fpage><lpage>3900</lpage><pub-id pub-id-type="doi">10.2337/db13-0095</pub-id><pub-id pub-id-type="pmid">24159000</pub-id><pub-id pub-id-type="pmcid">PMC3806607</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Qi Y, Xu Z, Zhu Q, Thomas C, Kumar R, Feng H, et al. Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38α MAPK during insulin resistance. Diabetes. 2013;62(11):3887–900. 10.2337/db13-0095.<pub-id pub-id-type="pmid">24159000</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db13-0095</pub-id><pub-id pub-id-type="pmcid">PMC3806607</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teshima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>S</given-names></name><name name-style="western"><surname>Saito</surname><given-names>S</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>H</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>A</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>K</given-names></name><name name-style="western"><surname>Yufu</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Saikawa</surname><given-names>T</given-names></name></person-group><article-title>Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase</article-title><source>Circ J</source><year>2014</year><volume>78</volume><issue>2</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1253/circj.cj-13-1187</pub-id><pub-id pub-id-type="pmid">24334638</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Teshima Y, Takahashi N, Nishio S, Saito S, Kondo H, Fukui A, et al. Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase. Circ J. 2014;78(2):300–6. 10.1253/circj.cj-13-1187.<pub-id pub-id-type="pmid">24334638</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.cj-13-1187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>JG</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>OH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CS</given-names></name><name name-style="western"><surname>Ihm</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>MG</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TW</given-names></name></person-group><article-title>Effects of alpha-lipoic acid on transforming growth factor beta1-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy</article-title><source>Metabolism</source><year>2009</year><volume>58</volume><issue>5</issue><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2008.12.006</pub-id><pub-id pub-id-type="pmid">19375583</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Lee SJ, Kang JG, Ryu OH, Kim CS, Ihm SH, Choi MG, et al. Effects of alpha-lipoic acid on transforming growth factor beta1-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy. Metabolism. 2009;58(5):616–23. 10.1016/j.metabol.2008.12.006. (PMID: 19375583).<pub-id pub-id-type="pmid">19375583</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2008.12.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Laine</surname><given-names>GA</given-names></name><name name-style="western"><surname>Dellsperger</surname><given-names>KC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>Feed-forward signaling of TNF-alpha and NF-kappaB via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice</article-title><source>Am J Physiol Heart Circ Physiol.</source><year>2009</year><volume>296</volume><issue>6</issue><fpage>H1850</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01199.2008</pub-id><pub-id pub-id-type="pmid">19363130</pub-id><pub-id pub-id-type="pmcid">PMC2716110</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Yang J, Park Y, Zhang H, Xu X, Laine GA, Dellsperger KC, et al. Feed-forward signaling of TNF-alpha and NF-kappaB via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2009;296(6):H1850-8. 10.1152/ajpheart.01199.2008. (Epub 2009 Apr 10. PMID: 19363130; PMCID: PMC2716110).<pub-id pub-id-type="pmid">19363130</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.01199.2008</pub-id><pub-id pub-id-type="pmcid">PMC2716110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariappan</surname><given-names>N</given-names></name><name name-style="western"><surname>Elks</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sriramula</surname><given-names>S</given-names></name><name name-style="western"><surname>Guggilam</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Borkhsenious</surname><given-names>O</given-names></name><name name-style="western"><surname>Francis</surname><given-names>J</given-names></name></person-group><article-title>NF-κB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes</article-title><source>Cardiovasc Res</source><year>2010</year><volume>85</volume><issue>3</issue><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp305</pub-id><pub-id pub-id-type="pmid">19729361</pub-id><pub-id pub-id-type="pmcid">PMC2860708</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O, et al. NF-κB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 2010;85(3):473–83. 10.1093/cvr/cvp305.<pub-id pub-id-type="pmid">19729361</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cvr/cvp305</pub-id><pub-id pub-id-type="pmcid">PMC2860708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egaña-Gorroño</surname><given-names>L</given-names></name><name name-style="western"><surname>López-Díez</surname><given-names>R</given-names></name><name name-style="western"><surname>Yepuri</surname><given-names>G</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>LS</given-names></name><name name-style="western"><surname>Reverdatto</surname><given-names>S</given-names></name><name name-style="western"><surname>Gugger</surname><given-names>PF</given-names></name><name name-style="western"><surname>Shekhtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramasamy</surname><given-names>R</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>AM</given-names></name></person-group><article-title>Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models</article-title><source>Front Cardiovasc Med</source><year>2020</year><volume>7</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2020.00037</pub-id><pub-id pub-id-type="pmid">32211423</pub-id><pub-id pub-id-type="pmcid">PMC7076074</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Egaña-Gorroño L, López-Díez R, Yepuri G, Ramirez LS, Reverdatto S, Gugger PF, et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models. Front Cardiovasc Med. 2020;7:37. 10.3389/fcvm.2020.00037.<pub-id pub-id-type="pmid">32211423</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2020.00037</pub-id><pub-id pub-id-type="pmcid">PMC7076074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>S</given-names></name><name name-style="western"><surname>Terentyev</surname><given-names>D</given-names></name></person-group><article-title>Proarrhythmic remodeling of calcium homeostasis in cardiac disease; implications for diabetes and obesity</article-title><source>Front Physiol</source><year>2018</year><volume>9</volume><fpage>1517</fpage><pub-id pub-id-type="doi">10.3389/fphys.2018.01517</pub-id><pub-id pub-id-type="pmid">30425651</pub-id><pub-id pub-id-type="pmcid">PMC6218530</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Hamilton S, Terentyev D. Proarrhythmic remodeling of calcium homeostasis in cardiac disease; implications for diabetes and obesity. Front Physiol. 2018;9:1517. 10.3389/fphys.2018.01517.<pub-id pub-id-type="pmid">30425651</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2018.01517</pub-id><pub-id pub-id-type="pmcid">PMC6218530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loescher</surname><given-names>CM</given-names></name><name name-style="western"><surname>Breitkreuz</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nickel</surname><given-names>A</given-names></name><name name-style="western"><surname>Unger</surname><given-names>A</given-names></name><name name-style="western"><surname>Dietl</surname><given-names>A</given-names></name><etal/></person-group><article-title>Regulation of titin-based cardiac stiffness by unfolded domain oxidation (UnDOx)</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>39</issue><fpage>24545</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004900117</pub-id><pub-id pub-id-type="pmid">32929035</pub-id><pub-id pub-id-type="pmcid">PMC7533878</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Loescher CM, Breitkreuz M, Li Y, Nickel A, Unger A, Dietl A, et al. Regulation of titin-based cardiac stiffness by unfolded domain oxidation (UnDOx). Proc Natl Acad Sci U S A. 2020;117(39):24545–56. 10.1073/pnas.2004900117.<pub-id pub-id-type="pmid">32929035</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2004900117</pub-id><pub-id pub-id-type="pmcid">PMC7533878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulus</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Zile</surname><given-names>MR</given-names></name></person-group><article-title>From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><issue>10</issue><fpage>1451</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318159</pub-id><pub-id pub-id-type="pmid">33983831</pub-id><pub-id pub-id-type="pmcid">PMC8351796</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021;128(10):1451–67. 10.1161/CIRCRESAHA.121.318159.<pub-id pub-id-type="pmid">33983831</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.121.318159</pub-id><pub-id pub-id-type="pmcid">PMC8351796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesulu</surname><given-names>BP</given-names></name><name name-style="western"><surname>Mahadevan</surname><given-names>LS</given-names></name><name name-style="western"><surname>Aliru</surname><given-names>ML</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Bodd</surname><given-names>MH</given-names></name><name name-style="western"><surname>Singh</surname><given-names>PK</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>SW</given-names></name><name name-style="western"><surname>Abe</surname><given-names>JI</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>S</given-names></name></person-group><article-title>Radiation-induced endothelial vascular injury: a review of possible mechanisms</article-title><source>JACC Basic Transl Sci</source><year>2018</year><volume>3</volume><issue>4</issue><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.jacbts.2018.01.014</pub-id><pub-id pub-id-type="pmid">30175280</pub-id><pub-id pub-id-type="pmcid">PMC6115704</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci. 2018;3(4):563–72. 10.1016/j.jacbts.2018.01.014. (PMID:30175280;PMCID:PMC6115704).<pub-id pub-id-type="pmid">30175280</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacbts.2018.01.014</pub-id><pub-id pub-id-type="pmcid">PMC6115704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>2900</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.827</pub-id><pub-id pub-id-type="pmid">15860848</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Ewer MS, et al. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2. 10.1200/JCO.2005.05.827.<pub-id pub-id-type="pmid">15860848</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.05.827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juan</surname><given-names>CA</given-names></name><name name-style="western"><surname>de la Pérez Lastra</surname><given-names>JM</given-names></name><name name-style="western"><surname>Plou</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Pérez-Lebeña</surname><given-names>E</given-names></name></person-group><article-title>The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>9</issue><fpage>4642</fpage><pub-id pub-id-type="doi">10.3390/ijms22094642</pub-id><pub-id pub-id-type="pmid">33924958</pub-id><pub-id pub-id-type="pmcid">PMC8125527</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Juan CA, de la Pérez Lastra JM, Plou FJ, Pérez-Lebeña E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int J Mol Sci. 2021;22(9):4642. 10.3390/ijms22094642.<pub-id pub-id-type="pmid">33924958</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22094642</pub-id><pub-id pub-id-type="pmcid">PMC8125527</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shields</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Traa</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Raamsdonk</surname><given-names>JM</given-names></name></person-group><article-title>Beneficial and detrimental effects of reactive oxygen species on lifespan: a comprehensive review of comparative and experimental studies</article-title><source>Front Cell Dev Biol</source><year>2021</year><volume>9</volume><fpage>628157</fpage><pub-id pub-id-type="doi">10.3389/fcell.2021.628157</pub-id><pub-id pub-id-type="pmid">33644065</pub-id><pub-id pub-id-type="pmcid">PMC7905231</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Shields HJ, Traa A, Van Raamsdonk JM. Beneficial and detrimental effects of reactive oxygen species on lifespan: a comprehensive review of comparative and experimental studies. Front Cell Dev Biol. 2021;9:628157. 10.3389/fcell.2021.628157.<pub-id pub-id-type="pmid">33644065</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2021.628157</pub-id><pub-id pub-id-type="pmcid">PMC7905231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iheagwam</surname><given-names>FN</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Adedoyin</surname><given-names>ED</given-names></name><name name-style="western"><surname>Iheagwam</surname><given-names>OT</given-names></name><name name-style="western"><surname>Ejoh</surname><given-names>SA</given-names></name></person-group><article-title>Mitochondrial dysfunction in diabetes: shedding light on a widespread oversight</article-title><source>Pathophysiology</source><year>2025</year><volume>32</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.3390/pathophysiology32010009</pub-id><pub-id pub-id-type="pmid">39982365</pub-id><pub-id pub-id-type="pmcid">PMC12077258</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Iheagwam FN, Joseph AJ, Adedoyin ED, Iheagwam OT, Ejoh SA. Mitochondrial dysfunction in diabetes: shedding light on a widespread oversight. Pathophysiology. 2025;32(1):9. 10.3390/pathophysiology32010009.<pub-id pub-id-type="pmid">39982365</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathophysiology32010009</pub-id><pub-id pub-id-type="pmcid">PMC12077258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LK</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>FM</given-names></name></person-group><article-title>The application and molecular mechanisms of mitochondria-targeted antioxidants in chemotherapy-induced cardiac injury</article-title><source>Curr Issues Mol Biol</source><year>2025</year><volume>47</volume><issue>3</issue><fpage>176</fpage><pub-id pub-id-type="doi">10.3390/cimb47030176</pub-id><pub-id pub-id-type="pmid">40136430</pub-id><pub-id pub-id-type="pmcid">PMC11941228</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Liu CJ, Wang LK, Tsai FM. The application and molecular mechanisms of mitochondria-targeted antioxidants in chemotherapy-induced cardiac injury. Curr Issues Mol Biol. 2025;47(3):176. 10.3390/cimb47030176.<pub-id pub-id-type="pmid">40136430</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb47030176</pub-id><pub-id pub-id-type="pmcid">PMC11941228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fei</surname><given-names>S</given-names></name><name name-style="western"><surname>Chan</surname><given-names>LWC</given-names></name><name name-style="western"><surname>Gan</surname><given-names>X</given-names></name><name name-style="western"><surname>Shao</surname><given-names>B</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inflammatory signaling pathways in pancreatic β-cell: new insights into type 2 diabetes pathogenesis</article-title><source>Pharmacol Res</source><year>2025</year><volume>216</volume><fpage>107776</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2025.107776</pub-id><pub-id pub-id-type="pmid">40378943</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Chen J, Fei S, Chan LWC, Gan X, Shao B, Jiang H, et al. Inflammatory signaling pathways in pancreatic β-cell: new insights into type 2 diabetes pathogenesis. Pharmacol Res. 2025;216:107776. 10.1016/j.phrs.2025.107776.<pub-id pub-id-type="pmid">40378943</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2025.107776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terwoord</surname><given-names>JD</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Gutterman</surname><given-names>DD</given-names></name></person-group><article-title>Endothelial dysfunction as a complication of anti-cancer therapy</article-title><source>Pharmacol Ther</source><year>2022</year><volume>237</volume><fpage>108116</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2022.108116</pub-id><pub-id pub-id-type="pmid">35063569</pub-id><pub-id pub-id-type="pmcid">PMC9294076</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Terwoord JD, Beyer AM, Gutterman DD. Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacol Ther. 2022;237:108116. 10.1016/j.pharmthera.2022.108116.<pub-id pub-id-type="pmid">35063569</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2022.108116</pub-id><pub-id pub-id-type="pmcid">PMC9294076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>B</given-names></name><name name-style="western"><surname>Fowlkes</surname><given-names>V</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>JG</given-names></name><name name-style="western"><surname>Carver</surname><given-names>W</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>EC</given-names></name></person-group><article-title>Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function</article-title><source>Microsc Microanal</source><year>2012</year><volume>18</volume><issue>1</issue><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1017/S1431927611012256</pub-id><pub-id pub-id-type="pmid">22221857</pub-id><pub-id pub-id-type="pmcid">PMC4045476</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Law B, Fowlkes V, Goldsmith JG, Carver W, Goldsmith EC. Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal. 2012;18(1):22–34. 10.1017/S1431927611012256.<pub-id pub-id-type="pmid">22221857</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1431927611012256</pub-id><pub-id pub-id-type="pmcid">PMC4045476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prakash</surname><given-names>J</given-names></name><name name-style="western"><surname>Shaked</surname><given-names>Y</given-names></name></person-group><article-title>The interplay between extracellular matrix remodeling and cancer therapeutics</article-title><source>Cancer Discov</source><year>2024</year><volume>14</volume><issue>8</issue><fpage>1375</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-24-0002</pub-id><pub-id pub-id-type="pmid">39091205</pub-id><pub-id pub-id-type="pmcid">PMC11294818</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024;14(8):1375–88. 10.1158/2159-8290.CD-24-0002.<pub-id pub-id-type="pmid">39091205</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-24-0002</pub-id><pub-id pub-id-type="pmcid">PMC11294818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S</given-names></name><name name-style="western"><surname>Jia</surname><given-names>H</given-names></name><etal/></person-group><article-title>Diabetes mellitus exacerbates post-myocardial infarction heart failure by reducing sarcolipin promoter methylation</article-title><source>ESC Heart Fail</source><year>2020</year><volume>7</volume><issue>4</issue><fpage>1935</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/ehf2.12789</pub-id><pub-id pub-id-type="pmid">32525286</pub-id><pub-id pub-id-type="pmcid">PMC7373908</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Liu Z, Zhang Y, Qiu C, Zhu H, Pan S, Jia H, et al. Diabetes mellitus exacerbates post-myocardial infarction heart failure by reducing sarcolipin promoter methylation. ESC Heart Fail. 2020;7(4):1935–48. 10.1002/ehf2.12789.<pub-id pub-id-type="pmid">32525286</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ehf2.12789</pub-id><pub-id pub-id-type="pmcid">PMC7373908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florea</surname><given-names>AM</given-names></name><name name-style="western"><surname>Büsselberg</surname><given-names>D</given-names></name></person-group><article-title>Anti-cancer drugs interfere with intracellular calcium signaling</article-title><source>Neurotoxicology</source><year>2009</year><volume>30</volume><issue>5</issue><fpage>803</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.neuro.2009.04.014</pub-id><pub-id pub-id-type="pmid">19465052</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Florea AM, Büsselberg D. Anti-cancer drugs interfere with intracellular calcium signaling. Neurotoxicology. 2009;30(5):803–10. 10.1016/j.neuro.2009.04.014.<pub-id pub-id-type="pmid">19465052</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuro.2009.04.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packer</surname><given-names>M</given-names></name><name name-style="western"><surname>Lam</surname><given-names>C</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?</article-title><source>JACC</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.jacc.2025.07.052</pub-id><pub-id pub-id-type="pmid">40960442</pub-id><pub-id pub-id-type="pmcid">PMC12766980</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Packer M, Lam C, Butler J, et al. Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction? JACC. 2025. 10.1016/j.jacc.2025.07.052.<pub-id pub-id-type="pmid">40960442</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2025.07.052</pub-id><pub-id pub-id-type="pmcid">PMC12766980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packer</surname><given-names>M</given-names></name></person-group><article-title>The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment</article-title><source>JACC</source><year>2025</year><volume>86</volume><issue>16</issue><fpage>1269</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2025.06.055</pub-id><pub-id pub-id-type="pmid">40886173</pub-id><pub-id pub-id-type="pmcid">PMC12766646</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Packer M. The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment. JACC. 2025;86(16):1269–373. 10.1016/j.jacc.2025.06.055.<pub-id pub-id-type="pmid">40886173</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2025.06.055</pub-id><pub-id pub-id-type="pmcid">PMC12766646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theodorakis</surname><given-names>N</given-names></name><name name-style="western"><surname>Kreouzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Hitas</surname><given-names>C</given-names></name><name name-style="western"><surname>Anagnostou</surname><given-names>D</given-names></name><name name-style="western"><surname>Nikolaou</surname><given-names>M</given-names></name></person-group><article-title>Adipokines and cardiometabolic heart failure with preserved ejection fraction: a state-of-the-art review</article-title><source>Diagnostics</source><year>2024</year><volume>14</volume><issue>23</issue><fpage>2677</fpage><pub-id pub-id-type="doi">10.3390/diagnostics14232677</pub-id><pub-id pub-id-type="pmid">39682585</pub-id><pub-id pub-id-type="pmcid">PMC11640255</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Theodorakis N, Kreouzi M, Hitas C, Anagnostou D, Nikolaou M. Adipokines and cardiometabolic heart failure with preserved ejection fraction: a state-of-the-art review. Diagnostics. 2024;14(23):2677. 10.3390/diagnostics14232677.<pub-id pub-id-type="pmid">39682585</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics14232677</pub-id><pub-id pub-id-type="pmcid">PMC11640255</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Kusminski</surname><given-names>CM</given-names></name><name name-style="western"><surname>Scherer</surname><given-names>PE</given-names></name></person-group><article-title>Adiponectin, leptin and cardiovascular disorders</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><issue>8</issue><fpage>136</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.314458</pub-id><pub-id pub-id-type="pmid">33411633</pub-id><pub-id pub-id-type="pmcid">PMC7799441</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128(8):136–49. 10.1161/CIRCRESAHA.120.314458.<pub-id pub-id-type="pmid">33411633</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.120.314458</pub-id><pub-id pub-id-type="pmcid">PMC7799441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z</given-names></name></person-group><article-title>Adipokines and their potential impacts on susceptibility to myocardial ischemia/reperfusion injury in diabetes</article-title><source>Lipids Health Dis</source><year>2024</year><volume>23</volume><issue>1</issue><fpage>372</fpage><pub-id pub-id-type="doi">10.1186/s12944-024-02357-w</pub-id><pub-id pub-id-type="pmid">39538244</pub-id><pub-id pub-id-type="pmcid">PMC11558907</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Han R, Huang H, Zhu J, Jin X, Wang Y, Xu Y, et al. Adipokines and their potential impacts on susceptibility to myocardial ischemia/reperfusion injury in diabetes. Lipids Health Dis. 2024;23(1):372. 10.1186/s12944-024-02357-w.<pub-id pub-id-type="pmid">39538244</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12944-024-02357-w</pub-id><pub-id pub-id-type="pmcid">PMC11558907</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T</given-names></name><name name-style="western"><surname>Ikegawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Ori</surname><given-names>D</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Decoding Toll-like receptors: recent insights and perspectives in innate immunity</article-title><source>Immunity</source><year>2024</year><volume>57</volume><issue>9</issue><fpage>649</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.004</pub-id><pub-id pub-id-type="pmid">38599164</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Kawai T, Ikegawa M, Ori D, Akira S. Decoding Toll-like receptors: recent insights and perspectives in innate immunity. Immunity. 2024;57(9):649–73. 10.1016/j.immuni.2024.03.004.<pub-id pub-id-type="pmid">38599164</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2024.03.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Dong</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H</given-names></name></person-group><article-title>Toll-like receptors in cardiac hypertrophy</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1143583</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1143583</pub-id><pub-id pub-id-type="pmid">37113698</pub-id><pub-id pub-id-type="pmcid">PMC10126280</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Zhang Y, Wu J, Dong E, Wang Z, Xiao H. Toll-like receptors in cardiac hypertrophy. Front Cardiovasc Med. 2023;10:1143583. 10.3389/fcvm.2023.1143583.<pub-id pub-id-type="pmid">37113698</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2023.1143583</pub-id><pub-id pub-id-type="pmcid">PMC10126280</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avagimyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Pogosova</surname><given-names>N</given-names></name><name name-style="western"><surname>Kakturskiy</surname><given-names>L</given-names></name><name name-style="western"><surname>Sheibani</surname><given-names>M</given-names></name><name name-style="western"><surname>Challa</surname><given-names>A</given-names></name><name name-style="western"><surname>Kogan</surname><given-names>E</given-names></name><etal/></person-group><article-title>Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury</article-title><source>Cardiovasc Pathol</source><year>2024</year><volume>73</volume><fpage>107683</fpage><pub-id pub-id-type="doi">10.1016/j.carpath.2024.107683</pub-id><pub-id pub-id-type="pmid">39111556</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Avagimyan A, Pogosova N, Kakturskiy L, Sheibani M, Challa A, Kogan E, et al. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovasc Pathol. 2024;73:107683. 10.1016/j.carpath.2024.107683.<pub-id pub-id-type="pmid">39111556</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carpath.2024.107683</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauro</surname><given-names>AG</given-names></name><name name-style="western"><surname>Mezzaroma</surname><given-names>E</given-names></name><name name-style="western"><surname>Toldo</surname><given-names>S</given-names></name><name name-style="western"><surname>Melendez</surname><given-names>GC</given-names></name><name name-style="western"><surname>Franco</surname><given-names>RL</given-names></name><name name-style="western"><surname>Lesnefsky</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful</article-title><source>Transl Res</source><year>2023</year><volume>252</volume><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2022.08.004</pub-id><pub-id pub-id-type="pmid">35948198</pub-id><pub-id pub-id-type="pmcid">PMC9839540</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Mauro AG, Mezzaroma E, Toldo S, Melendez GC, Franco RL, Lesnefsky EJ, et al. NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful. Transl Res. 2023;252:9–20. 10.1016/j.trsl.2022.08.004.<pub-id pub-id-type="pmid">35948198</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2022.08.004</pub-id><pub-id pub-id-type="pmcid">PMC9839540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>TT</given-names></name><name name-style="western"><surname>Baek</surname><given-names>IH</given-names></name><name name-style="western"><surname>Stoletniy</surname><given-names>L</given-names></name><name name-style="western"><surname>Hilliard</surname><given-names>A</given-names></name><name name-style="western"><surname>Sakr</surname><given-names>A</given-names></name><name name-style="western"><surname>Doycheva</surname><given-names>D</given-names></name></person-group><article-title>Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review.</article-title><source>Cardiovasc Diabetol</source><year>2025</year><volume>24</volume><issue>1</issue><fpage>227</fpage><pub-id pub-id-type="doi">10.1186/s12933-025-02777-7</pub-id><pub-id pub-id-type="pmid">40420176</pub-id><pub-id pub-id-type="pmcid">PMC12105141</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovasc Diabetol. 2025;24(1):227. 10.1186/s12933-025-02777-7.<pub-id pub-id-type="pmid">40420176</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-025-02777-7</pub-id><pub-id pub-id-type="pmcid">PMC12105141</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X-P</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q-R</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X</given-names></name><name name-style="western"><surname>Tian</surname><given-names>N-Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S-L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>K</given-names></name></person-group><article-title>NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals</article-title><source>Front Pharmacol</source><year>2025</year><volume>16</volume><fpage>1567312</fpage><pub-id pub-id-type="doi">10.3389/fphar.2025.1567312</pub-id><pub-id pub-id-type="pmid">40313623</pub-id><pub-id pub-id-type="pmcid">PMC12043718</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Zhao X-P, Duan L, Zhao Q-R, Lv X, Tian N-Y, Yang S-L, et al. NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals. Front Pharmacol. 2025;16:1567312. 10.3389/fphar.2025.1567312.<pub-id pub-id-type="pmid">40313623</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2025.1567312</pub-id><pub-id pub-id-type="pmcid">PMC12043718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldman</surname><given-names>SA</given-names></name><name name-style="western"><surname>Requena-Ibanez</surname><given-names>JA</given-names></name><name name-style="western"><surname>Devesa</surname><given-names>A</given-names></name><name name-style="western"><surname>Santos-Gallego</surname><given-names>CG</given-names></name><name name-style="western"><surname>Badimon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>V</given-names></name></person-group><article-title>Uncovering the role of epicardial adipose tissue in heart failure with preserved ejection fraction</article-title><source>JACC: Advances</source><year>2023</year><volume>2</volume><issue>9</issue><fpage>100657</fpage><pub-id pub-id-type="doi">10.1016/j.jacadv.2023.100657</pub-id><pub-id pub-id-type="pmid">38938732</pub-id><pub-id pub-id-type="pmcid">PMC11198699</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Goldman SA, Requena-Ibanez JA, Devesa A, Santos-Gallego CG, Badimon JJ, Fuster V. Uncovering the role of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC: Advances. 2023;2(9):100657. 10.1016/j.jacadv.2023.100657.<pub-id pub-id-type="pmid">38938732</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacadv.2023.100657</pub-id><pub-id pub-id-type="pmcid">PMC11198699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizzuto</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gelpi</surname><given-names>G</given-names></name><name name-style="western"><surname>Mangini</surname><given-names>A</given-names></name><name name-style="western"><surname>Carugo</surname><given-names>S</given-names></name><name name-style="western"><surname>Ruscica</surname><given-names>M</given-names></name><name name-style="western"><surname>Macchi</surname><given-names>C</given-names></name></person-group><article-title>Exploring the role of epicardial adipose-tissue-derived extracellular vesicles in cardiovascular diseases</article-title><source>iScience</source><year>2024</year><volume>27</volume><issue>4</issue><fpage>109359</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2024.109359</pub-id><pub-id pub-id-type="pmid">38510143</pub-id><pub-id pub-id-type="pmcid">PMC10951984</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Rizzuto AS, Gelpi G, Mangini A, Carugo S, Ruscica M, Macchi C. Exploring the role of epicardial adipose-tissue-derived extracellular vesicles in cardiovascular diseases. iScience. 2024;27(4):109359. 10.1016/j.isci.2024.109359.<pub-id pub-id-type="pmid">38510143</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2024.109359</pub-id><pub-id pub-id-type="pmcid">PMC10951984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><mixed-citation publication-type="other">Nakayama Y, Zhou Y, Okuzaki D, et al. Heart failure promotes multimorbidity through innate immune memory. Sci Immunol. 2024;9:eade3814. 10.1126/sciimmunol.ade3814.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.ade3814</pub-id><pub-id pub-id-type="pmid">38787963</pub-id></mixed-citation></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassem</surname><given-names>S</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>N</given-names></name><name name-style="western"><surname>Gressel</surname><given-names>O</given-names></name><name name-style="western"><surname>Stein</surname><given-names>N</given-names></name><name name-style="western"><surname>Golan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ben-Arye</surname><given-names>E</given-names></name></person-group><article-title>Diabetes comorbidity and quality of life in patients with cancer: a prospective study in an integrative oncology setting</article-title><source>J Clin Med</source><year>2025</year><volume>14</volume><issue>6</issue><fpage>1800</fpage><pub-id pub-id-type="doi">10.3390/jcm14061800</pub-id><pub-id pub-id-type="pmid">40142607</pub-id><pub-id pub-id-type="pmcid">PMC11942748</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Kassem S, Samuels N, Gressel O, Stein N, Golan M, Ben-Arye E. Diabetes comorbidity and quality of life in patients with cancer: a prospective study in an integrative oncology setting. J Clin Med. 2025;14(6):1800. 10.3390/jcm14061800.<pub-id pub-id-type="pmid">40142607</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm14061800</pub-id><pub-id pub-id-type="pmcid">PMC11942748</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-Almorós</surname><given-names>A</given-names></name><name name-style="western"><surname>Tuñón</surname><given-names>J</given-names></name><name name-style="western"><surname>Orejas</surname><given-names>M</given-names></name><name name-style="western"><surname>Cortés</surname><given-names>M</given-names></name><name name-style="western"><surname>Egido</surname><given-names>J</given-names></name><name name-style="western"><surname>Lorenzo</surname><given-names>Ó</given-names></name></person-group><article-title>Diagnostic approaches for diabetic cardiomyopathy</article-title><source>Cardiovasc Diabetol</source><year>2017</year><volume>16</volume><issue>23</issue><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0506-x</pub-id><pub-id pub-id-type="pmid">28231848</pub-id><pub-id pub-id-type="pmcid">PMC5324262</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Lorenzo-Almorós A, Tuñón J, Orejas M, Cortés M, Egido J, Lorenzo Ó. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16(23):28. 10.1186/s12933-017-0506-x.<pub-id pub-id-type="pmid">28231848</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-017-0506-x</pub-id><pub-id pub-id-type="pmcid">PMC5324262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hochman</surname><given-names>JS</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>HR</given-names></name><name name-style="western"><surname>Bangalore</surname><given-names>S</given-names></name><name name-style="western"><surname>O’Brien</surname><given-names>SM</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>KP</given-names></name><name name-style="western"><surname>Senior</surname><given-names>R</given-names></name><etal/></person-group><article-title>Baseline characteristics and risk profiles of participants in the ischemia randomized clinical trial</article-title><source>JAMA Cardiol</source><year>2019</year><volume>4</volume><issue>3</issue><fpage>273</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2019.0014</pub-id><pub-id pub-id-type="pmid">30810700</pub-id><pub-id pub-id-type="pmcid">PMC6439551</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Alexander KP, Senior R, et al. Baseline characteristics and risk profiles of participants in the ischemia randomized clinical trial. JAMA Cardiol. 2019;4(3):273–86. 10.1001/jamacardio.2019.0014.<pub-id pub-id-type="pmid">30810700</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2019.0014</pub-id><pub-id pub-id-type="pmcid">PMC6439551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazio</surname><given-names>S</given-names></name><name name-style="western"><surname>Mercurio</surname><given-names>V</given-names></name><name name-style="western"><surname>Tibullo</surname><given-names>L</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>V</given-names></name><name name-style="western"><surname>Affuso</surname><given-names>F</given-names></name></person-group><article-title>Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated</article-title><source>Front Cardiovasc Med</source><year>2024</year><volume>11</volume><fpage>1380506</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2024.1380506</pub-id><pub-id pub-id-type="pmid">38545338</pub-id><pub-id pub-id-type="pmcid">PMC10965550</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Fazio S, Mercurio V, Tibullo L, Fazio V, Affuso F. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated. Front Cardiovasc Med. 2024;11:1380506. 10.3389/fcvm.2024.1380506.<pub-id pub-id-type="pmid">38545338</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2024.1380506</pub-id><pub-id pub-id-type="pmcid">PMC10965550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winhofer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Krssák</surname><given-names>M</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Anderwald</surname><given-names>CH</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>G</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>A</given-names></name><name name-style="western"><surname>Trattnig</surname><given-names>S</given-names></name><name name-style="western"><surname>Luger</surname><given-names>A</given-names></name><name name-style="western"><surname>Krebs</surname><given-names>M</given-names></name></person-group><article-title>Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects</article-title><source>Diabetes</source><year>2012</year><volume>61</volume><issue>5</issue><fpage>1210</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2337/db11-1275</pub-id><pub-id pub-id-type="pmid">22396203</pub-id><pub-id pub-id-type="pmcid">PMC3331780</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Winhofer Y, Krssák M, Jankovic D, Anderwald CH, Reiter G, Hofer A, et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes. 2012;61(5):1210–6. 10.2337/db11-1275.<pub-id pub-id-type="pmid">22396203</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db11-1275</pub-id><pub-id pub-id-type="pmcid">PMC3331780</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamolodchikova</surname><given-names>TS</given-names></name><name name-style="western"><surname>Tolpygo</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kotov</surname><given-names>AV</given-names></name></person-group><article-title>Insulin in the regulation of the renin-angiotensin system: a new perspective on the mechanism of insulin resistance and diabetic complications</article-title><source>Front Endocrinol (Lausanne)</source><year>2024</year><volume>15</volume><fpage>1293221</fpage><pub-id pub-id-type="doi">10.3389/fendo.2024.1293221</pub-id><pub-id pub-id-type="pmid">38323106</pub-id><pub-id pub-id-type="pmcid">PMC10844507</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Zamolodchikova TS, Tolpygo SM, Kotov AV. Insulin in the regulation of the renin-angiotensin system: a new perspective on the mechanism of insulin resistance and diabetic complications. Front Endocrinol (Lausanne). 2024;15:1293221. 10.3389/fendo.2024.1293221.<pub-id pub-id-type="pmid">38323106</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2024.1293221</pub-id><pub-id pub-id-type="pmcid">PMC10844507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>DD</given-names></name><name name-style="western"><surname>Corkey</surname><given-names>BE</given-names></name><name name-style="western"><surname>Istfan</surname><given-names>NW</given-names></name><name name-style="western"><surname>Apovian</surname><given-names>CM</given-names></name></person-group><article-title>Hyperinsulinemia: an early indicator of metabolic dysfunction</article-title><source>J Endocr Soc</source><year>2019</year><volume>3</volume><issue>9</issue><fpage>1727</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1210/js.2019-00065</pub-id><pub-id pub-id-type="pmid">31528832</pub-id><pub-id pub-id-type="pmcid">PMC6735759</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc. 2019;3(9):1727–47. 10.1210/js.2019-00065.<pub-id pub-id-type="pmid">31528832</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/js.2019-00065</pub-id><pub-id pub-id-type="pmcid">PMC6735759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicentini</surname><given-names>M</given-names></name><name name-style="western"><surname>Ballotari</surname><given-names>P</given-names></name><name name-style="western"><surname>Venturelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Ottone</surname><given-names>M</given-names></name><name name-style="western"><surname>Manicardi</surname><given-names>V</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of insulin therapies on cancer incidence in type 1 and type 2 diabetes: a population-based cohort study in Reggio Emilia, Italy</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>11</issue><fpage>2719</fpage><pub-id pub-id-type="doi">10.3390/cancers14112719</pub-id><pub-id pub-id-type="pmid">35681699</pub-id><pub-id pub-id-type="pmcid">PMC9179836</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Vicentini M, Ballotari P, Venturelli F, Ottone M, Manicardi V, Gallo M, et al. Impact of insulin therapies on cancer incidence in type 1 and type 2 diabetes: a population-based cohort study in Reggio Emilia, Italy. Cancers (Basel). 2022;14(11):2719. 10.3390/cancers14112719.<pub-id pub-id-type="pmid">35681699</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14112719</pub-id><pub-id pub-id-type="pmcid">PMC9179836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowers</surname><given-names>LW</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>EL</given-names></name><name name-style="western"><surname>O’Flanagan</surname><given-names>CH</given-names></name><name name-style="western"><surname>deGraffenried</surname><given-names>LA</given-names></name><name name-style="western"><surname>Hursting</surname><given-names>SD</given-names></name></person-group><article-title>The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link</article-title><source>Front Endocrinol (Lausanne)</source><year>2015</year><volume>15</volume><issue>6</issue><fpage>77</fpage><pub-id pub-id-type="doi">10.3389/fendo.2015.00077</pub-id><pub-id pub-id-type="pmcid">PMC4432799</pub-id><pub-id pub-id-type="pmid">26029167</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Bowers LW, Rossi EL, O’Flanagan CH, deGraffenried LA, Hursting SD. The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link. Front Endocrinol (Lausanne). 2015;15(6):77. 10.3389/fendo.2015.00077.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2015.00077</pub-id><pub-id pub-id-type="pmcid">PMC4432799</pub-id><pub-id pub-id-type="pmid">26029167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagao</surname><given-names>H</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name><name name-style="western"><surname>Wewer Albrechtsen</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Steger</surname><given-names>M</given-names></name><name name-style="western"><surname>Batista</surname><given-names>TM</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><issue>27</issue><fpage>e2019474118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2019474118</pub-id><pub-id pub-id-type="pmid">33879610</pub-id><pub-id pub-id-type="pmcid">PMC8092608</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Nagao H, Cai W, Wewer Albrechtsen NJ, Steger M, Batista TM, Pan H, et al. Distinct signaling by insulin and IGF-1 receptors and their extra- and intracellular domains. Proc Natl Acad Sci U S A. 2021;118(27):e2019474118. 10.1073/pnas.2019474118.<pub-id pub-id-type="pmid">33879610</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2019474118</pub-id><pub-id pub-id-type="pmcid">PMC8092608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nwabo Kamdje</surname><given-names>AH</given-names></name><name name-style="western"><surname>Seke Etet</surname><given-names>PF</given-names></name><name name-style="western"><surname>Kipanyula</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Vecchio</surname><given-names>L</given-names></name><name name-style="western"><surname>Tagne Simo</surname><given-names>R</given-names></name><name name-style="western"><surname>Njamnshi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lukong</surname><given-names>KE</given-names></name><name name-style="western"><surname>Mimche</surname><given-names>PN</given-names></name></person-group><article-title>Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>9</volume><issue>13</issue><fpage>927390</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.927390</pub-id><pub-id pub-id-type="pmcid">PMC9395641</pub-id><pub-id pub-id-type="pmid">36017326</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Nwabo Kamdje AH, Seke Etet PF, Kipanyula MJ, Vecchio L, Tagne Simo R, Njamnshi AK, et al. Insulin-like growth factor-1 signaling in the tumor microenvironment: Carcinogenesis, cancer drug resistance, and therapeutic potential. Front Endocrinol (Lausanne). 2022;9(13):927390. 10.3389/fendo.2022.927390. (PMID:36017326;PMCID:PMC9395641).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.927390</pub-id><pub-id pub-id-type="pmcid">PMC9395641</pub-id><pub-id pub-id-type="pmid">36017326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukama</surname><given-names>T</given-names></name><name name-style="western"><surname>Srour</surname><given-names>B</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>T</given-names></name><name name-style="western"><surname>Katzke</surname><given-names>V</given-names></name><name name-style="western"><surname>Kaaks</surname><given-names>R</given-names></name></person-group><article-title>IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-Heidelberg</article-title><source>J Clin Endocrinol Metab</source><year>2023</year><volume>108</volume><issue>10</issue><fpage>e1092</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgad212</pub-id><pub-id pub-id-type="pmid">37066827</pub-id><pub-id pub-id-type="pmcid">PMC10505533</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Mukama T, Srour B, Johnson T, Katzke V, Kaaks R. IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-Heidelberg. J Clin Endocrinol Metab. 2023;108(10):e1092-105. 10.1210/clinem/dgad212.<pub-id pub-id-type="pmid">37066827</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgad212</pub-id><pub-id pub-id-type="pmcid">PMC10505533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name></person-group><article-title>Diabetes and cancer: cancer should be screened in routine diabetes assessment</article-title><source>Diabetes Metab J</source><year>2019</year><volume>43</volume><issue>6</issue><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.4093/dmj.2019.0177</pub-id><pub-id pub-id-type="pmid">31902143</pub-id><pub-id pub-id-type="pmcid">PMC6943263</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43(6):733–43. 10.4093/dmj.2019.0177.<pub-id pub-id-type="pmid">31902143</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4093/dmj.2019.0177</pub-id><pub-id pub-id-type="pmcid">PMC6943263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopkins</surname><given-names>BD</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>MD</given-names></name><name name-style="western"><surname>Cantley</surname><given-names>LC</given-names></name></person-group><article-title>Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer</article-title><source>Nat Rev Endocrinol</source><year>2020</year><volume>16</volume><issue>5</issue><fpage>276</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/s41574-020-0329-9</pub-id><pub-id pub-id-type="pmid">32127696</pub-id><pub-id pub-id-type="pmcid">PMC7286536</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020;16(5):276–83. 10.1038/s41574-020-0329-9.<pub-id pub-id-type="pmid">32127696</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-020-0329-9</pub-id><pub-id pub-id-type="pmcid">PMC7286536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LoRusso</surname><given-names>PM</given-names></name></person-group><article-title>Inhibition of the PI3K/AKT/mTOR pathway in solid tumors</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>31</issue><fpage>3803</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.0018</pub-id><pub-id pub-id-type="pmid">27621407</pub-id><pub-id pub-id-type="pmcid">PMC6366304</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803–15. 10.1200/JCO.2014.59.0018.<pub-id pub-id-type="pmid">27621407</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2014.59.0018</pub-id><pub-id pub-id-type="pmcid">PMC6366304</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsujimoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kajio</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>T</given-names></name></person-group><article-title>Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: a population-based observational study</article-title><source>Int J Cancer</source><year>2017</year><volume>141</volume><issue>1</issue><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1002/ijc.30729</pub-id><pub-id pub-id-type="pmid">28390156</pub-id><pub-id pub-id-type="pmcid">PMC5435954</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: a population-based observational study. Int J Cancer. 2017;141(1):102–11. 10.1002/ijc.30729.<pub-id pub-id-type="pmid">28390156</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.30729</pub-id><pub-id pub-id-type="pmcid">PMC5435954</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besse-Patin</surname><given-names>A</given-names></name><name name-style="western"><surname>Estall</surname><given-names>JL</given-names></name></person-group><article-title>An intimate relationship between ROS and insulin signalling: implications for antioxidant treatment of fatty liver disease</article-title><source>Int J Cell Biol</source><year>2014</year><volume>2014</volume><fpage>519153</fpage><pub-id pub-id-type="doi">10.1155/2014/519153</pub-id><pub-id pub-id-type="pmid">24672550</pub-id><pub-id pub-id-type="pmcid">PMC3944655</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Besse-Patin A, Estall JL. An intimate relationship between ROS and insulin signalling: implications for antioxidant treatment of fatty liver disease. Int J Cell Biol. 2014;2014:519153. 10.1155/2014/519153.<pub-id pub-id-type="pmid">24672550</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/519153</pub-id><pub-id pub-id-type="pmcid">PMC3944655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sergi</surname><given-names>D</given-names></name><name name-style="western"><surname>Naumovski</surname><given-names>N</given-names></name><name name-style="western"><surname>Heilbronn</surname><given-names>LK</given-names></name><name name-style="western"><surname>Abeywardena</surname><given-names>M</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>N</given-names></name><name name-style="western"><surname>Lionetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Luscombe-Marsh</surname><given-names>N</given-names></name></person-group><article-title>Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet</article-title><source>Front Physiol</source><year>2019</year><volume>3</volume><issue>10</issue><fpage>532</fpage><pub-id pub-id-type="doi">10.3389/fphys.2019.00532</pub-id><pub-id pub-id-type="pmcid">PMC6510277</pub-id><pub-id pub-id-type="pmid">31130874</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Sergi D, Naumovski N, Heilbronn LK, Abeywardena M, O’Callaghan N, Lionetti L, et al. Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet. Front Physiol. 2019;3(10):532. 10.3389/fphys.2019.00532. (PMID:31130874;PMCID:PMC6510277).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2019.00532</pub-id><pub-id pub-id-type="pmcid">PMC6510277</pub-id><pub-id pub-id-type="pmid">31130874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuleta</surname><given-names>I</given-names></name><name name-style="western"><surname>Frangogiannis</surname><given-names>NG</given-names></name></person-group><article-title>Diabetic fibrosis</article-title><source>Biochimica et Biophysica Acta (BBA)</source><year>2021</year><volume>1867</volume><issue>4</issue><fpage>166044</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.166044</pub-id><pub-id pub-id-type="pmcid">PMC7867637</pub-id><pub-id pub-id-type="pmid">33378699</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Tuleta I, Frangogiannis NG. Diabetic fibrosis. Biochimica et Biophysica Acta (BBA). 2021;1867(4):166044. 10.1016/j.bbadis.2020.166044.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2020.166044</pub-id><pub-id pub-id-type="pmcid">PMC7867637</pub-id><pub-id pub-id-type="pmid">33378699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muniyappa</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Montagnani</surname><given-names>M</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>A</given-names></name><name name-style="western"><surname>Quon</surname><given-names>MJ</given-names></name></person-group><article-title>Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling</article-title><source>Am J Physiol Endocrinol Metab</source><year>2020</year><volume>319</volume><issue>3</issue><fpage>E629</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00247.2020</pub-id><pub-id pub-id-type="pmid">32776829</pub-id><pub-id pub-id-type="pmcid">PMC7642854</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Muniyappa R, Chen H, Montagnani M, Sherman A, Quon MJ. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling. Am J Physiol Endocrinol Metab. 2020;319(3):E629-46. 10.1152/ajpendo.00247.2020.<pub-id pub-id-type="pmid">32776829</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpendo.00247.2020</pub-id><pub-id pub-id-type="pmcid">PMC7642854</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaidya</surname><given-names>RA</given-names></name><name name-style="western"><surname>Desai</surname><given-names>S</given-names></name><name name-style="western"><surname>Moitra</surname><given-names>P</given-names></name><name name-style="western"><surname>Salis</surname><given-names>S</given-names></name><name name-style="western"><surname>Agashe</surname><given-names>S</given-names></name><name name-style="western"><surname>Battalwar</surname><given-names>R</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A</given-names></name><name name-style="western"><surname>Madan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kalita</surname><given-names>S</given-names></name><name name-style="western"><surname>Udipi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>AB</given-names></name></person-group><article-title>Hyperinsulinemia: an early biomarker of metabolic dysfunction</article-title><source>Front Clin Diabetes Healthc</source><year>2023</year><volume>2</volume><issue>4</issue><fpage>1159664</fpage><pub-id pub-id-type="doi">10.3389/fcdhc.2023.1159664</pub-id><pub-id pub-id-type="pmcid">PMC10186728</pub-id><pub-id pub-id-type="pmid">37200851</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Vaidya RA, Desai S, Moitra P, Salis S, Agashe S, Battalwar R, et al. Hyperinsulinemia: an early biomarker of metabolic dysfunction. Front Clin Diabetes Healthc. 2023;2(4):1159664. 10.3389/fcdhc.2023.1159664. (PMID:37200851;PMCID:PMC10186728).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcdhc.2023.1159664</pub-id><pub-id pub-id-type="pmcid">PMC10186728</pub-id><pub-id pub-id-type="pmid">37200851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimobayashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Albert</surname><given-names>V</given-names></name><name name-style="western"><surname>Woelnerhanssen</surname><given-names>B</given-names></name><name name-style="western"><surname>Frei</surname><given-names>IC</given-names></name><name name-style="western"><surname>Weissenberger</surname><given-names>D</given-names></name><name name-style="western"><surname>Meyer-Gerspach</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Insulin resistance causes inflammation in adipose tissue</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><issue>4</issue><fpage>1538</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1172/JCI96139</pub-id><pub-id pub-id-type="pmid">29528335</pub-id><pub-id pub-id-type="pmcid">PMC5873875</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018;128(4):1538–50. 10.1172/JCI96139.<pub-id pub-id-type="pmid">29528335</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI96139</pub-id><pub-id pub-id-type="pmcid">PMC5873875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herman</surname><given-names>ME</given-names></name><name name-style="western"><surname>O’Keefe</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bell</surname><given-names>DSH</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>SS</given-names></name></person-group><article-title>Insulin therapy increases cardiovascular risk in type 2 diabetes</article-title><source>Prog Cardiovasc Dis</source><year>2017</year><volume>60</volume><issue>3</issue><fpage>422</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2017.09.001</pub-id><pub-id pub-id-type="pmid">28958751</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Herman ME, O’Keefe JH, Bell DSH, Schwartz SS. Insulin therapy increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis. 2017;60(3):422–34. 10.1016/j.pcad.2017.09.001.<pub-id pub-id-type="pmid">28958751</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pcad.2017.09.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Lopez</surname><given-names>C</given-names></name><name name-style="western"><surname>Wojeck</surname><given-names>BS</given-names></name></person-group><article-title>Role of metformin in the management of type 2 diabetes: recent advances</article-title><source>Pol Arch Intern Med</source><year>2023</year><volume>133</volume><issue>6</issue><fpage>16511</fpage><pub-id pub-id-type="doi">10.20452/pamw.16511</pub-id><pub-id pub-id-type="pmid">37317976</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Gonzalez-Lopez C, Wojeck BS. Role of metformin in the management of type 2 diabetes: recent advances. Pol Arch Intern Med. 2023;133(6):16511. 10.20452/pamw.16511.<pub-id pub-id-type="pmid">37317976</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.20452/pamw.16511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jia</surname><given-names>R</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>A</given-names></name></person-group><article-title>Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>403</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04263-8</pub-id><pub-id pub-id-type="pmid">37344841</pub-id><pub-id pub-id-type="pmcid">PMC10286395</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Hua Y, Zheng Y, Yao Y, Jia R, Ge S, Zhuang A. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. J Transl Med. 2023;21(1):403. 10.1186/s12967-023-04263-8.<pub-id pub-id-type="pmid">37344841</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04263-8</pub-id><pub-id pub-id-type="pmcid">PMC10286395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ye</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials</article-title><source>BMC Med</source><year>2022</year><volume>20</volume><fpage>402</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02599-4</pub-id><pub-id pub-id-type="pmid">36280839</pub-id><pub-id pub-id-type="pmcid">PMC9594974</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Wen J, Yi Z, Chen Y, Huang J, Mao X, Zhang L, et al. Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials. BMC Med. 2022;20:402. 10.1186/s12916-022-02599-4.<pub-id pub-id-type="pmid">36280839</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-022-02599-4</pub-id><pub-id pub-id-type="pmcid">PMC9594974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O’Connor</surname><given-names>L</given-names></name><name name-style="western"><surname>Bailey-Whyte</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M</given-names></name><name name-style="western"><surname>Butera</surname><given-names>G</given-names></name><name name-style="western"><surname>Hardell</surname><given-names>KNL</given-names></name><name name-style="western"><surname>Seidenberg</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Association of metformin use and cancer incidence: a systematic review and meta-analysis</article-title><source>J Natl Cancer Inst</source><year>2024</year><volume>116</volume><issue>4</issue><fpage>518</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1093/jnci/djae021</pub-id><pub-id pub-id-type="pmid">38291943</pub-id><pub-id pub-id-type="pmcid">PMC10995851</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">O’Connor L, Bailey-Whyte M, Bhattacharya M, Butera G, Hardell KNL, Seidenberg AB, et al. Association of metformin use and cancer incidence: a systematic review and meta-analysis. J Natl Cancer Inst. 2024;116(4):518–29. 10.1093/jnci/djae021.<pub-id pub-id-type="pmid">38291943</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djae021</pub-id><pub-id pub-id-type="pmcid">PMC10995851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms</article-title><source>J Cell Mol Med</source><year>2022</year><volume>26</volume><issue>19</issue><fpage>4886</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1111/jcmm.17519</pub-id><pub-id pub-id-type="pmid">36052760</pub-id><pub-id pub-id-type="pmcid">PMC9549498</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF, et al. Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms. J Cell Mol Med. 2022;26(19):4886–903. 10.1111/jcmm.17519.<pub-id pub-id-type="pmid">36052760</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.17519</pub-id><pub-id pub-id-type="pmcid">PMC9549498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>YR</given-names></name></person-group><article-title>Cardiovascular protection by metformin: latest advances in basic and clinical research</article-title><source>Cardiology</source><year>2023</year><volume>148</volume><issue>4</issue><fpage>374</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1159/000531432</pub-id><pub-id pub-id-type="pmid">37307806</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Li JZ, Li YR. Cardiovascular protection by metformin: latest advances in basic and clinical research. Cardiology. 2023;148(4):374–84. 10.1159/000531432. (Epub 2023 Jun 12 PMID: 37307806).<pub-id pub-id-type="pmid">37307806</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000531432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawood</surname><given-names>AF</given-names></name><name name-style="western"><surname>Alzamil</surname><given-names>NM</given-names></name><name name-style="western"><surname>Hewett</surname><given-names>PW</given-names></name><name name-style="western"><surname>Momenah</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dallak</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamar</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Metformin protects against diabetic cardiomyopathy: an association between desmin-sarcomere injury and the iNOS/mTOR/TIMP-1 fibrosis axis</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><issue>23</issue><fpage>984</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10050984</pub-id><pub-id pub-id-type="pmid">35625721</pub-id><pub-id pub-id-type="pmcid">PMC9139128</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Dawood AF, Alzamil NM, Hewett PW, Momenah MA, Dallak M, Kamar SS, et al. Metformin protects against diabetic cardiomyopathy: an association between desmin-sarcomere injury and the iNOS/mTOR/TIMP-1 fibrosis axis. Biomedicines. 2022;10(23):984. 10.3390/biomedicines10050984.<pub-id pub-id-type="pmid">35625721</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10050984</pub-id><pub-id pub-id-type="pmcid">PMC9139128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>HH</given-names></name><name name-style="western"><surname>Guo</surname><given-names>XL</given-names></name></person-group><article-title>Combinational strategies of metformin and chemotherapy in cancers</article-title><source>Cancer Chemother Pharmacol</source><year>2016</year><volume>78</volume><issue>1</issue><fpage>13</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3037-3</pub-id><pub-id pub-id-type="pmid">27118574</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Zhang HH, Guo XL. Combinational strategies of metformin and chemotherapy in cancers. Cancer Chemother Pharmacol. 2016;78(1):13–26. 10.1007/s00280-016-3037-3. (Epub 2016 Apr 27 PMID: 27118574).<pub-id pub-id-type="pmid">27118574</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-016-3037-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Khayat</surname><given-names>SM</given-names></name><name name-style="western"><surname>Abouegylah</surname><given-names>M</given-names></name><name name-style="western"><surname>Abdallah</surname><given-names>D</given-names></name><name name-style="western"><surname>Geweil</surname><given-names>AG</given-names></name><name name-style="western"><surname>Elenbaby</surname><given-names>AM</given-names></name><name name-style="western"><surname>Zahra</surname><given-names>OS</given-names></name></person-group><article-title>The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients</article-title><source>Med Oncol</source><year>2021</year><volume>39</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1007/s12032-021-01599-3</pub-id><pub-id pub-id-type="pmid">34739637</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">El-Khayat SM, Abouegylah M, Abdallah D, Geweil AG, Elenbaby AM, Zahra OS. The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients. Med Oncol. 2021;39(1):1. 10.1007/s12032-021-01599-3.<pub-id pub-id-type="pmid">34739637</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12032-021-01599-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>B</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AM</given-names></name><name name-style="western"><surname>Denduluri</surname><given-names>S</given-names></name><name name-style="western"><surname>Carver</surname><given-names>J</given-names></name><etal/></person-group><article-title>&lt;article-title update="added"&gt;The association of metformin with heart failure in patients with diabetes mellitus receiving anthracycline chemotherapy</article-title><source>JACC: CardioOncology</source><year>2023</year><volume>5</volume><issue>5</issue><fpage>674</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2023.05.013</pub-id><pub-id pub-id-type="pmid">37969650</pub-id><pub-id pub-id-type="pmcid">PMC10635887</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Onoue T, Kang Y, Lefebvre B, Smith AM, Denduluri S, Carver J, et al. &lt;article-title update="added"&gt;The association of metformin with heart failure in patients with diabetes mellitus receiving anthracycline chemotherapy. JACC: CardioOncology. 2023;5(5):674–82. 10.1016/j.jaccao.2023.05.013.<pub-id pub-id-type="pmid">37969650</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaccao.2023.05.013</pub-id><pub-id pub-id-type="pmcid">PMC10635887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inzucchi</surname><given-names>SE</given-names></name><name name-style="western"><surname>Lipska</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>H</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>CJ</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>DK</given-names></name></person-group><article-title>Metformin in patients with type 2 diabetes and kidney disease: a systematic review</article-title><source>JAMA</source><year>2014</year><volume>312</volume><issue>24</issue><fpage>2668</fpage><lpage>2675</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.15298</pub-id><pub-id pub-id-type="pmid">25536258</pub-id><pub-id pub-id-type="pmcid">PMC4427053</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75. 10.1001/jama.2014.15298.<pub-id pub-id-type="pmid">25536258</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.15298</pub-id><pub-id pub-id-type="pmcid">PMC4427053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeFronzo</surname><given-names>R</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>GA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Bicsak</surname><given-names>TA</given-names></name></person-group><article-title>Metformin-associated lactic acidosis: current perspectives on causes and risk</article-title><source>Metabolism</source><year>2016</year><volume>65</volume><issue>2</issue><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2015.10.014</pub-id><pub-id pub-id-type="pmid">26773926</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20–9. 10.1016/j.metabol.2015.10.014.<pub-id pub-id-type="pmid">26773926</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2015.10.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Król</surname><given-names>M</given-names></name><name name-style="western"><surname>Kupnicka</surname><given-names>P</given-names></name><name name-style="western"><surname>Żychowska</surname><given-names>J</given-names></name><name name-style="western"><surname>Kapczuk</surname><given-names>P</given-names></name><name name-style="western"><surname>Szućko-Kociuba</surname><given-names>I</given-names></name><name name-style="western"><surname>Prajwos</surname><given-names>E</given-names></name><etal/></person-group><article-title>Molecular insights into the potential cardiometabolic effects of GLP-1 receptor analogs and DPP-4 inhibitors</article-title><source>Int J Mol Sci</source><year>2025</year><volume>26</volume><issue>14</issue><fpage>6777</fpage><pub-id pub-id-type="doi">10.3390/ijms26146777</pub-id><pub-id pub-id-type="pmid">40725024</pub-id><pub-id pub-id-type="pmcid">PMC12295648</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Król M, Kupnicka P, Żychowska J, Kapczuk P, Szućko-Kociuba I, Prajwos E, et al. Molecular insights into the potential cardiometabolic effects of GLP-1 receptor analogs and DPP-4 inhibitors. Int J Mol Sci. 2025;26(14):6777. 10.3390/ijms26146777.<pub-id pub-id-type="pmid">40725024</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms26146777</pub-id><pub-id pub-id-type="pmcid">PMC12295648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biondi</surname><given-names>F</given-names></name><name name-style="western"><surname>Madonna</surname><given-names>R</given-names></name></person-group><article-title>The potential role of GLP1-RAs against anticancer-drug cardiotoxicity: a scoping review</article-title><source>J Clin Med</source><year>2025</year><volume>14</volume><issue>8</issue><fpage>2705</fpage><pub-id pub-id-type="doi">10.3390/jcm14082705</pub-id><pub-id pub-id-type="pmid">40283534</pub-id><pub-id pub-id-type="pmcid">PMC12027986</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Biondi F, Madonna R. The potential role of GLP1-RAs against anticancer-drug cardiotoxicity: a scoping review. J Clin Med. 2025;14(8):2705. 10.3390/jcm14082705.<pub-id pub-id-type="pmid">40283534</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm14082705</pub-id><pub-id pub-id-type="pmcid">PMC12027986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>152</volume><fpage>113236</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113236</pub-id><pub-id pub-id-type="pmid">35691154</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Yang F, Luo X, Li J, Lei Y, Zeng F, Huang X, et al. Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. Biomed Pharmacother. 2022;152:113236. 10.1016/j.biopha.2022.113236.<pub-id pub-id-type="pmid">35691154</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2022.113236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosiborod</surname><given-names>MN</given-names></name><name name-style="western"><surname>Abildstrøm</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Borlaug</surname><given-names>BA</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>S</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M</given-names></name><etal/></person-group><article-title>Semaglutide in patients with heart failure with preserved ejection fraction and obesity</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>12</issue><fpage>1069</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2306963</pub-id><pub-id pub-id-type="pmid">37622681</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84. 10.1056/NEJMoa2306963. (PMID: 37622681).<pub-id pub-id-type="pmid">37622681</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2306963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosiborod</surname><given-names>MN</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>MC</given-names></name><name name-style="western"><surname>Borlaug</surname><given-names>BA</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name><name name-style="western"><surname>Davies</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hovingh</surname><given-names>GK</given-names></name><etal/></person-group><article-title>Semaglutide in patients with obesity-related heart failure and type 2 diabetes</article-title><source>N Engl J Med</source><year>2024</year><volume>390</volume><issue>15</issue><fpage>1394</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2313917</pub-id><pub-id pub-id-type="pmid">38587233</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–407. 10.1056/NEJMoa2313917. (PMID: 38587233).<pub-id pub-id-type="pmid">38587233</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2313917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margulies</surname><given-names>KB</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>AF</given-names></name><name name-style="western"><surname>Redfield</surname><given-names>MM</given-names></name><name name-style="western"><surname>Givertz</surname><given-names>MM</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>GH</given-names></name><name name-style="western"><surname>Cole</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction (FIGHT)</article-title><source>JAMA</source><year>2016</year><volume>316</volume><issue>5</issue><fpage>500</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.10260</pub-id><pub-id pub-id-type="pmid">27483064</pub-id><pub-id pub-id-type="pmcid">PMC5021525</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction (FIGHT). JAMA. 2016;316(5):500–8. 10.1001/jama.2016.10260. (PMID: 27483064).<pub-id pub-id-type="pmid">27483064</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.10260</pub-id><pub-id pub-id-type="pmcid">PMC5021525</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busek</surname><given-names>P</given-names></name><name name-style="western"><surname>Duke-Cohan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Sedo</surname><given-names>A</given-names></name></person-group><article-title>Does DPP-IV inhibition offer new avenues for therapeutic intervention in malignant disease?</article-title><source>Cancers (Basel)</source><year>2022</year><volume>14</volume><issue>9</issue><fpage>2072</fpage><pub-id pub-id-type="doi">10.3390/cancers14092072</pub-id><pub-id pub-id-type="pmid">35565202</pub-id><pub-id pub-id-type="pmcid">PMC9103952</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Busek P, Duke-Cohan JS, Sedo A. Does DPP-IV inhibition offer new avenues for therapeutic intervention in malignant disease? Cancers (Basel). 2022;14(9):2072. 10.3390/cancers14092072.<pub-id pub-id-type="pmid">35565202</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14092072</pub-id><pub-id pub-id-type="pmcid">PMC9103952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Men</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Cai</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis</article-title><source>Lipids Health Dis</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/s12944-019-1086-4</pub-id><pub-id pub-id-type="pmid">31208420</pub-id><pub-id pub-id-type="pmcid">PMC6580696</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):144. 10.1186/s12944-019-1086-4.<pub-id pub-id-type="pmid">31208420</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12944-019-1086-4</pub-id><pub-id pub-id-type="pmcid">PMC6580696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>I</given-names></name><name name-style="western"><surname>Anker</surname><given-names>SD</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>AYY</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis</article-title><source>The Lancet Diabetes &amp; Endocrinology</source><year>2024</year><volume>12</volume><issue>7</issue><fpage>447</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(24)00102-5</pub-id><pub-id pub-id-type="pmid">38768620</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. The Lancet Diabetes &amp; Endocrinology. 2024;12(7):447–61. 10.1016/S2213-8587(24)00102-5.<pub-id pub-id-type="pmid">38768620</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(24)00102-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adrita</surname><given-names>S</given-names></name><name name-style="western"><surname>Bacsa</surname><given-names>J</given-names></name></person-group><article-title>A systematic review of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the management of heart failure: a comprehensive analysis of cardiovascular outcomes, hospitalizations, and quality of life</article-title><source>Cureus</source><year>2025</year><volume>17</volume><issue>6</issue><fpage>e86784</fpage><pub-id pub-id-type="doi">10.7759/cureus.86784</pub-id><pub-id pub-id-type="pmid">40718194</pub-id><pub-id pub-id-type="pmcid">PMC12296870</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Adrita S, Bacsa J. A systematic review of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the management of heart failure: a comprehensive analysis of cardiovascular outcomes, hospitalizations, and quality of life. Cureus. 2025;17(6):e86784. 10.7759/cureus.86784. (<bold>PMID:40718194;PMCID:PMC12296870</bold>).<pub-id pub-id-type="pmid">40718194</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.86784</pub-id><pub-id pub-id-type="pmcid">PMC12296870</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina-Hernández</surname><given-names>D</given-names></name><name name-style="western"><surname>Cádiz</surname><given-names>L</given-names></name><name name-style="western"><surname>Mastrangelo</surname><given-names>A</given-names></name><name name-style="western"><surname>Moreno-Arciniegas</surname><given-names>A</given-names></name><name name-style="western"><surname>Fernández Tocino</surname><given-names>M</given-names></name><name name-style="western"><surname>Cueto Becerra</surname><given-names>AA</given-names></name><name name-style="western"><surname>Díaz-Guerra Priego</surname><given-names>A</given-names></name><name name-style="western"><surname>Skoza</surname><given-names>WA</given-names></name><name name-style="western"><surname>Higuero-Verdejo</surname><given-names>MI</given-names></name><name name-style="western"><surname>López-Martín</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Pérez-Martínez</surname><given-names>C</given-names></name><name name-style="western"><surname>de Molina-Iracheta</surname><given-names>A</given-names></name><name name-style="western"><surname>Caballero-Valderrama</surname><given-names>M</given-names></name><name name-style="western"><surname>Sánchez-González</surname><given-names>J</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>V</given-names></name><name name-style="western"><surname>Galán-Arriola</surname><given-names>C</given-names></name><name name-style="western"><surname>Ibáñez</surname><given-names>B</given-names></name></person-group><article-title>SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics</article-title><source>JACC: CardioOncology</source><year>2025</year><volume>7</volume><issue>2</issue><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2024.12.004</pub-id><pub-id pub-id-type="pmid">39967204</pub-id><pub-id pub-id-type="pmcid">PMC11866421</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Medina-Hernández D, Cádiz L, Mastrangelo A, Moreno-Arciniegas A, Fernández Tocino M, Cueto Becerra AA, et al. SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics. JACC: CardioOncology. 2025;7(2):171–84. 10.1016/j.jaccao.2024.12.004.<pub-id pub-id-type="pmid">39967204</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaccao.2024.12.004</pub-id><pub-id pub-id-type="pmcid">PMC11866421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiviott</surname><given-names>SD</given-names></name><name name-style="western"><surname>Berg</surname><given-names>DD</given-names></name></person-group><article-title>SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death: clarity and consistency</article-title><source>J Am Coll Cardiol</source><year>2023</year><volume>81</volume><issue>25</issue><fpage>2388</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2023.04.035</pub-id><pub-id pub-id-type="pmid">37344039</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Wiviott SD, Berg DD. SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death: clarity and consistency. J Am Coll Cardiol. 2023;81(25):2388–90. 10.1016/j.jacc.2023.04.035.<pub-id pub-id-type="pmid">37344039</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2023.04.035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avula</surname><given-names>V</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>G</given-names></name><name name-style="western"><surname>Kosiborod</surname><given-names>MN</given-names></name><name name-style="western"><surname>Vaduganathan</surname><given-names>M</given-names></name><name name-style="western"><surname>Neilan</surname><given-names>TG</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>T</given-names></name><etal/></person-group><article-title>SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction</article-title><source>JACC: Heart Failure</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2023.08.026</pub-id><pub-id pub-id-type="pmid">37897456</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC: Heart Failure. 2024;12(1):67–78. 10.1016/j.jchf.2023.08.026.<pub-id pub-id-type="pmid">37897456</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jchf.2023.08.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatti</surname><given-names>AW</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R</given-names></name><name name-style="western"><surname>Dani</surname><given-names>SS</given-names></name><name name-style="western"><surname>Khadke</surname><given-names>S</given-names></name><name name-style="western"><surname>Makwana</surname><given-names>B</given-names></name><name name-style="western"><surname>Lessey</surname><given-names>C</given-names></name><etal/></person-group><article-title>SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes</article-title><source>JACC: CardioOncology</source><year>2024</year><volume>6</volume><issue>6</issue><fpage>863</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2024.08.001</pub-id><pub-id pub-id-type="pmid">39801650</pub-id><pub-id pub-id-type="pmcid">PMC11711834</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Bhatti AW, Patel R, Dani SS, Khadke S, Makwana B, Lessey C, et al. SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes. JACC: CardioOncology. 2024;6(6):863–75. 10.1016/j.jaccao.2024.08.001.<pub-id pub-id-type="pmid">39801650</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaccao.2024.08.001</pub-id><pub-id pub-id-type="pmcid">PMC11711834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniele</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gregorietti</surname><given-names>V</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D</given-names></name><name name-style="western"><surname>López-Fernández</surname><given-names>T</given-names></name></person-group><article-title>Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - pilot trial</article-title><source>Cardio-Oncology</source><year>2024</year><volume>10</volume><issue>1</issue><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s40959-024-00260-y</pub-id><pub-id pub-id-type="pmid">39237985</pub-id><pub-id pub-id-type="pmcid">PMC11375926</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Daniele AJ, Gregorietti V, Costa D, López-Fernández T. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - pilot trial. Cardio-Oncology. 2024;10(1):58. 10.1186/s40959-024-00260-y.<pub-id pub-id-type="pmid">39237985</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40959-024-00260-y</pub-id><pub-id pub-id-type="pmcid">PMC11375926</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis</article-title><source>Toxicol Res</source><year>2023</year><volume>12</volume><issue>2</issue><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1093/toxres/tfad007</pub-id><pub-id pub-id-type="pmcid">PMC10141765</pub-id><pub-id pub-id-type="pmid">37125336</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Chen M. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis. Toxicol Res. 2023;12(2):216–23. 10.1093/toxres/tfad007.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxres/tfad007</pub-id><pub-id pub-id-type="pmcid">PMC10141765</pub-id><pub-id pub-id-type="pmid">37125336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name></person-group><article-title>Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis</article-title><source>J Endocrinol Invest</source><year>2024</year><volume>47</volume><issue>10</issue><fpage>2421</fpage><lpage>2436</lpage><pub-id pub-id-type="doi">10.1007/s40618-024-02351-0</pub-id><pub-id pub-id-type="pmid">38530620</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Xu B, Kang B, Li S, Fan S, Zhou J. Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis. J Endocrinol Invest. 2024;47(10):2421–36. 10.1007/s40618-024-02351-0.<pub-id pub-id-type="pmid">38530620</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40618-024-02351-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautier</surname><given-names>P</given-names></name><name name-style="western"><surname>Elbaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouisset</surname><given-names>F</given-names></name><name name-style="western"><surname>Despas</surname><given-names>F</given-names></name><name name-style="western"><surname>Montastruc</surname><given-names>F</given-names></name></person-group><article-title>Investigating risk of cancer with sodium-glucose cotransporter 2 inhibitors: a disproportionality analysis in the WHO global pharmacovigilance database Vigibase®</article-title><source>Drug Saf</source><year>2025</year><volume>48</volume><issue>8</issue><fpage>933</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1007/s40264-025-01546-5</pub-id><pub-id pub-id-type="pmid">40232585</pub-id><pub-id pub-id-type="pmcid">PMC12259762</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Gautier P, Elbaz M, Bouisset F, Despas F, Montastruc F. Investigating risk of cancer with sodium-glucose cotransporter 2 inhibitors: a disproportionality analysis in the WHO global pharmacovigilance database Vigibase®. Drug Saf. 2025;48(8):933–41. 10.1007/s40264-025-01546-5.<pub-id pub-id-type="pmid">40232585</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-025-01546-5</pub-id><pub-id pub-id-type="pmcid">PMC12259762</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><mixed-citation publication-type="other">Bao Y, Liu J, Liu X, et al. SGLT2 inhibitors reduce epicardial adipose tissue more than other therapies: a network meta-analysis. <italic toggle="yes">Diabetes Obes Metab.</italic> 2024;26(12):-. 10.1111/dom.16107.</mixed-citation></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cinti</surname><given-names>F</given-names></name><name name-style="western"><surname>Falcioni</surname><given-names>S</given-names></name><name name-style="western"><surname>Anselmi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes</article-title><source>Cardiovasc Diabetol</source><year>2023</year><volume>22</volume><fpage>312</fpage><pub-id pub-id-type="doi">10.1186/s12933-023-02091-0</pub-id><pub-id pub-id-type="pmid">38115004</pub-id><pub-id pub-id-type="pmcid">PMC10731727</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Cinti F, Falcioni S, Anselmi A, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:312. 10.1186/s12933-023-02091-0.<pub-id pub-id-type="pmid">38115004</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-023-02091-0</pub-id><pub-id pub-id-type="pmcid">PMC10731727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kounatidis</surname><given-names>D</given-names></name><name name-style="western"><surname>Kounatidis</surname><given-names>I</given-names></name><name name-style="western"><surname>Efthimiou</surname><given-names>G</given-names></name><etal/></person-group><article-title>SGLT-2 inhibitors and the inflammasome</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>9</issue><fpage>8137</fpage><pub-id pub-id-type="doi">10.3390/ijms24098137</pub-id><pub-id pub-id-type="pmid">37175849</pub-id><pub-id pub-id-type="pmcid">PMC10179305</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Kounatidis D, Kounatidis I, Efthimiou G, et al. SGLT-2 inhibitors and the inflammasome. Int J Mol Sci. 2023;24(9):8137. 10.3390/ijms24098137.<pub-id pub-id-type="pmid">37175849</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24098137</pub-id><pub-id pub-id-type="pmcid">PMC10179305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><mixed-citation publication-type="other">Corrigendum to: 2024 EACTS Guidelines on perioperative medication in adult cardiac surgery, European Journal of Cardio-Thoracic Surgery, Volume 67, Issue 5, May 2025, ezaf169, 10.1093/ejcts/ezaf169<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ejcts/ezaf169</pub-id><pub-id pub-id-type="pmid">40411894</pub-id></mixed-citation></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eigl</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Elangovan</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JO</given-names></name><name name-style="western"><surname>Thoms</surname><given-names>J</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>M</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>M</given-names></name><name name-style="western"><surname>Fleshner</surname><given-names>N</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>H</given-names></name><name name-style="western"><surname>Vigneault</surname><given-names>E</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>F</given-names></name><name name-style="western"><surname>So</surname><given-names>A</given-names></name><name name-style="western"><surname>Cury</surname><given-names>F</given-names></name><name name-style="western"><surname>Quon</surname><given-names>H</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>R</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>C</given-names></name><name name-style="western"><surname>Klotz</surname><given-names>L</given-names></name><name name-style="western"><surname>Chi</surname><given-names>K</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>M</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>M</given-names></name><name name-style="western"><surname>Rebane</surname><given-names>L</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>L</given-names></name><name name-style="western"><surname>Courneya</surname><given-names>KS</given-names></name><name name-style="western"><surname>Usmani</surname><given-names>N</given-names></name></person-group><article-title>A randomized phase 3 trial of metformin in patients initiating androgen deprivation therapy as prevention and intervention of metabolic syndrome: the PRIME study</article-title><source>J Urol</source><year>2025</year><volume>214</volume><issue>5</issue><fpage>496</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1097/JU.0000000000004695</pub-id><pub-id pub-id-type="pmid">40711960</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Eigl BJ, Elangovan A, Ghosh S, Kim JO, Thoms J, Bouchard M, et al. A randomized phase 3 trial of metformin in patients initiating androgen deprivation therapy as prevention and intervention of metabolic syndrome: the PRIME study. J Urol. 2025;214(5):496–508. 10.1097/JU.0000000000004695. (<bold>Epub 2025 Jul 25 PMID: 40711960</bold>).<pub-id pub-id-type="pmid">40711960</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JU.0000000000004695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><mixed-citation publication-type="other">Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy (GAIN PC CONTROL). ClinicalTrials.gov identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06908694">NCT06908694</ext-link>. Bethesda (MD): National Library of Medicine (US); 2025 Jul 29</mixed-citation></ref><ref id="CR179"><label>179.</label><mixed-citation publication-type="other">Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y, Connell B, Upadhyay J, Dani SS, Hahn AW, Logothetis CJ, Al-Kindi S, Butler J, Nohria A, Ganatra S, Deswal A. Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Cardiovasc Drugs Ther. 2024 Nov 11. 10.1007/s10557-024-07646-1. Epub ahead of print. PMID: 39527237.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10557-024-07646-1</pub-id><pub-id pub-id-type="pmid">39527237</pub-id></mixed-citation></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Averina</surname><given-names>M</given-names></name><name name-style="western"><surname>Stylidis</surname><given-names>M</given-names></name><name name-style="western"><surname>Brox</surname><given-names>J</given-names></name><name name-style="western"><surname>Schirmer</surname><given-names>H</given-names></name></person-group><article-title>NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population</article-title><source>ESC Heart Fail</source><year>2022</year><volume>9</volume><issue>3</issue><fpage>1954</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13906</pub-id><pub-id pub-id-type="pmid">35322586</pub-id><pub-id pub-id-type="pmcid">PMC9065856</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Averina M, Stylidis M, Brox J, Schirmer H. NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population. ESC Heart Fail. 2022;9(3):1954–62. 10.1002/ehf2.13906.<pub-id pub-id-type="pmid">35322586</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ehf2.13906</pub-id><pub-id pub-id-type="pmcid">PMC9065856</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article id="ijbm5521416" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Biomater</journal-id><journal-id journal-id-type="iso-abbrev">Int J Biomater</journal-id><journal-id journal-id-type="pmc-domain-id">1118</journal-id><journal-id journal-id-type="pmc-domain">ijbm</journal-id><journal-id journal-id-type="publisher-id">IJBM</journal-id><journal-title-group><journal-title>International Journal of Biomaterials</journal-title></journal-title-group><issn pub-type="ppub">1687-8787</issn><issn pub-type="epub">1687-8795</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12911526</article-id><article-id pub-id-type="pmcid-ver">PMC12911526.1</article-id><article-id pub-id-type="pmcaid">12911526</article-id><article-id pub-id-type="pmcaiid">12911526</article-id><article-id pub-id-type="doi">10.1155/ijbm/5521416</article-id><article-id pub-id-type="publisher-id">IJBM5521416</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Bio‐Assisted Synthesis of Reduced Graphene Oxide Nanosheets From Graphene Oxide: Promising and Efficient Cytotoxic and Antidiabetic Potency in In Vitro, Kinetic, and In Silico Models</article-title></title-group><contrib-group><contrib id="cr-0001" contrib-type="author"><name name-style="western"><surname>Yadav</surname><given-names initials="M">Mansi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4536-5754</contrib-id><xref rid="aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cr-0002" contrib-type="author"><name name-style="western"><surname>Vashishth</surname><given-names initials="D">Divya</given-names></name><xref rid="aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cr-0003" contrib-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names initials="M">Monika</given-names></name><xref rid="aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cr-0004" contrib-type="author"><name name-style="western"><surname>Yadav</surname><given-names initials="JP">Jaya Parkash</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3500-6811</contrib-id><xref rid="aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Kataria</surname><given-names initials="SK">Sudhir Kumar</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2768-1964</contrib-id><xref rid="aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>sudhir.zoology24@mdurohtak.ac.in</email></address></contrib></contrib-group><contrib-group><contrib id="cr-0006" contrib-type="editor"><name name-style="western"><surname>Durairaj</surname><given-names initials="K">Kaliannan</given-names></name><address><email>kmdurairaj@gmail.com</email></address></contrib></contrib-group><aff id="aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Zoology</named-content>, <named-content content-type="organisation-division">Ramjas College</named-content>, <institution>University of Delhi</institution>, <city>Delhi</city>, <postal-code>110007</postal-code>, <country>India</country>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://du.ac.in" ext-link-type="uri">du.ac.in</ext-link>
</aff><aff id="aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Zoology</named-content>, <institution>Maharshi Dayanand University</institution>, <city>Rohtak</city>, Haryana, <postal-code>124001</postal-code>, <country>India</country>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://mdurohtak.ac.in" ext-link-type="uri">mdurohtak.ac.in</ext-link>
</aff><aff id="aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Government Girls Senior Secondary School</institution>, Rurki, <city>Rohtak</city>, Haryana, <postal-code>124001</postal-code>, <country>India</country>
</aff><aff id="aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Genetics</named-content>, <institution>Maharshi Dayanand University</institution>, <city>Rohtak</city>, Haryana, <postal-code>124001</postal-code>, <country>India</country>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://mdurohtak.ac.in" ext-link-type="uri">mdurohtak.ac.in</ext-link>
</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>2026</volume><issue-id pub-id-type="pmc-issue-id">504936</issue-id><elocation-id>5521416</elocation-id><history><date date-type="rev-recd"><day>17</day><month>12</month><year>2025</year></date><date date-type="received"><day>04</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>18</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 10:25:12.893"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">Copyright © 2026 Mansi Yadav et al. International Journal of Biomaterials published by John Wiley &amp; Sons Ltd.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IJBM-2026-5521416.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:IJBM-2026-5521416.pdf"/><abstract><p>Green chemistry has recently made strides in the sustainable synthesis of next‐generation nanomaterials using reducing agents sourced from plants. Biocompatible conversion of reduced graphene oxide from graphene oxide nanomaterials is of particular interest in medical applications. The leaf extract of <italic toggle="yes">C. igneus</italic> functions as a reducing agent to produce reduced graphene oxide nanosheets from its precursor graphene oxide. A variety of characterization techniques were employed to confirm the formation and stability of reduced graphene oxide nanosheets. The cytotoxicity and glucose uptake potential of nanosheets have been evaluated through in vitro cell‐based assays. The MTT assay revealed a concentration‐dependent cytotoxic effect on Chang liver and U87MG cells, with maximum 84.5% and 76.3% cell viability, respectively. Reduced graphene oxide exhibited a significant rise in glucose uptake, comparable to the metformin drug, with increasing concentration. Enhanced glucose transport mediated by the nanosheets resulted in increased glucose uptake. Effective IC<sub>50</sub> values of 84.46 μg·mL<sup>−1</sup> and 93.83 μg·mL<sup>−1</sup> were obtained in vitro enzyme inhibition studies against α‐amylase and α‐glucosidase, respectively. The enzyme kinetic investigation found noncompetitive inhibition for both enzymes. Molecular docking studies of <italic toggle="yes">C. igneus</italic> leaf derivatives were performed against α‐amylase and α‐glucosidase. Corosolic acid was selected based on favorable docking scores, binding interactions, and low root‐mean‐square deviation and was subjected to molecular dynamics simulations, which confirmed the stability of the resulting complex. This study concludes that reduced graphene oxide nanosheets derived from <italic toggle="yes">C. igneus</italic> leaves represent a novel antidiabetic agent that can reduce blood glucose levels and mitigate the complications associated with Type II diabetes.</p></abstract><kwd-group><title>Keywords</title><kwd id="kwd-0001">α-amylase</kwd><kwd id="kwd-0002">α-glucosidase</kwd><kwd id="kwd-0003"><italic toggle="yes">Costus igneus</italic></kwd><kwd id="kwd-0004">glucose uptake assay</kwd><kwd id="kwd-0005">MTT assay</kwd><kwd id="kwd-0006">reduced graphene oxide</kwd></kwd-group><counts><fig-count count="47"/><table-count count="4"/><ref-count count="76"/><page-count count="26"/><word-count count="13337"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:17.02.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ijbm5521416-cit-2001">
<string-name name-style="western">
<surname>Yadav</surname>, <given-names>Mansi</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Vashishth</surname>, <given-names>Divya</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Bhardwaj</surname>, <given-names>Monika</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yadav</surname>, <given-names>Jaya Parkash</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kataria</surname>, <given-names>Sudhir Kumar</given-names>
</string-name>, 
<article-title>Bio‐Assisted Synthesis of Reduced Graphene Oxide Nanosheets From Graphene Oxide: Promising and Efficient Cytotoxic and Antidiabetic Potency in In Vitro, Kinetic, and In Silico Models</article-title>, 
<source>International Journal of Biomaterials</source>, <volume>2026</volume>, <elocation-id>5521416</elocation-id>, 26 pages, <year>2026</year>. 
<pub-id pub-id-type="doi">10.1155/ijbm/5521416</pub-id>
</mixed-citation>
</p><fn-group><fn id="note-0001"><p>
<bold>Academic Editor:</bold> Kaliannan Durairaj</p></fn></fn-group></notes></front><body><sec id="sec-0001"><title>1. Introduction</title><p>The worldwide incidence of Type 2 diabetes mellitus (T2DM) is escalating rapidly, accounting for 90%–95% of all diabetes cases globally. This tendency is primarily influenced by alterations in lifestyle and socioeconomic factors, including diminished physical activity and heightened intake of high‐fat, high‐carbohydrate meals [<xref rid="bib-0001" ref-type="bibr">1</xref>]. Hyperglycemia is a fundamental characteristic of T2DM and significantly contributes to the majority of the disease’s pathogenic processes. It transpires when insulin sensitivity diminishes or insulin secretion from pancreatic β‐cells is compromised, which can subsequently inhibit insulin production and restrict glucose uptake in peripheral tissues. An essential approach to manage hyperglycemia entails the carbohydrate digestive enzymes inhibition, i.e., α‐amylase and α‐glucosidase, which are also pivotal in averting diabetes complications. Enzyme inhibitors impede carbohydrate breakdown, thereby diminishing glucose absorption from the small intestine and decreasing postprandial blood glucose levels. Therefore, the treatment and management of hyperglycemia and T2DM depend heavily on the repression of α‐amylase and α‐glucosidase [<xref rid="bib-0002" ref-type="bibr">2</xref>, <xref rid="bib-0003" ref-type="bibr">3</xref>]. Currently, numerous commonly prescribed amylolytic enzyme blockers, including acarbose, miglitol, and voglibose, are available; nonetheless, these pharmaceuticals are linked to adverse effects including flatulence, diarrhea, and abdominal discomfort, which may be intolerable for patients. This underscores the urgent necessity for the creation of novel alternatives. Enhanced therapeutic outcomes may be attained with medicines that specifically block α‐amylase and α‐glucosidase, ensuring nontoxicity to target cells while efficiently diminishing postprandial hyperglycemia. Ideally, substances derived from natural sources like medicinal plants would show substantial repression of α‐glucosidase and modest repression of α‐amylase [<xref rid="bib-0004" ref-type="bibr">4</xref>]. The integration of plant‐based alternatives in medicine is influenced by various critical aspects, including their therapeutic efficacy, cost‐effectiveness, and the growing inclination toward natural therapies. These reasons significantly contribute to the increasing incorporation of herbal medicines into conventional healthcare systems [<xref rid="bib-0005" ref-type="bibr">5</xref>, <xref rid="bib-0006" ref-type="bibr">6</xref>]. Notwithstanding these advantages, obstacles remain, particularly the necessity for comprehensive scientific validation and the standardization of herbal products to ensure their safety and efficacy. Certain plants possess potentially poisonous or carcinogenic compounds, making them inappropriate for medicinal use. Consequently, it is vital to perform thorough investigations into their cytotoxicity to validate their safety and to endorse the ongoing utilization of these therapeutic plants. The utilization of biological components and plant extracts to transform inorganic compounds into nanoparticles over the past 3 decades has attracted a lot of interest [<xref rid="bib-0007" ref-type="bibr">7</xref>].</p><p>Graphene is a monolayer‐thick honeycomb lattice of highly arranged sp2‐hybridized carbon atoms in six‐membered rings. This material boasts amazing features, including a huge surface area (∼2600 m<sup>2</sup>/g) [<xref rid="bib-0008" ref-type="bibr">8</xref>], light weight [<xref rid="bib-0009" ref-type="bibr">9</xref>], chemical stability [<xref rid="bib-0010" ref-type="bibr">10</xref>], and strong electron mobility (200,000 cm<sup>2</sup>·V<sup>−1</sup>·s<sup>−1</sup>) [<xref rid="bib-0011" ref-type="bibr">11</xref>], good mechanical and optical properties [<xref rid="bib-0012" ref-type="bibr">12</xref>], good transparency, good impermeability [<xref rid="bib-0013" ref-type="bibr">13</xref>], and good photocatalytic activity [<xref rid="bib-0014" ref-type="bibr">14</xref>]. The synthesis of graphene has been accomplished by a number of novel synthetic processes. The procedures include chemicals like NaBH<sub>4</sub> or hydrazine, which are extremely hazardous and can cause side effects in trace amounts. There are a lot of biological and environmental uses for rGO; however, this prevents them from being used. Therefore, there has to be continuous work to develop a method for synthesizing rGO that is safe for the environment and uses a nontoxic reductant [<xref rid="bib-0015" ref-type="bibr">15</xref>]. Graphene researchers are currently focusing on this process, which is known as biosynthesis or green synthesis. A literature review indicates that rGO has been synthesized utilizing an extensive array of naturally produced materials, including vitamin C [<xref rid="bib-0016" ref-type="bibr">16</xref>], saccharides [<xref rid="bib-0017" ref-type="bibr">17</xref>], carrot roots [<xref rid="bib-0018" ref-type="bibr">18</xref>], amino acids [<xref rid="bib-0019" ref-type="bibr">19</xref>, <xref rid="bib-0020" ref-type="bibr">20</xref>], and polyphenols from tea [<xref rid="bib-0021" ref-type="bibr">21</xref>]. In light of these methodologies, a straightforward and practical approach to synthesize rGO with <italic toggle="yes">Costus igneus</italic> leaf extract as the reducing agent was done.</p><p>A member of the family Costaceae, <italic toggle="yes">C. igneus</italic> (Figure <xref rid="fig-0001" ref-type="fig">1</xref>) goes by several names, including fiery <italic toggle="yes">costus</italic>, step ladder, and spiral flag. This plant originally hails from Central and South America. It is a tall, spreading perennial with spirally arranged leaves and the tallest stems measuring around two feet. Its leaves are used by indigenous people in India to control diabetes, and it is widely grown in gardens [<xref rid="bib-0022" ref-type="bibr">22</xref>]. The phytochemicals present in plants have been the subject of much research due to their importance in traditional medicine. These phytochemicals include alkaloids, flavonoids, saponins, tannins, terpenoids, glycosides, and phenolic compounds [<xref rid="bib-0023" ref-type="bibr">23</xref>, <xref rid="bib-0024" ref-type="bibr">24</xref>].</p><fig position="float" fig-type="Figure" id="fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>
<italic toggle="yes">Costus igneus</italic> plant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="IJBM-2026-5521416-g001.jpg"/></fig><p>Nanoscience, characterized by its diminutive scale, capacity to facilitate drug delivery across biomembranes, and biocompatibility, has recently garnered significant interest in antidiabetic research. Notwithstanding the extensive application of this plant in traditional medicine, its biological and pharmacological properties remain largely unknown. This study investigates the antidiabetic efficacy of <italic toggle="yes">C. igneus</italic> leaf extract and its associated rGO nanosheets through in vitro, kinetic, and in silico models.</p></sec><sec id="sec-0002"><title>2. Materials and Methods</title><sec id="sec-0003"><title>2.1. Acquisition of Plant Material</title><p>From Kanha Shanti Vanam, Hyderabad, India, leaves of the <italic toggle="yes">C. igneus</italic> plant were acquired. The plant leaves have been found and confirmed by former Chief Scientist Dr. Sunita Garg and Head of the Raw Material Herbarium and Museum at CSIR‐NIScPR, Delhi, Mr. R.S. Jayasomu.</p></sec><sec id="sec-0004"><title>2.2. Elicitation of Phytochemicals</title><p>A slightly altered version of the conventional method described for other leaf extracts was used to prepare the <italic toggle="yes">C. igneus</italic> leaf aqueous extract (Aq‐CI) [<xref rid="bib-0025" ref-type="bibr">25</xref>, <xref rid="bib-0026" ref-type="bibr">26</xref>]. The leaves were rinsed under a faucet to eradicate any dust or contaminants postharvest. The pristine leaves were desiccated in the shade for 21 days. The desiccated leaves were ground in an electric grinder, and the resultant fine powder was utilized for extract preparation. Ten grams of <italic toggle="yes">C. igneus</italic> powder was placed in a beaker, and one hundred milliliters of Milli‐Q water was added. The maceration process was conducted, during which the mixture was continually mixed for 3 days. The solution was filtered through muslin cloth and subsequently through Whatman filter paper to eliminate residue. For the subsequent analysis, the concentrated filtrate was freeze‐dried after being produced using a rotary evaporator. The resulting concentrated Aq‐CI was then preserved at 4°C. The Aq‐CI was analyzed and revealed the presence of various phytochemicals: Tannins were identified with the FeCl<sub>3</sub> test, glycosides were identified through the Legal test, alkaloids were identified using Dragendorff’s test, flavonoids were identified by Shinoda’s test, saponins through the vortex method, proteins through the biuret test, phytosterols with concentrated H<sub>2</sub>SO<sub>4</sub>, polyphenols using FeCl<sub>3</sub> and K<sub>3</sub>[Fe(CN)<sub>6</sub>], carbohydrates via the Molisch test, and amino acids via the ninhydrin test.</p></sec><sec id="sec-0005"><title>2.3. Synthesis of Graphene Oxide (GO)</title><p>A few tweaks to Hummer’s method were employed to produce GO from graphite powder [<xref rid="bib-0027" ref-type="bibr">27</xref>]. By mixing 30 mL of sulfuric acid with 10 g of potassium permanganate for half an hour at 20°C, a solution was created that contained 2 g of graphite flakes and 1 g of sodium nitrate. The mixture was then stirred for 3 h at 25°C. Subsequent to the addition of 150 mL of Milli‐Q water dropwise to the solution at 40°C, 30% hydrogen peroxide was added, and then, the mixture was aggressively stirred using a magnetic stirrer. Centrifugation at 3000 rpm for 10 min (three times) followed by rinsing with Milli‐Q water and ethanol until the pH was almost neutral. The GO powder was subsequently heated in an oven to dry it.</p></sec><sec id="sec-0006"><title>2.4. Reduced GO (rGO) Nanosheet Biosynthesis</title><p>Ultrasonication was applied to a solution containing 0.04 g of GO powder and 50 mL of Milli‐Q water for half an hour. Mixture of 40 mL of 0.8 mg/mL GO solution and 80 mL of 5% <italic toggle="yes">C. igneus</italic> leaf extract (reducing agent) was refluxed for 48 h at 24°C [<xref rid="bib-0028" ref-type="bibr">28</xref>]. After rinsing with Milli‐Q water and ethanol by centrifugation at 10,000 rpm for 10 min (three times) each, the resulting black powder was allowed to dry at room temperature. The preparation technique for GO and <italic toggle="yes">C. igneus</italic>–derived rGO (CIrGO) is delineated in Figure <xref rid="fig-0002" ref-type="fig">2</xref>.</p><fig-group position="float" id="fig-0002" content-type="Figure" orientation="portrait"><label>Figure 2</label><caption><p>Schematic representation of the green synthesis of rGO using <italic toggle="yes">Costus igneus</italic> leaf extract. (a) Preparation of graphene oxide (GO) using a modified Hummers’ method: Graphite is mixed with NaNO<sub>3</sub> and H<sub>2</sub>SO<sub>4</sub>, followed by KMnO<sub>4</sub> oxidation, reaction termination with H<sub>2</sub>O<sub>2</sub>, and subsequent washing and drying to obtain GO. (b) Green reduction of GO: Aqueous <italic toggle="yes">Costus igneus</italic> leaf extract is used as a natural reducing agent. GO is refluxed, followed by centrifugation and drying to obtain CIrGO.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0001" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="IJBM-2026-5521416-g047.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0002" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="IJBM-2026-5521416-g003.jpg"/></fig></fig-group></sec><sec id="sec-0007"><title>2.5. Structural and Morphological Characterization</title><p>The SHIMADZU spectrophotometer (Linco) was used to find the UV–vis spectra, which allowed us to determine the structural parameters of Aq‐CI, GO, and CIrGO. The spectral range of the instrument falls between 190 and 900 nm, and it has a precision of ±0.3 nm. Using Fourier‐transform infrared (FTIR) spectroscopy (Nicolet iS50 equipment from THERMO Electron Scientific Instruments LLC FTIR), the surface functional groups of Aq‐CI, GO, and CIrGO were analyzed. Spectra were obtained with an FTIR spectrophotometer having a spectral resolution of 4 cm<sup>−1</sup>, a step size of 1 s, and an infrared wavelength range of 4000–500 cm<sup>−1</sup>. A PANalytical PRO fitted with a radiation source of CuKα (<italic toggle="yes">λ</italic> = 1.5418 Å) piqued X‐ray diffraction (XRD) were examined. Diffraction intensities were logged at each 2<italic toggle="yes">θ</italic> angle ranging from 5° to 80°. The diffraction patterns were generated with a step size of 0.02°, and the scan rate was 2°/min. A JEOL 2100F transmission electron microscope (TEM) was employed to investigate the underlying structures of the gathered sheets operating at 200 kV, and SEM‐EDX (Zeiss EVO40, Carl Zeiss microscopy, coupled with Team Pegasus EDS‐EBSD, combining Octane Plus and Hikari Pro) showed the surface pictures and elemental composition percentages of GO and CIrGO. Spectra of Raman were recorded by means of a Varian FT‐Raman micro‐Raman spectrometer. In the range of 200–3500 cm<sup>−1</sup>, the spectra were recorded. To determine whether GO and CIrGO were stable in colloidal solutions and to evaluate their hydrodynamic particle size distribution, a Malvern PANalytical Zetasizer potential analyzer was used.</p></sec><sec id="sec-0008"><title>2.6. Cell Culture</title><p>Human glioblastoma U87MG cells and human Chang liver cells, sourced from the National Centre for Cell Sciences in Pune, Maharashtra, were cultured in a mixture of DMEM (HiMedia) augmented with L‐glutamine, FBS, streptomycin, and penicillin and maintained in a 5% CO<sub>2</sub> incubator at 37°C. Chang liver and U87MG cells are the commonly used human cell lines in biomedical research to study various metabolic activities, insulin response, and cancer metabolism.</p></sec><sec id="sec-0009"><title>2.7. Cytotoxicity Assessment</title><p>Using a cell viability experiment, the cytotoxicity of metformin, Aq‐CI extract, and CIrGO nanosheet was assessed. A total of 96‐well plates were utilized to culture Chang liver cells and U87MG cells, with 2.5 × 10<sup>4</sup> cells per well. After that, the cells were placed in a CO<sub>2</sub> incubator and left there for 24 h. The cells were treated to different concentrations of metformin, CIrGO nanosheets, and Aq‐CI extract (12.5–200 μg mL<sup>−1</sup>) in triplicate the next day to assess their cytotoxic effects. A vehicle control was established using DMSO. 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide (MTT) dye was added and incubated for 4 h at 37°C in the dark [<xref rid="bib-0021" ref-type="bibr">21</xref>], and100 μL DMSO (dimethyl sulfoxide) was added to the mixture, forming formazan crystals. The absorbance at 560 nm was measured with a BioTek microplate reader. To determine the percentage of viable cells, the following formula has been used:<disp-formula id="disp-0001">
<label>(1)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" display="block"><mml:mtable><mml:mlabeledtr id="EEq1"><mml:mtd><mml:mtext>cell viability</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>sample</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mtext> </mml:mtext></mml:mrow></mml:mfrac></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
</p></sec><sec id="sec-0010"><title>2.8. In Vitro Investigation of Antidiabetic Efficacy</title><sec id="sec-0011"><title>2.8.1. Glucose Uptake Assay</title><p>Using a modified glucose oxidase/peroxidase method, the effects of the plant extract on glucose utilization were evaluated in the Chang liver and U87MG cells [<xref rid="bib-0029" ref-type="bibr">29</xref>]. Following their 3 × 10<sup>4</sup> cells/mL inoculation, the cells adhered to a 96‐well plate overnight. The cells were treated to different quantities of Aq‐CI extract and CIrGO nanosheets (12.5–200 μg·mL<sup>−1</sup>) throughout 24 h. After adding 25 μL of incubation buffer per the media instructions, cells were washed with PBS and the medium was discarded. Mixing 0.1% BSA‐containing PBS until glucose reached 8 mM yielded this buffer. The presence of metformin, at a concentration that may vary between 12.5 and 200 μg·mL<sup>−1</sup>, served as a positive control. Following 4 h of incubation, the plates underwent treatment with 200 μL of glucose oxidase/peroxidase reagent. The absorbance at 510 nm was measured using a BioTek microplate reader following 15 min of room temperature incubation for the reaction. Using the red‐hued quinoamine dye complex, a colorimetric glucose oxidase/peroxidase test assessed the glucose concentration in the culture medium at 510 nm over time. Controls were cell‐free wells with incubation buffer and nutrient medium. A correlation was determined and shown between the amount of glucose that was absorbed in millimoles,<disp-formula id="disp-0002">
<label>(2)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2" display="block"><mml:mtable><mml:mlabeledtr id="EEq2"><mml:mtd><mml:mo>%</mml:mo><mml:mtext> glucose uptake</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mo>−</mml:mo><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>sample</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
</p><p>To ensure that fluctuations in glucose uptake were not caused by changes in cell viability, the MTT experiment was performed. In the MTT assay, a soluble tetrazolium salt is converted into an insoluble formazan product. The first material is soluble in water and has a yellow hue. Purple formazan crystals have been dispersed in DMSO. Viable cells are steadily proportionate to formazan concentration.</p></sec><sec id="sec-0012"><title>2.8.2. Inhibition Assay of Amylolytic Enzymes</title><sec id="sec-0013"><title>2.8.2.1. α‐Amylase Inhibition Assay</title><p>To inhibit pancreatic α‐amylase activity, samples were tested in a mixture of 100 μL of a suspension (2 U/mL) in PBS, 100 μL of each Aq‐CI extract, CIrGO, and acarbose (a positive control) at concentrations from 12.5 to 200 μg·mL<sup>−1</sup>. After a 10‐min shaking bath incubation at 37°C, 1% starch solution was added to the mixture to act as a substrate, and the incubation was proceeded for an additional 10 min. Samples were boiled in water at boiling point for 10 min after being mixed with dinitrosalicylic (DNS) acid color reagent, which contained 2 M sodium hydroxide, 5.3 M sodium potassium tartrate in 96 mM 3,5‐DNS acid in order to halt the reaction. Determined the inhibitory capacity at 540 nm after bringing it to room temperature using the following formula [<xref rid="bib-0030" ref-type="bibr">30</xref>]:<disp-formula id="disp-0003">
<label>(3)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3" display="block"><mml:mtable><mml:mlabeledtr id="EEq3"><mml:mtd><mml:mo>%</mml:mo><mml:mtext> inhibition</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mo>−</mml:mo><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>sample</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
where the average values of samples (Aq‐CI extract and CIrGO) or acarbose with enzyme are denoted by absorbance (sample), and the buffer with enzyme is denoted by sbsorbance (control).</p></sec><sec id="sec-0014"><title>2.8.2.2. α‐Glucosidase Inhibition Assay</title><p>The inhibition of α‐glucosidase was evaluated using a recent work with minor modifications [<xref rid="bib-0031" ref-type="bibr">31</xref>]. After mixing the samples that contained CIrGO and Aq‐CI extract with α‐glucosidase enzyme (phosphate buffer, 0.1 M, pH 6.9), the mixture was left to incubate for 10 min. Acarbose served as a positive control. 10 mM of 4‐nitrophenyl α‐D‐glucopyranoside was added. Two milliliters of 0.1 M Na<sub>2</sub>CO<sub>3</sub> was added after 20 min of incubation to halt the reaction. The inhibition rate was determined by measuring absorbance at 405 nm and applying the following formula:<disp-formula id="disp-0004">
<label>(4)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4" display="block"><mml:mtable><mml:mlabeledtr id="EEq4"><mml:mtd><mml:mo>%</mml:mo><mml:mtext> inhibition</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mo>−</mml:mo><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>sample</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mtext>absorbance</mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="(" close=")" separators="|"><mml:mrow><mml:mtext>control</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
</p></sec></sec><sec id="sec-0015"><title>2.8.3. Kinetic Study of Amylolytic Enzymes</title><sec id="sec-0016"><title>2.8.3.1. Kinetic Behavior of α‐Amylase With Inhibitors</title><p>The Michaelis–Menten and Lineweaver–Burk equations were employed to elucidate the mechanism by which alpha‐amylase is inhibited by CIrGO nanosheet and acarbose. Utilizing the IC<sub>50</sub> values of the samples to examine enzyme kinetics. For the substrate, soluble starch was utilized at concentrations of 0.1%, 0.25%, 0.5%, 1%, and 2% w/v. The enzyme kinetics were evaluated in the absence and presence of CIrGO nanosheet and Aq‐CI extracts. A 30 min preincubation at 37°C was performed using 100 μL of an alpha‐amylase enzyme solution at a concentration of 2 U/mL for the purpose of summarization. Subsequently, differing volumes of starch solution (750 μL) were introduced and allowed to incubate at 37°C for a duration of 10 min. The implementation of the DNS reagent brought the process to a standstill. Lineweaver–Burk plots represent the relationship between the inverse of velocities (1/V) and substrate concentrations (1/mM<sup>−1</sup>), and absorbance variations at 405 nm were measured spectrophotometrically [<xref rid="bib-0032" ref-type="bibr">32</xref>]. This enabled us to ascertain the type of enzyme inhibition. Both the intercept and slope values from the double inverse plots were utilized to get the kinetic constants Km and Vmax, which in turn led to the measurement of the reaction velocities (v). The concentration of reducing sugars was quantified utilizing a maltose standard curve, expressed in millimoles of maltose equivalent.</p></sec><sec id="sec-0017"><title>2.8.3.2. Kinetic Behavior of α‐Glucosidase With Inhibitors</title><p>The kinetic behavior of α‐glucosidase was examined when inhibitors were present.</p><p>The α‐glucosidase enzyme (1 U/mL) was suspended at 37°C for 5 min before using inhibitors (CIrGO nanosheets and acarbose, individually). A 100 mM phosphate buffer was used to dissolve the enzyme. Various amounts of sucrose were added after the enzyme‐inhibitor mixture had been preincubated at 37°C for 30 min. Data were evaluated to ascertain a category of inhibition (competitive, uncompetitive, noncompetitive, or mixed) using Lineweaver–Burk plots, which were derived from the results obtained using Michaelis–Menten kinetics. Plotting the reciprocal values of reaction velocities (<italic toggle="yes">V</italic>
<sub>
<italic toggle="yes">o</italic>
</sub>) and substrate concentrations (S) and fitting them to the Lineweaver–Burk equation allowed us to determine the maximum reaction velocity (<italic toggle="yes">V</italic>
<sub>max</sub>) and the Michaelis constant (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub>) [<xref rid="bib-0032" ref-type="bibr">32</xref>].</p><p>The Lineweaver–Burk equation (double reciprocal plot) is given as<disp-formula id="disp-0005">
<label>(5)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5" display="block"><mml:mtable><mml:mlabeledtr id="EEq5"><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mtext> </mml:mtext><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>,</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
<disp-formula id="disp-0006">
<label>(6)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6" display="block"><mml:mtable><mml:mlabeledtr id="EEq6"><mml:mtd><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mtext> </mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>S</mml:mi></mml:mfrac></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>.</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
</p></sec></sec></sec><sec id="sec-0018"><title>2.9. In Silico Analysis of Antidiabetic Efficacy</title><sec id="sec-0019"><title>2.9.1. Ligand Selection and Protein Structure Acquisition</title><p>Scopus, Web of Science, PubMed, and Google Scholar were utilized to search for articles pertaining to <italic toggle="yes">C. igneus</italic> leaves and extract their chemical makeup. Consequently, PubChem databases were used to create a database of bioactive chemicals discovered in the leaves of <italic toggle="yes">C. igneus</italic>. These compounds were identified using induced‐fit docking techniques with the Ligand Preparation Wizard of Maestro 11.1 [<xref rid="bib-0033" ref-type="bibr">33</xref>] combined with an OPLS3 force field. Refining the structures involved bringing the protein’s pH to a neutral level and removing water molecules. The α‐amylase and α‐glucosidase crystal structures were retrieved from the Protein Data Bank with the respective accession numbers of 1DHK and 4J5T. To come up with the optimal receptor, Chimera (Amber Force Field) in conjunction with SWISS‐PDB Viewer’s GROMACS 96 43B1 algorithm was used. Thiol and hydroxyl groups, amide groups of asparagine and glutamine, histidine’s imidazole ring, protonation states of histidine, aspartic acid, and glutamic acid were among the reformation products [<xref rid="bib-0034" ref-type="bibr">34</xref>].</p></sec><sec id="sec-0020"><title>2.9.2. ADME/T Analysis and Drug‐Likeliness Predictions</title><p>The toxicity was evaluated using pkCSM, and the ligand physicochemical characteristics were predicted using QikProp and SwissADME web server. Various criteria were employed to assess the compounds, including oral absorption rate, QlogP, and Lipinski’s rule of five [<xref rid="bib-0035" ref-type="bibr">35</xref>].</p></sec><sec id="sec-0021"><title>2.9.3. Grid Generation and Molecular Docking</title><p>Previous studies [<xref rid="bib-0036" ref-type="bibr">36</xref>, <xref rid="bib-0037" ref-type="bibr">37</xref>] employed similar modeling methods to the one used in this research, which involved the α‐amylase and α‐glucosidase enzymes (PDB codes: 1DHK and 4J5T, respectively). The protein structure was created and refined using the Schrödinger software suite. For crystallographic analysis, water molecules were removed, along with any heteroatoms or contaminants. Bond orders were assigned based on the presence or absence of hydrogens. Several issues, including errors in formal charges, side chains, and backbone chains, were addressed and corrected. The structure’s resonance, ionized states, ring arrangements, and tautomers were examined utilizing the LigPrep tool. A standard precision docking approach, employing the default OPLS 2005 Force Field, was applied to calculate docking scores and assess ligand‐binding affinities in detail.</p></sec><sec id="sec-0022"><title>2.9.4. Molecular Dynamics Modeling</title><p>The stability of the lead compounds in conjunction with the 1DHK and 4J5T proteins was assessed through molecular dynamics (MD) simulations, based on methodologies outlined in previous studies [<xref rid="bib-0038" ref-type="bibr">38</xref>, <xref rid="bib-0039" ref-type="bibr">39</xref>]. The Desmond tool was employed for the simulations. All computational tasks were carried out using 4GB NVIDIA Quadro, running on Ubuntu 18.04. The protein–ligand complex was generated in Glide software and subsequently imported to Schrödinger for further manipulation. The complex was centered in an orthorhombic box. Counter ions neutralized charges, and water molecules solvated the system. The Desmond system simulated physiological conditions with 0.15 M NaCl. Energy minimization was performed using the OPLS‐3e force field to resolve any electronic issues within the protein structures. At 298 K and 1 bar pressure, the NPT array performed a 100‐ns simulation run with 1000 steps. The barostat algorithm‐controlled pressure and temperature. Analysis of MD trajectories and prediction of ligand‐binding layout in complexes was done using Desmond’s modeling interface model.</p></sec></sec><sec id="sec-0023"><title>2.10. Statistical Analysis</title><p>Data were analyzed using GraphPad Prism. The results from all biological studies, triplicates shown as Mean ± SEM. The significance was verified by one‐way ANOVA and Tukey’s post hoc test. OriginPro created structural characterization graphical representations.</p></sec></sec><sec id="sec-0024"><title>3. Result</title><sec id="sec-0025"><title>3.1. Biosynthesis of CIrGO</title><p>A green approach was established to fabricate CIrGO nanosheets via its generic counterpart, GO, using <italic toggle="yes">C. igneus</italic> leaf extract as a reducing agent. The leaf extract can be easily and cheaply prepared. The production of CIrGO was confirmed by all spectroscopic investigations, and the results are detailed in this article.</p><sec id="sec-0026"><title>3.1.1. Phytochemical Screening</title><p>Phytochemicals were detected in both the synthesized CIrGO and the Aq‐CI during the preliminary qualitative screening. The phytochemicals found in the <italic toggle="yes">C. igneus</italic> extract included alkaloids, carbs, phenol, protein, saponin, and terpenoids; in contrast, the CIrGO exhibited phenol, protein, and terpenoids as its phytochemical components. A variety of plant biomolecules, including tannins, alkaloids, proteins, and enzymes, stabilize and reduce GO. In this study, alkaloids, carbohydrates, phenols, proteins, saponins, and terpenoids were all detected in the <italic toggle="yes">C. igneus</italic> extract. Translocation of metabolites such as phenols, terpenoids, and proteins from plant residues to rGO nanosheet during fabrication was also shown. These compounds likely reduced and stabilized synthesis. Studies on the screening of phytoconstituents of medicinal plants employed for rGO synthesis found that these phytochemicals capped and steadied the green synthesis [<xref rid="bib-0040" ref-type="bibr">40</xref>–<xref rid="bib-0043" ref-type="bibr">43</xref>].</p></sec><sec id="sec-0027"><title>3.1.2. Structural Characterization and Morphology</title><sec id="sec-0028"><title>3.1.2.1. UV–Visible Spectra Analysis</title><p>Analyzing the change in the UV–visible absorption spectra of CIrGO over time allowed us to study the GO reduction process (Figure <xref rid="fig-0003" ref-type="fig">3</xref>). A high absorption peak at 231 nm was observed in the aromatic C–C bonds (п–п transition) in GO, as revealed by the UV analysis. A weak shoulder at 300 nm was observed due to the n–п transitions in the carbon–oxygen bonds. With the completion of the reduction process, a new peak appeared and the characteristic peak shifted from 231 to 268 nm (Figure <xref rid="fig-0003" ref-type="fig">3</xref>), confirming the restoration of electronic conjugation in the graphene sheets. The extent of the red shift observed can be used to evaluate the effectiveness of the reducing agent [<xref rid="bib-0044" ref-type="bibr">44</xref>]. To illustrate the efficacy of the polyphenols found in the <italic toggle="yes">C. igneus</italic> extract as reducing agents, we observed that CIrGO with an absorption maximum at 268 nm, surpassing 254 nm observed when hydrazine [<xref rid="bib-0045" ref-type="bibr">45</xref>] and phenyl hydrazine [<xref rid="bib-0046" ref-type="bibr">46</xref>] reduced graphene, respectively. One possible explanation for the characteristic broad shoulder is that graphene nanosheets have alkaloids and polyphenols bonded to their surfaces, which inhibit graphene aggregation. Aq‐CI exhibits notable UV–vis absorption peaks, generally around the CIrGO peak at approximately 275 nm [<xref rid="bib-0047" ref-type="bibr">47</xref>].</p><fig position="float" fig-type="Figure" id="fig-0003" orientation="portrait"><label>Figure 3</label><caption><p>UV–vis spectrum of crude, GO, and CIrGO aqueous suspension.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="IJBM-2026-5521416-g004.jpg"/></fig></sec><sec id="sec-0029"><title>3.1.2.2. FTIR Study</title><p>Figure <xref rid="fig-0004" ref-type="fig">4</xref> shows the results of FTIR spectroscopy tests conducted on the GO and CIrGO samples, which were used to determine the level of reduction. O–H stretching vibrations seen in GO as a wide band in the 3100‐3400 cm<sup>−1</sup> range. The carbonyl group’s C=O stretch causes an absorption band at around 1722 cm<sup>−1</sup>, whereas vibrations in the epoxide ring and the O–H bending give rise to a band at about 1581 cm<sup>−1</sup>. GO’s surface carboxylic (COOH) groups narrow the absorption resonance approximately 1083 cm<sup>−1</sup> by causing the carbon–oxygen stretching resonance peak. A third‐order alcohol (C–OH) molecule might be responsible for the absorption band that centers at 1392 cm<sup>−1</sup>. GO’s oxygen functionalities, the O–H bonds, C=O groups, carbon oxide, and intermediate C–OH bands, significantly reduced in the FTIR spectra of CIrGO, as much as they were in graphene made from plant extracts. The spectra that were detected provide more evidence of this deoxygenation or decrease in the oxygen concentration. Furthermore, the FTIR bands observed for the crude <italic toggle="yes">C. igneus</italic> extract appearing at 3339, 2918, 2851, 1733, 1633, 1420, 1244, and 1021 cm<sup>−1</sup> showed good agreement with those found in the CIrGO, supporting the involvement of phytochemicals in the reduction and stabilization of the graphene sheets [<xref rid="bib-0048" ref-type="bibr">48</xref>].</p><fig position="float" fig-type="Figure" id="fig-0004" orientation="portrait"><label>Figure 4</label><caption><p>FTIR spectra of crude extract, GO, and CIrGO samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="IJBM-2026-5521416-g005.jpg"/></fig></sec><sec id="sec-0030"><title>3.1.2.3. Raman Analysis</title><p>GO and CIrGO’s D (disordered mode) and G (in‐plane vibration of sp<sup>2</sup> bonded carbon atoms) bands were seen by Raman spectroscopy (Figure <xref rid="fig-0005" ref-type="fig">5</xref>). The Raman absorption spectrum of GO and CIrGO revealed clear D and G bands at 1347 and 1339 cm<sup>−1</sup> and 1571 and 1575 cm<sup>−1</sup>, respectively, confirming their presence. The ID/IG ratio, which is the intensity ratio of the D band to the G band, was computed for GO and CIrGO to understand the reduction process, specifically oxygen removal from graphene. The increased adsorption of oxidized polyphenols on the graphene surface increases surface sp<sup>3</sup> domains and the ID/IG ratio following reduction. Initially, GO had an ID/IG ratio of 0.84. The ID/IG ratio for CIrGO was 0.81 after reduction, similar to the CIrGO intensity values of earlier research [<xref rid="bib-0047" ref-type="bibr">47</xref>, <xref rid="bib-0049" ref-type="bibr">49</xref>].</p><fig position="float" fig-type="Figure" id="fig-0005" orientation="portrait"><label>Figure 5</label><caption><p>Raman peak of GO and CIrGO nanosheets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="IJBM-2026-5521416-g006.jpg"/></fig></sec><sec id="sec-0031"><title>3.1.2.4. XRD Spectral Analysis</title><p>GO and CIrGO XRD diffractograms are illustrated in Figure <xref rid="fig-0006" ref-type="fig">6</xref>. Oxidation of graphite layers revealed a single diffraction signal at 11.18°, indicating water intercalation and carboxylic bonds with an intermediate d‐spacing of 0.76 nm. CIrGO showed a large dispersion peak at 2<italic toggle="yes">θ</italic> = 27.02° after reduction, with a 0.33‐nm interlayer d‐spacing. The Bragg reflection planes for GO were identified as (002), while for CIrGO, they were (111). The observed diffraction patterns were consistent with those of GO and rGO synthesized using the leaf extract of <italic toggle="yes">C. igneus</italic>. The full elimination of the oxygen group presence in GO following reduction was confirmed by the moderately lower d‐spacing value and the disappearance of the peak at 11.18° [<xref rid="bib-0048" ref-type="bibr">48</xref>, <xref rid="bib-0049" ref-type="bibr">49</xref>]. The following formula can be used to find the d‐spacing:<disp-formula id="disp-0007">
<label>(7)</label>
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7" display="block"><mml:mtable><mml:mlabeledtr id="EEq7"><mml:mtd><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>n</mml:mi><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi mathvariant="normal">sin</mml:mi><mml:mi mathvariant="normal">θ</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>,</mml:mo></mml:mtd></mml:mlabeledtr></mml:mtable></mml:math>
</disp-formula>
where <italic toggle="yes">n</italic> is the integer (assuming to be 1), <italic toggle="yes">λ</italic> is thewavelength of the incident X‐rays, and 2<italic toggle="yes">θ</italic> is the diffraction angle.</p><fig position="float" fig-type="Figure" id="fig-0006" orientation="portrait"><label>Figure 6</label><caption><p>X‐ray diffraction of GO and CIrGO nanosheets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="IJBM-2026-5521416-g007.jpg"/></fig></sec><sec id="sec-0032"><title>3.1.2.5. Dynamic Light Scattering and Zeta Potential</title><p>The zeta potential of CIrGO and GO is shown in Figures <xref rid="figpt-0003" ref-type="fig">7(a)</xref> and <xref rid="figpt-0004" ref-type="fig">7(b)</xref>. Surface charges of −24.8 and −22.9 mV, respectively, were recorded for GO and CIrGO. It was clear from those negative numbers that GO and rGO sheets were stable. GO may have a high negative zeta potential due to its carboxyl structural groups. A value of −22.9 mV is obtained following GO reduction with <italic toggle="yes">C. igneus</italic> leaves. This is because GO surfaces have had their carboxyl groups removed. Figures <xref rid="figpt-0005" ref-type="fig">7(c)</xref>, <xref rid="figpt-0006" ref-type="fig">7(d)</xref> depict dynamic light scattering evaluations of GO and CIrGO. The dispersion size of CIrGO in an aqueous solution was found to be 79.82 nm, while GO measured 80.89 nm, indicating that CIrGO is slightly smaller. According to previous investigations on rGO [<xref rid="bib-0048" ref-type="bibr">48</xref>], a reduction in the particle dimension was associated with the absence of long‐range graphitic order. Cavitation at the rGO nanosheet surface using ultrasonication weakens the influence of van der Waals forces, limiting clumping. This stabilizes rGO in aqueous solutions, resulting in well‐dispersed, smaller fragments.</p><fig-group position="float" id="fig-0007" content-type="Figure" orientation="portrait"><label>Figure 7</label><caption><p>Zeta potential of GO (a) and CIrGO (b) and dynamic light scattering spectra of GO (c) and CIrGO nanosheets (d).</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0003" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="IJBM-2026-5521416-g008.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0004" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-17" orientation="portrait" xlink:href="IJBM-2026-5521416-g009.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0005" orientation="portrait"><caption><p>(c)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-19" orientation="portrait" xlink:href="IJBM-2026-5521416-g010.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0006" orientation="portrait"><caption><p>(d)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-21" orientation="portrait" xlink:href="IJBM-2026-5521416-g011.jpg"/></fig></fig-group></sec><sec id="sec-0033"><title>3.1.2.6. Morphological Analysis</title><p>Figure <xref rid="fig-0008" ref-type="fig">8</xref> displays the chemical makeup and shape of rGO produced from the <italic toggle="yes">C. igneus</italic> leaf extract. Scanning electron micrographs of GO (Figure <xref rid="figpt-0007" ref-type="fig">8(a)</xref>) and CIrGO (Figure <xref rid="figpt-0008" ref-type="fig">8(b)</xref>) revealed thin nanosheet structures. At the same time, substantial signals for elemental C (61.94%) and O (23.98%) were observed in an EDAX spectrum that was acquired to validate the chemical composition of CIrGO. Table <xref rid="tbl-0001" ref-type="table">1</xref> shows the carbon‐ and oxygen‐containing groups in CIrGO EDAX data. Figure <xref rid="figpt-0009" ref-type="fig">8(c)</xref> shows the outcomes of the CIrGO morphology study by TEM. The CIrGO appeared as thin, edge‐fragmented sheets upon initial inspection. An arrangement of the thinly layered CIrGO nanosheet is also used to border the boundaries [<xref rid="bib-0047" ref-type="bibr">47</xref>].</p><fig-group position="float" id="fig-0008" content-type="Figure" orientation="portrait"><label>Figure 8</label><caption><p>SEM image of GO (a) and CIrGO (b) and TEM image of GO (c) and CIrGO nanosheets (d).</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0007" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-23" orientation="portrait" xlink:href="IJBM-2026-5521416-g012.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0008" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-25" orientation="portrait" xlink:href="IJBM-2026-5521416-g013.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0009" orientation="portrait"><caption><p>(c)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-27" orientation="portrait" xlink:href="IJBM-2026-5521416-g014.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0010" orientation="portrait"><caption><p>(d)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-29" orientation="portrait" xlink:href="IJBM-2026-5521416-g015.jpg"/></fig></fig-group><table-wrap position="float" id="tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>EDAX elemental composition of GO and CIrGO samples, showing carbon, oxygen percentages, and C/O ratio.</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Sample</th><th align="center" rowspan="1" colspan="1">C%</th><th align="center" rowspan="1" colspan="1">O%</th><th align="center" rowspan="1" colspan="1">C/O</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GO</td><td align="center" rowspan="1" colspan="1">57.34</td><td align="center" rowspan="1" colspan="1">32.5</td><td align="center" rowspan="1" colspan="1">1.76</td></tr><tr><td align="left" rowspan="1" colspan="1">CIrGO</td><td align="center" rowspan="1" colspan="1">61.94</td><td align="center" rowspan="1" colspan="1">23.98</td><td align="center" rowspan="1" colspan="1">2.58</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec-0034"><title>3.1.3. Plausible Reduction Mechanism</title><p>The transition in hue from brownish yellow (GO) to black (CIrGO) served as the most consistent signal of the successful transformation of GO to CIrGO. Aq‐CI contains a variety of phytochemicals that may act as reducing agents, including glycosides, sugars, alkaloids, saponins, flavonoids, phytosterols, tannins, phenolic compounds, proteins, and amino acids [<xref rid="bib-0025" ref-type="bibr">25</xref>, <xref rid="bib-0026" ref-type="bibr">26</xref>]. Each of these components’ testing methods verified their presence in the extract. The green production of rGO has been made possible by the identification and comprehensive characterization of individual molecules whose reduction pathways were excellent stabilizing agents. These substances include sugars, proteins, amino acids, and polyphenols [<xref rid="bib-0050" ref-type="bibr">50</xref>–<xref rid="bib-0052" ref-type="bibr">52</xref>]. Figure <xref rid="fig-0009" ref-type="fig">9</xref> shows the potential method by which the <italic toggle="yes">C. igneus</italic> extract reduces GO. Epoxide, hydroxyl, and carbonyl are just a few of the oxygen‐containing functional groups found on the GO surface. It is possible to convert the epoxide and carbonyl groups to hydroxyl groups under basic circumstances. The Aq‐CI contains several polyphenols with extremely acidic hydrogen atoms that readily dissociate into their anionic forms. Nucleophilic substitution interactions between anionic polyphenols and GO’s hydroxyl group yield an intermediate [<xref rid="bib-0052" ref-type="bibr">52</xref>]. The removal of a water molecule transforms the intermediate into rGO, referred to as CIrGO.</p><fig position="float" fig-type="Figure" id="fig-0009" orientation="portrait"><label>Figure 9</label><caption><p>An approach for the reduction of graphene oxide: Polyol‐rich phytochemicals react with epoxide and hydroxyl groups in GO, forming intermediates and removing oxygen functionalities, leading to the restoration of the graphitic rGO structure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-31" orientation="portrait" xlink:href="IJBM-2026-5521416-g016.jpg"/></fig></sec></sec><sec id="sec-0035"><title>3.2. Cytotoxicity Assay</title><p>The toxicity of the produced Aq‐CI extract and CIrGO at different concentrations was assessed against two cell lines (Chang liver and U87MG) with the MTT test. Various concentrations from 12.5 to 400 μg·mL<sup>−1</sup> of the Aq‐CI extract, CIrGO, and the positive control metformin were utilized. Assessing the compound’s toxicity is the initial phase in the therapeutic development process for a specific ailment. The findings indicated that the amalgamated CIrGO exhibited reduced toxicity, with cell mortality happening in a dose‐sensitive fashion. As the amount of CIrGO escalated, the toxicity level correspondingly increased, as depicted in Figure <xref rid="fig-0010" ref-type="fig">10</xref>. Chang liver cells showed a dose‐dependent reaction to the evaluated substances. At a dosage of 12.5 μg·mL<sup>−1</sup>, viability of cells was measured at 92.6% for the Aq‐CI extract, 84.5% for CIrGO, and 95.12% for metformin, establishing the baseline for comparison. Treatment with 25 μg ·mL<sup>−1</sup> led to a marginal reduction in cell viability to 82.79%, 7.13%, and 88.62% for Aq‐CI extract, CIrGO, and metformin, respectively, signifying negligible cytotoxicity. With increasing concentration, cell viability progressively diminished, exhibiting notable cytotoxic effects at 400 μg· mL<sup>−1</sup> (33.19% for the Aq‐CI extract, 28.26% for CIrGO, and 38.13% for metformin), with total cell loss likely occurring at higher concentrations. The results demonstrate a pronounced concentration‐dependent cytotoxic effect of the examined substances. The inhibitory concentration (IC<sub>50</sub>) of CIrGO was found to be 235.72 μg·mL<sup>−1</sup>, while IC<sub>50</sub> for the Aq‐CI extract was 303.89 μg·mL<sup>−1</sup>. In comparison, the positive control, metformin, exhibited an IC<sub>50</sub> of 327.01 μg·mL<sup>−1</sup>. At higher concentrations, CIrGO may generate reactive oxygen species, leading to damage to cellular components and ultimately causing cell death.</p><fig-group position="float" id="fig-0010" content-type="Figure" orientation="portrait"><label>Figure 10</label><caption><p>Cell viability assays were conducted using MTT. (a) The viability of Chang liver cells in response to CIrGO showed a dose‐dependent decline as the concentration increased. (b) U87MG cell viability also decreased significantly at higher concentrations of CIrGO. The bars denote the mean ± SEM (<sup>∗∗</sup>signifies a significant level compared to control (<italic toggle="yes">p</italic> ≤ 0.001) and <sup>∗∗∗</sup>signifies a level of significance compared to control (<italic toggle="yes">p</italic> ≤ 0.0001), relative to untreated cells, <italic toggle="yes">n</italic> = 3).</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0011" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-33" orientation="portrait" xlink:href="IJBM-2026-5521416-g017.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0012" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-35" orientation="portrait" xlink:href="IJBM-2026-5521416-g018.jpg"/></fig></fig-group><p>The response of U87MG cells to CIrGO exhibited a dose‐dependent effect. Beginning with a baseline viability of 76.425% at 12.5 μg ·mL<sup>−1</sup>, a minor decrease to 72.43% is seen at 25 μg· mL<sup>−1</sup>. At 400 μg· mL<sup>−1</sup>, viability drastically declined to 29.4%, indicating considerable cytotoxicity. Elevated doses resulted in total cell mortality, demonstrating the significant anticancer efficacy of CIrGO. The IC<sub>50</sub> of CIrGO was measured at 199.73 μg· mL<sup>−1</sup>, whereas the Aq‐CI extract exhibited an IC<sub>50</sub> of 276.34 μg· mL<sup>−1</sup>, in contrast to the positive control metformin, which had an IC<sub>50</sub> of 346.74 μg· mL<sup>−1</sup> (Figure <xref rid="fig-0011" ref-type="fig">11</xref>).</p><fig-group position="float" id="fig-0011" content-type="Figure" orientation="portrait"><label>Figure 11</label><caption><p>IC<sub>50</sub> values of the tested samples on (a) Chang liver cells and (b) U87MG cells. Values were calculated from concentration–response curves obtained from cell viability measurements. Data are presented as mean ± SEM (<italic toggle="yes">n</italic> = 3); <sup>∗∗∗</sup>denotes the statistical significance compared with untreated control cells (<italic toggle="yes">p</italic> ≤ 0.0001).</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0013" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-37" orientation="portrait" xlink:href="IJBM-2026-5521416-g019.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0014" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-39" orientation="portrait" xlink:href="IJBM-2026-5521416-g020.jpg"/></fig></fig-group><p>These findings closely correspond with other research that demonstrated analogous dose‐specific fatal repercussions of plant extracts on cells [<xref rid="bib-0053" ref-type="bibr">53</xref>]. Furthermore, another study demonstrated that elevated levels of rGO diminish cell viability by eliciting oxidative damage, cell death, and rupture of the cell membrane. Higher doses of CIrGO treatments led to enhanced cytotoxicity in cancer cells, indicating that CIrGO may augment the generation of free radicals in these cells. CIrGO’s capacity to induce apoptosis, as demonstrated in these assays, aligns with our findings of the substantial cytotoxic impact on Chang liver and U87MG cells.</p></sec><sec id="sec-0036"><title>3.3. Glucose Uptake Assay</title><p>A lineage of proteins known as glucose transporters (GLUTs) facilitates the translocation of glucose across the exterior of cells. This rapid glucose transport pathway is crucial for the postprandial retention of insulin‐dependent glucose in adipose and muscle tissues, facilitating the oversight of blood glucose levels. At different doses, the graph shows how the GO nanosheets and water‐based extract of <italic toggle="yes">C. igneus</italic> (CIrGO) affected glucose absorption in Chang liver and U87MG cells. At higher tested values, CIrGO improved glucose absorption relative to the control, according to the results (Figure <xref rid="fig-0012" ref-type="fig">12</xref>). The level of glucose absorption increased from 13.01% to 81.39% as the concentration of CIrGO in Chang liver cells increased from 12.5 to 200 μg· mL<sup>−1</sup>. A typical antidiabetic medicine, metformin, was used as a reference to assess the glucose absorption capability of CIrGO. The findings demonstrated that at a dosage of 50 μg ·mL<sup>−1</sup>, CIrGO displayed a glucose uptake capacity of 34.42%, which is comparable to metformin’s absorption rate of 38.56%. A 28.86% absorption rate is shown by the Aq‐CI extract. After successful clinical trials, Aq‐CI extract may replace metformin, the standard antidiabetic medicine, due to its similar absorption activity. After being administered to U87MG cells, CIrGO’s glucose absorption ability was also compared to that of metformin. The findings showed that at a dosage of 50 μg· mL<sup>−1</sup>, CIrGO had glucose uptake capacity of 22.74%, which is quite similar to metformin’s 30.31%. On the other hand, the Aq‐CI extract showed an uptake of 18.05%, which increased with stronger concentrations. The uptake activity of Chang liver cells was 81.39% when treated with CIrGO, which was significantly higher than U87MG cells’ 78.54%, and significantly different from the control (<italic toggle="yes">p</italic> &lt; 0.0001). It has been found that the type of cell used in the experiment affects how well cells absorb glucose [<xref rid="bib-0054" ref-type="bibr">54</xref>]. Yeast cells and other eukaryotic cells have quite different glucose uptake mechanisms. The rate of glucose metabolism and its intracellular concentration have a substantial impact on glucose absorption. Increased glucose absorption by the cell is promoted by a drop in the concentration of internal glucose caused by its transformation into other metabolites. These results suggest that enhanced glucose metabolism and improved diffusion may underlie the extract‐mediated glucose absorption by glioma cells and hepatocytes. Previous research indicates that insulin attaches to the tautomeric insulin receptor subunit on the myocyte cell membrane, initiating a cascade of events that facilitates the translocation of the GLUT 4 target to the membrane, thereby allowing glucose absorption into the cytosol [<xref rid="bib-0055" ref-type="bibr">55</xref>, <xref rid="bib-0056" ref-type="bibr">56</xref>]. The primary mechanism by which polyphenols exert hypoglycemic effects is their ability to inhibit carbohydrate utilization in the intestine, modulate enzymatic glucose uptake, enhance β‐cell functionality and insulin efficacy, stimulate insulin secretion, and exhibit anti‐inflammatory and antioxidant capabilities.</p><fig-group position="float" id="fig-0012" content-type="Figure" orientation="portrait"><label>Figure 12</label><caption><p>Glucose uptake assay: (a) Chang liver cells in response to CIrGO exhibited a dose‐dependent increase with escalating doses. (b) U87MG exhibited a notable enhancement at elevated concentrations of CIrGO. The bars denote the mean ± SEM (<sup>∗∗</sup>signifies a significant level compared to control (<italic toggle="yes">p</italic> ≤ 0.001) and <sup>∗∗∗</sup>signifies a significance level compared to control (<italic toggle="yes">p</italic> ≤ 0.0001), <italic toggle="yes">n</italic> = 3).</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0015" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-41" orientation="portrait" xlink:href="IJBM-2026-5521416-g021.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0016" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-43" orientation="portrait" xlink:href="IJBM-2026-5521416-g022.jpg"/></fig></fig-group></sec><sec id="sec-0037"><title>3.4. Amylolytic Enzymes Inhibition and Their Kinetic Study</title><sec id="sec-0038"><title>3.4.1. Inhibition Assay of α‐Amylase</title><p>Enzymes that break down carbohydrates, like α‐amylase in the pancreas and α‐glucosidase in the intestine, convert oligosaccharides and disaccharides into monosaccharides. This conversion leads to a significant increase in glucose production, which hampers its uptake by cells [<xref rid="bib-0057" ref-type="bibr">57</xref>]. Inhibition of these enzymes leads to a reduced level of blood sugar in diabetic persons. Following incubation with different concentrations, the results demonstrated that both of these enzymes were markedly inhibited, with inhibition exhibiting a concentration‐dependent relationship. The phenolic chemicals found in abundance in the Aq‐CI extract served as stabilizing elements in the production of CIrGO [<xref rid="bib-0058" ref-type="bibr">58</xref>]. Possible explanation for reduced enzyme activity is interactions between carbohydrate‐hydrolyzing enzyme’s amino acids and phytochemicals in the biosynthesized CIrGO. Molecular docking and interaction analysis were described later in the study to validate this relationship. At doses from 12.5 to 200 μg·mL<sup>−1</sup>, CIrGO showed a notable inhibition of α‐amylase. Compared to the control, the inhibitory effects of CIrGO increased dramatically (<italic toggle="yes">p</italic> &lt; 0.0001) as the dosage increased. Inhibition at 100 and 200 μg·mL<sup>−1</sup>showed a notable increase. In comparison with the positive control acarbose, which had an IC<sub>50</sub> of 65.46 μg·mL<sup>−1</sup>, the CIrGO exhibited an IC<sub>50</sub> of 84.46 μg·mL<sup>−1</sup> (Figure <xref rid="fig-0013" ref-type="fig">13</xref>). A larger quantity of polyphenols is responsible for the improved inhibitory activities displayed by Aq‐CI, which had an IC<sub>50</sub> of 92.62 μg·mL<sup>−1</sup>. Although there has been little research on the effects of naturally occurring rGO on alpha‐amylase inhibition, it has been demonstrated that the <italic toggle="yes">C. igneus</italic> plant’s leaves can considerably lower alpha‐amylase activity.</p><fig-group position="float" id="fig-0013" content-type="Figure" orientation="portrait"><label>Figure 13</label><caption><p>Findings of inhibition of the α‐amylase investigation displayed, with data points illustrating the results of three autonomous experimental studies. The facts are presented as mean ± SEM. Values deemed substantially different (<sup>∗∗</sup>p &lt; 0.001, <sup>∗∗∗</sup>p &lt; 0.0001) in comparison with the control at the same tested dosages.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0017" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-45" orientation="portrait" xlink:href="IJBM-2026-5521416-g023.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0018" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-47" orientation="portrait" xlink:href="IJBM-2026-5521416-g024.jpg"/></fig></fig-group><sec id="sec-0039"><title>3.4.1.1. Kinetics of Enzyme Inhibition</title><p>The kinetics of enzyme inhibition were examined using the Michaelis–Menten and Lineweaver–Burk plots for extracts at dosages aligned with their IC<sub>50</sub> values. The reaction rate [V] (μmol sec<sup>−1</sup>) was quantified at different substrate levels, utilizing a graph calibrated with maltose. A graphical depiction (Figure <xref rid="fig-0014" ref-type="fig">14</xref>) of the kinetic constant (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub> and <italic toggle="yes">V</italic>
<sub>max</sub>) was created by graphing the inverse of the level of substrate [S] against the reaction rate [V]. The Vmax diminished, although Km remained mostly unchanged, signifying noncompetitive inhibition of α‐amylase by the antagonists CIrGO and acarbose, as detailed in Table <xref rid="tbl-0002" ref-type="table">2</xref> [<xref rid="bib-0059" ref-type="bibr">59</xref>].</p><fig-group position="float" id="fig-0014" content-type="Figure" orientation="portrait"><label>Figure 14</label><caption><p>Michaelis–Menten (a) and Lineweaver–Burk plot (b) kinetic investigation of α‐amylase inhibition with and without an inhibitor.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0019" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-49" orientation="portrait" xlink:href="IJBM-2026-5521416-g025.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0020" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-51" orientation="portrait" xlink:href="IJBM-2026-5521416-g026.jpg"/></fig></fig-group><table-wrap position="float" id="tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>Kinetic constants, <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub> and <italic toggle="yes">V</italic>
<sub>max</sub>, of the α‐amylase enzyme in the presence and absence of an inhibitor.</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Inhibitors</th><th align="center" rowspan="1" colspan="1">IC<sub>50</sub> (μg·mL<sup>−1</sup>)</th><th align="center" rowspan="1" colspan="1">Km (mg mL<sup>−1</sup>)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>max</sub> (μmol sec<sup>−1</sup>)</th><th align="center" rowspan="1" colspan="1">Inhibition mode</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Without inhibitor</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">0.0023</td><td align="center" rowspan="1" colspan="1">14.9476</td><td rowspan="3" align="center" colspan="1">Noncompetitive</td></tr><tr><td align="left" rowspan="1" colspan="1">CIrGO</td><td align="center" rowspan="1" colspan="1">84.46</td><td align="center" rowspan="1" colspan="1">0.1478</td><td align="center" rowspan="1" colspan="1">2.08724</td></tr><tr><td align="left" rowspan="1" colspan="1">Acarbose</td><td align="center" rowspan="1" colspan="1">65.46</td><td align="center" rowspan="1" colspan="1">0.2541</td><td align="center" rowspan="1" colspan="1">1.49276</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec-0040"><title>3.4.2. α‐Glucosidase Inhibition Assay</title><p>In comparison with the standard drug acarbose (92.00% inhibition) and Aq‐CI extract (86.09% inhibition), CIrGO functions as a complete inhibitor, showing a maximal inhibition of approximately 89.55% at the highest concentration (200 μg·mL<sup>−1</sup>) (Figure <xref rid="fig-0015" ref-type="fig">15</xref>). At the prescribed dosages of 200, 100, 50, 25, and 12.5 μg·mL<sup>−1</sup>, CIrGO showed inhibition rates of 89.55 ± 0.03%, 52.43 ± 0.38%, 31.73 ± 0.57%, 20.23 ± 0.67%, and 11.87 ± 0.7%, respectively. At the given doses, acarbose exhibited inhibitory activities of 92.00 ± 0.01%, 64.97 ± 0.26%, 45.53 ± 0.44%, 32.77 ± 0.56%, and 18.66 ± 0.69%, respectively.</p><fig-group position="float" id="fig-0015" content-type="Figure" orientation="portrait"><label>Figure 15</label><caption><p>Results of the α‐glucosidase inhibition study displayed with counters reflecting findings from three distinct investigations. The facts are presented as mean ± SEM. Values are significantly different (<sup>∗∗∗</sup>
<italic toggle="yes">p</italic> &lt; 0.0001) in contrast to the control at equivalent concentrations.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0021" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-53" orientation="portrait" xlink:href="IJBM-2026-5521416-g027.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0022" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-55" orientation="portrait" xlink:href="IJBM-2026-5521416-g028.jpg"/></fig></fig-group><sec id="sec-0041"><title>3.4.2.1. Enzyme Inhibition Kinetics</title><p>The Lineweaver–Burk plot revealed the CIrGO’s kinetic inhibitory mechanism. Figure <xref rid="fig-0016" ref-type="fig">16</xref> displays the plot that was produced using the Lineweaver–Burk equation. According to the results, there was a singularity in the second quadrant where two reciprocal graphs with linear trajectories met. The graphs clearly illustrated the pattern of inhibition that is not competitive [<xref rid="bib-0060" ref-type="bibr">60</xref>]. The α‐glucosidase enzyme was inhibited by CIrGO and acarbose, which allowed the Km and Vmax values to be determined via the Lineweaver–Burk plot (Table <xref rid="tbl-0003" ref-type="table">3</xref>). Vmax was decreased, and Km was mostly unaltered due to the noncompetitive inhibition of α‐glucosidase by the inhibitors CIrGO and acarbose.</p><fig-group position="float" id="fig-0016" content-type="Figure" orientation="portrait"><label>Figure 16</label><caption><p>Michaelis–Menten (a) and Lineweaver–Burk plot (b) kinetic analysis of the mode of inhibition of α‐glucosidase with and without an inhibitor.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0023" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-57" orientation="portrait" xlink:href="IJBM-2026-5521416-g029.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0024" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-59" orientation="portrait" xlink:href="IJBM-2026-5521416-g030.jpg"/></fig></fig-group><table-wrap position="float" id="tbl-0003" content-type="Table" orientation="portrait"><label>Table 3</label><caption><p>Kinetic constants, Km and <italic toggle="yes">V</italic>
<sub>max</sub>, of the α‐glucosidase enzyme in the presence and absence of an inhibitor.</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Inhibitors</th><th align="center" rowspan="1" colspan="1">IC<sub>50</sub> (μg·mL<sup>−1</sup>)</th><th align="center" rowspan="1" colspan="1">Km (mg mL<sup>−1</sup>)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>max</sub> (μmol sec<sup>−1</sup>)</th><th align="center" rowspan="1" colspan="1">Inhibition mode</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Without inhibitor</td><td align="center" rowspan="1" colspan="1">—</td><td align="center" rowspan="1" colspan="1">0.0024</td><td align="center" rowspan="1" colspan="1">13.581</td><td rowspan="3" align="center" colspan="1">Noncompetitive</td></tr><tr><td align="left" rowspan="1" colspan="1">CIrGO</td><td align="center" rowspan="1" colspan="1">93.83</td><td align="center" rowspan="1" colspan="1">0.0091</td><td align="center" rowspan="1" colspan="1">2.3342</td></tr><tr><td align="left" rowspan="1" colspan="1">Acarbose</td><td align="center" rowspan="1" colspan="1">56.54</td><td align="center" rowspan="1" colspan="1">0.1723</td><td align="center" rowspan="1" colspan="1">1.6007</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="sec-0042"><title>3.5. Plausible Mechanism of Enzyme Inhibition and Glucose Uptake Activity</title><p>Nanoparticles have not been extensively studied in relation to α‐amylase and α‐glucosidase inhibition, but what little is known suggests that<list list-type="simple"><list-item><label>i.</label><p>these particles can bind to the enzymes and form conjugates with the amine or carboxyl groups at their N‐ or C‐termini, respectively, and</p></list-item><list-item><label>ii.</label><p>this binding process can alter the native protein structure.</p></list-item></list>
</p><p>The CIrGO binding may have altered the structure of these enzymes, as shown by the noncompetitive inhibitory technique of CIrGO in this study. Phytoconstituents, particularly polyphenols, found plentiful in <italic toggle="yes">C. igneus</italic> leaves. The antioxidant activity of the phytoconstituents enhanced due to their superior hydrogen‐donating capacity. Furthermore, it has been demonstrated that phytoconstituents derived from several plants can block amylolytic enzymes [<xref rid="bib-0057" ref-type="bibr">57</xref>, <xref rid="bib-0061" ref-type="bibr">61</xref>]. Therefore, it is highly probable that the organic phytoconstituent components attached to the CIrGO surface significantly contribute to the enhanced effectiveness of the reduced carbon component, resulting in a synergistic conferring of biological function. When it comes to antidiabetic medication therapy strategies in vivo, CIrGO might be a strong competitor. The dynamics of different cells during glucose uptake and amylolytic enzyme inhibition in the presence and absence of a CIrGO nanosheet is depicted in Figure <xref rid="fig-0017" ref-type="fig">17</xref>.</p><fig-group position="float" id="fig-0017" content-type="Figure" orientation="portrait"><label>Figure 17</label><caption><p>The process of amylolytic enzymes inhibition, and the glucose uptake activity in hepatocytes (Chang liver) and glioma cells (U87MG), shown in the illustration (a) in the absence of CIrGO nanosheets (b) in the presence of CIrGO nanosheets: CIrGO modulates intestinal carbohydrate digestion and glucose transporters and enhances glucose uptake in the liver and brain, contributing to improved glucose homeostasis.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0025" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-61" orientation="portrait" xlink:href="IJBM-2026-5521416-g031.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0026" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-63" orientation="portrait" xlink:href="IJBM-2026-5521416-g032.jpg"/></fig></fig-group></sec><sec id="sec-0043"><title>3.6. Computational Analysis of Amylolytic Enzymes</title><sec id="sec-0044"><title>3.6.1. Identification of the Binding Site and Ligand Parameterization</title><p>The selected protein structures for assessing relative affinity were α‐amylase (PDB‐ID: 1DHK) and α‐glucosidase (PDB‐ID: 4J5T). The acarbose molecule (41774) was selected as the reference ligand for comparison because of its established efficacy in inhibiting glycoside hydrolases (103). The selected ligands were quercetin (5280343), oleic acid (445639), diosgenin (99474), corosolic acid (6918774), cianidanol (9064), and β‐sitosterol (222284). Prior to conducting molecular docking, α‐amylase (PDB‐ID: 1DHK) and α‐glucosidase (PDB‐ID: 4J5T) structures were constructed and confirmed.</p><p>Active site residues of 1DHK (Figure <xref rid="figpt-0027" ref-type="fig">18(a)</xref>), depicted in turquoise, shown as HIS101, GLU149, TYR151, ASP197, LYS200, HIS201, GLU233, and GLU240, underlined in red (stick) and named [<xref rid="bib-0062" ref-type="bibr">62</xref>]. The residues Trp391, Asp392, Arg428, Gly566, Asp568, Trp710, and Glu771 were identified in the catalytic region as the ligand‐binding site in 4J5T (Figure <xref rid="figpt-0028" ref-type="fig">18(b)</xref>). The single‐ring ligands that bind to Site B establish polar interactions with the Cwht1p residues Glu361, Glu443, Arg428, Glu429, Phe444, Val446, Gln447, and Asn448 in 4J5T (turquoise) emphasized in red (stick) and annotated [<xref rid="bib-0063" ref-type="bibr">63</xref>].</p><fig-group position="float" id="fig-0018" content-type="Figure" orientation="portrait"><label>Figure 18</label><caption><p>Active site residues (a) α‐amylase (PDB‐ID: 1DHK) and (b) α‐glucosidase (PDB‐ID: 4J5T).</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0027" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-65" orientation="portrait" xlink:href="IJBM-2026-5521416-g033.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0028" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-67" orientation="portrait" xlink:href="IJBM-2026-5521416-g034.jpg"/></fig></fig-group></sec><sec id="sec-0045"><title>3.6.2. Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Analysis</title><p>An optimum pharmacokinetic, pharmacologically active, and physicochemically stable chemical molecule is required for use as a drug candidate in pharmaceutical research. New drug development studies have reduced time, money, and effort by using computer‐assisted calculations of the ADME features of therapeutic candidates. Based on the data shown in Table <xref rid="tbl-0004" ref-type="table">4</xref>, the physicochemical features, pharmacokinetic parameters, and drug‐like qualities of substances were determined in this investigation using the Swiss ADME online web tool.</p><table-wrap position="float" id="tbl-0004" content-type="Table" orientation="portrait"><label>Table 4</label><caption><p>ADME/T profile of major phytoconstituents from the <italic toggle="yes">Costus igneus</italic> extract, summarizing absorption, distribution, metabolism, excretion, and toxicity parameters.</p></caption><table frame="hsides" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Compound</th><th align="center" rowspan="1" colspan="1">Quercetin</th><th align="center" rowspan="1" colspan="1">Oleic acid</th><th align="center" rowspan="1" colspan="1">Diosgenin</th><th align="center" rowspan="1" colspan="1">Corosolic acid</th><th align="center" rowspan="1" colspan="1">Cianidanol</th><th align="center" rowspan="1" colspan="1">β‐Sitosterol</th><th align="center" rowspan="1" colspan="1">Reference: acarbose</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Molecular weight (g mol<sup>−1</sup>)</td><td align="center" rowspan="1" colspan="1">302.24</td><td align="center" rowspan="1" colspan="1">282.46</td><td align="center" rowspan="1" colspan="1">414.62</td><td align="center" rowspan="1" colspan="1">472.70</td><td align="center" rowspan="1" colspan="1">290.27</td><td align="center" rowspan="1" colspan="1">414.71</td><td align="center" rowspan="1" colspan="1">645.60</td></tr><tr><td align="left" rowspan="1" colspan="1">Rotatable bonds</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">H‐bond acceptors</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">H‐bond donors</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">TPSA (Å)</td><td align="center" rowspan="1" colspan="1">131.36</td><td align="center" rowspan="1" colspan="1">37.30</td><td align="center" rowspan="1" colspan="1">38.69</td><td align="center" rowspan="1" colspan="1">77.76</td><td align="center" rowspan="1" colspan="1">110.38</td><td align="center" rowspan="1" colspan="1">20.23</td><td align="center" rowspan="1" colspan="1">321.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipinski violations</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">iLOGP</td><td align="center" rowspan="1" colspan="1">1.63</td><td align="center" rowspan="1" colspan="1">4.01</td><td align="center" rowspan="1" colspan="1">4.49</td><td align="center" rowspan="1" colspan="1">3.35</td><td align="center" rowspan="1" colspan="1">1.33</td><td align="center" rowspan="1" colspan="1">5.05</td><td align="center" rowspan="1" colspan="1">1.43</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP1A2 inhibitor</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C9 inhibitor</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2D6 inhibitor</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP2C19 inhibitor</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">CYP3A4 inhibitor</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Synthetic accessibility</td><td align="center" rowspan="1" colspan="1">3.23</td><td align="center" rowspan="1" colspan="1">3.07</td><td align="center" rowspan="1" colspan="1">6.94</td><td align="center" rowspan="1" colspan="1">6.34</td><td align="center" rowspan="1" colspan="1">3.50</td><td align="center" rowspan="1" colspan="1">6.30</td><td align="center" rowspan="1" colspan="1">7.34</td></tr></tbody></table></table-wrap><p>All the derivatives adhered to Lipinski’s rule of 5, as shown by hydrogen bond donors, hydrogen bond acceptors, number of rotatable bonds, and the value of log Po/w (iLOGP, lipophilicity). Because of its poor absorption in the intestines, the reference molecule acarbose is an outlier. The correlation between a molecule’s hydrogen bonding and its topological polar surface area (TPSA) makes it a good bioavailability predictor. Except for quercetin and acarbose, all the compounds displayed a TPSA that fell within the ideal range of 99–117.4 Å. As a result, these compounds displayed drug‐like behavior when taking ADME‐anticipated factors into account. Drug metabolism relies on cytochrome P450 (CYP) enzymes, making its inhibition an important target in research, development, and patient care. Several enzymes, including CYP1A2, CYP2C9, CYP2D6, CYP2C19, and CYP3A4, were inhibited by all the drugs [<xref rid="bib-0064" ref-type="bibr">64</xref>]. A predictive model based on the lipophilicity (log P) and polarity (TPSA) of substances has been developed and used to assess the possibility of GI absorption and BBB permeability. This model is known as the BOILED‐Egg plot, which has three distinct parts to the design. According to Figure <xref rid="fig-0018" ref-type="fig">18</xref>, molecules with a high GI absorption capacity are shown by the white area (albumin) of the cooked egg plot, whereas molecules with a probable permeability across the BBB are shown by the yellow area. For compounds with little brain penetration and poor gastrointestinal absorption, the gray area is reserved. When given orally, quercetin, oleic acid, corosolic acid, and cianidanol are more likely to show bioavailability since they are placed in the white zone, which indicates a considerable potential for gastrointestinal absorption. Indicating BBB permeability was diosgenin, which was in the yellow zone. The specified range of these levels was exceeded by two compounds, β‐sitosterol and acarbose. Predicting glycoprotein permeability (PGP) is another function of the BOILED‐Egg plot. The red dots on the graph (Figure <xref rid="fig-0019" ref-type="fig">19</xref>) show chemicals that are not expected to be pumped out of cells by P‐glycoprotein (Pgp). This means that these compounds may have higher absorption qualities [<xref rid="bib-0065" ref-type="bibr">65</xref>]. The bioavailability score of each chemical was 0.55. Therefore, the in silico data indicated that these compounds could be a good choice for creating new orally active medications, and it also confirmed that all the compounds had the ability to be bioavailable when taken orally.</p><fig position="float" fig-type="Figure" id="fig-0019" orientation="portrait"><label>Figure 19</label><caption><p>BOILED‐Egg plot showing BBB permeation (yellow), gastrointestinal absorption (white), and P‐gp behavior of key phytochemicals; two molecules fall outside the optimal range.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-69" orientation="portrait" xlink:href="IJBM-2026-5521416-g035.jpg"/></fig><p>The ADMET data (Table <xref rid="tbl-0004" ref-type="table">4</xref>) provide a comprehensive assessment, acting as a crucial resource for directing future development and research of the evaluated drugs for possible therapeutic applications. In addition to the individual evaluations of each chemical, the comprehensive data in the ADMET table provide new perspectives on the toxicological and pharmacokinetic profiles of the synthesized metal compounds. It is possible to see trends and patterns in the collective characteristics of all molecules that would not be obvious when examining each compound alone. Recognizing similarities and differences among the chemicals is a crucial part. For instance, certain compounds may have similar solubility or blood–brain barrier penetration, whereas others may have distinctive features. Strategies for improving medication development or targeting specific biological pathways might be formulated by understanding these common qualities and distinctions. Furthermore, the combined results provide insight into possible adverse interactions or synergistic effects that could occur when multiple medications are taken simultaneously. By meticulously examining the CYP2D6 breakdown, toxicity to the liver, and adherence to plasma proteins of all pharmaceuticals, investigators can improve the safety as well as efficacy of combination therapy. This methodology will facilitate the prediction and prevention of probable drug–drug interactions. The extensive findings underscore the necessity of considering several elements in pharmaceutical research and development. Drug acceptability and safety are affected by characteristics such as metabolism and hepatotoxicity, whereas bioavailability and CNS targeting depend on features including blood–brain barrier permeability and solubility [<xref rid="bib-0066" ref-type="bibr">66</xref>]. By consolidating diverse criteria into a cohesive analysis, researchers can attain a more profound comprehension of the pharmacological attributes and possible hazards of substances, facilitating more enhanced decision‐making in drug development. The findings offer an extensive summary of the toxicological and pharmacokinetic characteristics of these nanosheets, representing a significant progress in enhancing their therapeutic effectiveness and minimizing potential risks in healthcare settings. This aspect represents the novel and significant contribution of the findings.</p></sec><sec id="sec-0046"><title>3.6.3. Induced‐Fit Docking</title><p>To find out how ligands attached to α‐amylase (PDB: 1DHK) and α‐glucosidase (PDB: 4J5T) conform, molecular docking was used. To ascertain the optimal complex, various metrics were employed, including the value of root‐mean‐square deviation (RMSD), the least binding affinity, and the quantity of interfacing residues. To determine the distance between the atoms of the complex’s constituents, the RMSD value was utilized. The lowest RMSD would indicate the most stable binding conformation. One biomolecule’s binding affinity to its ligand or binding partner is the strength of the interaction between the two biomolecules. For an association to be stable and strong, the binding affinity should have a small negative value [<xref rid="bib-0067" ref-type="bibr">67</xref>]. When it comes to finding the optimal position, residues involved in binding were crucial. One method for screening potential ligands is by evaluating their ability to bind to the residues of the active site. The data supporting the docking results are provided in the Supporting file.</p><sec id="sec-0047"><title>3.6.3.1. Elucidating Molecular Docking Interactions of Compounds With α‐Amylase</title><p>Quercetin (5280343): Docking of 1DHK was conducted with quercetin utilizing AutoDockTools. The docking contacts occur at residues HIS101, LYS200, ASP197, and LYS200. The interactions transpire at the active site or within the pocket housing the active site residue. Four hydrogen bonds were found, indicating stable interactions, with −7.35 kcal/mol binding energy (Supporting Table <xref rid="sec-0059" ref-type="sec">1</xref>, Figure <xref rid="sec-0059" ref-type="sec">S1</xref>).</p><p>Oleic acid (445639): Interactions occur at residues LYS200 and ILE235. Two hydrogen bonds were found, contributing to stable interactions, with −5.03 kcal/mol binding energy (Supporting Table <xref rid="sec-0059" ref-type="sec">2</xref>, Figure <xref rid="sec-0059" ref-type="sec">S2</xref>).</p><p>Diosgenin (99474): Interactions occur at residues GLU233 and ASN298. One of the interactions (GLU233) occurs at the active site or within the pocket housing the active site residue. The residue, ASN298, is located inside the pocket’s range. Two hydrogen bonds were detected, indicating stable interactions, despite a binding energy of −9.08 kcal/mol (Supporting Table <xref rid="sec-0059" ref-type="sec">3</xref>, Figure <xref rid="sec-0059" ref-type="sec">S3</xref>).</p><p>Corosolic acid (6918774): The docking findings indicated that the contact occurs at residue VAL163. The interaction is not taking place at the active site or within the pocket housing the active site residue. Upon inspection, we discovered that VAL163 is in close proximity to the active site residues. Consequently, a single hydrogen bond demonstrates an inferior binding energy of −9.42 kcal/mol relative to others (Supporting Table <xref rid="sec-0059" ref-type="sec">4</xref>, Figure <xref rid="sec-0059" ref-type="sec">S4</xref>).</p><p>Cianidanol (9064): Interactions occur at residues ASP 300, TYR 151, LYS 200, and GLU 233. Four interactions are taking place at the active site or within the pocket housing the active site residue. Upon inspection, we discovered that interactions with TYR151, LYS200, and GLU233 are located in the pocket, while one interaction with ASP300 is near the active site residue, exhibiting favorable binding energy. Consequently, the presence of hydrogen bonds and a favorable binding energy of −7.08 kcal/mol suggests that cianidanol may exhibit activity (Supporting Table <xref rid="sec-0059" ref-type="sec">5</xref>, Figure <xref rid="sec-0059" ref-type="sec">S5</xref>).</p><p>β‐Sitosterol (222284): The interaction occurs at residue LYS200. One hydrogen bond is detected, contributing to a stable contact, despite a binding energy of −9.03 kcal/mol (Supporting Table <xref rid="sec-0059" ref-type="sec">6</xref>, Figure <xref rid="sec-0059" ref-type="sec">S6</xref>).</p><p>Acarbose (41774): Interactions occur at residues GLU233, TY151, GLU240, and ILE235. The interactions transpire at the active site or within the pocket housing the active site residue. Five hydrogen bonds were discovered, indicating stable interactions, despite a binding energy of −4.49 kcal/mol. Therefore, it may be stated that “reference” may demonstrate the anticipated activity with the protein target 1DHK, albeit the stability of contacts requires verification (Supporting Table <xref rid="sec-0059" ref-type="sec">7</xref>, Figure <xref rid="sec-0059" ref-type="sec">S7</xref>).</p></sec><sec id="sec-0048"><title>3.6.3.2. Elucidating Molecular Docking Interactions of Compounds With α‐Glucosidase</title><p>Quercetin (5280343): The docking of 4J5T with quercetin was conducted with AutoDockTools. The interactions occur at residues GLN447, ILE362, LEU364, PHE444, and ARG428. Three out of five interactions occur at the active site or within the pocket housing the active site residue. Five hydrogen bonds were found, indicating stable interactions, with −8.58 kcal/mol binding energy (Supporting Table <xref rid="sec-0059" ref-type="sec">8</xref>, Figure <xref rid="sec-0059" ref-type="sec">S8</xref>).</p><p>Oleic acid (445639): Interactions occur at residues TRP425 and ASN448. One of the interactions occurs at the active site or within the pocket housing the active site residue. Two hydrogen bonds were found, indicating stable interactions, with a low binding energy of −6.27 kcal/mol (Supporting Table <xref rid="sec-0059" ref-type="sec">9</xref>, Figure <xref rid="sec-0059" ref-type="sec">S9</xref>).</p><p>Diosgenin (99474): Interaction at residue ILE362. The contact is taking place outside the active site or pocket. The residue ILE362 is next to the active site pocket. Despite the binding energy being −8.41 kcal/mol, the interaction occurs outside the active site pocket. Consequently, we can conclude that diosgenin may demonstrate activity, albeit with modest efficacy, thus rendering it an inadequate choice against this target (Supporting Table <xref rid="sec-0059" ref-type="sec">10</xref>, Figure <xref rid="sec-0059" ref-type="sec">S10</xref>).</p><p>Corosolic acid (6918774): The interaction occurs at residue ASP568, either in the active site or within the pocket housing the active site residue. The system achieved a stable binding energy minimum of −9.7 kcal/mol (Supporting Table <xref rid="sec-0059" ref-type="sec">11</xref>, Figure <xref rid="sec-0059" ref-type="sec">S11</xref>).</p><p>Cianidanol (9064): Interactions occur at residues GLU361, GLN447, ASN448, and ILE362. Four interactions are taking place at the active site or within the pocket housing the active site residue. Upon inspection, we discovered that one interaction with ILE362 is in close proximity to the active site residue, exhibiting favorable binding energy. Consequently, the presence of hydrogen bonds and a favorable binding energy of −8.71 kcal/mol suggest that cianidanol may exhibit activity (Supporting Table <xref rid="sec-0059" ref-type="sec">12</xref>, Figure <xref rid="sec-0059" ref-type="sec">S12</xref>).</p><p>β‐Sitosterol (222284): The interaction occurs at residue GLU771. The interaction takes place at the active site or within the pocket housing the active site residue. One hydrogen bond is detected, contributing to a stable contact, with −8.93 kcal/mol binding energy (Supporting Table <xref rid="sec-0059" ref-type="sec">13</xref>, Figure <xref rid="sec-0059" ref-type="sec">S13</xref>).</p><p>Acarbose (41774): Interactions occur at residues GLU771, ASN448, GLU429, ILE362, GLU361, GLN447, ARG428, and GLU429. Eight out of nine interactions occur at the active site or within the pocket housing the active site residue. Nine hydrogen bonds were found, indicating stable interactions, with −7.43 kcal/mol binding energy (Supporting Table <xref rid="sec-0059" ref-type="sec">14</xref>, Figure <xref rid="sec-0059" ref-type="sec">S14</xref>).</p><p>Quercetin, oleic acid, diosgenin, corosolic acid, cianidanol, and β‐sitosterol derivatives were docked against α‐amylase and α‐glucosidase. Corosolic acid was selected for exhibiting inferior binding energy, i.e., −9.42 kcal/mol when compared to acarbose (−4.49 kcal/mol) for α‐amylase. In opposition to α‐glucosidase once more, corosolic acid has the lowest binding affinity, i.e., −9.72 kcal/mol as compared to the acarbose control (−7.43 kcal/mol). Corosolic acid interacts with α‐amylase at site Val163 (Figure <xref rid="figpt-0029" ref-type="fig">20(a)</xref>), while the control, acarbose, interacts with GLU233, TYR151, ILE235, and GLU240 (Figure <xref rid="figpt-0031" ref-type="fig">20(c)</xref>). α‐Glucosidase is associated with the ASP568 residue (Figure <xref rid="figpt-0030" ref-type="fig">20(b)</xref>), while acarbose is linked to the GLU771, ASN448, GLU429, ILE362, GLN447, and ARG428 residues (Figure <xref rid="figpt-0032" ref-type="fig">20(d)</xref>). The ideal binding conformation with α‐glucosidase and α‐amylase with 2D and 3D interactions of ligand–receptor, as compared to acarbose, is mentioned in the Supporting file. For the simulation investigation, corosolic acid was selected due to its low binding energy and good docking position in comparison with reference acarbose.</p><fig-group position="float" id="fig-0020" content-type="Figure" orientation="portrait"><label>Figure 20</label><caption><p>Using AutoDockTools, complex showing interaction between 1DHK with (a) corosolic acid and (c) acarbose; complex showing interaction between 4J5T with (b) corosolic acid and (d) acarbose.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0029" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-71" orientation="portrait" xlink:href="IJBM-2026-5521416-g036.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0030" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-73" orientation="portrait" xlink:href="IJBM-2026-5521416-g037.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0031" orientation="portrait"><caption><p>(c)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-75" orientation="portrait" xlink:href="IJBM-2026-5521416-g038.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0032" orientation="portrait"><caption><p>(d)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-77" orientation="portrait" xlink:href="IJBM-2026-5521416-g039.jpg"/></fig></fig-group></sec></sec><sec id="sec-0049"><title>3.6.4. Simulation Modeling</title><sec id="sec-0050"><title>3.6.4.1. Delving Into the Simulated Dynamic Interplay of 1DHK and Complex Corosolic Acid</title><p>Using GROMACS, the COMPLEX corosolic acid‐1DHK was simulated. When it comes to MD simulation, GROMACS is lightning fast. It can work with force fields from GROMOS, OPLS, AMBER, and ENCAD, but it does not have one built‐in. The tool is quite adaptable, and it is easy to personalize the analysis. Roughly one hundred analysis and utility programs are part of the bundle. According to the General Public License, GROMACS is free and open to anybody to use. The dynamics studies utilized CHARMM36 force field. Potential energy (Epot) is one of the key metrics to evaluate the efficacy of energy minimization (109). System size and the amount of water molecules determine the minimum value of Epot, which should be negative and in the order of 10<sup>5</sup>. For COMPLEX corosolic acid‐1DHK, the Epot was measured to be −1.03737 × 10<sup>−6</sup> kJ/mol. The energy‐minimizing and potential‐energy‐stable COMPLEX corosolic acid‐1DHK is shown in the plot (Figure <xref rid="figpt-0033" ref-type="fig">21(a)</xref>). A solid foundation for the subsequent simulations is guaranteed by energy minimization. Attaining equilibration for the system was possible after it was energy reduced and appraised positively for potential energy. Within 1 nanosecond, the system was equilibrated with respect to both pressure and temperature. Temperature equilibration was accomplished by the COMPLEX corosolic acid‐1DHK in 1000 ps or 1 nanosecond. The stabilization of the system’s temperature is achieved through temperature equilibration. The system also achieved pressure equilibration in less than one thousandth of a second. The system is well‐equilibrated after the energy minimization and temperature and pressure balancing processes. This was accomplished using GROMACS for the final MD simulation [<xref rid="bib-0068" ref-type="bibr">68</xref>]. A 100‐ns simulation was conducted on the system, and its trajectory was subsequently utilized for the investigation of RMSD, RMSF, and radius of gyration.</p><fig-group position="float" id="fig-0021" content-type="Figure" orientation="portrait"><label>Figure 21</label><caption><p>The graphs illustrate (a) potential energy plot, (b) root‐mean‐square deviation plot, (c) radius of gyration plot, (d) root‐mean‐square fluctuation plot of complex corosolic acid‐1DHK.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0033" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-79" orientation="portrait" xlink:href="IJBM-2026-5521416-g040.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0034" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-81" orientation="portrait" xlink:href="IJBM-2026-5521416-g041.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0035" orientation="portrait"><caption><p>(c)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-83" orientation="portrait" xlink:href="IJBM-2026-5521416-g042.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0036" orientation="portrait"><caption><p>(d)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-85" orientation="portrait" xlink:href="IJBM-2026-5521416-g043.jpg"/></fig></fig-group><p>A built‐in utility called rms is included in GROMACS for calculating RMSD. Based on the data, it was concluded that the COMPLEX corosolic acid‐1DHK protein exhibits an RMSD of less than 0.2 nm for the whole 100‐ns period (Figure <xref rid="figpt-0034" ref-type="fig">21(b)</xref>). The protein (in complex) is exhibiting very little structural variation, suggesting that it is quite stable, as RMSD displays the protein’s variation when all factors are included. Protein compactness can be assessed using GROMACS’s built‐in feature for calculating the radius of gyration. A robust protein conformation guarantees that its radius of gyration remains comparatively steady. Protein gyration radius in COMPLEX corosolic acid‐1DHK is quite constant, according to the graph (Figure <xref rid="figpt-0035" ref-type="fig">21(c)</xref>). Colors red, blue, and green represent the radii of rotation in the <italic toggle="yes">x</italic>, <italic toggle="yes">y</italic>, and <italic toggle="yes">z</italic> dimensions, respectively. These values are used to construct 3D structures, as illustrated in black. Throughout the experiment, the protein managed to keep its compactness, as shown by the stable graph (black color).</p><p>Analysis of the docked complex using RMS fluctuation (RMSF) demonstrated its stability. No significant change to the protein’s structure is indicated by the observed range of RMSF, which is less than 0.3 nm (Figure <xref rid="figpt-0036" ref-type="fig">21(d)</xref>). The stability of the complex is indicated by the aforementioned investigation.</p></sec><sec id="sec-0051"><title>3.6.4.2. Delving Into the Simulated Dynamic Interplay of 4J5T and Complex Corosolic Acid</title><p>For COMPLEX corosolic acid‐4J5T, the calculated Epot was −1.92737 × 10‐6 kJ/mol. The energy‐minimizing and potential‐energy‐stable COMPLEX corosolic acid‐4J5T is shown in the plot (Figure <xref rid="figpt-0037" ref-type="fig">22(a)</xref>).</p><fig-group position="float" id="fig-0022" content-type="Figure" orientation="portrait"><label>Figure 22</label><caption><p>The graphs illustrate (a) potential energy plot, (b) root‐mean‐square deviation plot, (c) radius of gyration plot, (d) root‐mean‐square fluctuation plot of COMPLEX corosolic acid‐4J5T.</p></caption><fig position="anchor" fig-type="Figure" id="figpt-0037" orientation="portrait"><caption><p>(a)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-87" orientation="portrait" xlink:href="IJBM-2026-5521416-g044.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0038" orientation="portrait"><caption><p>(b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-89" orientation="portrait" xlink:href="IJBM-2026-5521416-g045.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0039" orientation="portrait"><caption><p>(c)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-91" orientation="portrait" xlink:href="IJBM-2026-5521416-g046.jpg"/></fig><fig position="anchor" fig-type="Figure" id="figpt-0040" orientation="portrait"><caption><p>(d)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-93" orientation="portrait" xlink:href="IJBM-2026-5521416-g002.jpg"/></fig></fig-group><p>Analysis of Figure <xref rid="figpt-0038" ref-type="fig">22(b)</xref> indicates that over a period of 100 ns, the protein in the COMPLEX corosolic acid‐4J5T demonstrates a minimal RMSD, fluctuating between 0.20 and 0.25 nm. This RMSD reflects the protein’s variation, implying that the protein (in complex) undergoes negligible structural alteration, thereby indicating its remarkable stability.</p><p>The protein in COMPLEX corosolic acid‐4J5T has a reasonably steady radius of gyration, according to the graph analysis (Figure <xref rid="figpt-0039" ref-type="fig">22(c)</xref>). As illustrated in black, the radii of gyration in the <italic toggle="yes">x</italic>, <italic toggle="yes">y</italic>, and <italic toggle="yes">z</italic> dimensions are represented by red, blue, and green, respectively. These dimensions are used in the 3D structure. It is demonstrated that the protein may preserve its compactness during the simulation by the stable graph, which is black in color.</p><p>The stability of the docked complex was demonstrated by the analysis of RMSF. As seen in Figure <xref rid="figpt-0040" ref-type="fig">22(d)</xref>, the RMSF range is less than 0.5 nm, indicating that there has been no notable alteration to the protein structure. All the preceding analysis points to a stable complex.</p></sec></sec></sec></sec><sec id="sec-0052"><title>4. Discussion</title><p>Nanotechnology has emerged as a significant technological advancement with widespread applications across various sectors, including agriculture, food production, medicine, and biomedical engineering. Renowned for their minuscule size, versatility, and compatibility with a variety of materials such as optical, textile, magnetic, electronic, mechanical, and chemical substances, nanoparticles offer promising possibilities for therapeutic applications [<xref rid="bib-0005" ref-type="bibr">5</xref>, <xref rid="bib-0007" ref-type="bibr">7</xref>]. These nanoparticles exhibit diverse properties, including antibacterial, antioxidant, antidiabetic, and anticancer effects. Graphene, selected for green synthesis, is lightweight and chemically stable and exhibits excellent electron conductivity [<xref rid="bib-0009" ref-type="bibr">9</xref>–<xref rid="bib-0015" ref-type="bibr">15</xref>]. Graphene is synthesized through various innovative methods. Natural graphite is oxidized to graphite oxide, which is subsequently exfoliated by sonication to yield GO. The reduction process is indicated by a color change from brownish–yellow to black [<xref rid="bib-0069" ref-type="bibr">69</xref>]. The study and utilization of nanoparticles are deeply rooted in the integration of physical, chemical, and biological scientific disciplines [<xref rid="bib-0070" ref-type="bibr">70</xref>]. rGO has garnered significant interest due to its exceptional thermal conductivity, electrical properties, high Young’s modulus, mechanical robustness, optical transparency, and relevance in theoretical studies [<xref rid="bib-0015" ref-type="bibr">15</xref>]. Owing to these properties, rGO is extensively employed across a wide spectrum of technological applications and is typically synthesized via the chemical reduction of GO. Conventional reducing agents, such as hydrazine, though effective, pose considerable environmental and health risks due to their toxic nature. Consequently, there is a growing research focus on identifying environmentally benign alternatives for the reduction of GO [<xref rid="bib-0071" ref-type="bibr">71</xref>]. The leaves of <italic toggle="yes">C. igneus</italic>, a plant from the <italic toggle="yes">Costaceae</italic> family, contain various phytochemicals such as glycosides, carbohydrates, alkaloids, saponins, flavonoids, tannins, phytosterols, proteins, phenolic compounds, and amino acids that serve as effective reducing agents [<xref rid="bib-0016" ref-type="bibr">16</xref>–<xref rid="bib-0020" ref-type="bibr">20</xref>, <xref rid="bib-0025" ref-type="bibr">25</xref>]. <italic toggle="yes">C. igneus</italic>, also known as fiery costus or the “insulin plant,” is of particular interest due to its potential therapeutic uses, particularly in the treatment of diabetes [<xref rid="bib-0026" ref-type="bibr">26</xref>]. The successful synthesis of graphene nanosheet from this plant has been confirmed through various analytical techniques, including XRD, Raman spectroscopy, UV–vis, and FTIR spectroscopy. The surface of GO contains various oxygen‐rich functional groups, including epoxide, hydroxyl, and carbonyl. Under basic conditions, epoxide and carbonyl groups can be converted into hydroxyl groups. <italic toggle="yes">C. igneus</italic> leaf extract is abundant in polyphenols, which possess highly acidic hydrogen atoms that readily ionize into their anionic forms. These anionic polyphenols engage in nucleophilic substitution with GO’s hydroxyl groups, leading to the formation of an intermediate. The subsequent removal of a water molecule facilitates the transformation of this intermediate into rGO [<xref rid="bib-0047" ref-type="bibr">47</xref>–<xref rid="bib-0049" ref-type="bibr">49</xref>]. The biosynthesis of nanoparticles, particularly from plant extracts, has attracted significant attention in biomedical research due to their biocompatibility and broad range of applications. Many conventional oral antidiabetic medications struggle to maintain stable blood glucose control. In contrast, extracts from medicinal plants have demonstrated efficacy in reducing blood glucose levels, making them valuable alternatives for managing diabetes. This study investigates the antidiabetic potential of the <italic toggle="yes">C. igneus</italic> leaf extract and its rGO nanosheet using in vitro, kinetic, and in silico models. The glucose oxidase‐peroxidase method was employed to measure glucose absorption in Chang liver and U87MG cells. The results demonstrated a significant increase in glucose uptake in both cell types treated with the plant extract and nanosheets compared to the positive control, metformin. At higher concentrations, nanosheets enhanced glucose absorption in both cell lines; i.e., the uptake activity of Chang liver cells was 81.39% when treated with CIrGO, which was significantly higher than U87MG cells’ 78.54%, and significantly different from the control (<italic toggle="yes">p</italic> &lt; 0.0001). These findings suggest that the type of cell used in glucose absorption assays influences the results. Additionally, the rate of glucose metabolism and the internal glucose concentration within cells play critical roles in determining glucose uptake. The enhanced glucose uptake in hepatocytes and glioma cells may be attributed to facilitated diffusion and enhanced glucose metabolism [<xref rid="bib-0054" ref-type="bibr">54</xref>]. The hypoglycemic effects of polyphenols are primarily attributed to their ability to inhibit carbohydrate absorption in the intestine, modulate glucose absorption by modifying enzyme activity, enhance β‐cell function and insulin action, promote insulin secretion, and provide antioxidant and anti‐inflammatory benefits. These findings were consistent with studies investigating the metabolic effects of CIrGO derivatives. Angiopep‐2‐modified doxorubicin‐loaded GO (ANG‐Dox‐GO) in U87MG cells, showing enhanced cellular uptake and antiproliferative effects. Although glucose uptake was not directly measured, the increased metabolic activity suggests that such nanomaterials could influence glucose metabolism. Similarly, another study involving hyaluronic acid–modified rGO for targeted therapy in U87 glioblastoma cells demonstrated that rGO nanocomposites facilitated enhanced intracellular uptake, which could imply alterations in glucose utilization. Although direct studies on glucose uptake in Chang liver cells treated with rGO are limited, there are relevant studies on HepG2 liver cells that provide insights into the potential effects of rGO on cellular metabolism [<xref rid="bib-0072" ref-type="bibr">72</xref>]. Fe<sub>3</sub>O<sub>4</sub>‐rGO nanocomposites demonstrate cytotoxicity in HepG2 cells by triggering oxidative stress and apoptosis, which may subsequently disrupt glucose metabolism through indirect pathways. These findings suggest that rGO derivatives could play a role in altering glucose metabolism, even though direct evidence from glucose uptake assays in liver cells is scarce [<xref rid="bib-0073" ref-type="bibr">73</xref>]. The digestion of oligosaccharides and disaccharides into monosaccharides by enzymes like pancreatic α‐amylase and intestinal α‐glucosidase leads to an increase in blood glucose levels. Inhibiting these enzymes can, therefore, reduce blood glucose levels in diabetic patients [<xref rid="bib-0057" ref-type="bibr">57</xref>]. The study found that both the aqueous <italic toggle="yes">C. igneus</italic> extract and its nanosheets inhibited α‐amylase and α‐glucosidase in a concentration‐dependent manner, with significant inhibition compared to the positive control, acarbose. Although acarbose is effective in controlling blood glucose levels, it can cause side effects, such as abdominal discomfort and flatulence. This has led to the exploration of natural alternatives with fewer side effects. CIrGO demonstrated a dose‐dependent inhibitory effect against both enzymes, with an IC<sub>50</sub> of 84.46 μg·mL<sup>−1</sup>, compared to acarbose’s IC<sub>50</sub> of 65.46 μg·mL<sup>−1</sup>. The aqueous <italic toggle="yes">C. igneus</italic> extract exhibited a slightly higher IC<sub>50</sub> of 92.62 μg·mL<sup>−1</sup>. At 50 μg·mL<sup>−1</sup>, CIrGO inhibited α‐glucosidase by 89%, while acarbose showed 92.05% inhibition. Kinetic analysis revealed a noncompetitive inhibition pattern for both α‐amylase and α‐glucosidase, with both CIrGO and acarbose causing a decrease in Vmax while maintaining nearly the same <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">m</italic>
</sub>. Despite the limited number of studies examining the impact of biologically synthesized rGO on α‐amylase and α‐glucosidase inhibition, this research demonstrates that <italic toggle="yes">C. igneus</italic> leaf extract and its rGO nanosheet effectively inhibit this enzyme. Further studies have explored the inhibitory effects of rGO‐based nanocomposites on α‐glucosidase activity. A study involving palladium‐decorated rGO (Pd‐rGO) demonstrated significant α‐glucosidase inhibition, highlighting the potential of rGO derivatives in managing postprandial hyperglycemia [<xref rid="bib-0074" ref-type="bibr">74</xref>]. Additionally, research on rGO has revealed significant changes in membrane potential and gene expression following treatment. This suggests that rGO may alter cellular functions related to ion transport and metabolic processes, which could indirectly influence the activity of amylolytic enzymes. However, direct evidence of rGO’s effect on α‐amylase and α‐glucosidase remains limited [<xref rid="bib-0075" ref-type="bibr">75</xref>]. Cytotoxicity assays confirmed that both the Aq‐CI extract and CIrGO exhibited concentration‐dependent toxicity, with higher concentrations increasing cell toxicity. In Chang liver cells, IC<sub>50</sub> for CIrGO was 235.72 μg·mL<sup>−1</sup>, and for Aq‐CI, it was 303.89 μg·mL<sup>−1</sup>, compared to metformin’s IC<sub>50</sub> of 327.01 μg·mL<sup>−1</sup>. In U87MG cells, IC<sub>50</sub> for CIrGO was 199.73 μg·mL<sup>−1</sup>, and for the Aq‐CI extract, it was 276.34 μg·mL<sup>−1</sup>, compared to metformin’s IC<sub>50</sub> of 346.74 μg·mL<sup>−1</sup>. These results align with previous studies [<xref rid="bib-0021" ref-type="bibr">21</xref>, <xref rid="bib-0053" ref-type="bibr">53</xref>] that report dose‐dependent cytotoxic effects of plant extracts on cells. Furthermore, studies have shown that rGO can reduce cancer cell viability by inducing oxidative stress, apoptosis, and damage to cell membranes. The higher cytotoxicity observed in U87MG cells suggests that CIrGO selectively induces apoptosis in cancer cells more effectively than in normal cells. This selectivity may stem from the enhanced generation of ROS in malignant cells, leading to oxidative stress, disruption of cellular membranes, and programmed cell death. These findings align with earlier reports indicating that elevated concentrations of rGO induce ROS‐mediated cytotoxicity and apoptosis in cancer models [<xref rid="bib-0053" ref-type="bibr">53</xref>]. Furthermore, the presence of phytochemicals adsorbed onto CIrGO surfaces may enhance its bioactivity and cellular uptake. This synergistic combination of CIrGO’s nanostructure and the flavonoid‐rich plant extract contributes to its multifunctionality [<xref rid="bib-0076" ref-type="bibr">76</xref>]. Molecular docking studies identified corosolic acid as a promising antidiabetic compound within <italic toggle="yes">C. igneus</italic> leaf extract among various derivatives investigated based on literature search [<xref rid="bib-0025" ref-type="bibr">25</xref>, <xref rid="bib-0026" ref-type="bibr">26</xref>, <xref rid="bib-0062" ref-type="bibr">62</xref>, <xref rid="bib-0063" ref-type="bibr">63</xref>]. ADMET profiling indicated that corosolic acid has favorable pharmacokinetic properties, with no adverse effects on absorption, and it adheres to various drug‐likeness criteria. The stability of the corosolic acid–protein complex was confirmed through MD simulations, which showed minimal structural changes, suggesting the stability of the compound. This study highlights corosolic acid as the key bioactive compound contributing to the antidiabetic effects of the <italic toggle="yes">C. igneus</italic> leaf extract.</p></sec><sec id="sec-0053"><title>5. Conclusion</title><p>The <italic toggle="yes">C. igneus</italic> was successfully utilized to synthesize CIrGO, which was subsequently analyzed using conventional analytical techniques. The synthesized CIrGO was found to be in the form of a thin nanosheet. The EDAX spectrum confirmed the elemental composition with carbon (86%) and oxygen (13%) as the predominant elements. The Aq‐CI contains a variety of phytochemicals, including glycosides, carbohydrates, alkaloids, saponins, flavonoids, tannins, phytosterols, proteins, phenolic compounds, and amino acids, which serve as effective reducing agents during the synthesis process. At higher concentrations, CIrGO exhibited toxicity, with 28.26% cell viability at 400 μg·mL<sup>−1</sup>. Upon incubation with different concentrations, CIrGO significantly inhibited the activities of α‐amylase and α‐glucosidase in a concentration‐dependent manner while enhancing glucose uptake in both Chang liver and U87MG cells. Human glucose regulation is primarily controlled by insulin and glucagon, and dysregulation of these hormones can lead to conditions such as diabetes and hyperglycemia. The study demonstrated that eco‐friendly synthesis of CIrGO and the phytochemicals in the <italic toggle="yes">C. igneus</italic> extract interacted with these hormones to modulate glucose metabolism. The interaction between the graphene nanosheet and the phytochemicals involved in the biosynthesis of CIrGO with the amino acid residues of carbohydrate‐hydrolyzing enzymes likely contributed to the observed reduction in enzyme activity. Further validation through molecular docking and interaction studies supported these findings, revealing how the plant‐derived phytochemicals interacted with the amino acid residues of α‐amylase and α‐glucosidase to regulate glucose metabolism. According to these insights, the produced CIrGO could be a promising nanomedicine for the management of diabetes.</p></sec><sec><def-list list-content="abbreviations" list-type="simple"><title>Nomenclature</title><def-item><term>GO</term><def><p>Graphene oxide</p></def></def-item><def-item><term>rGO</term><def><p>Reduced graphene oxide</p></def></def-item><def-item><term>CIrGO</term><def><p>
<italic toggle="yes">Costus igneus</italic>–derived reduced graphene oxide</p></def></def-item><def-item><term>T2DM</term><def><p>Type II diabetes mellitus</p></def></def-item><def-item><term>Aq‐CI</term><def><p>
<italic toggle="yes">Costus igneus</italic> leaves aqueous extract</p></def></def-item><def-item><term>DNS</term><def><p>Dinitrosalicylic acid</p></def></def-item><def-item><term>ADMET</term><def><p>Absorption, distribution, metabolism, excretion, and toxicity</p></def></def-item><def-item><term>FTIR</term><def><p>Fourier‐transform infrared</p></def></def-item><def-item><term>XRD</term><def><p>X‐ray diffraction</p></def></def-item><def-item><term>TPSA</term><def><p>Topological polar surface area</p></def></def-item><def-item><term>CYP</term><def><p>Cytochrome P450</p></def></def-item><def-item><term>BBB</term><def><p>Blood–brain barrier</p></def></def-item></def-list></sec><sec id="sec-0054"><title>Author Contributions</title><p>Mansi Yadav: writing–original draft, conceptualization, methodology, and data curation; Divya Vashishth: writing–review and editing; Monika Bhardwaj: writing–review and editing; Jaya Parkash Yadav: conceptualization and supervision; Sudhir Kumar Kataria: conceptualization and supervision.</p></sec><sec id="sec-0055"><title>Funding</title><p>No funding was received for this manuscript.</p></sec><sec sec-type="COI-statement" id="sec-0056"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="sec-0059"><title>Supporting Information</title><p>Supporting Information Description: This supporting information provides additional information and data supporting the study presented in the main manuscript. It includes additional data and images related to molecular docking analyses of selected bioactive compounds with human pancreatic α‐amylase (PDB‐ID: 1DHK) and α‐glucosidase (PDB‐ID: 4J5T) to elucidate their docking parameters and visualization images of their interactions.</p><p>Figure S1 (visualization for the docking of 1DHK with quercetin), Figure S2 (visualization for the docking of 1DHK with oleic acid), Figure S3 (visualization for the docking of 1DHK with diosgenin), Figure S4 (visualization for the docking of 1DHK with corosolic acid), Figure S5 (visualization for the docking of 1DHK with cianidanol), Figure S6 (visualization for the docking of 1DHK with β‐sitosterol), Figure S7 (visualization for the docking of 1DHK with reference acarbose), Figure S8 (visualization for the docking of 4J5T with quercetin), Figure S9 (visualization for the docking of 4J5T with oleic acid), Figure S10 (visualization for the docking of 4J5T with diosgenin), Figure S11 (visualization for the docking of 4J5T with corosolic acid), Figure S12 (visualization for the docking of 4J5T with cianidanol), Figure S13 (visualization for the docking of4J5T with β‐sitosterol), Figure S14 (visualization for the docking of 4J5T with reference acarbose), TableS1 (docking parameters for 1DHK with quercetin), Table S2 (docking parameters for 1DHK with oleic acid), Table S3 (docking parameters for 1DHK with diosgenin), Table S4 (docking parameters for 1DHK with corosolic acid), Table S5 (docking parameters for 1DHK with cianidanol), Table S6 (docking parameters for 1DHK with β‐sitosterol), Table S7 (docking parameters for 1DHK with reference acarbose), Table S8 (docking parameters for 4J5T with quercetin), Table S9 (docking parameters for 4J5T with oleic acid), Table S10 (docking parameters for 4J5T with diosgenin), Table S11 (docking parameters for 4J5T with corosolic acid), Table S12 (docking parameters for 4J5T with cianidanol), Table S13 (docking parameters for 4J5T with β‐sitosterol), and Table S14 (docking parameters for 4J5T with reference acarbose).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="link-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Supporting Information</bold> Additional supporting information can be found online in the Supporting Information section.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IJBM-2026-5521416-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="sec-0058"><title>Data Availability Statement</title><p>The data that support the findings of this study are available in the supporting information of this article.</p></sec><ref-list><ref id="bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cit-0001">
<string-name name-style="western">
<surname>Wild</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Roglic</surname>
<given-names>G.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Green</surname>
<given-names>A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Sicree</surname>
<given-names>R.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>King</surname>
<given-names>H.</given-names>
</string-name>, <article-title>Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030</article-title>, <source>Diabetes Care</source>. (<year>2004</year>) <volume>27</volume>, no. 5, <fpage>1047</fpage>–<lpage>1053</lpage>, <pub-id pub-id-type="doi">10.2337/diacare.27.5.1047</pub-id>, 2-s2.0-2342466734.<pub-id pub-id-type="pmid">15111519</pub-id>
</mixed-citation></ref><ref id="bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cit-0002">
<string-name name-style="western">
<surname>Chipiti</surname>
<given-names>T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Mbukwa</surname>
<given-names>E.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Mukaratirwa</surname>
<given-names>S.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Moyo</surname>
<given-names>D.</given-names>
</string-name>, <article-title>In Vitro α-Amylase and α-Glucosidase Inhibitory Effects and Cytotoxic Activity of <italic toggle="yes">Albizia antunesiana</italic> Extracts</article-title>, <source>Pharmacognosy Magazine</source>. (<year>2015</year>) <volume>11</volume>, no. Suppl 2.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0973-1296.166018</pub-id><pub-id pub-id-type="pmcid">PMC4653332</pub-id><pub-id pub-id-type="pmid">26664010</pub-id></mixed-citation></ref><ref id="bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cit-0003">
<string-name name-style="western">
<surname>Jhong</surname>
<given-names>C. H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Riyaphan</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lin</surname>
<given-names>S. H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Chia</surname>
<given-names>Y. C.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Weng</surname>
<given-names>C. F.</given-names>
</string-name>, <article-title>Screening Alpha-Glucosidase and Alpha-Amylase Inhibitors From Natural Compounds by Molecular Docking in Silico</article-title>, <source>BioFactors</source>. (<year>2015</year>) <volume>41</volume>, no. 4, <fpage>242</fpage>–<lpage>251</lpage>, <pub-id pub-id-type="doi">10.1002/biof.1219</pub-id>, 2-s2.0-84939572208.<pub-id pub-id-type="pmid">26154585</pub-id>
</mixed-citation></ref><ref id="bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cit-0004">
<string-name name-style="western">
<surname>Wang</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Chen</surname>
<given-names>Y.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Wang</surname>
<given-names>L.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Liu</surname>
<given-names>Q.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yang</surname>
<given-names>S.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Wang</surname>
<given-names>C.</given-names>
</string-name>, <article-title>Advancing Herbal Medicine: Enhancing Product Quality and Safety Through Robust Quality Control Practices</article-title>, <source>Frontiers in Pharmacology</source>. (<year>2023</year>) <volume>14</volume>, <pub-id pub-id-type="doi">10.3389/fphar.2023.1265178</pub-id>.<pub-id pub-id-type="pmcid">PMC10561302</pub-id><pub-id pub-id-type="pmid">37818188</pub-id></mixed-citation></ref><ref id="bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cit-0005">
<string-name name-style="western">
<surname>Madiha</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Al-Sulimani</surname>
<given-names>A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Shaikh</surname>
<given-names>O.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Salim</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>El-Hamidy</surname>
<given-names>I.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Abu-Zeid</surname>
<given-names>I. M.</given-names>
</string-name>, <article-title>Therapeutic Efficacy of Nanoparticles in the Treatment of Diabetes Mellitus: An Overview</article-title>, <source>Acta Socio-Medica Scandinavica</source>. (<year>2023</year>) <volume>7</volume>, <pub-id pub-id-type="doi">10.31080/asms.2023.07.1702</pub-id>.</mixed-citation></ref><ref id="bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cit-0006">
<string-name name-style="western">
<surname>Nitesh</surname>
<given-names>K. Y.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Mazumder</surname>
<given-names>R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Rani</surname>
<given-names>A.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Kumar</surname>
<given-names>A.</given-names>
</string-name>, <article-title>Current Perspectives on Using Nanoparticles for Diabetes Management</article-title>, <source>International Journal of Applied Pharmaceutics</source>. (<year>2024</year>) <volume>16</volume>, <pub-id pub-id-type="doi">10.22159/ijap.2024v16i5.51084</pub-id>.</mixed-citation></ref><ref id="bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cit-0007">
<string-name name-style="western">
<surname>Kedar</surname>
<given-names>P. M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Sahu</surname>
<given-names>B. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Karri</surname>
<given-names>T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Samal</surname>
<given-names>P.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Jaiswal</surname>
<given-names>D.</given-names>
</string-name>, <article-title>Development and Characterization of Pioglitazone Hydrochloride-Loaded Nanoparticles for the Management of Diabetes Mellitus</article-title>, <source>Research Journal of Pharmacy and Technology</source>. (<year>2024</year>) <volume>2024</volume>, <pub-id pub-id-type="doi">10.52711/0974-360x.2024.00277</pub-id>.</mixed-citation></ref><ref id="bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cit-0008">
<string-name name-style="western">
<surname>Li</surname>
<given-names>X.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Wang</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Robinson</surname>
<given-names>J. T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Sanchez</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Diankov</surname>
<given-names>G.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Dai</surname>
<given-names>H.</given-names>
</string-name>, <article-title>Simultaneous Nitrogen Doping and Reduction of Graphene Oxide</article-title>, <source>Journal of the American Chemical Society</source>. (<year>2009</year>) <volume>131</volume>, no. 43, <fpage>15939</fpage>–<lpage>15944</lpage>, <pub-id pub-id-type="doi">10.1021/ja907098f</pub-id>, 2-s2.0-70350645271.<pub-id pub-id-type="pmid">19817436</pub-id>
</mixed-citation></ref><ref id="bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cit-0009">
<string-name name-style="western">
<surname>Wen</surname>
<given-names>B.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Cao</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lu</surname>
<given-names>M.</given-names>
</string-name> et al., <article-title>Reduced Graphene Oxides: Lightweight and High-Efficiency Electromagnetic Interference Shielding at Elevated Temperatures</article-title>, <source>Advances in Materials</source>. (<year>2014</year>) <volume>26</volume>, no. 21, <fpage>3484</fpage>–<lpage>3489</lpage>, <pub-id pub-id-type="doi">10.1002/adma.201400108</pub-id>, 2-s2.0-84901929085.<pub-id pub-id-type="pmid">24648151</pub-id></mixed-citation></ref><ref id="bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cit-0010">
<string-name name-style="western">
<surname>Novoselov</surname>
<given-names>K. S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Geim</surname>
<given-names>A. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Morozov</surname>
<given-names>S. V.</given-names>
</string-name> et al., <article-title>Electric Field Effect in Atomically Thin Carbon Films</article-title>, <source>Science</source>. (<year>2004</year>) <volume>306</volume>, no. 5696, <fpage>666</fpage>–<lpage>669</lpage>, <pub-id pub-id-type="doi">10.1126/science.1102896</pub-id>, 2-s2.0-7444220645.<pub-id pub-id-type="pmid">15499015</pub-id>
</mixed-citation></ref><ref id="bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cit-0011">
<string-name name-style="western">
<surname>Bolotin</surname>
<given-names>K. I.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Sikes</surname>
<given-names>K. J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Jiang</surname>
<given-names>Z.</given-names>
</string-name> et al., <article-title>Ultrahigh Electron Mobility in Suspended Graphene</article-title>, <source>Solid State Communications</source>. (<year>2008</year>) <volume>146</volume>, no. 9-10, <fpage>351</fpage>–<lpage>355</lpage>, <pub-id pub-id-type="doi">10.1016/j.ssc.2008.02.024</pub-id>, 2-s2.0-43049170468.</mixed-citation></ref><ref id="bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cit-0012">
<string-name name-style="western">
<surname>Falkovsky</surname>
<given-names>L. A.</given-names>
</string-name>, <article-title>Optical Properties of Graphene</article-title>, <source>Journal of Physics. Conference Series</source>. (<year>2008</year>) <volume>129</volume>, <pub-id pub-id-type="doi">10.1088/1742-6596/129/1/012004</pub-id>, 2-s2.0-65549145927.</mixed-citation></ref><ref id="bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cit-0013">
<string-name name-style="western">
<surname>Berry</surname>
<given-names>V.</given-names>
</string-name>, <article-title>Impermeability of Graphene and Its Applications</article-title>, <source>Carbon</source>. (<year>2013</year>) <volume>62</volume>, <fpage>1</fpage>–<lpage>10</lpage>, <pub-id pub-id-type="doi">10.1016/j.carbon.2013.05.052</pub-id>, 2-s2.0-84880278573.</mixed-citation></ref><ref id="bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cit-0014">
<string-name name-style="western">
<surname>Xiang</surname>
<given-names>Q.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yu</surname>
<given-names>J.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Jaroniec</surname>
<given-names>M.</given-names>
</string-name>, <article-title>Graphene-Based Semiconductor Photocatalysts</article-title>, <source>Chemical Society Reviews</source>. (<year>2012</year>) <volume>41</volume>, no. 2, <fpage>782</fpage>–<lpage>796</lpage>, <pub-id pub-id-type="doi">10.1039/C1CS15172J</pub-id>, 2-s2.0-80054954337.<pub-id pub-id-type="pmid">21853184</pub-id>
</mixed-citation></ref><ref id="bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cit-0015">
<string-name name-style="western">
<surname>Nair</surname>
<given-names>R. R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Blake</surname>
<given-names>P.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Grigorenko</surname>
<given-names>A. N.</given-names>
</string-name> et al., <article-title>Fine Structure Constant Defines Visual Transparency of Graphene</article-title>, <source>Science</source>. (<year>2008</year>) <volume>320</volume>, no. 5881, <pub-id pub-id-type="doi">10.1126/science.1156965</pub-id>, 2-s2.0-45349092986.<pub-id pub-id-type="pmid">18388259</pub-id></mixed-citation></ref><ref id="bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cit-0016">
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yang</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Shen</surname>
<given-names>G.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Cheng</surname>
<given-names>P.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>J.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Guo</surname>
<given-names>S.</given-names>
</string-name>, <article-title>Reduction of Graphene Oxide via L-Ascorbic Acid</article-title>, <source>Chsem Commun</source>. (<year>2010</year>) <volume>46</volume>, no. 7, <fpage>1112</fpage>–<lpage>1114</lpage>, <pub-id pub-id-type="doi">10.1039/B917705A</pub-id>, 2-s2.0-76249106647.<pub-id pub-id-type="pmid">20126730</pub-id></mixed-citation></ref><ref id="bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cit-0017">
<string-name name-style="western">
<surname>Zhu</surname>
<given-names>C.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Guo</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Fang</surname>
<given-names>Y.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Dong</surname>
<given-names>S.</given-names>
</string-name>, <article-title>Reducing Sugar: New Functional Molecules for the Green Synthesis of Graphene Nanosheet</article-title>, <source>ACS Nano</source>. (<year>2010</year>) <volume>4</volume>, <fpage>2429</fpage>–<lpage>2437</lpage>, <pub-id pub-id-type="doi">10.1021/nn1002387</pub-id>, 2-s2.0-77951704609.<pub-id pub-id-type="pmid">20359169</pub-id>
</mixed-citation></ref><ref id="bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cit-0018">
<string-name name-style="western">
<surname>Kuila</surname>
<given-names>T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Bose</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Khanra</surname>
<given-names>P.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Mishra</surname>
<given-names>A. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kim</surname>
<given-names>N. H.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Lee</surname>
<given-names>J. H.</given-names>
</string-name>, <article-title>A Green Approach for the Reduction of Graphene Oxide by Wild Carrot Root</article-title>, <source>Carbon</source>. (<year>2012</year>) <volume>50</volume>, no. 3, <fpage>914</fpage>–<lpage>921</lpage>, <pub-id pub-id-type="doi">10.1016/j.carbon.2011.09.053</pub-id>, 2-s2.0-84155170920.</mixed-citation></ref><ref id="bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cit-0019">
<string-name name-style="western">
<surname>Chen</surname>
<given-names>D.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Li</surname>
<given-names>L.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Guo</surname>
<given-names>L.</given-names>
</string-name>, <article-title>An Environment-Friendly Preparation of Reduced Graphene Oxide Nanosheet via Amino Acid</article-title>, <source>Nanotechnology</source>. (<year>2011</year>) <volume>22</volume>, no. 32, <pub-id pub-id-type="doi">10.1088/0957-4484/22/32/325601</pub-id>, 2-s2.0-79960781730.<pub-id pub-id-type="pmid">21757797</pub-id></mixed-citation></ref><ref id="bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cit-0020">
<string-name name-style="western">
<surname>Wang</surname>
<given-names>Y.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Shi</surname>
<given-names>Z.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Yin</surname>
<given-names>J.</given-names>
</string-name>, <article-title>Facile Synthesis of Soluble Graphene via a Green Reduction of Graphene Oxide in Tea Solution and Its Biocomposites</article-title>, <source>ACS Applied Materials and Interfaces</source>. (<year>2011</year>) <volume>3</volume>, no. 4, <fpage>1127</fpage>–<lpage>1133</lpage>, <pub-id pub-id-type="doi">10.1021/am1012613</pub-id>, 2-s2.0-79961001267.<pub-id pub-id-type="pmid">21438576</pub-id>
</mixed-citation></ref><ref id="bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cit-0021">
<string-name name-style="western">
<surname>Josephine</surname>
<given-names>I. G.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Punnagai</surname>
<given-names>K.</given-names>
</string-name>, <article-title>In Vitro Cytotoxicity Activity of Ethanolic Leaf Extract of <italic toggle="yes">Costus igneus</italic> Against Hepatocellular Carcinoma (HepG2) Cells</article-title>, <source>Biomedicine &amp; Pharmacotherapy J</source>. (<year>2019</year>) <volume>12</volume>, no. 2, <fpage>901+</fpage>–<lpage>906</lpage>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://link.gale.com/apps/doc/A600551847/HRCA" ext-link-type="uri">https://link.gale.com/apps/doc/A600551847/HRCA</ext-link>, <pub-id pub-id-type="doi">10.13005/bpj/1715</pub-id>, 2-s2.0-85069619432.</mixed-citation></ref><ref id="bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cit-0022">
<string-name name-style="western">
<surname>Damam</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Rana</surname>
<given-names>K.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Gaddam</surname>
<given-names>B.</given-names>
</string-name>, <article-title>Primary Screening of Phytochemicals Present in Crude Extracts of Leaf, Stem and Rhizome of <italic toggle="yes">Costus igneus</italic> (Insulin Plant)</article-title>, <source>International Journal of Research in Ayurveda and Pharmacy</source>. (<year>2019</year>) <volume>7</volume>, no. 3, <fpage>1252</fpage>–<lpage>1257</lpage>, <pub-id pub-id-type="doi">10.32622/IJRAT.73201975</pub-id>.</mixed-citation></ref><ref id="bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cit-0023">
<string-name name-style="western">
<surname>Vijaya</surname>
<given-names>V.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Balan</surname>
<given-names>K. S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Paul</surname>
<given-names>J. A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>John</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ramya</surname>
<given-names>R.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Jayakumararaj</surname>
<given-names>R.</given-names>
</string-name>, <article-title>Phytochemical Screening, GC-MS and FTIR Analysis of Bioactive Compounds in Methanolic Leaf Extracts of <italic toggle="yes">Costus igneus</italic> (CIMLE) as a Natural Source of Drug Lead Molecules for Next-Generation Drug Design, Development and Therapeutics</article-title>, <source>Journal of Drug Delivery and Therapeutics</source>. (<year>2022</year>) <volume>12</volume>, no. 5-S, <fpage>142</fpage>–<lpage>155</lpage>, <pub-id pub-id-type="doi">10.22270/jddt.v12i5-s.5658</pub-id>.</mixed-citation></ref><ref id="bib-0024"><label>24</label><mixed-citation publication-type="book" id="cit-0024">
<string-name name-style="western">
<surname>Upadhyay</surname>
<given-names>T. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Das</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Mathur</surname>
<given-names>M.</given-names>
</string-name> et al., <part-title>Medicinal Plants and Their Bioactive Components With Antidiabetic Potentials</part-title>, <source>Antidiabetic Medicinal Plants</source>, <year>2024</year>.</mixed-citation></ref><ref id="bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cit-0025">
<string-name name-style="western">
<surname>Deogade</surname>
<given-names>M. S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Wanjari</surname>
<given-names>A.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Lohakare</surname>
<given-names>S. C.</given-names>
</string-name>, <article-title>Pharmacognostical and Phytochemical Study of <italic toggle="yes">Costus igneus</italic> NE Br Leaf</article-title>, <source>Journal of Indian System of Medicine</source>. (<year>2014</year>) <volume>2</volume>, no. 4, <fpage>174</fpage>–<lpage>178</lpage>, <pub-id pub-id-type="doi">10.5005/jism-11051-02403</pub-id>.</mixed-citation></ref><ref id="bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cit-0026">
<string-name name-style="western">
<surname>Mathew</surname>
<given-names>F.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Varghese</surname>
<given-names>B.</given-names>
</string-name>, <article-title>A Review on Medicinal Exploration of <italic toggle="yes">Costus igneus</italic>: The Insulin Plant</article-title>, <source>International Journal of Pharmaceutical Sciences Review and Research</source>. (<year>2019</year>) <volume>54</volume>, no. 2, <fpage>51</fpage>–<lpage>57</lpage>.</mixed-citation></ref><ref id="bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cit-0027">
<string-name name-style="western">
<surname>Yu</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>B.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Bulin</surname>
<given-names>C.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Li</surname>
<given-names>R.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Xing</surname>
<given-names>R.</given-names>
</string-name>, <article-title>High-Efficient Synthesis of Graphene Oxide Based on Improved Hummers Method</article-title>, <source>Scientific Reports</source>. (<year>2016</year>) <volume>6</volume>, no. 1, <pub-id pub-id-type="doi">10.1038/srep36143</pub-id>, 2-s2.0-84994219129.<pub-id pub-id-type="pmcid">PMC5093679</pub-id><pub-id pub-id-type="pmid">27808164</pub-id></mixed-citation></ref><ref id="bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cit-0028">
<string-name name-style="western">
<surname>Zengin Kurt</surname>
<given-names>B.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Durmus</surname>
<given-names>Z.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Sevgi</surname>
<given-names>E.</given-names>
</string-name>, <article-title>In Situ Reduction of Graphene Oxide by Different Plant Extracts as a Green Catalyst for Selective Hydrogenation of Nitroarenes</article-title>, <source>International Journal of Hydrogen Energy</source>. (<year>2019</year>) <volume>44</volume>, no. 48, <fpage>26322</fpage>–<lpage>26337</lpage>, <pub-id pub-id-type="doi">10.1016/j.ijhydene.2019.08.090</pub-id>, 2-s2.0-85071860321.</mixed-citation></ref><ref id="bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cit-0029">
<string-name name-style="western">
<surname>Okaiyeto</surname>
<given-names>K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kerebba</surname>
<given-names>N.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Rautenbach</surname>
<given-names>F.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kumar Singh</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Dua</surname>
<given-names>K.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Oguntibeju</surname>
<given-names>O. O.</given-names>
</string-name>, <article-title>UPLC-ESI-QTOF-MS Phenolic Compounds Identification and Quantification From Ethanolic Extract of <italic toggle="yes">Myrtus communis</italic> ‘Variegatha’: In Vitro Antioxidant and Antidiabetic Potentials</article-title>, <source>Arabian Journal of Chemistry</source>. (<year>2023</year>) <volume>16</volume>, no. 2, <pub-id pub-id-type="doi">10.1016/j.arabjc.2022.104447</pub-id>.</mixed-citation></ref><ref id="bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cit-0030">
<string-name name-style="western">
<surname>Li</surname>
<given-names>K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yao</surname>
<given-names>F.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Du</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Deng</surname>
<given-names>X.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Li</surname>
<given-names>C.</given-names>
</string-name>, <article-title>Persimmon Tannin Decreased the Glycemic Response Through Decreasing the Digestibility of Starch and Inhibiting α-Amylase, α-Glucosidase, and Intestinal Glucose Uptake</article-title>, <source>Journal of Agricultural and Food Chemistry</source>. (<year>2018</year>) <volume>66</volume>, no. 7, <fpage>1629</fpage>–<lpage>1637</lpage>, <pub-id pub-id-type="doi">10.1021/acs.jafc.7b05833</pub-id>, 2-s2.0-85042371466.<pub-id pub-id-type="pmid">29388426</pub-id>
</mixed-citation></ref><ref id="bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cit-0031">
<string-name name-style="western">
<surname>Kusumawardani</surname>
<given-names>S.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Luangsakul</surname>
<given-names>N.</given-names>
</string-name>, <article-title>Assessment of Polyphenols in Purple and Red Rice Bran: Phenolic Profiles, Antioxidant Activities, and Mechanism of Inhibition Against Amylolytic Enzymes</article-title>, <source>Current Research in Food Science</source>. (<year>2024</year>) <volume>9</volume>, <pub-id pub-id-type="doi">10.1016/j.crfs.2024.100828</pub-id>.<pub-id pub-id-type="pmcid">PMC11403441</pub-id><pub-id pub-id-type="pmid">39286431</pub-id></mixed-citation></ref><ref id="bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cit-0032">
<string-name name-style="western">
<surname>Saleem</surname>
<given-names>F.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kanwal</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Khan</surname>
<given-names>K. M.</given-names>
</string-name> et al., <article-title>Dicyanoanilines as Potential and Dual Inhibitors of α-Amylase and α-Glucosidase Enzymes: Synthesis, Characterization, in Vitro, In Silico, and Kinetics Studies</article-title>, <source>Arabian Journal of Chemistry</source>. (<year>2022</year>) <volume>15</volume>.</mixed-citation></ref><ref id="bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cit-0033">
<string-name name-style="western">
<surname>Alhawday</surname>
<given-names>F.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Alminderej</surname>
<given-names>F.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ghannay</surname>
<given-names>S.</given-names>
</string-name> et al., <article-title>In Silico Design, Synthesis, and Evaluation of Novel Enantiopure Isoxazolidines as Promising Dual Inhibitors of α-Amylase and α-Glucosidase</article-title>, <source>Molecules</source>. (<year>2024</year>) <volume>29</volume>, no. 2, <pub-id pub-id-type="doi">10.3390/molecules29020305</pub-id>.<pub-id pub-id-type="pmcid">PMC10818600</pub-id><pub-id pub-id-type="pmid">38257218</pub-id></mixed-citation></ref><ref id="bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cit-0034">
<string-name name-style="western">
<surname>Ahmed</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ali</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ruma</surname>
<given-names>R.</given-names>
</string-name> et al., <article-title>Molecular Docking and Dynamics Simulation of Natural Compounds From Betel Leaves (<italic toggle="yes">Piper betle</italic> L.) for Investigating the Potential Inhibition of Alpha-Amylase and Alpha-Glucosidase of Type 2 Diabetes</article-title>, <source>Molecules</source>. (<year>2022</year>) <volume>27.14</volume>, no. 14, <pub-id pub-id-type="doi">10.3390/molecules27144526</pub-id>.<pub-id pub-id-type="pmcid">PMC9316265</pub-id><pub-id pub-id-type="pmid">35889399</pub-id></mixed-citation></ref><ref id="bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cit-0035">
<string-name name-style="western">
<surname>Margulis</surname>
<given-names>E.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Dagan-Wiener</surname>
<given-names>A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ives</surname>
<given-names>R. S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Jaffari</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Siems</surname>
<given-names>K.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Niv</surname>
<given-names>M. Y.</given-names>
</string-name>, <article-title>Intense Bitterness of Molecules: Machine Learning for Expediting Drug Discovery</article-title>, <source>Computational and Structural Biotechnology Journal</source>. (<year>2021</year>) <volume>19</volume>, <fpage>568</fpage>–<lpage>576</lpage>, <pub-id pub-id-type="doi">10.1016/j.csbj.2020.12.030</pub-id>.<pub-id pub-id-type="pmid">33510862</pub-id>
<pub-id pub-id-type="pmcid">PMC7807207</pub-id></mixed-citation></ref><ref id="bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cit-0036">
<string-name name-style="western">
<surname>Chen</surname>
<given-names>F.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Liu</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Sun</surname>
<given-names>H.</given-names>
</string-name> et al., <article-title>Assessing the Performance of the MM/PBSA and MM/GBSA Methods</article-title>, <source>Physical Chemistry Chemical Physics</source>. (<year>2016</year>) <volume>18</volume>, no. 32, <fpage>22129</fpage>–<lpage>22139</lpage>, <pub-id pub-id-type="doi">10.1039/c6cp03670h</pub-id>, 2-s2.0-84981489489.<pub-id pub-id-type="pmid">27444142</pub-id>
</mixed-citation></ref><ref id="bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cit-0037">
<string-name name-style="western">
<surname>Madhavi</surname>
<given-names>S. G.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Adzhigirey</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Day</surname>
<given-names>T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Annabhimoju</surname>
<given-names>R.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Sherman</surname>
<given-names>W.</given-names>
</string-name>, <article-title>Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments</article-title>, <source>Journal of Computer-Aided Molecular Design</source>. (<year>2013</year>) <volume>27</volume>, no. 3, <fpage>221</fpage>–<lpage>234</lpage>, <pub-id pub-id-type="doi">10.1007/s10822-013-9644-8</pub-id>, 2-s2.0-84880529288.<pub-id pub-id-type="pmid">23579614</pub-id>
</mixed-citation></ref><ref id="bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cit-0038">
<string-name name-style="western">
<surname>Etsassala</surname>
<given-names>N. G. E. R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Badmus</surname>
<given-names>J. A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Marnewick</surname>
<given-names>J. L.</given-names>
</string-name> et al., <article-title>Alpha-Glucosidase and Alpha-Amylase Inhibitory Activities, Molecular Docking, and Antioxidant Capacities of Plectranthus ecklonii Constituents</article-title>, <source>Antioxidants</source>. (<year>2022</year>) <volume>11</volume>, no. 2, <pub-id pub-id-type="doi">10.3390/antiox11020378</pub-id>.<pub-id pub-id-type="pmcid">PMC8869333</pub-id><pub-id pub-id-type="pmid">35204260</pub-id></mixed-citation></ref><ref id="bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cit-0039">
<string-name name-style="western">
<surname>Mahnashi</surname>
<given-names>M. H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Alqahtani</surname>
<given-names>Y. S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Alyami</surname>
<given-names>B. A.</given-names>
</string-name> et al., <article-title>Phytochemical Analysis, α‐glucosidase and Amylase Inhibitory, and Molecular Docking Studies on <italic toggle="yes">Persicaria hydropiper</italic> L. Leaves Essential Oils</article-title>, <source>Evidence-Based Complementary and Alternative Medicine</source>. (<year>2022</year>) <volume>2022</volume>, no. 1, <fpage>7924171</fpage>–<lpage>11</lpage>, <pub-id pub-id-type="doi">10.1155/2022/7924171</pub-id>.<pub-id pub-id-type="pmid">35096118</pub-id>
<pub-id pub-id-type="pmcid">PMC8791729</pub-id></mixed-citation></ref><ref id="bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cit-0040">
<string-name name-style="western">
<surname>Tran</surname>
<given-names>T. T. T.</given-names>
</string-name>, <article-title>
<italic toggle="yes">Tithonia diversifolia</italic> Pectin–Reduced Graphene Oxide and Its Cytotoxic Activity</article-title>, <source>Materials Letters</source>. (<year>2016</year>) <volume>183</volume>, <fpage>127</fpage>–<lpage>130</lpage>.</mixed-citation></ref><ref id="bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cit-0041">
<string-name name-style="western">
<surname>Khan</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Al-Marri</surname>
<given-names>A. H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Khan</surname>
<given-names>M.</given-names>
</string-name> et al., <article-title>
<italic toggle="yes">Pulicaria glutinosa</italic> Plant Extract: A Green and Eco-Friendly Reducing Agent for the Preparation of Highly Reduced Graphene Oxide</article-title>, <source>RSC Advances</source>. (<year>2014</year>) <volume>4</volume>, no. 46, <fpage>24119</fpage>–<lpage>24125</lpage>, <pub-id pub-id-type="doi">10.1039/c4ra01296h</pub-id>, 2-s2.0-84902318650.</mixed-citation></ref><ref id="bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cit-0042">
<string-name name-style="western">
<surname>Yang</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Xia</surname>
<given-names>X.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>He</surname>
<given-names>K.</given-names>
</string-name> et al., <article-title>Green Synthesis of Reduced Graphene Oxide (RGO) Using the Plant Extract of <italic toggle="yes">Salvia spinosa</italic> and Evaluation of Photothermal Effect on Pancreatic Cancer Cells</article-title>, <source>Journal of Molecular Structure</source>. (<year>2021</year>) <volume>1245</volume>, <pub-id pub-id-type="doi">10.1016/j.molstruc.2021.131064</pub-id>.</mixed-citation></ref><ref id="bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cit-0043">
<string-name name-style="western">
<surname>Upadhyay</surname>
<given-names>R. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Soin</surname>
<given-names>N.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Bhattacharya</surname>
<given-names>G.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Saha</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Barman</surname>
<given-names>A.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Roy</surname>
<given-names>S. S.</given-names>
</string-name>, <article-title>Grape Extract Assisted Green Synthesis of Reduced Graphene Oxide for Water Treatment Application</article-title>, <source>Materials Letters</source>. (<year>2015</year>) <volume>160</volume>, <fpage>355</fpage>–<lpage>358</lpage>, <pub-id pub-id-type="doi">10.1016/j.matlet.2015.07.144</pub-id>, 2-s2.0-84938924687.</mixed-citation></ref><ref id="bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cit-0044">
<string-name name-style="western">
<surname>Fernández-Merino</surname>
<given-names>M. J.</given-names>
</string-name> et al., <article-title>Vitamin C as an Innocuous and Safe Reductant for the Preparation of Graphene Suspensions from Graphite Oxide</article-title>, <source>Journal of Physical Chemistry C</source>. (<year>2010</year>) <volume>114</volume>, <fpage>6426</fpage>–<lpage>6432</lpage>.</mixed-citation></ref><ref id="bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cit-0045">
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>Z.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lu</surname>
<given-names>Z. H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Tan</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Chen</surname>
<given-names>X.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Yao</surname>
<given-names>Q.</given-names>
</string-name>, <article-title>CeOx-modified RhNi Nanoparticles Grown on rGO as Highly Efficient Catalysts for Complete Hydrogen Generation from Hydrazine Borane and Hydrazine</article-title>, <source>Journal of Materials Chemistry A</source>. (<year>2015</year>) <volume>3</volume>, no. 46, <fpage>23520</fpage>–<lpage>23529</lpage>, <pub-id pub-id-type="doi">10.1039/c5ta06197k</pub-id>, 2-s2.0-84947803313.</mixed-citation></ref><ref id="bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cit-0046">
<string-name name-style="western">
<surname>Li</surname>
<given-names>D.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Müller</surname>
<given-names>M. B.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Gilje</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kaner</surname>
<given-names>R. B.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Wallace</surname>
<given-names>G. G.</given-names>
</string-name>, <article-title>Processable Aqueous Dispersions of Graphene Nanosheet</article-title>, <source>Nature Nanotechnology</source>. (<year>2008</year>) <volume>3</volume>, no. 2, <fpage>101</fpage>–<lpage>105</lpage>, <pub-id pub-id-type="doi">10.1038/nnano.2007.451</pub-id>, 2-s2.0-38949108623.<pub-id pub-id-type="pmid">18654470</pub-id></mixed-citation></ref><ref id="bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cit-0047">
<string-name name-style="western">
<surname>Maddinedi</surname>
<given-names>S. B.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Mandal</surname>
<given-names>B. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Vankayala</surname>
<given-names>R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kalluru</surname>
<given-names>P.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Pamanji</surname>
<given-names>S. R.</given-names>
</string-name>, <article-title>Bioinspired Reduced Graphene Oxide Nanosheet Using <italic toggle="yes">Terminalia chebula</italic> Seeds Extract</article-title>, <source>Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</source>. (<year>2015</year>) <volume>145</volume>, <fpage>117</fpage>–<lpage>124</lpage>, <pub-id pub-id-type="doi">10.1016/j.saa.2015.02.037</pub-id>, 2-s2.0-84924598700.<pub-id pub-id-type="pmid">25770934</pub-id>
</mixed-citation></ref><ref id="bib-0048"><label>48</label><mixed-citation publication-type="journal" id="cit-0048">
<string-name name-style="western">
<surname>Thiyagarajulu</surname>
<given-names>N.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Arumugam</surname>
<given-names>S.</given-names>
</string-name>, <article-title>Green Synthesis of Reduced Graphene Oxide Nanosheet Using Leaf Extract of <italic toggle="yes">Lantana camara</italic> and Its In Vitro Biological Activities</article-title>, <source>Journal of Cluster Science</source>. (<year>2021</year>) <volume>32</volume>, no. 3, <fpage>559</fpage>–<lpage>568</lpage>, <pub-id pub-id-type="doi">10.1007/s10876-020-01814-7</pub-id>.</mixed-citation></ref><ref id="bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cit-0049">
<string-name name-style="western">
<surname>Chu</surname>
<given-names>H. J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lee</surname>
<given-names>C. Y.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Tai</surname>
<given-names>N. H.</given-names>
</string-name>, <article-title>Green Reduction of Graphene Oxide by <italic toggle="yes">Hibiscus sabdariffa</italic> L. to Fabricate Flexible Graphene Electrode</article-title>, <source>Carbon</source>. (<year>2014</year>) <volume>80</volume>, <fpage>725</fpage>–<lpage>733</lpage>, <pub-id pub-id-type="doi">10.1016/j.carbon.2014.09.019</pub-id>, 2-s2.0-84920492078.</mixed-citation></ref><ref id="bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cit-0050">
<string-name name-style="western">
<surname>Malik</surname>
<given-names>A. R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Sharif</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Shaheen</surname>
<given-names>F.</given-names>
</string-name> et al., <article-title>Green Synthesis of RGO-ZnO Mediated <italic toggle="yes">Ocimum basilicum</italic> Leaves Extract Nanocomposite for Antioxidant, Antibacterial, Antidiabetic and Photocatalytic Activity</article-title>, <source>Journal of Saudi Chemical Society</source>. (<year>2022</year>) <volume>26</volume>, no. 2, <pub-id pub-id-type="doi">10.1016/j.jscs.2022.101438</pub-id>.</mixed-citation></ref><ref id="bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cit-0051">
<string-name name-style="western">
<surname>Rashid</surname>
<given-names>A. R. A.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Rosli</surname>
<given-names>H.</given-names>
</string-name>, <article-title>Green Synthesis of Reduced Graphene Oxide by Using Reducing Sugars</article-title>, <source>Nano Hybrids and Composites</source>. (<year>2021</year>) <volume>31</volume>, <fpage>17</fpage>–<lpage>24</lpage>, <pub-id pub-id-type="doi">10.4028/www.scientific.net/nhc.31.17</pub-id>.</mixed-citation></ref><ref id="bib-0052"><label>52</label><mixed-citation publication-type="journal" id="cit-0052">
<string-name name-style="western">
<surname>Ponrasu</surname>
<given-names>T.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Suguna</surname>
<given-names>L.</given-names>
</string-name>, <article-title>Efficacy of <italic toggle="yes">Annona squamosa</italic> on Wound Healing in Streptozotocin-Induced Diabetic Rats</article-title>, <source>International Wound Journal</source>. (<year>2012</year>) <volume>9</volume>, no. 6, <fpage>613</fpage>–<lpage>623</lpage>, <pub-id pub-id-type="doi">10.1111/j.1742-481X.2011.00924.x</pub-id>, 2-s2.0-84866984089.<pub-id pub-id-type="pmid">22233431</pub-id>
<pub-id pub-id-type="pmcid">PMC7950626</pub-id></mixed-citation></ref><ref id="bib-0053"><label>53</label><mixed-citation publication-type="journal" id="cit-0053">
<string-name name-style="western">
<surname>Dhanasekaran</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Akshaya</surname>
<given-names>M.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Preethi</surname>
<given-names>S.</given-names>
</string-name>, <article-title>In Vitro Anti-Proliferative Potential of Leaves of <italic toggle="yes">Costus igneus</italic>
</article-title>, <source>International Journal of Engineering and Technology</source>. (<year>2014</year>) <volume>4</volume>, no. 4, <fpage>277</fpage>–<lpage>283</lpage>.</mixed-citation></ref><ref id="bib-0054"><label>54</label><mixed-citation publication-type="journal" id="cit-0054">
<string-name name-style="western">
<surname>Greulich</surname>
<given-names>C.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Diendorf</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Geßmann</surname>
<given-names>J.</given-names>
</string-name> et al., <article-title>Cell Type-Specific Responses of Peripheral Blood Mononuclear Cells to Silver Nanoparticles</article-title>, <source>Acta Biomaterialia</source>. (<year>2011</year>) <volume>7</volume>, no. 9, <fpage>3505</fpage>–<lpage>3514</lpage>, <pub-id pub-id-type="doi">10.1016/j.actbio.2011.05.030</pub-id>, 2-s2.0-79961011911.<pub-id pub-id-type="pmid">21651999</pub-id>
</mixed-citation></ref><ref id="bib-0055"><label>55</label><mixed-citation publication-type="journal" id="cit-0055">
<string-name name-style="western">
<surname>Rajarajeshwari</surname>
<given-names>T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Shivashri</surname>
<given-names>C.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Rajasekar</surname>
<given-names>P.</given-names>
</string-name>, <article-title>Synthesis and Characterization of Biocompatible Gymnemic acid-gold Nanoparticles: A Study on Glucose Uptake Stimulatory Effect in 3T3-L1 Adipocytes</article-title>, <source>RSC Advances</source>. (<year>2014</year>) <volume>4</volume>, no. 108, <fpage>63285</fpage>–<lpage>63295</lpage>, <pub-id pub-id-type="doi">10.1039/c4ra07087a</pub-id>, 2-s2.0-84914128977.</mixed-citation></ref><ref id="bib-0056"><label>56</label><mixed-citation publication-type="journal" id="cit-0056">
<string-name name-style="western">
<surname>Wright</surname>
<given-names>J. B.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lam</surname>
<given-names>K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Buret</surname>
<given-names>A. G.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Olson</surname>
<given-names>M. E.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Burrell</surname>
<given-names>R. E.</given-names>
</string-name>, <article-title>Early Healing Events in a Porcine Model of Contaminated Wounds: Effects of Nanocrystalline Silver on Matrix Metalloproteinases, Cell Apoptosis, and Healing</article-title>, <source>Wound Repair and Regeneration</source>. (<year>2002</year>) <volume>10</volume>, no. 3, <fpage>141</fpage>–<lpage>151</lpage>, <pub-id pub-id-type="doi">10.1046/j.1524-475x.2002.10308.x</pub-id>, 2-s2.0-0036310367.<pub-id pub-id-type="pmid">12100375</pub-id>
</mixed-citation></ref><ref id="bib-0057"><label>57</label><mixed-citation publication-type="journal" id="cit-0057">
<string-name name-style="western">
<surname>Yadav</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yadav</surname>
<given-names>P.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yadav</surname>
<given-names>J. P.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Kataria</surname>
<given-names>S. K.</given-names>
</string-name>, <article-title>Novel Derivatives of <italic toggle="yes">Costus igneus</italic> Towards Potentiality Against Diabetes Mellitus Receptors: Adme/Tox Profiling, Computational Docking, and Molecular Dynamics Simulation Study</article-title>, <source>Journal of Taibah University for Science</source>. (<year>2024</year>) <volume>18</volume>, no. 1, <pub-id pub-id-type="doi">10.1080/16583655.2024.2370107</pub-id>.</mixed-citation></ref><ref id="bib-0058"><label>58</label><mixed-citation publication-type="journal" id="cit-0058">
<string-name name-style="western">
<surname>Sanjana</surname>
<given-names>V.</given-names>
</string-name>, <article-title>Comparative Study of <italic toggle="yes">Costus igneus</italic> and Metformin in In Vitro Inhibitory Activity of α-Amylase and α-Glucosidase Activity</article-title>, <source>Journal of Research in Medical and Dental Science</source>. (<year>2022</year>) <volume>10</volume>, no. 10, <fpage>206</fpage>–<lpage>209</lpage>.</mixed-citation></ref><ref id="bib-0059"><label>59</label><mixed-citation publication-type="journal" id="cit-0059">
<string-name name-style="western">
<surname>Tamboli</surname>
<given-names>E.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Bhatnagar</surname>
<given-names>A.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Mishra</surname>
<given-names>A.</given-names>
</string-name>, <article-title>Alpha-Amylase Inhibitors From Mycelium of an Oyster Mushroom</article-title>, <source>Preparative Biochemistry &amp; Biotechnology</source>. (<year>2018</year>) <volume>48</volume>, no. 8, <fpage>693</fpage>–<lpage>699</lpage>, <pub-id pub-id-type="doi">10.1080/10826068.2018.1487849</pub-id>, 2-s2.0-85049966029.<pub-id pub-id-type="pmid">30015540</pub-id>
</mixed-citation></ref><ref id="bib-0060"><label>60</label><mixed-citation publication-type="journal" id="cit-0060">
<string-name name-style="western">
<surname>Ho</surname>
<given-names>G. T. T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Nguyen</surname>
<given-names>T. K. Y.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kase</surname>
<given-names>E. T.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Tadesse</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Barsett</surname>
<given-names>H.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Wangensteen</surname>
<given-names>H.</given-names>
</string-name>, <article-title>Enhanced Glucose Uptake in Human Liver Cells and Inhibition of Carbohydrate Hydrolyzing Enzymes by Nordic Berry Extracts</article-title>, <source>Molecules</source>. (<year>2017</year>) <volume>22</volume>, no. 10, <pub-id pub-id-type="doi">10.3390/molecules22101806</pub-id>, 2-s2.0-85032922323.<pub-id pub-id-type="pmcid">PMC6151378</pub-id><pub-id pub-id-type="pmid">29064442</pub-id></mixed-citation></ref><ref id="bib-0061"><label>61</label><mixed-citation publication-type="journal" id="cit-0061">
<string-name name-style="western">
<surname>Yoon</surname>
<given-names>S. H.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Robyt</surname>
<given-names>J. F.</given-names>
</string-name>, <article-title>Study of the Inhibition of Four Alpha Amylases by Acarbose and Its 4IV-α-Maltohexaosyl and 4IV-α-Maltododecaosyl Analogues</article-title>, <source>Carbohydrate Research</source>. (<year>2003</year>) <volume>338</volume>, no. 19, <fpage>1969</fpage>–<lpage>1980</lpage>, <pub-id pub-id-type="doi">10.1016/s0008-6215(03)00293-3</pub-id>, 2-s2.0-0142026917.<pub-id pub-id-type="pmid">14499573</pub-id>
</mixed-citation></ref><ref id="bib-0062"><label>62</label><mixed-citation publication-type="journal" id="cit-0062">
<string-name name-style="western">
<surname>Bompard-Gilles</surname>
<given-names>C.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Rousseau</surname>
<given-names>P.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Rougé</surname>
<given-names>P.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Payan</surname>
<given-names>F.</given-names>
</string-name>, <article-title>Substrate Mimicry in the Active Center of a Mammalian α-Amylase: Structural Analysis of an Enzyme–Inhibitor Complex</article-title>, <source>Structure</source>. (<year>1996</year>) <volume>4</volume>, no. 12, <fpage>1441</fpage>–<lpage>1452</lpage>, <pub-id pub-id-type="doi">10.1016/s0969-2126(96)00151-7</pub-id>, 2-s2.0-0030589635.<pub-id pub-id-type="pmid">8994970</pub-id>
</mixed-citation></ref><ref id="bib-0063"><label>63</label><mixed-citation publication-type="journal" id="cit-0063">
<string-name name-style="western">
<surname>Barker</surname>
<given-names>M. K.</given-names>
</string-name> and 
<string-name name-style="western">
<surname>Rose</surname>
<given-names>D. R.</given-names>
</string-name>, <article-title>Specificity of Processing α-Glucosidase I Is Guided by the Substrate Conformation: Crystallographic and In Silico Studies</article-title>, <source>Journal of Biological Chemistry</source>. (<year>2013</year>) <volume>288</volume>, no. 19, <fpage>13563</fpage>–<lpage>13574</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.m113.460436</pub-id>, 2-s2.0-84877713668.<pub-id pub-id-type="pmid">23536181</pub-id>
<pub-id pub-id-type="pmcid">PMC3650392</pub-id></mixed-citation></ref><ref id="bib-0064"><label>64</label><mixed-citation publication-type="journal" id="cit-0064">
<string-name name-style="western">
<surname>Raut</surname>
<given-names>B. K.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Upadhyaya</surname>
<given-names>S. R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Bashyal</surname>
<given-names>J.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Parajuli</surname>
<given-names>N.</given-names>
</string-name>, <article-title>In Silico and In Vitro Analyses to Repurpose Quercetin as a Human Pancreatic α-Amylase Inhibitor</article-title>, <source>ACS Omega</source>. (<year>2023</year>) <volume>8</volume>, no. 46, <fpage>43617</fpage>–<lpage>43631</lpage>, <pub-id pub-id-type="doi">10.1021/acsomega.3c05082</pub-id>.<pub-id pub-id-type="pmid">38027372</pub-id>
<pub-id pub-id-type="pmcid">PMC10666247</pub-id></mixed-citation></ref><ref id="bib-0065"><label>65</label><mixed-citation publication-type="journal" id="cit-0065">
<string-name name-style="western">
<surname>Çapan</surname>
<given-names>İ.</given-names>
</string-name>, <article-title>Novel Carbazole-Thiadiazole Derivatives as α-Amylase and α-Glucosidase Inhibitors: Design, Biological Evaluation, and Computational Insights</article-title>, <source>Bioorganic Chemistry</source>. (<year>2025</year>) .<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2025.108243</pub-id><pub-id pub-id-type="pmid">39955835</pub-id></mixed-citation></ref><ref id="bib-0066"><label>66</label><mixed-citation publication-type="journal" id="cit-0066">
<string-name name-style="western">
<surname>Kimani</surname>
<given-names>N. M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ochieng</surname>
<given-names>C. O.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ogutu</surname>
<given-names>M. D.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yamo</surname>
<given-names>K. O.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Onyango</surname>
<given-names>J. O.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Santos</surname>
<given-names>C. B. R.</given-names>
</string-name>, <article-title>Inhibition Kinetics and Theoretical Studies on <italic toggle="yes">Zanthoxylum chalybeum</italic> Engl. Dual Inhibitors of α-Glucosidase and α-Amylase</article-title>, <source>Journal of Xenobiotics</source>. (<year>2023</year>) <volume>13</volume>, no. 1, <fpage>102</fpage>–<lpage>120</lpage>, <pub-id pub-id-type="doi">10.3390/jox13010009</pub-id>.<pub-id pub-id-type="pmid">36976158</pub-id>
<pub-id pub-id-type="pmcid">PMC10059848</pub-id></mixed-citation></ref><ref id="bib-0067"><label>67</label><mixed-citation publication-type="journal" id="cit-0067">
<string-name name-style="western">
<surname>Khan</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Iqbal</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Rahim</surname>
<given-names>F.</given-names>
</string-name> et al., <article-title>New Biologically Hybrid Pharmacophore Thiazolidinone-Based Indole Derivatives: Synthesis, In Vitro Alpha-Amylase and Alpha-Glucosidase Along With Molecular Docking Investigations</article-title>, <source>Molecules</source>. (<year>2022</year>) <volume>27</volume>, no. 19, <pub-id pub-id-type="doi">10.3390/molecules27196564</pub-id>.<pub-id pub-id-type="pmcid">PMC9571711</pub-id><pub-id pub-id-type="pmid">36235098</pub-id></mixed-citation></ref><ref id="bib-0068"><label>68</label><mixed-citation publication-type="journal" id="cit-0068">
<string-name name-style="western">
<surname>Rai</surname>
<given-names>P. V.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ramu</surname>
<given-names>R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Akhileshwari</surname>
<given-names>P.</given-names>
</string-name> et al., <article-title>Novel Benzimidazole-Endowed Chalcones as α-Glucosidase and α-Amylase Inhibitors: An Insight Into Structural and Computational Studies</article-title>, <source>Molecules</source>. (<year>2024</year>) <volume>29</volume>, no. 23, <pub-id pub-id-type="doi">10.3390/molecules29235599</pub-id>.<pub-id pub-id-type="pmcid">PMC11643225</pub-id><pub-id pub-id-type="pmid">39683757</pub-id></mixed-citation></ref><ref id="bib-0069"><label>69</label><mixed-citation publication-type="journal" id="cit-0069">
<string-name name-style="western">
<surname>Setiadji</surname>
<given-names>S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Nuryadin</surname>
<given-names>B. W.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Ramadhan</surname>
<given-names>H.</given-names>
</string-name> et al., <article-title>Preparation of Reduced Graphene Oxide (Rgo) Assisted by Microwave Irradiation and Hydrothermal for Reduction Methods</article-title>, <source>IOP Conference Series: Materials Science and Engineering</source>. (<year>2018</year>) <volume>434</volume>, no. 1, <pub-id pub-id-type="doi">10.1088/1757-899x/434/1/012079</pub-id>, 2-s2.0-85058349581.</mixed-citation></ref><ref id="bib-0070"><label>70</label><mixed-citation publication-type="journal" id="cit-0070">
<string-name name-style="western">
<surname>Ahmed</surname>
<given-names>A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Singh</surname>
<given-names>A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Young</surname>
<given-names>S. J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Gupta</surname>
<given-names>V.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Singh</surname>
<given-names>M.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Arya</surname>
<given-names>S.</given-names>
</string-name>, <article-title>Synthesis Techniques and Advances in Sensing Applications of Reduced Graphene Oxide (Rgo) Composites: A Review</article-title>, <source>Composites Part A: Applied Science and Manufacturing</source>. (<year>2023</year>) <volume>165</volume>, <pub-id pub-id-type="doi">10.1016/j.compositesa.2022.107373</pub-id>.</mixed-citation></ref><ref id="bib-0071"><label>71</label><mixed-citation publication-type="journal" id="cit-0071">
<string-name name-style="western">
<surname>Ragupathi</surname>
<given-names>H.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Jarvin</surname>
<given-names>M.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Inbanathan</surname>
<given-names>S. S. R.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Nayak</surname>
<given-names>A. K.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Choe</surname>
<given-names>Y.</given-names>
</string-name>, <article-title>Hydrothermal Synthesis of an SnO2–rGO Nanocomposite Using Tea Extract as a Reducing Agent for Daylight-Driven Photocatalyst and Supercapacitors</article-title>, <source>New Journal of Chemistry</source>. (<year>2023</year>) <volume>47</volume>, no. 10, <fpage>4644</fpage>–<lpage>4655</lpage>, <pub-id pub-id-type="doi">10.1039/d2nj05912f</pub-id>.</mixed-citation></ref><ref id="bib-0072"><label>72</label><mixed-citation publication-type="journal" id="cit-0072">
<string-name name-style="western">
<surname>Zhao</surname>
<given-names>Y.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Yin</surname>
<given-names>H.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>X.</given-names>
</string-name>, <article-title>Modification of Graphene Oxide by angiopep-2 Enhances Anti-Glioma Efficiency of the Nanoscaled Delivery System for Doxorubicin</article-title>, <source>Aging (Albany NY)</source>. (<year>2020</year>) <volume>12</volume>, no. 11, <fpage>10506</fpage>–<lpage>10516</lpage>, <pub-id pub-id-type="doi">10.18632/aging.103275</pub-id>.<pub-id pub-id-type="pmid">32474457</pub-id>
<pub-id pub-id-type="pmcid">PMC7346081</pub-id></mixed-citation></ref><ref id="bib-0073"><label>73</label><mixed-citation publication-type="journal" id="cit-0073">
<string-name name-style="western">
<surname>Dash</surname>
<given-names>B. S.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lu</surname>
<given-names>Y. J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Pejrprim</surname>
<given-names>P.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Lan</surname>
<given-names>Y. H.</given-names>
</string-name>, and 
<string-name name-style="western">
<surname>Chen</surname>
<given-names>J. P.</given-names>
</string-name>, <article-title>Hyaluronic Acid-Modified, IR780-Conjugated and Doxorubicin-Loaded Reduced Graphene Oxide for Targeted Cancer Chemo/Photothermal/Photodynamic Therapy</article-title>, <source>Biomaterials Advances</source>. (<year>2022</year>) <volume>136</volume>, <pub-id pub-id-type="doi">10.1016/j.bioadv.2022.212764</pub-id>.<pub-id pub-id-type="pmid">35929292</pub-id></mixed-citation></ref><ref id="bib-0074"><label>74</label><mixed-citation publication-type="journal" id="cit-0074">
<string-name name-style="western">
<surname>Joy</surname>
<given-names>A.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Unnikrishnan</surname>
<given-names>G.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Megha</surname>
<given-names>M.</given-names>
</string-name> et al., <article-title>A Novel Combination of Graphene Oxide/Palladium Integrated Polycaprolactone Nanocomposite for Biomedical Applications</article-title>, <source>Diamond and Related Materials</source>. (<year>2023</year>) <volume>136</volume>, <pub-id pub-id-type="doi">10.1016/j.diamond.2023.110033</pub-id>.</mixed-citation></ref><ref id="bib-0075"><label>75</label><mixed-citation publication-type="journal" id="cit-0075">
<string-name name-style="western">
<surname>Szczepaniak</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Jagiello</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Wierzbicki</surname>
<given-names>M.</given-names>
</string-name> et al., <article-title>Reduced Graphene Oxides Modulate the Expression of Cell Receptors and Voltage-Dependent Ion Channel Genes of Glioblastoma Multiforme</article-title>, <source>International Journal of Molecular Sciences</source>. (<year>2021</year>) <volume>22</volume>, no. 2, <pub-id pub-id-type="doi">10.3390/ijms22020515</pub-id>.<pub-id pub-id-type="pmcid">PMC7825604</pub-id><pub-id pub-id-type="pmid">33419226</pub-id></mixed-citation></ref><ref id="bib-0076"><label>76</label><mixed-citation publication-type="journal" id="cit-0076">
<string-name name-style="western">
<surname>Han</surname>
<given-names>J.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Jun</surname>
<given-names>Y.</given-names>
</string-name>, 
<string-name name-style="western">
<surname>Kim</surname>
<given-names>S. H.</given-names>
</string-name> et al., <article-title>Rapid Emergence and Mechanisms of Resistance by U87 Glioblastoma Cells to Doxorubicin in an In Vitro Tumor Microfluidic Ecology</article-title>, <source>Proceedings of the National Academy of Sciences</source>. (<year>2016</year>) <volume>113</volume>, no. 50, <fpage>14283</fpage>–<lpage>14288</lpage>, <pub-id pub-id-type="doi">10.1073/pnas.1614898113</pub-id>, 2-s2.0-85005987202.<pub-id pub-id-type="pmcid">PMC5167174</pub-id><pub-id pub-id-type="pmid">27911816</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>